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Abstract 
Upregulation	 ﾠof	 ﾠthe	 ﾠextracellular	 ﾠsignal-ﾭ‐regulated	 ﾠkinase	 ﾠ(ERK)	 ﾠpathway	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠ
to	 ﾠcontribute	 ﾠto	 ﾠtumour	 ﾠinvasion	 ﾠand	 ﾠprogression.	 ﾠSince	 ﾠthe	 ﾠtwo	 ﾠpredominant	 ﾠERK	 ﾠ
isoforms	 ﾠ(ERK1	 ﾠand	 ﾠERK2)	 ﾠare	 ﾠhighly	 ﾠhomologous	 ﾠand	 ﾠhave	 ﾠindistinguishable	 ﾠkinase	 ﾠ
activities	 ﾠin	 ﾠvitro,	 ﾠboth	 ﾠenzymes	 ﾠwere	 ﾠbelieved	 ﾠto	 ﾠbe	 ﾠredundant	 ﾠand	 ﾠinterchangeable.	 ﾠTo	 ﾠ
challenge	 ﾠthis	 ﾠview,	 ﾠhere	 ﾠwe	 ﾠshow	 ﾠthat	 ﾠERK2	 ﾠsilencing	 ﾠinhibits	 ﾠinvasive	 ﾠmigration	 ﾠof	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠand	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠrestores	 ﾠthe	 ﾠnormal	 ﾠinvasive	 ﾠ
phenotype.	 ﾠA	 ﾠdetailed	 ﾠquantitative	 ﾠanalysis	 ﾠof	 ﾠcell	 ﾠmovement	 ﾠon	 ﾠ3D	 ﾠmatrices	 ﾠindicates	 ﾠ
that	 ﾠERK2	 ﾠknockdown	 ﾠimpairs	 ﾠcellular	 ﾠmotility	 ﾠby	 ﾠdecreasing	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠas	 ﾠwell	 ﾠ
as	 ﾠincreasing	 ﾠthe	 ﾠtime	 ﾠthat	 ﾠcells	 ﾠremain	 ﾠstationary.	 ﾠWe	 ﾠused	 ﾠgene	 ﾠexpression	 ﾠarrays	 ﾠto	 ﾠ
identify	 ﾠrab17	 ﾠand	 ﾠliprin-ﾭ‐β2	 ﾠas	 ﾠgenes	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠincreased	 ﾠby	 ﾠknockdown	 ﾠof	 ﾠ
ERK2	 ﾠand	 ﾠrestored	 ﾠto	 ﾠnormal	 ﾠlevels	 ﾠfollowing	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1).	 ﾠ
Moreover,	 ﾠwe	 ﾠestablished	 ﾠthat	 ﾠboth	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠplay	 ﾠinhibitory	 ﾠroles	 ﾠin	 ﾠthe	 ﾠ
invasive	 ﾠbehaviour	 ﾠof	 ﾠthree	 ﾠindependent	 ﾠcancer	 ﾠcell	 ﾠlines,	 ﾠindicating	 ﾠa	 ﾠsuppressive	 ﾠrole	 ﾠfor	 ﾠ
these	 ﾠproteins	 ﾠin	 ﾠtumour	 ﾠprogression.	 ﾠImportantly,	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠ
Liprin-ﾭ‐β2	 ﾠrestores	 ﾠinvasiveness	 ﾠof	 ﾠERK2-ﾭ‐depleted	 ﾠcells,	 ﾠindicating	 ﾠthat	 ﾠERK2	 ﾠdrives	 ﾠ
invasion	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠby	 ﾠsuppressing	 ﾠexpression	 ﾠof	 ﾠthese	 ﾠgenes.	 ﾠ
Taken	 ﾠtogether,	 ﾠour	 ﾠdata	 ﾠprovides	 ﾠevidence	 ﾠthat	 ﾠtrue	 ﾠfunctional	 ﾠdisparities	 ﾠbetween	 ﾠERK1	 ﾠ
and	 ﾠERK2	 ﾠexist	 ﾠwith	 ﾠregards	 ﾠto	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠidentifies	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠas	 ﾠtwo	 ﾠ
novel	 ﾠmotility	 ﾠsuppressors	 ﾠdownstream	 ﾠof	 ﾠERK2.	 ﾠ3 
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MDR  multi-drug resistance 
MEF2C  myocyte enhancer factor 2C 
MEK  MAP/ERK kinase  
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Ras  Rat sarcoma protein 
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Ser  serine 
SF-tag  streptavidin-flag tag 
SH3  src homology domain 
siRNA  short-interfering RNA 
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1  Introduction 
1.1  The nature of cancer 
1.1.1  Hallmarks of malignancy 
Cancer,	 ﾠa	 ﾠdisease	 ﾠwith	 ﾠmore	 ﾠthan	 ﾠ100	 ﾠdistinct	 ﾠtypes	 ﾠand	 ﾠsubtypes,	 ﾠis	 ﾠdriven	 ﾠby	 ﾠrandomly	 ﾠ
occurring	 ﾠmutations	 ﾠand	 ﾠepigenetic	 ﾠchanges	 ﾠ[1].	 ﾠThese	 ﾠgenetic	 ﾠalterations	 ﾠproduce	 ﾠ
oncogenes	 ﾠwith	 ﾠa	 ﾠdominant	 ﾠgain	 ﾠof	 ﾠfunction	 ﾠand	 ﾠablate	 ﾠtumour	 ﾠsuppressor	 ﾠgenes,	 ﾠgiving	 ﾠ
rise	 ﾠto	 ﾠa	 ﾠrecessive	 ﾠloss	 ﾠof	 ﾠfunction	 ﾠ[2].	 ﾠSeveral	 ﾠlines	 ﾠof	 ﾠevidence	 ﾠhave	 ﾠshown	 ﾠthat	 ﾠ
tumourigenesis	 ﾠis	 ﾠa	 ﾠmultistep	 ﾠprocess	 ﾠanalogous	 ﾠto	 ﾠDarwinian	 ﾠevolution	 ﾠin	 ﾠwhich	 ﾠnormal	 ﾠ
cells	 ﾠgradually	 ﾠevolve	 ﾠinto	 ﾠmalignant	 ﾠtumour	 ﾠcells	 ﾠthrough	 ﾠdynamic	 ﾠchanges	 ﾠin	 ﾠthe	 ﾠ
genome	 ﾠ[3-ﾭ‐5].	 ﾠDepending	 ﾠon	 ﾠthe	 ﾠdegree	 ﾠof	 ﾠaggressiveness	 ﾠtumours	 ﾠare	 ﾠdivided	 ﾠinto	 ﾠtwo	 ﾠ
main	 ﾠcategories.	 ﾠThose	 ﾠwhich	 ﾠgrow	 ﾠat	 ﾠthe	 ﾠsite	 ﾠof	 ﾠorigin	 ﾠwithout	 ﾠinvading	 ﾠthe	 ﾠsurrounding	 ﾠ
tissue	 ﾠare	 ﾠclassed	 ﾠas	 ﾠbenign	 ﾠtumours,	 ﾠwhereas	 ﾠtumours	 ﾠwhich	 ﾠhave	 ﾠinfiltrated	 ﾠthe	 ﾠnearby	 ﾠ
tissue	 ﾠor	 ﾠspread	 ﾠto	 ﾠdistant	 ﾠorgans	 ﾠare	 ﾠclassified	 ﾠas	 ﾠmalignant.	 ﾠThe	 ﾠterm	 ﾠcancer	 ﾠrefers	 ﾠto	 ﾠa	 ﾠ
malignant	 ﾠtumour	 ﾠ[6].	 ﾠ	 ﾠ
Histological	 ﾠanalysis	 ﾠof	 ﾠcancer	 ﾠtissues	 ﾠallows	 ﾠfurther	 ﾠsubdivision	 ﾠinto	 ﾠfour	 ﾠmain	 ﾠclasses.	 ﾠ
The	 ﾠmost	 ﾠcommon	 ﾠtype,	 ﾠthe	 ﾠcarcinoma,	 ﾠarises	 ﾠfrom	 ﾠepithelial	 ﾠcells	 ﾠand	 ﾠaccounts	 ﾠfor	 ﾠmore	 ﾠ
than	 ﾠ80%	 ﾠof	 ﾠcancer-ﾭ‐related	 ﾠdeaths.	 ﾠSarcomas,	 ﾠwhich	 ﾠderive	 ﾠfrom	 ﾠa	 ﾠvariety	 ﾠof	 ﾠ
mesenchymal	 ﾠcell	 ﾠtypes,	 ﾠconstitute	 ﾠapproximately	 ﾠ1%	 ﾠof	 ﾠclinically-ﾭ‐treated	 ﾠcancers.	 ﾠThe	 ﾠ
third	 ﾠclass	 ﾠof	 ﾠcancers	 ﾠare	 ﾠtermed	 ﾠhematopoietic	 ﾠcancers,	 ﾠwhich	 ﾠarise	 ﾠfrom	 ﾠblood-ﾭ‐forming	 ﾠ
and	 ﾠimmune	 ﾠcells.	 ﾠLastly,	 ﾠneuroectodermal	 ﾠtumours	 ﾠform	 ﾠthe	 ﾠfourth	 ﾠclass	 ﾠand	 ﾠderive	 ﾠ
from	 ﾠcells	 ﾠof	 ﾠthe	 ﾠcentral	 ﾠand	 ﾠperipheral	 ﾠnervous	 ﾠsystem.	 ﾠIt	 ﾠis	 ﾠimportant	 ﾠto	 ﾠstress	 ﾠthat	 ﾠ
some	 ﾠtypes	 ﾠof	 ﾠcancers,	 ﾠsuch	 ﾠas	 ﾠmelanoma,	 ﾠdo	 ﾠnot	 ﾠneatly	 ﾠfit	 ﾠinto	 ﾠthis	 ﾠclassification	 ﾠ
scheme	 ﾠ[7].	 ﾠ	 ﾠ
Surprisingly,	 ﾠtaking	 ﾠinto	 ﾠaccount	 ﾠthe	 ﾠvast	 ﾠvariety	 ﾠof	 ﾠgenomic	 ﾠchanges	 ﾠidentified	 ﾠas	 ﾠdrivers	 ﾠ
of	 ﾠoncogenesis,	 ﾠonly	 ﾠnine	 ﾠphysiological	 ﾠhallmarks	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠdevelopment	 ﾠhave	 ﾠthus	 ﾠ
far	 ﾠbeen	 ﾠdeclared	 ﾠessential	 ﾠfor	 ﾠmalignant	 ﾠgrowth	 ﾠ(Figure	 ﾠ1-ﾭ‐1)	 ﾠ[1,	 ﾠ8].	 ﾠFirstly,	 ﾠtumour	 ﾠcells	 ﾠ
must	 ﾠacquire	 ﾠto	 ﾠability	 ﾠto	 ﾠgrow	 ﾠautonomously.	 ﾠTumour	 ﾠcells	 ﾠreduce	 ﾠtheir	 ﾠdependency	 ﾠon	 ﾠ
extracellular	 ﾠstimuli	 ﾠeither	 ﾠby	 ﾠgenerating	 ﾠtheir	 ﾠown	 ﾠgrowth	 ﾠsignals,	 ﾠaltering	 ﾠthe	 ﾠ
ligand-ﾭ‐dependency	 ﾠof	 ﾠthe	 ﾠgrowth	 ﾠreceptors	 ﾠor	 ﾠby	 ﾠmodifying	 ﾠthe	 ﾠcytoplasmic	 ﾠcircuitry	 ﾠ
downstream	 ﾠof	 ﾠgrowth	 ﾠreceptors.	 ﾠSecondly,	 ﾠtumour	 ﾠcells	 ﾠmust	 ﾠbecome	 ﾠinsensitive	 ﾠto	 ﾠ	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Figure 1-1 Nine hallmarks acquired by cancer 
Adapted from [8]. 
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anti-ﾭ‐growth	 ﾠsignals,	 ﾠwhich	 ﾠeither	 ﾠinduce	 ﾠcell	 ﾠdifferentiation	 ﾠor	 ﾠforce	 ﾠproliferating	 ﾠcells	 ﾠinto	 ﾠ
a	 ﾠquiescent	 ﾠG0	 ﾠstate.	 ﾠThirdly,	 ﾠtumour	 ﾠcells	 ﾠmust	 ﾠfind	 ﾠa	 ﾠway	 ﾠto	 ﾠevade	 ﾠprogrammed	 ﾠcell	 ﾠ
death,	 ﾠa	 ﾠprocess	 ﾠtermed	 ﾠapoptosis.	 ﾠAbnormal	 ﾠsignalling	 ﾠcaused	 ﾠby	 ﾠoncogenes	 ﾠcan	 ﾠbe	 ﾠ
recognised	 ﾠby	 ﾠapoptotic	 ﾠsensors	 ﾠand	 ﾠtrigger	 ﾠthe	 ﾠonset	 ﾠof	 ﾠapoptosis,	 ﾠthereby	 ﾠproviding	 ﾠa	 ﾠ
means	 ﾠby	 ﾠwhich	 ﾠtransformed	 ﾠcells	 ﾠare	 ﾠremoved	 ﾠfrom	 ﾠthe	 ﾠtissue.	 ﾠHaving	 ﾠgained	 ﾠthe	 ﾠability	 ﾠ
to	 ﾠgrow	 ﾠand	 ﾠproliferate,	 ﾠtumour	 ﾠcells	 ﾠfurthermore	 ﾠhave	 ﾠto	 ﾠovercome	 ﾠthe	 ﾠhurdle	 ﾠof	 ﾠa	 ﾠfinite	 ﾠ
cellular	 ﾠlifespan	 ﾠof	 ﾠ60	 ﾠto	 ﾠ70	 ﾠdoublings.	 ﾠEvery	 ﾠDNA	 ﾠreplication	 ﾠresults	 ﾠin	 ﾠa	 ﾠshortening	 ﾠof	 ﾠthe	 ﾠ
chromosome	 ﾠends,	 ﾠcalled	 ﾠtelomeres,	 ﾠdue	 ﾠto	 ﾠthe	 ﾠinability	 ﾠof	 ﾠthe	 ﾠDNA	 ﾠpolymerases	 ﾠto	 ﾠ
completely	 ﾠreplicate	 ﾠthe	 ﾠ3’	 ﾠends	 ﾠof	 ﾠthe	 ﾠchromosomes.	 ﾠIn	 ﾠorder	 ﾠto	 ﾠovercome	 ﾠthis	 ﾠnatural	 ﾠ
limit	 ﾠof	 ﾠreplication,	 ﾠtumour	 ﾠcells	 ﾠacquire	 ﾠthe	 ﾠtrait	 ﾠto	 ﾠmaintain	 ﾠand	 ﾠrenew	 ﾠtelomeres,	 ﾠthus	 ﾠ
becoming	 ﾠimmortal.	 ﾠ	 ﾠ
The	 ﾠresulting	 ﾠuncontrolled	 ﾠproliferation,	 ﾠhowever,	 ﾠdemands	 ﾠa	 ﾠgood	 ﾠsupply	 ﾠof	 ﾠoxygen	 ﾠand	 ﾠ
nutrients	 ﾠby	 ﾠthe	 ﾠvasculature,	 ﾠwhich	 ﾠis	 ﾠensured	 ﾠwhen	 ﾠa	 ﾠcell	 ﾠresides	 ﾠwithin	 ﾠ100	 ﾠµm	 ﾠof	 ﾠa	 ﾠ
capillary	 ﾠblood	 ﾠvessel.	 ﾠAs	 ﾠthe	 ﾠtumour	 ﾠmass	 ﾠgrows	 ﾠpast	 ﾠa	 ﾠdiameter	 ﾠof	 ﾠ0.1-ﾭ‐0.2	 ﾠmm,	 ﾠtumour	 ﾠ
cells	 ﾠmust	 ﾠacquire	 ﾠthe	 ﾠability	 ﾠto	 ﾠinduce,	 ﾠattract	 ﾠand	 ﾠsustain	 ﾠnew	 ﾠblood	 ﾠvessel	 ﾠformation	 ﾠin	 ﾠ
a	 ﾠprocess	 ﾠtermed	 ﾠangiogenesis.	 ﾠ	 ﾠMoreover,	 ﾠthe	 ﾠincrease	 ﾠin	 ﾠproliferation	 ﾠrequires	 ﾠrapid	 ﾠ
production	 ﾠof	 ﾠadenosine	 ﾠtriphosphate	 ﾠ(ATP),	 ﾠlipids,	 ﾠnucleotides	 ﾠand	 ﾠamino	 ﾠacids.	 ﾠThus,	 ﾠa	 ﾠ
metabolic	 ﾠswitch	 ﾠin	 ﾠtumour	 ﾠcells	 ﾠto	 ﾠmeet	 ﾠthe	 ﾠgrowing	 ﾠdemand	 ﾠfor	 ﾠenergy	 ﾠand	 ﾠcellular	 ﾠ
building	 ﾠblocks	 ﾠhas	 ﾠbeen	 ﾠproposed	 ﾠas	 ﾠa	 ﾠhallmark	 ﾠof	 ﾠtumour	 ﾠcells.	 ﾠ	 ﾠAnother	 ﾠimportant	 ﾠtrait	 ﾠ
of	 ﾠtumour	 ﾠcells	 ﾠis	 ﾠthe	 ﾠability	 ﾠto	 ﾠevade	 ﾠimmunosurveillance.	 ﾠImmune	 ﾠcells	 ﾠare	 ﾠan	 ﾠimportant	 ﾠ
player	 ﾠin	 ﾠtissue	 ﾠhomeostasis	 ﾠand	 ﾠcan	 ﾠeliminate	 ﾠtransformed	 ﾠcells	 ﾠby	 ﾠtriggering	 ﾠan	 ﾠinnate	 ﾠ
immune	 ﾠresponse.	 ﾠHowever,	 ﾠas	 ﾠthe	 ﾠdisease	 ﾠprogresses	 ﾠtumour	 ﾠcell	 ﾠvariants,	 ﾠwhich	 ﾠare	 ﾠ
able	 ﾠto	 ﾠescape	 ﾠthe	 ﾠimmune	 ﾠattack,	 ﾠdevelop.	 ﾠParadoxically,	 ﾠimmune	 ﾠcells	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠ
shown	 ﾠto	 ﾠpromote	 ﾠtumourigenesis,	 ﾠthus,	 ﾠinflammation	 ﾠhas	 ﾠemerged	 ﾠas	 ﾠa	 ﾠnew	 ﾠhallmark	 ﾠof	 ﾠ
cancer	 ﾠin	 ﾠthe	 ﾠlast	 ﾠdecade.	 ﾠImmune	 ﾠcells	 ﾠcontribute	 ﾠtowards	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠcancer	 ﾠby	 ﾠ
supplying	 ﾠtumour	 ﾠcells	 ﾠwith	 ﾠgrowth	 ﾠsignals,	 ﾠpromoting	 ﾠepithelial-ﾭ‐to-ﾭ‐mesenchymal	 ﾠ(EMT)	 ﾠ
transition	 ﾠand	 ﾠby	 ﾠremodelling	 ﾠthe	 ﾠextracellular	 ﾠmatrix,	 ﾠwhich	 ﾠfacilitates	 ﾠtumour	 ﾠcell	 ﾠ
migration,	 ﾠinvasion	 ﾠand	 ﾠthe	 ﾠprocess	 ﾠof	 ﾠangiogenesis	 ﾠ[9].	 ﾠLastly,	 ﾠmalignant	 ﾠtumour	 ﾠcells	 ﾠ
gain	 ﾠthe	 ﾠability	 ﾠto	 ﾠinvade	 ﾠand	 ﾠmetastasise	 ﾠat	 ﾠdistant	 ﾠsites	 ﾠin	 ﾠthe	 ﾠbody	 ﾠ[1,	 ﾠ10,	 ﾠ11].	 ﾠ	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1.1.2  Invasion-metastasis cascade 
The	 ﾠmetamorphosis	 ﾠof	 ﾠa	 ﾠnormal	 ﾠcell	 ﾠto	 ﾠa	 ﾠmalignant	 ﾠone	 ﾠrequires	 ﾠmany	 ﾠphenotypic	 ﾠand	 ﾠ
biochemical	 ﾠchanges,	 ﾠwhich	 ﾠare	 ﾠacquired	 ﾠin	 ﾠa	 ﾠmulti-ﾭ‐step	 ﾠprocess	 ﾠcalled	 ﾠthe	 ﾠ
invasion-ﾭ‐metastasis	 ﾠcascade.	 ﾠThe	 ﾠdevelopment	 ﾠof	 ﾠmetastases	 ﾠhas	 ﾠbeen	 ﾠsubdivided	 ﾠinto	 ﾠ
five	 ﾠcrucial	 ﾠsteps:	 ﾠprimary	 ﾠinvasion,	 ﾠintravasation,	 ﾠcirculation,	 ﾠextravasation	 ﾠand	 ﾠ
homing	 ﾠ(Figure	 ﾠ1-ﾭ‐2)	 ﾠ[12,	 ﾠ13].	 ﾠ	 ﾠ
In	 ﾠthe	 ﾠfirst	 ﾠinstance	 ﾠtumour	 ﾠcells	 ﾠneed	 ﾠto	 ﾠdetach	 ﾠfrom	 ﾠthe	 ﾠprimary	 ﾠtumour	 ﾠmass,	 ﾠwhich	 ﾠis	 ﾠ
achieved	 ﾠthrough	 ﾠthe	 ﾠalteration	 ﾠof	 ﾠcell	 ﾠadhesion	 ﾠmolecules	 ﾠ(CAMs),	 ﾠmediating	 ﾠcell-ﾭ‐cell	 ﾠ
and	 ﾠcell-ﾭ‐matrix	 ﾠinteractions.	 ﾠOne	 ﾠof	 ﾠthe	 ﾠmost	 ﾠcommon	 ﾠchanges	 ﾠin	 ﾠcarcinomas	 ﾠallowing	 ﾠ
detachment	 ﾠis	 ﾠthe	 ﾠfunctional	 ﾠloss	 ﾠof	 ﾠE-ﾭ‐cadherin,	 ﾠa	 ﾠhomotypic	 ﾠCAM,	 ﾠwhich	 ﾠis	 ﾠan	 ﾠimportant	 ﾠ
signalling	 ﾠmolecule	 ﾠfor	 ﾠconveying	 ﾠanti-ﾭ‐growth	 ﾠsignals	 ﾠto	 ﾠthe	 ﾠintracellular	 ﾠsignalling	 ﾠcircuit	 ﾠ
of	 ﾠβ-ﾭ‐catenin	 ﾠand	 ﾠthe	 ﾠLef/Tcf	 ﾠtranscription	 ﾠfactor.	 ﾠE-ﾭ‐cadherin	 ﾠfunction	 ﾠis	 ﾠlost	 ﾠby	 ﾠseveral	 ﾠ
mechanisms	 ﾠincluding	 ﾠmutational	 ﾠinactivation,	 ﾠtranscriptional	 ﾠrepression	 ﾠand	 ﾠproteolysis	 ﾠ
of	 ﾠthe	 ﾠextracellular	 ﾠdomain	 ﾠ[14].	 ﾠA	 ﾠloss	 ﾠin	 ﾠE-ﾭ‐cadherin	 ﾠis	 ﾠoften	 ﾠaccompanied	 ﾠby	 ﾠincreased	 ﾠ
N-ﾭ‐cadherin	 ﾠexpression.	 ﾠThe	 ﾠdisplay	 ﾠof	 ﾠN-ﾭ‐cadherin	 ﾠmolecules	 ﾠon	 ﾠthe	 ﾠcell	 ﾠsurface	 ﾠallows	 ﾠ
binding	 ﾠto	 ﾠstromal	 ﾠcells	 ﾠand	 ﾠeventually	 ﾠfavours	 ﾠmigration	 ﾠfrom	 ﾠthe	 ﾠepithelium	 ﾠtowards	 ﾠ
the	 ﾠconnective	 ﾠtissue	 ﾠcalled	 ﾠstroma	 ﾠ[15,	 ﾠ16].	 ﾠYet,	 ﾠepithelium	 ﾠand	 ﾠstroma	 ﾠare	 ﾠseparated	 ﾠby	 ﾠ
the	 ﾠbasement	 ﾠmembrane,	 ﾠa	 ﾠdense	 ﾠmeshwork	 ﾠof	 ﾠglycoproteins	 ﾠand	 ﾠproteoglycans	 ﾠ
consisting	 ﾠmainly	 ﾠof	 ﾠtype	 ﾠIV	 ﾠcollagen	 ﾠand	 ﾠlaminin.	 ﾠThe	 ﾠsecretion	 ﾠof	 ﾠmatrix-ﾭ‐degrading	 ﾠ
proteases	 ﾠby	 ﾠtumour	 ﾠcells	 ﾠor	 ﾠrecruited	 ﾠstromal	 ﾠcells	 ﾠdisrupts	 ﾠthis	 ﾠstructural	 ﾠbarrier	 ﾠand	 ﾠ
allows	 ﾠmigration	 ﾠinto	 ﾠthe	 ﾠadjacent	 ﾠconnective	 ﾠtissue.	 ﾠUnder	 ﾠnormal	 ﾠcircumstances,	 ﾠ
protease	 ﾠactivity	 ﾠis	 ﾠtightly	 ﾠregulated	 ﾠthrough	 ﾠboth	 ﾠautoinhibition	 ﾠand	 ﾠsecreted	 ﾠinhibitors.	 ﾠ
However,	 ﾠin	 ﾠtumours	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠproteases	 ﾠis	 ﾠcommonly	 ﾠaugmented,	 ﾠwhile	 ﾠ
protease	 ﾠinhibitors	 ﾠare	 ﾠdown-ﾭ‐regulated	 ﾠ[17].	 ﾠThe	 ﾠbiochemical	 ﾠand	 ﾠphenotypical	 ﾠchanges	 ﾠ
observed	 ﾠduring	 ﾠthe	 ﾠinvasive	 ﾠprocess	 ﾠadditionally	 ﾠfacilitate	 ﾠintrusion	 ﾠof	 ﾠtumour	 ﾠcells	 ﾠinto	 ﾠ
the	 ﾠlumen	 ﾠof	 ﾠlymphatic	 ﾠor	 ﾠblood	 ﾠvessels.	 ﾠDuring	 ﾠthis	 ﾠstep,	 ﾠwhich	 ﾠis	 ﾠtermed	 ﾠintravasation,	 ﾠ
tumour	 ﾠcells	 ﾠpenetrate	 ﾠinto	 ﾠthe	 ﾠlumen	 ﾠof	 ﾠeither	 ﾠlymphatic	 ﾠor	 ﾠblood	 ﾠvessels	 ﾠand	 ﾠare	 ﾠthen	 ﾠ
transported	 ﾠto	 ﾠdistant	 ﾠtissue	 ﾠsites.	 ﾠThis	 ﾠmode	 ﾠof	 ﾠtravel,	 ﾠhowever,	 ﾠposes	 ﾠmany	 ﾠrisks	 ﾠfor	 ﾠ
tumour	 ﾠcells.	 ﾠFirstly,	 ﾠthey	 ﾠhave	 ﾠto	 ﾠevade	 ﾠanoikis,	 ﾠa	 ﾠspecial	 ﾠform	 ﾠof	 ﾠprogrammed	 ﾠcell	 ﾠdeath	 ﾠ
activated	 ﾠupon	 ﾠloss	 ﾠof	 ﾠanchorage	 ﾠas	 ﾠnormal	 ﾠ(untransformed)	 ﾠcells	 ﾠcannot	 ﾠsurvive	 ﾠin	 ﾠ
conditions	 ﾠwhen	 ﾠcell-ﾭ‐cell	 ﾠor	 ﾠcell-ﾭ‐substratum	 ﾠinteractions	 ﾠare	 ﾠlost.	 ﾠTumour	 ﾠcells	 ﾠtherefore	 ﾠ	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Figure 1-2 The invasion-metastasis cascade 
Metastasis formation is a multistep process during which tumour cells invade the surrounding, enter blood 
vessels, adhere at distant sites, where the leave the blood stream to form new secondary lesions. Figure 
adapted from [7]  
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have	 ﾠto	 ﾠgain	 ﾠthe	 ﾠability	 ﾠto	 ﾠproliferate	 ﾠand	 ﾠsurvive	 ﾠin	 ﾠan	 ﾠanchorage-ﾭ‐independent	 ﾠ
manner	 ﾠ[18].	 ﾠSecondly,	 ﾠhigh	 ﾠshear	 ﾠforces	 ﾠpose	 ﾠthe	 ﾠrisk	 ﾠof	 ﾠdamaging	 ﾠthe	 ﾠcells	 ﾠphysically.	 ﾠAs	 ﾠ
a	 ﾠway	 ﾠto	 ﾠoppose	 ﾠthese	 ﾠnon-ﾭ‐viable	 ﾠconditions,	 ﾠtumour	 ﾠcells	 ﾠform	 ﾠso	 ﾠcalled	 ﾠmicro-ﾭ‐emboli,	 ﾠ
which	 ﾠare	 ﾠaggregations	 ﾠof	 ﾠtumour	 ﾠcells	 ﾠwith	 ﾠthrombocytes	 ﾠand	 ﾠerythrocytes.	 ﾠThis	 ﾠ
clumping	 ﾠis	 ﾠdriven	 ﾠby	 ﾠa	 ﾠprotein	 ﾠcalled	 ﾠtissue	 ﾠfactor,	 ﾠwhich	 ﾠis	 ﾠhighly	 ﾠexpressed	 ﾠin	 ﾠmalignant	 ﾠ
carcinomas	 ﾠcells	 ﾠ[19,	 ﾠ20].	 ﾠMice	 ﾠdeficient	 ﾠin	 ﾠmicro-ﾭ‐emboli	 ﾠformation	 ﾠshow	 ﾠan	 ﾠover	 ﾠ90%	 ﾠ
decrease	 ﾠin	 ﾠmetastasis	 ﾠformation,	 ﾠstressing	 ﾠthe	 ﾠadverse	 ﾠconditions	 ﾠtumour	 ﾠcells	 ﾠface	 ﾠ
when	 ﾠin	 ﾠcirculation	 ﾠ[21].	 ﾠ
Next,	 ﾠcancer	 ﾠcells	 ﾠneed	 ﾠto	 ﾠlodge	 ﾠat	 ﾠa	 ﾠdistant	 ﾠsite	 ﾠbefore	 ﾠextravasating	 ﾠfrom	 ﾠthe	 ﾠ
vasculature.	 ﾠSpecific	 ﾠcell	 ﾠsurface	 ﾠreceptors,	 ﾠsuch	 ﾠas	 ﾠintegrins	 ﾠand	 ﾠthe	 ﾠCXCR4-ﾭ‐receptor,	 ﾠ
have	 ﾠbeen	 ﾠdemonstrated	 ﾠto	 ﾠfacilitate	 ﾠlodging	 ﾠat	 ﾠthe	 ﾠendothelium	 ﾠof	 ﾠblood	 ﾠvessels	 ﾠof	 ﾠ
specific	 ﾠorgans	 ﾠ[22,	 ﾠ23].	 ﾠThe	 ﾠprocess	 ﾠof	 ﾠextravasation	 ﾠis	 ﾠthought	 ﾠto	 ﾠoccur	 ﾠin	 ﾠtwo	 ﾠdifferent	 ﾠ
ways.	 ﾠTumour	 ﾠcells	 ﾠeither	 ﾠstart	 ﾠto	 ﾠproliferate	 ﾠin	 ﾠthe	 ﾠlumen	 ﾠof	 ﾠthe	 ﾠvessel,	 ﾠthereby	 ﾠ
destroying	 ﾠthe	 ﾠadjacent	 ﾠendothelium.	 ﾠAlternatively,	 ﾠthey	 ﾠcan	 ﾠpenetrate	 ﾠa	 ﾠdistant	 ﾠtissue	 ﾠin	 ﾠ
a	 ﾠprocess	 ﾠsimilar	 ﾠto	 ﾠintravasation	 ﾠby	 ﾠinvading	 ﾠthe	 ﾠendothelium	 ﾠand	 ﾠ	 ﾠthen	 ﾠdegrading	 ﾠ
basement	 ﾠmembrane	 ﾠwith	 ﾠthe	 ﾠhelp	 ﾠof	 ﾠproteases	 ﾠ[12].	 ﾠYet,	 ﾠin	 ﾠorder	 ﾠto	 ﾠcolonise	 ﾠand	 ﾠ
proliferate	 ﾠsuccessfully	 ﾠat	 ﾠectopic	 ﾠsites,	 ﾠcancer	 ﾠcells	 ﾠneed	 ﾠto	 ﾠadapt	 ﾠto	 ﾠthe	 ﾠnew	 ﾠ
micro-ﾭ‐environment,	 ﾠwhere	 ﾠsurvival	 ﾠand	 ﾠgrowth	 ﾠsignals	 ﾠdiffer	 ﾠfrom	 ﾠthe	 ﾠoriginal	 ﾠtumour	 ﾠ
site.	 ﾠIndeed,	 ﾠhoming	 ﾠrepresents	 ﾠthe	 ﾠmost	 ﾠcomplex	 ﾠand	 ﾠchallenging	 ﾠstep	 ﾠof	 ﾠthe	 ﾠ
invasion-ﾭ‐metastasis	 ﾠcascade.	 ﾠThus,	 ﾠmost	 ﾠcells	 ﾠthat	 ﾠhave	 ﾠspread	 ﾠto	 ﾠectopic	 ﾠsites	 ﾠdo	 ﾠnot	 ﾠ
develop	 ﾠinto	 ﾠmacroscopic	 ﾠlesions,	 ﾠbut	 ﾠdie	 ﾠrapidly	 ﾠor	 ﾠsurvive	 ﾠas	 ﾠdormant	 ﾠmicro-ﾭ‐metastases.	 ﾠ
In	 ﾠthe	 ﾠearly	 ﾠ1990s,	 ﾠgenes,	 ﾠwhich	 ﾠinhibit	 ﾠcolonisation,	 ﾠwere	 ﾠidentified.	 ﾠThese	 ﾠso-ﾭ‐called	 ﾠ
metastasis	 ﾠsuppressor	 ﾠgenes	 ﾠoften	 ﾠalter	 ﾠfundamental	 ﾠsignalling	 ﾠpathways	 ﾠregulating	 ﾠ
cellular	 ﾠgrowth	 ﾠand	 ﾠproliferation	 ﾠsuch	 ﾠas	 ﾠthe	 ﾠMAPK/ERK	 ﾠ(mitogen	 ﾠactivated	 ﾠprotein	 ﾠ
kinase/extracellular	 ﾠsignal-ﾭ‐regulated	 ﾠkinase)	 ﾠpathway.	 ﾠOne	 ﾠexample	 ﾠis	 ﾠthe	 ﾠhistidine	 ﾠ
kinase,	 ﾠnm23-ﾭ‐Hi,	 ﾠthe	 ﾠfirst	 ﾠmetastasis	 ﾠsuppressor	 ﾠgene	 ﾠto	 ﾠbe	 ﾠidentified.	 ﾠNm23-ﾭ‐Hi	 ﾠ
phosphorylates	 ﾠthe	 ﾠkinase	 ﾠsuppressor	 ﾠof	 ﾠRas	 ﾠ(KSR)	 ﾠprotein	 ﾠand	 ﾠthereby	 ﾠinhibits	 ﾠ
Ras-ﾭ‐mediated	 ﾠactivation	 ﾠof	 ﾠERK	 ﾠ[24-ﾭ‐26].	 ﾠ	 ﾠ
The	 ﾠmolecular	 ﾠprinciples	 ﾠof	 ﾠcancer	 ﾠinvasion	 ﾠand	 ﾠmetastasis	 ﾠare	 ﾠhighly	 ﾠcomplex	 ﾠand	 ﾠ
therefore	 ﾠremain	 ﾠa	 ﾠmajor	 ﾠchallenge	 ﾠin	 ﾠbasic	 ﾠcancer	 ﾠresearch.	 ﾠMoreover,	 ﾠmalignant	 ﾠ
tumours	 ﾠaccount	 ﾠfor	 ﾠapproximately	 ﾠ90%	 ﾠof	 ﾠall	 ﾠcancer-ﾭ‐related	 ﾠdeaths,	 ﾠthus	 ﾠnew	 ﾠinsight	 ﾠ
into	 ﾠthe	 ﾠinvasion-ﾭ‐metastasis	 ﾠcascade	 ﾠmay	 ﾠopen	 ﾠup	 ﾠa	 ﾠnovel	 ﾠtherapeutic	 ﾠwindow.	 ﾠ	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1.1.3  Modes of tumour cell migration 
Cell	 ﾠmigration	 ﾠis	 ﾠan	 ﾠessential	 ﾠcharacteristic	 ﾠduring	 ﾠembryonic	 ﾠdevelopment,	 ﾠimmune	 ﾠ
system	 ﾠfunction	 ﾠand	 ﾠtissue	 ﾠrepair,	 ﾠbut	 ﾠis	 ﾠalso	 ﾠplaying	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠinflammatory	 ﾠ
diseases	 ﾠand	 ﾠtumourigenesis	 ﾠ[27].	 ﾠCellular	 ﾠmotility	 ﾠrelies	 ﾠon	 ﾠthe	 ﾠestablishment	 ﾠof	 ﾠtwo	 ﾠ
physical	 ﾠforces.	 ﾠAt	 ﾠthe	 ﾠcellular	 ﾠfront	 ﾠprotrusive	 ﾠforces	 ﾠinitiated	 ﾠby	 ﾠactin	 ﾠpolymerisation	 ﾠ
and	 ﾠdepolymerisation	 ﾠallow	 ﾠmembrane	 ﾠextension,	 ﾠwhereas	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠrear	 ﾠretraction	 ﾠ
forces	 ﾠgenerated	 ﾠby	 ﾠmyosin-ﾭ‐based	 ﾠmotors	 ﾠinitiate	 ﾠcontraction	 ﾠ[27].	 ﾠProtrusion	 ﾠand	 ﾠ
retraction	 ﾠneed	 ﾠto	 ﾠbe	 ﾠtightly	 ﾠregulated	 ﾠin	 ﾠorder	 ﾠto	 ﾠallow	 ﾠnet	 ﾠtranslocation	 ﾠof	 ﾠthe	 ﾠcellular	 ﾠ
body.	 ﾠThis	 ﾠis	 ﾠachieved	 ﾠthrough	 ﾠan	 ﾠinternal	 ﾠspatial	 ﾠasymmetry	 ﾠcalled	 ﾠcellular	 ﾠpolarisation,	 ﾠ
which	 ﾠdefines	 ﾠa	 ﾠcellular	 ﾠfront	 ﾠand	 ﾠrear.	 ﾠIndeed,	 ﾠunpolarised	 ﾠcells,	 ﾠwhich	 ﾠsimultaneously	 ﾠ
extend	 ﾠprotrusions	 ﾠin	 ﾠopposite	 ﾠdirections,	 ﾠhave	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠbe	 ﾠimmobile	 ﾠ[28].	 ﾠThus,	 ﾠ
polarisation	 ﾠis	 ﾠa	 ﾠprerequisite	 ﾠfor	 ﾠall	 ﾠmodes	 ﾠof	 ﾠcellular	 ﾠmigration,	 ﾠand	 ﾠthe	 ﾠinterplay	 ﾠof	 ﾠ
physical	 ﾠand	 ﾠmolecular	 ﾠparameters	 ﾠof	 ﾠthe	 ﾠcell	 ﾠand	 ﾠits	 ﾠsurroundings	 ﾠdetermines	 ﾠhow	 ﾠa	 ﾠcell	 ﾠ
migrates	 ﾠ(Figure	 ﾠ1-ﾭ‐3).	 ﾠ
1.1.3.1  Amoeboid migration 
Leukocytes	 ﾠ[29]	 ﾠand	 ﾠhematopoietic	 ﾠstem	 ﾠcells	 ﾠ[30]	 ﾠexhibit	 ﾠa	 ﾠcrawling	 ﾠtype	 ﾠof	 ﾠcell	 ﾠ
movement,	 ﾠwhich	 ﾠrelies	 ﾠon	 ﾠrapid	 ﾠcycles	 ﾠof	 ﾠmembrane	 ﾠextensions	 ﾠand	 ﾠcontractions	 ﾠand	 ﾠis	 ﾠ
referred	 ﾠto	 ﾠas	 ﾠamoeboid	 ﾠmigration.	 ﾠAmoeboid	 ﾠlocomotion	 ﾠrelies	 ﾠon	 ﾠcellular	 ﾠblebbing	 ﾠ
which	 ﾠis	 ﾠdriven	 ﾠby	 ﾠcortical	 ﾠactin	 ﾠfibre	 ﾠcontractions.	 ﾠContractile	 ﾠforces	 ﾠinitiate	 ﾠmembrane	 ﾠ
blebbing	 ﾠby	 ﾠseparating	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠfrom	 ﾠthe	 ﾠcortex,	 ﾠthus	 ﾠallowing	 ﾠthe	 ﾠinherent	 ﾠ
hydrostatic	 ﾠpotential	 ﾠto	 ﾠcause	 ﾠbleb	 ﾠformation.	 ﾠA	 ﾠconcentration	 ﾠof	 ﾠblebs	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠ
front	 ﾠcreates	 ﾠa	 ﾠprotrusive	 ﾠforce	 ﾠnecessary	 ﾠfor	 ﾠcellular	 ﾠlocomotion	 ﾠ[31].	 ﾠOne	 ﾠof	 ﾠthe	 ﾠ
features	 ﾠof	 ﾠamoeboid	 ﾠmigration	 ﾠis	 ﾠthe	 ﾠlow	 ﾠand	 ﾠshort-ﾭ‐lived	 ﾠbinding	 ﾠforce	 ﾠtowards	 ﾠthe	 ﾠ
extracellular	 ﾠmatrix	 ﾠ(ECM).	 ﾠThus,	 ﾠβ1	 ﾠintegrin	 ﾠmediated	 ﾠadhesions	 ﾠare	 ﾠcompletely	 ﾠor	 ﾠ
partially	 ﾠdispensable	 ﾠduring	 ﾠamoeboid	 ﾠmigration	 ﾠ[32,	 ﾠ33].	 ﾠThe	 ﾠlack	 ﾠof	 ﾠstable	 ﾠfocal	 ﾠcontacts	 ﾠ
marks	 ﾠanother	 ﾠfeature	 ﾠof	 ﾠamoeboid	 ﾠmigration,	 ﾠi.e.	 ﾠextraordinary	 ﾠdeformability.	 ﾠThus,	 ﾠcells	 ﾠ
overcome	 ﾠmatrix	 ﾠbarriers	 ﾠby	 ﾠmeans	 ﾠof	 ﾠshape	 ﾠadaptations	 ﾠrather	 ﾠthan	 ﾠECM	 ﾠremodelling.	 ﾠ
This	 ﾠshape-ﾭ‐driven	 ﾠmode	 ﾠof	 ﾠcell	 ﾠmovement	 ﾠis	 ﾠcontrolled	 ﾠby	 ﾠthe	 ﾠsmall	 ﾠGTPase	 ﾠRhoA	 ﾠand	 ﾠits	 ﾠ
effector	 ﾠkinase	 ﾠROCK	 ﾠ(Rho-ﾭ‐associated	 ﾠcoiled-ﾭ‐coil	 ﾠprotein	 ﾠkinase)	 ﾠ[34].	 ﾠ
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Figure 1-3 Characteristics of different modes of migration 
A. Depiction of the well-established five-step migration cycle characteristic of mesenchymal cells. 
B. Comparison of individual migration modes, comprising amoeboid and mesenchymal migration, with 
collective cell migration in the form of cell clusters and strands. Adapted from [35] 
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Amoeboid	 ﾠtumour	 ﾠcells,	 ﾠcommonly	 ﾠobserved	 ﾠin	 ﾠlymphomas	 ﾠand	 ﾠsmall-ﾭ‐cell	 ﾠlung	 ﾠ
carcinomas,	 ﾠexpress	 ﾠlow	 ﾠlevels	 ﾠof	 ﾠβ1	 ﾠand	 ﾠβ3	 ﾠintegrins,	 ﾠwhich	 ﾠis	 ﾠthought	 ﾠto	 ﾠaccount	 ﾠfor	 ﾠ
their	 ﾠhighly	 ﾠmetastatic	 ﾠand	 ﾠmotile	 ﾠbehaviour	 ﾠ[36,	 ﾠ37].	 ﾠ
1.1.3.2  Mesenchymal migration 
In	 ﾠcontrast	 ﾠto	 ﾠthe	 ﾠpath-ﾭ‐finding	 ﾠmotility	 ﾠdescribed	 ﾠfor	 ﾠamoeboid	 ﾠmigration,	 ﾠmesenchymal	 ﾠ
cells	 ﾠfollow	 ﾠa	 ﾠpath-ﾭ‐generating	 ﾠstrategy	 ﾠwhich	 ﾠinvolves	 ﾠECM	 ﾠdegradation	 ﾠand	 ﾠremodelling.	 ﾠ
Mesenchymal	 ﾠcells	 ﾠare	 ﾠcharacterised	 ﾠby	 ﾠan	 ﾠelongated,	 ﾠspindle-ﾭ‐shaped	 ﾠmorphology	 ﾠwhich	 ﾠ
is	 ﾠbrought	 ﾠabout	 ﾠby	 ﾠstable	 ﾠintegrin-ﾭ‐mediated	 ﾠadhesions	 ﾠwith	 ﾠthe	 ﾠECM	 ﾠ[34].	 ﾠThis	 ﾠmode	 ﾠof	 ﾠ
motility	 ﾠfollows	 ﾠa	 ﾠwell-ﾭ‐defined	 ﾠfive-ﾭ‐step	 ﾠmigration	 ﾠcycle	 ﾠ(Figure	 ﾠ1-ﾭ‐3).	 ﾠActin	 ﾠprotrusions	 ﾠat	 ﾠ
the	 ﾠcellular	 ﾠfront	 ﾠlead	 ﾠto	 ﾠpseudopod	 ﾠformation,	 ﾠwhere	 ﾠadhesion	 ﾠmolecules,	 ﾠmost	 ﾠnotably	 ﾠ
integrin	 ﾠreceptors,	 ﾠinitiate	 ﾠbinding	 ﾠto	 ﾠthe	 ﾠmatrix	 ﾠ[35].	 ﾠEnrichment	 ﾠof	 ﾠintegrins	 ﾠat	 ﾠthe	 ﾠcell	 ﾠ
front	 ﾠsubsequently	 ﾠleads	 ﾠto	 ﾠformation	 ﾠof	 ﾠstable	 ﾠfocal	 ﾠcontacts.	 ﾠAs	 ﾠdifferent	 ﾠintegrins	 ﾠbind	 ﾠ
to	 ﾠdifferent	 ﾠECM	 ﾠsubstrates,	 ﾠe.g.	 ﾠα5β1	 ﾠbinds	 ﾠfibronectin	 ﾠ[38]	 ﾠand	 ﾠα2β1	 ﾠbinds	 ﾠfibrillar	 ﾠ
collagen	 ﾠ[39],	 ﾠthis	 ﾠmode	 ﾠof	 ﾠmotility	 ﾠis	 ﾠhighly	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠECM	 ﾠcomposition.	 ﾠ
Engagement	 ﾠof	 ﾠsurface	 ﾠreceptors	 ﾠwith	 ﾠthe	 ﾠmatrix	 ﾠtriggers	 ﾠrecruitment	 ﾠof	 ﾠsurface	 ﾠ
proteases	 ﾠto	 ﾠfocal	 ﾠcontacts	 ﾠ[40].	 ﾠSubsequent	 ﾠdegradation	 ﾠof	 ﾠECM	 ﾠcomponents	 ﾠin	 ﾠthe	 ﾠ
proximity	 ﾠof	 ﾠthe	 ﾠleading	 ﾠedge	 ﾠpaves	 ﾠthe	 ﾠway	 ﾠfor	 ﾠthe	 ﾠadvancing	 ﾠcell	 ﾠbody.	 ﾠIn	 ﾠcontrast,	 ﾠfocal	 ﾠ
adhesions	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠback	 ﾠare	 ﾠdisassembled	 ﾠand	 ﾠcontractile	 ﾠforces	 ﾠpropel	 ﾠthe	 ﾠcellular	 ﾠ
body	 ﾠforward	 ﾠ[35].	 ﾠMesenchymal	 ﾠmigration	 ﾠis	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠcoordination	 ﾠof	 ﾠthree	 ﾠ
small	 ﾠGTPases,	 ﾠnamely	 ﾠRac,	 ﾠCdc42	 ﾠand	 ﾠRhoA.	 ﾠAt	 ﾠthe	 ﾠcellular	 ﾠfront	 ﾠRac	 ﾠand	 ﾠCdc42	 ﾠactivity	 ﾠ
promote	 ﾠrapid	 ﾠturnover	 ﾠof	 ﾠfocal	 ﾠcontacts,	 ﾠwhereas	 ﾠRhoA	 ﾠactivity	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠback	 ﾠ
controls	 ﾠcontractions	 ﾠforces,	 ﾠwhich	 ﾠpropel	 ﾠthe	 ﾠcell	 ﾠbody	 ﾠforward	 ﾠ[41,	 ﾠ42].	 ﾠHigh	 ﾠturnover	 ﾠof	 ﾠ
focal	 ﾠadhesion	 ﾠresults	 ﾠin	 ﾠlow	 ﾠadhesiveness	 ﾠand	 ﾠincreases	 ﾠthe	 ﾠmigratory	 ﾠspeed,	 ﾠwhile	 ﾠ
strong	 ﾠintegrin-ﾭ‐substrate	 ﾠlinkages	 ﾠimpair	 ﾠcell	 ﾠmotility.	 ﾠGiven	 ﾠthat	 ﾠcells	 ﾠemploying	 ﾠan	 ﾠ
amoeboid	 ﾠmode	 ﾠof	 ﾠmigration	 ﾠform	 ﾠvery	 ﾠweak	 ﾠECM	 ﾠinteractions,	 ﾠit	 ﾠis	 ﾠnot	 ﾠsurprising	 ﾠthat	 ﾠ
they	 ﾠmove	 ﾠwith	 ﾠvelocities	 ﾠof	 ﾠup	 ﾠto	 ﾠ10-ﾭ‐30	 ﾠfold	 ﾠhigher	 ﾠthan	 ﾠmesenchymal	 ﾠcells	 ﾠ[43].	 ﾠ
1.1.3.3  Collective cell migration 
Collective	 ﾠmigration,	 ﾠas	 ﾠthe	 ﾠname	 ﾠsuggests,	 ﾠdescribes	 ﾠthe	 ﾠlocomotion	 ﾠof	 ﾠa	 ﾠmulticellular	 ﾠ
contractile	 ﾠbody,	 ﾠwhere	 ﾠcell-ﾭ‐cell	 ﾠjunctions	 ﾠare	 ﾠkept	 ﾠintact.	 ﾠThis	 ﾠphenomenon	 ﾠoccurs	 ﾠ
naturally	 ﾠduring	 ﾠembryonic	 ﾠ[44,	 ﾠ45]	 ﾠas	 ﾠwells	 ﾠas	 ﾠmammary	 ﾠdevelopment	 ﾠ[46].	 ﾠIn	 ﾠtumours,	 ﾠ
two	 ﾠtypes	 ﾠof	 ﾠcollective	 ﾠmigration	 ﾠhave	 ﾠbeen	 ﾠdescribed	 ﾠhistologically,	 ﾠi.e.	 ﾠthe	 ﾠinvasion	 ﾠof	 ﾠChapter 1 – Introduction    24 
sheets	 ﾠand	 ﾠstrands	 ﾠof	 ﾠtumour	 ﾠcells	 ﾠwhich	 ﾠretain	 ﾠcontact	 ﾠwith	 ﾠthe	 ﾠprimary	 ﾠtumour,	 ﾠand	 ﾠthe	 ﾠ
invasion	 ﾠof	 ﾠdetached	 ﾠcell	 ﾠclusters.	 ﾠCollective	 ﾠmigration	 ﾠcan	 ﾠonly	 ﾠbe	 ﾠachieved	 ﾠwhen	 ﾠ
contractile	 ﾠforces	 ﾠare	 ﾠcoordinated.	 ﾠTherefore,	 ﾠthe	 ﾠcontractile	 ﾠbody	 ﾠis	 ﾠdivided	 ﾠinto	 ﾠhighly	 ﾠ
motile	 ﾠpath-ﾭ‐generating	 ﾠcells	 ﾠat	 ﾠthe	 ﾠfront,	 ﾠwhich	 ﾠengage	 ﾠwith	 ﾠthe	 ﾠECM	 ﾠand	 ﾠremodel	 ﾠit	 ﾠwith	 ﾠ
the	 ﾠhelp	 ﾠof	 ﾠproteolytic	 ﾠdegradation,	 ﾠand	 ﾠcells	 ﾠin	 ﾠthe	 ﾠinner	 ﾠor	 ﾠtrailing	 ﾠregions	 ﾠwhich	 ﾠare	 ﾠ
thought	 ﾠto	 ﾠbe	 ﾠdragged	 ﾠalong	 ﾠpassively.	 ﾠOne	 ﾠcharacteristic	 ﾠof	 ﾠcollective	 ﾠmigration	 ﾠis	 ﾠthe	 ﾠ
assembly	 ﾠof	 ﾠa	 ﾠspecific	 ﾠform	 ﾠof	 ﾠcortical	 ﾠactin	 ﾠfilaments	 ﾠalong	 ﾠcell-ﾭ‐cell	 ﾠjunctions,	 ﾠwhich	 ﾠallow	 ﾠ
the	 ﾠconcerted	 ﾠmovement	 ﾠof	 ﾠthe	 ﾠmulticellular	 ﾠbody	 ﾠ[47].	 ﾠ
Collective	 ﾠcell	 ﾠmigration	 ﾠis	 ﾠpredominantly	 ﾠfound	 ﾠin	 ﾠhighly	 ﾠdifferentiated	 ﾠtumours,	 ﾠsuch	 ﾠas	 ﾠ
oral	 ﾠsquamous-ﾭ‐cell	 ﾠcarcinoma	 ﾠ[48]	 ﾠand	 ﾠcolon	 ﾠcarcinoma	 ﾠ[49],	 ﾠwhereas	 ﾠsingle	 ﾠcell	 ﾠ
migration	 ﾠis	 ﾠbelieved	 ﾠto	 ﾠprovide	 ﾠa	 ﾠmeans	 ﾠfor	 ﾠthe	 ﾠdissemination	 ﾠof	 ﾠhaematological	 ﾠ
neoplasias.	 ﾠTravelling	 ﾠas	 ﾠa	 ﾠconnective	 ﾠunit	 ﾠis	 ﾠthought	 ﾠto	 ﾠprovide	 ﾠadvantages	 ﾠduring	 ﾠ
tumourigenesis.	 ﾠFirstly,	 ﾠthe	 ﾠlarge	 ﾠcell	 ﾠmass	 ﾠcan	 ﾠproduce	 ﾠa	 ﾠhigher	 ﾠconcentration	 ﾠof	 ﾠ
pro-ﾭ‐migratory	 ﾠas	 ﾠwell	 ﾠas	 ﾠpro-ﾭ‐survival	 ﾠsignals	 ﾠthan	 ﾠsingle	 ﾠcells,	 ﾠthereby	 ﾠincreasing	 ﾠthe	 ﾠ
overall	 ﾠchances	 ﾠof	 ﾠsurvival	 ﾠand	 ﾠinvasion.	 ﾠSecondly,	 ﾠinner	 ﾠcells	 ﾠof	 ﾠthe	 ﾠsheet	 ﾠor	 ﾠcluster	 ﾠare	 ﾠ
protected	 ﾠfrom	 ﾠimmunosurveillance,	 ﾠirradiation	 ﾠand	 ﾠcytostatic	 ﾠdrugs	 ﾠ[50].	 ﾠThirdly,	 ﾠless	 ﾠ
motile	 ﾠcells,	 ﾠwhich	 ﾠmay	 ﾠpossess	 ﾠother	 ﾠadvantageous	 ﾠbiological	 ﾠabilities,	 ﾠcan	 ﾠwork	 ﾠtogether	 ﾠ
with	 ﾠhighly	 ﾠmobile	 ﾠcells	 ﾠas	 ﾠone	 ﾠfunctional	 ﾠunit	 ﾠ[35].	 ﾠ
1.1.3.4  Plasticity in tumour cell migration 
Although	 ﾠmost	 ﾠcell	 ﾠtypes	 ﾠpreferentially	 ﾠemploy	 ﾠa	 ﾠparticular	 ﾠtype	 ﾠof	 ﾠmigration,	 ﾠchanges	 ﾠin	 ﾠ
the	 ﾠmicroenvironment	 ﾠ(such	 ﾠas	 ﾠfluctuations	 ﾠin	 ﾠthe	 ﾠECM	 ﾠdensity)	 ﾠor	 ﾠcellular	 ﾠproperties	 ﾠ
(such	 ﾠas	 ﾠloss-ﾭ‐of-ﾭ‐function	 ﾠmutations	 ﾠof	 ﾠadhesion	 ﾠreceptors)	 ﾠcan	 ﾠinduce	 ﾠa	 ﾠswitch	 ﾠfrom	 ﾠone	 ﾠ
migration	 ﾠmode	 ﾠto	 ﾠanother,	 ﾠrather	 ﾠthan	 ﾠinhibiting	 ﾠmotility	 ﾠaltogether	 ﾠ(Figure	 ﾠ1-ﾭ‐4)	 ﾠ[51].	 ﾠ
The	 ﾠmost	 ﾠwell-ﾭ‐established	 ﾠexample	 ﾠof	 ﾠtumour	 ﾠcell	 ﾠplasticity	 ﾠis	 ﾠcalled	 ﾠ
epithelial-ﾭ‐to-ﾭ‐mesenchymal	 ﾠtransition	 ﾠ(EMT)	 ﾠand	 ﾠis	 ﾠmarked	 ﾠby	 ﾠthe	 ﾠloss	 ﾠof	 ﾠcell-ﾭ‐cell	 ﾠjunctions	 ﾠ
while	 ﾠadhesive	 ﾠand	 ﾠproteolytic	 ﾠcapacities	 ﾠare	 ﾠretained.	 ﾠEMT	 ﾠspontaneously	 ﾠoccurs	 ﾠduring	 ﾠ
the	 ﾠcourse	 ﾠof	 ﾠtumour	 ﾠprogression	 ﾠand	 ﾠhas	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠan	 ﾠincreased	 ﾠrisk	 ﾠin	 ﾠmetastatic	 ﾠ
spread	 ﾠand	 ﾠpoor	 ﾠprognosis	 ﾠ[52-ﾭ‐54].	 ﾠIn	 ﾠcontrast,	 ﾠthe	 ﾠprocess	 ﾠof	 ﾠcollective-ﾭ‐to-ﾭ‐amoeboid	 ﾠ
transition	 ﾠ(CAT)	 ﾠis	 ﾠcharacterised	 ﾠby	 ﾠthe	 ﾠdissemination	 ﾠof	 ﾠsingle	 ﾠcells	 ﾠdisplaying	 ﾠan	 ﾠ
amoeboid	 ﾠmigration	 ﾠmode,	 ﾠwhich	 ﾠcan	 ﾠdispense	 ﾠwith	 ﾠβ1	 ﾠintegrin-ﾭ‐mediated	 ﾠadhesion	 ﾠand	 ﾠ
ECM	 ﾠproteolysis.	 ﾠIn	 ﾠaddition,	 ﾠfactors,	 ﾠincluding	 ﾠweakening	 ﾠof	 ﾠcell-ﾭ‐matrix	 ﾠinteractions	 ﾠChapter 1 – Introduction    25 
observed	 ﾠin	 ﾠloose	 ﾠinterstitial	 ﾠtissues,	 ﾠinhibition	 ﾠof	 ﾠECM	 ﾠremodelling	 ﾠor	 ﾠaugmentation	 ﾠof	 ﾠ
RhoA/ROCK	 ﾠsignalling,	 ﾠcan	 ﾠtrigger	 ﾠmesenchymal-ﾭ‐to-ﾭ‐amoeboid	 ﾠtransition	 ﾠ(MAT)	 ﾠ[35,	 ﾠ51].	 ﾠ
Notably,	 ﾠanti-ﾭ‐invasive	 ﾠdrugs,	 ﾠtargeting	 ﾠone	 ﾠmode	 ﾠof	 ﾠmigration	 ﾠonly,	 ﾠcan	 ﾠinduce	 ﾠa	 ﾠswitch	 ﾠin	 ﾠ
motile	 ﾠbehaviour	 ﾠ[34].	 ﾠTherefore,	 ﾠit	 ﾠis	 ﾠbelieved	 ﾠthat	 ﾠa	 ﾠsuccessful	 ﾠanti-ﾭ‐invasive	 ﾠtherapeutic	 ﾠ
strategy	 ﾠmust	 ﾠtarget	 ﾠmultiple	 ﾠmotility	 ﾠpathways.	 ﾠ
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Figure 1-4 Plasticity of tumour cell migration 
Changes in the microenvironment can induce a switch from one migration mode to another rather than 
inhibiting cell motility. Depicted are migration transitions monitored in vivo. Adapted from [35] 
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1.2  Mammalian MAPK pathways 
1.2.1  The history of the MAPK cascade 
The	 ﾠfirst	 ﾠmammalian	 ﾠmitogen-ﾭ‐activated	 ﾠprotein	 ﾠkinase	 ﾠ(MAPK)	 ﾠwas	 ﾠidentified	 ﾠin	 ﾠ1990	 ﾠin	 ﾠ
an	 ﾠattempt	 ﾠto	 ﾠisolate	 ﾠprotein	 ﾠkinases	 ﾠactivated	 ﾠby	 ﾠgrowth	 ﾠfactors.	 ﾠThe	 ﾠpurified	 ﾠprotein	 ﾠ
was	 ﾠphosphorylated	 ﾠfollowing	 ﾠinsulin	 ﾠtreatment,	 ﾠ44	 ﾠkDa	 ﾠin	 ﾠsize	 ﾠand	 ﾠcontained	 ﾠsequences	 ﾠ
reminiscent	 ﾠof	 ﾠserine/threonine	 ﾠprotein	 ﾠkinases.	 ﾠWith	 ﾠthe	 ﾠhelp	 ﾠof	 ﾠdegenerate	 ﾠprimers	 ﾠ
based	 ﾠon	 ﾠthese	 ﾠsequences,	 ﾠextracellular	 ﾠsignal-ﾭ‐regulated	 ﾠkinase	 ﾠ1	 ﾠ(ERK1)	 ﾠwas	 ﾠcloned	 ﾠfrom	 ﾠ
rat	 ﾠfibroblasts	 ﾠ[55].	 ﾠERK1	 ﾠshowed	 ﾠan	 ﾠover	 ﾠ50%	 ﾠsequence	 ﾠidentity	 ﾠto	 ﾠthe	 ﾠyeast	 ﾠprotein	 ﾠ
kinases,	 ﾠKss1	 ﾠand	 ﾠFus3,	 ﾠwhich	 ﾠhad	 ﾠpreviously	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠregulate	 ﾠthe	 ﾠcell	 ﾠcycle	 ﾠin	 ﾠ
response	 ﾠto	 ﾠpheromones	 ﾠ[56,	 ﾠ57].	 ﾠSubsequent	 ﾠscreening	 ﾠof	 ﾠa	 ﾠrat	 ﾠbrain	 ﾠcDNA	 ﾠlibrary	 ﾠwith	 ﾠ
an	 ﾠERK1	 ﾠprobe	 ﾠunder	 ﾠlow	 ﾠstringency	 ﾠled	 ﾠto	 ﾠthe	 ﾠidentification	 ﾠof	 ﾠERK2	 ﾠand	 ﾠERK3,	 ﾠand	 ﾠthis	 ﾠ
marked	 ﾠthe	 ﾠbirth	 ﾠof	 ﾠa	 ﾠnew	 ﾠprotein	 ﾠkinase	 ﾠfamily	 ﾠ[58].	 ﾠTraditionally,	 ﾠkinase	 ﾠactivities	 ﾠof	 ﾠ
ERK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠwere	 ﾠmeasured	 ﾠusing	 ﾠthe	 ﾠtwo	 ﾠsubstrates,	 ﾠmyelin	 ﾠbasic	 ﾠprotein	 ﾠ(MBP)	 ﾠand	 ﾠ
microtubule-ﾭ‐associated	 ﾠprotein-ﾭ‐2	 ﾠ(MAP2),	 ﾠwhich	 ﾠgave	 ﾠrise	 ﾠto	 ﾠthe	 ﾠhistoric	 ﾠnomenclature	 ﾠof	 ﾠ
MBP	 ﾠkinase	 ﾠand	 ﾠMAP2	 ﾠkinase.	 ﾠIn	 ﾠthe	 ﾠfollowing	 ﾠyears	 ﾠthe	 ﾠMAP	 ﾠacronym	 ﾠwas	 ﾠretained	 ﾠwith	 ﾠ
a	 ﾠnovel	 ﾠdenotation	 ﾠin	 ﾠorder	 ﾠto	 ﾠacknowledge	 ﾠthe	 ﾠactivation	 ﾠof	 ﾠthe	 ﾠkinases	 ﾠafter	 ﾠmitogen	 ﾠ
stimulation,	 ﾠwhich	 ﾠoriginally	 ﾠled	 ﾠto	 ﾠits	 ﾠidentification	 ﾠ[59].	 ﾠ
MAPK	 ﾠenzymes	 ﾠare	 ﾠactivated	 ﾠvia	 ﾠa	 ﾠphosphorylation	 ﾠ(kinase)	 ﾠcascade,	 ﾠwhich	 ﾠis	 ﾠ
evolutionary	 ﾠconserved	 ﾠin	 ﾠplants,	 ﾠfungi	 ﾠand	 ﾠanimals.	 ﾠClassically,	 ﾠthe	 ﾠcascade	 ﾠis	 ﾠorganised	 ﾠ
into	 ﾠa	 ﾠfour-ﾭ‐tier	 ﾠmodule	 ﾠcomprising	 ﾠthe	 ﾠMAP	 ﾠkinase	 ﾠkinase	 ﾠkinase	 ﾠ(MAPKKK),	 ﾠMAP	 ﾠkinase	 ﾠ
kinase	 ﾠ(MAPKK),	 ﾠMAP	 ﾠkinase	 ﾠ(MAPK)	 ﾠand	 ﾠthe	 ﾠMAP	 ﾠkinase-ﾭ‐activated	 ﾠ
protein	 ﾠ(MAPKAP)	 ﾠ[59].	 ﾠThe	 ﾠsequential	 ﾠactivation	 ﾠof	 ﾠkinases	 ﾠenables	 ﾠamplification	 ﾠof	 ﾠthe	 ﾠ
input	 ﾠsignal,	 ﾠfeedback	 ﾠregulation	 ﾠas	 ﾠwell	 ﾠas	 ﾠthe	 ﾠintegration	 ﾠof	 ﾠinformation	 ﾠfrom	 ﾠother	 ﾠ
signalling	 ﾠpathways.	 ﾠThus,	 ﾠcrosstalk	 ﾠof	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠMAPK	 ﾠpathway	 ﾠwith	 ﾠother	 ﾠ
signalling	 ﾠcircuits	 ﾠenables	 ﾠfine	 ﾠtuning	 ﾠ(i.e.	 ﾠenhancement,	 ﾠsuppression	 ﾠand	 ﾠlocalisation)	 ﾠof	 ﾠ
the	 ﾠtransmitted	 ﾠsignal.	 ﾠ
1.2.2  Overview of the six distinct mammalian MAPK pathways 
In	 ﾠmammals,	 ﾠnearly	 ﾠ20	 ﾠMAPK	 ﾠhave	 ﾠthus	 ﾠfar	 ﾠbeen	 ﾠidentified	 ﾠ(Table	 ﾠ1-ﾭ‐1).	 ﾠBased	 ﾠon	 ﾠtheir	 ﾠ
sequence	 ﾠsimilarity	 ﾠthey	 ﾠare	 ﾠgrouped	 ﾠinto	 ﾠsix	 ﾠdistinct	 ﾠMAPK	 ﾠpathways,	 ﾠwhich	 ﾠregulate	 ﾠ	 ﾠChapter 1 – Introduction    28 



























MAPK1  ERK2, p42MAPK, 
MAPK2 
85% identical to ERK1  [58] 
MAPK3  ERK1, p44MAPK  First MAPK to be identified  [55] 
MAPK4  ERK4, p63MAPK  Cloned in 1992 by virtue of its homology to 
ERK1 
[60] 
MAPK6  ERK3, p97MAPK  Suggested to have evolved recently through 
gene duplication 
[59] 
MAPK7  ERK5, BMK1  N-terminal domain exhibits a 66% sequence 
similarity to ERK1/2  
[61] 
MAPK8  JNK1, SAPKγ  Ubiquitously expressed with multiple splice 
variants 
[62] 
MAPK9  JNK2, SAPKα  Ubiquitously expressed with multiple splice 
variants 
[62] 
MAPK10  JNK3, SAPKβ  Expression restricted to brain, heart and testis  [62] 
MAPK11  p38β  Phosphorylates MK2 and is sensitive to 
pyridinyl imidazole compounds 
[63] 




MAPK13  p38δ  Activated by novel PKC (nPKC) in response to 
TPA 
[65] 
MAPK14  p38α  Phosphorylates MK2 and is sensitive to 
pyridinyl imidazole compounds 
[63] 
MAPK15  ERK7, ERK8  Breast cancer progression correlated with loss 






















































NLK  Nemo-like kinase  Regulates Wnt/β-catenin signalling positively 
and negatively 
Phosphoacceptor site: TQY 
[67, 
68] 
MAK  Male germ cell 
associated kinase 
Transcriptionally induced by androgen in 
prostate cancer 
Phosphoacceptor site: TDY 
[69] 
MRK  MAK-related kinase  87% identical to MAK, role in heart 
development  
Phosphoacceptor site: TDY 
[70] 
MOK  MAPK/MAK/MRK 
overlapping kinase 
Activated by okadaic acid and phorbol ester, 
Phosphoacceptor site: TEY 
[71] 
KKIALRE  CDKL1  Related to cdc2 kinase,  
Phosphoacceptor site: TDY 
[72] 
KKIAMRE  CDKL2  Phosphorylation of TDY motif not required for 
kinase activity 
Phosphoacceptor site: TDY 
[73] 
Table 1-1 Overview of all Mammalian MAPK identified 
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diverse	 ﾠcellular	 ﾠfunctions	 ﾠsuch	 ﾠas	 ﾠembryogenesis,	 ﾠgrowth,	 ﾠproliferation,	 ﾠapoptosis,	 ﾠ
differentiation	 ﾠand	 ﾠmigration	 ﾠ[59,	 ﾠ62,	 ﾠ63].	 ﾠPhylogenetically,	 ﾠMAPKs	 ﾠbelong	 ﾠto	 ﾠthe	 ﾠCMGC	 ﾠ
family	 ﾠof	 ﾠprotein	 ﾠkinases	 ﾠ(termed	 ﾠafter	 ﾠits	 ﾠmembers,	 ﾠi.e.	 ﾠcyclin-ﾭ‐dependent	 ﾠkinases	 ﾠ(CDKs),	 ﾠ
MAPKs,	 ﾠglycogen	 ﾠsynthase	 ﾠkinases	 ﾠ(GSKs)	 ﾠand	 ﾠCDK-ﾭ‐like	 ﾠkinases	 ﾠ(CLK))	 ﾠ[74].	 ﾠMembers	 ﾠof	 ﾠ
the	 ﾠMAPK	 ﾠbranch	 ﾠare	 ﾠfurther	 ﾠsubdivided	 ﾠinto	 ﾠconventional	 ﾠand	 ﾠatypical	 ﾠkinases	 ﾠ(Table	 ﾠ
1-ﾭ‐2).	 ﾠConventional	 ﾠMAPK	 ﾠinclude	 ﾠERK1/2,	 ﾠERK5,	 ﾠp38s	 ﾠand	 ﾠJNKs	 ﾠ(c-ﾭ‐Jun	 ﾠN-ﾭ‐terminal	 ﾠkinases),	 ﾠ
which	 ﾠcontain	 ﾠa	 ﾠThr-ﾭ‐Xaa-ﾭ‐Tyr	 ﾠmotif	 ﾠin	 ﾠthe	 ﾠactivation	 ﾠloop	 ﾠand	 ﾠare	 ﾠactivated	 ﾠby	 ﾠMEKs	 ﾠ
(MAP/ERK	 ﾠkinases).	 ﾠAtypical	 ﾠkinases,	 ﾠincluding	 ﾠERK3/4	 ﾠand	 ﾠERK7/8,	 ﾠeither	 ﾠcontain	 ﾠa	 ﾠsingle	 ﾠ
phosphoacceptor	 ﾠsite	 ﾠin	 ﾠthe	 ﾠactivation	 ﾠloop	 ﾠor	 ﾠpossess	 ﾠa	 ﾠnovel	 ﾠactivation	 ﾠmechanism	 ﾠ
dispensable	 ﾠof	 ﾠMEKs	 ﾠ[75].	 ﾠAll	 ﾠMAPKs,	 ﾠhowever,	 ﾠdisplay	 ﾠtwo	 ﾠcommon	 ﾠfeatures.	 ﾠFirstly,	 ﾠ
they	 ﾠall	 ﾠpreferentially	 ﾠphosphorylate	 ﾠserine	 ﾠor	 ﾠthreonine	 ﾠresidues	 ﾠfollowed	 ﾠby	 ﾠproline	 ﾠin	 ﾠ
their	 ﾠrespective	 ﾠMAPKAP.	 ﾠSecondly,	 ﾠall	 ﾠMAPKs	 ﾠare	 ﾠactivated	 ﾠby	 ﾠphosphorylation	 ﾠin	 ﾠthe	 ﾠ
absence	 ﾠof	 ﾠa	 ﾠregulatory	 ﾠsubunit	 ﾠ[59].	 ﾠ
The	 ﾠfollowing	 ﾠsubsections	 ﾠaim	 ﾠto	 ﾠhighlight	 ﾠthe	 ﾠmain	 ﾠfeatures	 ﾠof	 ﾠthe	 ﾠdifferent	 ﾠMAPK	 ﾠ
groups	 ﾠidentified	 ﾠto	 ﾠdate	 ﾠwith	 ﾠthe	 ﾠexception	 ﾠof	 ﾠERK1/2,	 ﾠwhich	 ﾠwill	 ﾠbe	 ﾠcovered	 ﾠin	 ﾠdetail	 ﾠin	 ﾠ
section	 ﾠ1.3.	 ﾠ	 ﾠ
1.2.2.1  c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (SAPK) 
The	 ﾠfirst	 ﾠJNK	 ﾠfamily	 ﾠmember	 ﾠwas	 ﾠpurified	 ﾠfrom	 ﾠrat	 ﾠlivers	 ﾠafter	 ﾠcycloheximide	 ﾠtreatment	 ﾠin	 ﾠ
1990	 ﾠ[76].	 ﾠShortly	 ﾠafterwards,	 ﾠtwo	 ﾠfurther	 ﾠJNKs	 ﾠwere	 ﾠpurified	 ﾠin	 ﾠGST-ﾭ‐pulldown	 ﾠassays	 ﾠ
using	 ﾠc-ﾭ‐Jun	 ﾠas	 ﾠa	 ﾠbait	 ﾠ[77].	 ﾠThe	 ﾠJNK	 ﾠfamily	 ﾠof	 ﾠMAPK	 ﾠis	 ﾠencoded	 ﾠby	 ﾠthree	 ﾠgenes	 ﾠ(jnk1,	 ﾠjnk2	 ﾠ
and	 ﾠjnk3),	 ﾠwhich	 ﾠgive	 ﾠrise	 ﾠto	 ﾠ13	 ﾠsplice	 ﾠvariants.	 ﾠJNK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠare	 ﾠubiquitously	 ﾠexpressed,	 ﾠ
whereas	 ﾠJNK3’s	 ﾠexpression	 ﾠis	 ﾠrestricted	 ﾠto	 ﾠthe	 ﾠbrain,	 ﾠheart	 ﾠand	 ﾠtestis.	 ﾠNotably,	 ﾠJNKs	 ﾠare	 ﾠ
predominantly	 ﾠactivated	 ﾠby	 ﾠstress	 ﾠsignals	 ﾠsuch	 ﾠas	 ﾠcytokines,	 ﾠUV	 ﾠradiation,	 ﾠoxidative	 ﾠstress,	 ﾠ
growth	 ﾠfactor	 ﾠdeprivation	 ﾠand	 ﾠDNA-ﾭ‐damaging	 ﾠagents.	 ﾠHence,	 ﾠthese	 ﾠkinases	 ﾠhave	 ﾠalso	 ﾠ
been	 ﾠdescribed	 ﾠas	 ﾠthe	 ﾠfamily	 ﾠof	 ﾠstress-ﾭ‐activated	 ﾠprotein	 ﾠkinases	 ﾠ(SAPK)	 ﾠ[59,	 ﾠ78].	 ﾠMEK4	 ﾠ
and	 ﾠ-ﾭ‐7	 ﾠactivate	 ﾠJNKs	 ﾠsynergistically	 ﾠat	 ﾠthe	 ﾠThr-ﾭ‐Pro-ﾭ‐Tyr	 ﾠmotif	 ﾠin	 ﾠthe	 ﾠactivation	 ﾠloop,	 ﾠwith	 ﾠ
MEK4	 ﾠpreferentially	 ﾠphosphorylating	 ﾠthe	 ﾠtyrosine	 ﾠresidue	 ﾠand	 ﾠMEK7	 ﾠphosphorylating	 ﾠthe	 ﾠ
threonine	 ﾠresidue.	 ﾠFollowing	 ﾠactivation,	 ﾠJNKs	 ﾠtranslocate	 ﾠfrom	 ﾠthe	 ﾠcytoplasm	 ﾠto	 ﾠthe	 ﾠ
nucleus,	 ﾠwhere	 ﾠthey	 ﾠphosphorylate	 ﾠand	 ﾠregulate	 ﾠtranscription	 ﾠfactors	 ﾠsuch	 ﾠas	 ﾠc-ﾭ‐Jun,	 ﾠATF2	 ﾠ
and	 ﾠp53	 ﾠ[79,	 ﾠ80].	 ﾠTo	 ﾠdate	 ﾠvery	 ﾠlittle	 ﾠis	 ﾠknown	 ﾠabout	 ﾠJNKs’	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠcytoplasmic	 ﾠ
effectors.	 ﾠMEK4	 ﾠand	 ﾠ-ﾭ‐7	 ﾠthemselves	 ﾠare	 ﾠactivated	 ﾠby	 ﾠnumerous	 ﾠ	 ﾠChapter 1 – Introduction    30 
MAPKKKs,	 ﾠincluding	 ﾠMEKK1-ﾭ‐4,	 ﾠMLK2/3,	 ﾠYTpl-ﾭ‐2,	 ﾠDLK,	 ﾠTAO1/2,	 ﾠTAK1	 ﾠand	 ﾠASK1/2	 ﾠ(Table	 ﾠ
1-ﾭ‐2)	 ﾠ[62].The	 ﾠrole	 ﾠof	 ﾠJNK	 ﾠkinases	 ﾠin	 ﾠtumour	 ﾠdevelopment	 ﾠis	 ﾠhighly	 ﾠcontroversial.	 ﾠSome	 ﾠ
reports	 ﾠhave	 ﾠshown	 ﾠa	 ﾠpro-ﾭ‐tumourigenic	 ﾠrole	 ﾠ[81-ﾭ‐83],	 ﾠwhereas	 ﾠothers	 ﾠhave	 ﾠdemonstrated	 ﾠ
an	 ﾠanti-ﾭ‐tumourigenic	 ﾠcapacity	 ﾠfor	 ﾠJNK	 ﾠsignalling	 ﾠ[84].	 ﾠJNK	 ﾠactivity	 ﾠenhances	 ﾠtumour	 ﾠ
development	 ﾠby	 ﾠdecreasing	 ﾠthe	 ﾠproliferation	 ﾠinhibitor	 ﾠp21
CIP1,	 ﾠincreasing	 ﾠsignalling	 ﾠof	 ﾠthe	 ﾠ
growth	 ﾠpromoter	 ﾠc-ﾭ‐Myc,	 ﾠand	 ﾠallowing	 ﾠthe	 ﾠformation	 ﾠof	 ﾠan	 ﾠinflammatory	 ﾠenvironment,	 ﾠ
which	 ﾠhas	 ﾠrecently	 ﾠbeen	 ﾠappreciated	 ﾠas	 ﾠa	 ﾠnovel	 ﾠhallmark	 ﾠof	 ﾠcancer.	 ﾠIn	 ﾠcontrast,	 ﾠJNK	 ﾠ
signalling	 ﾠis	 ﾠalso	 ﾠrequired	 ﾠfor	 ﾠthe	 ﾠinduction	 ﾠof	 ﾠapoptosis,	 ﾠwhich	 ﾠmight	 ﾠaccount	 ﾠfor	 ﾠits	 ﾠ
putative	 ﾠtumour	 ﾠsuppressive	 ﾠfunction	 ﾠ[85].	 ﾠThus,	 ﾠthe	 ﾠusefulness	 ﾠof	 ﾠJNK	 ﾠinhibitors	 ﾠin	 ﾠ
clinical	 ﾠsettings	 ﾠis	 ﾠstill	 ﾠin	 ﾠdebate.	 ﾠ
1.2.2.2  p38 kinases 
The	 ﾠfamily	 ﾠof	 ﾠp38	 ﾠkinases	 ﾠform	 ﾠanother	 ﾠgroup	 ﾠof	 ﾠMAPKs	 ﾠactivated	 ﾠby	 ﾠstress	 ﾠsignals.	 ﾠIn	 ﾠ
contrast	 ﾠto	 ﾠJNK	 ﾠenzymes,	 ﾠstress	 ﾠstimuli	 ﾠnot	 ﾠonly	 ﾠactivate	 ﾠp38s,	 ﾠbut	 ﾠalso	 ﾠinduce	 ﾠtheir	 ﾠgene	 ﾠ
expression.	 ﾠFour	 ﾠgenes	 ﾠencode	 ﾠthis	 ﾠgroup	 ﾠof	 ﾠenzymes	 ﾠcomprising,	 ﾠi.e.	 ﾠp38α,	 ﾠp38β,	 ﾠp38γ	 ﾠ
(which	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠtermed	 ﾠERK6),	 ﾠand	 ﾠp38δ.	 ﾠOnly	 ﾠthe	 ﾠgene	 ﾠencoding	 ﾠthe	 ﾠα-ﾭ‐isoform	 ﾠ
gives	 ﾠrise	 ﾠto	 ﾠfour	 ﾠsplice	 ﾠvariants.	 ﾠp38α	 ﾠand	 ﾠ–β	 ﾠare	 ﾠubiquitously	 ﾠexpressed,	 ﾠwhereas	 ﾠp38γ	 ﾠ
and	 ﾠ–δ	 ﾠexpression	 ﾠis	 ﾠtissue	 ﾠrestricted	 ﾠ[63].	 ﾠNotably,	 ﾠp38α	 ﾠand	 ﾠ–β	 ﾠactivity	 ﾠis	 ﾠinhibited	 ﾠby	 ﾠ
pyridinyl	 ﾠimidazole,	 ﾠwhich	 ﾠoriginally	 ﾠled	 ﾠto	 ﾠits	 ﾠidentification	 ﾠin	 ﾠ1994	 ﾠ[86],	 ﾠwhereas	 ﾠp38γ	 ﾠ
and	 ﾠ–δ	 ﾠare	 ﾠinsensitive	 ﾠto	 ﾠthe	 ﾠdrug.	 ﾠFurthermore,	 ﾠp38	 ﾠisoforms	 ﾠshow	 ﾠdifferences	 ﾠin	 ﾠtheir	 ﾠ
substrate	 ﾠspecificity.	 ﾠWhereas	 ﾠthe	 ﾠα-ﾭ‐	 ﾠand	 ﾠβ-ﾭ‐isoform	 ﾠphosphorylate	 ﾠMAPKAP	 ﾠkinase-ﾭ‐2	 ﾠ
(MK2),	 ﾠp38γ	 ﾠand	 ﾠ–δ	 ﾠdo	 ﾠnot	 ﾠ[63].	 ﾠp38	 ﾠenzymes	 ﾠare	 ﾠgenerally	 ﾠactivated	 ﾠby	 ﾠMEK3	 ﾠand	 ﾠMEK6,	 ﾠ
although	 ﾠMEK4	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠcontribute	 ﾠto	 ﾠthe	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠdistinct	 ﾠ
Thr-ﾭ‐Gly-ﾭ‐Tyr	 ﾠmotif	 ﾠupon	 ﾠUV	 ﾠradiation	 ﾠin	 ﾠvivo	 ﾠ[87].	 ﾠMEK3	 ﾠand	 ﾠ-ﾭ‐6	 ﾠin	 ﾠturn	 ﾠare	 ﾠactivated	 ﾠby	 ﾠ
MAPKKKs	 ﾠsimilar	 ﾠto	 ﾠJNK	 ﾠenzymes	 ﾠsuch	 ﾠas	 ﾠMEKK1-ﾭ‐4,	 ﾠTAO1/2,	 ﾠTAK1	 ﾠand	 ﾠASK1/2.	 ﾠTo	 ﾠdate	 ﾠ
little	 ﾠis	 ﾠknown	 ﾠas	 ﾠto	 ﾠhow	 ﾠstress	 ﾠstimuli	 ﾠcan	 ﾠproduce	 ﾠa	 ﾠdistinct	 ﾠp38	 ﾠor	 ﾠJNK	 ﾠsignalling	 ﾠoutput	 ﾠ
with	 ﾠoverlapping	 ﾠMAPKKKs	 ﾠ(Table	 ﾠ1-ﾭ‐2).	 ﾠ
Interestingly,	 ﾠdisruption	 ﾠof	 ﾠthe	 ﾠp38	 ﾠpathway	 ﾠin	 ﾠmice	 ﾠleads	 ﾠto	 ﾠincreased	 ﾠtumourigenesis	 ﾠ
due	 ﾠto	 ﾠdefects	 ﾠin	 ﾠgrowth	 ﾠarrest	 ﾠ[87].	 ﾠFurthermore,	 ﾠa	 ﾠdecrease	 ﾠin	 ﾠp38	 ﾠactivity	 ﾠhas	 ﾠbeen	 ﾠ
observed	 ﾠin	 ﾠhepatocellular	 ﾠcarcinomas	 ﾠin	 ﾠcomparison	 ﾠto	 ﾠthe	 ﾠadjacent	 ﾠnormal	 ﾠtissue	 ﾠ[88].	 ﾠ
Taking	 ﾠthese	 ﾠfinding	 ﾠtogether,	 ﾠp38	 ﾠsignalling	 ﾠmight	 ﾠhave	 ﾠtumour	 ﾠsuppressive	 ﾠfunctions	 ﾠby	 ﾠ
inducing	 ﾠcell	 ﾠcycle	 ﾠarrest,	 ﾠsenescence	 ﾠand	 ﾠapoptosis	 ﾠ[89].	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TEY  TPY  TGY  TEY  SEG  TEY 
Predicted size 
(kDa) 
41/43  46  38  98  97/63  60 
Encoding genes  2  3  4  1  2  1 
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2  1 (ERK3) 
1 (ERK4) 
3 
Table 1-2 Overview of the common and divergent features of the 6 distinct mammalian MAPK 
pathways 
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1.2.2.3  ERK5 
ERK5	 ﾠwas	 ﾠidentified	 ﾠby	 ﾠtwo	 ﾠindependent	 ﾠresearch	 ﾠgroups	 ﾠin	 ﾠ1995	 ﾠ[90,	 ﾠ91]	 ﾠand	 ﾠis	 ﾠone	 ﾠof	 ﾠ
the	 ﾠlargest	 ﾠMAPKs	 ﾠknown	 ﾠto	 ﾠdate	 ﾠ(98	 ﾠkDa).	 ﾠTherefore,	 ﾠit	 ﾠwas	 ﾠoriginally	 ﾠtermed	 ﾠthe	 ﾠbig	 ﾠ
MAP	 ﾠkinase	 ﾠ1	 ﾠ(BMK1)	 ﾠby	 ﾠLee	 ﾠet	 ﾠal.	 ﾠ[90].	 ﾠAlternative	 ﾠsplicing	 ﾠgives	 ﾠrise	 ﾠto	 ﾠ4	 ﾠdistinct	 ﾠ
transcript	 ﾠvariants	 ﾠand	 ﾠ2	 ﾠisoforms.	 ﾠThe	 ﾠN-ﾭ‐terminal	 ﾠhalf	 ﾠof	 ﾠthe	 ﾠprotein,	 ﾠcomprising	 ﾠthe	 ﾠ
kinase	 ﾠdomain	 ﾠwith	 ﾠa	 ﾠThr-ﾭ‐Glu-ﾭ‐Tyr	 ﾠactivation	 ﾠmotif,	 ﾠexhibits	 ﾠa	 ﾠ66%	 ﾠsequence	 ﾠsimilarity	 ﾠto	 ﾠ
ERK1/2	 ﾠ[61].	 ﾠERK5’s	 ﾠunique	 ﾠC-ﾭ‐terminal	 ﾠdomain,	 ﾠwhich	 ﾠcontains	 ﾠa	 ﾠbipartite	 ﾠnuclear	 ﾠ
localisation	 ﾠsignal	 ﾠ(NLS)	 ﾠ[92]	 ﾠand	 ﾠhas	 ﾠtranscriptional	 ﾠactivation	 ﾠactivity	 ﾠ[93],	 ﾠsets	 ﾠthis	 ﾠ
enzyme	 ﾠapart	 ﾠfrom	 ﾠother	 ﾠMAPKs	 ﾠ[94].	 ﾠIn	 ﾠunstimulated	 ﾠcells,	 ﾠintramolecular	 ﾠinteractions	 ﾠ
between	 ﾠthe	 ﾠN-ﾭ‐	 ﾠand	 ﾠC-ﾭ‐terminal	 ﾠdomain	 ﾠpromote	 ﾠnuclear	 ﾠexport.	 ﾠIt	 ﾠis	 ﾠbelieved	 ﾠthat	 ﾠthe	 ﾠ
association	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠdomains	 ﾠallows	 ﾠthe	 ﾠformation	 ﾠof	 ﾠa	 ﾠregion	 ﾠwhich	 ﾠitself	 ﾠmight	 ﾠ
constitute	 ﾠa	 ﾠnuclear	 ﾠexport	 ﾠsignal	 ﾠ(NES),	 ﾠor	 ﾠallow	 ﾠbinding	 ﾠto	 ﾠa	 ﾠcytoplasmic	 ﾠanchor	 ﾠprotein.	 ﾠ
Upon	 ﾠkinase	 ﾠactivation	 ﾠa	 ﾠconformational	 ﾠchange	 ﾠdisrupts	 ﾠthis	 ﾠassociation	 ﾠand	 ﾠpromotes	 ﾠ
nuclear	 ﾠlocalisation	 ﾠof	 ﾠERK5	 ﾠ[92],	 ﾠwhere	 ﾠits	 ﾠtwo	 ﾠfunctional	 ﾠdomains	 ﾠallow	 ﾠeither	 ﾠ
phosphorylation	 ﾠof	 ﾠtarget	 ﾠmolecules	 ﾠ(N-ﾭ‐terminal	 ﾠregion)	 ﾠor	 ﾠenhancement	 ﾠof	 ﾠtranscription	 ﾠ
activity	 ﾠ(C-ﾭ‐terminal	 ﾠregion)	 ﾠ[93].	 ﾠDespite	 ﾠthe	 ﾠsimilarity	 ﾠto	 ﾠERK1/2,	 ﾠthis	 ﾠenzyme	 ﾠis	 ﾠactivated	 ﾠ
by	 ﾠa	 ﾠunique	 ﾠMAPKK,	 ﾠnamely	 ﾠMEK5,	 ﾠwhich	 ﾠitself	 ﾠis	 ﾠphosphorylated	 ﾠby	 ﾠMEKK2/3,	 ﾠalso	 ﾠ
associated	 ﾠwith	 ﾠp38	 ﾠand	 ﾠJNK	 ﾠsignalling	 ﾠ[94].	 ﾠERK5	 ﾠis	 ﾠactivated	 ﾠin	 ﾠresponse	 ﾠto	 ﾠstress	 ﾠsignals,	 ﾠ
such	 ﾠas	 ﾠoxidative	 ﾠstress	 ﾠand	 ﾠhyperosmolarity,	 ﾠand	 ﾠto	 ﾠa	 ﾠlesser	 ﾠextent	 ﾠby	 ﾠmitogenic	 ﾠsignals,	 ﾠ
such	 ﾠas	 ﾠserum	 ﾠand	 ﾠnerve	 ﾠgrowth	 ﾠfactor	 ﾠ(NFG).	 ﾠFunctional	 ﾠstudies	 ﾠin	 ﾠcultured	 ﾠcells	 ﾠhave	 ﾠ
demonstrated	 ﾠa	 ﾠrole	 ﾠfor	 ﾠERK5	 ﾠin	 ﾠcell	 ﾠproliferation	 ﾠ[95],	 ﾠand	 ﾠmigration	 ﾠ[96].	 ﾠIn	 ﾠvivo,	 ﾠERK5	 ﾠ
was	 ﾠshown	 ﾠto	 ﾠplay	 ﾠa	 ﾠrole	 ﾠin	 ﾠblood	 ﾠvessel	 ﾠand	 ﾠheart	 ﾠdevelopment	 ﾠ[97]	 ﾠas	 ﾠwell	 ﾠas	 ﾠneural	 ﾠ
differentiation	 ﾠ(Table	 ﾠ1-ﾭ‐2)	 ﾠ[98].	 ﾠ
The	 ﾠfirst	 ﾠERK5	 ﾠsubstrate	 ﾠidentified	 ﾠwas	 ﾠmyocyte	 ﾠenhancer	 ﾠfactor	 ﾠ2C	 ﾠ(MEF2C),	 ﾠwhich	 ﾠupon	 ﾠ
phosphorylation	 ﾠenhances	 ﾠc-ﾭ‐jun	 ﾠgene	 ﾠexpression	 ﾠin	 ﾠluciferase	 ﾠassays	 ﾠ[99].	 ﾠMoreover,	 ﾠ
ERK5	 ﾠwas	 ﾠshown	 ﾠto	 ﾠphosphorylate	 ﾠknown	 ﾠERK1/2	 ﾠsubstrates	 ﾠsuch	 ﾠas	 ﾠSap1a	 ﾠand	 ﾠc-ﾭ‐Myc	 ﾠin	 ﾠ
vitro	 ﾠ[100,	 ﾠ101].	 ﾠHowever,	 ﾠto	 ﾠwhat	 ﾠextent	 ﾠERK5	 ﾠsignalling	 ﾠregulates	 ﾠthese	 ﾠtranscription	 ﾠ
factors	 ﾠin	 ﾠvivo	 ﾠin	 ﾠcomparison	 ﾠto	 ﾠERK1/2	 ﾠremains	 ﾠto	 ﾠbe	 ﾠdetermined.	 ﾠThe	 ﾠunderstanding	 ﾠof	 ﾠ
ERK5’s	 ﾠinvolvement	 ﾠin	 ﾠtumourigenesis	 ﾠis	 ﾠstill	 ﾠin	 ﾠits	 ﾠinfancy.	 ﾠRecent	 ﾠwork,	 ﾠhowever,	 ﾠshowed	 ﾠ
MEK5	 ﾠoverexpression	 ﾠin	 ﾠmetastatic	 ﾠprostate	 ﾠcancer	 ﾠbiopsies	 ﾠ[102]	 ﾠand	 ﾠincreased	 ﾠERK5	 ﾠ
activity	 ﾠin	 ﾠa	 ﾠpanel	 ﾠof	 ﾠhuman	 ﾠcancer	 ﾠcell	 ﾠlines	 ﾠ[103].	 ﾠThis	 ﾠincreased	 ﾠsignalling	 ﾠis	 ﾠthought	 ﾠto	 ﾠ
drive	 ﾠtumour	 ﾠcell	 ﾠproliferation,	 ﾠmotility	 ﾠand	 ﾠinvasion.	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1.2.2.4  ERK3/4 
ERK3	 ﾠwas	 ﾠone	 ﾠof	 ﾠthe	 ﾠfirst	 ﾠMAPKs	 ﾠto	 ﾠbe	 ﾠidentified	 ﾠalongside	 ﾠERK2	 ﾠin	 ﾠan	 ﾠattempt	 ﾠto	 ﾠclone	 ﾠ
ERK1-ﾭ‐related	 ﾠserine/threonine	 ﾠprotein	 ﾠkinases	 ﾠ[58].	 ﾠIt	 ﾠis	 ﾠencoded	 ﾠby	 ﾠone	 ﾠgene	 ﾠand	 ﾠ
translates	 ﾠinto	 ﾠa	 ﾠ97	 ﾠkDa	 ﾠprotein.	 ﾠIn	 ﾠ1992	 ﾠa	 ﾠshorter	 ﾠisoform	 ﾠ(63	 ﾠkDa),	 ﾠhighly	 ﾠhomologous	 ﾠto	 ﾠ
ERK3,	 ﾠwas	 ﾠidentified	 ﾠand	 ﾠtermed	 ﾠERK4	 ﾠ[60].	 ﾠComparative	 ﾠanalysis	 ﾠhighlighted	 ﾠa	 ﾠsimilar	 ﾠ
genomic	 ﾠarrangement	 ﾠof	 ﾠintrons	 ﾠand	 ﾠexons	 ﾠas	 ﾠwell	 ﾠas	 ﾠhigh	 ﾠsequence	 ﾠidentity	 ﾠin	 ﾠthe	 ﾠ
catalytic	 ﾠdomain	 ﾠ[104].	 ﾠThese	 ﾠobservations,	 ﾠin	 ﾠconjunction	 ﾠwith	 ﾠthe	 ﾠlack	 ﾠof	 ﾠ
ERK3/4-ﾭ‐encoding	 ﾠgenes	 ﾠin	 ﾠyeast	 ﾠand	 ﾠCaenorhabditis	 ﾠelegans	 ﾠ[105,	 ﾠ106],	 ﾠsuggest	 ﾠa	 ﾠvery	 ﾠ
recent	 ﾠevolutionary	 ﾠemergence	 ﾠvia	 ﾠgene	 ﾠduplication.	 ﾠIn	 ﾠcontrast	 ﾠto	 ﾠconventional	 ﾠMAPK,	 ﾠ
ERK3	 ﾠand	 ﾠ-ﾭ‐4	 ﾠpossess	 ﾠa	 ﾠsingle	 ﾠphosphoacceptor	 ﾠsite	 ﾠ(Ser-ﾭ‐Glu-ﾭ‐Gly).	 ﾠMoreover,	 ﾠboth	 ﾠkinases	 ﾠ
are	 ﾠcharacterised	 ﾠby	 ﾠa	 ﾠSer-ﾭ‐Pro-ﾭ‐Arg	 ﾠmotif	 ﾠin	 ﾠthe	 ﾠactivation	 ﾠloop,	 ﾠwhich	 ﾠreplaces	 ﾠthe	 ﾠhighly	 ﾠ
conserved	 ﾠAla-ﾭ‐Pro-ﾭ‐Glu	 ﾠmotif	 ﾠfound	 ﾠin	 ﾠalmost	 ﾠall	 ﾠprotein	 ﾠkinases	 ﾠ(Table	 ﾠ1-ﾭ‐2)	 ﾠ[61].	 ﾠAlthough	 ﾠ
the	 ﾠglutamic	 ﾠacid	 ﾠresidue	 ﾠhas	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠstructural	 ﾠstabilisation	 ﾠand	 ﾠultimately	 ﾠkinase	 ﾠ
activity	 ﾠ[107],	 ﾠsubstitution	 ﾠof	 ﾠthis	 ﾠresidue	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠobserved	 ﾠin	 ﾠcasein	 ﾠprotein	 ﾠ
kinases	 ﾠ[108].	 ﾠTherefore,	 ﾠan	 ﾠarginine	 ﾠreplacement	 ﾠis	 ﾠstill	 ﾠcompatible	 ﾠwith	 ﾠkinase	 ﾠactivity.	 ﾠ
Despite	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠa	 ﾠNLS	 ﾠERK4	 ﾠis	 ﾠpredominantly	 ﾠfound	 ﾠin	 ﾠthe	 ﾠnucleus	 ﾠ[109].	 ﾠIn	 ﾠ
contrast,	 ﾠERK3	 ﾠis	 ﾠlocalised	 ﾠto	 ﾠnuclear	 ﾠand	 ﾠcytoplasmic	 ﾠcompartments.	 ﾠEfforts	 ﾠto	 ﾠidentify	 ﾠ
stimuli	 ﾠaltering	 ﾠthe	 ﾠsubcellular	 ﾠlocalisation	 ﾠof	 ﾠERK3	 ﾠhave	 ﾠproven	 ﾠunsuccessful	 ﾠ[110].	 ﾠ
Another	 ﾠdifference	 ﾠbetween	 ﾠERK3	 ﾠand	 ﾠERK4	 ﾠis	 ﾠtheir	 ﾠrespective	 ﾠhalf-ﾭ‐lives,	 ﾠwhich	 ﾠargues	 ﾠfor	 ﾠ
isoform-ﾭ‐specific	 ﾠfunctions.	 ﾠERK3	 ﾠis	 ﾠhighly	 ﾠunstable	 ﾠwith	 ﾠa	 ﾠhalf-ﾭ‐life	 ﾠof	 ﾠ30-ﾭ‐40	 ﾠmin,	 ﾠwhereas	 ﾠ
ERK4	 ﾠis	 ﾠvery	 ﾠstable	 ﾠ[75].	 ﾠERK3/4	 ﾠkinases	 ﾠare	 ﾠactivated	 ﾠby	 ﾠphorbol	 ﾠester	 ﾠand	 ﾠserum	 ﾠ
treatment,	 ﾠbut	 ﾠnot	 ﾠinsulin	 ﾠor	 ﾠEGF	 ﾠ[111].	 ﾠNo	 ﾠresearch	 ﾠgroup	 ﾠhas	 ﾠyet	 ﾠidentified	 ﾠupstream	 ﾠ
MAPKKKs	 ﾠor	 ﾠMAPKKs	 ﾠfor	 ﾠERK3	 ﾠand	 ﾠ-ﾭ‐4.	 ﾠAlthough	 ﾠCheng	 ﾠet	 ﾠal.	 ﾠdescribed	 ﾠan	 ﾠERK3	 ﾠkinase	 ﾠ
capable	 ﾠof	 ﾠspecifically	 ﾠphosphorylating	 ﾠERK3,	 ﾠthey	 ﾠdid	 ﾠnot	 ﾠidentify	 ﾠthe	 ﾠenzyme	 ﾠ[112].	 ﾠ
Moreover,	 ﾠdata	 ﾠon	 ﾠERK3/4	 ﾠsubstrates	 ﾠis	 ﾠlimited	 ﾠand	 ﾠcontradictory.	 ﾠAlthough	 ﾠSauma	 ﾠet	 ﾠal.	 ﾠ
have	 ﾠdemonstrated	 ﾠphosphorylation	 ﾠof	 ﾠMBP	 ﾠ[113],	 ﾠCheng	 ﾠet	 ﾠal.	 ﾠdid	 ﾠnot	 ﾠobserve	 ﾠ
phosphorylation	 ﾠof	 ﾠtraditional	 ﾠMAPK	 ﾠeffectors	 ﾠsuch	 ﾠas	 ﾠMBP,	 ﾠMAP-ﾭ‐2,	 ﾠc-ﾭ‐Jun	 ﾠor	 ﾠElk-ﾭ‐1	 ﾠin	 ﾠ
vitro	 ﾠ[109].	 ﾠERK3	 ﾠexpression	 ﾠis	 ﾠmarkedly	 ﾠincreased	 ﾠduring	 ﾠearly	 ﾠorganogenesis	 ﾠin	 ﾠ
mice	 ﾠ[104].	 ﾠMoreover,	 ﾠcell	 ﾠculture	 ﾠstudies	 ﾠhave	 ﾠshown	 ﾠstabilisation	 ﾠof	 ﾠERK3	 ﾠupon	 ﾠcellular	 ﾠ
differentiation	 ﾠ[114].	 ﾠ	 ﾠThus,	 ﾠERK3	 ﾠmight	 ﾠplay	 ﾠa	 ﾠrole	 ﾠin	 ﾠcommitting	 ﾠcells	 ﾠto	 ﾠacquire	 ﾠa	 ﾠ
quiescent	 ﾠdifferentiated	 ﾠstate.	 ﾠFuture	 ﾠstudies,	 ﾠin	 ﾠparticular	 ﾠERK3
-ﾭ‐/-ﾭ‐	 ﾠand	 ﾠERK4
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phenotypes,	 ﾠwill	 ﾠhopefully	 ﾠshed	 ﾠmore	 ﾠlight	 ﾠon	 ﾠthe	 ﾠbiological	 ﾠfunctions	 ﾠand	 ﾠregulation	 ﾠof	 ﾠ
this	 ﾠMAPK	 ﾠsubfamily.	 ﾠ	 ﾠ
1.2.2.5  ERK7 
ERK7	 ﾠwas	 ﾠcloned	 ﾠin	 ﾠ1999	 ﾠfrom	 ﾠa	 ﾠneonatal	 ﾠrat	 ﾠbrain	 ﾠcDNA	 ﾠlibrary	 ﾠ[115]	 ﾠand	 ﾠconsists	 ﾠof	 ﾠan	 ﾠ
N-ﾭ‐terminal	 ﾠkinase	 ﾠdomain,	 ﾠwhich	 ﾠis	 ﾠ45%	 ﾠidentical	 ﾠto	 ﾠERK1.	 ﾠA	 ﾠfurther	 ﾠC-ﾭ‐terminal	 ﾠextension,	 ﾠ
unique	 ﾠto	 ﾠERK7,	 ﾠwhich	 ﾠcontains	 ﾠa	 ﾠputative	 ﾠNLS	 ﾠand	 ﾠtwo	 ﾠalleged	 ﾠSH3-ﾭ‐binding	 ﾠdomains	 ﾠ[75].	 ﾠ
The	 ﾠERK7	 ﾠgene	 ﾠtranslates	 ﾠinto	 ﾠa	 ﾠ60	 ﾠkDa	 ﾠprotein	 ﾠand	 ﾠis	 ﾠwidely	 ﾠexpressed	 ﾠ[116].	 ﾠNotably,	 ﾠ
this	 ﾠkinase,	 ﾠalthough	 ﾠfound	 ﾠacross	 ﾠmany	 ﾠspecies,	 ﾠis	 ﾠless	 ﾠconserved	 ﾠthroughout	 ﾠevolution	 ﾠ
than	 ﾠother	 ﾠMAPK	 ﾠ[75].	 ﾠTo	 ﾠdate	 ﾠwork	 ﾠon	 ﾠthe	 ﾠbiological	 ﾠregulation	 ﾠand	 ﾠfunction	 ﾠof	 ﾠthis	 ﾠ
MAPK	 ﾠis	 ﾠlimited.	 ﾠOverexpressed	 ﾠERK7	 ﾠis	 ﾠpredominantly	 ﾠlocalised	 ﾠto	 ﾠthe	 ﾠnucleus,	 ﾠwhereas	 ﾠ
the	 ﾠlocalisation	 ﾠof	 ﾠthe	 ﾠendogenous	 ﾠprotein	 ﾠis	 ﾠunknown	 ﾠ[115].	 ﾠThe	 ﾠenzymatic	 ﾠregulation	 ﾠof	 ﾠ
this	 ﾠMAPK	 ﾠis	 ﾠunique	 ﾠin	 ﾠthat	 ﾠthe	 ﾠThr-ﾭ‐Glu-ﾭ‐Tyr	 ﾠmotif	 ﾠwithin	 ﾠthe	 ﾠactivation	 ﾠloop	 ﾠis	 ﾠsubject	 ﾠto	 ﾠ
autophosphorylation	 ﾠand	 ﾠnot	 ﾠto	 ﾠbe	 ﾠphosphorylated	 ﾠby	 ﾠupstream	 ﾠMAPKKs	 ﾠ(Table	 ﾠ1-ﾭ‐2)	 ﾠ
[115].	 ﾠThis	 ﾠposes	 ﾠthe	 ﾠquestion;	 ﾠhow	 ﾠcan	 ﾠERK7	 ﾠbe	 ﾠregulated	 ﾠin	 ﾠvivo?	 ﾠSo	 ﾠfar,	 ﾠthere	 ﾠis	 ﾠ
evidence	 ﾠthat	 ﾠERK7	 ﾠactivity	 ﾠand	 ﾠexpression	 ﾠis	 ﾠregulated	 ﾠby	 ﾠprotein	 ﾠturnover	 ﾠ[117].	 ﾠ
Although	 ﾠERK7	 ﾠcan	 ﾠphosphorylate	 ﾠclassical	 ﾠMAPK	 ﾠsubstrates	 ﾠsuch	 ﾠas	 ﾠMBP	 ﾠin	 ﾠvitro,	 ﾠ
physiological	 ﾠsubstrates	 ﾠremain	 ﾠunidentified.	 ﾠNotably,	 ﾠERK7	 ﾠcan	 ﾠphosphorylate	 ﾠMBP	 ﾠon	 ﾠ
sites	 ﾠthat	 ﾠare	 ﾠdistinct	 ﾠfrom	 ﾠERK1/2	 ﾠphosphorylation.	 ﾠThus,	 ﾠERK7	 ﾠexhibits	 ﾠdistinct	 ﾠsubstrate	 ﾠ
specificity	 ﾠin	 ﾠcomparison	 ﾠto	 ﾠERK1/2	 ﾠ[115,	 ﾠ116].	 ﾠPhysiological	 ﾠfunctions	 ﾠof	 ﾠERK7	 ﾠalso	 ﾠ
remain	 ﾠto	 ﾠbe	 ﾠdetermined.	 ﾠSo	 ﾠfar,	 ﾠERK7	 ﾠhas	 ﾠbeen	 ﾠproposed	 ﾠto	 ﾠplay	 ﾠa	 ﾠrole	 ﾠin	 ﾠ
proliferation	 ﾠ[115],	 ﾠchloride	 ﾠtransport	 ﾠ[118]	 ﾠand	 ﾠnuclear	 ﾠreceptor	 ﾠsignalling	 ﾠ[66].	 ﾠ
Intriguingly,	 ﾠERK7	 ﾠdisplays	 ﾠfunctions	 ﾠdependent	 ﾠ(degradation	 ﾠof	 ﾠestrogen	 ﾠreceptor	 ﾠα)	 ﾠand	 ﾠ
independent	 ﾠ(regulation	 ﾠof	 ﾠS-ﾭ‐phase	 ﾠentry)	 ﾠof	 ﾠits	 ﾠcatalytic	 ﾠactivity.	 ﾠ
Interestingly,	 ﾠERK7	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠtumourigenesis.	 ﾠA	 ﾠsmall	 ﾠstudy	 ﾠcomparing	 ﾠ
ERK7	 ﾠprotein	 ﾠlevels	 ﾠin	 ﾠnormal	 ﾠand	 ﾠtumour	 ﾠtissues	 ﾠof	 ﾠthe	 ﾠbreast	 ﾠobserved	 ﾠan	 ﾠERK7	 ﾠloss	 ﾠin	 ﾠ
the	 ﾠcancerous	 ﾠsamples	 ﾠ[66].	 ﾠYet,	 ﾠfuture	 ﾠwork	 ﾠwith	 ﾠlarger	 ﾠpatient	 ﾠcohorts	 ﾠand	 ﾠmice	 ﾠmodels	 ﾠ
will	 ﾠbe	 ﾠnecessary	 ﾠto	 ﾠfurther	 ﾠsubstantiate	 ﾠthese	 ﾠobservations.	 ﾠ
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1.2.3  MAPK docking sites 
MAPK	 ﾠcascades	 ﾠregulate	 ﾠa	 ﾠvariety	 ﾠof	 ﾠbiological	 ﾠfunctions,	 ﾠsuch	 ﾠas	 ﾠcell	 ﾠproliferation,	 ﾠ
differentiation	 ﾠand	 ﾠstress	 ﾠresponses.	 ﾠMoreover,	 ﾠaberrant	 ﾠMAPK	 ﾠsignalling	 ﾠhas	 ﾠbeen	 ﾠ
associated	 ﾠwith	 ﾠnumerous	 ﾠdiseases	 ﾠsuch	 ﾠas	 ﾠcancer	 ﾠ(ERK1/2),	 ﾠrheumatoid	 ﾠarthritis	 ﾠ(p38	 ﾠ
kinases)	 ﾠand	 ﾠAlzheimer’s	 ﾠdisease	 ﾠ(JNKs)	 ﾠ[119-ﾭ‐121].	 ﾠBesides	 ﾠthe	 ﾠneed	 ﾠfor	 ﾠtight	 ﾠregulation,	 ﾠ
these	 ﾠcascades	 ﾠrequire	 ﾠhigh	 ﾠefficiency	 ﾠand	 ﾠfidelity	 ﾠin	 ﾠsignal	 ﾠtransduction,	 ﾠwhich	 ﾠis	 ﾠ
achieved	 ﾠthrough	 ﾠsubstrate	 ﾠbinding	 ﾠmotifs,	 ﾠalso	 ﾠknown	 ﾠas	 ﾠsubstrate	 ﾠdocking	 ﾠsites.	 ﾠ
Conventional	 ﾠMAPKs	 ﾠand	 ﾠtheir	 ﾠsubstrate	 ﾠbinding	 ﾠmotifs	 ﾠhave	 ﾠbeen	 ﾠstudied	 ﾠextensively	 ﾠin	 ﾠ
search	 ﾠfor	 ﾠputative	 ﾠdrug	 ﾠinhibition	 ﾠsites.	 ﾠOn	 ﾠthe	 ﾠother	 ﾠhand,	 ﾠour	 ﾠunderstanding	 ﾠof	 ﾠatypical	 ﾠ
MAPKs	 ﾠis	 ﾠstill	 ﾠin	 ﾠits	 ﾠinfancy	 ﾠin	 ﾠregards	 ﾠto	 ﾠregulation	 ﾠand	 ﾠbiological	 ﾠfunctions.	 ﾠThus,	 ﾠno	 ﾠ
docking	 ﾠdomains	 ﾠhave	 ﾠyet	 ﾠbeen	 ﾠdescribed	 ﾠfor	 ﾠthis	 ﾠMAPK	 ﾠsubgroup.	 ﾠ
1.2.3.1  Common docking site 
As	 ﾠthe	 ﾠname	 ﾠsuggests,	 ﾠthis	 ﾠdocking	 ﾠsite	 ﾠmediates	 ﾠbinding	 ﾠof	 ﾠnumerous	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠ
MEKs,	 ﾠphosphatases	 ﾠand	 ﾠtranscription	 ﾠfactors	 ﾠ[63].	 ﾠIt	 ﾠwas	 ﾠoriginally	 ﾠidentified	 ﾠin	 ﾠan	 ﾠ
attempt	 ﾠto	 ﾠabolish	 ﾠMEK	 ﾠbinding	 ﾠto	 ﾠERK2	 ﾠthrough	 ﾠmutations	 ﾠand	 ﾠtermed	 ﾠthe	 ﾠcytoplasmic	 ﾠ
retention	 ﾠsequence	 ﾠ(CRS)	 ﾠ[122].	 ﾠLater,	 ﾠhowever,	 ﾠthis	 ﾠregion	 ﾠwas	 ﾠshown	 ﾠto	 ﾠfacilitate	 ﾠ
interaction	 ﾠof	 ﾠERK	 ﾠwith	 ﾠa	 ﾠvariety	 ﾠof	 ﾠproteins	 ﾠand	 ﾠtherefore	 ﾠtermed	 ﾠthe	 ﾠcommon	 ﾠdocking	 ﾠ
(CD)	 ﾠdomain	 ﾠ[123].	 ﾠMoreover,	 ﾠthis	 ﾠbinding	 ﾠsite,	 ﾠwhich	 ﾠis	 ﾠlocated	 ﾠC-ﾭ‐terminal	 ﾠto	 ﾠthe	 ﾠ
catalytic	 ﾠdomain,	 ﾠis	 ﾠconserved	 ﾠamong	 ﾠall	 ﾠconventional	 ﾠMAPKs	 ﾠ(Figure	 ﾠ1-ﾭ‐5)	 ﾠand	 ﾠcomprises	 ﾠ
negatively-ﾭ‐charged	 ﾠaspartate	 ﾠ(D)	 ﾠand	 ﾠglutamate	 ﾠ(E)	 ﾠresidues	 ﾠ[123].	 ﾠCrystal	 ﾠstructures	 ﾠof	 ﾠ
ERK2,	 ﾠp38α	 ﾠand	 ﾠJNK3	 ﾠhave	 ﾠshown	 ﾠthat	 ﾠthe	 ﾠconserved	 ﾠamino	 ﾠacids	 ﾠare	 ﾠnot	 ﾠonly	 ﾠexposed	 ﾠ
on	 ﾠthe	 ﾠsurface	 ﾠof	 ﾠthese	 ﾠenzymes,	 ﾠbut	 ﾠalso	 ﾠreside	 ﾠclose	 ﾠto	 ﾠone	 ﾠanother,	 ﾠthus	 ﾠforming	 ﾠa	 ﾠ
negatively	 ﾠcharged	 ﾠinteraction	 ﾠplatform	 ﾠopposite	 ﾠto	 ﾠthe	 ﾠcatalytic	 ﾠcentre	 ﾠ[124-ﾭ‐126].	 ﾠ
Indeed,	 ﾠthis	 ﾠregion	 ﾠwas	 ﾠshown	 ﾠto	 ﾠbind	 ﾠto	 ﾠa	 ﾠconserved	 ﾠsequence	 ﾠof	 ﾠbasic	 ﾠamino	 ﾠacids	 ﾠin	 ﾠ
MAPK	 ﾠsubstrates,	 ﾠtermed	 ﾠthe	 ﾠD-ﾭ‐motif	 ﾠ[123,	 ﾠ127].	 ﾠNotably,	 ﾠERK1/2	 ﾠsubstrates	 ﾠgenerally	 ﾠ
possess	 ﾠtwo	 ﾠconsecutive	 ﾠbasic	 ﾠamino	 ﾠacids	 ﾠin	 ﾠtheir	 ﾠD-ﾭ‐motif,	 ﾠwhereas	 ﾠsubstrates	 ﾠfor	 ﾠJNK	 ﾠ
and	 ﾠp38	 ﾠkinases	 ﾠdisplay	 ﾠthree	 ﾠor	 ﾠmore	 ﾠconsecutive	 ﾠlysines	 ﾠ(L)	 ﾠand	 ﾠarginines	 ﾠ(R)	 ﾠ(Table	 ﾠ
1-ﾭ‐3).	 ﾠThus,	 ﾠsubstrate	 ﾠspecificity	 ﾠmight	 ﾠbe	 ﾠachieved	 ﾠthrough	 ﾠvarying	 ﾠnumbers	 ﾠof	 ﾠpositively	 ﾠ
charged	 ﾠamino	 ﾠacids	 ﾠon	 ﾠthe	 ﾠD-ﾭ‐motif	 ﾠ[124,	 ﾠ128].	 ﾠ
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MAPK substrate  Proposed D-motif  MAPK 
specificity 
MAPKK  MEK1  MPKKKPTPIQLNPNP 
ERK1/2 
MEK2  MLARRKPVLPALTINP 
MKK3  KGKSKRKKDLRI 
p38s 
MKK6  SKGKKRNPGLKIP 
MKK4  QGKRKALKLNF 
JNKs 
MKK7  EARRRIDLNLDISP 
MEK5  LKKSSAELRKIL  ERK5 
MAPKAPK  RSK1  SSILAQRRVRKLPSTTL 
ERK1/2 
RSK2  RSTLAQRRGIKKITSTAL 
MAPKAPK2  NPLLLKRRKKARALEAAA 
p38s 
MAPKAPK3  NRLLNKRRKKQAGSSSAS 








Table 1-3 Overview of proposed D-motifs of various MAPK substrates 
The D-motif is characterised by a cluster of positively charged amino acids (coloured in grey). The number 
of consecutive arginines or lysines determines the MAPK-binding specificity.  
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Figure 1-5 MAPK docking sites 
A. Human amino acid sequences of the CD domains of various members of the MAPK family. Coloured 
characters represent negatively charged amino acids in the CD domain, which are supposed to be exposed at 
the surface and mediate substrate binding. Adapted from [124].  
B. MAPKs comprise various docking domains, which mediate substrate binding. ED and CD domains 
mediate docking of D-motifs, whereas the FXFP-docking site allows binding of DEF-motifs. 
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1.2.3.2  ERK docking site 
The	 ﾠERK	 ﾠdocking	 ﾠ(ED)	 ﾠsite	 ﾠis	 ﾠlocated	 ﾠclose	 ﾠto	 ﾠthe	 ﾠCD	 ﾠdomain	 ﾠin	 ﾠthe	 ﾠcrystal	 ﾠstructure	 ﾠand	 ﾠ
consists	 ﾠof	 ﾠhydrophobic	 ﾠresidues	 ﾠfrom	 ﾠhelices	 ﾠαD,	 ﾠαE	 ﾠand	 ﾠa	 ﾠreverse	 ﾠturn	 ﾠof	 ﾠβ7-ﾭ‐β8	 ﾠ[129].	 ﾠ
This	 ﾠdocking	 ﾠsite	 ﾠis	 ﾠsignificantly	 ﾠdifferent	 ﾠin	 ﾠERK1/2,	 ﾠp38	 ﾠkinases	 ﾠand	 ﾠJNKs	 ﾠand	 ﾠtherefore	 ﾠ
provides	 ﾠa	 ﾠmeans	 ﾠfor	 ﾠsubstrate	 ﾠspecificity	 ﾠwithin	 ﾠthe	 ﾠMAPK	 ﾠfamily	 ﾠ[130].	 ﾠMoreover,	 ﾠthe	 ﾠ
CD	 ﾠand	 ﾠED	 ﾠdomains,	 ﾠwhich	 ﾠare	 ﾠclose	 ﾠto	 ﾠone	 ﾠanother	 ﾠin	 ﾠthe	 ﾠfolded	 ﾠprotein,	 ﾠform	 ﾠa	 ﾠdocking	 ﾠ
groove	 ﾠon	 ﾠthe	 ﾠsurface	 ﾠof	 ﾠthe	 ﾠkinases	 ﾠ(Figure	 ﾠ1-ﾭ‐5).	 ﾠThus,	 ﾠstructural	 ﾠdifferences	 ﾠbrought	 ﾠ
about	 ﾠby	 ﾠdifferent	 ﾠhydrophobic	 ﾠresidues	 ﾠcan	 ﾠconfer	 ﾠsubstrate	 ﾠspecificity	 ﾠand	 ﾠalter	 ﾠ
substrate	 ﾠaffinity	 ﾠ[124].	 ﾠIndeed,	 ﾠexchange	 ﾠof	 ﾠonly	 ﾠtwo	 ﾠamino	 ﾠacids	 ﾠin	 ﾠthe	 ﾠED	 ﾠdomain	 ﾠof	 ﾠ
p38α	 ﾠand	 ﾠERK2	 ﾠ(Glu160	 ﾠand	 ﾠAsp161	 ﾠin	 ﾠp38	 ﾠwith	 ﾠThr157	 ﾠand	 ﾠThr158	 ﾠin	 ﾠERK2)	 ﾠis	 ﾠenough	 ﾠto	 ﾠ
alter	 ﾠsubstrate	 ﾠspecificity	 ﾠ[124].	 ﾠIt	 ﾠhas	 ﾠto	 ﾠbe	 ﾠnoted,	 ﾠhowever,	 ﾠthat	 ﾠamino	 ﾠacids	 ﾠclose	 ﾠto	 ﾠthe	 ﾠ
docking	 ﾠgroove	 ﾠare	 ﾠlikely	 ﾠto	 ﾠalso	 ﾠbe	 ﾠinvolved	 ﾠin	 ﾠdocking	 ﾠinteractions.	 ﾠMoreover,	 ﾠsubstrates	 ﾠ
might	 ﾠdifferentially	 ﾠrecognise	 ﾠthe	 ﾠED	 ﾠand	 ﾠCD	 ﾠdomain,	 ﾠthus	 ﾠproviding	 ﾠanother	 ﾠmeans	 ﾠof	 ﾠ
variability.	 ﾠ
1.2.3.3  FXFP binding site 
In	 ﾠaddition	 ﾠto	 ﾠthe	 ﾠhydrophobic	 ﾠgroove,	 ﾠanother	 ﾠinteraction	 ﾠmotif	 ﾠhas	 ﾠbeen	 ﾠdescribed	 ﾠfor	 ﾠ
ERK1/2	 ﾠand	 ﾠp38α,	 ﾠwhich	 ﾠis	 ﾠcalled	 ﾠthe	 ﾠFXFP	 ﾠbinding	 ﾠsite.	 ﾠThis	 ﾠsite	 ﾠwas	 ﾠidentified	 ﾠusing	 ﾠ
hydrogen	 ﾠexchange	 ﾠmass	 ﾠspectrometry,	 ﾠand	 ﾠis	 ﾠmarked	 ﾠby	 ﾠa	 ﾠcluster	 ﾠof	 ﾠhydrophobic	 ﾠamino	 ﾠ
acids	 ﾠdistinct	 ﾠfrom	 ﾠthe	 ﾠED	 ﾠdomain,	 ﾠwhich	 ﾠspecifically	 ﾠinteracts	 ﾠwith	 ﾠa	 ﾠPhe-ﾭ‐X-ﾭ‐Phe	 ﾠ(FXF)	 ﾠ
motif	 ﾠ[131,	 ﾠ132].	 ﾠThe	 ﾠFXFP	 ﾠbinding	 ﾠsite	 ﾠis	 ﾠsituated	 ﾠclose	 ﾠto	 ﾠthe	 ﾠactive	 ﾠcentre	 ﾠand	 ﾠis	 ﾠ
occluded	 ﾠin	 ﾠthe	 ﾠinactive	 ﾠenzyme	 ﾠthrough	 ﾠintramolecular	 ﾠinteractions	 ﾠ(Figure	 ﾠ1-ﾭ‐5).	 ﾠMany	 ﾠ
ERK1/2	 ﾠsubstrates,	 ﾠincluding	 ﾠSAP-ﾭ‐1	 ﾠand	 ﾠElk-ﾭ‐1,	 ﾠhave	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠbind	 ﾠto	 ﾠthe	 ﾠFXFP	 ﾠ
binding	 ﾠsite	 ﾠwith	 ﾠtheir	 ﾠcorresponding	 ﾠDEF	 ﾠdomain	 ﾠ(docking	 ﾠsite	 ﾠfor	 ﾠERK	 ﾠand	 ﾠFXFP)	 ﾠ[132].	 ﾠ
Notably,	 ﾠthe	 ﾠhydrophobic	 ﾠresidues	 ﾠimportant	 ﾠin	 ﾠERK-ﾭ‐DEF	 ﾠbinding	 ﾠare	 ﾠconserved	 ﾠamong	 ﾠ
various	 ﾠMAPK	 ﾠfamily	 ﾠmembers,	 ﾠyet	 ﾠDEF	 ﾠmotif	 ﾠinteractions	 ﾠhave	 ﾠonly	 ﾠbeen	 ﾠobserved	 ﾠin	 ﾠ
ERK1/2	 ﾠand	 ﾠp38α,	 ﾠbut	 ﾠnot	 ﾠp38β/γ/δ	 ﾠand	 ﾠJNK2	 ﾠ[131].	 ﾠThis	 ﾠsuggests	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠ
tertiary	 ﾠstructure	 ﾠof	 ﾠthese	 ﾠkinases	 ﾠwhich	 ﾠlead	 ﾠto	 ﾠthe	 ﾠexposure	 ﾠof	 ﾠspecific	 ﾠsubstrate	 ﾠ
recognition	 ﾠpatterns.	 ﾠ
1.2.3.4  Other MAPK-binding domains 
Although	 ﾠmany	 ﾠMAPK	 ﾠsubstrates	 ﾠand	 ﾠregulators	 ﾠcontain	 ﾠone	 ﾠor	 ﾠmore	 ﾠMAPK	 ﾠdockings	 ﾠsites	 ﾠ
described	 ﾠabove,	 ﾠsome	 ﾠinteracting	 ﾠproteins	 ﾠlack	 ﾠthese	 ﾠconserved	 ﾠdomains,	 ﾠbut	 ﾠstill	 ﾠbind	 ﾠ	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to	 ﾠthe	 ﾠenzymes	 ﾠefficiently.	 ﾠOne	 ﾠsuch	 ﾠMAPK	 ﾠtarget	 ﾠis	 ﾠthe	 ﾠwell-ﾭ‐known	 ﾠtranscription	 ﾠfactor	 ﾠ
Ets-ﾭ‐1,	 ﾠwhich	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠbind	 ﾠto	 ﾠERK2	 ﾠvia	 ﾠa	 ﾠunique	 ﾠpointed	 ﾠdomain	 ﾠ[133].	 ﾠMITF	 ﾠ
(microphtalmia-ﾭ‐associated	 ﾠtranscription	 ﾠfactor)	 ﾠalso	 ﾠfalls	 ﾠinto	 ﾠthis	 ﾠcategory,	 ﾠas	 ﾠits	 ﾠC-ﾭ‐
terminal	 ﾠsequence	 ﾠrequired	 ﾠfor	 ﾠERK2	 ﾠbinding	 ﾠdoes	 ﾠnot	 ﾠresemble	 ﾠa	 ﾠD-ﾭ‐	 ﾠor	 ﾠDEF-ﾭ‐motif	 ﾠ[134].	 ﾠ
1.2.3.5  Kinase inhibitor binding sites 
Due	 ﾠto	 ﾠthe	 ﾠinvolvement	 ﾠof	 ﾠMAPKs	 ﾠin	 ﾠnumerous	 ﾠdiseases,	 ﾠsignificant	 ﾠeffort	 ﾠhas	 ﾠbeen	 ﾠmade	 ﾠ
by	 ﾠthe	 ﾠpharmaceutical	 ﾠindustry	 ﾠto	 ﾠdevelop	 ﾠinhibitors	 ﾠthat	 ﾠblock	 ﾠspecific	 ﾠMAPK	 ﾠpathways.	 ﾠ
This	 ﾠhas	 ﾠled	 ﾠto	 ﾠthe	 ﾠidentification	 ﾠof	 ﾠtwo	 ﾠnovel	 ﾠinhibitor	 ﾠbinding	 ﾠsites,	 ﾠi.e.	 ﾠbackside	 ﾠbinding	 ﾠ
pocket	 ﾠand	 ﾠthe	 ﾠ“DFG-ﾭ‐out”-ﾭ‐site,	 ﾠwhere	 ﾠinhibitor	 ﾠinteractions	 ﾠdo	 ﾠnot	 ﾠcompete	 ﾠwith	 ﾠATP	 ﾠ
binding	 ﾠ[135].	 ﾠThe	 ﾠbackside	 ﾠbinding	 ﾠpocket	 ﾠis	 ﾠa	 ﾠregion	 ﾠin	 ﾠthe	 ﾠvicinity	 ﾠof	 ﾠthe	 ﾠCD	 ﾠdomain	 ﾠin	 ﾠ
p38α	 ﾠand	 ﾠbinds	 ﾠinhibitors	 ﾠsuch	 ﾠas	 ﾠPD98056	 ﾠ[136].	 ﾠIn	 ﾠcontrast,	 ﾠthe	 ﾠ“DFG-ﾭ‐out”-ﾭ‐site	 ﾠis	 ﾠa	 ﾠ
docking	 ﾠdomain	 ﾠadjacent	 ﾠto	 ﾠthe	 ﾠactive	 ﾠsite.	 ﾠInhibitor	 ﾠbinding	 ﾠto	 ﾠthe	 ﾠconserved	 ﾠDFG	 ﾠ
sequence	 ﾠinduces	 ﾠa	 ﾠconformational	 ﾠchange	 ﾠin	 ﾠthe	 ﾠactivation	 ﾠloop	 ﾠof	 ﾠthe	 ﾠenzyme	 ﾠand	 ﾠ
thereby	 ﾠblocks	 ﾠits	 ﾠactivity	 ﾠ[135,	 ﾠ137].	 ﾠ“DFG-ﾭ‐out”-ﾭ‐sites,	 ﾠhowever,	 ﾠare	 ﾠnot	 ﾠunique	 ﾠfor	 ﾠMAPK	 ﾠ
as	 ﾠthey	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠdescribed	 ﾠfor	 ﾠMEK1/2	 ﾠ[138]	 ﾠand	 ﾠc-ﾭ‐Abl	 ﾠ[139].	 ﾠ
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1.3  The ERK-MAPK pathway 
The	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠis	 ﾠone	 ﾠof	 ﾠthe	 ﾠbest	 ﾠstudied	 ﾠmammalian	 ﾠkinase	 ﾠcascades	 ﾠand	 ﾠit	 ﾠhas	 ﾠ
diverse	 ﾠcellular	 ﾠand	 ﾠphysiological	 ﾠfunctions.	 ﾠERK1/2	 ﾠsignalling	 ﾠmodulates	 ﾠcellular	 ﾠ
processes	 ﾠsuch	 ﾠas	 ﾠcell	 ﾠcycle	 ﾠprogression,	 ﾠproliferation,	 ﾠdifferentiation,	 ﾠmigration,	 ﾠ
apoptosis	 ﾠand	 ﾠsenescence	 ﾠ[140].	 ﾠPhysiologically,	 ﾠthis	 ﾠpathway	 ﾠis	 ﾠinvolved	 ﾠin	 ﾠcardiogenesis,	 ﾠ
immune	 ﾠsystem	 ﾠdevelopment	 ﾠand	 ﾠhomeostasis,	 ﾠand	 ﾠplays	 ﾠa	 ﾠcritical	 ﾠrole	 ﾠin	 ﾠtransducing	 ﾠ
responses	 ﾠto	 ﾠmany	 ﾠhormones,	 ﾠgrowth	 ﾠfactors	 ﾠand	 ﾠinsulin.	 ﾠThus,	 ﾠaberrant	 ﾠERK1/2	 ﾠ
signalling	 ﾠhas	 ﾠbeen	 ﾠassociated	 ﾠwith	 ﾠequally	 ﾠdiverse	 ﾠpathologies,	 ﾠincluding	 ﾠcancer	 ﾠ[141-ﾭ‐
143],	 ﾠdiabetes	 ﾠ[144],	 ﾠand	 ﾠcardiovascular	 ﾠdisease	 ﾠ[145].	 ﾠThe	 ﾠcascade	 ﾠcan	 ﾠbe	 ﾠactivated	 ﾠby	 ﾠa	 ﾠ
variety	 ﾠof	 ﾠextracellular	 ﾠstimuli,	 ﾠsuch	 ﾠas	 ﾠmitogens,	 ﾠgrowth	 ﾠfactors,	 ﾠphorbol	 ﾠesters,	 ﾠ
cytokines,	 ﾠand	 ﾠinsulin	 ﾠ[63].	 ﾠMoreover,	 ﾠERK	 ﾠsignalling	 ﾠcan	 ﾠbe	 ﾠinduced	 ﾠby	 ﾠmeans	 ﾠof	 ﾠ
membrane	 ﾠdepolarisation	 ﾠand	 ﾠCa
2+	 ﾠinflux	 ﾠ[142].	 ﾠ	 ﾠ
The	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠis	 ﾠgenerally	 ﾠinitiated	 ﾠthrough	 ﾠthe	 ﾠactivation	 ﾠof	 ﾠsmall	 ﾠGTPases,	 ﾠsuch	 ﾠ
as	 ﾠRas	 ﾠor	 ﾠRap1,	 ﾠwhich	 ﾠrecruit	 ﾠRaf	 ﾠkinases	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠ[146].	 ﾠTo	 ﾠdate	 ﾠthree	 ﾠ
Raf	 ﾠkinase	 ﾠfamily	 ﾠmembers,	 ﾠnamely	 ﾠA-ﾭ‐Raf,	 ﾠB-ﾭ‐Raf	 ﾠand	 ﾠc-ﾭ‐Raf,	 ﾠhave	 ﾠbeen	 ﾠidentified.	 ﾠAll	 ﾠ
isoforms	 ﾠcontain	 ﾠthree	 ﾠconserved	 ﾠregions,	 ﾠtermed	 ﾠCR1,	 ﾠCR2	 ﾠand	 ﾠCR3	 ﾠ[147].	 ﾠThe	 ﾠfirst	 ﾠtwo	 ﾠ
conserved	 ﾠregions	 ﾠhave	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠregulating	 ﾠthe	 ﾠcatalytic	 ﾠdomain,	 ﾠwhich	 ﾠis	 ﾠ
located	 ﾠin	 ﾠCR3.	 ﾠActivation	 ﾠof	 ﾠRaf	 ﾠkinases	 ﾠis	 ﾠa	 ﾠcomplex	 ﾠprocess,	 ﾠrequiring	 ﾠprotein-ﾭ‐protein	 ﾠ
interaction,	 ﾠdimerization,	 ﾠas	 ﾠwell	 ﾠas	 ﾠvarious	 ﾠphosphorylation	 ﾠand	 ﾠdephosphorylation	 ﾠ
events	 ﾠ[147,	 ﾠ148].	 ﾠIn	 ﾠaddition,	 ﾠRaf	 ﾠkinase	 ﾠactivity	 ﾠcan	 ﾠexist	 ﾠin	 ﾠmultiple	 ﾠgraded	 ﾠstates,	 ﾠ
which	 ﾠare	 ﾠregulated	 ﾠby	 ﾠvarious	 ﾠkinases	 ﾠfrom	 ﾠother	 ﾠsignalling	 ﾠpathways	 ﾠand	 ﾠallow	 ﾠsignal	 ﾠ
modulation.	 ﾠFor	 ﾠexample,	 ﾠc-ﾭ‐Raf	 ﾠphosphorylation	 ﾠat	 ﾠSer338	 ﾠand	 ﾠTyr340/341	 ﾠby	 ﾠPAK	 ﾠ
(p21-ﾭ‐activated	 ﾠkinase)	 ﾠor	 ﾠSrc,	 ﾠrespectively,	 ﾠenhances	 ﾠthe	 ﾠcatalytic	 ﾠactivity,	 ﾠwhereas	 ﾠ
phosphorylation	 ﾠof	 ﾠSer259	 ﾠby	 ﾠAKT	 ﾠor	 ﾠPKA	 ﾠis	 ﾠinhibitory	 ﾠ[149-ﾭ‐151].	 ﾠ
Activated	 ﾠRafs	 ﾠsubsequently	 ﾠphosphorylate	 ﾠand	 ﾠthereby	 ﾠactivate	 ﾠMEK1/2	 ﾠat	 ﾠtwo	 ﾠserine	 ﾠ
residues	 ﾠlocated	 ﾠin	 ﾠthe	 ﾠSer-ﾭ‐Xaa-ﾭ‐Ala-ﾭ‐Xaa-ﾭ‐Ser/Thr	 ﾠmotif	 ﾠcommon	 ﾠto	 ﾠall	 ﾠMAPKKs	 ﾠ[152].	 ﾠ
During	 ﾠthis	 ﾠstep	 ﾠthe	 ﾠincoming	 ﾠsignal	 ﾠis	 ﾠamplified,	 ﾠas	 ﾠMEKs	 ﾠare	 ﾠmore	 ﾠabundant	 ﾠthan	 ﾠRaf	 ﾠ
kinases.	 ﾠMEK1/2	 ﾠconstitute	 ﾠan	 ﾠevolutionary	 ﾠconserved	 ﾠgroup	 ﾠof	 ﾠdual	 ﾠspecificity	 ﾠkinases,	 ﾠ
which	 ﾠshare	 ﾠan	 ﾠ85%	 ﾠsequence	 ﾠhomology.	 ﾠStructurally,	 ﾠMEK	 ﾠisoforms	 ﾠare	 ﾠcomposed	 ﾠof	 ﾠa	 ﾠ
kinase	 ﾠdomain,	 ﾠwhich	 ﾠis	 ﾠsurrounded	 ﾠby	 ﾠan	 ﾠN-ﾭ‐terminal	 ﾠregulatory	 ﾠand	 ﾠa	 ﾠshort	 ﾠC-ﾭ‐terminal	 ﾠ
domain	 ﾠ[138].	 ﾠThe	 ﾠtwo	 ﾠgenes	 ﾠencoding	 ﾠMEK1/2	 ﾠgive	 ﾠrise	 ﾠto	 ﾠthree	 ﾠisoforms,	 ﾠwhich	 ﾠare	 ﾠChapter 1 – Introduction    41 
MEK1,	 ﾠits	 ﾠalternatively	 ﾠspliced	 ﾠform	 ﾠMEK1b,	 ﾠand	 ﾠMEK2	 ﾠ[153].	 ﾠAlthough	 ﾠall	 ﾠkinases	 ﾠdisplay	 ﾠ
catalytic	 ﾠactivity,	 ﾠMEK1b	 ﾠdoes	 ﾠnot	 ﾠphosphorylate	 ﾠthe	 ﾠcanonical	 ﾠERK1/2	 ﾠproteins,	 ﾠbut	 ﾠ
stimulates	 ﾠactivation	 ﾠof	 ﾠthe	 ﾠsplice	 ﾠvariant	 ﾠERK1c	 ﾠ[154].	 ﾠOnce	 ﾠactivated,	 ﾠMEK	 ﾠisoforms	 ﾠ
phosphorylate	 ﾠERK1/2	 ﾠat	 ﾠthe	 ﾠconserved	 ﾠThr-ﾭ‐Glu-ﾭ‐Tyr	 ﾠmotif	 ﾠ(human	 ﾠERK1:	 ﾠaa	 ﾠ202-ﾭ‐204,	 ﾠ
human	 ﾠERK2:	 ﾠaa	 ﾠ185-ﾭ‐187)	 ﾠin	 ﾠa	 ﾠtwo-ﾭ‐collision,	 ﾠdistributive	 ﾠmanner	 ﾠrather	 ﾠthan	 ﾠa	 ﾠ
single-ﾭ‐collision,	 ﾠprocessive	 ﾠmanner	 ﾠ[155].	 ﾠThis	 ﾠallows	 ﾠthe	 ﾠestablishment	 ﾠof	 ﾠa	 ﾠthreshold,	 ﾠ
where	 ﾠtyrosine-ﾭ‐phosphorylated	 ﾠERKs	 ﾠhave	 ﾠto	 ﾠaccumulate	 ﾠbefore	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠ
threonine	 ﾠresidue	 ﾠcan	 ﾠoccur.	 ﾠAs	 ﾠsingly	 ﾠphosphorylated	 ﾠERK1/2	 ﾠshow	 ﾠvery	 ﾠlittle	 ﾠkinase	 ﾠ
activity,	 ﾠthis	 ﾠmode	 ﾠof	 ﾠactivation	 ﾠallows	 ﾠsignal	 ﾠpropagation	 ﾠonly	 ﾠwhen	 ﾠMEKs	 ﾠare	 ﾠactivated	 ﾠ
for	 ﾠa	 ﾠprolonged	 ﾠperiod.	 ﾠUpon	 ﾠstimulation,	 ﾠERK1/2	 ﾠphosphorylate	 ﾠa	 ﾠmultitude	 ﾠof	 ﾠ
substrates,	 ﾠincluding	 ﾠtranscription	 ﾠfactors,	 ﾠmembrane	 ﾠproteins,	 ﾠcytoskeletal	 ﾠelements,	 ﾠ
phosphatases	 ﾠand	 ﾠkinases.	 ﾠSo	 ﾠfar	 ﾠmore	 ﾠthan	 ﾠ160	 ﾠERK	 ﾠsubstrates	 ﾠhave	 ﾠbeen	 ﾠidentified,	 ﾠyet	 ﾠ
the	 ﾠnumber	 ﾠis	 ﾠever-ﾭ‐growing	 ﾠ[156].	 ﾠERKs	 ﾠare	 ﾠproline-ﾭ‐directed	 ﾠkinases,	 ﾠwhich	 ﾠphosphorylate	 ﾠ
substrates	 ﾠon	 ﾠa	 ﾠPro-ﾭ‐Xaa-ﾭ‐Ser/Thr-ﾭ‐Pro	 ﾠconsensus	 ﾠsite.	 ﾠHowever,	 ﾠnot	 ﾠall	 ﾠsubstrates	 ﾠcontain	 ﾠ
this	 ﾠperfect	 ﾠconsensus	 ﾠmotif,	 ﾠbut	 ﾠa	 ﾠshorter	 ﾠSer/Thr-ﾭ‐Pro	 ﾠsequence,	 ﾠwhich	 ﾠis	 ﾠstill	 ﾠsufficient	 ﾠ
to	 ﾠdirect	 ﾠERK’s	 ﾠphosphorylation	 ﾠ[157].	 ﾠ
1.3.1  ERK1/2 isoforms and splice variants 
The	 ﾠtwo	 ﾠpredominant	 ﾠERK	 ﾠisoforms,	 ﾠnamely	 ﾠERK1	 ﾠ(44	 ﾠkDa)	 ﾠand	 ﾠERK2	 ﾠ(42	 ﾠkDa),	 ﾠare	 ﾠ
evolutionary	 ﾠconserved	 ﾠenzymes,	 ﾠwhich	 ﾠshow	 ﾠan	 ﾠoverall	 ﾠsequence	 ﾠidentity	 ﾠof	 ﾠnearly	 ﾠ
85%	 ﾠ[58].	 ﾠBoth	 ﾠkinases	 ﾠare	 ﾠubiquitously	 ﾠexpressed,	 ﾠalbeit	 ﾠtheir	 ﾠrelative	 ﾠabundance	 ﾠmay	 ﾠ
vary	 ﾠacross	 ﾠtissues.	 ﾠFor	 ﾠexample,	 ﾠERK1	 ﾠis	 ﾠhighly	 ﾠexpressed	 ﾠin	 ﾠintestines	 ﾠand	 ﾠplacenta,	 ﾠ
whereas	 ﾠERK2	 ﾠexpression	 ﾠpredominates	 ﾠin	 ﾠmuscle,	 ﾠthymus	 ﾠand	 ﾠheart	 ﾠtissues	 ﾠ[58].	 ﾠ
Notably,	 ﾠtwo	 ﾠgenes,	 ﾠlocated	 ﾠon	 ﾠchromosomes	 ﾠ16	 ﾠ(erk1)	 ﾠand	 ﾠ22	 ﾠ(erk2),	 ﾠgive	 ﾠrise	 ﾠto	 ﾠthe	 ﾠ
canonical	 ﾠtranscripts	 ﾠof	 ﾠERK1,	 ﾠERK2,	 ﾠand	 ﾠalternatively	 ﾠspliced	 ﾠforms	 ﾠ[158,	 ﾠ159].	 ﾠ
To	 ﾠdate,	 ﾠtwo	 ﾠtranscript	 ﾠvariants	 ﾠhave	 ﾠbeen	 ﾠdescribed	 ﾠfor	 ﾠERK2,	 ﾠwhich	 ﾠencode	 ﾠthe	 ﾠsame	 ﾠ
protein,	 ﾠbut	 ﾠdiffer	 ﾠin	 ﾠtheir	 ﾠ3ˊuntranslated	 ﾠregion	 ﾠ(UTR).	 ﾠIn	 ﾠcontrast,	 ﾠalternative	 ﾠsplicing	 ﾠof	 ﾠ
the	 ﾠERK1	 ﾠtranscript	 ﾠresults	 ﾠin	 ﾠthree	 ﾠdistinct	 ﾠisoforms	 ﾠ(Figure	 ﾠ1-ﾭ‐6	 ﾠB).	 ﾠIsoform	 ﾠ1	 ﾠrepresents	 ﾠ
the	 ﾠcanonical	 ﾠERK1	 ﾠsequence,	 ﾠwhich	 ﾠtranslates	 ﾠinto	 ﾠa	 ﾠ44	 ﾠkDa	 ﾠprotein	 ﾠ[55,	 ﾠ58].	 ﾠIn	 ﾠ
comparison,	 ﾠisoform	 ﾠ3	 ﾠlacks	 ﾠan	 ﾠin-ﾭ‐frame	 ﾠexon	 ﾠin	 ﾠthe	 ﾠ3ˊ	 ﾠcoding	 ﾠregion,	 ﾠthus	 ﾠrendering	 ﾠa	 ﾠ
shorter	 ﾠtranscript.	 ﾠSo	 ﾠfar,	 ﾠthere	 ﾠis	 ﾠno	 ﾠevidence	 ﾠfor	 ﾠexpression	 ﾠof	 ﾠthis	 ﾠvariant	 ﾠat	 ﾠa	 ﾠprotein	 ﾠ
level,	 ﾠthus	 ﾠquestioning	 ﾠits	 ﾠphysiological	 ﾠfunction.	 ﾠOn	 ﾠthe	 ﾠother	 ﾠhand,	 ﾠisoform	 ﾠ2	 ﾠretains	 ﾠthe	 ﾠChapter 1 – Introduction    42 
 
Figure 1-6 Structural differences between ERK1b and ERK1c 
A. Sequence alignment of the intron 7 of human ERK1c and rat ERK1b. Identical amino acids are marked as 
(:). Introduced gaps to maximise the alignment are indicated by a dash.  
B. Exon organisation of human ERK1, ERK1c and rat ERK1c. Adapted from [158]. 
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intron	 ﾠ7,	 ﾠwhich,	 ﾠdepending	 ﾠon	 ﾠits	 ﾠsequence,	 ﾠresults	 ﾠin	 ﾠan	 ﾠERK1	 ﾠisoform	 ﾠof	 ﾠvarying	 ﾠsize.	 ﾠIn	 ﾠ
the	 ﾠcase	 ﾠof	 ﾠrodents,	 ﾠthe	 ﾠ78	 ﾠbp	 ﾠintron	 ﾠsequence	 ﾠis	 ﾠtranslated	 ﾠin	 ﾠframe	 ﾠand	 ﾠgives	 ﾠrise	 ﾠto	 ﾠa	 ﾠ
46	 ﾠkDa	 ﾠprotein,	 ﾠcalled	 ﾠERK1b	 ﾠ[159].	 ﾠIn	 ﾠprimates,	 ﾠhowever,	 ﾠthe	 ﾠintron	 ﾠsequence	 ﾠ(103	 ﾠbp	 ﾠ
long)	 ﾠcontains	 ﾠa	 ﾠpremature	 ﾠstop	 ﾠcodon,	 ﾠthus	 ﾠcreating	 ﾠa	 ﾠshorter	 ﾠ40	 ﾠkDa	 ﾠprotein,	 ﾠtermed	 ﾠ
ERK1c	 ﾠ(Figure	 ﾠ1-ﾭ‐6)	 ﾠ[158].	 ﾠRodent	 ﾠERK1b	 ﾠand	 ﾠprimate	 ﾠERK1c	 ﾠshare	 ﾠmany	 ﾠcommon	 ﾠ
features	 ﾠ(Table	 ﾠ1-ﾭ‐4).	 ﾠFirstly,	 ﾠboth	 ﾠproteins	 ﾠare	 ﾠcatalytically	 ﾠactive,	 ﾠas	 ﾠdemonstrated	 ﾠby	 ﾠin	 ﾠ
vitro	 ﾠkinase	 ﾠassays.	 ﾠSecondly,	 ﾠthe	 ﾠinserted	 ﾠregion	 ﾠsterically	 ﾠalters	 ﾠthe	 ﾠCD-ﾭ‐docking	 ﾠsite,	 ﾠ
which	 ﾠleads	 ﾠto	 ﾠreduced	 ﾠinteraction	 ﾠwith	 ﾠD-ﾭ‐motif	 ﾠcontaining	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠMEK1	 ﾠand	 ﾠ
ELK1	 ﾠ[156].	 ﾠThus,	 ﾠunlike	 ﾠERK1/2,	 ﾠboth	 ﾠsplice	 ﾠvariants	 ﾠfail	 ﾠto	 ﾠbind	 ﾠto	 ﾠthe	 ﾠcytoplasmic	 ﾠ
retention	 ﾠsignal	 ﾠin	 ﾠMEK	 ﾠand	 ﾠare	 ﾠconstitutively	 ﾠlocalised	 ﾠto	 ﾠthe	 ﾠnucleus	 ﾠ[158,	 ﾠ159].	 ﾠ
Moreover,	 ﾠreduced	 ﾠbinding	 ﾠof	 ﾠprotein	 ﾠtyrosine	 ﾠphosphatases	 ﾠ(PTP),	 ﾠsuch	 ﾠas	 ﾠPTP-ﾭ‐SL,	 ﾠ
results	 ﾠin	 ﾠa	 ﾠprolonged	 ﾠactivation	 ﾠof	 ﾠthese	 ﾠenzymes	 ﾠ[158,	 ﾠ159].	 ﾠDespite	 ﾠthe	 ﾠlatter	 ﾠ
similarities,	 ﾠERK1b	 ﾠand	 ﾠERK1c	 ﾠalso	 ﾠpossess	 ﾠdistinct	 ﾠfeatures	 ﾠ(Table	 ﾠ1-ﾭ‐4).	 ﾠFor	 ﾠexample,	 ﾠ
ERK1b	 ﾠis	 ﾠactivated	 ﾠby	 ﾠMEK1/2	 ﾠwith	 ﾠcomparable	 ﾠkinetics	 ﾠto	 ﾠthose	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2,	 ﾠ
whereas	 ﾠERK1c	 ﾠis	 ﾠactivated	 ﾠprimarily	 ﾠby	 ﾠthe	 ﾠalternatively	 ﾠspliced	 ﾠisoform	 ﾠMEK1b	 ﾠ[154,	 ﾠ
159].	 ﾠMoreover,	 ﾠmono-ﾭ‐ubiquitination	 ﾠof	 ﾠERK1c	 ﾠdirects	 ﾠthis	 ﾠenzyme	 ﾠto	 ﾠthe	 ﾠGolgi	 ﾠ
apparatus,	 ﾠwhere	 ﾠit	 ﾠinduces	 ﾠGolgi	 ﾠfragmentation	 ﾠ[160].	 ﾠInterestingly,	 ﾠERK1c	 ﾠexpression	 ﾠis	 ﾠ
increased	 ﾠin	 ﾠtumour	 ﾠtissues,	 ﾠsuggesting	 ﾠa	 ﾠputative	 ﾠrole	 ﾠfor	 ﾠthis	 ﾠenzyme	 ﾠin	 ﾠ
tumourigenesis	 ﾠ[160].	 ﾠIn	 ﾠcontrast,	 ﾠphysiological	 ﾠfunctions	 ﾠfor	 ﾠERK1b	 ﾠare	 ﾠstill	 ﾠunknown.	 ﾠIt	 ﾠis	 ﾠ
assumed,	 ﾠhowever,	 ﾠthat	 ﾠERK1b	 ﾠis	 ﾠparticularly	 ﾠimportant	 ﾠfor	 ﾠsignal	 ﾠtransduction	 ﾠvia	 ﾠthe	 ﾠ
ERK-ﾭ‐MAPK	 ﾠpathway	 ﾠin	 ﾠconditions,	 ﾠwhere	 ﾠthe	 ﾠactive	 ﾠpool	 ﾠof	 ﾠERK1/2	 ﾠis	 ﾠlimited	 ﾠ[159].	 ﾠ
  	 ﾠChapter 1 – Introduction    44 

















Derivation  Alternative splicing leads to incorporation of intron 7 
Enzymatic activity  Catalytically active 
Structure  Disrupted CD domain 
Protein-protein 
interaction 
Weak interaction with MEK and phosphatases 
Subcellular 
localisation 



















Predicted size  46 kDa  40 kDa  
Insert size  78 bp  103 bp with in-frame stop codon 
Activation by MEK  Activated by MEK1/2 with similar 
kinetics to ERK1/2 
Activated by splice variant MEK1b 
Posttranslational 
modification 
•  Phosphorylation of TEY motif 
•  No ubiquitination 
•  Phosphorylation of TEY motif 




Unknown  Involved in Golgi fragmentation  
necessary during mitosis 
Table 1-4 Common and distinct features of the alternatively spliced ERK1 isoforms 
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1.3.2  ERK signalling specificity 
One	 ﾠof	 ﾠthe	 ﾠintriguing	 ﾠfeatures	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠis	 ﾠits	 ﾠability	 ﾠto	 ﾠstimulate	 ﾠ
different,	 ﾠand	 ﾠsometimes	 ﾠeven	 ﾠopposing,	 ﾠcellular	 ﾠfunctions.	 ﾠThis	 ﾠraises	 ﾠthe	 ﾠquestion	 ﾠas	 ﾠto	 ﾠ
how	 ﾠdifferent	 ﾠinput	 ﾠsignals	 ﾠcan	 ﾠevoke	 ﾠdistinct	 ﾠfunctional	 ﾠoutcomes.	 ﾠSeveral	 ﾠmechanisms,	 ﾠ
determining	 ﾠsignalling	 ﾠspecificity,	 ﾠhave	 ﾠbeen	 ﾠidentified	 ﾠin	 ﾠrecent	 ﾠyears,	 ﾠincluding:	 ﾠ
(i)	 ﾠduration	 ﾠand	 ﾠstrength	 ﾠof	 ﾠsignals	 ﾠ[161],	 ﾠ(ii)	 ﾠinteraction	 ﾠwith	 ﾠscaffold	 ﾠand	 ﾠadaptor	 ﾠ
proteins	 ﾠ[148],	 ﾠ(iii)	 ﾠsubcellular	 ﾠlocalisation	 ﾠ[162,	 ﾠ163],	 ﾠ(iv)	 ﾠcrosstalk	 ﾠand	 ﾠinterplay	 ﾠbetween	 ﾠ
the	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠand	 ﾠother	 ﾠsignalling	 ﾠcascades	 ﾠ[149-ﾭ‐151,	 ﾠ164],	 ﾠ(v)	 ﾠisoform	 ﾠ
specificity	 ﾠ[59,	 ﾠ154],	 ﾠand	 ﾠ(vi)	 ﾠcell-ﾭ‐specific	 ﾠERK	 ﾠsubstrates	 ﾠ[156].	 ﾠNotably,	 ﾠthese	 ﾠ
mechanisms	 ﾠwork	 ﾠcooperatively,	 ﾠrather	 ﾠthan	 ﾠindependently,	 ﾠto	 ﾠensure	 ﾠproper	 ﾠ
downstream	 ﾠsignalling.	 ﾠThe	 ﾠfollowing	 ﾠsubsections	 ﾠfocus	 ﾠon	 ﾠhow	 ﾠERK	 ﾠactivity	 ﾠis	 ﾠregulated	 ﾠ
in	 ﾠa	 ﾠcellular	 ﾠcontext	 ﾠby	 ﾠmeans	 ﾠof	 ﾠprotein	 ﾠphosphatases,	 ﾠscaffold	 ﾠproteins,	 ﾠsubcellular	 ﾠ
localisation	 ﾠand	 ﾠfeedback	 ﾠloops.	 ﾠ
1.3.2.1  Regulation of ERK activity through protein phosphatases 
Phosphorylation	 ﾠevents	 ﾠare	 ﾠkey	 ﾠregulators	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway.	 ﾠNot	 ﾠonly	 ﾠare	 ﾠall	 ﾠ
members	 ﾠof	 ﾠthe	 ﾠMAPK	 ﾠcascade	 ﾠactivated	 ﾠby	 ﾠphosphorylation,	 ﾠthe	 ﾠaddition	 ﾠof	 ﾠphospho	 ﾠ
groups	 ﾠto	 ﾠMEKs	 ﾠand	 ﾠRafs	 ﾠcan	 ﾠalso	 ﾠinhibit	 ﾠkinase	 ﾠactivity.	 ﾠThus,	 ﾠprotein	 ﾠphosphates	 ﾠcan	 ﾠ
impact	 ﾠboth	 ﾠnegatively	 ﾠand	 ﾠpositively	 ﾠon	 ﾠERK	 ﾠsignalling.	 ﾠFull	 ﾠactivation	 ﾠof	 ﾠERK1/2	 ﾠrequires	 ﾠ
dual	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠThr-ﾭ‐Glu-ﾭ‐Tyr	 ﾠmotif.	 ﾠSingle	 ﾠphosphorylation	 ﾠof	 ﾠeither	 ﾠthreonine	 ﾠ
or	 ﾠtyrosine	 ﾠresults	 ﾠin	 ﾠa	 ﾠmarginally	 ﾠactive	 ﾠkinase.	 ﾠTherefore,	 ﾠERK	 ﾠactivity	 ﾠcan	 ﾠbe	 ﾠinhibited	 ﾠ
through	 ﾠthe	 ﾠremoval	 ﾠof	 ﾠeither	 ﾠone	 ﾠor	 ﾠtwo	 ﾠphospho	 ﾠgroups.	 ﾠGenerally,	 ﾠthree	 ﾠgroups	 ﾠof	 ﾠ
protein	 ﾠphosphatases	 ﾠact	 ﾠon	 ﾠERK1/2	 ﾠ(Table	 ﾠ1-ﾭ‐5),	 ﾠi.e.	 ﾠserine/threonine	 ﾠprotein	 ﾠ
phosphatases	 ﾠ(Ser/Thr-ﾭ‐PPs),	 ﾠphosphotyrosine	 ﾠphosphatases	 ﾠ(PTPs)	 ﾠand	 ﾠMAPK	 ﾠ
phosphatases	 ﾠ(MKPs).	 ﾠMAPK	 ﾠphosphatases,	 ﾠas	 ﾠthe	 ﾠname	 ﾠsuggests,	 ﾠconstitute	 ﾠa	 ﾠunique	 ﾠ
class	 ﾠof	 ﾠdual	 ﾠspecificity	 ﾠphosphatases	 ﾠthat	 ﾠact	 ﾠselectively	 ﾠon	 ﾠMAPKs	 ﾠand	 ﾠremove	 ﾠboth	 ﾠ
phospho	 ﾠgroups	 ﾠsimultaneously	 ﾠ(Figure	 ﾠ1-ﾭ‐7).	 ﾠ
Despite	 ﾠits	 ﾠbroad	 ﾠsubstrate	 ﾠspecificity,	 ﾠthe	 ﾠSer/Thr	 ﾠprotein	 ﾠphosphatase,	 ﾠPP2A,	 ﾠis	 ﾠan	 ﾠ
important	 ﾠregulator	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠ[165-ﾭ‐167].	 ﾠThe	 ﾠholoenzyme	 ﾠconsists	 ﾠof	 ﾠ
three	 ﾠsubunits,	 ﾠi.e.	 ﾠa	 ﾠscaffolding	 ﾠsubunit	 ﾠA,	 ﾠa	 ﾠregulatory	 ﾠsubunit	 ﾠB,	 ﾠand	 ﾠa	 ﾠcatalytic	 ﾠsubunit	 ﾠ
C.	 ﾠDifferent	 ﾠcombinations	 ﾠof	 ﾠA,	 ﾠB	 ﾠand	 ﾠC	 ﾠgive	 ﾠrise	 ﾠto	 ﾠover	 ﾠ50	 ﾠPP2A	 ﾠtrimers	 ﾠ[168,	 ﾠ169].	 ﾠB	 ﾠ
subunits,	 ﾠwhich	 ﾠtarget	 ﾠPP2A	 ﾠto	 ﾠdistinct	 ﾠsubcellular	 ﾠlocalisations	 ﾠand	 ﾠare	 ﾠinvolved	 ﾠin	 ﾠ	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NAME  Alternative name  Size (kDa)  Substrate specificity  Localisation 
A. Ser/Thr PP         
PP2A    37  ERK (when trimer 
with B￿ subunit) 
cytosolic 
B. PTP         
He-PTP    38  ERK = p38  cytosolic 
STEP    20-61  ERK  cytosolic 
PTP-SL  PCPTP-1  42,65  ERK = p38  cytosolic 
C. MKPs         
DUSP1*  MKP-1, CL100  39  P38 = JNK > ERK  nuclear 
DUSP2*  PAC-1  34  ERK = p38 > JNK  nuclear 
DUSP 4*  MKP-2  43  ERK = p38 > JNK  nuclear 
DUSP5*  hVHR3  42  ERK  nuclear 
DUSP6  MKP-3  43  ERK > JNK = p38  cytosolic 
DUSP7  MKP-X  40  ERK > JNK = p38  cytosolic 
DUSP8  hVH5  66  JNK = p38 > ERK  nuclear and cytosolic 
DUSP9  MKP-4  42  ERK > p38 > JNK  nuclear and cytosolic 
DUSP10*  MKP-5  53  P38 = JNK > ERK  nuclear and cytosolic 
DUSP16  MKP-7  73  JNK = p38 > ERK  cytosolic 
Table 1-5 Overview of the different groups of ERK phosphatases 
Phosphatases marked with * are encoded by ERK1/2 inducible genes. 
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Figure 1-7 ERK signalling is regulated by cytoplasmic and nuclear phosphatases 
ERK activity is regulated by three groups of phosphatases, namely Ser/Thr PPs, PTPs and DUSPs, which 
possess specific subcellular localisations. DUSP6 is subject to ERK phosphorylation, which targets the 
phosphatase for proteasomal degradation. Thus, ERK can prolong its own activity by inhibiting cytoplasmic 
inactivation. On the other hand, ERK can induce its inhibition, as the expression of multiple phosphatases 
marked here with (*) is induced by ERK signalling. 
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substrate	 ﾠrecognition,	 ﾠhave	 ﾠbeen	 ﾠdivided	 ﾠinto	 ﾠthree	 ﾠgene	 ﾠfamilies,	 ﾠnamed	 ﾠB	 ﾠ(or	 ﾠPR55),	 ﾠBˊ	 ﾠ
(or	 ﾠB56)	 ﾠand	 ﾠBˊˊ	 ﾠ(PR72)	 ﾠ[170].	 ﾠDephosphorylation	 ﾠof	 ﾠERK1/2	 ﾠis	 ﾠmediated	 ﾠby	 ﾠBˊ	 ﾠsubunit	 ﾠ
containing	 ﾠenzymes	 ﾠin	 ﾠa	 ﾠprocess	 ﾠthat	 ﾠis	 ﾠnot	 ﾠyet	 ﾠfully	 ﾠunderstood.	 ﾠInterestingly,	 ﾠERK1/2	 ﾠ
itself	 ﾠcan	 ﾠmodulate	 ﾠPP2A	 ﾠactivity	 ﾠby	 ﾠphosphorylating	 ﾠthe	 ﾠBˊ	 ﾠsubunits	 ﾠat	 ﾠa	 ﾠconserved	 ﾠserine	 ﾠ
residue.	 ﾠThis	 ﾠprocess,	 ﾠhowever,	 ﾠrequires	 ﾠexpression	 ﾠof	 ﾠthe	 ﾠimmediate	 ﾠearly	 ﾠgene	 ﾠIEX-ﾭ‐1,	 ﾠ
which	 ﾠserves	 ﾠas	 ﾠan	 ﾠadaptor	 ﾠprotein	 ﾠby	 ﾠpositioning	 ﾠthe	 ﾠBˊ	 ﾠsubunit	 ﾠfor	 ﾠERK-ﾭ‐mediated	 ﾠ
phosphorylation	 ﾠ[171].	 ﾠThus,	 ﾠIEX-ﾭ‐1	 ﾠinduction	 ﾠresults	 ﾠin	 ﾠenhanced	 ﾠphosphorylation	 ﾠof	 ﾠBˊ,	 ﾠ
subsequent	 ﾠinhibition	 ﾠof	 ﾠPP2A	 ﾠand	 ﾠprolonged	 ﾠERK	 ﾠactivation.	 ﾠ
Phosphorylation	 ﾠrepresents	 ﾠa	 ﾠcommon	 ﾠmechanism	 ﾠfor	 ﾠregulating	 ﾠphosphatase	 ﾠactivity.	 ﾠ
For	 ﾠexample,	 ﾠinteraction	 ﾠof	 ﾠthe	 ﾠhematopoietic	 ﾠprotein	 ﾠtyrosine	 ﾠphosphatase	 ﾠ(He-ﾭ‐PTP)	 ﾠ
with	 ﾠERK1/2	 ﾠis	 ﾠinhibited	 ﾠby	 ﾠPKA-ﾭ‐mediated	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠD-ﾭ‐motif	 ﾠ[172].	 ﾠLikewise,	 ﾠ
phosphorylation	 ﾠof	 ﾠthe	 ﾠstriatal-ﾭ‐enriched	 ﾠprotein	 ﾠtyrosine	 ﾠphosphatase	 ﾠ(STEP)	 ﾠprevents	 ﾠ
ERK1/2	 ﾠdephosphorylation	 ﾠ[173].	 ﾠThus	 ﾠfar,	 ﾠthree	 ﾠPTPs	 ﾠwith	 ﾠERK1/2	 ﾠactivity	 ﾠhave	 ﾠbeen	 ﾠ
identified:	 ﾠHe-ﾭ‐PTP,	 ﾠwhich	 ﾠis	 ﾠthe	 ﾠonly	 ﾠPTP	 ﾠexpressed	 ﾠin	 ﾠhematopoietic	 ﾠcells,	 ﾠSTEP,	 ﾠwhich	 ﾠis	 ﾠ
mainly	 ﾠexpressed	 ﾠin	 ﾠthe	 ﾠbrain	 ﾠand	 ﾠPTP-ﾭ‐SL,	 ﾠwhich	 ﾠis	 ﾠexpressed	 ﾠin	 ﾠlung,	 ﾠheart	 ﾠand	 ﾠ
brain	 ﾠ[174].	 ﾠInterestingly,	 ﾠPTPs	 ﾠand	 ﾠPP2A	 ﾠsometimes	 ﾠform	 ﾠa	 ﾠcomplex	 ﾠwith	 ﾠdual	 ﾠspecificity,	 ﾠ
thus	 ﾠmimicking	 ﾠthe	 ﾠactivity	 ﾠof	 ﾠMKPs	 ﾠ[174].	 ﾠ
MKPs	 ﾠrepresent	 ﾠa	 ﾠwell-ﾭ‐characterised	 ﾠsubgroup	 ﾠof	 ﾠdual	 ﾠspecificity	 ﾠphosphatases	 ﾠ(DUSP),	 ﾠ
which	 ﾠantagonize	 ﾠMAPK	 ﾠsignalling.	 ﾠIn	 ﾠgeneral,	 ﾠMKPs	 ﾠare	 ﾠsubdivided	 ﾠinto	 ﾠtwo	 ﾠgroups:	 ﾠ
(i)	 ﾠMKPs,	 ﾠwhich	 ﾠare	 ﾠencoded	 ﾠby	 ﾠgrowth	 ﾠfactor	 ﾠor	 ﾠstress-ﾭ‐inducible	 ﾠgenes	 ﾠand	 ﾠare	 ﾠlargely	 ﾠ
located	 ﾠin	 ﾠthe	 ﾠnucleus,	 ﾠor	 ﾠ(ii)	 ﾠMKPs,	 ﾠwhose	 ﾠactivity	 ﾠis	 ﾠnot	 ﾠregulated	 ﾠby	 ﾠgene	 ﾠtranscription	 ﾠ
and	 ﾠare	 ﾠprimarily	 ﾠfound	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠ[59].	 ﾠAll	 ﾠMKPs,	 ﾠhowever,	 ﾠare	 ﾠcomposed	 ﾠof	 ﾠan	 ﾠ
N-ﾭ‐terminal	 ﾠregulatory	 ﾠand	 ﾠa	 ﾠC-ﾭ‐terminal	 ﾠcatalytic	 ﾠdomain.	 ﾠSome	 ﾠMKPs,	 ﾠsuch	 ﾠas	 ﾠDUSP5	 ﾠand	 ﾠ
DUSP6	 ﾠdemonstrate	 ﾠan	 ﾠincreased	 ﾠspecificity	 ﾠtowards	 ﾠERK1/2,	 ﾠwhereas	 ﾠothers,	 ﾠsuch	 ﾠas	 ﾠ
DUSP1,	 ﾠpreferentially	 ﾠdephosphorylate	 ﾠp38s	 ﾠand	 ﾠJNKs	 ﾠ[175].	 ﾠThe	 ﾠactivity	 ﾠof	 ﾠMKPs	 ﾠcan	 ﾠbe	 ﾠ
regulated	 ﾠby	 ﾠmeans	 ﾠof	 ﾠprotein-ﾭ‐protein	 ﾠinteraction,	 ﾠphosphorylation	 ﾠand	 ﾠoxidation.	 ﾠFor	 ﾠ
example,	 ﾠDUSP6	 ﾠinteraction	 ﾠwith	 ﾠERK1/2	 ﾠinduces	 ﾠa	 ﾠconformational	 ﾠchange,	 ﾠwhich	 ﾠresults	 ﾠ
in	 ﾠthe	 ﾠactivation	 ﾠof	 ﾠthe	 ﾠphosphatase.	 ﾠHowever,	 ﾠDUSP6	 ﾠcontains	 ﾠan	 ﾠERK	 ﾠconsensus	 ﾠsite,	 ﾠ
which,	 ﾠwhen	 ﾠphosphorylated,	 ﾠtargets	 ﾠthe	 ﾠenzyme	 ﾠfor	 ﾠproteasomal	 ﾠdegradation	 ﾠwithout	 ﾠ
altering	 ﾠits	 ﾠcatalytic	 ﾠactivity	 ﾠ[176].	 ﾠIn	 ﾠcontrast,	 ﾠphosphorylation	 ﾠof	 ﾠDUSP1	 ﾠby	 ﾠERK1/2	 ﾠ
results	 ﾠin	 ﾠthe	 ﾠstabilisation	 ﾠof	 ﾠthe	 ﾠphosphatase	 ﾠ[177].	 ﾠAdditionally,	 ﾠreactive	 ﾠoxygen	 ﾠspecies,	 ﾠ
such	 ﾠas	 ﾠH2O2,	 ﾠoxidise	 ﾠMKPs,	 ﾠrendering	 ﾠthe	 ﾠenzymes	 ﾠinactive	 ﾠ[178].	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1.3.2.2  Regulation of ERK activity through upstream and downstream scaffold 
proteins 
One	 ﾠimportant	 ﾠdeterminant	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠstrength	 ﾠand	 ﾠduration	 ﾠis	 ﾠthe	 ﾠefficiency	 ﾠof	 ﾠits	 ﾠ
activation.	 ﾠWhen	 ﾠall	 ﾠcomponents	 ﾠof	 ﾠthe	 ﾠcascade	 ﾠare	 ﾠbrought	 ﾠinto	 ﾠclose	 ﾠproximity,	 ﾠoptimal	 ﾠ
pathway	 ﾠactivation	 ﾠthrough	 ﾠsequential	 ﾠphosphorylation	 ﾠof	 ﾠRafs,	 ﾠMEK1/2,	 ﾠand	 ﾠERK1/2	 ﾠcan	 ﾠ
occur.	 ﾠOne	 ﾠway	 ﾠof	 ﾠbringing	 ﾠthese	 ﾠprotein	 ﾠkinases	 ﾠinto	 ﾠthe	 ﾠvicinity	 ﾠof	 ﾠone	 ﾠanother,	 ﾠis	 ﾠ
through	 ﾠdirect	 ﾠinteraction	 ﾠof	 ﾠpathway	 ﾠmembers.	 ﾠFor	 ﾠexample,	 ﾠMEK1/2	 ﾠbind	 ﾠinactive	 ﾠERK	 ﾠ
constitutively	 ﾠand	 ﾠthereby	 ﾠnot	 ﾠonly	 ﾠserve	 ﾠas	 ﾠcytoplasmic	 ﾠanchor	 ﾠproteins,	 ﾠbut	 ﾠalso	 ﾠallow	 ﾠ
the	 ﾠformation	 ﾠof	 ﾠa	 ﾠsignalling	 ﾠmodule,	 ﾠwhich	 ﾠfacilitates	 ﾠERK	 ﾠactivation	 ﾠ[179].	 ﾠThe	 ﾠsame	 ﾠis	 ﾠ
valid	 ﾠfor	 ﾠRSK	 ﾠ(ribosomal	 ﾠS6	 ﾠkinase)	 ﾠproteins,	 ﾠwhich	 ﾠbind	 ﾠinactive	 ﾠERK	 ﾠand	 ﾠthereby	 ﾠretain	 ﾠ
the	 ﾠkinase	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠ[180].	 ﾠAlternatively,	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠcan	 ﾠ
be	 ﾠorganised	 ﾠinto	 ﾠmulti-ﾭ‐enzyme	 ﾠcomplexes	 ﾠthrough	 ﾠscaffold	 ﾠproteins.	 ﾠBy	 ﾠdefinition,	 ﾠ
scaffolds	 ﾠserve	 ﾠas	 ﾠstructural	 ﾠdocking	 ﾠplatforms,	 ﾠwhich	 ﾠbind	 ﾠtwo	 ﾠor	 ﾠmore	 ﾠmembers	 ﾠof	 ﾠa	 ﾠ
signalling	 ﾠpathway	 ﾠand	 ﾠfacilitate	 ﾠsignal	 ﾠtransduction.	 ﾠBesides	 ﾠthis	 ﾠobvious	 ﾠfunction,	 ﾠ
however,	 ﾠscaffold	 ﾠproteins	 ﾠalso	 ﾠinfluence	 ﾠpathway	 ﾠsignalling	 ﾠby	 ﾠtargeting	 ﾠmulti-ﾭ‐enzyme	 ﾠ
complexes	 ﾠto	 ﾠspecific	 ﾠsubcellular	 ﾠlocalisations	 ﾠ(Figure	 ﾠ1-ﾭ‐8	 ﾠand	 ﾠTable	 ﾠ1-ﾭ‐6).	 ﾠMoreover,	 ﾠ
scaffolds	 ﾠcan	 ﾠprevent	 ﾠcrosstalk	 ﾠwith	 ﾠother	 ﾠsignalling	 ﾠpathways	 ﾠby	 ﾠmasking	 ﾠinteraction	 ﾠor	 ﾠ
modification	 ﾠsites	 ﾠof	 ﾠits	 ﾠbinding	 ﾠpartners.	 ﾠAdditionally,	 ﾠscaffolds	 ﾠcan	 ﾠintegrate	 ﾠsignals	 ﾠfrom	 ﾠ
otherwise	 ﾠdiscrete	 ﾠsignalling	 ﾠpathways,	 ﾠas	 ﾠtheir	 ﾠability	 ﾠto	 ﾠbind	 ﾠsignalling	 ﾠmolecules	 ﾠcan	 ﾠbe	 ﾠ
regulated	 ﾠthrough	 ﾠpost-ﾭ‐translational	 ﾠmodifications.	 ﾠFurthermore,	 ﾠadaptor	 ﾠproteins	 ﾠcan	 ﾠ
link	 ﾠa	 ﾠsignalling	 ﾠpathway	 ﾠto	 ﾠspecific	 ﾠactivating	 ﾠsignals.	 ﾠTaken	 ﾠtogether,	 ﾠscaffolds	 ﾠcan	 ﾠ
provide	 ﾠsignalling	 ﾠspecificity	 ﾠto	 ﾠthe	 ﾠmulti-ﾭ‐functional	 ﾠERK-ﾭ‐MAPK	 ﾠpathway.	 ﾠAn	 ﾠoverview	 ﾠof	 ﾠ
the	 ﾠERK-ﾭ‐MAPK	 ﾠscaffolds	 ﾠknown	 ﾠto	 ﾠdate	 ﾠwill	 ﾠbe	 ﾠgiven	 ﾠin	 ﾠthe	 ﾠfollowing	 ﾠsections.	 ﾠ	 ﾠ
Kinase suppressor of Ras (KSR; binds Rafs, MEK1/2, ERK1/2 and 14-3-3) 
Kinase	 ﾠsuppressor	 ﾠof	 ﾠRas	 ﾠ(KSR)	 ﾠwas	 ﾠoriginally	 ﾠidentified	 ﾠas	 ﾠa	 ﾠsuppressor	 ﾠof	 ﾠan	 ﾠactivated	 ﾠ
Ras	 ﾠphenotype	 ﾠin	 ﾠgenetic	 ﾠstudies	 ﾠof	 ﾠC.	 ﾠelegans	 ﾠand	 ﾠDrosophila	 ﾠ[181,	 ﾠ182].	 ﾠTo	 ﾠdate,	 ﾠtwo	 ﾠ
KSR	 ﾠproteins	 ﾠ(KSR1	 ﾠand	 ﾠKSR2)	 ﾠhave	 ﾠbeen	 ﾠdiscovered	 ﾠin	 ﾠmammals,	 ﾠboth	 ﾠof	 ﾠwhich	 ﾠcontain	 ﾠ
five	 ﾠconserved	 ﾠdomains	 ﾠ(CA1-ﾭ‐5).	 ﾠThe	 ﾠpresence	 ﾠof	 ﾠa	 ﾠkinase-ﾭ‐like	 ﾠdomain	 ﾠand	 ﾠstructural	 ﾠ
similarity	 ﾠto	 ﾠc-ﾭ‐Raf	 ﾠsparked	 ﾠinvestigations	 ﾠinto	 ﾠa	 ﾠputative	 ﾠcatalytic	 ﾠactivity.	 ﾠWhether	 ﾠor	 ﾠnot	 ﾠ
the	 ﾠkinase	 ﾠdomain	 ﾠis	 ﾠfunctionally	 ﾠactive,	 ﾠhowever,	 ﾠremains	 ﾠan	 ﾠopen	 ﾠissue	 ﾠ[148,	 ﾠ183].	 ﾠKSR	 ﾠ
proteins	 ﾠinteract	 ﾠwith	 ﾠall	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠ[184,	 ﾠ185].	 ﾠBoth	 ﾠMEK	 ﾠ	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Figure 1-8 Subcellular localisation of ERK activity through scaffold proteins 
Scaffold proteins facilitate ERK activation by assembling cascade components into functional modules. 
Moreover, scaffolds localise ERK activity at specific subcellular localisations and link the ERK activation to 
specific extracellular signals. 
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Acronym  Name  Size 
(kDa) 
Protein interactions  Subcellular target 
KSR  Kinase suppressor of Ras  ~100  Raf, 14-3-3, MEK1/2, 
ERK1/2 
plasma membrane 
MP1  MEK partner 1  13.5  MEK1, ERK1  MP1/p14:  
late endosomes 
MP1/Morg-1: 
vesicular structures  
β-arrestin    ~46  c-Raf, MEK1/2, ERK1/2  early endosomes 
MEKK1  MEK kinase 1  195  c-Raf, MEK1/2, ERK1/2  cytoskeleton 
CNK  Connector enhancer of KSR  61-117  Rafs  plasma membrane 
Sur-8  Suppressor of Ras 8  65  K-/N-Ras, Rafs  plasma membrane 
IQGAP1    190  B-Raf, MEK1/2, ERK1/2  cytoplasm 
Paxillin    68  Raf, MEK1/2, ERK1/2  focal adhesions 
PEA-15  Phosphoprotein enriched in 
astrocytes 
15  ERK1/2, RSK2  cytoplasm 
RKIP  Raf kinase inhibitor protein  21  c-Raf, MEK1/2, ERK1/2   
Table 1-6 Mammalian scaffold proteins for the ERK-MAPK pathway 
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isoforms	 ﾠbind	 ﾠdirectly	 ﾠto	 ﾠthe	 ﾠkinase-ﾭ‐like	 ﾠdomain,	 ﾠCA5,	 ﾠERK1/2	 ﾠinteract	 ﾠwith	 ﾠthe	 ﾠDEF-ﾭ‐motif	 ﾠ
found	 ﾠin	 ﾠCA4	 ﾠand	 ﾠRaf	 ﾠassociation,	 ﾠat	 ﾠleast	 ﾠin	 ﾠDrosophila,	 ﾠis	 ﾠmediated	 ﾠvia	 ﾠthe	 ﾠCA1	 ﾠ
domain	 ﾠ[183,	 ﾠ186].	 ﾠKSR	 ﾠlocalisation	 ﾠis	 ﾠdynamic	 ﾠand	 ﾠregulated	 ﾠby	 ﾠphosphorylation	 ﾠand	 ﾠ
protein	 ﾠinteractions.	 ﾠIn	 ﾠquiescent	 ﾠcells,	 ﾠKSR,	 ﾠwhich	 ﾠis	 ﾠphosphorylated	 ﾠat	 ﾠSer392,	 ﾠbinds	 ﾠto	 ﾠ
14-ﾭ‐3-ﾭ‐3	 ﾠto	 ﾠlocalise	 ﾠthe	 ﾠsignalling	 ﾠcomplex	 ﾠto	 ﾠthe	 ﾠcytoplasm.	 ﾠUpon	 ﾠRas	 ﾠactivation,	 ﾠthis	 ﾠ
critical	 ﾠresidue	 ﾠis	 ﾠdephosphorylated	 ﾠand	 ﾠ14-ﾭ‐3-ﾭ‐3	 ﾠassociation	 ﾠis	 ﾠdisrupted.	 ﾠSubsequently,	 ﾠ
the	 ﾠKSR	 ﾠsignalling	 ﾠcomplex	 ﾠis	 ﾠtranslocated	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠwhere	 ﾠthe	 ﾠkinase	 ﾠ
cascade	 ﾠbecomes	 ﾠactivated.	 ﾠUpon	 ﾠactivation,	 ﾠERK	 ﾠis	 ﾠreleased	 ﾠfrom	 ﾠthe	 ﾠKSR	 ﾠplatform	 ﾠand	 ﾠ
accumulates	 ﾠe.g.	 ﾠin	 ﾠthe	 ﾠnucleus	 ﾠto	 ﾠregulate	 ﾠgene	 ﾠtranscription.	 ﾠ
MEK partner 1 (MP1; binds MEK1 and ERK1) 
MP1	 ﾠwas	 ﾠidentified	 ﾠin	 ﾠa	 ﾠyeast	 ﾠtwo-ﾭ‐hybrid	 ﾠscreen	 ﾠfor	 ﾠMEK1	 ﾠinteracting	 ﾠpartners	 ﾠin	 ﾠ
1998	 ﾠ[187].	 ﾠOriginal	 ﾠwork	 ﾠdemonstrated	 ﾠa	 ﾠselective	 ﾠbinding	 ﾠof	 ﾠMP1	 ﾠto	 ﾠMEK1	 ﾠand	 ﾠERK1	 ﾠ
and	 ﾠsuggested	 ﾠspecific	 ﾠactivation	 ﾠof	 ﾠERK1	 ﾠover	 ﾠERK2.	 ﾠSubsequent	 ﾠwork,	 ﾠhowever,	 ﾠ
challenged	 ﾠthis	 ﾠby	 ﾠshowing	 ﾠthat	 ﾠMP1	 ﾠis	 ﾠrequired	 ﾠfor	 ﾠactivation	 ﾠof	 ﾠboth	 ﾠERK1	 ﾠand	 ﾠ
ERK2	 ﾠ[188].	 ﾠThus,	 ﾠin	 ﾠcontrast	 ﾠto	 ﾠthe	 ﾠoriginal	 ﾠdata,	 ﾠMP1	 ﾠmight	 ﾠeither	 ﾠrepresent	 ﾠa	 ﾠdocking	 ﾠ
platform	 ﾠfor	 ﾠMEK2	 ﾠand	 ﾠERK2,	 ﾠor	 ﾠactivate	 ﾠERK2	 ﾠindirectly	 ﾠas	 ﾠpart	 ﾠof	 ﾠthe	 ﾠsame	 ﾠsignalling	 ﾠ
complex.	 ﾠInteraction	 ﾠwith	 ﾠthe	 ﾠadaptor	 ﾠprotein,	 ﾠp14,	 ﾠlocalises	 ﾠthe	 ﾠMP1	 ﾠcomplex	 ﾠto	 ﾠlate	 ﾠ
endosomes,	 ﾠwhere	 ﾠit	 ﾠenhances	 ﾠPAK1	 ﾠphosphorylation	 ﾠand	 ﾠdrives	 ﾠcellular	 ﾠspreading	 ﾠ[189,	 ﾠ
190].	 ﾠInterestingly,	 ﾠthe	 ﾠMP1/p14	 ﾠcomplex	 ﾠis	 ﾠrequired	 ﾠfor	 ﾠfull	 ﾠERK	 ﾠactivation	 ﾠupon	 ﾠEGF	 ﾠ
stimulation,	 ﾠwhereas	 ﾠanother	 ﾠMP1	 ﾠadaptor,	 ﾠnamely	 ﾠMorg-ﾭ‐1	 ﾠ(mitogen-ﾭ‐activated	 ﾠprotein	 ﾠ
kinase	 ﾠorganiser	 ﾠ1)	 ﾠpromotes	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠresponse	 ﾠto	 ﾠserum,	 ﾠlysophosphatidic	 ﾠacid,	 ﾠ
and	 ﾠphorbol	 ﾠester	 ﾠ[191].	 ﾠThus,	 ﾠMP1	 ﾠlinks	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠto	 ﾠEGF	 ﾠsignalling	 ﾠthrough	 ﾠ
p14	 ﾠinteraction	 ﾠand	 ﾠto	 ﾠG-ﾭ‐protein	 ﾠcoupled	 ﾠreceptor	 ﾠ(GPCR)	 ﾠsignalling	 ﾠthrough	 ﾠMorg-ﾭ‐1	 ﾠ
association.	 ﾠLike	 ﾠp14,	 ﾠMorg-ﾭ‐1	 ﾠtargets	 ﾠMP1	 ﾠto	 ﾠvesicular	 ﾠstructures,	 ﾠthe	 ﾠnature	 ﾠof	 ﾠwhich	 ﾠhas	 ﾠ
not	 ﾠbeen	 ﾠdetermined	 ﾠyet	 ﾠ[191].	 ﾠ
β-Arrestins (bind c-Raf, MEK1/2 and ERK1/2) 
It	 ﾠis	 ﾠwell-ﾭ‐established	 ﾠthat	 ﾠβ-ﾭ‐arrestins	 ﾠterminate	 ﾠGPCR	 ﾠsignalling	 ﾠby	 ﾠmediating	 ﾠreceptor	 ﾠ
internalisation	 ﾠ[192].	 ﾠHowever,	 ﾠevidence	 ﾠis	 ﾠemerging	 ﾠthat	 ﾠsuggests	 ﾠan	 ﾠadditional	 ﾠ
scaffolding	 ﾠfunction	 ﾠfor	 ﾠβ-ﾭ‐arrestins	 ﾠ[193].	 ﾠIn	 ﾠmammalian	 ﾠtissues,	 ﾠtwo	 ﾠβ-ﾭ‐arrestin	 ﾠproteins,	 ﾠ
named	 ﾠβ-ﾭ‐arrestin	 ﾠ1	 ﾠand	 ﾠβ-ﾭ‐arrestin	 ﾠ2,	 ﾠare	 ﾠexpressed.	 ﾠFollowing	 ﾠactivation	 ﾠof	 ﾠGPCRs,	 ﾠ
β-ﾭ‐arrestins	 ﾠtranslocate	 ﾠfrom	 ﾠthe	 ﾠcytoplasm	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane,	 ﾠwhich	 ﾠtargets	 ﾠthe	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receptors	 ﾠfor	 ﾠinternalisation.	 ﾠDuring	 ﾠsubsequent	 ﾠendocytosis,	 ﾠa	 ﾠmulti-ﾭ‐enzyme	 ﾠsignalling	 ﾠ
complex	 ﾠencompassing	 ﾠthe	 ﾠinternalised	 ﾠGPCR,	 ﾠβ-ﾭ‐arrestin,	 ﾠc-ﾭ‐Raf,	 ﾠMEK1/2	 ﾠand	 ﾠERK1/2	 ﾠis	 ﾠ
formed	 ﾠand	 ﾠERK	 ﾠsignalling	 ﾠis	 ﾠactivated	 ﾠ[194,	 ﾠ195].	 ﾠInterestingly,	 ﾠβ-ﾭ‐arrestins	 ﾠenhance	 ﾠ
cytosolic	 ﾠERK	 ﾠactivity	 ﾠand	 ﾠreduce	 ﾠtranscriptional	 ﾠresponses,	 ﾠthereby	 ﾠproviding	 ﾠa	 ﾠcounter	 ﾠ
to	 ﾠKSR-ﾭ‐mediated	 ﾠERK	 ﾠsignalling	 ﾠ[196].	 ﾠ
MEK Kinase 1 (binds to c-Raf, MEK1/2 and ERK1/2) 
MEK	 ﾠkinase	 ﾠ1	 ﾠ(MEKK1)	 ﾠis	 ﾠa	 ﾠmulti-ﾭ‐functional	 ﾠprotein	 ﾠthat	 ﾠis	 ﾠmainly	 ﾠappreciated	 ﾠas	 ﾠan	 ﾠ
upstream	 ﾠMAPKKK	 ﾠfor	 ﾠJNK	 ﾠand	 ﾠp38	 ﾠ(Table	 ﾠ1-ﾭ‐2)	 ﾠ[62,	 ﾠ197].	 ﾠIn	 ﾠaddition	 ﾠto	 ﾠits	 ﾠkinase	 ﾠactivity,	 ﾠ
MEKK1	 ﾠexhibits	 ﾠan	 ﾠE3	 ﾠubiquitin	 ﾠligase	 ﾠactivity	 ﾠ[198]	 ﾠand	 ﾠcan	 ﾠact	 ﾠas	 ﾠa	 ﾠscaffold	 ﾠfor	 ﾠmembers	 ﾠ
of	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠdue	 ﾠto	 ﾠits	 ﾠlarge	 ﾠnon-ﾭ‐catalytic	 ﾠN-ﾭ‐terminal	 ﾠdomain,	 ﾠwhich	 ﾠserves	 ﾠ
as	 ﾠa	 ﾠdocking	 ﾠplatform	 ﾠ[199].	 ﾠMEKK1	 ﾠbinds	 ﾠc-ﾭ‐Raf,	 ﾠMEK1/2,	 ﾠERK1/2	 ﾠconstitutively	 ﾠ[200]	 ﾠand	 ﾠ
is	 ﾠbelieved	 ﾠto	 ﾠregulate	 ﾠERK	 ﾠactivation.	 ﾠThis	 ﾠis	 ﾠbased	 ﾠon	 ﾠits	 ﾠability	 ﾠto	 ﾠenhance	 ﾠERK	 ﾠsignalling	 ﾠ
when	 ﾠoverexpressed	 ﾠ[197]	 ﾠand	 ﾠbecause	 ﾠERK	 ﾠactivation	 ﾠis	 ﾠreduced	 ﾠin	 ﾠMEKK1-ﾭ‐deficient	 ﾠ
cells	 ﾠ[201].	 ﾠIntriguingly,	 ﾠMEKK1	 ﾠis	 ﾠtightly	 ﾠassociated	 ﾠwith	 ﾠthe	 ﾠcytoskeleton,	 ﾠand	 ﾠthis	 ﾠmight	 ﾠ
therefore	 ﾠprovide	 ﾠa	 ﾠmeans	 ﾠof	 ﾠtargeting	 ﾠERK	 ﾠsignalling	 ﾠto	 ﾠcytoskeletal	 ﾠelements.	 ﾠIn	 ﾠ
addition,	 ﾠMEKK1	 ﾠcan	 ﾠserve	 ﾠto	 ﾠreduce	 ﾠERK	 ﾠactivity	 ﾠby	 ﾠubiquitinating	 ﾠERK1/2	 ﾠand	 ﾠthus	 ﾠ
targeting	 ﾠit	 ﾠfor	 ﾠproteasomal	 ﾠdegradation	 ﾠ[198].	 ﾠ	 ﾠ
Connector enhancer of KSR (CNK; binds c-Raf and B-Raf) 
In	 ﾠan	 ﾠattempt	 ﾠto	 ﾠidentify	 ﾠfunctional	 ﾠbinding	 ﾠpartners	 ﾠof	 ﾠKSR,	 ﾠthe	 ﾠconnector	 ﾠenhancer	 ﾠof	 ﾠ
KSR	 ﾠ(CNK)	 ﾠwas	 ﾠidentified	 ﾠin	 ﾠDrosophila	 ﾠin	 ﾠ1998.	 ﾠCNK	 ﾠis	 ﾠa	 ﾠlarge	 ﾠnon-ﾭ‐catalytic	 ﾠadaptor	 ﾠ
protein	 ﾠwith	 ﾠmultiple	 ﾠprotein	 ﾠinteraction	 ﾠdomains.	 ﾠIt	 ﾠcontains	 ﾠa	 ﾠsterile	 ﾠα	 ﾠmotif	 ﾠ(SAM),	 ﾠa	 ﾠ
conserved	 ﾠregion	 ﾠin	 ﾠCNK	 ﾠ(CRIC),	 ﾠa	 ﾠPDZ	 ﾠdomain,	 ﾠSrc-ﾭ‐homology-ﾭ‐3	 ﾠ(SH3)-ﾭ‐binding	 ﾠsites	 ﾠand	 ﾠa	 ﾠ
pleckstrin	 ﾠhomology	 ﾠ(PH)	 ﾠdomain,	 ﾠwhich	 ﾠmediates	 ﾠmembrane	 ﾠlocalisation	 ﾠ[202].	 ﾠIn	 ﾠ
mammals,	 ﾠthree	 ﾠCNK	 ﾠisoforms	 ﾠ(CNK1,	 ﾠCNK2A	 ﾠand	 ﾠits	 ﾠtruncated	 ﾠsplice	 ﾠvariant	 ﾠCNK2B)	 ﾠhave	 ﾠ
been	 ﾠidentified	 ﾠ[203,	 ﾠ204],	 ﾠall	 ﾠof	 ﾠwhich	 ﾠassociate	 ﾠwith	 ﾠRaf	 ﾠbut	 ﾠno	 ﾠother	 ﾠmember	 ﾠof	 ﾠthe	 ﾠ
ERK	 ﾠcascade	 ﾠand	 ﾠenhance	 ﾠits	 ﾠactivation	 ﾠvia	 ﾠSrc	 ﾠand	 ﾠRas	 ﾠ[205,	 ﾠ206].	 ﾠSo	 ﾠfar,	 ﾠit	 ﾠhas	 ﾠbeen	 ﾠ
shown	 ﾠthat	 ﾠCNK	 ﾠenhances	 ﾠERK	 ﾠactivation,	 ﾠbut	 ﾠthe	 ﾠexact	 ﾠmechanism	 ﾠthrough	 ﾠwhich	 ﾠthis	 ﾠis	 ﾠ
achieved	 ﾠremains	 ﾠto	 ﾠbe	 ﾠelucidated.	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Suppressor of Ras 8 (Sur-8; binds Ras and c-Raf) 
The	 ﾠSuppressor	 ﾠof	 ﾠRas	 ﾠhas	 ﾠbeen	 ﾠisolated	 ﾠin	 ﾠC.	 ﾠelegans	 ﾠas	 ﾠan	 ﾠadaptor	 ﾠprotein,	 ﾠwhich	 ﾠ
increases	 ﾠRas-ﾭ‐mediated	 ﾠsignal	 ﾠtransduction	 ﾠ[207].	 ﾠSur-ﾭ‐8	 ﾠis	 ﾠa	 ﾠconserved	 ﾠprotein,	 ﾠwhich	 ﾠ
mainly	 ﾠconsists	 ﾠof	 ﾠleucine	 ﾠrepeats	 ﾠand	 ﾠforms	 ﾠa	 ﾠcomplex	 ﾠwith	 ﾠmammalian	 ﾠRas	 ﾠand	 ﾠc-ﾭ‐Raf,	 ﾠ
thus	 ﾠcoupling	 ﾠRaf	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠin	 ﾠthe	 ﾠvicinity	 ﾠof	 ﾠits	 ﾠupstream	 ﾠregulator	 ﾠ[208].	 ﾠ
Interestingly,	 ﾠSur-ﾭ‐8	 ﾠmay	 ﾠprovide	 ﾠsignalling	 ﾠspecificity	 ﾠby	 ﾠbinding	 ﾠto	 ﾠN-ﾭ‐Ras	 ﾠand	 ﾠK-ﾭ‐Ras,	 ﾠbut	 ﾠ
not	 ﾠH-ﾭ‐Ras	 ﾠin	 ﾠvitro	 ﾠ[207].	 ﾠ	 ﾠ
IQGAP1 (binds B-Raf, MEK1/2 and ERK1/2) 
IQGAPs	 ﾠform	 ﾠa	 ﾠconserved	 ﾠclass	 ﾠof	 ﾠmultidomain	 ﾠproteins,	 ﾠwhich	 ﾠmediate	 ﾠinteractions	 ﾠwith	 ﾠ
a	 ﾠvariety	 ﾠof	 ﾠsignalling	 ﾠmolecules	 ﾠand	 ﾠregulate	 ﾠmultiple	 ﾠcellular	 ﾠprocesses,	 ﾠsuch	 ﾠas	 ﾠcell-ﾭ‐cell	 ﾠ
adhesion,	 ﾠtranscription	 ﾠand	 ﾠcytoskeletal	 ﾠremodelling.	 ﾠTo	 ﾠdate,	 ﾠthree	 ﾠIQGAP	 ﾠisoforms	 ﾠ
(IQGAP1,	 ﾠ-ﾭ‐2	 ﾠand	 ﾠ-ﾭ‐3)	 ﾠhave	 ﾠbeen	 ﾠidentified	 ﾠin	 ﾠhumans,	 ﾠwith	 ﾠIQGAP1	 ﾠbeing	 ﾠthe	 ﾠmost	 ﾠ
intensively	 ﾠstudied.	 ﾠIQGAP1	 ﾠhas	 ﾠrecently	 ﾠbeen	 ﾠidentified	 ﾠas	 ﾠa	 ﾠnovel	 ﾠMAPK	 ﾠscaffold,	 ﾠwhich	 ﾠ
binds	 ﾠdirectly	 ﾠto	 ﾠB-ﾭ‐Raf,	 ﾠMEK1/2	 ﾠand	 ﾠERK1/2	 ﾠ[209-ﾭ‐211].	 ﾠThis	 ﾠis	 ﾠparticularly	 ﾠinteresting	 ﾠas	 ﾠ
oncogenic	 ﾠRas,	 ﾠprevalent	 ﾠin	 ﾠover	 ﾠ15%	 ﾠof	 ﾠall	 ﾠhuman	 ﾠcancers,	 ﾠprimarily	 ﾠsignals	 ﾠthrough	 ﾠ
B-ﾭ‐Raf	 ﾠ[212,	 ﾠ213].	 ﾠThus,	 ﾠIQGAP1’s	 ﾠfunction	 ﾠas	 ﾠa	 ﾠMAPK	 ﾠscaffold	 ﾠmight	 ﾠbe	 ﾠan	 ﾠimportant	 ﾠ
contributor	 ﾠto	 ﾠtumourigenesis.	 ﾠIntriguingly,	 ﾠIQGAP1	 ﾠbinding	 ﾠto	 ﾠB-ﾭ‐Raf	 ﾠenhances	 ﾠits	 ﾠactivity	 ﾠ
in	 ﾠvitro	 ﾠand	 ﾠthis	 ﾠmay	 ﾠprovide	 ﾠa	 ﾠnovel	 ﾠmechanism	 ﾠfor	 ﾠpathway	 ﾠregulation.	 ﾠAlthough	 ﾠEGF	 ﾠ
stimulation	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠrequires	 ﾠIQGAP1,	 ﾠthe	 ﾠexact	 ﾠmechanism	 ﾠof	 ﾠERK	 ﾠactivation	 ﾠ
remains	 ﾠto	 ﾠbe	 ﾠelucidated	 ﾠ[210].	 ﾠ
Paxillin (binds Raf, MEK1/2 and ERK1/2) 
Paxillin	 ﾠis	 ﾠa	 ﾠscaffold	 ﾠprotein,	 ﾠwhich	 ﾠrecruits	 ﾠboth	 ﾠstructural	 ﾠand	 ﾠsignalling	 ﾠmolecules	 ﾠto	 ﾠ
adhesion	 ﾠsites	 ﾠand	 ﾠregulates	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠgene	 ﾠtranscription.	 ﾠIt	 ﾠis	 ﾠessential	 ﾠfor	 ﾠ
adhesion-ﾭ‐mediated	 ﾠactivation	 ﾠof	 ﾠERK	 ﾠ[214],	 ﾠand	 ﾠseveral	 ﾠmechanisms	 ﾠhave	 ﾠbeen	 ﾠproposed	 ﾠ
to	 ﾠexplain	 ﾠhow	 ﾠthis	 ﾠoccurs.	 ﾠOne	 ﾠmechanism	 ﾠsuggests	 ﾠthe	 ﾠassembly	 ﾠof	 ﾠa	 ﾠfunctional	 ﾠERK	 ﾠ
module	 ﾠon	 ﾠpaxillin	 ﾠitself,	 ﾠwhich	 ﾠexhibits	 ﾠdistinct	 ﾠbinding	 ﾠefficiencies	 ﾠfor	 ﾠall	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠ
ERK	 ﾠcascade.	 ﾠIt	 ﾠassociates	 ﾠconstitutively	 ﾠwith	 ﾠMEK,	 ﾠbut	 ﾠonly	 ﾠinteracts	 ﾠwith	 ﾠactivated	 ﾠRaf.	 ﾠ
ERK	 ﾠassociation	 ﾠwith	 ﾠthis	 ﾠscaffold	 ﾠis	 ﾠregulated	 ﾠby	 ﾠSrc.	 ﾠDuring	 ﾠcell	 ﾠadhesion	 ﾠSrc	 ﾠ
phosphorylates	 ﾠpaxillin	 ﾠat	 ﾠTyr118,	 ﾠwhich	 ﾠpromotes	 ﾠbinding	 ﾠof	 ﾠinactive	 ﾠERK	 ﾠto	 ﾠthe	 ﾠscaffold	 ﾠ
and	 ﾠinitiates	 ﾠERK	 ﾠactivation	 ﾠ[215].	 ﾠERK,	 ﾠin	 ﾠturn,	 ﾠphosphorylates	 ﾠpaxillin,	 ﾠwhich	 ﾠenhances	 ﾠ
the	 ﾠbinding	 ﾠof	 ﾠfocal	 ﾠadhesion	 ﾠkinase	 ﾠ(FAK)	 ﾠto	 ﾠthe	 ﾠscaffold	 ﾠand	 ﾠactivates	 ﾠRac	 ﾠsignalling	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further	 ﾠdownstream	 ﾠ[216].	 ﾠAs	 ﾠa	 ﾠresult,	 ﾠFAK	 ﾠpromotes	 ﾠthe	 ﾠturnover	 ﾠof	 ﾠfocal	 ﾠadhesions,	 ﾠ
whereas	 ﾠRac	 ﾠinitiates	 ﾠlamellipodia	 ﾠformation.	 ﾠThus,	 ﾠa	 ﾠfunctional	 ﾠERK	 ﾠmodule	 ﾠon	 ﾠpaxillin	 ﾠ
gives	 ﾠrise	 ﾠto	 ﾠa	 ﾠpositive	 ﾠfeedback	 ﾠloop	 ﾠthat	 ﾠcoordinates	 ﾠcell	 ﾠmotility.	 ﾠAlternatively,	 ﾠthe	 ﾠ
paxillin	 ﾠbinding	 ﾠprotein	 ﾠGIT1	 ﾠmay	 ﾠprovide	 ﾠa	 ﾠdocking	 ﾠplatform	 ﾠfor	 ﾠERK	 ﾠsignalling	 ﾠmolecules	 ﾠ
at	 ﾠfocal	 ﾠcomplexes	 ﾠ[217].	 ﾠGIT1	 ﾠinteracts	 ﾠwith	 ﾠMEK	 ﾠand	 ﾠERK1/2	 ﾠto	 ﾠinduce	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠ
response	 ﾠto	 ﾠEGF	 ﾠ[218,	 ﾠ219].	 ﾠAnother	 ﾠmechanism	 ﾠfor	 ﾠlocalising	 ﾠERK	 ﾠat	 ﾠfocal	 ﾠadhesions	 ﾠ
involves	 ﾠFAK.	 ﾠIndeed,	 ﾠFAK	 ﾠcan	 ﾠrecruit	 ﾠMEKK1,	 ﾠwhich	 ﾠitself	 ﾠis	 ﾠa	 ﾠdocking	 ﾠplatform	 ﾠfor	 ﾠthe	 ﾠ
ERK-ﾭ‐MAPK	 ﾠcascade	 ﾠ[220].	 ﾠ
Phosphoprotein enriched in astrocytes 15 (PEA-15; binds ERK1/2 and RSK2) 
The	 ﾠphosphoprotein	 ﾠPEA-ﾭ‐15	 ﾠwas	 ﾠoriginally	 ﾠidentified	 ﾠin	 ﾠastrocytes,	 ﾠwhere	 ﾠits	 ﾠexpression	 ﾠis	 ﾠ
enriched	 ﾠ[221].	 ﾠIt	 ﾠconsists	 ﾠof	 ﾠa	 ﾠdeath	 ﾠeffector	 ﾠdomain	 ﾠ(DED)	 ﾠand	 ﾠan	 ﾠunstructured	 ﾠ
C-ﾭ‐terminal	 ﾠtail,	 ﾠwhich	 ﾠis	 ﾠinvolved	 ﾠin	 ﾠERK	 ﾠbinding	 ﾠ[222].	 ﾠPEA-ﾭ‐15	 ﾠis	 ﾠthe	 ﾠonly	 ﾠdownstream	 ﾠERK	 ﾠ
scaffold	 ﾠknown	 ﾠto	 ﾠdate	 ﾠand	 ﾠforms	 ﾠa	 ﾠcomplex	 ﾠwith	 ﾠERK1/2	 ﾠand	 ﾠRSK2	 ﾠ(ribosomal	 ﾠS6	 ﾠ
kinase)	 ﾠ[223].	 ﾠFurthermore,	 ﾠPEA-ﾭ‐15	 ﾠfunctions	 ﾠas	 ﾠa	 ﾠcytoplasmic	 ﾠanchor	 ﾠprotein,	 ﾠalthough	 ﾠit	 ﾠ
is	 ﾠnot	 ﾠcompletely	 ﾠunderstood	 ﾠhow.	 ﾠThe	 ﾠphosphoprotein	 ﾠcontains	 ﾠa	 ﾠNES,	 ﾠwhich	 ﾠmight	 ﾠ
represent	 ﾠone	 ﾠpossibility	 ﾠfor	 ﾠkeeping	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠ[224].	 ﾠMoreover,	 ﾠ
PEA-ﾭ‐15	 ﾠand	 ﾠnucleoporins	 ﾠcompete	 ﾠfor	 ﾠthe	 ﾠsame	 ﾠbinding	 ﾠsite	 ﾠon	 ﾠERK.	 ﾠThus,	 ﾠPEA-ﾭ‐15	 ﾠ
complex	 ﾠformations	 ﾠblocks	 ﾠnuclear	 ﾠimport	 ﾠof	 ﾠERK	 ﾠand	 ﾠmight	 ﾠprovide	 ﾠanother	 ﾠmeans	 ﾠof	 ﾠ
cytoplasmic	 ﾠanchoring	 ﾠ[225].	 ﾠ	 ﾠ
Raf kinase inhibitor protein (RKIP; binds c-Raf/B-Raf, MEK1/2 and ERK1/2) 
The	 ﾠRaf	 ﾠkinase	 ﾠinhibitor	 ﾠprotein	 ﾠis	 ﾠset	 ﾠapart	 ﾠfrom	 ﾠother	 ﾠknown	 ﾠscaffolds	 ﾠin	 ﾠthat	 ﾠit	 ﾠprevents	 ﾠ
efficient	 ﾠERK	 ﾠactivation	 ﾠrather	 ﾠthan	 ﾠfacilitating	 ﾠit.	 ﾠRKIP	 ﾠcontains	 ﾠoverlapping	 ﾠdocking	 ﾠsites	 ﾠ
for	 ﾠMEK1/2	 ﾠand	 ﾠRaf.	 ﾠThus,	 ﾠbinding	 ﾠof	 ﾠthese	 ﾠtwo	 ﾠkinases	 ﾠis	 ﾠmutually	 ﾠexclusive	 ﾠand	 ﾠRKIP	 ﾠ
either	 ﾠforms	 ﾠa	 ﾠternary	 ﾠcomplex	 ﾠwith	 ﾠMEK	 ﾠand	 ﾠERK,	 ﾠor	 ﾠinteracts	 ﾠwith	 ﾠRaf	 ﾠin	 ﾠa	 ﾠbinary	 ﾠ
complex.	 ﾠCompetitive	 ﾠbinding	 ﾠof	 ﾠMEK	 ﾠand	 ﾠRaf	 ﾠprevents	 ﾠthe	 ﾠassembly	 ﾠof	 ﾠa	 ﾠfunctional	 ﾠERK	 ﾠ
module	 ﾠand	 ﾠthereby	 ﾠsuppresses	 ﾠERK	 ﾠactivation	 ﾠ[226].	 ﾠ	 ﾠ
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1.3.2.3  Localising ERK activity to specific subcellular compartments 
The	 ﾠlocalisation	 ﾠof	 ﾠERK	 ﾠto	 ﾠspecific	 ﾠsubcellular	 ﾠcompartments	 ﾠprovides	 ﾠan	 ﾠimportant	 ﾠmeans	 ﾠ
of	 ﾠcontrolling	 ﾠdownstream	 ﾠsubstrates	 ﾠand	 ﾠbiological	 ﾠoutcomes.	 ﾠNeuronal	 ﾠdifferentiation	 ﾠ
of	 ﾠPC12	 ﾠcells,	 ﾠfor	 ﾠexample,	 ﾠrequires	 ﾠnuclear	 ﾠERK	 ﾠsignalling.	 ﾠThus,	 ﾠblocking	 ﾠERK’s	 ﾠ
translocation	 ﾠto	 ﾠthe	 ﾠnucleus	 ﾠthrough	 ﾠcytoplasmic	 ﾠanchoring	 ﾠproteins	 ﾠinhibits	 ﾠthe	 ﾠ
formation	 ﾠof	 ﾠneurite	 ﾠextensions	 ﾠ[227].	 ﾠAs	 ﾠthe	 ﾠprevious	 ﾠsection	 ﾠ(1.3.2.2)	 ﾠhas	 ﾠhighlighted	 ﾠ
how	 ﾠdocking	 ﾠplatforms	 ﾠcan	 ﾠact	 ﾠto	 ﾠlocalise	 ﾠERK	 ﾠto	 ﾠdistinct	 ﾠsubcellular	 ﾠlocations,	 ﾠthe	 ﾠ
following	 ﾠparagraphs	 ﾠaim	 ﾠto	 ﾠdescribe	 ﾠhow	 ﾠERK-ﾭ‐specific	 ﾠanchoring	 ﾠproteins	 ﾠother	 ﾠthan	 ﾠ
scaffolds	 ﾠcan	 ﾠfunction	 ﾠto	 ﾠrecruit	 ﾠERKs	 ﾠto	 ﾠspecific	 ﾠcellular	 ﾠlocales.	 ﾠ
The	 ﾠcellular	 ﾠdistribution	 ﾠof	 ﾠERK	 ﾠchanges	 ﾠupon	 ﾠits	 ﾠactivation.	 ﾠWhereas,	 ﾠin	 ﾠquiescent	 ﾠcells	 ﾠ
the	 ﾠenzyme	 ﾠis	 ﾠmainly	 ﾠcytoplasmic,	 ﾠERK	 ﾠactivation	 ﾠtriggers	 ﾠits	 ﾠredistribution	 ﾠto	 ﾠdifferent	 ﾠ
cellular	 ﾠloci.	 ﾠThus,	 ﾠactive	 ﾠenzyme	 ﾠthen	 ﾠaccumulates	 ﾠin	 ﾠthe	 ﾠnucleus,	 ﾠwhere	 ﾠit	 ﾠdrives	 ﾠor	 ﾠ
inhibits	 ﾠtranscriptional	 ﾠevents.	 ﾠThis	 ﾠdynamic	 ﾠshuttling	 ﾠof	 ﾠERK	 ﾠis	 ﾠcontrolled	 ﾠby	 ﾠvarious	 ﾠ
anchoring	 ﾠproteins,	 ﾠincluding	 ﾠMEK,	 ﾠwhich	 ﾠwas	 ﾠthe	 ﾠfirst	 ﾠcytoplasmic	 ﾠretainer	 ﾠto	 ﾠbe	 ﾠ
identified	 ﾠ[179].	 ﾠERK	 ﾠactivation	 ﾠby	 ﾠMEK1/2	 ﾠtriggers	 ﾠa	 ﾠconformational	 ﾠchange,	 ﾠwhich	 ﾠ
disrupts	 ﾠthe	 ﾠinteraction	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠkinases	 ﾠ[130].	 ﾠThus,	 ﾠMEK-ﾭ‐mediated	 ﾠretention	 ﾠof	 ﾠ
ERK	 ﾠis	 ﾠstimulus-ﾭ‐dependent	 ﾠand	 ﾠreversible.	 ﾠIn	 ﾠcontrast,	 ﾠPEA-ﾭ‐15	 ﾠassociation	 ﾠwith	 ﾠERK	 ﾠis	 ﾠ
non-ﾭ‐reversible	 ﾠand	 ﾠtherefore	 ﾠindependent	 ﾠof	 ﾠERK’s	 ﾠphosphorylation	 ﾠstatus	 ﾠ[224].	 ﾠ
Although	 ﾠthe	 ﾠbiggest	 ﾠportion	 ﾠof	 ﾠactive	 ﾠERK	 ﾠis	 ﾠeither	 ﾠlocalised	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠor	 ﾠnucleus,	 ﾠ
about	 ﾠ10%	 ﾠof	 ﾠthe	 ﾠenzyme	 ﾠtranslocates	 ﾠto	 ﾠthe	 ﾠsurface	 ﾠof	 ﾠorganelles.	 ﾠSef-ﾭ‐1	 ﾠ(similar	 ﾠ
expression	 ﾠto	 ﾠfgf	 ﾠ1	 ﾠ[228])	 ﾠis	 ﾠan	 ﾠexample	 ﾠof	 ﾠan	 ﾠorganelle	 ﾠrecruiter,	 ﾠthat	 ﾠtargets	 ﾠERK	 ﾠ
specifically	 ﾠto	 ﾠmembrane	 ﾠruffles	 ﾠand	 ﾠthe	 ﾠGolgi.	 ﾠInterestingly,	 ﾠRas	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠfound	 ﾠto	 ﾠ
reside	 ﾠat	 ﾠthe	 ﾠGolgi,	 ﾠwhere	 ﾠit	 ﾠis	 ﾠactivated	 ﾠby	 ﾠthe	 ﾠRasGRP1,	 ﾠrather	 ﾠthan	 ﾠSOS.	 ﾠThus,	 ﾠlocalising	 ﾠ
ERK	 ﾠat	 ﾠthe	 ﾠGolgi	 ﾠmight	 ﾠspecifically	 ﾠinduce	 ﾠkinase	 ﾠactivity	 ﾠthrough	 ﾠmechanisms	 ﾠother	 ﾠthan	 ﾠ
the	 ﾠcanonical	 ﾠstimuli	 ﾠ[229].	 ﾠMoreover,	 ﾠSef-ﾭ‐1	 ﾠinhibits	 ﾠnuclear	 ﾠERK	 ﾠtranslocation	 ﾠwithout	 ﾠ
altering	 ﾠphosphorylation	 ﾠof	 ﾠcytoplasmic	 ﾠtargets.	 ﾠIt	 ﾠacts	 ﾠas	 ﾠa	 ﾠcytoplasmic	 ﾠretainer	 ﾠby	 ﾠ
binding	 ﾠto	 ﾠactivated	 ﾠMEK	 ﾠand	 ﾠinhibiting	 ﾠstimulus-ﾭ‐dependent	 ﾠdissociation	 ﾠof	 ﾠERK	 ﾠfrom	 ﾠ
MEK	 ﾠ[230].	 ﾠIn	 ﾠcontrast,	 ﾠa	 ﾠprotein	 ﾠcalled	 ﾠMxi2	 ﾠhas	 ﾠrecently	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠpromote	 ﾠ
stimulus-ﾭ‐independent	 ﾠtranslocation	 ﾠof	 ﾠERK	 ﾠto	 ﾠthe	 ﾠnucleus	 ﾠ[231].	 ﾠTwo	 ﾠfeatures	 ﾠof	 ﾠthis	 ﾠ
p38α	 ﾠsplice	 ﾠisoform	 ﾠ[232]	 ﾠaid	 ﾠto	 ﾠaccumulate	 ﾠERK	 ﾠmolecules	 ﾠin	 ﾠthe	 ﾠnucleus.	 ﾠFirstly,	 ﾠMxi2	 ﾠ
binds	 ﾠdirectly	 ﾠto	 ﾠERK1/2	 ﾠand	 ﾠthereby	 ﾠdisrupts	 ﾠpre-ﾭ‐existing	 ﾠPEA-ﾭ‐15/ERK	 ﾠcomplexes	 ﾠ[140].	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Secondly,	 ﾠMxi2	 ﾠinteracts	 ﾠwith	 ﾠnucleoporins,	 ﾠthus	 ﾠlocalising	 ﾠERK	 ﾠin	 ﾠthe	 ﾠvicinity	 ﾠof	 ﾠnuclear	 ﾠ
transporters	 ﾠand	 ﾠin	 ﾠdoing	 ﾠso	 ﾠincreasing	 ﾠits	 ﾠnuclear	 ﾠimport	 ﾠ[231].	 ﾠMoreover,	 ﾠMxi2	 ﾠhas	 ﾠbeen	 ﾠ
shown	 ﾠto	 ﾠprolong	 ﾠnuclear	 ﾠERK	 ﾠactivity	 ﾠ[233].	 ﾠOne	 ﾠpossible	 ﾠexplanation	 ﾠfor	 ﾠthis	 ﾠobservation	 ﾠ
is	 ﾠthat	 ﾠMxi2	 ﾠmasks	 ﾠphosphatase	 ﾠbinding	 ﾠsites	 ﾠon	 ﾠERK.	 ﾠFuture	 ﾠwork,	 ﾠincluding	 ﾠcompetition	 ﾠ
binding	 ﾠassays	 ﾠand	 ﾠcrystal	 ﾠstructures	 ﾠof	 ﾠthe	 ﾠMxi2/ERK	 ﾠcomplex,	 ﾠwill	 ﾠshed	 ﾠlight	 ﾠon	 ﾠhow	 ﾠ
Mxi2	 ﾠextends	 ﾠnuclear	 ﾠERK	 ﾠsignalling.	 ﾠ
DUSPs	 ﾠ(described	 ﾠin	 ﾠ1.3.2.1)	 ﾠmay	 ﾠalso	 ﾠserve	 ﾠas	 ﾠnuclear	 ﾠor	 ﾠcytoplasmic	 ﾠanchoring	 ﾠproteins.	 ﾠ
DUSP6,	 ﾠfor	 ﾠexample,	 ﾠanchors	 ﾠERK	 ﾠmolecules	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠvia	 ﾠits	 ﾠNES	 ﾠ[234].	 ﾠIn	 ﾠ
contrast,	 ﾠDUSP5	 ﾠcomprises	 ﾠa	 ﾠNLS	 ﾠadjacent	 ﾠto	 ﾠits	 ﾠD-ﾭ‐motif	 ﾠand	 ﾠthis	 ﾠsequesters	 ﾠERK	 ﾠin	 ﾠthe	 ﾠ
nucleus	 ﾠ[235].	 ﾠIn	 ﾠaddition,	 ﾠDUSP2	 ﾠand	 ﾠ-ﾭ‐4	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠretain	 ﾠERK	 ﾠin	 ﾠthe	 ﾠ
nucleus	 ﾠthrough	 ﾠdirect	 ﾠbinding	 ﾠ[236].	 ﾠGiven	 ﾠthe	 ﾠsignificant	 ﾠrole	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠ
regulating	 ﾠtranscriptional	 ﾠevents,	 ﾠmore	 ﾠnuclear	 ﾠanchoring	 ﾠproteins	 ﾠare	 ﾠexpected	 ﾠto	 ﾠbe	 ﾠ
identified.	 ﾠ
1.3.2.4  Regulating ERK activity through feedback loops 
ERK	 ﾠplays	 ﾠa	 ﾠcentral	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠmany	 ﾠbiological	 ﾠprocesses.	 ﾠPrevious	 ﾠsections	 ﾠhave	 ﾠ
described	 ﾠhow	 ﾠtargeting	 ﾠERK	 ﾠactivity	 ﾠto	 ﾠsubcellular	 ﾠloci	 ﾠcan	 ﾠachieve	 ﾠsignalling	 ﾠspecificity.	 ﾠ
Studies	 ﾠin	 ﾠPC12	 ﾠcells,	 ﾠhowever,	 ﾠprovide	 ﾠevidence	 ﾠthat	 ﾠsignal	 ﾠduration	 ﾠcan	 ﾠalso	 ﾠbe	 ﾠa	 ﾠ
determining	 ﾠfactor	 ﾠin	 ﾠbiological	 ﾠoutcomes;	 ﾠas	 ﾠsustained	 ﾠactivation	 ﾠof	 ﾠERK	 ﾠby	 ﾠNGF	 ﾠinduces	 ﾠ
differentiation	 ﾠin	 ﾠthis	 ﾠcell	 ﾠsystem,	 ﾠwhereas	 ﾠtransient	 ﾠsignalling	 ﾠresults	 ﾠin	 ﾠ
proliferation	 ﾠ[237].	 ﾠTherefore,	 ﾠERK	 ﾠsubstrates	 ﾠthat	 ﾠeither	 ﾠfeedback	 ﾠto	 ﾠincrease	 ﾠor	 ﾠ
decrease	 ﾠsignal	 ﾠduration	 ﾠare	 ﾠof	 ﾠparticular	 ﾠinterest	 ﾠin	 ﾠunderstanding	 ﾠthe	 ﾠMAPK	 ﾠcascade.	 ﾠ	 ﾠ
Several	 ﾠpoints	 ﾠof	 ﾠnegative	 ﾠfeedback	 ﾠhave	 ﾠbeen	 ﾠdescribed	 ﾠfor	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠ
pathway	 ﾠ(Figure	 ﾠ1-ﾭ‐9).	 ﾠFirstly,	 ﾠERK	 ﾠregulates	 ﾠits	 ﾠown	 ﾠactivation	 ﾠby	 ﾠphosphorylating	 ﾠMEK	 ﾠat	 ﾠ
Thr292.	 ﾠThe	 ﾠadded	 ﾠphospho	 ﾠgroup	 ﾠprevents	 ﾠfurther	 ﾠenhancement	 ﾠof	 ﾠMEK	 ﾠactivity	 ﾠand	 ﾠ
diminishes	 ﾠERK	 ﾠsignalling	 ﾠ[238].	 ﾠAnother	 ﾠexample	 ﾠof	 ﾠa	 ﾠnegative	 ﾠfeedback	 ﾠloop	 ﾠinvolves	 ﾠ
PAK1	 ﾠphosphorylation.	 ﾠGenerally,	 ﾠPAK1	 ﾠinfluences	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠby	 ﾠpriming	 ﾠ
MEK	 ﾠfor	 ﾠc-ﾭ‐Raf	 ﾠactivation.	 ﾠBy	 ﾠphosphorylating	 ﾠThr212,	 ﾠERK	 ﾠinhibits	 ﾠpriming	 ﾠof	 ﾠMEK	 ﾠand	 ﾠ
therefore	 ﾠlimits	 ﾠits	 ﾠown	 ﾠsignalling	 ﾠ[239,	 ﾠ240].	 ﾠAdditionally,	 ﾠmultiple	 ﾠERK	 ﾠphosphorylation	 ﾠ
sites	 ﾠon	 ﾠRaf	 ﾠhave	 ﾠbeen	 ﾠdescribed.	 ﾠHyperphosphorylation	 ﾠof	 ﾠthese	 ﾠresidues	 ﾠinhibits	 ﾠ
membrane	 ﾠrecruitment	 ﾠof	 ﾠRaf	 ﾠand	 ﾠpromotes	 ﾠits	 ﾠinactivation	 ﾠby	 ﾠPP2A	 ﾠ[241].	 ﾠIntriguingly,	 ﾠa	 ﾠ
positive	 ﾠfeedback	 ﾠloop	 ﾠto	 ﾠRaf	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠreported.	 ﾠThus,	 ﾠRaf	 ﾠphosphorylation	 ﾠby	 ﾠERK	 ﾠ	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 ﾠ
Figure 1-9 ERK pathway regulation by feedback loops 
Canonical activation of the ERK-MAPK pathway is depicted in its simplest form. EGF molecules bind to 
EGFR receptors and initiate receptor dimerisation followed by transphosphorylation. Next, Grb-2 binds to 
phosphotyrosine residues in the cytoplasmic receptor tail and recruits the guanine nucleotide exchange factor 
SOS. Subsequent activation of Ras leads to the recruitment of Raf to the plasma membrane, where the kinase 
is activated and sequential phosphorylation of MEK and ERK finalise the activation of the pathway. Active 
ERK can increase its activity through positive feedback loops (depicted in green) or diminish its signalling 
capacity through negative feedback loops (depicted in red). Negative feedback loops display a mechanisms 
by which ERK signalling can be shut down to basal levels following pathway activation. Adapted from 
[140]. 
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can	 ﾠeither	 ﾠincrease	 ﾠor	 ﾠreduce	 ﾠits	 ﾠactivity	 ﾠ[242].	 ﾠPhosphoacceptor	 ﾠsites	 ﾠidentified	 ﾠto	 ﾠ
increase	 ﾠRaf	 ﾠsignalling	 ﾠare	 ﾠalso	 ﾠinvolved	 ﾠin	 ﾠinhibiting	 ﾠthe	 ﾠkinase,	 ﾠand	 ﾠit	 ﾠis	 ﾠunclear	 ﾠwhat	 ﾠ
determines	 ﾠa	 ﾠpositive	 ﾠor	 ﾠnegative	 ﾠfeedback	 ﾠloop	 ﾠto	 ﾠRaf.	 ﾠ	 ﾠ
The	 ﾠguanine	 ﾠnucleotide	 ﾠexchange	 ﾠfactor	 ﾠSOS	 ﾠ(son	 ﾠof	 ﾠsevenless)	 ﾠis	 ﾠsubject	 ﾠto	 ﾠERK	 ﾠ
phosphorylation.	 ﾠSOS	 ﾠactivates	 ﾠRas	 ﾠby	 ﾠpromoting	 ﾠa	 ﾠGTP-ﾭ‐bound	 ﾠstate	 ﾠand	 ﾠis	 ﾠusually	 ﾠ
localised	 ﾠin	 ﾠthe	 ﾠcytoplasm.	 ﾠUpon	 ﾠactivation	 ﾠof	 ﾠtransmembrane	 ﾠreceptor	 ﾠtyrosine	 ﾠ
kinases	 ﾠ(RTK),	 ﾠSOS	 ﾠis	 ﾠrecruited	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠto	 ﾠactivate	 ﾠRas.	 ﾠPhosphorylation	 ﾠ
by	 ﾠERK	 ﾠprevents	 ﾠthis	 ﾠrecruitment	 ﾠand	 ﾠblocks	 ﾠpathway	 ﾠactivation	 ﾠ[243].	 ﾠFurthermore,	 ﾠ
sustained	 ﾠERK	 ﾠactivation	 ﾠinduces	 ﾠthe	 ﾠtranscription	 ﾠof	 ﾠMKPs,	 ﾠsuch	 ﾠas	 ﾠDUSP2	 ﾠand	 ﾠ-ﾭ‐5,	 ﾠwhich	 ﾠ
turn	 ﾠoff	 ﾠERK	 ﾠsignalling	 ﾠby	 ﾠdephosphorylating	 ﾠthe	 ﾠenzyme	 ﾠ[244].	 ﾠIn	 ﾠaddition,	 ﾠDUSPs	 ﾠmay	 ﾠ
also	 ﾠbe	 ﾠsubject	 ﾠto	 ﾠERK	 ﾠphosphorylation,	 ﾠalthough	 ﾠthis	 ﾠcan	 ﾠinitiate	 ﾠa	 ﾠpositive	 ﾠor	 ﾠnegative	 ﾠ
feedback	 ﾠloop	 ﾠdepending	 ﾠon	 ﾠthe	 ﾠphosphatase.	 ﾠPhosphorylation	 ﾠof	 ﾠDUSP1	 ﾠstabilises	 ﾠthe	 ﾠ
phosphatase	 ﾠand	 ﾠultimately	 ﾠdecreases	 ﾠERK	 ﾠactivity	 ﾠin	 ﾠthe	 ﾠnucleus	 ﾠ[177].	 ﾠOn	 ﾠthe	 ﾠother	 ﾠ
hand,	 ﾠDUSP6	 ﾠphosphorylation	 ﾠmarks	 ﾠthe	 ﾠphosphatase	 ﾠfor	 ﾠproteasomal	 ﾠdegradation	 ﾠ
without	 ﾠaltering	 ﾠits	 ﾠactivity	 ﾠ[176].	 ﾠMoreover,	 ﾠdirect	 ﾠinteraction	 ﾠof	 ﾠERK	 ﾠand	 ﾠDUSPs	 ﾠ(e.g.	 ﾠ
DUSP5)	 ﾠmay	 ﾠstabilise	 ﾠthe	 ﾠphosphatases	 ﾠand	 ﾠreinforce	 ﾠtheir	 ﾠenzymatic	 ﾠactivity	 ﾠ[245].	 ﾠTaken	 ﾠ
together,	 ﾠfeedback	 ﾠloops	 ﾠplay	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠERK	 ﾠactivity.	 ﾠThey	 ﾠenable	 ﾠ
fine-ﾭ‐tuning	 ﾠsignalling	 ﾠstrength	 ﾠand	 ﾠduration,	 ﾠwhich	 ﾠultimately	 ﾠgoverns	 ﾠbiological	 ﾠ
processes.	 ﾠ
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1.4  The ERK-MAPK pathway in cancer 
It	 ﾠhas	 ﾠlong	 ﾠbeen	 ﾠappreciated	 ﾠthat	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠhas	 ﾠa	 ﾠkey	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠ
fundamental	 ﾠcellular	 ﾠprocesses	 ﾠsuch	 ﾠas	 ﾠproliferation,	 ﾠdifferentiation	 ﾠand	 ﾠcell	 ﾠmotility.	 ﾠ
Cellular	 ﾠhomeostasis,	 ﾠtherefore,	 ﾠrequires	 ﾠtight	 ﾠregulation	 ﾠof	 ﾠthe	 ﾠcascade	 ﾠand	 ﾠaberrant	 ﾠERK	 ﾠ
signalling	 ﾠcontributes	 ﾠto	 ﾠmultiple	 ﾠdiseases,	 ﾠincluding	 ﾠcancer.	 ﾠIndeed,	 ﾠhyperactivation	 ﾠof	 ﾠ
the	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠis	 ﾠprevalent	 ﾠin	 ﾠone	 ﾠthird	 ﾠof	 ﾠall	 ﾠhuman	 ﾠtumours	 ﾠand	 ﾠis	 ﾠimplicated	 ﾠ
in	 ﾠmany	 ﾠhallmarks	 ﾠof	 ﾠcancer	 ﾠ[246].	 ﾠSubsequent	 ﾠsections	 ﾠwill	 ﾠdescribe	 ﾠhow	 ﾠERK	 ﾠsignalling	 ﾠ
promotes	 ﾠtumourigenesis	 ﾠand	 ﾠdiscuss	 ﾠtherapeutic	 ﾠstrategies	 ﾠtargeting	 ﾠthe	 ﾠpathway.	 ﾠ
1.4.1  Activating mutations of the ERK-MAPK pathway 
Aberrant	 ﾠERK	 ﾠsignalling	 ﾠis	 ﾠtriggered	 ﾠby	 ﾠactivating	 ﾠmutations	 ﾠand/or	 ﾠoverexpression	 ﾠof	 ﾠ
upstream	 ﾠcomponents	 ﾠof	 ﾠthe	 ﾠcascade.	 ﾠCanonically,	 ﾠERK	 ﾠis	 ﾠstimulated	 ﾠby	 ﾠgrowth	 ﾠfactors,	 ﾠ
which	 ﾠbind	 ﾠto	 ﾠtransmembrane	 ﾠreceptor	 ﾠtyrosine	 ﾠkinases	 ﾠ(RTK),	 ﾠsuch	 ﾠas	 ﾠPDGFR,	 ﾠEGFR,	 ﾠ
ErbB2	 ﾠand	 ﾠc-ﾭ‐Met.	 ﾠLigand	 ﾠbinding	 ﾠactivates	 ﾠthe	 ﾠreceptor	 ﾠby	 ﾠinitiating	 ﾠreceptor	 ﾠdimerisation	 ﾠ
(or	 ﾠin	 ﾠsome	 ﾠcases	 ﾠoligomerisation)	 ﾠand	 ﾠsubsequent	 ﾠtransphosphorylation.	 ﾠIn	 ﾠcancer,	 ﾠ
several	 ﾠmechanisms	 ﾠcan	 ﾠstimulate	 ﾠinappropriate	 ﾠreceptor	 ﾠactivation.	 ﾠFirstly,	 ﾠtumour	 ﾠcells	 ﾠ
often	 ﾠsynthesize	 ﾠtheir	 ﾠown	 ﾠgrowth	 ﾠfactors,	 ﾠwhich	 ﾠtrigger	 ﾠconstitutive	 ﾠreceptor	 ﾠactivation	 ﾠ
in	 ﾠan	 ﾠautocrine	 ﾠmanner.	 ﾠClinical	 ﾠexamples	 ﾠinclude	 ﾠPDGF	 ﾠand	 ﾠTGFα	 ﾠ(a	 ﾠligand	 ﾠfor	 ﾠEGFR)	 ﾠ
secretion	 ﾠin	 ﾠglioblastomas	 ﾠand	 ﾠsarcomas,	 ﾠrespectively	 ﾠ[1].	 ﾠMoreover,	 ﾠcell	 ﾠsurface	 ﾠ
receptors	 ﾠthemselves	 ﾠcan	 ﾠbe	 ﾠsubject	 ﾠto	 ﾠderegulation.	 ﾠIn	 ﾠmany	 ﾠtumours	 ﾠgenes,	 ﾠencoding	 ﾠ
RTKs,	 ﾠare	 ﾠamplified	 ﾠand	 ﾠlead	 ﾠto	 ﾠreceptor	 ﾠoverexpression.	 ﾠExamples	 ﾠinclude	 ﾠegfr	 ﾠ
amplification	 ﾠin	 ﾠbrain	 ﾠand	 ﾠbreast	 ﾠtumours	 ﾠ[247,	 ﾠ248]	 ﾠor	 ﾠHer2	 ﾠoverexpression	 ﾠin	 ﾠmammary	 ﾠ
and	 ﾠovarian	 ﾠcarcinomas	 ﾠ[249,	 ﾠ250].	 ﾠIncreasing	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠone	 ﾠparticular	 ﾠ
receptor	 ﾠchanges	 ﾠthe	 ﾠoverall	 ﾠcomposition	 ﾠof	 ﾠsurface	 ﾠreceptors	 ﾠin	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠ
and	 ﾠswitches	 ﾠgrowth	 ﾠfactor	 ﾠresponsiveness	 ﾠof	 ﾠthe	 ﾠtumour	 ﾠcell	 ﾠto	 ﾠpreviously	 ﾠ
non-ﾭ‐stimulating	 ﾠligands.	 ﾠIntriguingly,	 ﾠgross	 ﾠoverexpression	 ﾠof	 ﾠsurface	 ﾠreceptors	 ﾠcan	 ﾠtrigger	 ﾠ
receptor	 ﾠdimerization	 ﾠand	 ﾠsubsequent	 ﾠactivation	 ﾠin	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠextracellular	 ﾠ
ligands	 ﾠ[251].	 ﾠMoreover,	 ﾠactivating	 ﾠtruncations	 ﾠand	 ﾠmutations	 ﾠof	 ﾠRTKs	 ﾠhave	 ﾠbeen	 ﾠ
observed	 ﾠin	 ﾠhuman	 ﾠtumours	 ﾠ[252].	 ﾠ
Further	 ﾠdownstream,	 ﾠRas	 ﾠproteins,	 ﾠof	 ﾠwhich	 ﾠthere	 ﾠare	 ﾠfour	 ﾠisoforms	 ﾠ(N-ﾭ‐Ras,	 ﾠH-ﾭ‐Ras,	 ﾠK-ﾭ‐Ras	 ﾠ
a	 ﾠand	 ﾠb),	 ﾠmay	 ﾠbe	 ﾠsubject	 ﾠto	 ﾠderegulation.	 ﾠIndeed,	 ﾠRas	 ﾠmutations	 ﾠoccur	 ﾠvery	 ﾠfrequently	 ﾠin	 ﾠ
human	 ﾠtumours	 ﾠand	 ﾠare	 ﾠfound	 ﾠin	 ﾠ90%	 ﾠof	 ﾠpancreatic	 ﾠlesions,	 ﾠ50%	 ﾠof	 ﾠcolon	 ﾠcarcinomas	 ﾠand	 ﾠChapter 1 – Introduction    61 
40%	 ﾠof	 ﾠlung	 ﾠcarcinomas	 ﾠ[213].	 ﾠRas	 ﾠproteins	 ﾠbelong	 ﾠto	 ﾠthe	 ﾠprotein	 ﾠfamily	 ﾠof	 ﾠsmall	 ﾠGTPases,	 ﾠ
which	 ﾠhave	 ﾠbeen	 ﾠcharacterised	 ﾠas	 ﾠmolecular	 ﾠswitches,	 ﾠbecause	 ﾠthey	 ﾠcycle	 ﾠbetween	 ﾠan	 ﾠ
inactive	 ﾠGDP-ﾭ‐bound	 ﾠand	 ﾠan	 ﾠactive	 ﾠGTP-ﾭ‐bound	 ﾠstate.	 ﾠGTP	 ﾠexchange	 ﾠfactors	 ﾠ(GEFs)	 ﾠcan	 ﾠturn	 ﾠ
these	 ﾠmolecular	 ﾠswitches	 ﾠon	 ﾠby	 ﾠpromoting	 ﾠGDP	 ﾠdissociation	 ﾠand	 ﾠsubsequent	 ﾠGTP	 ﾠbinding.	 ﾠ
In	 ﾠcontrast,	 ﾠGTPase	 ﾠactivating	 ﾠproteins	 ﾠ(GAPs)	 ﾠact	 ﾠto	 ﾠaccelerate	 ﾠGTP	 ﾠhydrolysis,	 ﾠthus	 ﾠ
turning	 ﾠRas	 ﾠsignalling	 ﾠoff.	 ﾠIn	 ﾠhuman	 ﾠcancers,	 ﾠsingle	 ﾠamino	 ﾠacid	 ﾠsubstitutions	 ﾠimpair	 ﾠthe	 ﾠ
intrinsic	 ﾠhydrolase	 ﾠactivity,	 ﾠthus	 ﾠrendering	 ﾠRas	 ﾠconstitutively	 ﾠGTP-ﾭ‐bound	 ﾠand	 ﾠactivated.	 ﾠ
Single	 ﾠpoint	 ﾠmutations	 ﾠhave	 ﾠbeen	 ﾠidentified	 ﾠfor	 ﾠcodon	 ﾠ12,	 ﾠ61	 ﾠand	 ﾠless	 ﾠfrequently	 ﾠ13	 ﾠ[253,	 ﾠ
254].	 ﾠ
Raf	 ﾠoncogenes	 ﾠcomprise	 ﾠanother	 ﾠgroup	 ﾠof	 ﾠderegulated	 ﾠsignalling	 ﾠmolecules	 ﾠin	 ﾠhuman	 ﾠ
cancers.	 ﾠAmong	 ﾠthe	 ﾠthree	 ﾠRaf	 ﾠkinases,	 ﾠB-ﾭ‐Raf	 ﾠis	 ﾠfrequently	 ﾠmutated	 ﾠin	 ﾠmany	 ﾠcancer	 ﾠ
subtypes,	 ﾠsuch	 ﾠas	 ﾠmelanomas	 ﾠ(70%),	 ﾠthyroid	 ﾠcancer	 ﾠ(53%),	 ﾠcolorectal	 ﾠcancer	 ﾠ(22%)	 ﾠand	 ﾠ
ovarian	 ﾠcarcinoma	 ﾠ(30%)	 ﾠ[255,	 ﾠ256].	 ﾠInterestingly,	 ﾠc-ﾭ‐Raf	 ﾠmutations	 ﾠare	 ﾠrare	 ﾠand	 ﾠvery	 ﾠlittle	 ﾠ
evidence	 ﾠexists	 ﾠfor	 ﾠA-ﾭ‐Raf	 ﾠmutations.	 ﾠA	 ﾠscreen	 ﾠof	 ﾠcolorectal	 ﾠadenocarcinomas	 ﾠidentified	 ﾠ
one	 ﾠsilent	 ﾠexogenic	 ﾠmutation	 ﾠin	 ﾠthe	 ﾠA-ﾭ‐raf	 ﾠgene	 ﾠand	 ﾠno	 ﾠexogenic	 ﾠmutation	 ﾠfor	 ﾠc-ﾭ‐Raf	 ﾠ[257].	 ﾠ
In	 ﾠcontrast,	 ﾠover	 ﾠ30	 ﾠmutations	 ﾠhave	 ﾠbeen	 ﾠdetected	 ﾠfor	 ﾠthe	 ﾠB-ﾭ‐raf	 ﾠgene,	 ﾠwith	 ﾠthe	 ﾠV600E	 ﾠ
mutation	 ﾠbeing	 ﾠthe	 ﾠmost	 ﾠfrequent	 ﾠone	 ﾠ(>90%).	 ﾠIt	 ﾠis	 ﾠnot	 ﾠentirely	 ﾠclear,	 ﾠwhy	 ﾠA-ﾭ‐Raf	 ﾠand	 ﾠc-ﾭ‐Raf	 ﾠ
mutations	 ﾠare	 ﾠunderpresented	 ﾠin	 ﾠhuman	 ﾠtumours.	 ﾠOne	 ﾠpossible	 ﾠexplanation	 ﾠis	 ﾠbased	 ﾠon	 ﾠ
the	 ﾠactivation	 ﾠmechanism	 ﾠof	 ﾠthe	 ﾠthree	 ﾠkinases,	 ﾠwhich	 ﾠrequires	 ﾠa	 ﾠnegative	 ﾠcharge	 ﾠin	 ﾠthe	 ﾠ
N-ﾭ‐region.	 ﾠIn	 ﾠA-ﾭ‐Raf	 ﾠand	 ﾠc-ﾭ‐Raf,	 ﾠthis	 ﾠis	 ﾠachieved	 ﾠthrough	 ﾠactivating	 ﾠphosphorylation	 ﾠof	 ﾠtwo	 ﾠ
residues.	 ﾠIn	 ﾠB-ﾭ‐Raf	 ﾠhowever,	 ﾠthe	 ﾠN-ﾭ‐region	 ﾠis	 ﾠconstitutively	 ﾠphosphorylated	 ﾠand	 ﾠthereby	 ﾠ
primed	 ﾠfor	 ﾠactivation.	 ﾠConsequently,	 ﾠactivation	 ﾠof	 ﾠB-ﾭ‐Raf	 ﾠcan	 ﾠbe	 ﾠaccomplished	 ﾠin	 ﾠa	 ﾠsingle	 ﾠ
mutation	 ﾠevent,	 ﾠwhereas	 ﾠconstitutive	 ﾠactivation	 ﾠof	 ﾠeither	 ﾠA-ﾭ‐Raf	 ﾠor	 ﾠC-ﾭ‐Raf	 ﾠrequires	 ﾠat	 ﾠleast	 ﾠ
two	 ﾠgenetic	 ﾠalterations	 ﾠ[258].	 ﾠIn	 ﾠgeneral,	 ﾠB-ﾭ‐Raf	 ﾠmutations	 ﾠare	 ﾠsubdivided	 ﾠinto	 ﾠtwo	 ﾠgroups:	 ﾠ
(i)	 ﾠthose	 ﾠwhich	 ﾠgive	 ﾠrise	 ﾠto	 ﾠa	 ﾠconstitutively	 ﾠactive	 ﾠkinases	 ﾠand	 ﾠ(ii)	 ﾠmutations,	 ﾠwhich	 ﾠentail	 ﾠ
an	 ﾠimpaired	 ﾠor	 ﾠunaltered	 ﾠkinase	 ﾠactivity	 ﾠ[259].	 ﾠThe	 ﾠV600E	 ﾠmutation	 ﾠconstitutively	 ﾠ
activates	 ﾠB-ﾭ‐Raf	 ﾠand	 ﾠtriggers	 ﾠcontinuous	 ﾠphosphorylation	 ﾠof	 ﾠMEK	 ﾠin	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠ
extracellular	 ﾠstimuli	 ﾠand	 ﾠactive	 ﾠRas.	 ﾠIn	 ﾠcontrast,	 ﾠsome	 ﾠB-ﾭ‐Raf	 ﾠmutations	 ﾠare	 ﾠcompromised	 ﾠ
in	 ﾠtheir	 ﾠability	 ﾠto	 ﾠactivate	 ﾠMEK,	 ﾠbut	 ﾠrather	 ﾠelevate	 ﾠERK	 ﾠsignalling	 ﾠindirectly	 ﾠby	 ﾠactivating	 ﾠ
wildtype	 ﾠc-ﾭ‐Raf	 ﾠin	 ﾠan	 ﾠuncontrolled	 ﾠmanner	 ﾠ[259].	 ﾠ
Notably,	 ﾠno	 ﾠactivating	 ﾠMEK	 ﾠor	 ﾠERK	 ﾠmutations	 ﾠhave	 ﾠbeen	 ﾠidentified	 ﾠin	 ﾠhuman	 ﾠcancers.	 ﾠThis	 ﾠ
is	 ﾠno	 ﾠsurprise,	 ﾠas	 ﾠboth	 ﾠkinases	 ﾠrequire	 ﾠdual	 ﾠphosphorylation	 ﾠfor	 ﾠfull	 ﾠenzymatic	 ﾠactivity.	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Thus,	 ﾠtwo	 ﾠgenetic	 ﾠalterations	 ﾠwould	 ﾠbe	 ﾠrequired	 ﾠfor	 ﾠconstitutive	 ﾠactivation	 ﾠof	 ﾠthese	 ﾠ
enzymes.	 ﾠ
1.4.2  The role of ERK in growth and proliferation 
Enhanced	 ﾠbiosynthesis	 ﾠof	 ﾠmacromolecules,	 ﾠmembranes	 ﾠand	 ﾠorganelles,	 ﾠincreases	 ﾠthe	 ﾠ
cellular	 ﾠvolume	 ﾠand	 ﾠrepresents	 ﾠa	 ﾠprerequisite	 ﾠfor	 ﾠcell	 ﾠdivision.	 ﾠThus,	 ﾠit	 ﾠis	 ﾠno	 ﾠsurprise	 ﾠthat	 ﾠ
cell	 ﾠgrowth	 ﾠand	 ﾠcell	 ﾠcycle	 ﾠentry	 ﾠare	 ﾠtightly	 ﾠcoordinated	 ﾠto	 ﾠmaintain	 ﾠa	 ﾠconstant	 ﾠcell	 ﾠsize.	 ﾠ
ERK	 ﾠsignalling	 ﾠstimulates	 ﾠprotein	 ﾠsynthesis	 ﾠthrough	 ﾠvarious	 ﾠmechanisms	 ﾠ(see	 ﾠTable	 ﾠ1-ﾭ‐7).	 ﾠ
Firstly,	 ﾠERK1/2	 ﾠphosphorylate	 ﾠand	 ﾠthereby	 ﾠactivate	 ﾠMAPKAPKs,	 ﾠMNK1	 ﾠand	 ﾠMNK2,	 ﾠwhich	 ﾠ
subsequently	 ﾠphosphorylate	 ﾠthe	 ﾠtranslation	 ﾠinitiation	 ﾠfactor	 ﾠeIF4E	 ﾠat	 ﾠSer209	 ﾠ[260,	 ﾠ261].	 ﾠ
Although	 ﾠeIF4E	 ﾠis	 ﾠa	 ﾠgeneral	 ﾠtranslation	 ﾠinitiation	 ﾠfactor,	 ﾠthe	 ﾠphosphorylated	 ﾠprotein	 ﾠ
preferentially	 ﾠaugments	 ﾠtranslation	 ﾠof	 ﾠmRNAs	 ﾠwith	 ﾠextensive	 ﾠ5ˊUTRs,	 ﾠincluding	 ﾠribosomal,	 ﾠ
growth-ﾭ‐related	 ﾠand	 ﾠanti-ﾭ‐apoptotic	 ﾠmRNAs	 ﾠ[262].	 ﾠMoreover,	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠ
impinges	 ﾠon	 ﾠthe	 ﾠmTOR	 ﾠ(mammalian	 ﾠtarget	 ﾠof	 ﾠrapamycin)	 ﾠpathway,	 ﾠwhich	 ﾠis	 ﾠregarded	 ﾠas	 ﾠ
the	 ﾠmaster	 ﾠregulator	 ﾠof	 ﾠgrowth,	 ﾠbecause	 ﾠit	 ﾠmodulates	 ﾠribosome	 ﾠbiogenesis	 ﾠand	 ﾠ
translation	 ﾠinitiation.	 ﾠThe	 ﾠmTOR	 ﾠkinase	 ﾠis	 ﾠsterically	 ﾠactivated	 ﾠby	 ﾠa	 ﾠsmall	 ﾠGTPase	 ﾠcalled	 ﾠ
Rheb	 ﾠ[263].	 ﾠThe	 ﾠheterodimer	 ﾠof	 ﾠthe	 ﾠtuberous	 ﾠsclerosis	 ﾠcomplex	 ﾠ1	 ﾠand	 ﾠ2	 ﾠ(TSC1/TSC2)	 ﾠacts	 ﾠ
as	 ﾠa	 ﾠGAP	 ﾠfor	 ﾠRheb	 ﾠand	 ﾠthus	 ﾠantagonises	 ﾠmTOR	 ﾠstimulation.	 ﾠDirect	 ﾠphosphorylation	 ﾠof	 ﾠ
TSC2	 ﾠby	 ﾠERK1/2	 ﾠdisrupts	 ﾠheterodimer	 ﾠformation	 ﾠand	 ﾠconsequently	 ﾠenhances	 ﾠmTOR	 ﾠ
signalling	 ﾠ[264].	 ﾠMoreover,	 ﾠRSK1,	 ﾠa	 ﾠdownstream	 ﾠERK	 ﾠsubstrate,	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠ
inactivate	 ﾠthe	 ﾠTSC1/TSC2	 ﾠcomplex	 ﾠthrough	 ﾠphosphorylation	 ﾠof	 ﾠSer1798	 ﾠ[265].	 ﾠ
Additionally,	 ﾠRNA	 ﾠpolymerase	 ﾠI	 ﾠ(Pol	 ﾠI)-ﾭ‐mediated	 ﾠtranscription	 ﾠof	 ﾠribosomal	 ﾠgenes	 ﾠis	 ﾠ
subject	 ﾠto	 ﾠERK	 ﾠregulation.	 ﾠInitiation	 ﾠof	 ﾠPol	 ﾠI	 ﾠtranscription	 ﾠrequires	 ﾠthe	 ﾠsequential	 ﾠbinding	 ﾠ
of	 ﾠtwo	 ﾠtranscription	 ﾠfactors,	 ﾠi.e.	 ﾠUBF	 ﾠand	 ﾠSL1,	 ﾠat	 ﾠthe	 ﾠtranscription	 ﾠinitiation	 ﾠsite.	 ﾠFirst,	 ﾠthe	 ﾠ
upstream	 ﾠbinding	 ﾠfactor	 ﾠ(UBF)	 ﾠbinds	 ﾠto	 ﾠthe	 ﾠpromoter	 ﾠelement	 ﾠand	 ﾠthe	 ﾠupstream	 ﾠcontrol	 ﾠ
element,	 ﾠthus	 ﾠbringing	 ﾠthem	 ﾠtogether	 ﾠand	 ﾠcreating	 ﾠa	 ﾠplatform	 ﾠfor	 ﾠSL1	 ﾠ(selectivity	 ﾠfactor	 ﾠ1)	 ﾠ
binding.	 ﾠSubsequently,	 ﾠPol	 ﾠI	 ﾠis	 ﾠrecruited	 ﾠto	 ﾠthe	 ﾠpromoter	 ﾠsite	 ﾠand	 ﾠan	 ﾠinitiation	 ﾠcomplex	 ﾠis	 ﾠ
formed.	 ﾠInterestingly,	 ﾠUBF	 ﾠis	 ﾠsubject	 ﾠto	 ﾠdirect	 ﾠphosphorylation	 ﾠby	 ﾠERK1/2	 ﾠand	 ﾠonly	 ﾠ
modified	 ﾠUBF	 ﾠcan	 ﾠrecognise	 ﾠrRNA	 ﾠpromoter	 ﾠsites.	 ﾠThus,	 ﾠthe	 ﾠinitiation	 ﾠof	 ﾠPol	 ﾠI	 ﾠtranscription	 ﾠ
directly	 ﾠdepends	 ﾠon	 ﾠERK1/2	 ﾠsignalling	 ﾠ[266].	 ﾠIn	 ﾠaddition,	 ﾠERK1/2	 ﾠphosphorylate	 ﾠthe	 ﾠ
transcription	 ﾠinitiation	 ﾠfactor-ﾭ‐1A	 ﾠ(TIF1A)	 ﾠat	 ﾠSer633	 ﾠto	 ﾠpromote	 ﾠRNA	 ﾠPol	 ﾠI	 ﾠ
transcription	 ﾠ[267].	 ﾠInterestingly,	 ﾠtranscriptional	 ﾠevents	 ﾠof	 ﾠPol	 ﾠII	 ﾠand	 ﾠIII	 ﾠare	 ﾠalso	 ﾠmodulated	 ﾠ
through	 ﾠERK-ﾭ‐mediated	 ﾠphosphorylation	 ﾠevents.	 ﾠThus,	 ﾠTFII-ﾭ‐I	 ﾠpromotes	 ﾠtranscriptional	 ﾠ	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Cellular function  Protein  Name  Phosphorylation site(s)  Ref 
Cellular growth  TSC2  tuberous sclerosis complex 2  Ser664  [264] 
TFII-I  transcription factor II-I  Ser627, Ser633  [268] 
Brf1  subunit of transcription factor 
III B 
unknown  [269] 
TIF1A  transcription factor 1A  Ser633  [267] 
UBF  upstream binding factor  Thr117  [266] 
RNA Pol II  RNA polymerase II  multiple sites  [270] 
Proliferation  Tob1  transducer of Erbb2  Ser152, Ser154, Ser164  [271] 
c-Myc  myelocytomatosis oncogene  Ser62  [272] 
Survival  FOXO3A  forkhead box O3  Ser294, Ser344, Ser425  [273] 
BimEL  Bcl-2 like 11  Ser109, Thr110  [274] 
Caspase 9    Thr125  [275] 
Cell migration  FAK  focal adhesion kinase  Ser910  [276] 
MLCK  myosin light chain kinase  Ser13  [277] 
Cortactin    Ser405, Ser418  [278] 
Paxillin    unknown, Ser83 (mouse)  [216] 
Stathmin    Ser16, Ser25, Ser38  [279] 
Vinexinβ    Ser189  [280] 
Calpain    Ser50  [281] 
Table 1-7 Bona fide ERK substrates grouped according to their biological functions 
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activity	 ﾠon	 ﾠthe	 ﾠc-ﾭ‐Fos	 ﾠpromoter	 ﾠas	 ﾠa	 ﾠresult	 ﾠof	 ﾠdirect	 ﾠphosphorylation	 ﾠby	 ﾠERK	 ﾠ[268].	 ﾠ
Moreover,	 ﾠthe	 ﾠtranscriptional	 ﾠactivity	 ﾠof	 ﾠRNA	 ﾠPol	 ﾠII	 ﾠis	 ﾠinduced	 ﾠthrough	 ﾠdirect	 ﾠ
phosphorylation	 ﾠof	 ﾠERK	 ﾠat	 ﾠmultiple	 ﾠsites	 ﾠ[270].	 ﾠLikewise,	 ﾠRNA	 ﾠPol	 ﾠIII	 ﾠtranscription	 ﾠis	 ﾠ
induced	 ﾠas	 ﾠa	 ﾠresult	 ﾠof	 ﾠdirect	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠTFIIIB	 ﾠsubunit,	 ﾠBrf1	 ﾠ[269].	 ﾠ
In	 ﾠaddition	 ﾠto	 ﾠan	 ﾠincreased	 ﾠdemand	 ﾠfor	 ﾠproteins,	 ﾠgrowing	 ﾠcells	 ﾠrequire	 ﾠde	 ﾠnovo	 ﾠsynthesis	 ﾠ
of	 ﾠRNA,	 ﾠDNA,	 ﾠlipids	 ﾠand	 ﾠglycogen.	 ﾠPyrimidine	 ﾠnucleotides	 ﾠare	 ﾠprecursors	 ﾠfor	 ﾠthe	 ﾠ
production	 ﾠof	 ﾠall	 ﾠthese	 ﾠmolecules	 ﾠand	 ﾠits	 ﾠbiosynthesis	 ﾠis	 ﾠcarried	 ﾠout	 ﾠby	 ﾠa	 ﾠmulti-ﾭ‐enzyme	 ﾠ
complex	 ﾠcalled	 ﾠCAD.	 ﾠERK1/2	 ﾠphosphorylates	 ﾠCAD	 ﾠon	 ﾠThr456	 ﾠand	 ﾠthereby	 ﾠpromotes	 ﾠ
pyrimidine	 ﾠsynthesis	 ﾠ[282].	 ﾠ
The	 ﾠprocess	 ﾠof	 ﾠcell	 ﾠdivision	 ﾠis	 ﾠgoverned	 ﾠby	 ﾠthree	 ﾠregulatory	 ﾠmolecules,	 ﾠnamely	 ﾠcyclins,	 ﾠ
cyclin-ﾭ‐dependent	 ﾠkinases	 ﾠ(CDKs)	 ﾠand	 ﾠcyclin-ﾭ‐dependent	 ﾠkinase	 ﾠinhibitors	 ﾠ(CDKI).	 ﾠDuring	 ﾠthe	 ﾠ
first	 ﾠstep	 ﾠof	 ﾠthe	 ﾠcell	 ﾠcycle,	 ﾠwhich	 ﾠmarks	 ﾠthe	 ﾠprogression	 ﾠfrom	 ﾠG0/G1	 ﾠto	 ﾠS	 ﾠphase,	 ﾠcyclin	 ﾠD	 ﾠ
expression	 ﾠis	 ﾠinitiated	 ﾠand	 ﾠaccumulates	 ﾠin	 ﾠthe	 ﾠnucleus.	 ﾠThe	 ﾠregulatory	 ﾠsubunit	 ﾠinteracts	 ﾠ
with	 ﾠCDK4	 ﾠand	 ﾠCDK6,	 ﾠto	 ﾠform	 ﾠa	 ﾠcatalytic	 ﾠcomplex,	 ﾠwhich	 ﾠphosphorylates	 ﾠthe	 ﾠ
retinoblastoma	 ﾠ(Rb)	 ﾠprotein.	 ﾠIn	 ﾠquiescent	 ﾠcells,	 ﾠRb	 ﾠinhibits	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠE2F	 ﾠfamily	 ﾠof	 ﾠ
transcription	 ﾠfactors	 ﾠthrough	 ﾠdirect	 ﾠinteraction.	 ﾠPhosphorylation	 ﾠof	 ﾠRb,	 ﾠhowever,	 ﾠdisrupts	 ﾠ
the	 ﾠassociation	 ﾠwith	 ﾠE2F	 ﾠand	 ﾠpromotes	 ﾠexpression	 ﾠof	 ﾠE2F	 ﾠtarget	 ﾠgenes,	 ﾠsuch	 ﾠas	 ﾠcyclin	 ﾠE.	 ﾠ
Subsequent	 ﾠaccumulation	 ﾠof	 ﾠcyclin	 ﾠE	 ﾠinduces	 ﾠan	 ﾠactive	 ﾠE/CDK2	 ﾠcomplex,	 ﾠwhich	 ﾠ
phosphorylates	 ﾠRb	 ﾠfurther	 ﾠand	 ﾠstimulates	 ﾠS	 ﾠphase	 ﾠentry	 ﾠ[283].	 ﾠInterestingly,	 ﾠcyclin	 ﾠD	 ﾠ
expression	 ﾠis	 ﾠunder	 ﾠthe	 ﾠcontrol	 ﾠof	 ﾠsustained	 ﾠERK	 ﾠactivation.	 ﾠThus,	 ﾠactive	 ﾠERK	 ﾠinduces	 ﾠ
transcription	 ﾠof	 ﾠthe	 ﾠimmediate	 ﾠearly	 ﾠgenes	 ﾠ(including	 ﾠfos,	 ﾠjun	 ﾠand	 ﾠegr)	 ﾠfirst,	 ﾠthen	 ﾠstabilises	 ﾠ
the	 ﾠresulting	 ﾠAP1	 ﾠtranscription	 ﾠfactors	 ﾠthrough	 ﾠdirect	 ﾠphosphorylation,	 ﾠwhich	 ﾠthen	 ﾠ
promotes	 ﾠtranscription	 ﾠof	 ﾠthe	 ﾠdelayed	 ﾠearly	 ﾠgenes,	 ﾠone	 ﾠof	 ﾠwhich	 ﾠis	 ﾠcyclin	 ﾠD	 ﾠ[284].	 ﾠ
Moreover,	 ﾠERK1/2	 ﾠdecreases	 ﾠexpression	 ﾠof	 ﾠanti-ﾭ‐proliferative	 ﾠgenes,	 ﾠsuch	 ﾠas	 ﾠtob1.	 ﾠTob1	 ﾠis	 ﾠ
a	 ﾠtranscriptional	 ﾠco-ﾭ‐repressor,	 ﾠwhich	 ﾠinhibits	 ﾠcyclin	 ﾠD	 ﾠexpression	 ﾠby	 ﾠrecruiting	 ﾠhistone	 ﾠ
deacetylases	 ﾠto	 ﾠthe	 ﾠcyclin	 ﾠD	 ﾠpromoter	 ﾠ[285].	 ﾠMoreover,	 ﾠexisting	 ﾠTob1	 ﾠproteins	 ﾠare	 ﾠ
inhibited	 ﾠby	 ﾠERK1/2-ﾭ‐dependent	 ﾠphosphorylation,	 ﾠalthough	 ﾠit	 ﾠis	 ﾠunclear	 ﾠhow	 ﾠthe	 ﾠphospho	 ﾠ
transfer	 ﾠrenders	 ﾠthe	 ﾠTF	 ﾠinactive	 ﾠ[271].	 ﾠIn	 ﾠaddition,	 ﾠRb/E2F	 ﾠassociation	 ﾠcan	 ﾠbe	 ﾠdisrupted	 ﾠby	 ﾠ
direct	 ﾠphosphorylation	 ﾠof	 ﾠRb	 ﾠby	 ﾠERK1/2,	 ﾠthus	 ﾠrelieving	 ﾠthe	 ﾠinhibitory	 ﾠfunction	 ﾠof	 ﾠRb	 ﾠ[286].	 ﾠ
The	 ﾠtranscription	 ﾠfactor	 ﾠc-ﾭ‐Myc	 ﾠis	 ﾠanother	 ﾠcritical	 ﾠregulator	 ﾠof	 ﾠthe	 ﾠcell	 ﾠcycle.	 ﾠIts	 ﾠexpression	 ﾠ
is	 ﾠinduced	 ﾠupon	 ﾠmitogen	 ﾠstimulation	 ﾠas	 ﾠpart	 ﾠof	 ﾠthe	 ﾠimmediate	 ﾠearly	 ﾠgenes	 ﾠ[287].	 ﾠc-ﾭ‐Myc	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heterodimerises	 ﾠwith	 ﾠother	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠMyc	 ﾠfamily	 ﾠof	 ﾠtranscription	 ﾠfactors,	 ﾠincluding	 ﾠ
Max	 ﾠand	 ﾠMiz-ﾭ‐1.	 ﾠThe	 ﾠMyc/Max	 ﾠtranscription	 ﾠfactor	 ﾠcomplex	 ﾠinduces	 ﾠcyclin	 ﾠD2	 ﾠand	 ﾠCDK4	 ﾠ
expression	 ﾠ[288,	 ﾠ289],	 ﾠwhile	 ﾠthe	 ﾠMyc/Miz-ﾭ‐1	 ﾠcomplex	 ﾠrepresses	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠthe	 ﾠCDK	 ﾠ
inhibitors	 ﾠp15
INK4	 ﾠand	 ﾠp21
Cip1	 ﾠ[290-ﾭ‐292].	 ﾠAdditionally,	 ﾠc-ﾭ‐Myc	 ﾠimpacts	 ﾠprofoundly	 ﾠon	 ﾠ
cellular	 ﾠgrowth	 ﾠby	 ﾠactivating	 ﾠgene	 ﾠtranscription	 ﾠof	 ﾠribosomal	 ﾠproteins	 ﾠand	 ﾠtranslation	 ﾠ
factors	 ﾠ[293].	 ﾠHowever,	 ﾠc-ﾭ‐Myc	 ﾠhas	 ﾠan	 ﾠextremely	 ﾠshort	 ﾠhalf-ﾭ‐life	 ﾠ(less	 ﾠthan	 ﾠ30	 ﾠminutes	 ﾠin	 ﾠ
growing	 ﾠcells)	 ﾠ[294].	 ﾠThus,	 ﾠin	 ﾠorder	 ﾠto	 ﾠinduce	 ﾠcell	 ﾠcycle	 ﾠprogression,	 ﾠthe	 ﾠprotein	 ﾠmust	 ﾠbe	 ﾠ
stabilised.	 ﾠActive	 ﾠERK1/2	 ﾠmarkedly	 ﾠenhance	 ﾠc-ﾭ‐Myc	 ﾠstability	 ﾠas	 ﾠa	 ﾠresult	 ﾠof	 ﾠdirect	 ﾠ
phosphorylation	 ﾠof	 ﾠSer62	 ﾠ[287,	 ﾠ295].	 ﾠThus,	 ﾠERK	 ﾠsignalling	 ﾠpromotes	 ﾠboth	 ﾠthe	 ﾠexpression	 ﾠ
of	 ﾠc-ﾭ‐Myc	 ﾠand	 ﾠsubsequently	 ﾠincreases	 ﾠthe	 ﾠprotein’s	 ﾠhalf-ﾭ‐life.	 ﾠ
Moreover,	 ﾠstimulation	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠinduces	 ﾠthe	 ﾠtranscription	 ﾠof	 ﾠthe	 ﾠCDK	 ﾠ
inhibitors,	 ﾠp21
Cip1,	 ﾠwhich	 ﾠparadoxically	 ﾠpromotes	 ﾠcell	 ﾠcycle	 ﾠprogression.	 ﾠThe	 ﾠinhibitor	 ﾠhas	 ﾠ
conflicting	 ﾠfunctions:	 ﾠWhile	 ﾠit	 ﾠinhibits	 ﾠthe	 ﾠactivity	 ﾠof	 ﾠcyclin	 ﾠE/CDK2	 ﾠand	 ﾠcyclin	 ﾠA/CDK2,	 ﾠ
p21
Cip1	 ﾠstimulates	 ﾠcyclin	 ﾠD/CDK4/6	 ﾠcomplexes	 ﾠupon	 ﾠbinding.	 ﾠThus,	 ﾠan	 ﾠERK-ﾭ‐dependent	 ﾠ
expression	 ﾠof	 ﾠthe	 ﾠprotein	 ﾠpromotes	 ﾠG1	 ﾠprogression	 ﾠto	 ﾠS	 ﾠphase	 ﾠ[296].	 ﾠ
It	 ﾠhas	 ﾠto	 ﾠbe	 ﾠnoted	 ﾠthat	 ﾠsignal	 ﾠduration	 ﾠas	 ﾠwell	 ﾠas	 ﾠsignal	 ﾠstrength	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠ
are	 ﾠkey	 ﾠin	 ﾠdetermining	 ﾠwhether	 ﾠor	 ﾠnot	 ﾠa	 ﾠcell	 ﾠcommits	 ﾠto	 ﾠmitosis,	 ﾠas	 ﾠstrong	 ﾠactivation	 ﾠof	 ﾠ
ERK	 ﾠcause	 ﾠcell	 ﾠcycle	 ﾠarrest	 ﾠ[297].	 ﾠMutational	 ﾠactivation	 ﾠof	 ﾠother	 ﾠsignalling	 ﾠmolecules,	 ﾠe.g.	 ﾠ
Rb,	 ﾠhowever,	 ﾠcan	 ﾠoverride	 ﾠthis	 ﾠhalt	 ﾠand	 ﾠdrive	 ﾠproliferation	 ﾠdespite	 ﾠstrong	 ﾠERK	 ﾠsignalling.	 ﾠ	 ﾠ
1.4.3  The role of ERK in cell survival 
A	 ﾠdual	 ﾠsignal	 ﾠmodel,	 ﾠproposed	 ﾠby	 ﾠHarrington	 ﾠet	 ﾠal.,	 ﾠsuggests	 ﾠa	 ﾠdirect	 ﾠlink	 ﾠbetween	 ﾠcell	 ﾠ
proliferation	 ﾠand	 ﾠcell	 ﾠdeath.	 ﾠIt	 ﾠargues	 ﾠthat	 ﾠproliferative	 ﾠsignals	 ﾠprime	 ﾠthe	 ﾠcell	 ﾠdeath	 ﾠ
machinery,	 ﾠwhich,	 ﾠunless	 ﾠoverruled	 ﾠby	 ﾠsurvival	 ﾠsignals,	 ﾠwill	 ﾠpromote	 ﾠapoptosis	 ﾠ[298].	 ﾠ
Consequently,	 ﾠproliferative	 ﾠautonomy	 ﾠconveyed	 ﾠby	 ﾠoncogenes	 ﾠcan	 ﾠtrigger	 ﾠapoptosis	 ﾠ
unless	 ﾠcell	 ﾠsurvival	 ﾠsignals	 ﾠcountermand	 ﾠthe	 ﾠdeath	 ﾠprogramme	 ﾠ[299].	 ﾠIt	 ﾠis	 ﾠtherefore	 ﾠnot	 ﾠ
surprising	 ﾠthat	 ﾠthe	 ﾠERK	 ﾠpathway	 ﾠcooperatively	 ﾠenhances	 ﾠcellular	 ﾠgrowth,	 ﾠproliferation	 ﾠand	 ﾠ
survival	 ﾠ(see	 ﾠTable	 ﾠ1-ﾭ‐7).	 ﾠ
The	 ﾠmitochondrial	 ﾠ(or	 ﾠintrinsic)	 ﾠapoptotic	 ﾠpathway	 ﾠis	 ﾠregulated	 ﾠby	 ﾠthe	 ﾠBcl-ﾭ‐2	 ﾠfamily	 ﾠof	 ﾠ
proteins,	 ﾠwhich	 ﾠare	 ﾠgenerally	 ﾠsubdivided	 ﾠinto	 ﾠpro-ﾭ‐apoptotic	 ﾠfactors	 ﾠ(e.g.	 ﾠBax	 ﾠand	 ﾠBak),	 ﾠ
pro-ﾭ‐survival	 ﾠfactors	 ﾠ(e.g.	 ﾠBcl-ﾭ‐2,	 ﾠBcl-ﾭ‐xL	 ﾠand	 ﾠMcl-ﾭ‐1)	 ﾠand	 ﾠapoptotic	 ﾠsensors	 ﾠ(e.g.	 ﾠBid,	 ﾠBim	 ﾠand	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Puma).	 ﾠAll	 ﾠBcl-ﾭ‐2	 ﾠproteins	 ﾠcomprise	 ﾠmultiple	 ﾠBcl-ﾭ‐homology	 ﾠ(BH)	 ﾠdomains	 ﾠ(BH1-ﾭ‐4)	 ﾠwith	 ﾠthe	 ﾠ
exception	 ﾠof	 ﾠthe	 ﾠapoptotic	 ﾠsensors,	 ﾠwhich	 ﾠonly	 ﾠcontain	 ﾠthe	 ﾠBH3	 ﾠdomain.	 ﾠTherefore,	 ﾠthey	 ﾠ
are	 ﾠtermed	 ﾠBH3-ﾭ‐only	 ﾠproteins	 ﾠ(BOPs).	 ﾠIn	 ﾠgeneral,	 ﾠcell	 ﾠdeath	 ﾠis	 ﾠinhibited	 ﾠwhen	 ﾠthe	 ﾠ
pro-ﾭ‐apoptotic	 ﾠproteins	 ﾠlike	 ﾠBax	 ﾠand	 ﾠBak	 ﾠare	 ﾠkept	 ﾠin	 ﾠa	 ﾠcomplex	 ﾠwith	 ﾠpro-ﾭ‐survival	 ﾠBcl-ﾭ‐2	 ﾠ
proteins.	 ﾠCellular	 ﾠstress	 ﾠstimulates	 ﾠthe	 ﾠexpression	 ﾠor	 ﾠactivation	 ﾠof	 ﾠBOPs,	 ﾠwhich	 ﾠ
subsequently	 ﾠform	 ﾠa	 ﾠcomplex	 ﾠwith	 ﾠpro-ﾭ‐survival	 ﾠproteins	 ﾠto	 ﾠrelease	 ﾠBax	 ﾠand	 ﾠBak	 ﾠat	 ﾠthe	 ﾠ
mitochondria	 ﾠand	 ﾠinduce	 ﾠcytochrome	 ﾠC	 ﾠrelease	 ﾠ[300,	 ﾠ301].	 ﾠ
ERK1/2	 ﾠstimulates	 ﾠcell	 ﾠsurvival	 ﾠby	 ﾠmodulating	 ﾠmultiple	 ﾠcomponents	 ﾠof	 ﾠthe	 ﾠapoptotic	 ﾠ
programme.	 ﾠFirstly,	 ﾠit	 ﾠrepresses	 ﾠBim	 ﾠexpression	 ﾠby	 ﾠphosphorylating	 ﾠthe	 ﾠregulatory	 ﾠ
transcription	 ﾠfactor	 ﾠFOXO3A	 ﾠand	 ﾠtargeting	 ﾠit	 ﾠfor	 ﾠproteasomal	 ﾠdegradation	 ﾠ[273].	 ﾠ
Moreover,	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠsplice	 ﾠisoform	 ﾠof	 ﾠBim,	 ﾠBimEL,	 ﾠis	 ﾠsubject	 ﾠto	 ﾠERK	 ﾠ
phosphorylation,	 ﾠwhich	 ﾠpromotes	 ﾠdissociation	 ﾠfrom	 ﾠpro-ﾭ‐survival	 ﾠfactors	 ﾠ[302]	 ﾠand	 ﾠ
subsequent	 ﾠdegradation	 ﾠ[303,	 ﾠ304].	 ﾠThe	 ﾠapoptotic	 ﾠsensor	 ﾠBad	 ﾠcontains	 ﾠthree	 ﾠinhibitory	 ﾠ
phosphorylation	 ﾠsites.	 ﾠSer112	 ﾠis	 ﾠphosphorylated	 ﾠby	 ﾠthe	 ﾠERK	 ﾠsubstrate	 ﾠRSK	 ﾠ[305],	 ﾠSer136	 ﾠ
phosphorylation	 ﾠis	 ﾠcatalysed	 ﾠby	 ﾠAKT	 ﾠ[306]	 ﾠand	 ﾠSer155	 ﾠis	 ﾠphosphorylated	 ﾠby	 ﾠPKA	 ﾠ[307].	 ﾠ
ERK-ﾭ‐dependent	 ﾠphosphorylation	 ﾠof	 ﾠSer112	 ﾠmight	 ﾠfacilitate	 ﾠphospho	 ﾠtransfer	 ﾠonto	 ﾠSer155	 ﾠ
by	 ﾠPKA,	 ﾠwhich	 ﾠultimately	 ﾠblocks	 ﾠassociation	 ﾠwith	 ﾠpro-ﾭ‐survival	 ﾠproteins	 ﾠ[308].	 ﾠMoreover,	 ﾠ
phosphorylation	 ﾠat	 ﾠSer112	 ﾠtargets	 ﾠBad	 ﾠfor	 ﾠubiquitination	 ﾠfollowed	 ﾠby	 ﾠproteasomal	 ﾠ
degradation	 ﾠ[309].	 ﾠERK,	 ﾠfurthermore,	 ﾠmediates	 ﾠthe	 ﾠphosphorylation	 ﾠof	 ﾠcaspase	 ﾠ9	 ﾠand	 ﾠ
inhibits	 ﾠsubsequent	 ﾠcaspase	 ﾠ3	 ﾠcleavage,	 ﾠthus	 ﾠpreventing	 ﾠthe	 ﾠonset	 ﾠof	 ﾠthe	 ﾠcaspase	 ﾠ
cascade	 ﾠ[275].	 ﾠ
There	 ﾠis	 ﾠevidence	 ﾠthat	 ﾠsignalling	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠstimulates	 ﾠthe	 ﾠtranscription	 ﾠof	 ﾠ
pro-ﾭ‐survival	 ﾠfactors,	 ﾠBcl-ﾭ‐2,	 ﾠBcl-ﾭ‐xL	 ﾠand	 ﾠMcl-ﾭ‐1	 ﾠ[310].	 ﾠNotably,	 ﾠthe	 ﾠ5ˊ	 ﾠregulatory	 ﾠelements	 ﾠof	 ﾠ
all	 ﾠthree	 ﾠgenes	 ﾠcontain	 ﾠa	 ﾠCREB-ﾭ‐binding	 ﾠsite	 ﾠand	 ﾠthe	 ﾠtranscription	 ﾠfactor	 ﾠCREB	 ﾠ(cAMP	 ﾠ
responsive	 ﾠelement	 ﾠbinding	 ﾠprotein)	 ﾠis	 ﾠactivated	 ﾠas	 ﾠa	 ﾠresult	 ﾠof	 ﾠRSK	 ﾠor	 ﾠMSK	 ﾠ(mitogen-ﾭ‐	 ﾠand	 ﾠ
stress-ﾭ‐activated	 ﾠprotein	 ﾠkinase)	 ﾠphosphorylation	 ﾠat	 ﾠSer133	 ﾠ[311,	 ﾠ312].	 ﾠAdditionally,	 ﾠdirect	 ﾠ
phosphorylation	 ﾠof	 ﾠMcl-ﾭ‐1	 ﾠat	 ﾠThr163	 ﾠby	 ﾠERK1/2	 ﾠstabilises	 ﾠthis	 ﾠpro-ﾭ‐survival	 ﾠfactor	 ﾠwhich	 ﾠ
otherwise	 ﾠhas	 ﾠa	 ﾠvery	 ﾠshort	 ﾠhalf-ﾭ‐life	 ﾠ[313].	 ﾠ	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1.4.4  The role of ERK in cell migration 
Over	 ﾠthe	 ﾠpast	 ﾠdecade,	 ﾠmore	 ﾠand	 ﾠmore	 ﾠevidence	 ﾠsupporting	 ﾠa	 ﾠcritical	 ﾠrole	 ﾠfor	 ﾠthe	 ﾠ
ERK-ﾭ‐MAPK	 ﾠpathway	 ﾠin	 ﾠthe	 ﾠacquisition	 ﾠof	 ﾠan	 ﾠinvasive	 ﾠphenotype	 ﾠhas	 ﾠbeen	 ﾠrevealed.	 ﾠMost	 ﾠ
importantly,	 ﾠan	 ﾠinvasive	 ﾠresponse	 ﾠrequires	 ﾠERK	 ﾠactivity	 ﾠin	 ﾠthe	 ﾠnucleus	 ﾠas	 ﾠwell	 ﾠas	 ﾠin	 ﾠthe	 ﾠ
cytoplasm	 ﾠ[314].	 ﾠHowever,	 ﾠthe	 ﾠunderlying	 ﾠmechanisms	 ﾠby	 ﾠwhich	 ﾠERK	 ﾠsignalling	 ﾠis	 ﾠ
connected	 ﾠto	 ﾠmigratory	 ﾠprocesses	 ﾠare	 ﾠstill	 ﾠbeing	 ﾠunravelled.	 ﾠThus,	 ﾠthe	 ﾠfollowing	 ﾠ
paragraphs	 ﾠwill	 ﾠtry	 ﾠto	 ﾠgive	 ﾠan	 ﾠoverview	 ﾠof	 ﾠERK-ﾭ‐mediated	 ﾠresponses	 ﾠlinked	 ﾠto	 ﾠcell	 ﾠ
migration	 ﾠand	 ﾠinvasion	 ﾠand	 ﾠdiscuss	 ﾠhow	 ﾠbona	 ﾠfide	 ﾠtargets	 ﾠof	 ﾠthe	 ﾠkinases	 ﾠmay	 ﾠbe	 ﾠlinked	 ﾠto	 ﾠ
these	 ﾠprocesses	 ﾠ(see	 ﾠTable	 ﾠ1-ﾭ‐7	 ﾠalso).	 ﾠ
Cell	 ﾠmigration	 ﾠis	 ﾠa	 ﾠcomplex	 ﾠand	 ﾠhighly	 ﾠregulated	 ﾠprocess,	 ﾠwhich	 ﾠrequires	 ﾠthe	 ﾠcontinuous	 ﾠ
assembly	 ﾠand	 ﾠdisassembly	 ﾠof	 ﾠadhesion	 ﾠcomplexes.	 ﾠThere	 ﾠis	 ﾠevidence	 ﾠthat	 ﾠERK	 ﾠregulates	 ﾠ
both	 ﾠof	 ﾠthese	 ﾠprocesses	 ﾠby	 ﾠmodulating	 ﾠthe	 ﾠsignalling	 ﾠof	 ﾠthe	 ﾠRHO	 ﾠfamily	 ﾠof	 ﾠsmall	 ﾠGTPases,	 ﾠ
including	 ﾠRho,	 ﾠRac	 ﾠand	 ﾠCdc42,	 ﾠalthough	 ﾠthe	 ﾠprecise	 ﾠmechanism	 ﾠby	 ﾠwhich	 ﾠit	 ﾠdoes	 ﾠso	 ﾠis	 ﾠstill	 ﾠ
unknown.	 ﾠTogether,	 ﾠthese	 ﾠthree	 ﾠGTPases	 ﾠare	 ﾠcentral	 ﾠregulators	 ﾠof	 ﾠcell	 ﾠmotility	 ﾠand	 ﾠ
require	 ﾠtight	 ﾠspatial	 ﾠand	 ﾠtemporal	 ﾠregulation.	 ﾠAt	 ﾠthe	 ﾠleading	 ﾠedge	 ﾠRac	 ﾠand	 ﾠCdc42	 ﾠpromote	 ﾠ
actin	 ﾠpolymerisation	 ﾠand	 ﾠbranching	 ﾠthrough	 ﾠWAVE	 ﾠand	 ﾠWASP,	 ﾠrespectively.	 ﾠIn	 ﾠcontrast,	 ﾠ
RhoA	 ﾠactivity	 ﾠcan	 ﾠoppose	 ﾠRac	 ﾠand	 ﾠCdc42	 ﾠfunction	 ﾠby	 ﾠpromoting	 ﾠstress	 ﾠfibre	 ﾠformation	 ﾠand	 ﾠ
initiating	 ﾠcellular	 ﾠcontraction	 ﾠ[315].	 ﾠ	 ﾠ
At	 ﾠthe	 ﾠcell	 ﾠfront	 ﾠERK	 ﾠsignalling	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠdrive	 ﾠlamellipodium	 ﾠand	 ﾠpseudopod	 ﾠ
formation	 ﾠby	 ﾠenhancing	 ﾠactin	 ﾠprotrusions.	 ﾠOne	 ﾠimportant	 ﾠplayer	 ﾠin	 ﾠthis	 ﾠprocess	 ﾠis	 ﾠ
cortactin,	 ﾠa	 ﾠcytoskeletal	 ﾠscaffold	 ﾠprotein	 ﾠthat	 ﾠcan	 ﾠbe	 ﾠdirectly	 ﾠphosphorylated	 ﾠby	 ﾠERK	 ﾠat	 ﾠ
Ser405	 ﾠand	 ﾠSer418.	 ﾠThis	 ﾠpost-ﾭ‐translational	 ﾠmodification	 ﾠenhances	 ﾠcortactin-ﾭ‐mediated	 ﾠ
N-ﾭ‐WASP	 ﾠactivation	 ﾠand	 ﾠpromotes	 ﾠactin	 ﾠpolymerisation	 ﾠat	 ﾠthe	 ﾠleading	 ﾠedge	 ﾠ[278].	 ﾠ
Interestingly,	 ﾠERK	 ﾠsignalling	 ﾠis	 ﾠproposed	 ﾠto	 ﾠspatially	 ﾠrestrict	 ﾠRac,	 ﾠCdc42	 ﾠand	 ﾠRhoA	 ﾠ
activation	 ﾠby	 ﾠregulating	 ﾠGEF	 ﾠlocalisation	 ﾠand	 ﾠthis	 ﾠmay	 ﾠbe	 ﾠachieved	 ﾠby	 ﾠcontrolling	 ﾠ
microtubule	 ﾠdynamics.	 ﾠERK	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠphosphorylate	 ﾠstathmin,	 ﾠalso	 ﾠknown	 ﾠas	 ﾠ
oncoprotein	 ﾠ18	 ﾠat	 ﾠSer25	 ﾠwhich	 ﾠinhibits	 ﾠsequestration	 ﾠof	 ﾠtubulin	 ﾠand	 ﾠfrees	 ﾠthe	 ﾠmolecular	 ﾠ
building	 ﾠblock	 ﾠfor	 ﾠmicrotubule	 ﾠassembly	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠfront	 ﾠ[279,	 ﾠ316].	 ﾠMoreover,	 ﾠkinesin	 ﾠ
motors	 ﾠare	 ﾠimplicated	 ﾠin	 ﾠtransporting	 ﾠGEFs	 ﾠalong	 ﾠpolarised	 ﾠmicrotubules	 ﾠ[315].	 ﾠGiven	 ﾠthat	 ﾠ
small	 ﾠGTPases	 ﾠof	 ﾠthe	 ﾠRab	 ﾠfamily,	 ﾠwhich	 ﾠinteract	 ﾠwith	 ﾠmotor	 ﾠproteins,	 ﾠwere	 ﾠshown	 ﾠto	 ﾠbe	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subject	 ﾠto	 ﾠERK	 ﾠphosphorylation	 ﾠ[315,	 ﾠ317],	 ﾠit	 ﾠis	 ﾠconceivable	 ﾠthat	 ﾠERK	 ﾠmight	 ﾠalso	 ﾠregulate	 ﾠ
microtubule-ﾭ‐directed	 ﾠtransport	 ﾠof	 ﾠGEFs	 ﾠto	 ﾠthe	 ﾠcell	 ﾠfront.	 ﾠ
Stress	 ﾠfibres	 ﾠare	 ﾠimportant	 ﾠto	 ﾠthe	 ﾠcontractility	 ﾠof	 ﾠmigrating	 ﾠcells,	 ﾠand	 ﾠit	 ﾠis	 ﾠknown	 ﾠthat	 ﾠthey	 ﾠ
contribute	 ﾠto	 ﾠthe	 ﾠretraction	 ﾠof	 ﾠthe	 ﾠcell	 ﾠrear	 ﾠto	 ﾠenable	 ﾠeffective	 ﾠforward	 ﾠmovement.	 ﾠStress	 ﾠ
fibres	 ﾠare	 ﾠcomposed	 ﾠof	 ﾠactin	 ﾠfilaments	 ﾠassociated	 ﾠwith	 ﾠmyosin	 ﾠfilaments.	 ﾠIn	 ﾠnon-ﾭ‐muscle	 ﾠ
cells	 ﾠmyosin	 ﾠactivity	 ﾠis	 ﾠknown	 ﾠto	 ﾠbe	 ﾠcontrolled	 ﾠby	 ﾠphosphorylation	 ﾠand	 ﾠthe	 ﾠinterplay	 ﾠof	 ﾠ
three	 ﾠregulatory	 ﾠproteins;	 ﾠnamely	 ﾠthe	 ﾠmyosin	 ﾠkinases	 ﾠROCK	 ﾠ(Rho	 ﾠkinase)	 ﾠand	 ﾠMLCK	 ﾠ
(myosin	 ﾠlight	 ﾠchain	 ﾠkinase),	 ﾠand	 ﾠthe	 ﾠmyosin	 ﾠlight	 ﾠchain	 ﾠphosphatase,	 ﾠwhich	 ﾠdictate	 ﾠthe	 ﾠ
phosphorylation	 ﾠstate	 ﾠof	 ﾠmyosin	 ﾠand	 ﾠthus	 ﾠcontrol	 ﾠcellular	 ﾠcontractility.	 ﾠIntriguingly,	 ﾠERK	 ﾠ
can	 ﾠenhance	 ﾠMLCK	 ﾠactivity	 ﾠby	 ﾠphosphorylating	 ﾠthe	 ﾠmyosin	 ﾠkinase	 ﾠat	 ﾠSer13	 ﾠand	 ﾠpossibly	 ﾠ
Ser19	 ﾠ[156,	 ﾠ277,	 ﾠ314].	 ﾠMoreover,	 ﾠERK	 ﾠindirectly	 ﾠcontrols	 ﾠROCK	 ﾠsignalling	 ﾠby	 ﾠaltering	 ﾠthe	 ﾠ
activity	 ﾠof	 ﾠRhoA	 ﾠas	 ﾠmentioned	 ﾠabove	 ﾠ[315].	 ﾠ	 ﾠ
There	 ﾠare	 ﾠseveral	 ﾠlines	 ﾠof	 ﾠevidence	 ﾠthat	 ﾠsuggest	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠfor	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠ
pathway	 ﾠin	 ﾠdriving	 ﾠfocal	 ﾠadhesion	 ﾠdisassembly	 ﾠ(Figure	 ﾠ1-ﾭ‐10).	 ﾠFirstly,	 ﾠthe	 ﾠscaffolding	 ﾠ
protein	 ﾠpaxillin	 ﾠhas	 ﾠbeen	 ﾠidentified	 ﾠas	 ﾠa	 ﾠbona	 ﾠfide	 ﾠERK	 ﾠtarget,	 ﾠwhich	 ﾠregulates	 ﾠintegrin	 ﾠ
signalling	 ﾠat	 ﾠfocal	 ﾠcomplexes.	 ﾠPhosphorylation	 ﾠof	 ﾠpaxillin	 ﾠby	 ﾠERK	 ﾠpromotes	 ﾠthe	 ﾠ
recruitment	 ﾠand	 ﾠactivation	 ﾠof	 ﾠFAK,	 ﾠwhich	 ﾠultimately	 ﾠinduces	 ﾠadhesion	 ﾠdisassembly	 ﾠ[156].	 ﾠ
Paradoxically,	 ﾠFAK	 ﾠitself	 ﾠis	 ﾠsubject	 ﾠto	 ﾠERK	 ﾠphosphorylation,	 ﾠwhich	 ﾠrenders	 ﾠthe	 ﾠkinase	 ﾠ
inactive,	 ﾠthereby	 ﾠimpairing	 ﾠfocal	 ﾠadhesion	 ﾠturnover	 ﾠ[276].	 ﾠThus,	 ﾠERK	 ﾠlocalisation	 ﾠwith	 ﾠ
respect	 ﾠto	 ﾠpaxillin	 ﾠand	 ﾠFAK	 ﾠcan	 ﾠbe	 ﾠa	 ﾠdetermining	 ﾠfactor	 ﾠin	 ﾠthe	 ﾠstability	 ﾠof	 ﾠfocal	 ﾠadhesions.	 ﾠ
Vinexin-ﾭ‐β	 ﾠposes	 ﾠanother	 ﾠinteresting	 ﾠERK	 ﾠsubstrate,	 ﾠwhich	 ﾠis	 ﾠenriched	 ﾠat	 ﾠthe	 ﾠleading	 ﾠedge	 ﾠ
of	 ﾠmigrating	 ﾠcells.	 ﾠIndeed,	 ﾠphosphorylation	 ﾠof	 ﾠvinexin-ﾭ‐β	 ﾠat	 ﾠSer189	 ﾠis	 ﾠimplicated	 ﾠin	 ﾠ
promoting	 ﾠadhesion	 ﾠturnover	 ﾠand	 ﾠthus	 ﾠinhibiting	 ﾠcellular	 ﾠspreading	 ﾠ[280,	 ﾠ318].	 ﾠLastly,	 ﾠthe	 ﾠ
protease	 ﾠcalpain	 ﾠ2	 ﾠis	 ﾠsubject	 ﾠto	 ﾠERK	 ﾠphosphorylation	 ﾠat	 ﾠSer50	 ﾠwhich	 ﾠincreases	 ﾠits	 ﾠ
proteolytic	 ﾠactivity	 ﾠand	 ﾠpromotes	 ﾠits	 ﾠassociation	 ﾠwith	 ﾠFAK	 ﾠat	 ﾠfocal	 ﾠcomplexes,	 ﾠwhere	 ﾠ
calpain	 ﾠcleaves	 ﾠcytoskeletal	 ﾠproteins	 ﾠ[281,	 ﾠ319].	 ﾠDepending	 ﾠon	 ﾠthe	 ﾠdownstream	 ﾠeffector,	 ﾠ
calpain-ﾭ‐induced	 ﾠcleavage	 ﾠcan	 ﾠhave	 ﾠopposing	 ﾠeffects	 ﾠon	 ﾠadhesion	 ﾠstability.	 ﾠFor	 ﾠexample,	 ﾠ
paxillin	 ﾠcleavage	 ﾠstabilises	 ﾠfocal	 ﾠadhesions	 ﾠ[320],	 ﾠwhereas	 ﾠsevering	 ﾠof	 ﾠtalin	 ﾠwas	 ﾠshown	 ﾠto	 ﾠ
promote	 ﾠadhesion	 ﾠturnover	 ﾠ[321].	 ﾠMoreover,	 ﾠproteolysis	 ﾠof	 ﾠthe	 ﾠprotein	 ﾠtyrosine	 ﾠ
phosphatase	 ﾠPTP1B	 ﾠenhances	 ﾠSrc	 ﾠactivity,	 ﾠwhich	 ﾠin	 ﾠturn	 ﾠpromotes	 ﾠadhesion	 ﾠ
disassembly	 ﾠ[322].	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Figure 1-10 Role of ERK in cell contractility and focal adhesion disassembly 
Multiple ERK substrates are involved in focal adhesion turnover. Firstly, myosin light chain kinase (MLCK) 
regulates cell contractility which promotes forward migration and is activated by phosphorylation. Secondly, 
ERK-mediated phosphorylation of calpain enhances its proteolytic activity and subsequent cleavage of talin 
and protein tyrosine phosphatase (PTP1B) stimulate focal adhesion turnover. Moreover, phosphorylation of 
the adaptor protein paxillin promotes the recruitment of focal adhesion kinase (FAK), a central regulator of 
adhesion disassembly.  
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Besides	 ﾠmany	 ﾠcytoplasmic	 ﾠeffectors,	 ﾠnuclear	 ﾠERK	 ﾠtargets	 ﾠalso	 ﾠplay	 ﾠa	 ﾠpivotal	 ﾠrole	 ﾠin	 ﾠ
stimulating	 ﾠcell	 ﾠmigration.	 ﾠOne	 ﾠof	 ﾠthe	 ﾠbest-ﾭ‐studied	 ﾠnuclear	 ﾠtargets	 ﾠis	 ﾠElk-ﾭ‐1	 ﾠ[323,	 ﾠ324].	 ﾠ
Phosphorylation	 ﾠenhances	 ﾠDNA-ﾭ‐binding	 ﾠand	 ﾠincreases	 ﾠthe	 ﾠtranscriptional	 ﾠactivity	 ﾠof	 ﾠElk-ﾭ‐1,	 ﾠ
which	 ﾠdrives	 ﾠthe	 ﾠtranscription	 ﾠof	 ﾠc-ﾭ‐fos	 ﾠ[156,	 ﾠ325].	 ﾠc-ﾭ‐Fos	 ﾠis	 ﾠa	 ﾠbasic	 ﾠleucine	 ﾠzipper	 ﾠ
transcription	 ﾠfactor	 ﾠthat,	 ﾠtogether	 ﾠwith	 ﾠJun	 ﾠor	 ﾠATF	 ﾠproteins,	 ﾠforms	 ﾠthe	 ﾠAP-ﾭ‐1	 ﾠtranscription	 ﾠ
factor.	 ﾠSustained	 ﾠnuclear	 ﾠERK	 ﾠsignalling	 ﾠprovokes	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠnewly	 ﾠ
synthesised	 ﾠc-ﾭ‐Fos	 ﾠprotein	 ﾠby	 ﾠERK,	 ﾠwhich	 ﾠstabilises	 ﾠthe	 ﾠtranscription	 ﾠfactor	 ﾠand	 ﾠallows	 ﾠthe	 ﾠ
formation	 ﾠof	 ﾠa	 ﾠfunctional	 ﾠAP-ﾭ‐1	 ﾠcomplex	 ﾠ[326].	 ﾠSubsequently,	 ﾠAP-ﾭ‐1	 ﾠdrives	 ﾠthe	 ﾠtranscription	 ﾠ
of	 ﾠmany	 ﾠproteolytic	 ﾠenzymes	 ﾠsuch	 ﾠas	 ﾠmatrix	 ﾠmetalloproteinase-ﾭ‐1	 ﾠ(MMP-ﾭ‐1),	 ﾠMMP-ﾭ‐3,	 ﾠ
MMP-ﾭ‐7,	 ﾠMMP-ﾭ‐9,	 ﾠurokinase-ﾭ‐type	 ﾠplasminogen	 ﾠactivator	 ﾠ(uPA)	 ﾠ[314].	 ﾠThese	 ﾠproteases	 ﾠin	 ﾠ
turn	 ﾠregulate	 ﾠmatrix	 ﾠdegradation	 ﾠ–	 ﾠan	 ﾠimportant	 ﾠparameter	 ﾠof	 ﾠtumour	 ﾠinvasion	 ﾠand	 ﾠ
metastasis	 ﾠ[1,	 ﾠ327].	 ﾠ
1.4.5  The role of ERK in angiogenesis 
Highly	 ﾠproliferating	 ﾠtumour	 ﾠcells	 ﾠdisplay	 ﾠan	 ﾠincreased	 ﾠdemand	 ﾠfor	 ﾠoxygen	 ﾠand	 ﾠnutrients.	 ﾠ
Yet,	 ﾠwhen	 ﾠtumour	 ﾠislets	 ﾠgrow	 ﾠpast	 ﾠa	 ﾠdiameter	 ﾠof	 ﾠ0.2	 ﾠmm,	 ﾠthis	 ﾠdemand	 ﾠcannot	 ﾠbe	 ﾠmet	 ﾠand	 ﾠ
tumour	 ﾠcells	 ﾠbecome	 ﾠhypoxic.	 ﾠThis,	 ﾠin	 ﾠturn,	 ﾠtriggers	 ﾠthe	 ﾠonset	 ﾠof	 ﾠapoptosis	 ﾠand	 ﾠprovides	 ﾠa	 ﾠ
natural	 ﾠconstraint	 ﾠto	 ﾠgrow	 ﾠpast	 ﾠa	 ﾠcritical	 ﾠvolume.	 ﾠHowever,	 ﾠtumour	 ﾠcells	 ﾠeventually	 ﾠ
overcome	 ﾠthis	 ﾠlimitation	 ﾠby	 ﾠactivating	 ﾠangiogenesis.	 ﾠIn	 ﾠnormal	 ﾠtissues	 ﾠvascular	 ﾠsprouting	 ﾠ
is	 ﾠsuppressed	 ﾠby	 ﾠangiogenic	 ﾠinhibitors,	 ﾠsuch	 ﾠas	 ﾠthrombospondin,	 ﾠendostatin	 ﾠand	 ﾠ
angiostatin.	 ﾠDuring	 ﾠtumourigenesis,	 ﾠhowever,	 ﾠan	 ﾠenhanced	 ﾠexpression	 ﾠof	 ﾠpro-ﾭ‐angiogenic	 ﾠ
factors,	 ﾠsuch	 ﾠas	 ﾠVEGF	 ﾠ(vascular	 ﾠendothelial	 ﾠgrowth	 ﾠfactor),	 ﾠPDGF	 ﾠand	 ﾠTGF-ﾭ‐β,	 ﾠwith	 ﾠa	 ﾠ
concomitant	 ﾠdecrease	 ﾠof	 ﾠangiogenic	 ﾠinhibitors	 ﾠand	 ﾠstromal	 ﾠremodelling,	 ﾠtriggers	 ﾠthe	 ﾠ
onset	 ﾠof	 ﾠvascular	 ﾠsprouting	 ﾠ[328].	 ﾠ
Oncogenic	 ﾠRas	 ﾠsignalling	 ﾠincreases	 ﾠangiogenesis	 ﾠin	 ﾠa	 ﾠprocess,	 ﾠwhich	 ﾠmainly	 ﾠrelies	 ﾠon	 ﾠAKT	 ﾠ
activation	 ﾠ[329].	 ﾠHowever,	 ﾠinhibition	 ﾠof	 ﾠMEK1/2	 ﾠmarkedly	 ﾠreduces	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠVEGF	 ﾠ
in	 ﾠresponse	 ﾠto	 ﾠhypoxia	 ﾠand	 ﾠsuggests	 ﾠat	 ﾠleast	 ﾠsome	 ﾠrole	 ﾠfor	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠin	 ﾠ
regulating	 ﾠvascular	 ﾠsprouting	 ﾠ[330].	 ﾠAlthough	 ﾠit	 ﾠis	 ﾠstill	 ﾠunclear	 ﾠhow	 ﾠERK	 ﾠsignalling	 ﾠ
contributes	 ﾠto	 ﾠVEGF	 ﾠexpression,	 ﾠall	 ﾠevidence	 ﾠpoints	 ﾠtowards	 ﾠAP-ﾭ‐1	 ﾠ(activating	 ﾠprotein-ﾭ‐1).	 ﾠ
VEGF	 ﾠexpression	 ﾠis	 ﾠdependent	 ﾠon	 ﾠAP-ﾭ‐1	 ﾠactivity	 ﾠand	 ﾠthe	 ﾠvegf	 ﾠpromoter	 ﾠcontains	 ﾠan	 ﾠAP-ﾭ‐1	 ﾠ
consensus	 ﾠsite	 ﾠ[331].	 ﾠERK’s	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠAP-ﾭ‐1	 ﾠis	 ﾠwell-ﾭ‐established	 ﾠand	 ﾠthus	 ﾠERK	 ﾠmay	 ﾠ
induce	 ﾠtranscription	 ﾠof	 ﾠvegf	 ﾠby	 ﾠactivating	 ﾠAP-ﾭ‐1.	 ﾠMoreover,	 ﾠERK	 ﾠsignalling	 ﾠhas	 ﾠrecently	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been	 ﾠshown	 ﾠto	 ﾠmediate	 ﾠthe	 ﾠdownregulation	 ﾠof	 ﾠthrombospondin-ﾭ‐1	 ﾠ[332].	 ﾠThe	 ﾠunderlying	 ﾠ
mechanism,	 ﾠhowever,	 ﾠremains	 ﾠto	 ﾠbe	 ﾠelucidated.	 ﾠ	 ﾠ
The	 ﾠextracellular	 ﾠmatrix	 ﾠ(ECM)	 ﾠfunctions	 ﾠas	 ﾠa	 ﾠnatural	 ﾠbarrier	 ﾠduring	 ﾠthe	 ﾠprocess	 ﾠof	 ﾠ
angiogenesis,	 ﾠbecause	 ﾠit	 ﾠefficiently	 ﾠsequesters	 ﾠangiogenic	 ﾠfactors	 ﾠand	 ﾠphysically	 ﾠobstructs	 ﾠ
infiltration	 ﾠof	 ﾠnewly	 ﾠforming	 ﾠvessels.	 ﾠWith	 ﾠthe	 ﾠhelp	 ﾠof	 ﾠproteolytic	 ﾠenzymes,	 ﾠwhich	 ﾠliberate	 ﾠ
angiogenic	 ﾠfactors	 ﾠand	 ﾠcreate	 ﾠspace	 ﾠfor	 ﾠnewly	 ﾠforming	 ﾠvessels,	 ﾠthis	 ﾠbarrier	 ﾠcan	 ﾠbe	 ﾠ
overcome	 ﾠ[333,	 ﾠ334].	 ﾠInterestingly,	 ﾠthe	 ﾠpromoters	 ﾠof	 ﾠmany	 ﾠproteinases	 ﾠcontain	 ﾠan	 ﾠAP-ﾭ‐1	 ﾠ
consensus	 ﾠsite,	 ﾠthus	 ﾠlinking	 ﾠERK	 ﾠsignalling	 ﾠto	 ﾠthe	 ﾠproteolytic	 ﾠinduction	 ﾠof	 ﾠangiogenesis.	 ﾠ
Moreover,	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠstimulates	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠtissue	 ﾠfactor,	 ﾠan	 ﾠ
important	 ﾠregulator	 ﾠof	 ﾠangiogenesis,	 ﾠwhich	 ﾠtriggers	 ﾠstromal	 ﾠremodelling	 ﾠand	 ﾠpromotes	 ﾠ
VEGF	 ﾠexpression	 ﾠ[335,	 ﾠ336].	 ﾠ
1.4.6  ERK-MAPK pathway and multi-drug resistance 
Tumour	 ﾠcells	 ﾠare	 ﾠmarked	 ﾠby	 ﾠhighly	 ﾠinstable	 ﾠgenomes	 ﾠwhich	 ﾠgive	 ﾠrise	 ﾠto	 ﾠcontinuous	 ﾠ
generation	 ﾠof	 ﾠnovel	 ﾠgenetic	 ﾠconfigurations.	 ﾠThus,	 ﾠa	 ﾠcancer	 ﾠcell	 ﾠhas	 ﾠscope	 ﾠto	 ﾠadapt	 ﾠto	 ﾠ
changes	 ﾠin	 ﾠthe	 ﾠmicroenvironment	 ﾠand	 ﾠmodify	 ﾠsignalling	 ﾠcircuits	 ﾠto	 ﾠpromote	 ﾠsurvival	 ﾠand	 ﾠ
proliferation.	 ﾠThis	 ﾠhallmark,	 ﾠhowever,	 ﾠcomplicates	 ﾠtherapeutic	 ﾠintervention	 ﾠand	 ﾠ
ultimately	 ﾠdecreases	 ﾠclinical	 ﾠsuccess	 ﾠrates,	 ﾠwhen	 ﾠtumour	 ﾠcells	 ﾠacquire	 ﾠthe	 ﾠability	 ﾠto	 ﾠ
withstand	 ﾠcytotoxic	 ﾠdrugs	 ﾠor	 ﾠbecome	 ﾠresistance	 ﾠin	 ﾠresponse	 ﾠto	 ﾠionisation.	 ﾠThe	 ﾠERK-ﾭ‐MAPK	 ﾠ
pathway	 ﾠhas	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠacquired	 ﾠresistance	 ﾠduring	 ﾠe.g.	 ﾠradiation	 ﾠtherapy	 ﾠ[337]	 ﾠor	 ﾠ
doxorubicin	 ﾠtreatment	 ﾠ[338].	 ﾠAs	 ﾠdescribed	 ﾠin	 ﾠsection	 ﾠ1.4.3,	 ﾠERK	 ﾠsignalling	 ﾠpromotes	 ﾠcell	 ﾠ
survival	 ﾠby	 ﾠstimulating	 ﾠthe	 ﾠexpression	 ﾠpro-ﾭ‐survival	 ﾠfactors	 ﾠand	 ﾠinhibiting	 ﾠBH3-ﾭ‐only	 ﾠ
proteins	 ﾠ(BOPs).	 ﾠThis	 ﾠmechanism	 ﾠmay	 ﾠalso	 ﾠprovide	 ﾠa	 ﾠmeans	 ﾠby	 ﾠwhich	 ﾠcancer	 ﾠcells	 ﾠcan	 ﾠbe	 ﾠ
protected	 ﾠfrom	 ﾠdrug-ﾭ‐induced	 ﾠapoptosis.	 ﾠMoreover,	 ﾠincreased	 ﾠERK	 ﾠsignalling	 ﾠhas	 ﾠbeen	 ﾠ
shown	 ﾠto	 ﾠeither	 ﾠstimulate	 ﾠor	 ﾠenhance	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠmulti-ﾭ‐drug	 ﾠresistance	 ﾠ(MDR)	 ﾠ
genes,	 ﾠwhich	 ﾠencode	 ﾠtransmembrane	 ﾠdrug	 ﾠefflux	 ﾠpumps	 ﾠ[339,	 ﾠ340].	 ﾠThe	 ﾠMDR	 ﾠtransporter	 ﾠ
belongs	 ﾠto	 ﾠthe	 ﾠsuperfamily	 ﾠof	 ﾠATP-ﾭ‐binding	 ﾠcassette	 ﾠ(ABC)	 ﾠtransporters	 ﾠwhich	 ﾠenable	 ﾠ
cancer	 ﾠcells	 ﾠto	 ﾠactively	 ﾠexpel	 ﾠvarious	 ﾠchemical	 ﾠcompounds	 ﾠfrom	 ﾠthe	 ﾠcytoplasm,	 ﾠthereby	 ﾠ
decreasing	 ﾠthe	 ﾠintracellular	 ﾠconcentration	 ﾠof	 ﾠthe	 ﾠdrugs	 ﾠto	 ﾠsub-ﾭ‐toxic	 ﾠlevels.	 ﾠDrug	 ﾠresistance	 ﾠ
represents	 ﾠa	 ﾠgeneral	 ﾠchallenge	 ﾠin	 ﾠcancer	 ﾠtreatment	 ﾠand	 ﾠhas	 ﾠled	 ﾠto	 ﾠthe	 ﾠintroduction	 ﾠof	 ﾠChapter 1 – Introduction    72 
combination	 ﾠtherapies,	 ﾠwhich	 ﾠare	 ﾠthought	 ﾠto	 ﾠminimise	 ﾠtumour	 ﾠcell	 ﾠadaptions	 ﾠand	 ﾠprovide	 ﾠ
a	 ﾠpromising	 ﾠstrategy	 ﾠto	 ﾠcuring	 ﾠcancer.	 ﾠ 	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1.4.7  Inhibiting ERK signalling as a therapeutic strategy 
Owing	 ﾠto	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠis	 ﾠcommonly	 ﾠderegulated	 ﾠin	 ﾠcancer	 ﾠand	 ﾠ
plays	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠthe	 ﾠacquisition	 ﾠof	 ﾠa	 ﾠmalignant	 ﾠphenotype,	 ﾠthe	 ﾠcascade	 ﾠand	 ﾠits	 ﾠ
upstream	 ﾠactivators	 ﾠare	 ﾠattractive	 ﾠtargets	 ﾠfor	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠanticancer	 ﾠdrugs.	 ﾠ
Overexpression	 ﾠof	 ﾠEGFR	 ﾠis	 ﾠcommonly	 ﾠobserved	 ﾠin	 ﾠcancer	 ﾠ[341]	 ﾠand	 ﾠthis	 ﾠtriggers	 ﾠactivation	 ﾠ
of	 ﾠthe	 ﾠERK	 ﾠcascade.	 ﾠTwo	 ﾠstrategies	 ﾠhave	 ﾠbeen	 ﾠemployed	 ﾠto	 ﾠinhibit	 ﾠEGFR	 ﾠsignalling,	 ﾠand	 ﾠ
they	 ﾠinclude	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠmonoclonal	 ﾠantibodies	 ﾠ(mAbs)	 ﾠdirected	 ﾠagainst	 ﾠthe	 ﾠ
extracellular	 ﾠdomain	 ﾠof	 ﾠEGFR,	 ﾠand	 ﾠsmall-ﾭ‐molecule	 ﾠtyrosine	 ﾠkinase	 ﾠinhibitors	 ﾠwhich	 ﾠblock	 ﾠ
the	 ﾠintracellular	 ﾠkinase	 ﾠdomain.	 ﾠCetuximab	 ﾠwas	 ﾠthe	 ﾠfirst	 ﾠFDA-ﾭ‐approved	 ﾠchimeric	 ﾠantibody	 ﾠ
directed	 ﾠagainst	 ﾠEGFR	 ﾠ[342].	 ﾠAlthough	 ﾠthe	 ﾠdrug	 ﾠhas	 ﾠproven	 ﾠsuccessful	 ﾠin	 ﾠthe	 ﾠclinic,	 ﾠthe	 ﾠ
patient	 ﾠresponse	 ﾠdid	 ﾠnot	 ﾠcorrelate	 ﾠwith	 ﾠthe	 ﾠdegree	 ﾠof	 ﾠEGFR	 ﾠoverexpression.	 ﾠMoreover,	 ﾠ
the	 ﾠrisk	 ﾠfor	 ﾠanaphylactic	 ﾠreactions	 ﾠled	 ﾠto	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠhumanised	 ﾠ(e.g.	 ﾠ
matuzumab)	 ﾠand	 ﾠfully	 ﾠhuman	 ﾠ(e.g.	 ﾠpanitumumab)	 ﾠmAbs	 ﾠ[343,	 ﾠ344].	 ﾠPanitumumab	 ﾠhas	 ﾠ
shown	 ﾠa	 ﾠsignificant	 ﾠimprovement	 ﾠon	 ﾠprogression-ﾭ‐free	 ﾠsurvival	 ﾠand	 ﾠdemonstrated	 ﾠno	 ﾠ
antibody-ﾭ‐dependent	 ﾠcell-ﾭ‐mediated	 ﾠcytotoxicity,	 ﾠthus	 ﾠproving	 ﾠpromising	 ﾠcandidate	 ﾠfor	 ﾠ
future	 ﾠtherapies	 ﾠ[345].	 ﾠ
Ras	 ﾠis	 ﾠmutationally	 ﾠactivated	 ﾠin	 ﾠapproximately	 ﾠone	 ﾠthird	 ﾠof	 ﾠall	 ﾠhuman	 ﾠcancers	 ﾠ[213]	 ﾠand	 ﾠ
therefore	 ﾠhuge	 ﾠefforts	 ﾠhave	 ﾠbeen	 ﾠmade	 ﾠto	 ﾠtarget	 ﾠthe	 ﾠsmall	 ﾠGTPase	 ﾠin	 ﾠtherapeutic	 ﾠ
strategies.	 ﾠAs	 ﾠmutational	 ﾠactivation	 ﾠof	 ﾠthe	 ﾠRas	 ﾠmolecules	 ﾠinhibits	 ﾠGTP	 ﾠhydrolysis,	 ﾠoriginal	 ﾠ
work	 ﾠattempted	 ﾠto	 ﾠreactivate	 ﾠthe	 ﾠintrinsic	 ﾠGTPase	 ﾠor	 ﾠantagonise	 ﾠGTP	 ﾠbinding	 ﾠto	 ﾠRas	 ﾠ
molecules.	 ﾠHowever,	 ﾠthese	 ﾠefforts	 ﾠwere	 ﾠnot	 ﾠsuccessful.	 ﾠAs	 ﾠRas	 ﾠrequires	 ﾠcorrect	 ﾠsubcellular	 ﾠ
localisation	 ﾠfor	 ﾠdownstream	 ﾠsignalling,	 ﾠresearchers	 ﾠthen	 ﾠattempted	 ﾠto	 ﾠblock	 ﾠmembrane	 ﾠ
localisation	 ﾠof	 ﾠRas	 ﾠby	 ﾠinhibiting	 ﾠfarnesylation	 ﾠof	 ﾠits	 ﾠC-ﾭ‐terminus	 ﾠ[346].	 ﾠFarnesyltransferase	 ﾠ
inhibitors,	 ﾠhowever,	 ﾠdid	 ﾠnot	 ﾠprove	 ﾠvery	 ﾠeffective	 ﾠin	 ﾠblocking	 ﾠmembrane	 ﾠtargeting,	 ﾠas	 ﾠ
N-ﾭ‐	 ﾠand	 ﾠK-ﾭ‐Ras	 ﾠcan	 ﾠundergo	 ﾠalternative	 ﾠprenylation	 ﾠin	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠfarnesyltransferase.	 ﾠ
Current	 ﾠwork	 ﾠfocuses	 ﾠon	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠinhibitors	 ﾠagainst	 ﾠRce1	 ﾠ(Ras	 ﾠconverting	 ﾠ
enzyme	 ﾠ1)	 ﾠand	 ﾠICMT	 ﾠ(isoprenylcysteine-ﾭ‐O-ﾭ‐carboxyl	 ﾠmethyltransferase),	 ﾠwhich	 ﾠprime	 ﾠthe	 ﾠ
C-ﾭ‐terminus	 ﾠof	 ﾠRas	 ﾠfor	 ﾠfarnesylation	 ﾠor	 ﾠprenylation	 ﾠ[341].	 ﾠ	 ﾠ
Considerable	 ﾠefforts	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠmade	 ﾠto	 ﾠdevelop	 ﾠchemical	 ﾠinhibitors	 ﾠtargeting	 ﾠRaf	 ﾠ
kinases.	 ﾠOne	 ﾠof	 ﾠthe	 ﾠmost	 ﾠsuccessful	 ﾠRaf	 ﾠinhibitors	 ﾠis	 ﾠsorafenib,	 ﾠwhich	 ﾠbinds	 ﾠto	 ﾠthe	 ﾠ
ATP-ﾭ‐binding	 ﾠpocket	 ﾠand	 ﾠprevents	 ﾠkinase	 ﾠactivation	 ﾠ[259].	 ﾠAlthough	 ﾠphase	 ﾠIII	 ﾠclinical	 ﾠtrials	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showed	 ﾠimproved	 ﾠsurvival,	 ﾠit	 ﾠis	 ﾠdifficult	 ﾠto	 ﾠdetermine	 ﾠwhether	 ﾠsorafenib’s	 ﾠsuccess	 ﾠcan	 ﾠbe	 ﾠ
attributed	 ﾠto	 ﾠRaf	 ﾠinhibition,	 ﾠas	 ﾠit	 ﾠalso	 ﾠpotently	 ﾠinhibits	 ﾠVEGFR,	 ﾠPDGRR,	 ﾠFGFR	 ﾠand	 ﾠc-ﾭ‐Kit	 ﾠ
signalling	 ﾠ[347].	 ﾠOther	 ﾠinhibitors,	 ﾠwhich	 ﾠselectively	 ﾠtarget	 ﾠmutant	 ﾠB-ﾭ‐Raf	 ﾠhave	 ﾠbeen	 ﾠ
developed.	 ﾠOne	 ﾠsuch	 ﾠexample	 ﾠis	 ﾠPLX4032	 ﾠalso	 ﾠknown	 ﾠas	 ﾠverumafenib,	 ﾠwhich	 ﾠproved	 ﾠvery	 ﾠ
successful	 ﾠin	 ﾠphase	 ﾠIII	 ﾠclinical	 ﾠtrials	 ﾠand	 ﾠis	 ﾠcurrently	 ﾠawaiting	 ﾠFDA-ﾭ‐approval	 ﾠ[348].	 ﾠYet,	 ﾠ
sorafenib’s	 ﾠsuccess	 ﾠhas	 ﾠsparked	 ﾠthe	 ﾠdebate	 ﾠon	 ﾠwhether	 ﾠmulti-ﾭ‐kinase	 ﾠinhibitors	 ﾠdue	 ﾠto	 ﾠ
their	 ﾠresemblance	 ﾠto	 ﾠcombination	 ﾠtherapy	 ﾠare	 ﾠmore	 ﾠpotent	 ﾠin	 ﾠcancer	 ﾠtherapy.	 ﾠ
In	 ﾠcontrast	 ﾠto	 ﾠsorafenib,	 ﾠMEK	 ﾠinhibitors,	 ﾠwhich	 ﾠprevent	 ﾠMEK	 ﾠactivation	 ﾠin	 ﾠa	 ﾠnon-ﾭ‐ATP	 ﾠ
competitive	 ﾠmanner,	 ﾠare	 ﾠhighly	 ﾠspecific.	 ﾠThe	 ﾠfirst	 ﾠtwo	 ﾠinhibitors	 ﾠdeveloped	 ﾠagainst	 ﾠMEK	 ﾠ
were	 ﾠPD98059	 ﾠand	 ﾠU0126	 ﾠand	 ﾠproved	 ﾠnot	 ﾠsuitable	 ﾠas	 ﾠclinical	 ﾠcandidates	 ﾠ[349].	 ﾠHowever,	 ﾠ
due	 ﾠto	 ﾠtheir	 ﾠpotent	 ﾠinhibition,	 ﾠthey	 ﾠhave	 ﾠbeen	 ﾠinvaluable	 ﾠtools	 ﾠin	 ﾠacademic	 ﾠresearch.	 ﾠThe	 ﾠ
first	 ﾠMEK	 ﾠinhibitor	 ﾠto	 ﾠenter	 ﾠclinical	 ﾠtrials	 ﾠwas	 ﾠPD184352.	 ﾠDespite	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠpoor	 ﾠ
pharmacokinetic	 ﾠproperties	 ﾠrendered	 ﾠthe	 ﾠcompound	 ﾠunsuitable	 ﾠin	 ﾠphase	 ﾠII	 ﾠclinical	 ﾠ
trials	 ﾠ[350],	 ﾠderivatives	 ﾠof	 ﾠPD184352	 ﾠwith	 ﾠbetter	 ﾠpharmacokinetic	 ﾠfeatures	 ﾠhave	 ﾠbeen	 ﾠ
developed	 ﾠand	 ﾠare	 ﾠcurrently	 ﾠundergoing	 ﾠclinical	 ﾠtrials	 ﾠin	 ﾠphase	 ﾠI.	 ﾠ
So	 ﾠfar,	 ﾠno	 ﾠERK	 ﾠinhibitors	 ﾠhave	 ﾠentered	 ﾠclinical	 ﾠtrials	 ﾠalthough,	 ﾠin	 ﾠprinciple,	 ﾠERK	 ﾠrepresents	 ﾠ
a	 ﾠputative	 ﾠdrug	 ﾠtarget	 ﾠin	 ﾠcancer	 ﾠtherapy.	 ﾠPotential	 ﾠinhibitors	 ﾠcan	 ﾠbe	 ﾠdesigned	 ﾠto	 ﾠblock	 ﾠERK	 ﾠ
activity	 ﾠby	 ﾠcompeting	 ﾠwith	 ﾠATP	 ﾠbinding	 ﾠor	 ﾠinhibiting	 ﾠspecific	 ﾠsubstrate	 ﾠbinding.	 ﾠAs	 ﾠthe	 ﾠtwo	 ﾠ
primary	 ﾠdocking	 ﾠdomains	 ﾠon	 ﾠERK	 ﾠare	 ﾠsterically	 ﾠseparated,	 ﾠsmall	 ﾠmolecular	 ﾠweight	 ﾠ
compounds	 ﾠcould	 ﾠbe	 ﾠdesigned	 ﾠto	 ﾠinterfere	 ﾠwith	 ﾠthe	 ﾠinteractions	 ﾠof	 ﾠDEF-ﾭ‐motif	 ﾠor	 ﾠD-ﾭ‐motif	 ﾠ
containing	 ﾠsubstrates.	 ﾠIn	 ﾠthis	 ﾠway,	 ﾠa	 ﾠsubset	 ﾠof	 ﾠERK	 ﾠtargets	 ﾠmay	 ﾠspecifically	 ﾠbe	 ﾠinhibited	 ﾠ
while	 ﾠother	 ﾠERK	 ﾠfunctions	 ﾠare	 ﾠunaltered.	 ﾠFuture	 ﾠstudies	 ﾠexpanding	 ﾠour	 ﾠknowledge	 ﾠon	 ﾠhow	 ﾠ
ERK	 ﾠsubstrates	 ﾠare	 ﾠinvolved	 ﾠin	 ﾠacquiring	 ﾠmalignant	 ﾠphenotypes	 ﾠand	 ﾠa	 ﾠbetter	 ﾠ
understanding	 ﾠof	 ﾠERK	 ﾠdocking	 ﾠplatforms,	 ﾠwill	 ﾠfacilitate	 ﾠthe	 ﾠdesign	 ﾠof	 ﾠsuch	 ﾠERK-ﾭ‐specific	 ﾠ
inhibitors.	 ﾠ
  	 ﾠChapter 1 – Introduction    75 
1.5  Project Aims 
Upregulation	 ﾠof	 ﾠthe	 ﾠERK/MAPK	 ﾠpathway	 ﾠoccurs	 ﾠin	 ﾠapproximately	 ﾠone	 ﾠthird	 ﾠof	 ﾠall	 ﾠhuman	 ﾠ
cancers	 ﾠand	 ﾠwas	 ﾠshown	 ﾠto	 ﾠpromote	 ﾠtumour	 ﾠcell	 ﾠinvasion	 ﾠand	 ﾠprogression	 ﾠ[314].	 ﾠTo	 ﾠdate,	 ﾠ
however,	 ﾠit	 ﾠis	 ﾠunclear	 ﾠwhether	 ﾠor	 ﾠnot	 ﾠthe	 ﾠtwo	 ﾠpredominant	 ﾠERK	 ﾠisoforms	 ﾠhave	 ﾠdistinct	 ﾠ
functions	 ﾠin	 ﾠthese	 ﾠprocesses.	 ﾠTherefore,	 ﾠthis	 ﾠproject	 ﾠset	 ﾠout	 ﾠto	 ﾠaddress	 ﾠthe	 ﾠquestion	 ﾠin	 ﾠ
dispute	 ﾠby	 ﾠstudying	 ﾠthe	 ﾠrole	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠin	 ﾠ2D	 ﾠand	 ﾠ3D	 ﾠ
microenvironments.	 ﾠMoreover,	 ﾠwe	 ﾠaimed	 ﾠto	 ﾠinvestigate	 ﾠwhether	 ﾠtrue	 ﾠisoform-ﾭ‐specific	 ﾠ
functions	 ﾠwith	 ﾠregard	 ﾠto	 ﾠcell	 ﾠmigration	 ﾠdo	 ﾠexist	 ﾠor	 ﾠwhether	 ﾠgene	 ﾠdosage	 ﾠeffects	 ﾠare	 ﾠ
accountable.	 ﾠ	 ﾠ	 ﾠ
Although	 ﾠsome	 ﾠcytoplasmic	 ﾠand	 ﾠnuclear	 ﾠERK	 ﾠtargets	 ﾠinvolved	 ﾠin	 ﾠmigratory	 ﾠprocesses	 ﾠhave	 ﾠ
recently	 ﾠbeen	 ﾠidentified,	 ﾠthe	 ﾠunderlying	 ﾠmechanisms	 ﾠby	 ﾠwhich	 ﾠinvasive	 ﾠcell	 ﾠmigration	 ﾠis	 ﾠ
linked	 ﾠto	 ﾠERK	 ﾠsignalling	 ﾠare	 ﾠat	 ﾠpresent	 ﾠpoorly	 ﾠunderstood.	 ﾠTo	 ﾠshine	 ﾠlight	 ﾠon	 ﾠthis	 ﾠ
understudied	 ﾠarea,	 ﾠwe	 ﾠset	 ﾠout	 ﾠto	 ﾠidentify	 ﾠnovel	 ﾠERK	 ﾠeffectors	 ﾠby	 ﾠcarrying	 ﾠout	 ﾠa	 ﾠ
comparative	 ﾠgene	 ﾠexpression	 ﾠanalysis	 ﾠin	 ﾠa	 ﾠ3D-ﾭ‐like	 ﾠmicroenvironment.	 ﾠPutative	 ﾠERK	 ﾠ
mediators	 ﾠwere	 ﾠsubsequently	 ﾠstudied	 ﾠin	 ﾠcell	 ﾠmigration	 ﾠassays.	 ﾠ	 ﾠ76 
2  Materials and methods 
2.1  Materials 
2.1.1  Reagents 
Reagent	 ﾠ Details	 ﾠ Supplier	 ﾠ
2%	 ﾠgelatine	 ﾠ diluted	 ﾠin	 ﾠPBS	 ﾠ Sigma	 ﾠ
2-ﾭ‐Propanol	 ﾠ 	 ﾠ Merck	 ﾠ
Agarose	 ﾠ(High	 ﾠGel	 ﾠStrength)	 ﾠ 	 ﾠ Melford	 ﾠ
Laboratories	 ﾠLtd	 ﾠ
Ascorbic	 ﾠacid	 ﾠ 	 ﾠ Sigma	 ﾠ
Blue/Orange	 ﾠLoading	 ﾠDye	 ﾠ 	 ﾠ6X	 ﾠ Fermentas	 ﾠ
Calcein-ﾭ‐AM	 ﾠ 	 ﾠ Invitrogen	 ﾠ
Calf	 ﾠintestine	 ﾠalkaline	 ﾠ
phosphatase	 ﾠ
	 ﾠ New	 ﾠEngland	 ﾠ
Biolabs	 ﾠ
Cryo-ﾭ‐SFM	 ﾠ 	 ﾠ PromoCell	 ﾠ
DB3.1	 ﾠCompetent	 ﾠCells	 ﾠ 	 ﾠ Invitrogen	 ﾠ
DNase1	 ﾠ 	 ﾠ Roche	 ﾠ
dNTP	 ﾠ 100	 ﾠmM	 ﾠ Invitrogen	 ﾠ
Dulbecco's	 ﾠModified	 ﾠEagle	 ﾠ
Medium	 ﾠ(DMEM)	 ﾠ
	 ﾠ Gibco	 ﾠ
ECL	 ﾠWestern	 ﾠblotting	 ﾠ
substrate	 ﾠ
	 ﾠ Pierce	 ﾠ
EGF	 ﾠ 	 ﾠ Peprotech	 ﾠ
Ethidium	 ﾠbromide	 ﾠ 10	 ﾠmg/ml	 ﾠ Sigma	 ﾠ
Foetal	 ﾠCalf	 ﾠSerum	 ﾠ 	 ﾠ Autogen	 ﾠ
Bioclear	 ﾠ
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Reagent	 ﾠ Details	 ﾠ Supplier	 ﾠ
Fungizone	 ﾠ 250	 ﾠµg	 ﾠof	 ﾠamphotericin	 ﾠB	 ﾠand	 ﾠ205	 ﾠµg	 ﾠof	 ﾠ










	 ﾠ Invitrogen	 ﾠ
GeneRuler™	 ﾠ 1kb	 ﾠDNA	 ﾠLadder	 ﾠ Fermentas	 ﾠ
Glutaraldehyde	 ﾠ 25%	 ﾠ Sigma	 ﾠ
HiPerFect	 ﾠ 	 ﾠ Qiagen	 ﾠ
Hybond-ﾭ‐P	 ﾠPVDF	 ﾠmembrane	 ﾠ 	 ﾠ GE	 ﾠHealthcare	 ﾠ
Illumina	 ﾠHumanHT-ﾭ‐12	 ﾠv4	 ﾠ
Expression	 ﾠBeadChips	 ﾠ
	 ﾠ Illumina	 ﾠ
ImProm-ﾭ‐IITM	 ﾠReverse	 ﾠ
Transcription	 ﾠSystem	 ﾠ
	 ﾠ Promega	 ﾠ




	 ﾠ Becton	 ﾠ
Dickinson	 ﾠ
NuPAGE	 ﾠMOPS	 ﾠSDS	 ﾠRunning	 ﾠ
Buffer	 ﾠ
20x	 ﾠ Invitrogen	 ﾠ
NuPAGE	 ﾠpre-ﾭ‐cast	 ﾠgels	 ﾠ 	 ﾠ Invitrogen	 ﾠ
NuPAGE	 ﾠSample	 ﾠBuffer	 ﾠ 4x	 ﾠ Invitrogen	 ﾠ
NuPAGE	 ﾠTransfer	 ﾠBuffer	 ﾠ 20x	 ﾠ Invitrogen	 ﾠ
Orange	 ﾠG	 ﾠ 	 ﾠ Sigma	 ﾠ
Parafilm	 ﾠWrap	 ﾠ 	 ﾠ Fisher	 ﾠ
PBS	 ﾠcontaining	 ﾠCalcium	 ﾠand	 ﾠ
Magnesium	 ﾠ
	 ﾠ Sigma	 ﾠ
PCRX	 ﾠEnhancer	 ﾠSolution	 ﾠ 10X	 ﾠ Invitrogen	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Reagent	 ﾠ Details	 ﾠ Supplier	 ﾠ
pDONR
TM	 ﾠ201	 ﾠ 	 ﾠ Invitrogen	 ﾠ
Penicillin/Streptomycin	 ﾠ 5,000	 ﾠunits	 ﾠof	 ﾠpenicillin	 ﾠ(base)	 ﾠand	 ﾠ5,000	 ﾠ
µg	 ﾠof	 ﾠstreptomycin	 ﾠ(base)/ml	 ﾠ
Invitrogen	 ﾠ
PLATINUM®	 ﾠTaq	 ﾠDNA	 ﾠ
Polymerase	 ﾠHigh	 ﾠFidelity	 ﾠ
	 ﾠ Invitrogen	 ﾠ
Precision	 ﾠPlus	 ﾠProtein	 ﾠAll	 ﾠ
Blue	 ﾠstandard	 ﾠ
	 ﾠ Biorad	 ﾠ
Rapid	 ﾠLigation	 ﾠBuffer	 ﾠ 	 ﾠ2X	 ﾠ Promega	 ﾠ
RMPI-ﾭ‐1640	 ﾠmedium	 ﾠ 	 ﾠ Gibco	 ﾠ
SOC	 ﾠmedia	 ﾠ 	 ﾠ Invitrogen	 ﾠ
soluble	 ﾠfibronectin	 ﾠ 1	 ﾠmg/ml	 ﾠ Sigma	 ﾠ
Super	 ﾠRX	 ﾠBlue	 ﾠmedical	 ﾠX-ﾭ‐ray	 ﾠ
film	 ﾠ
	 ﾠ Fuji	 ﾠ
SURE2	 ﾠSuper	 ﾠCompetent	 ﾠ
Cells	 ﾠ
	 ﾠ Stratagene	 ﾠ
T4	 ﾠDNA	 ﾠLigase	 ﾠ 	 ﾠ Promega	 ﾠ
TOP10	 ﾠOneShot	 ﾠCells	 ﾠ 	 ﾠ Invitrogen	 ﾠ
Transwell	 ﾠPermeable	 ﾠ
Support	 ﾠ
pore	 ﾠsize	 ﾠof	 ﾠ8	 ﾠµm	 ﾠdiameter	 ﾠ Fisher	 ﾠ
Trypsin	 ﾠ 	 ﾠ Invitrogen	 ﾠ
U0126	 ﾠMEK	 ﾠinhibitor	 ﾠ used	 ﾠat	 ﾠ10	 ﾠµM	 ﾠ Sigma	 ﾠ
Vectashield	 ﾠmounting	 ﾠ
medium	 ﾠwith	 ﾠDAPI	 ﾠ
	 ﾠ Vector	 ﾠ
laboratories	 ﾠ
Table 2-1 List of all reagents 
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2.1.2  Solutions 
Solution	 ﾠ Recipe	 ﾠ
DNA	 ﾠloading	 ﾠdye	 ﾠ 30%	 ﾠ(w/v)	 ﾠsucrose,	 ﾠ0.35%	 ﾠOrange	 ﾠG	 ﾠ
HEPES	 ﾠlysis	 ﾠbuffer	 ﾠ 20	 ﾠmM	 ﾠHEPES	 ﾠpH	 ﾠ7.5,	 ﾠ150	 ﾠmM	 ﾠNaCl,	 ﾠ2	 ﾠmM	 ﾠEDTA	 ﾠ
pH	 ﾠ7.4,	 ﾠ1	 ﾠ%	 ﾠNP-ﾭ‐40	 ﾠ(v/v),	 ﾠ1	 ﾠmM	 ﾠNa3VO4,	 ﾠ10	 ﾠmM	 ﾠNaF,	 ﾠ
1	 ﾠmM	 ﾠPMSF,	 ﾠ5	 ﾠµg/ml	 ﾠleupeptin	 ﾠ
LB-ﾭ‐agar:	 ﾠ 85	 ﾠmM	 ﾠNaCl,	 ﾠ1%	 ﾠ(w/v)	 ﾠbacto-ﾭ‐trypton,	 ﾠ0.5%	 ﾠ(w/v)	 ﾠ
yeast	 ﾠextract,	 ﾠ1.5%	 ﾠ(w/v)	 ﾠagarose	 ﾠ
addition	 ﾠof	 ﾠeither:	 ﾠ
100	 ﾠµg/ml	 ﾠAmpicillin,	 ﾠ50	 ﾠµg/ml	 ﾠKanamycin,	 ﾠor	 ﾠ
30	 ﾠµg/ml	 ﾠChloramphenicol	 ﾠ
LB-ﾭ‐broth	 ﾠ 85	 ﾠmM	 ﾠNaCl,	 ﾠ1%	 ﾠ(w/v)	 ﾠbacto-ﾭ‐trypton,	 ﾠ0.5%	 ﾠ(w/v)	 ﾠ
yeast	 ﾠextract	 ﾠ
addition	 ﾠof	 ﾠeither:	 ﾠ
100	 ﾠµg/ml	 ﾠAmpicillin,	 ﾠ50	 ﾠµg/ml	 ﾠKanamycin,	 ﾠor	 ﾠ30	 ﾠ
µg/ml	 ﾠChloramphenicol	 ﾠ
Lysis	 ﾠbuffer:	 ﾠ 20	 ﾠmM	 ﾠHEPES	 ﾠpH	 ﾠ7.5,	 ﾠ150	 ﾠmM	 ﾠNaCl,	 ﾠ2	 ﾠmM	 ﾠEDTA	 ﾠpH	 ﾠ
7.4,	 ﾠ1	 ﾠ%NP-ﾭ‐40,	 ﾠ1	 ﾠmM	 ﾠNa3VO4,	 ﾠ2	 ﾠmM	 ﾠNaF,	 ﾠ1	 ﾠmM	 ﾠ
PMSF,	 ﾠ5	 ﾠµg/m	 ﾠl	 ﾠmM	 ﾠleupeptin	 ﾠ
NDLB	 ﾠlysis	 ﾠbuffer	 ﾠ 50	 ﾠmM	 ﾠTris	 ﾠHCl	 ﾠ(pH	 ﾠ7.0),	 ﾠ150	 ﾠmM	 ﾠNaCl,	 ﾠ10	 ﾠmM	 ﾠNaF,	 ﾠ
1	 ﾠmM	 ﾠNa3VO3,	 ﾠ5	 ﾠmM	 ﾠEDTA,	 ﾠ5	 ﾠmM	 ﾠEGTA,	 ﾠ1%	 ﾠTriton	 ﾠX	 ﾠ
100	 ﾠ(v/v),	 ﾠ0.5%	 ﾠNP	 ﾠ40	 ﾠ(v/v),	 ﾠ5	 ﾠµg/ml	 ﾠleupeptin,	 ﾠ
1	 ﾠmM	 ﾠPMSF	 ﾠ
PBS	 ﾠ(phosphate	 ﾠbuffered	 ﾠsaline)	 ﾠ 170	 ﾠmM	 ﾠNaCl,	 ﾠ3.3	 ﾠmM	 ﾠKCl,	 ﾠ1.8	 ﾠmM	 ﾠNa2HPO4,	 ﾠ
10.6	 ﾠmM	 ﾠH2PO4	 ﾠ
PBST	 ﾠ PBS,	 ﾠ0.1%	 ﾠTriton	 ﾠX-ﾭ‐100	 ﾠ
PE	 ﾠ PBS,	 ﾠ1	 ﾠmM	 ﾠEDTA	 ﾠ
Penicillin/Streptomycin	 ﾠ 5,000	 ﾠunits	 ﾠof	 ﾠpenicillin	 ﾠ(base)	 ﾠand	 ﾠ5,000	 ﾠµg	 ﾠof	 ﾠ
streptomycin	 ﾠ(base)/ml	 ﾠ
RIPA	 ﾠlysis	 ﾠbuffer	 ﾠ 50	 ﾠmM	 ﾠTris	 ﾠHCl	 ﾠ(pH	 ﾠ7.0),	 ﾠ150	 ﾠmM	 ﾠNaCl,	 ﾠ0.5%	 ﾠsodium	 ﾠ
deoxycholate,	 ﾠ1%	 ﾠNP	 ﾠ40	 ﾠ(v/v),	 ﾠ1	 ﾠmM	 ﾠPMSF,	 ﾠ1	 ﾠmM	 ﾠ
Na3VO4,	 ﾠ10	 ﾠmM	 ﾠNaF,	 ﾠ5	 ﾠµg/ml	 ﾠleupeptin	 ﾠ
TBE	 ﾠ10x:	 ﾠ 890	 ﾠmM	 ﾠTris-ﾭ‐base,	 ﾠ890	 ﾠmM	 ﾠboric	 ﾠacid,	 ﾠ25	 ﾠmM	 ﾠEDTA,	 ﾠ
pH	 ﾠ=	 ﾠ8.3	 ﾠ
TBS	 ﾠ(Tris-ﾭ‐buffered	 ﾠsaline)	 ﾠ 10	 ﾠmM	 ﾠTris-ﾭ‐HCl	 ﾠ(pH	 ﾠ7.4),	 ﾠ150	 ﾠmM	 ﾠNaCl	 ﾠ
TE	 ﾠ 10.0	 ﾠmM	 ﾠTris
.HCl,	 ﾠ1.0	 ﾠmM	 ﾠEDTA,	 ﾠpH	 ﾠ8.0	 ﾠ
Table 2-2 List of all solutions 
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2.1.3  Antibodies and dyes 
Antigen	 ﾠ Species	 ﾠ Dilutions	 ﾠ WB	 ﾠIncubation	 ﾠ Supplier	 ﾠ
Total	 ﾠERK1/2	 ﾠ Rabbit	 ﾠ WB:	 ﾠ1/5K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ 1	 ﾠhour	 ﾠat	 ﾠRT	 ﾠ Sigma	 ﾠ
pERK1/2	 ﾠ Mouse	 ﾠ WB:	 ﾠ1/5K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ 1	 ﾠhour	 ﾠat	 ﾠRT	 ﾠ Sigma	 ﾠ
β-ﾭ‐tubulin	 ﾠ Mouse	 ﾠ WB:	 ﾠ1/5K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ 1	 ﾠhour	 ﾠat	 ﾠRT	 ﾠ Insight	 ﾠ
Fra-ﾭ‐1	 ﾠ Rabbit	 ﾠ WB:	 ﾠ1/1K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ o/n	 ﾠat	 ﾠ4˚C	 ﾠ Abcam	 ﾠ
PARP	 ﾠ mouse	 ﾠ WB:	 ﾠ1/1K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ o/n	 ﾠat	 ﾠ4˚C	 ﾠ BD	 ﾠ
EEA-ﾭ‐1	 ﾠ Mouse	 ﾠ IF:	 ﾠ1/100	 ﾠ 	 ﾠ Transduction	 ﾠ
Labs	 ﾠ
β1	 ﾠintegrin	 ﾠ Mouse	 ﾠ WB:	 ﾠ1/2K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ
IF:	 ﾠ1/200	 ﾠ
o/n	 ﾠat	 ﾠ4˚C	 ﾠ Chemicon	 ﾠ
EGFR	 ﾠ Mouse	 ﾠ WB:	 ﾠ1/2K,	 ﾠ5%	 ﾠBSA	 ﾠ(w/v)	 ﾠ o/n	 ﾠat	 ﾠ4˚C	 ﾠ BD	 ﾠ
GFP	 ﾠ Mouse	 ﾠ IP:	 ﾠ1.5	 ﾠµl	 ﾠper	 ﾠ10	 ﾠcm	 ﾠdish	 ﾠ 	 ﾠ Abcam	 ﾠ
GFP	 ﾠ Rabbit	 ﾠ WB:	 ﾠ1/10K,	 ﾠ5%	 ﾠmilk	 ﾠin	 ﾠ
TBST(w/v)	 ﾠ
1	 ﾠhour	 ﾠat	 ﾠRT	 ﾠ Abcam	 ﾠ
FITC	 ﾠ Mouse	 ﾠ IF:	 ﾠ1/200	 ﾠ 	 ﾠ Southern	 ﾠ
Biotech	 ﾠ
Alexa	 ﾠ488	 ﾠ Rabbit	 ﾠ IF:	 ﾠ1/200	 ﾠ 	 ﾠ Invitrogen	 ﾠ
Table 2-3 Antibodies and dyes 
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2.1.4  Enzymes and kits 
Kit	 ﾠ Supplier	 ﾠ
QIAquick®	 ﾠGel	 ﾠExtraction	 ﾠKit	 ﾠ Qiagen	 ﾠ
Cell	 ﾠLine	 ﾠNucleofactor®	 ﾠKit	 ﾠT	 ﾠ Amaxa	 ﾠ
Cell	 ﾠLine	 ﾠNucleofactor®	 ﾠKit	 ﾠV	 ﾠ Amaxa	 ﾠ
F-ﾭ‐410	 ﾠDyNAmo
TM	 ﾠSYBR®	 ﾠGreen	 ﾠqPCR	 ﾠkit	 ﾠ Thermo	 ﾠScientific	 ﾠ
Illumina®	 ﾠTotalPrep
TM	 ﾠRNA	 ﾠLabelling	 ﾠKit	 ﾠ	 ﾠ Ambion	 ﾠ
Nuclear	 ﾠExtract	 ﾠKit	 ﾠ Active	 ﾠMotif	 ﾠ
Pierce®	 ﾠBCA	 ﾠProtein	 ﾠAssay	 ﾠKit	 ﾠ Thermo	 ﾠScientific	 ﾠ
QIAGEN	 ﾠPlasmid	 ﾠMaxi	 ﾠKit	 ﾠ QIAGEN	 ﾠ
QIAprep®	 ﾠSpin	 ﾠMiniprep	 ﾠKit	 ﾠ Qiagen	 ﾠ
QIAquick®	 ﾠPCR	 ﾠPurification	 ﾠKit	 ﾠ	 ﾠ Qiagen	 ﾠ
Quick	 ﾠChange®	 ﾠSite-ﾭ‐Directed	 ﾠMutagenesis	 ﾠKit	 ﾠ Stratagene	 ﾠ
Table 2-4 List of kits 
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2.1.5  Primers for qPCR 
Gene	 ﾠname	 ﾠ Assay	 ﾠname	 ﾠ Catalogue	 ﾠNumber	 ﾠ
ERK1	 ﾠ Hs_MAPK3_1S_SG	 ﾠ QT00000532	 ﾠ
ERK2	 ﾠ Hs_MAPK1_1_SG	 ﾠ QT00065933	 ﾠ
Rab17	 ﾠ Hs_RAB17_1_SG	 ﾠ QT00009590	 ﾠ
Liprin-ﾭ‐β2	 ﾠ Hs_PPFIBP2_1_SG	 ﾠ QT00005012	 ﾠ
Liprin-ﾭ‐β1	 ﾠ Hs_PPFIBP1_2_SG	 ﾠ QT01666378	 ﾠ
Liprin-ﾭ‐α2	 ﾠ Hs_PPFIA2_1_SG	 ﾠ QT00072296	 ﾠ
Liprin-ﾭ‐α4	 ﾠ Hs_PPFIA4_1_SG	 ﾠ QT00027251	 ﾠ
Rab20	 ﾠ Hs_RAB20_1_SG	 ﾠ QT00229495	 ﾠ
GAPDH	 ﾠ Hs_GAPDH_2_SG	 ﾠ QT01192646	 ﾠ
CSF2	 ﾠ Hs_CSF2_1_SG	 ﾠ QT00000896	 ﾠ
Table 2-5 List of Qiagen Quantitect primers 
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2.1.6  Tissue culture plastic ware 
Plastic	 ﾠware	 ﾠ Supplier	 ﾠ
Falcon	 ﾠtissue	 ﾠculture	 ﾠdishes	 ﾠ(6	 ﾠcm,	 ﾠ10	 ﾠcm,	 ﾠ15	 ﾠcm)	 ﾠ BD	 ﾠBiosciences	 ﾠ
Falcon	 ﾠmulti-ﾭ‐well	 ﾠplates	 ﾠ BD	 ﾠBiosciences	 ﾠ
IWAKI-ﾭ‐3cm	 ﾠglass	 ﾠbottom	 ﾠdishes	 ﾠ Appleton	 ﾠWoods	 ﾠ
Nunc	 ﾠtissue	 ﾠculture	 ﾠflasks	 ﾠand	 ﾠdishes	 ﾠ TCS	 ﾠBiologicals	 ﾠ
Nunc	 ﾠcryotubes	 ﾠ TCS	 ﾠBiologicals	 ﾠ
Table 2-6 List of plastic ware and supplier 
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2.2  Methods 
2.2.1  Molecular biology 
2.2.1.1  Polymerase chain reaction (PCR) 
PCR	 ﾠwas	 ﾠperformed	 ﾠusing	 ﾠthe	 ﾠfollowing	 ﾠset-ﾭ‐up:	 ﾠ
Reagent	 ﾠ Sample	 ﾠ(µl)	 ﾠ
10x	 ﾠHigh	 ﾠFidelity	 ﾠPCR	 ﾠBuffer	 ﾠ 2	 ﾠ
10x	 ﾠPCRX	 ﾠEnhancer	 ﾠSolution	 ﾠ 2	 ﾠ
50	 ﾠmM	 ﾠMgSO4	 ﾠ(0-ﾭ‐4	 ﾠmM)	 ﾠ 0-ﾭ‐1.6	 ﾠ
Template	 ﾠ(10	 ﾠng/µl):	 ﾠ 1	 ﾠ
Primer	 ﾠfwd:	 ﾠ(5	 ﾠµM)	 ﾠ 1	 ﾠ
Primer	 ﾠrev:	 ﾠ	 ﾠ(5	 ﾠµM)	 ﾠ 1	 ﾠ
2.5	 ﾠmM	 ﾠdNTPs	 ﾠ	 ﾠ 2	 ﾠ
autoclaved	 ﾠddH2O	 ﾠ 9.2-ﾭ‐10.8	 ﾠ
Platinum
®	 ﾠHigh-ﾭ‐Fidelity	 ﾠPolymerase	 ﾠ 0.2	 ﾠ
total	 ﾠvolume	 ﾠ 20	 ﾠ
Temperature	 ﾠcycling	 ﾠwas	 ﾠperformed	 ﾠin	 ﾠa	 ﾠDNA	 ﾠEngine	 ﾠThermal	 ﾠCycler	 ﾠ(Biorad)	 ﾠusing	 ﾠthe	 ﾠ
following	 ﾠconditions:	 ﾠ
Initial	 ﾠdenaturation	 ﾠ 95˚C	 ﾠ 2	 ﾠmin	 ﾠ










Final	 ﾠextension	 ﾠ 72˚C	 ﾠ 7	 ﾠmin	 ﾠ
Final	 ﾠhold	 ﾠ 4˚C	 ﾠ ∞	 ﾠ













The	 ﾠintegrity	 ﾠof	 ﾠgenerated	 ﾠDNA	 ﾠfragments	 ﾠwas	 ﾠtested	 ﾠby	 ﾠagarose	 ﾠgel	 ﾠelectrophoresis.	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2.2.1.2  Agarose gel electrophoresis 
Depending	 ﾠon	 ﾠthe	 ﾠexpected	 ﾠlength	 ﾠof	 ﾠthe	 ﾠDNA	 ﾠfragment,	 ﾠgels	 ﾠcontaining	 ﾠbetween	 ﾠ0.8%	 ﾠto	 ﾠ
2%	 ﾠagarose	 ﾠwere	 ﾠprepared.	 ﾠFor	 ﾠthis,	 ﾠthe	 ﾠagarose	 ﾠwas	 ﾠsuspended	 ﾠin	 ﾠ1x	 ﾠTBE	 ﾠand	 ﾠboiled	 ﾠin	 ﾠ
the	 ﾠmicrowave	 ﾠoven	 ﾠuntil	 ﾠthe	 ﾠagarose	 ﾠwas	 ﾠcompletely	 ﾠdissolved.	 ﾠAfter	 ﾠthe	 ﾠsolution	 ﾠhad	 ﾠ
cooled	 ﾠdown	 ﾠto	 ﾠapproximately	 ﾠ55°C,	 ﾠethidium	 ﾠbromide	 ﾠfrom	 ﾠthe	 ﾠstock	 ﾠsolution	 ﾠ
(0.2	 ﾠmg/ml)	 ﾠwas	 ﾠadded	 ﾠat	 ﾠa	 ﾠdilution	 ﾠof	 ﾠ1:1000.	 ﾠAs	 ﾠsoon	 ﾠas	 ﾠthe	 ﾠgel	 ﾠcompletely	 ﾠsolidified,	 ﾠit	 ﾠ
was	 ﾠput	 ﾠinto	 ﾠa	 ﾠgel	 ﾠchamber	 ﾠcontaining	 ﾠ1x	 ﾠTBE	 ﾠas	 ﾠrunning	 ﾠbuffer.	 ﾠDNA	 ﾠloading	 ﾠbuffer	 ﾠwas	 ﾠ
added	 ﾠto	 ﾠthe	 ﾠrespective	 ﾠnucleic	 ﾠacid	 ﾠsamples	 ﾠand	 ﾠthe	 ﾠgel	 ﾠwas	 ﾠloaded.	 ﾠGels	 ﾠwere	 ﾠrun	 ﾠat	 ﾠ
75	 ﾠV	 ﾠfor	 ﾠapproximately	 ﾠone	 ﾠhour.	 ﾠDNA	 ﾠwas	 ﾠvisualised	 ﾠusing	 ﾠUV	 ﾠtransillumination.	 ﾠIf	 ﾠDNA	 ﾠ
fragments	 ﾠwere	 ﾠrequired	 ﾠin	 ﾠsubsequent	 ﾠcloning	 ﾠsteps,	 ﾠgel	 ﾠslices	 ﾠcontaining	 ﾠthe	 ﾠDNA	 ﾠwere	 ﾠ
excised	 ﾠfrom	 ﾠthe	 ﾠgel	 ﾠand	 ﾠpurified	 ﾠusing	 ﾠthe	 ﾠQIAquick	 ﾠGel	 ﾠExtraction	 ﾠKit	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠ
manufacturer’s	 ﾠprotocol.	 ﾠ
2.2.1.3  Restriction digestion 
Digestion	 ﾠof	 ﾠDNA	 ﾠwith	 ﾠrestriction	 ﾠendonucleases	 ﾠwas	 ﾠperformed	 ﾠfor	 ﾠ2	 ﾠhours	 ﾠ(plasmid	 ﾠ
DNA,	 ﾠDNA	 ﾠfragments)	 ﾠwith	 ﾠa	 ﾠtwo-ﾭ‐fold	 ﾠexcess	 ﾠ(2	 ﾠU/µg	 ﾠDNA)	 ﾠof	 ﾠrestriction	 ﾠenzyme.	 ﾠ
Temperature	 ﾠand	 ﾠbuffer	 ﾠfor	 ﾠthe	 ﾠrespective	 ﾠdigestion	 ﾠwere	 ﾠused	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠ
manufacturer’s	 ﾠprotocol.	 ﾠIn	 ﾠorder	 ﾠto	 ﾠseparate	 ﾠdigested	 ﾠDNA	 ﾠfragments	 ﾠand	 ﾠconfirm	 ﾠthe	 ﾠ
enzymatic	 ﾠreaction,	 ﾠthe	 ﾠdigested	 ﾠDNA	 ﾠwas	 ﾠsubjected	 ﾠto	 ﾠagarose	 ﾠgel	 ﾠelectrophoresis.	 ﾠDNA	 ﾠ
of	 ﾠinterest	 ﾠwas	 ﾠthen	 ﾠpurified	 ﾠfrom	 ﾠthe	 ﾠgel	 ﾠslice	 ﾠusing	 ﾠthe	 ﾠQIAquick	 ﾠGel	 ﾠextraction	 ﾠKit	 ﾠ
according	 ﾠto	 ﾠthe	 ﾠmanufacturer’s	 ﾠprotocol.	 ﾠ	 ﾠ
2.2.1.4  Ligation of DNA 
To	 ﾠinhibit	 ﾠself-ﾭ‐ligation,	 ﾠthe	 ﾠdigested	 ﾠvector	 ﾠwas	 ﾠdephosphorylated	 ﾠbefore	 ﾠligation.	 ﾠTo	 ﾠdo	 ﾠ
this,	 ﾠthe	 ﾠDNA	 ﾠwas	 ﾠdiluted	 ﾠin	 ﾠNEBuffer	 ﾠ3	 ﾠto	 ﾠa	 ﾠfinal	 ﾠa	 ﾠconcentration	 ﾠof	 ﾠ0.05	 ﾠµg/µl	 ﾠand	 ﾠ1	 ﾠunit	 ﾠ
of	 ﾠCIP	 ﾠwas	 ﾠadded	 ﾠto	 ﾠthe	 ﾠsolution.	 ﾠAfter	 ﾠ15	 ﾠminutes	 ﾠat	 ﾠ37°C	 ﾠan	 ﾠadditional	 ﾠunit	 ﾠof	 ﾠCIP	 ﾠwas	 ﾠ
added	 ﾠand	 ﾠincubation	 ﾠcontinued	 ﾠfor	 ﾠanother	 ﾠ15	 ﾠminutes.	 ﾠAfterwards	 ﾠthe	 ﾠDNA	 ﾠwas	 ﾠ
purified	 ﾠwith	 ﾠthe	 ﾠQIAquick	 ﾠPCR	 ﾠpurification	 ﾠkit	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠmanufacturer’s	 ﾠ
instruction.	 ﾠFor	 ﾠthe	 ﾠactual	 ﾠligation	 ﾠprocess,	 ﾠ50	 ﾠng	 ﾠof	 ﾠdephosphorylated	 ﾠvector	 ﾠand	 ﾠ150	 ﾠng	 ﾠ
of	 ﾠDNA	 ﾠinsert	 ﾠwere	 ﾠadded	 ﾠto	 ﾠ5	 ﾠµl	 ﾠof	 ﾠ2x	 ﾠRapid	 ﾠligation	 ﾠbuffer	 ﾠand	 ﾠ1	 ﾠµl	 ﾠligase	 ﾠ(4	 ﾠU/µl)	 ﾠto	 ﾠgive	 ﾠ
a	 ﾠtotal	 ﾠvolume	 ﾠof	 ﾠ10	 ﾠµl.	 ﾠLigation	 ﾠwas	 ﾠperformed	 ﾠfor	 ﾠ2	 ﾠhours	 ﾠat	 ﾠroom	 ﾠtemperature.	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2.2.1.5  Recombination 
For	 ﾠthe	 ﾠBP	 ﾠclonase	 ﾠreaction	 ﾠTE	 ﾠbuffer	 ﾠ(pH	 ﾠ8.0),	 ﾠattB-ﾭ‐PCR	 ﾠproduct	 ﾠ(15-ﾭ‐150ng)	 ﾠand	 ﾠDonor	 ﾠ
vector	 ﾠ(150ng/µl)	 ﾠwere	 ﾠmixed	 ﾠtogether	 ﾠat	 ﾠroom	 ﾠtemperature	 ﾠin	 ﾠa	 ﾠmicrocentrifuge	 ﾠtube	 ﾠ
(Figure	 ﾠ2-ﾭ‐1	 ﾠA).	 ﾠFor	 ﾠthe	 ﾠLR	 ﾠclonase	 ﾠreaction	 ﾠTE	 ﾠbuffer,	 ﾠentry	 ﾠvector	 ﾠand	 ﾠdestination	 ﾠvector	 ﾠ
were	 ﾠmixed	 ﾠtogether	 ﾠin	 ﾠa	 ﾠmicrocentrifuge	 ﾠtube	 ﾠ(Figure	 ﾠ2-ﾭ‐1	 ﾠB).	 ﾠThe	 ﾠrespective	 ﾠClonase
TM	 ﾠII	 ﾠ
enzyme	 ﾠmix	 ﾠ(stored	 ﾠat	 ﾠ-ﾭ‐80°C)	 ﾠwas	 ﾠbriefly	 ﾠthawed	 ﾠon	 ﾠice,	 ﾠvortexed	 ﾠtwice	 ﾠfor	 ﾠ2	 ﾠsec	 ﾠand	 ﾠspun	 ﾠ
down,	 ﾠbefore	 ﾠit	 ﾠwas	 ﾠadded	 ﾠto	 ﾠthe	 ﾠreaction	 ﾠmix,	 ﾠwhich	 ﾠwas	 ﾠset	 ﾠup	 ﾠas	 ﾠfollows:	 ﾠ
BP	 ﾠclonase	 ﾠreaction	 ﾠ Sample	 ﾠ(µl)	 ﾠ
attB-ﾭ‐PCR	 ﾠproduct	 ﾠ 150	 ﾠng	 ﾠ
Donor	 ﾠvector	 ﾠ(pDONR
TM	 ﾠ201)	 ﾠ 150	 ﾠng	 ﾠ
TE	 ﾠBuffer	 ﾠ To	 ﾠ8	 ﾠ
BP	 ﾠClonase	 ﾠEnzyme	 ﾠMix	 ﾠ 2	 ﾠ
total	 ﾠvolume	 ﾠ 10	 ﾠ
	 ﾠ
LR	 ﾠclonase	 ﾠreaction	 ﾠ Sample	 ﾠ(µl)	 ﾠ
attB-ﾭ‐PCR	 ﾠproduct	 ﾠ 150	 ﾠng	 ﾠ
Donor	 ﾠvector	 ﾠ(pDONR
TM	 ﾠ201)	 ﾠ 150	 ﾠng	 ﾠ
TE	 ﾠBuffer	 ﾠ To	 ﾠ8	 ﾠ
LR	 ﾠClonase	 ﾠEnzyme	 ﾠMix	 ﾠ 2	 ﾠ
total	 ﾠvolume	 ﾠ 10	 ﾠ
	 ﾠ
The	 ﾠreaction	 ﾠwas	 ﾠincubated	 ﾠat	 ﾠ25°C	 ﾠfor	 ﾠ1	 ﾠhour.	 ﾠThen,	 ﾠ1	 ﾠµl	 ﾠProteinase	 ﾠK	 ﾠsolution	 ﾠwas	 ﾠadded	 ﾠ
and	 ﾠthe	 ﾠsolution	 ﾠbriefly	 ﾠvortexed.	 ﾠA	 ﾠ10	 ﾠminute	 ﾠincubation	 ﾠat	 ﾠ37°C	 ﾠstopped	 ﾠthe	 ﾠreaction.	 ﾠ
1.5	 ﾠµl	 ﾠof	 ﾠthis	 ﾠsolution	 ﾠwas	 ﾠsubsequently	 ﾠused	 ﾠfor	 ﾠbacterial	 ﾠtransformation.	 ﾠ
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 ﾠ
Figure 2-1 Schematic outline of the Gateway®-system 
A. Preparation of the Entry clone containing the gene of interest. B. Construction of an expression vector via 
recombination of any destination vector with any entry vector. Images adapted from 
http://www.invitrogen.com/etc/medialib/en/filelibrary/html.Par.74823.File.tmp/gateway-entry-options-seminar.html. 
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2.2.1.6  Site-directed mutagenesis 
Site-ﾭ‐directed	 ﾠmutagenesis	 ﾠwas	 ﾠperformed	 ﾠusing	 ﾠthe	 ﾠfollowing	 ﾠset-ﾭ‐up:	 ﾠ
Reagent	 ﾠ Sample	 ﾠ(µl)	 ﾠ
10x	 ﾠReaction	 ﾠBuffer	 ﾠ 5	 ﾠ
dsDNA	 ﾠtemplate	 ﾠ 0.5-ﾭ‐1	 ﾠµg	 ﾠ
Primer	 ﾠfwd:	 ﾠ(5	 ﾠµM)	 ﾠ 125	 ﾠng-ﾭ‐0.5	 ﾠµg	 ﾠ
Primer	 ﾠrev:	 ﾠ	 ﾠ(5	 ﾠµM)	 ﾠ 125	 ﾠng-ﾭ‐0.5	 ﾠµg	 ﾠ
dNTPs	 ﾠ(30	 ﾠµM)	 ﾠ 1	 ﾠ
autoclaved	 ﾠddH2O	 ﾠ up	 ﾠto	 ﾠ50	 ﾠ
Pfu	 ﾠturbo	 ﾠDNA	 ﾠpolymerase	 ﾠ 1	 ﾠ
total	 ﾠvolume	 ﾠ 50	 ﾠ
Temperature	 ﾠcycling	 ﾠwas	 ﾠperformed	 ﾠin	 ﾠa	 ﾠDNA	 ﾠEngine	 ﾠThermal	 ﾠCycler	 ﾠ(Biorad)	 ﾠusing	 ﾠthe	 ﾠ
following	 ﾠconditions:	 ﾠ
Initial	 ﾠdenaturation	 ﾠ 95˚C	 ﾠ 2	 ﾠmin	 ﾠ










Final	 ﾠextension	 ﾠ 72˚C	 ﾠ 7	 ﾠmin	 ﾠ
Final	 ﾠhold	 ﾠ 4˚C	 ﾠ ∞	 ﾠ
Primers	 ﾠused	 ﾠduring	 ﾠthis	 ﾠproject	 ﾠwere	 ﾠsynthesised	 ﾠby	 ﾠInvitrogen	 ﾠand	 ﾠare	 ﾠlisted	 ﾠbelow:	 ﾠ
ERK2	 ﾠforward	 ﾠ 5ˊ-ﾭ‐GCCTACGGCATGGTGTGTAGTGCTTATGATAATGTCAACAAAGTTCG-ﾭ‐3ˊ	 ﾠ
ERK2	 ﾠreverse	 ﾠ 5ˊ-ﾭ‐CGAACTTTGTTGACATTATCATAAGCACTACACACCATGCCGTAGGC-ﾭ‐3ˊ	 ﾠ
2.2.1.7  Bacterial strains 
E.	 ﾠcoli	 ﾠDH5α	 ﾠor	 ﾠTOP10	 ﾠOneShot	 ﾠcells	 ﾠwere	 ﾠutilised	 ﾠfor	 ﾠmost	 ﾠcloning	 ﾠprocedures.	 ﾠWhere	 ﾠ
plasmids	 ﾠcontained	 ﾠthe	 ﾠccdB	 ﾠgene,	 ﾠDB3.1	 ﾠcells	 ﾠwere	 ﾠused	 ﾠinstead.	 ﾠ
2.2.1.8  Heat-shock transformation of competent bacteria 
A	 ﾠvial	 ﾠof	 ﾠfrozen	 ﾠcompetent	 ﾠbacteria	 ﾠwas	 ﾠthawed	 ﾠon	 ﾠice.	 ﾠSubsequently	 ﾠ1.5	 ﾠµl	 ﾠof	 ﾠthe	 ﾠ
respective	 ﾠligation	 ﾠreaction	 ﾠmix	 ﾠwas	 ﾠadded	 ﾠto	 ﾠ50	 ﾠµl	 ﾠof	 ﾠcompetent	 ﾠcells	 ﾠand	 ﾠincubated	 ﾠon	 ﾠ
ice	 ﾠfor	 ﾠ30	 ﾠminutes.	 ﾠThe	 ﾠbacteria	 ﾠwere	 ﾠthen	 ﾠheat-ﾭ‐shocked	 ﾠfor	 ﾠ45	 ﾠseconds	 ﾠin	 ﾠa	 ﾠwater	 ﾠbath	 ﾠat	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42°C	 ﾠand	 ﾠput	 ﾠon	 ﾠice	 ﾠfor	 ﾠ2	 ﾠminutes.	 ﾠAfter	 ﾠadding	 ﾠ250	 ﾠµl	 ﾠof	 ﾠSOC	 ﾠmedium	 ﾠ(at	 ﾠroom	 ﾠ
temperature),	 ﾠthe	 ﾠvials	 ﾠwere	 ﾠshaken	 ﾠhorizontally	 ﾠat	 ﾠ37°C	 ﾠfor	 ﾠ1	 ﾠhour	 ﾠat	 ﾠ225	 ﾠrpm	 ﾠin	 ﾠa	 ﾠrotary-ﾭ‐
shaking	 ﾠincubator.	 ﾠ150	 ﾠµl	 ﾠof	 ﾠeach	 ﾠtransformation	 ﾠwas	 ﾠthen	 ﾠspread	 ﾠon	 ﾠLB	 ﾠagar	 ﾠplates	 ﾠ
containing	 ﾠthe	 ﾠantibiotic	 ﾠof	 ﾠchoice	 ﾠ(100	 ﾠµg/ml	 ﾠAmpicillin	 ﾠ/	 ﾠ50	 ﾠµg/ml	 ﾠKanamycin	 ﾠ/	 ﾠ30	 ﾠµg/ml	 ﾠ
Chloramphenicol).	 ﾠIn	 ﾠthe	 ﾠcase	 ﾠof	 ﾠa	 ﾠretransformation	 ﾠ5	 ﾠng	 ﾠof	 ﾠvector	 ﾠDNA	 ﾠwere	 ﾠused	 ﾠand	 ﾠ
only	 ﾠ50	 ﾠµl	 ﾠwere	 ﾠplated.	 ﾠAfter	 ﾠthe	 ﾠliquid	 ﾠwas	 ﾠtotally	 ﾠabsorbed,	 ﾠthe	 ﾠplates	 ﾠwere	 ﾠinverted	 ﾠand	 ﾠ
placed	 ﾠin	 ﾠa	 ﾠ37°C	 ﾠincubator	 ﾠfor	 ﾠat	 ﾠleast	 ﾠ18	 ﾠhours.	 ﾠLater	 ﾠthey	 ﾠwere	 ﾠwrapped	 ﾠin	 ﾠparafilm	 ﾠand	 ﾠ
stored	 ﾠat	 ﾠ4°C.	 ﾠ
2.2.1.9  Plasmid preparation (Miniprep) 
4	 ﾠml	 ﾠof	 ﾠLB	 ﾠmedia	 ﾠcontaining	 ﾠthe	 ﾠappropriate	 ﾠantibiotic	 ﾠwere	 ﾠinoculated	 ﾠwith	 ﾠindividual	 ﾠ
colonies	 ﾠand	 ﾠincubated	 ﾠat	 ﾠ37°C	 ﾠovernight.	 ﾠThe	 ﾠfollowing	 ﾠmorning,	 ﾠglycerol	 ﾠstocks	 ﾠwere	 ﾠ
prepared	 ﾠfor	 ﾠlong	 ﾠterm	 ﾠstorage	 ﾠby	 ﾠmixing	 ﾠ500	 ﾠµl	 ﾠof	 ﾠbacterial	 ﾠculture	 ﾠwith	 ﾠequal	 ﾠvolumes	 ﾠ
of	 ﾠglycerol	 ﾠand	 ﾠstored	 ﾠat	 ﾠ-ﾭ‐80°C.	 ﾠThe	 ﾠremainder	 ﾠof	 ﾠthe	 ﾠovernight	 ﾠbacterial	 ﾠculture	 ﾠwas	 ﾠ
pelleted	 ﾠby	 ﾠcentrifugation	 ﾠat	 ﾠ3,000	 ﾠrpm	 ﾠfor	 ﾠ10	 ﾠminutes	 ﾠin	 ﾠa	 ﾠBeckham	 ﾠCoulter	 ﾠcentrifuge.	 ﾠ
DNA	 ﾠwas	 ﾠisolated	 ﾠfrom	 ﾠthe	 ﾠpellets	 ﾠusing	 ﾠthe	 ﾠQIAprep®	 ﾠSpin	 ﾠMiniprep	 ﾠKit	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠ
manufacturer’s	 ﾠinstructions.	 ﾠNext,	 ﾠthe	 ﾠDNA	 ﾠwas	 ﾠsequenced	 ﾠby	 ﾠthe	 ﾠBeatson	 ﾠMolecular	 ﾠ
Technology	 ﾠServices	 ﾠon	 ﾠan	 ﾠApplied	 ﾠBiosystems	 ﾠ3130xl	 ﾠsequencer.	 ﾠThe	 ﾠresulting	 ﾠdata	 ﾠwas	 ﾠ
analysed	 ﾠusing	 ﾠVectorNTI	 ﾠ(Invitrogen).	 ﾠ
2.2.1.10 Plasmid preparation (Maxiprep) 
Large	 ﾠscale	 ﾠ(200-ﾭ‐500	 ﾠml)	 ﾠovernight	 ﾠbacterial	 ﾠcultures	 ﾠwere	 ﾠset	 ﾠup	 ﾠin	 ﾠLB	 ﾠmedia	 ﾠcontaining	 ﾠ
the	 ﾠappropriate	 ﾠantibiotic	 ﾠand	 ﾠ20	 ﾠµl	 ﾠof	 ﾠa	 ﾠstarting	 ﾠculture	 ﾠwere	 ﾠused	 ﾠfor	 ﾠinoculation.	 ﾠThe	 ﾠ
following	 ﾠmorning	 ﾠcultures	 ﾠwere	 ﾠpelleted	 ﾠat	 ﾠ3,000	 ﾠrpm	 ﾠfor	 ﾠ30	 ﾠminutes.	 ﾠThe	 ﾠDNA	 ﾠwas	 ﾠthen	 ﾠ
isolated	 ﾠusing	 ﾠthe	 ﾠQIAprep®	 ﾠSpin	 ﾠMaxiprep	 ﾠKit	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠmanufacturer’s	 ﾠprotocol.	 ﾠ
The	 ﾠDNA	 ﾠconcentration	 ﾠof	 ﾠthe	 ﾠresulting	 ﾠplasmid	 ﾠsolution	 ﾠwas	 ﾠmeasured	 ﾠusing	 ﾠan	 ﾠ
Eppendorf	 ﾠBiophotometer	 ﾠwith	 ﾠan	 ﾠabsorbance	 ﾠof	 ﾠ260	 ﾠnm.	 ﾠ
2.2.2  Tissue Culture 
2.2.2.1  Cell origin 
Stable	 ﾠclones	 ﾠof	 ﾠA2780-ﾭ‐DNA3	 ﾠand	 ﾠA2780-ﾭ‐Rab25	 ﾠwere	 ﾠgenerated	 ﾠas	 ﾠpreviously	 ﾠdescribed	 ﾠ
by	 ﾠCheng	 ﾠet	 ﾠal.	 ﾠ[351]	 ﾠand	 ﾠgenerously	 ﾠprovided	 ﾠby	 ﾠGordon	 ﾠMills.	 ﾠMDA-ﾭ‐MB-ﾭ‐231	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purchased	 ﾠfrom	 ﾠthe	 ﾠAmerican	 ﾠType	 ﾠCulture	 ﾠCollection	 ﾠcell	 ﾠbank.	 ﾠVarious	 ﾠother	 ﾠcell	 ﾠlines	 ﾠ
used	 ﾠin	 ﾠthis	 ﾠproject	 ﾠwere	 ﾠobtained	 ﾠfrom	 ﾠresearch	 ﾠgroups	 ﾠwithin	 ﾠthe	 ﾠBeatson	 ﾠInstitute	 ﾠfor	 ﾠ
Cancer	 ﾠResearch,	 ﾠincluding	 ﾠTelomerase-ﾭ‐immortalised	 ﾠhuman	 ﾠfibroblasts	 ﾠ(TIFs)	 ﾠand	 ﾠcolon	 ﾠ
carcinoma	 ﾠBE	 ﾠcells.	 ﾠ
2.2.2.2  Cultivation of cells 
A2780	 ﾠcells	 ﾠwere	 ﾠcultured	 ﾠin	 ﾠRPMI-ﾭ‐1640	 ﾠmedium	 ﾠsupplemented	 ﾠwith	 ﾠ10%	 ﾠ(v/v)	 ﾠfoetal	 ﾠcalf	 ﾠ
serum	 ﾠand	 ﾠ2	 ﾠmM	 ﾠL-ﾭ‐glutamine	 ﾠat	 ﾠ37°C	 ﾠin	 ﾠa	 ﾠhumidified	 ﾠatmosphere	 ﾠcontaining	 ﾠ5%	 ﾠCO2.	 ﾠAll	 ﾠ
other	 ﾠcell	 ﾠlines	 ﾠwere	 ﾠcultured	 ﾠin	 ﾠDMEM	 ﾠcontaining	 ﾠ10%	 ﾠ(v/v)	 ﾠfoetal	 ﾠcalf	 ﾠserum	 ﾠand	 ﾠ
2	 ﾠmM	 ﾠL-ﾭ‐glutamine	 ﾠunder	 ﾠthe	 ﾠsame	 ﾠconditions	 ﾠas	 ﾠdescribed	 ﾠabove.	 ﾠWhen	 ﾠcells	 ﾠreached	 ﾠ
80%	 ﾠconfluence,	 ﾠthey	 ﾠwere	 ﾠsub-ﾭ‐cultured.	 ﾠTo	 ﾠdo	 ﾠthis,	 ﾠthe	 ﾠculture	 ﾠmedium	 ﾠwas	 ﾠremoved,	 ﾠ
the	 ﾠcellular	 ﾠmonolayer	 ﾠthen	 ﾠrinsed	 ﾠwith	 ﾠPBS	 ﾠand	 ﾠa	 ﾠ10%	 ﾠTrypsin/PE	 ﾠsolution	 ﾠwas	 ﾠadded.	 ﾠ
After	 ﾠa	 ﾠbrief	 ﾠincubation,	 ﾠthe	 ﾠdetached	 ﾠcells	 ﾠwere	 ﾠre-ﾭ‐suspended	 ﾠin	 ﾠthe	 ﾠappropriate	 ﾠcell	 ﾠ
culture	 ﾠmedium	 ﾠand	 ﾠcentrifuged	 ﾠfor	 ﾠ2	 ﾠminute	 ﾠat	 ﾠ900	 ﾠrpm.	 ﾠNext,	 ﾠthe	 ﾠcell	 ﾠpellet	 ﾠwas	 ﾠ
resuspended	 ﾠin	 ﾠfresh	 ﾠmedium	 ﾠand	 ﾠan	 ﾠaliquot	 ﾠwas	 ﾠseeded	 ﾠinto	 ﾠan	 ﾠappropriate	 ﾠtissue	 ﾠ
culture	 ﾠdish	 ﾠor	 ﾠflask.	 ﾠ
2.2.2.3  Freezing and thawing of cells 
At	 ﾠleast	 ﾠ1x10
6	 ﾠcells	 ﾠin	 ﾠexcellent	 ﾠcondition	 ﾠwere	 ﾠtrypsinised	 ﾠand	 ﾠcentrifuged	 ﾠfor	 ﾠ2	 ﾠminutes	 ﾠ
at	 ﾠ900	 ﾠrpm.	 ﾠOnce	 ﾠthe	 ﾠsupernatant	 ﾠwas	 ﾠcompletely	 ﾠremoved,	 ﾠthe	 ﾠcell	 ﾠpellet	 ﾠwas	 ﾠ
resuspended	 ﾠin	 ﾠ1	 ﾠml	 ﾠCryo-ﾭ‐SFM	 ﾠmedium	 ﾠand	 ﾠtransferred	 ﾠinto	 ﾠa	 ﾠlabelled	 ﾠcryo	 ﾠvial	 ﾠand	 ﾠ
placed	 ﾠin	 ﾠa	 ﾠfreezing	 ﾠcontainer	 ﾠ(NALGENE™	 ﾠ1°C	 ﾠCryo	 ﾠFreezing	 ﾠContainer)	 ﾠat	 ﾠ-ﾭ‐80°C.	 ﾠWhen	 ﾠ
cells	 ﾠwere	 ﾠto	 ﾠbe	 ﾠstored	 ﾠlonger	 ﾠthan	 ﾠ6	 ﾠmonths	 ﾠthey	 ﾠwere	 ﾠtransferred	 ﾠinto	 ﾠliquid	 ﾠnitrogen	 ﾠ
the	 ﾠfollowing	 ﾠday.	 ﾠ
According	 ﾠto	 ﾠthe	 ﾠrule	 ﾠof	 ﾠ“freeze	 ﾠslowly,	 ﾠthaw	 ﾠfast”,	 ﾠfrozen	 ﾠcells	 ﾠwere	 ﾠput	 ﾠimmediately	 ﾠinto	 ﾠ
a	 ﾠ37°C	 ﾠwater	 ﾠbath.	 ﾠWhen	 ﾠonly	 ﾠa	 ﾠsmall	 ﾠlump	 ﾠof	 ﾠice	 ﾠwas	 ﾠleft,	 ﾠthe	 ﾠvial	 ﾠwas	 ﾠopened	 ﾠand	 ﾠthe	 ﾠ
cells	 ﾠwere	 ﾠimmediately	 ﾠtransferred	 ﾠinto	 ﾠ5	 ﾠml	 ﾠof	 ﾠpre-ﾭ‐warmed	 ﾠmedium.	 ﾠAfter	 ﾠcentrifugation	 ﾠ
for	 ﾠ2	 ﾠminutes	 ﾠat	 ﾠ900	 ﾠrpm,	 ﾠthe	 ﾠsupernatant	 ﾠwas	 ﾠremoved	 ﾠand	 ﾠcells	 ﾠwere	 ﾠresuspended	 ﾠin	 ﾠ
their	 ﾠspecified	 ﾠgrowth	 ﾠmedium	 ﾠand	 ﾠplated	 ﾠonto	 ﾠa	 ﾠcell	 ﾠculture	 ﾠdish.	 ﾠThe	 ﾠfollowing	 ﾠmorning,	 ﾠ
the	 ﾠmedium	 ﾠwas	 ﾠreplaced.	 ﾠ	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2.2.2.4  Transfection using the Amaxa™ Nucleofector™ 
Amaxa	 ﾠnucleofection	 ﾠprovides	 ﾠan	 ﾠefficient	 ﾠway	 ﾠto	 ﾠintroduce	 ﾠDNA	 ﾠplasmids	 ﾠor	 ﾠsiRNA	 ﾠ
oligos.	 ﾠHence,	 ﾠthis	 ﾠmethod	 ﾠwas	 ﾠused	 ﾠfor	 ﾠA2780-ﾭ‐Rab25	 ﾠand	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠwhich	 ﾠ
were	 ﾠgrown	 ﾠto	 ﾠ70-ﾭ‐85%	 ﾠconfluency,	 ﾠtrypsinised	 ﾠand	 ﾠresuspended	 ﾠin	 ﾠgrowth	 ﾠmedium.	 ﾠ
Depending	 ﾠon	 ﾠthe	 ﾠcell	 ﾠline	 ﾠbetween	 ﾠ1-ﾭ‐5x10
6	 ﾠcells	 ﾠwere	 ﾠused	 ﾠfor	 ﾠone	 ﾠtransfection	 ﾠreaction.	 ﾠ
The	 ﾠappropriate	 ﾠnumber	 ﾠof	 ﾠcells	 ﾠwere	 ﾠcentrifuged	 ﾠat	 ﾠ900	 ﾠrpm	 ﾠfor	 ﾠ2	 ﾠmin.	 ﾠThe	 ﾠsupernatant	 ﾠ
was	 ﾠaspirated	 ﾠoff	 ﾠand	 ﾠ100-ﾭ‐200	 ﾠpmol	 ﾠof	 ﾠsiRNA	 ﾠor	 ﾠappropriate	 ﾠamounts	 ﾠof	 ﾠDNA	 ﾠwere	 ﾠadded	 ﾠ
on	 ﾠtop	 ﾠof	 ﾠthe	 ﾠcell	 ﾠpellet.	 ﾠAfterwards,	 ﾠ100	 ﾠµl	 ﾠof	 ﾠsolution	 ﾠT	 ﾠ(A2780-ﾭ‐Rab25)	 ﾠor	 ﾠ
V	 ﾠ(MDA-ﾭ‐MB-ﾭ‐231)	 ﾠwere	 ﾠadded	 ﾠand	 ﾠmixed	 ﾠthoroughly	 ﾠby	 ﾠpipetting	 ﾠup	 ﾠand	 ﾠdown.	 ﾠThe	 ﾠ
mixture	 ﾠwas	 ﾠthen	 ﾠtransferred	 ﾠinto	 ﾠa	 ﾠNucleofector	 ﾠcuvette	 ﾠand	 ﾠinserted	 ﾠinto	 ﾠthe	 ﾠAmaxa
TM	 ﾠ
Nucleofector
TM.	 ﾠTransfections	 ﾠwere	 ﾠcarried	 ﾠout	 ﾠusing	 ﾠthe	 ﾠappropriate	 ﾠprogramme	 ﾠ(see	 ﾠ
table	 ﾠbelow).	 ﾠSubsequently,	 ﾠtransfected	 ﾠcells	 ﾠwere	 ﾠtaken	 ﾠup	 ﾠin	 ﾠ500	 ﾠµl	 ﾠpre-ﾭ‐warmed	 ﾠgrowth	 ﾠ
medium	 ﾠand	 ﾠseeded	 ﾠonto	 ﾠtissue	 ﾠculture	 ﾠdishes.	 ﾠTransfected	 ﾠcells	 ﾠwere	 ﾠallowed	 ﾠto	 ﾠrecover	 ﾠ
and	 ﾠsettle	 ﾠfor	 ﾠat	 ﾠleast	 ﾠ12	 ﾠhours	 ﾠprior	 ﾠto	 ﾠany	 ﾠexperiments.	 ﾠ
Cell	 ﾠline	 ﾠ Nucleofection	 ﾠprogramme	 ﾠ
A2780	 ﾠ A-ﾭ‐023	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠ X-ﾭ‐013	 ﾠ
Typically,	 ﾠ3	 ﾠµg	 ﾠof	 ﾠDNA	 ﾠplasmid	 ﾠwere	 ﾠtransfected	 ﾠunless	 ﾠotherwise	 ﾠstated	 ﾠin	 ﾠthe	 ﾠtable	 ﾠ
below:	 ﾠ
Plasmid	 ﾠ Transfected	 ﾠamount	 ﾠ(µg)	 ﾠ
GFP	 ﾠ 1	 ﾠ
Destination	 ﾠvector	 ﾠ 1	 ﾠ
SF-ﾭ‐ERK1	 ﾠ 0.4	 ﾠ
SF-ﾭ‐ERK2	 ﾠ 1.5	 ﾠ
2.2.2.5  Transfection using HiPerFect 
For	 ﾠRNA	 ﾠinterference	 ﾠexperiments,	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠand	 ﾠBE	 ﾠcells	 ﾠwere	 ﾠtransfected	 ﾠusing	 ﾠ
HiPerFect,	 ﾠbecause	 ﾠthis	 ﾠincreased	 ﾠcellular	 ﾠviability.	 ﾠWhen	 ﾠcells	 ﾠreached	 ﾠ80%	 ﾠconfluence,	 ﾠa	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solution	 ﾠof	 ﾠ500	 ﾠµl	 ﾠof	 ﾠDMEM	 ﾠsupplemented	 ﾠwith	 ﾠL-ﾭ‐glutamine	 ﾠonly,	 ﾠ7.5	 ﾠµl	 ﾠHiPerFect	 ﾠand	 ﾠ
1.5	 ﾠµl	 ﾠsiRNA	 ﾠ(from	 ﾠ20	 ﾠµM	 ﾠstock)	 ﾠwas	 ﾠprepared	 ﾠand	 ﾠleft	 ﾠat	 ﾠroom	 ﾠtemperature	 ﾠfor	 ﾠ10	 ﾠ
minutes	 ﾠto	 ﾠallow	 ﾠtransfection	 ﾠcomplex	 ﾠformation.	 ﾠNext,	 ﾠthe	 ﾠmixture	 ﾠwas	 ﾠadded	 ﾠonto	 ﾠthe	 ﾠ
cells	 ﾠand	 ﾠthe	 ﾠplates	 ﾠwere	 ﾠgently	 ﾠswirled	 ﾠto	 ﾠensure	 ﾠa	 ﾠuniform	 ﾠdistribution.	 ﾠTransfected	 ﾠcells	 ﾠ
were	 ﾠthen	 ﾠincubated	 ﾠunder	 ﾠnormal	 ﾠgrowth	 ﾠconditions.	 ﾠTwo	 ﾠdays	 ﾠlater,	 ﾠthe	 ﾠcells	 ﾠwere	 ﾠ
passaged	 ﾠat	 ﾠa	 ﾠratio	 ﾠof	 ﾠone	 ﾠin	 ﾠthree	 ﾠand	 ﾠtransfected	 ﾠimmediately	 ﾠafter	 ﾠsub-ﾭ‐culturing	 ﾠ
following	 ﾠthe	 ﾠabove	 ﾠprotocol.	 ﾠAfter	 ﾠthe	 ﾠsecond	 ﾠround	 ﾠof	 ﾠtransfection	 ﾠgene	 ﾠsilencing	 ﾠwas	 ﾠ
monitored	 ﾠby	 ﾠWestern	 ﾠblotting	 ﾠor	 ﾠqRT-ﾭ‐PCR.	 ﾠ	 ﾠ
2.2.2.6  Cell proliferation assays 
10.000	 ﾠcells	 ﾠwere	 ﾠseeded	 ﾠper	 ﾠ6-ﾭ‐well	 ﾠdish	 ﾠand	 ﾠleft	 ﾠto	 ﾠsettle	 ﾠovernight.	 ﾠThe	 ﾠfollowing	 ﾠ
morning	 ﾠcells	 ﾠwere	 ﾠcounted	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠtime.	 ﾠFor	 ﾠeach	 ﾠmeasurement,	 ﾠcells	 ﾠwere	 ﾠ
thoroughly	 ﾠtrypsinised	 ﾠin	 ﾠ200	 ﾠµl	 ﾠof	 ﾠTrypsin/PE	 ﾠsolution.	 ﾠNext,	 ﾠthe	 ﾠtrypsin	 ﾠwas	 ﾠinactivated	 ﾠ
with	 ﾠ200	 ﾠµl	 ﾠof	 ﾠmedium.	 ﾠThe	 ﾠcell	 ﾠnumber	 ﾠwas	 ﾠdetermined	 ﾠby	 ﾠadding	 ﾠ20	 ﾠml	 ﾠof	 ﾠPBS	 ﾠto	 ﾠthe	 ﾠ
0.4	 ﾠml	 ﾠof	 ﾠcell	 ﾠsuspension	 ﾠand	 ﾠmeasuring	 ﾠthe	 ﾠcell	 ﾠnumber	 ﾠwith	 ﾠa	 ﾠCasy
®	 ﾠ1	 ﾠcell	 ﾠcounter.	 ﾠCell	 ﾠ
proliferation	 ﾠwas	 ﾠassayed	 ﾠover	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠ5-ﾭ‐6	 ﾠdays.	 ﾠRelative	 ﾠcell	 ﾠnumbers	 ﾠwere	 ﾠ
determined	 ﾠby	 ﾠusing	 ﾠday	 ﾠone	 ﾠas	 ﾠa	 ﾠreference	 ﾠpoint.	 ﾠEvery	 ﾠcondition	 ﾠwas	 ﾠset	 ﾠup	 ﾠin	 ﾠtriplicate	 ﾠ
and	 ﾠthe	 ﾠexperiments	 ﾠwere	 ﾠrepeated	 ﾠtwice.	 ﾠMoreover,	 ﾠCasy
®	 ﾠ1	 ﾠcell	 ﾠcounter	 ﾠmeasurements	 ﾠ
were	 ﾠchecked	 ﾠmanually	 ﾠusing	 ﾠa	 ﾠhaemocytometer.	 ﾠ
2.2.2.7  Inverted invasion assay 
Inverted	 ﾠinvasion	 ﾠassays,	 ﾠpreviously	 ﾠdescribed	 ﾠby	 ﾠHennigan	 ﾠet	 ﾠal.	 ﾠwere	 ﾠmodified	 ﾠas	 ﾠ
follows	 ﾠ[352].	 ﾠAn	 ﾠaliquot	 ﾠof	 ﾠMatrigel	 ﾠwas	 ﾠslowly	 ﾠthawed	 ﾠon	 ﾠice	 ﾠand	 ﾠthen	 ﾠdiluted	 ﾠ1:1	 ﾠin	 ﾠ
ice-ﾭ‐cold	 ﾠPBS	 ﾠsupplemented	 ﾠwith	 ﾠ25	 ﾠµg/ml	 ﾠfibronectin.	 ﾠSubsequently,	 ﾠ100	 ﾠµl	 ﾠof	 ﾠthis	 ﾠ
solution	 ﾠwas	 ﾠcarefully	 ﾠpipetted	 ﾠinto	 ﾠa	 ﾠTranswell	 ﾠ(pore	 ﾠsize	 ﾠof	 ﾠ8	 ﾠµm),	 ﾠwhich	 ﾠhad	 ﾠbeen	 ﾠ
inserted	 ﾠinto	 ﾠa	 ﾠwell	 ﾠof	 ﾠa	 ﾠ24-ﾭ‐well	 ﾠtissue	 ﾠculture	 ﾠplate.	 ﾠIn	 ﾠorder	 ﾠfor	 ﾠthe	 ﾠMatrigel	 ﾠto	 ﾠ
polymerize,	 ﾠthe	 ﾠplate	 ﾠwas	 ﾠincubated	 ﾠfor	 ﾠat	 ﾠleast	 ﾠ30	 ﾠminutes	 ﾠat	 ﾠ37˚C.	 ﾠMeanwhile,	 ﾠcell	 ﾠ
suspensions	 ﾠbetween	 ﾠ1x10
5	 ﾠand	 ﾠ4x10
5	 ﾠcells	 ﾠper	 ﾠml	 ﾠwere	 ﾠprepared	 ﾠin	 ﾠthe	 ﾠappropriate	 ﾠ
growth	 ﾠmedium.	 ﾠAfter	 ﾠthe	 ﾠMatrigel	 ﾠset,	 ﾠthe	 ﾠTranswells	 ﾠwere	 ﾠinverted	 ﾠand	 ﾠ100	 ﾠµl	 ﾠof	 ﾠthe	 ﾠ
cell	 ﾠsuspension	 ﾠwere	 ﾠpipetted	 ﾠonto	 ﾠthe	 ﾠunderside	 ﾠof	 ﾠthe	 ﾠfilter.	 ﾠThe	 ﾠTranswells	 ﾠwere	 ﾠthen	 ﾠ
carefully	 ﾠcovered	 ﾠwith	 ﾠthe	 ﾠbase	 ﾠof	 ﾠthe	 ﾠ24-ﾭ‐well	 ﾠtissue	 ﾠculture	 ﾠplate	 ﾠso	 ﾠthat	 ﾠit	 ﾠcontacted	 ﾠthe	 ﾠ
droplet	 ﾠof	 ﾠcell	 ﾠsuspension.	 ﾠNext,	 ﾠthe	 ﾠinverted	 ﾠplate	 ﾠwas	 ﾠincubated	 ﾠat	 ﾠ37˚C,	 ﾠ5%	 ﾠCO2	 ﾠfor	 ﾠ4	 ﾠ
hours	 ﾠto	 ﾠallow	 ﾠcells	 ﾠto	 ﾠattach	 ﾠto	 ﾠthe	 ﾠfilter.	 ﾠAfterwards,	 ﾠthe	 ﾠTranswells	 ﾠwere	 ﾠturned	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right-ﾭ‐side-ﾭ‐up,	 ﾠwashed	 ﾠby	 ﾠsequential	 ﾠdipping	 ﾠin	 ﾠ1	 ﾠml	 ﾠof	 ﾠthe	 ﾠappropriate	 ﾠserum-ﾭ‐free	 ﾠgrowth	 ﾠ
medium	 ﾠtwice	 ﾠand	 ﾠfinally	 ﾠplaced	 ﾠinto	 ﾠ1	 ﾠml	 ﾠof	 ﾠthe	 ﾠserum-ﾭ‐free	 ﾠmedium.	 ﾠThen,	 ﾠ100	 ﾠµl	 ﾠof	 ﾠ
growth	 ﾠmedium	 ﾠcontaining	 ﾠ10%	 ﾠserum	 ﾠand	 ﾠthe	 ﾠchemoattractant	 ﾠEGF	 ﾠ(25ng/ml)	 ﾠwas	 ﾠ
gently	 ﾠpipetted	 ﾠon	 ﾠtop	 ﾠof	 ﾠthe	 ﾠMatrigel.	 ﾠCells	 ﾠwere	 ﾠallowed	 ﾠto	 ﾠinvade	 ﾠinto	 ﾠthe	 ﾠMatrigel	 ﾠ
over	 ﾠa	 ﾠcourse	 ﾠof	 ﾠ2-ﾭ‐3	 ﾠdays	 ﾠat	 ﾠ37˚C	 ﾠand	 ﾠ5%	 ﾠCO2.	 ﾠ
In	 ﾠorder	 ﾠto	 ﾠvisualize	 ﾠthe	 ﾠmigrated	 ﾠcells,	 ﾠthe	 ﾠTranswells	 ﾠwere	 ﾠtransferred	 ﾠinto	 ﾠa	 ﾠnew	 ﾠ
24-ﾭ‐well	 ﾠtissue	 ﾠplate	 ﾠand	 ﾠcovered	 ﾠdrop-ﾭ‐wise	 ﾠwith	 ﾠ1	 ﾠml	 ﾠof	 ﾠcalcein	 ﾠacetomethyl	 ﾠester	 ﾠdiluted	 ﾠ
to	 ﾠ4	 ﾠµM	 ﾠin	 ﾠserum	 ﾠfree	 ﾠmedium.	 ﾠAfter	 ﾠone	 ﾠhour	 ﾠat	 ﾠ37˚C	 ﾠsamples	 ﾠwere	 ﾠassayed	 ﾠusing	 ﾠa	 ﾠ
LEICA	 ﾠSP2	 ﾠconfocal	 ﾠmicroscope	 ﾠwith	 ﾠa	 ﾠ20x	 ﾠobjective.	 ﾠThe	 ﾠfluorescent	 ﾠdye	 ﾠwas	 ﾠexcited	 ﾠwith	 ﾠ
a	 ﾠwavelength	 ﾠof	 ﾠ488	 ﾠnm	 ﾠand	 ﾠemitted	 ﾠat	 ﾠ515	 ﾠnm.	 ﾠOptical	 ﾠsections	 ﾠwere	 ﾠcaptured	 ﾠat	 ﾠ15	 ﾠµm	 ﾠ
intervals	 ﾠstarting	 ﾠfrom	 ﾠthe	 ﾠunderside	 ﾠof	 ﾠthe	 ﾠTranswell	 ﾠfilter	 ﾠand	 ﾠmoving	 ﾠupwards	 ﾠin	 ﾠthe	 ﾠ
direction	 ﾠof	 ﾠcell	 ﾠinvasion.	 ﾠThe	 ﾠresulting	 ﾠimages	 ﾠwere	 ﾠquantified	 ﾠusing	 ﾠthe	 ﾠarea	 ﾠcalculator	 ﾠ
tool	 ﾠfrom	 ﾠthe	 ﾠImageJ	 ﾠsoftware.	 ﾠThe	 ﾠthreshold	 ﾠfluorescence	 ﾠintensity	 ﾠwas	 ﾠset	 ﾠso	 ﾠthat	 ﾠ
background	 ﾠintensities	 ﾠwere	 ﾠerased	 ﾠand	 ﾠonly	 ﾠcells	 ﾠwithin	 ﾠthe	 ﾠoptical	 ﾠslice	 ﾠwere	 ﾠvisualised.	 ﾠ
The	 ﾠsum	 ﾠof	 ﾠfluorescence	 ﾠof	 ﾠthe	 ﾠsections	 ﾠfrom	 ﾠ45	 ﾠµm	 ﾠand	 ﾠabove	 ﾠwas	 ﾠdivided	 ﾠby	 ﾠthe	 ﾠtotal	 ﾠ
fluorescence	 ﾠof	 ﾠall	 ﾠthe	 ﾠoptical	 ﾠsections,	 ﾠthus	 ﾠgiving	 ﾠan	 ﾠinvasion	 ﾠindex	 ﾠof	 ﾠ≥45	 ﾠµm.	 ﾠMean	 ﾠ
values	 ﾠwere	 ﾠgenerated	 ﾠfrom	 ﾠthree	 ﾠindividual	 ﾠexperiments.	 ﾠWithin	 ﾠone	 ﾠexperiment	 ﾠeach	 ﾠ
condition	 ﾠwas	 ﾠset	 ﾠup	 ﾠin	 ﾠduplicate	 ﾠand	 ﾠoptical	 ﾠsections	 ﾠfor	 ﾠthree	 ﾠareas	 ﾠwere	 ﾠtaken	 ﾠfor	 ﾠeach	 ﾠ
Transwell.	 ﾠ	 ﾠ
2.2.2.8  Generation of cell-derived matrix 
Cell-ﾭ‐derived	 ﾠmatrix	 ﾠwas	 ﾠgenerated	 ﾠas	 ﾠpreviously	 ﾠdescribed	 ﾠ[38,	 ﾠ353].	 ﾠBriefly,	 ﾠtissue	 ﾠculture	 ﾠ
plates	 ﾠwere	 ﾠcoated	 ﾠwith	 ﾠ0.2%	 ﾠsterile	 ﾠgelatine	 ﾠfor	 ﾠone	 ﾠhour	 ﾠat	 ﾠ37˚C.	 ﾠNext,	 ﾠthe	 ﾠgelatine	 ﾠ
solution	 ﾠwas	 ﾠaspirated	 ﾠoff	 ﾠand	 ﾠplates	 ﾠwere	 ﾠwashed	 ﾠtwice	 ﾠwith	 ﾠPBS.	 ﾠIn	 ﾠorder	 ﾠto	 ﾠcrosslink	 ﾠ
the	 ﾠlayer	 ﾠof	 ﾠgelatine,	 ﾠ1%	 ﾠsterile	 ﾠglutaraldehyde	 ﾠwas	 ﾠadded	 ﾠfor	 ﾠ30	 ﾠminutes	 ﾠat	 ﾠroom	 ﾠ
temperature.	 ﾠFollowing	 ﾠtwo	 ﾠwashes	 ﾠwith	 ﾠPBS,	 ﾠthe	 ﾠcrosslinking	 ﾠreaction	 ﾠwas	 ﾠquenched	 ﾠ
with	 ﾠ1	 ﾠM	 ﾠsterile	 ﾠglycine	 ﾠin	 ﾠPBS	 ﾠ(pH	 ﾠ~7)	 ﾠfor	 ﾠ20	 ﾠminutes	 ﾠat	 ﾠroom	 ﾠtemperature.	 ﾠAfter	 ﾠanother	 ﾠ
2	 ﾠwashes,	 ﾠthe	 ﾠtissue	 ﾠculture	 ﾠdishes	 ﾠwere	 ﾠequilibrated	 ﾠwith	 ﾠDMEM	 ﾠcontaining	 ﾠ10%	 ﾠfoetal	 ﾠ
calf	 ﾠserum	 ﾠand	 ﾠ2	 ﾠmM	 ﾠL-ﾭ‐glutamine.	 ﾠThen,	 ﾠhuman	 ﾠtelomerase-ﾭ‐immortalised	 ﾠfibroblasts	 ﾠ
were	 ﾠplated	 ﾠat	 ﾠnear	 ﾠconfluence	 ﾠ(~2x10
4/cm
2).	 ﾠThe	 ﾠfollowing	 ﾠday,	 ﾠcollagen	 ﾠproduction	 ﾠwas	 ﾠ
stimulated	 ﾠthrough	 ﾠsupplementation	 ﾠof	 ﾠthe	 ﾠmedium	 ﾠwith	 ﾠ50	 ﾠµg/ml	 ﾠascorbic	 ﾠacid.	 ﾠ
Fibroblasts	 ﾠwere	 ﾠcultured	 ﾠfor	 ﾠ10-ﾭ‐14	 ﾠdays	 ﾠand	 ﾠthe	 ﾠmedium	 ﾠ(supplemented	 ﾠwith	 ﾠascorbic	 ﾠChapter 2 – Materials and methods    94 
acid)	 ﾠwas	 ﾠexchanged	 ﾠevery	 ﾠother	 ﾠday.	 ﾠMatrices	 ﾠwere	 ﾠthen	 ﾠdenuded	 ﾠof	 ﾠliving	 ﾠfibroblasts	 ﾠby	 ﾠ
incubating	 ﾠthe	 ﾠdishes	 ﾠwith	 ﾠPBS	 ﾠcontaining	 ﾠ20	 ﾠmM	 ﾠNH4OH	 ﾠand	 ﾠ0.5%	 ﾠTriton	 ﾠX-ﾭ‐100	 ﾠfor	 ﾠ2	 ﾠ
minutes,	 ﾠafter	 ﾠwhich	 ﾠcell	 ﾠlysis	 ﾠwas	 ﾠexamined	 ﾠusing	 ﾠa	 ﾠphase	 ﾠlight	 ﾠmicroscope.	 ﾠNext,	 ﾠthe	 ﾠ
extraction	 ﾠbuffer	 ﾠwas	 ﾠaspirated	 ﾠoff	 ﾠand	 ﾠmatrices	 ﾠwere	 ﾠwashed	 ﾠtwice	 ﾠin	 ﾠPHS	 ﾠcontaining	 ﾠ
calcium	 ﾠand	 ﾠmagnesium.	 ﾠResidual	 ﾠDNA	 ﾠwas	 ﾠdigested	 ﾠwith	 ﾠPBS	 ﾠcontaining	 ﾠcalcium,	 ﾠ
magnesium	 ﾠand	 ﾠ10	 ﾠµg/ml	 ﾠDNase1	 ﾠat	 ﾠ37˚C	 ﾠfor	 ﾠ30	 ﾠminutes.	 ﾠFollowing	 ﾠanother	 ﾠtwo	 ﾠwashes	 ﾠ
with	 ﾠPBS	 ﾠcontaining	 ﾠmagnesium	 ﾠand	 ﾠcalcium,	 ﾠmatrices	 ﾠwere	 ﾠstored	 ﾠat	 ﾠ4˚C	 ﾠin	 ﾠthe	 ﾠsame	 ﾠ
solution	 ﾠsupplemented	 ﾠwith	 ﾠpen/strep	 ﾠand	 ﾠfungizone.	 ﾠBefore	 ﾠuse,	 ﾠthe	 ﾠmatrix	 ﾠcondition	 ﾠ
was	 ﾠexamined	 ﾠby	 ﾠphase	 ﾠlight	 ﾠmicroscopy.	 ﾠPrior	 ﾠto	 ﾠseeding	 ﾠthe	 ﾠcell	 ﾠline	 ﾠof	 ﾠinterest,	 ﾠ
matrices	 ﾠwere	 ﾠwashed	 ﾠtwice	 ﾠwith	 ﾠPBS	 ﾠand	 ﾠequilibrated	 ﾠwith	 ﾠcomplete	 ﾠmedium	 ﾠfor	 ﾠ20	 ﾠ
minutes	 ﾠat	 ﾠ37˚C.	 ﾠ
2.2.2.9  Migration on cell-derived matrix 
Respective	 ﾠcells	 ﾠ(50,000	 ﾠcells	 ﾠfor	 ﾠA2780-ﾭ‐Rab25	 ﾠcells,	 ﾠ100,000	 ﾠcells	 ﾠin	 ﾠthe	 ﾠcase	 ﾠof	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells)	 ﾠwere	 ﾠseeded	 ﾠinto	 ﾠa	 ﾠwell	 ﾠof	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠdish	 ﾠcoated	 ﾠwith	 ﾠcell-ﾭ‐derived	 ﾠ
matrix	 ﾠand	 ﾠallowed	 ﾠto	 ﾠadhere	 ﾠfor	 ﾠ4	 ﾠhours	 ﾠprior	 ﾠto	 ﾠimaging.	 ﾠMigration	 ﾠwas	 ﾠmonitored	 ﾠusing	 ﾠ
a	 ﾠNikon	 ﾠtime-ﾭ‐lapse	 ﾠmicroscope	 ﾠand	 ﾠmigration	 ﾠcharacteristics	 ﾠwere	 ﾠanalysed	 ﾠusing	 ﾠthe	 ﾠ
Manual	 ﾠTracking	 ﾠand	 ﾠChemotaxis	 ﾠtool	 ﾠof	 ﾠImageJ	 ﾠand	 ﾠa	 ﾠcustomised	 ﾠMATLAB	 ﾠscript	 ﾠwritten	 ﾠ
by	 ﾠDr.	 ﾠMarc	 ﾠBirtwistle.	 ﾠ
2.2.2.10 Scratch wound assays 
Cells	 ﾠwere	 ﾠseeded	 ﾠinto	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠdish,	 ﾠso	 ﾠthat	 ﾠthey	 ﾠreached	 ﾠconfluence	 ﾠ48	 ﾠhours	 ﾠpost	 ﾠ
transfection.	 ﾠNext,	 ﾠa	 ﾠwound	 ﾠwas	 ﾠintroduced	 ﾠby	 ﾠscratching	 ﾠthe	 ﾠplastic	 ﾠdish	 ﾠwith	 ﾠa	 ﾠ200	 ﾠµl	 ﾠ
pipette	 ﾠtip.	 ﾠFollowing	 ﾠthree	 ﾠwashes	 ﾠin	 ﾠfully-ﾭ‐supplemented	 ﾠmedium	 ﾠwound	 ﾠclosure	 ﾠwas	 ﾠ
monitored	 ﾠat	 ﾠ10	 ﾠminute	 ﾠintervals	 ﾠusing	 ﾠa	 ﾠtime-ﾭ‐lapse	 ﾠmicroscope.	 ﾠImages	 ﾠfor	 ﾠeach	 ﾠ
condition	 ﾠwere	 ﾠtaken	 ﾠfrom	 ﾠfive	 ﾠdistinct	 ﾠfields	 ﾠalong	 ﾠthe	 ﾠwound	 ﾠand	 ﾠa	 ﾠminimum	 ﾠof	 ﾠfive	 ﾠ
cells	 ﾠwere	 ﾠtracked	 ﾠfor	 ﾠeach	 ﾠfield.	 ﾠMigration	 ﾠcharacteristics	 ﾠfrom	 ﾠthree	 ﾠindependent	 ﾠ
experiments	 ﾠwere	 ﾠanalysed	 ﾠusing	 ﾠthe	 ﾠImageJ	 ﾠcell	 ﾠtracking	 ﾠsoftware.	 ﾠ
2.2.2.11 Immunofluorescence 
Cells	 ﾠwere	 ﾠcultured	 ﾠon	 ﾠsterile	 ﾠcoverslips	 ﾠplaced	 ﾠin	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠtissue	 ﾠculture	 ﾠdish.	 ﾠWhere	 ﾠ
indicated,	 ﾠcoverslips	 ﾠwere	 ﾠcoated	 ﾠwith	 ﾠfibronectin	 ﾠ(20	 ﾠµg/ml	 ﾠin	 ﾠPBS)	 ﾠfor	 ﾠ20	 ﾠminutes	 ﾠat	 ﾠ
37˚C.	 ﾠMedium	 ﾠwas	 ﾠremoved	 ﾠand	 ﾠthe	 ﾠcells	 ﾠwere	 ﾠwashed	 ﾠtwice	 ﾠwith	 ﾠPBS	 ﾠand	 ﾠfixed	 ﾠin	 ﾠa	 ﾠ4%	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paraformaldehyde	 ﾠsolution.	 ﾠAfter	 ﾠ15	 ﾠminutes,	 ﾠthe	 ﾠcrosslinking	 ﾠreaction	 ﾠwas	 ﾠquenched	 ﾠby	 ﾠ
adding	 ﾠan	 ﾠequal	 ﾠvolume	 ﾠof	 ﾠa	 ﾠ2M	 ﾠglycine	 ﾠsolution.	 ﾠNext,	 ﾠthe	 ﾠcoverslips	 ﾠwere	 ﾠwashed	 ﾠtwice	 ﾠ
with	 ﾠPBS,	 ﾠafter	 ﾠwhich	 ﾠcells	 ﾠwere	 ﾠpermeabilised	 ﾠwith	 ﾠ0.05%	 ﾠTriton	 ﾠX-ﾭ‐100	 ﾠin	 ﾠPBS	 ﾠfor	 ﾠ
2	 ﾠminutes,	 ﾠwhich	 ﾠwas	 ﾠfollowed	 ﾠby	 ﾠ3	 ﾠwashes	 ﾠin	 ﾠPBS.	 ﾠIn	 ﾠorder	 ﾠto	 ﾠblock	 ﾠnon-ﾭ‐specific	 ﾠantibody	 ﾠ
binding,	 ﾠcells	 ﾠwere	 ﾠincubated	 ﾠin	 ﾠPBS	 ﾠcontaining	 ﾠ1%	 ﾠBSA	 ﾠfor	 ﾠone	 ﾠhour.	 ﾠThen,	 ﾠprimary	 ﾠ
antibodies	 ﾠdiluted	 ﾠin	 ﾠblocking	 ﾠsolution	 ﾠwere	 ﾠapplied	 ﾠfor	 ﾠone	 ﾠhour.	 ﾠFollowing	 ﾠanother	 ﾠ
three	 ﾠwashes,	 ﾠsecondary	 ﾠantibodies	 ﾠin	 ﾠblocking	 ﾠsolution	 ﾠwere	 ﾠapplied	 ﾠfor	 ﾠ45	 ﾠminutes.	 ﾠ
Coverslips	 ﾠwere	 ﾠwashed	 ﾠanother	 ﾠtwo	 ﾠtimes	 ﾠwith	 ﾠPBS	 ﾠbefore	 ﾠbeing	 ﾠmounted	 ﾠonto	 ﾠglass	 ﾠ
slides	 ﾠusing	 ﾠVectashield	 ﾠcontaining	 ﾠDAPI.	 ﾠSlides	 ﾠwere	 ﾠdried	 ﾠovernight	 ﾠat	 ﾠ4˚C.	 ﾠColocalisation	 ﾠ
studies	 ﾠwere	 ﾠperformed	 ﾠon	 ﾠa	 ﾠZeiss	 ﾠ710	 ﾠupright	 ﾠconfocal	 ﾠmicroscope	 ﾠwith	 ﾠa	 ﾠ64x	 ﾠobjective.	 ﾠ
Different	 ﾠfluorescent	 ﾠchannels	 ﾠwere	 ﾠrecorded	 ﾠsequentially	 ﾠto	 ﾠprevent	 ﾠbleed-ﾭ‐through.	 ﾠ
2.2.3  Protein biology 
2.2.3.1  Cell lysis 
After	 ﾠcells	 ﾠwere	 ﾠgrown	 ﾠto	 ﾠ80%	 ﾠconfluence,	 ﾠthe	 ﾠcell	 ﾠculture	 ﾠdishes	 ﾠwere	 ﾠplaced	 ﾠon	 ﾠice,	 ﾠthe	 ﾠ
medium	 ﾠwas	 ﾠaspirated	 ﾠoff	 ﾠand	 ﾠthe	 ﾠcells	 ﾠwere	 ﾠwashed	 ﾠtwice	 ﾠwith	 ﾠice-ﾭ‐cold	 ﾠPBS.	 ﾠDepending	 ﾠ
on	 ﾠthe	 ﾠexperiment	 ﾠdifferent	 ﾠlysis	 ﾠbuffers	 ﾠwere	 ﾠused	 ﾠ(Table	 ﾠ2-ﾭ‐7).	 ﾠSubsequently,	 ﾠprotein	 ﾠ
extracts	 ﾠwere	 ﾠgenerated	 ﾠby	 ﾠadding	 ﾠlysis	 ﾠbuffer	 ﾠto	 ﾠthe	 ﾠdishes	 ﾠ(0.4	 ﾠml	 ﾠper	 ﾠ10	 ﾠcm	 ﾠdish,	 ﾠ1	 ﾠml	 ﾠ
per	 ﾠ15	 ﾠcm	 ﾠdish)	 ﾠand	 ﾠscrapping	 ﾠthe	 ﾠcells	 ﾠoff	 ﾠthe	 ﾠplate.	 ﾠThe	 ﾠlysates	 ﾠwere	 ﾠthen	 ﾠtransferred	 ﾠ
into	 ﾠ1.5	 ﾠml	 ﾠmicrocentrifuge	 ﾠtubes	 ﾠand	 ﾠincubated	 ﾠon	 ﾠice	 ﾠfor	 ﾠ10	 ﾠminutes	 ﾠwith	 ﾠoccasional	 ﾠ
vortexing.	 ﾠAfterwards,	 ﾠlysates	 ﾠwere	 ﾠcleared	 ﾠby	 ﾠcentrifugation	 ﾠat	 ﾠ14,000	 ﾠrpm	 ﾠin	 ﾠa	 ﾠ
pre-ﾭ‐cooled	 ﾠbenchtop	 ﾠcentrifuge	 ﾠfor	 ﾠ10	 ﾠminutes.	 ﾠCleared	 ﾠlysates	 ﾠwere	 ﾠcollected	 ﾠin	 ﾠnew	 ﾠ
tubes	 ﾠand	 ﾠeither	 ﾠprocessed	 ﾠfurther	 ﾠor	 ﾠstored	 ﾠat	 ﾠ-ﾭ‐20˚C.	 ﾠ
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Lysis	 ﾠbuffer	 ﾠ Composition	 ﾠ Application	 ﾠ
HEPES	 ﾠlysis	 ﾠbuffer	 ﾠ 20	 ﾠmM	 ﾠHEPES	 ﾠpH	 ﾠ7.5	 ﾠ
150	 ﾠmM	 ﾠNaCl	 ﾠ
2	 ﾠmM	 ﾠEDTA	 ﾠpH	 ﾠ7.4	 ﾠ
1	 ﾠ%	 ﾠNP-ﾭ‐40	 ﾠ(v/v)	 ﾠ
1	 ﾠmM	 ﾠNa3VO4	 ﾠ
10	 ﾠmM	 ﾠNaF	 ﾠ
1	 ﾠmM	 ﾠPMSF	 ﾠ
5	 ﾠµg/ml	 ﾠleupeptin	 ﾠ
Western	 ﾠblot	 ﾠ
NDLB	 ﾠlysis	 ﾠbuffer	 ﾠ 50	 ﾠmM	 ﾠTris-ﾭ‐HCl	 ﾠ(pH	 ﾠ7.0)	 ﾠ
150	 ﾠmM	 ﾠNaCl	 ﾠ
10	 ﾠmM	 ﾠNaF	 ﾠ
1	 ﾠmM	 ﾠNa3VO3	 ﾠ
5	 ﾠmM	 ﾠEDTA	 ﾠ
5	 ﾠmM	 ﾠEGTA	 ﾠ
1%	 ﾠTriton	 ﾠX-ﾭ‐100	 ﾠ(v/v)	 ﾠ
0.5%	 ﾠNP-ﾭ‐40	 ﾠ(v/v)	 ﾠ
5	 ﾠµg/ml	 ﾠleupeptin	 ﾠ
1	 ﾠmM	 ﾠPMSF	 ﾠ
Immunoprecipitation	 ﾠ
RIPA	 ﾠlysis	 ﾠbuffer	 ﾠ 50	 ﾠmM	 ﾠTris-ﾭ‐HCl	 ﾠ(pH	 ﾠ7.0)	 ﾠ
150	 ﾠmM	 ﾠNaCl	 ﾠ
0.5%	 ﾠsodium	 ﾠdeoxycholate	 ﾠ
1%	 ﾠNP-ﾭ‐40	 ﾠ(v/v)	 ﾠ
1	 ﾠmM	 ﾠPMSF	 ﾠ
1	 ﾠmM	 ﾠNa3VO4	 ﾠ
10	 ﾠmM	 ﾠNaF	 ﾠ
5	 ﾠµg/ml	 ﾠleupeptin	 ﾠ
Western	 ﾠblot,	 ﾠwhen	 ﾠ
interested	 ﾠin	 ﾠmembrane	 ﾠ
proteins	 ﾠ
Table 2-7 Comparison of different lysis buffers: Composition and Application 
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2.2.3.2  Protein quantification 
Protein	 ﾠconcentrations	 ﾠwere	 ﾠmeasured	 ﾠusing	 ﾠthe	 ﾠPierce®	 ﾠBCA	 ﾠProtein	 ﾠAssay	 ﾠKit	 ﾠaccording	 ﾠ
to	 ﾠthe	 ﾠmanufacturer’s	 ﾠinstructions.	 ﾠIn	 ﾠbrief,	 ﾠdiluted	 ﾠalbumin	 ﾠstandards	 ﾠwere	 ﾠprepared	 ﾠ
(0.08,	 ﾠ0.1,	 ﾠ0.2,	 ﾠ0.4,	 ﾠ1,	 ﾠ2	 ﾠmg/ml)	 ﾠand	 ﾠthe	 ﾠappropriate	 ﾠlysis	 ﾠbuffer	 ﾠwas	 ﾠused	 ﾠas	 ﾠa	 ﾠblank.	 ﾠA	 ﾠ
standard	 ﾠcurve	 ﾠwas	 ﾠdetermined	 ﾠby	 ﾠadding	 ﾠ20	 ﾠµl	 ﾠof	 ﾠblank	 ﾠand	 ﾠstandards	 ﾠto	 ﾠthe	 ﾠbottom	 ﾠof	 ﾠa	 ﾠ
96-ﾭ‐well	 ﾠplate.	 ﾠProtein	 ﾠlysates	 ﾠwere	 ﾠalso	 ﾠadded	 ﾠin	 ﾠduplicate.	 ﾠ200	 ﾠµl	 ﾠof	 ﾠthe	 ﾠconstituted	 ﾠ
protein	 ﾠassay	 ﾠreagent	 ﾠ(50:1,	 ﾠreagent	 ﾠA:B)	 ﾠwere	 ﾠadded	 ﾠto	 ﾠall	 ﾠwells	 ﾠand	 ﾠincubated	 ﾠat	 ﾠ37˚C	 ﾠ
for	 ﾠ15	 ﾠminutes.	 ﾠNext,	 ﾠabsorbance	 ﾠvalues	 ﾠwere	 ﾠmeasured	 ﾠusing	 ﾠa	 ﾠDynatech	 ﾠMR7000	 ﾠplate	 ﾠ
reader	 ﾠat	 ﾠ595	 ﾠnm	 ﾠand	 ﾠplotted	 ﾠto	 ﾠgenerate	 ﾠa	 ﾠstandard	 ﾠcurve.	 ﾠLastly,	 ﾠprotein	 ﾠconcentrations	 ﾠ
were	 ﾠdetermined	 ﾠfrom	 ﾠthe	 ﾠcurve	 ﾠand	 ﾠlysates	 ﾠdiluted	 ﾠif	 ﾠnecessary.	 ﾠ
2.2.3.3  Co-immunoprecipitation 
Prior	 ﾠto	 ﾠco-ﾭ‐immunoprecipitation	 ﾠexperiments,	 ﾠthe	 ﾠGFP	 ﾠantibody	 ﾠwas	 ﾠcoupled	 ﾠto	 ﾠbeads.	 ﾠTo	 ﾠ
do	 ﾠthis,	 ﾠ1.5	 ﾠµl	 ﾠof	 ﾠantibody	 ﾠper	 ﾠlysate	 ﾠwere	 ﾠincubated	 ﾠwith	 ﾠ25	 ﾠµl	 ﾠof	 ﾠmagnetic	 ﾠbeads	 ﾠin	 ﾠ
100	 ﾠµl	 ﾠof	 ﾠPBS	 ﾠcontaining	 ﾠ0.1%	 ﾠBSA	 ﾠfor	 ﾠ1	 ﾠhour	 ﾠat	 ﾠ4˚C.	 ﾠAfter	 ﾠ2	 ﾠwashes	 ﾠwith	 ﾠPBS	 ﾠcontaining	 ﾠ
0.1%	 ﾠBSA,	 ﾠthe	 ﾠlysate	 ﾠwas	 ﾠapplied	 ﾠ(containing	 ﾠapproximately	 ﾠ400	 ﾠµg	 ﾠof	 ﾠprotein)	 ﾠand	 ﾠ
incubated	 ﾠat	 ﾠ4˚C	 ﾠfor	 ﾠ2	 ﾠhours.	 ﾠThen,	 ﾠbeads	 ﾠwere	 ﾠwashed	 ﾠ3	 ﾠtimes	 ﾠwith	 ﾠlysis	 ﾠbuffer	 ﾠand	 ﾠ
boiled	 ﾠin	 ﾠlysis	 ﾠbuffer	 ﾠsupplemented	 ﾠwith	 ﾠreducing	 ﾠsample	 ﾠbuffer	 ﾠat	 ﾠ95˚C	 ﾠfor	 ﾠ5	 ﾠminutes.	 ﾠ
Protein	 ﾠinteractions	 ﾠwere	 ﾠexamined	 ﾠby	 ﾠWestern	 ﾠblot.	 ﾠ	 ﾠ
2.2.3.4  SDS-PAGE and Coomassie staining 
SDS-ﾭ‐polyacrylamide	 ﾠgels	 ﾠwere	 ﾠused	 ﾠto	 ﾠresolve	 ﾠprotein	 ﾠsamples	 ﾠaccording	 ﾠto	 ﾠtheir	 ﾠ
molecular	 ﾠweight.	 ﾠFirstly,	 ﾠthe	 ﾠprotein	 ﾠlysate	 ﾠwas	 ﾠmixed	 ﾠwith	 ﾠ4x	 ﾠreducing	 ﾠsample	 ﾠbuffer	 ﾠ
and	 ﾠheated	 ﾠto	 ﾠ95˚C	 ﾠfor	 ﾠ5	 ﾠminutes	 ﾠon	 ﾠa	 ﾠthermomixer	 ﾠto	 ﾠdenature	 ﾠthe	 ﾠproteins.	 ﾠAfter	 ﾠa	 ﾠ
brief	 ﾠcentrifugation,	 ﾠ5	 ﾠµg	 ﾠof	 ﾠprotein	 ﾠwere	 ﾠresolved	 ﾠon	 ﾠa	 ﾠdenaturing,	 ﾠpre-ﾭ‐cast	 ﾠNuPAGE	 ﾠ
polyacrylamide	 ﾠgel	 ﾠ(4-ﾭ‐12%	 ﾠgradient	 ﾠor	 ﾠ10%).	 ﾠMolecular	 ﾠweight	 ﾠmarkers	 ﾠwere	 ﾠloaded	 ﾠonto	 ﾠ
the	 ﾠgel	 ﾠnext	 ﾠto	 ﾠlysate	 ﾠsamples.	 ﾠIn	 ﾠgeneral,	 ﾠgels	 ﾠwere	 ﾠrun	 ﾠin	 ﾠtanks	 ﾠcontaining	 ﾠ1x	 ﾠMOPS	 ﾠ
running	 ﾠbuffer	 ﾠat	 ﾠ150	 ﾠV	 ﾠfor	 ﾠapproximately	 ﾠ1.5	 ﾠhours.	 ﾠAfterwards,	 ﾠthe	 ﾠgel	 ﾠwas	 ﾠeither	 ﾠ
stained	 ﾠwith	 ﾠCoomassie	 ﾠreagent	 ﾠto	 ﾠvisualize	 ﾠthe	 ﾠresolved	 ﾠproteins	 ﾠin	 ﾠthe	 ﾠgel	 ﾠor	 ﾠtransferred	 ﾠ
onto	 ﾠa	 ﾠPVDF	 ﾠmembrane	 ﾠby	 ﾠWestern	 ﾠblotting.	 ﾠ	 ﾠ
For	 ﾠCoomassie	 ﾠstaining,	 ﾠthe	 ﾠgel	 ﾠwas	 ﾠtransferred	 ﾠinto	 ﾠa	 ﾠclean	 ﾠbacterial	 ﾠcell	 ﾠculture	 ﾠdish	 ﾠand	 ﾠ
washed	 ﾠ3	 ﾠtimes	 ﾠfor	 ﾠ5	 ﾠminutes	 ﾠwith	 ﾠdistilled	 ﾠwater.	 ﾠAfterwards,	 ﾠthe	 ﾠgel	 ﾠwas	 ﾠincubated	 ﾠwith	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SimplyBlue	 ﾠSafesStain
®	 ﾠCoomassie	 ﾠreagent	 ﾠfor	 ﾠ45	 ﾠminutes.	 ﾠNext,	 ﾠbackground	 ﾠstaining	 ﾠwas	 ﾠ
removed	 ﾠby	 ﾠseveral	 ﾠwashes	 ﾠwith	 ﾠwater	 ﾠover	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠ3	 ﾠhours.	 ﾠAll	 ﾠwashing	 ﾠand	 ﾠ
staining	 ﾠsteps	 ﾠwere	 ﾠcarried	 ﾠout	 ﾠunder	 ﾠgentle	 ﾠagitation.	 ﾠ
2.2.3.5  Western Blotting 
Proteins	 ﾠpreviously	 ﾠseparated	 ﾠby	 ﾠSDS-ﾭ‐PAGE	 ﾠwere	 ﾠtransferred	 ﾠonto	 ﾠa	 ﾠPVDF	 ﾠmembrane	 ﾠin	 ﾠ
1x	 ﾠNuPAGE	 ﾠBlotting	 ﾠbuffer	 ﾠfor	 ﾠone	 ﾠhour	 ﾠat	 ﾠ30	 ﾠV.	 ﾠThe	 ﾠmembrane	 ﾠwas	 ﾠthen	 ﾠblocked	 ﾠfor	 ﾠ30	 ﾠ
minutes	 ﾠwith	 ﾠ5%	 ﾠ(w/v)	 ﾠmilk	 ﾠpowder	 ﾠin	 ﾠTBST.	 ﾠAfter	 ﾠthorough	 ﾠwashing	 ﾠwith	 ﾠTBST,	 ﾠthe	 ﾠ
primary	 ﾠantibody	 ﾠof	 ﾠchoice	 ﾠwas	 ﾠadded	 ﾠat	 ﾠa	 ﾠsuitable	 ﾠdilution	 ﾠin	 ﾠ5%	 ﾠ(w/v)	 ﾠBSA	 ﾠcontaining	 ﾠ
0.02%	 ﾠ(w/v)	 ﾠof	 ﾠsodium	 ﾠazide.	 ﾠIncubation	 ﾠtimes	 ﾠvaried	 ﾠdepending	 ﾠon	 ﾠthe	 ﾠprimary	 ﾠantibody	 ﾠ
employed	 ﾠ(Table	 ﾠ2-ﾭ‐3).	 ﾠMembranes	 ﾠwere	 ﾠthen	 ﾠwashed	 ﾠ3	 ﾠtimes	 ﾠin	 ﾠTBST	 ﾠfor	 ﾠ5	 ﾠminutes	 ﾠeach.	 ﾠ
The	 ﾠblots	 ﾠwere	 ﾠthen	 ﾠincubated	 ﾠwith	 ﾠthe	 ﾠappropriate	 ﾠsecondary	 ﾠantibody	 ﾠconjugated	 ﾠto	 ﾠ
horseradish	 ﾠperoxidase	 ﾠfor	 ﾠone	 ﾠhour	 ﾠat	 ﾠroom	 ﾠtemperature.	 ﾠProteins	 ﾠwere	 ﾠvisualised	 ﾠby	 ﾠ
chemiluminescence	 ﾠusing	 ﾠthe	 ﾠPierce	 ﾠECL	 ﾠWestern	 ﾠBlotting	 ﾠSubstrate	 ﾠand	 ﾠsubsequent	 ﾠ
autoradiography	 ﾠwith	 ﾠFuji	 ﾠSuper	 ﾠRX	 ﾠmedical	 ﾠX-ﾭ‐ray	 ﾠfilms	 ﾠusing	 ﾠa	 ﾠKodak	 ﾠX-ﾭ‐Omat	 ﾠ480	 ﾠRA	 ﾠ
X-ﾭ‐Ray	 ﾠprocessor.	 ﾠ
2.2.4  Microarray screen and validation 
2.2.4.1  RNA extraction and quality control 
Total	 ﾠcellular	 ﾠRNA	 ﾠwas	 ﾠextracted	 ﾠfrom	 ﾠrespective	 ﾠcells	 ﾠgrown	 ﾠon	 ﾠcell-ﾭ‐derived	 ﾠmatrix	 ﾠ(see	 ﾠ
2.2.2.8)	 ﾠor	 ﾠplastic	 ﾠsurfaces	 ﾠfor	 ﾠ16	 ﾠhours	 ﾠfollowing	 ﾠtransfection.	 ﾠRNA	 ﾠisolation	 ﾠwas	 ﾠcarried	 ﾠ
out	 ﾠusing	 ﾠthe	 ﾠRNeasy	 ﾠkit	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠmanufacturer’s	 ﾠprotocol.	 ﾠBriefly,	 ﾠcells	 ﾠwere	 ﾠ
washed	 ﾠtwice	 ﾠwith	 ﾠice-ﾭ‐cold	 ﾠPBS	 ﾠ(pH	 ﾠ7.4),	 ﾠand	 ﾠlysed	 ﾠin	 ﾠRLT	 ﾠbuffer	 ﾠsupplemented	 ﾠwith	 ﾠ
β-ﾭ‐mercaptoethanol.	 ﾠNext,	 ﾠcell	 ﾠlysates	 ﾠwere	 ﾠhomogenised	 ﾠusing	 ﾠQIAshredder	 ﾠcolumns	 ﾠand	 ﾠ
RNA	 ﾠwas	 ﾠextracted	 ﾠand	 ﾠpurified.	 ﾠResidual	 ﾠgenomic	 ﾠDNA	 ﾠwas	 ﾠremoved	 ﾠthrough	 ﾠan	 ﾠ
on-ﾭ‐column	 ﾠDNase1	 ﾠdigest.	 ﾠFollowing	 ﾠelution	 ﾠof	 ﾠthe	 ﾠpurified	 ﾠRNA,	 ﾠsamples	 ﾠwere	 ﾠ
snap-ﾭ‐frozen	 ﾠon	 ﾠdry	 ﾠice	 ﾠand	 ﾠstored	 ﾠat	 ﾠ-ﾭ‐80˚C	 ﾠuntil	 ﾠfurther	 ﾠuse.	 ﾠ
2.2.4.2  RNA labelling for the microarray screen 
Isolated	 ﾠRNA	 ﾠwas	 ﾠlabelled	 ﾠusing	 ﾠthe	 ﾠIllumina®	 ﾠTotalPrep
TM	 ﾠRNA	 ﾠLabelling	 ﾠKit	 ﾠaccording	 ﾠto	 ﾠ
the	 ﾠmanufacturer’s	 ﾠinstructions.	 ﾠIn	 ﾠbrief,	 ﾠ0.5	 ﾠµg	 ﾠof	 ﾠisolated	 ﾠRNA	 ﾠwere	 ﾠplaced	 ﾠinto	 ﾠa	 ﾠPCR	 ﾠ
plate	 ﾠfor	 ﾠfirst	 ﾠstrand	 ﾠcDNA	 ﾠsynthesis	 ﾠand	 ﾠbrought	 ﾠup	 ﾠto	 ﾠa	 ﾠvolume	 ﾠof	 ﾠ11	 ﾠµl	 ﾠbefore	 ﾠ9	 ﾠµl	 ﾠof	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the	 ﾠreverse	 ﾠtranscription	 ﾠmaster	 ﾠmix	 ﾠwere	 ﾠadded.	 ﾠAfter	 ﾠmixing	 ﾠthe	 ﾠsolution	 ﾠwas	 ﾠincubated	 ﾠ
at	 ﾠ42˚C	 ﾠfor	 ﾠ2	 ﾠhours	 ﾠusing	 ﾠa	 ﾠthermal	 ﾠcycler.	 ﾠFor	 ﾠsecond	 ﾠstrand	 ﾠcDNA	 ﾠsynthesis,	 ﾠ80	 ﾠµl	 ﾠof	 ﾠ
master	 ﾠmix	 ﾠwere	 ﾠadded	 ﾠto	 ﾠeach	 ﾠsample	 ﾠand	 ﾠincubated	 ﾠat	 ﾠ16˚C	 ﾠfor	 ﾠtwo	 ﾠhours.	 ﾠThe	 ﾠ
synthesised	 ﾠcDNA	 ﾠwas	 ﾠpurified	 ﾠand	 ﾠlabelled	 ﾠcRNA	 ﾠwas	 ﾠtranscribed	 ﾠin	 ﾠvitro	 ﾠover	 ﾠ14	 ﾠhours	 ﾠ
at	 ﾠ37˚C.	 ﾠThe	 ﾠresulting	 ﾠcRNA	 ﾠwas	 ﾠpurified	 ﾠand	 ﾠthe	 ﾠyield	 ﾠevaluated	 ﾠby	 ﾠmeasuring	 ﾠthe	 ﾠ
absorbance	 ﾠat	 ﾠ260	 ﾠnm	 ﾠon	 ﾠa	 ﾠNanoVue	 ﾠspectrophotometer.	 ﾠThe	 ﾠRNA	 ﾠintegrity	 ﾠwas	 ﾠ
examined	 ﾠon	 ﾠa	 ﾠbioanalyser	 ﾠprior	 ﾠto	 ﾠcomparative	 ﾠwhole-ﾭ‐genome	 ﾠexpression	 ﾠprofiling,	 ﾠ
which	 ﾠwas	 ﾠperformed	 ﾠusing	 ﾠtwo	 ﾠIllumina	 ﾠHumanHT-ﾭ‐12	 ﾠv4	 ﾠExpression	 ﾠBeadChips.	 ﾠ
2.2.4.3  Microarray data analysis 
Gene	 ﾠsignal	 ﾠprofiles	 ﾠof	 ﾠ24	 ﾠsamples	 ﾠwere	 ﾠnormalised	 ﾠand	 ﾠanalysed	 ﾠin	 ﾠPartek®	 ﾠGenomics	 ﾠ
Suite	 ﾠSoftware	 ﾠ(version	 ﾠ6.5).	 ﾠQuantile	 ﾠnormalisation	 ﾠand	 ﾠlog2	 ﾠtransformation	 ﾠof	 ﾠthe	 ﾠdata	 ﾠ
was	 ﾠfollowed	 ﾠby	 ﾠremoval	 ﾠof	 ﾠbatch	 ﾠeffects	 ﾠbetween	 ﾠthree	 ﾠgroups	 ﾠof	 ﾠreplicates.	 ﾠOutliers	 ﾠ
were	 ﾠremoved	 ﾠand	 ﾠremaining	 ﾠ19	 ﾠsamples	 ﾠre-ﾭ‐normalised.	 ﾠDifferentiated	 ﾠgenes	 ﾠwere	 ﾠ
identified	 ﾠby	 ﾠANOVA	 ﾠand	 ﾠpost-ﾭ‐hoc	 ﾠlinear	 ﾠcontrasts	 ﾠperformed	 ﾠbetween	 ﾠall	 ﾠpairs	 ﾠof	 ﾠ
experimental	 ﾠconditions.	 ﾠMultiple	 ﾠtest	 ﾠcorrections	 ﾠwere	 ﾠperformed	 ﾠfor	 ﾠall	 ﾠcalculated	 ﾠ
p-ﾭ‐values.	 ﾠGenes,	 ﾠwhich	 ﾠshowed	 ﾠsignificant	 ﾠchanges	 ﾠin	 ﾠexpression	 ﾠlevel	 ﾠwhen	 ﾠcomparing	 ﾠ
ERK2	 ﾠknockdown	 ﾠversus	 ﾠcontrol	 ﾠ(step-ﾭ‐up	 ﾠp-ﾭ‐value	 ﾠ<0.05)	 ﾠand	 ﾠinverse	 ﾠchanges	 ﾠwhen	 ﾠ
comparing	 ﾠERK2	 ﾠknockdown	 ﾠversus	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK2	 ﾠ(step-ﾭ‐up	 ﾠp-ﾭ‐value	 ﾠ<0.05,	 ﾠfold	 ﾠ
change	 ﾠ>±1.3)	 ﾠwere	 ﾠidentified.	 ﾠERK2-ﾭ‐specific	 ﾠgenes	 ﾠalso	 ﾠhad	 ﾠto	 ﾠmeet	 ﾠthe	 ﾠcriteria	 ﾠof	 ﾠa	 ﾠstep-ﾭ‐
up	 ﾠp-ﾭ‐values	 ﾠgreater	 ﾠthan	 ﾠ0.5	 ﾠwhen	 ﾠcomparing	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠto	 ﾠERK1	 ﾠ
re-ﾭ‐expression.	 ﾠ	 ﾠ
2.2.4.4  First strand cDNA synthesis 
The	 ﾠfollowing	 ﾠcomponents	 ﾠwere	 ﾠadded	 ﾠto	 ﾠa	 ﾠnuclease-ﾭ‐free	 ﾠmicrocentrifuge	 ﾠtube:	 ﾠ
Reagent	 ﾠ Sample	 ﾠ(µl)	 ﾠ
oligo	 ﾠ(dT)15	 ﾠ 1	 ﾠ
purified	 ﾠRNA	 ﾠ 1	 ﾠµg	 ﾠ
RNase/DNase-ﾭ‐free	 ﾠddH2O	 ﾠ 	 ﾠ up	 ﾠto	 ﾠ10	 ﾠ
total	 ﾠvolume	 ﾠ 10	 ﾠ
The	 ﾠmixture	 ﾠwas	 ﾠheated	 ﾠto	 ﾠ70˚C	 ﾠfor	 ﾠ10	 ﾠminutes	 ﾠand	 ﾠincubated	 ﾠon	 ﾠice	 ﾠfor	 ﾠat	 ﾠleast	 ﾠ1	 ﾠminute.	 ﾠ
Afterwards,	 ﾠ10	 ﾠµl	 ﾠof	 ﾠa	 ﾠmaster	 ﾠmix,	 ﾠprepared	 ﾠas	 ﾠfollows,	 ﾠwas	 ﾠadded:	 ﾠChapter 2 – Materials and methods    100 
Reagent	 ﾠ Sample	 ﾠ(µl)	 ﾠ
ImProm-ﾭ‐II
TM	 ﾠ5X	 ﾠReaction	 ﾠBuffer	 ﾠ 4	 ﾠ
MgCl2	 ﾠ 3	 ﾠ
dNTPs	 ﾠ Mix	 ﾠ 1	 ﾠ
RNasin	 ﾠ 0.5	 ﾠ
IMProm-ﾭ‐II
TM	 ﾠReverse	 ﾠTranscriptase	 ﾠ 	 ﾠ 1	 ﾠ
total	 ﾠvolume	 ﾠ 10	 ﾠ
The	 ﾠsolution	 ﾠwas	 ﾠgently	 ﾠmixed	 ﾠby	 ﾠpipetting	 ﾠup	 ﾠand	 ﾠdown.	 ﾠThe	 ﾠsample	 ﾠwas	 ﾠthen	 ﾠincubated	 ﾠ
at	 ﾠ25˚C	 ﾠfor	 ﾠ5	 ﾠminutes	 ﾠto	 ﾠallow	 ﾠinitial	 ﾠannealing	 ﾠof	 ﾠthe	 ﾠoligos.	 ﾠFollowing	 ﾠthe	 ﾠannealing,	 ﾠthe	 ﾠ
sample	 ﾠwas	 ﾠincubated	 ﾠat	 ﾠ42˚C	 ﾠfor	 ﾠ1	 ﾠhour	 ﾠfor	 ﾠcDNA	 ﾠextension.	 ﾠAfterwards,	 ﾠthe	 ﾠreaction	 ﾠ
was	 ﾠheat-ﾭ‐inactivated	 ﾠat	 ﾠ70˚C	 ﾠfor	 ﾠ10	 ﾠminutes	 ﾠand	 ﾠcooled	 ﾠto	 ﾠ4˚C	 ﾠbefore	 ﾠsample	 ﾠwas	 ﾠfrozen	 ﾠ
at	 ﾠ-ﾭ‐20˚C	 ﾠuntil	 ﾠfurther	 ﾠuse.	 ﾠ
2.2.4.5  qPCR 
The	 ﾠDyNAmoTM	 ﾠSYBR®	 ﾠGreen	 ﾠqPCR	 ﾠkit	 ﾠwas	 ﾠused	 ﾠto	 ﾠperform	 ﾠquantitative	 ﾠPCR	 ﾠon	 ﾠa	 ﾠ
BioRAD	 ﾠDNA	 ﾠEngine	 ﾠthermal	 ﾠcycler	 ﾠfitted	 ﾠwith	 ﾠa	 ﾠChromo4	 ﾠEngine	 ﾠand	 ﾠcoupled	 ﾠto	 ﾠOpticon	 ﾠ
Monitor3	 ﾠsoftware.	 ﾠThe	 ﾠfollowing	 ﾠreagents	 ﾠwere	 ﾠpipetted	 ﾠtogether:	 ﾠ
Reagent	 ﾠ Sample	 ﾠ(µl)	 ﾠ
2x	 ﾠMasterMix	 ﾠ 10	 ﾠ
Quantitect	 ﾠprimer	 ﾠ 2	 ﾠ
cDNA	 ﾠtemplate	 ﾠ 1	 ﾠ
RNase/DNase-ﾭ‐free	 ﾠH2O	 ﾠ 7	 ﾠ
total	 ﾠvolume	 ﾠ 20	 ﾠ
PCR	 ﾠreactions	 ﾠwere	 ﾠperformed	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠfollowing	 ﾠprotocol:	 ﾠ
Initial	 ﾠdenaturation	 ﾠ 95˚C	 ﾠ 10	 ﾠmin	 ﾠ










Plate	 ﾠread	 ﾠ 	 ﾠ 	 ﾠ
Final	 ﾠextension	 ﾠ 72˚C	 ﾠ 5	 ﾠmin	 ﾠ
Dissociation	 ﾠcurve	 ﾠ 70˚C-ﾭ‐90˚C	 ﾠin	 ﾠ0.3˚C	 ﾠincrements	 ﾠ
Final	 ﾠhold	 ﾠ 4˚C	 ﾠ ∞	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Extracted	 ﾠdata	 ﾠwas	 ﾠused	 ﾠto	 ﾠdetermine	 ﾠchanges	 ﾠin	 ﾠgene	 ﾠexpression	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠΔΔCt	 ﾠ
method	 ﾠpreviously	 ﾠdescribed	 ﾠ[354].	 ﾠGAPDH	 ﾠwas	 ﾠused	 ﾠas	 ﾠa	 ﾠreference.	 ﾠControl	 ﾠtransfected	 ﾠ
transcript	 ﾠlevels	 ﾠwere	 ﾠassigned	 ﾠthe	 ﾠarbitrary	 ﾠvalue	 ﾠof	 ﾠ1.	 ﾠEach	 ﾠexperiment	 ﾠwas	 ﾠperformed	 ﾠ
in	 ﾠtriplicate	 ﾠand	 ﾠreplicas	 ﾠincorporated	 ﾠthree	 ﾠtechnical	 ﾠrepeats.	 ﾠ
2.2.4.6  Statistical analysis 
All	 ﾠexperiments	 ﾠwere	 ﾠdone	 ﾠin	 ﾠtriplicates.	 ﾠStatistical	 ﾠsignificance	 ﾠof	 ﾠdifferences	 ﾠwas	 ﾠ
determined	 ﾠby	 ﾠnonparametric	 ﾠMann-ﾭ‐Whitney	 ﾠU	 ﾠtests	 ﾠusing	 ﾠGraphPad	 ﾠPrism	 ﾠ5.	 ﾠP	 ﾠvalues	 ﾠof	 ﾠ
less	 ﾠthan	 ﾠ0.05	 ﾠwere	 ﾠconsidered	 ﾠsignificant.	 ﾠ
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3  ERK2 but not ERK1 contributes to invasive cell 
migration 
3.1  Introduction 
3.1.1  Common features of ERK1 and ERK2 
The	 ﾠtwo	 ﾠmajor	 ﾠERK	 ﾠisoforms,	 ﾠERK1	 ﾠand	 ﾠERK2,	 ﾠdemonstrate	 ﾠan	 ﾠoverall	 ﾠsequence	 ﾠidentity	 ﾠof	 ﾠ
nearly	 ﾠ85%	 ﾠand	 ﾠare	 ﾠencoded	 ﾠby	 ﾠseparate	 ﾠgenes	 ﾠlocated	 ﾠon	 ﾠchromosome	 ﾠ16	 ﾠand	 ﾠ22,	 ﾠ
respectively	 ﾠ(Figure	 ﾠ3-ﾭ‐1).	 ﾠIn	 ﾠhumans,	 ﾠboth	 ﾠisoforms	 ﾠare	 ﾠubiquitously	 ﾠexpressed,	 ﾠalbeit	 ﾠ
their	 ﾠrelative	 ﾠabundance	 ﾠvaries	 ﾠ[58].	 ﾠWith	 ﾠthe	 ﾠexception	 ﾠof	 ﾠa	 ﾠfew	 ﾠstudies	 ﾠdemonstrating	 ﾠa	 ﾠ
preferential	 ﾠactivation	 ﾠof	 ﾠa	 ﾠsingle	 ﾠERK	 ﾠisoform	 ﾠ[355,	 ﾠ356],	 ﾠmost	 ﾠreports	 ﾠhave	 ﾠ
demonstrated	 ﾠthat	 ﾠERK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠare	 ﾠco-ﾭ‐activated	 ﾠin	 ﾠresponse	 ﾠto	 ﾠextracellular	 ﾠstimuli.	 ﾠ
Moreover,	 ﾠboth	 ﾠenzymes	 ﾠrely	 ﾠon	 ﾠthe	 ﾠsame	 ﾠupstream	 ﾠkinase	 ﾠmodule,	 ﾠwhich	 ﾠdoes	 ﾠnot	 ﾠ
discriminate	 ﾠbetween	 ﾠthem.	 ﾠAdditionally,	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠdisplay	 ﾠindistinguishable	 ﾠkinase	 ﾠ
activities	 ﾠin	 ﾠvitro	 ﾠ[357]	 ﾠand	 ﾠphosphorylate	 ﾠcommon	 ﾠsubstrates	 ﾠsuch	 ﾠas	 ﾠMBP	 ﾠkinase	 ﾠand	 ﾠ
MAP2	 ﾠkinase	 ﾠat	 ﾠthe	 ﾠsame	 ﾠphosphoacceptor	 ﾠsites	 ﾠ[55,	 ﾠ58].	 ﾠ
Owing	 ﾠto	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠERK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠare	 ﾠhighly	 ﾠhomologous,	 ﾠboth	 ﾠproteins	 ﾠshare	 ﾠcommon	 ﾠ
features	 ﾠin	 ﾠtheir	 ﾠtertiary	 ﾠstructure	 ﾠand	 ﾠare	 ﾠcomposed	 ﾠof	 ﾠtwo	 ﾠdomains	 ﾠ(N-ﾭ‐terminal	 ﾠand	 ﾠ
C-ﾭ‐terminal),	 ﾠwhich	 ﾠare	 ﾠconnected	 ﾠby	 ﾠa	 ﾠflexible	 ﾠlinker.	 ﾠThe	 ﾠN-ﾭ‐terminal	 ﾠdomain	 ﾠ
predominantly	 ﾠconsists	 ﾠof	 ﾠß-ﾭ‐sheets,	 ﾠwhereas	 ﾠthe	 ﾠC-ﾭ‐terminal	 ﾠdomain	 ﾠmainly	 ﾠcomprises	 ﾠ
α-ﾭ‐helices	 ﾠ[358].	 ﾠMost	 ﾠsubstrates	 ﾠbind	 ﾠto	 ﾠERK	 ﾠvia	 ﾠtwo	 ﾠdocking	 ﾠsites,	 ﾠthe	 ﾠhydrophobic	 ﾠ
groove	 ﾠformed	 ﾠby	 ﾠthe	 ﾠCD	 ﾠand	 ﾠED	 ﾠdomain,	 ﾠor	 ﾠthe	 ﾠFXFP-ﾭ‐motif	 ﾠ[123,	 ﾠ129,	 ﾠ131-ﾭ‐133].	 ﾠ
Co-ﾭ‐crystallisation	 ﾠstudies	 ﾠof	 ﾠERK	 ﾠwith	 ﾠa	 ﾠD-ﾭ‐motif	 ﾠpeptide	 ﾠelucidated	 ﾠwhich	 ﾠERK	 ﾠamino	 ﾠacids	 ﾠ
are	 ﾠinvolved	 ﾠin	 ﾠsubstrate	 ﾠbinding.	 ﾠOut	 ﾠof	 ﾠthe	 ﾠ11	 ﾠresidues	 ﾠdetermined,	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠonly	 ﾠ
differ	 ﾠin	 ﾠone	 ﾠamino	 ﾠacid,	 ﾠwith	 ﾠERK1	 ﾠdisplaying	 ﾠan	 ﾠisoleucine	 ﾠinstead	 ﾠof	 ﾠa	 ﾠleucine	 ﾠ[130].	 ﾠ
Moreover,	 ﾠDEF-ﾭ‐motif	 ﾠinteracting	 ﾠresidues	 ﾠare	 ﾠfully	 ﾠconserved	 ﾠbetween	 ﾠERK1	 ﾠand	 ﾠ
ERK2	 ﾠ[131].	 ﾠTaken	 ﾠtogether,	 ﾠthe	 ﾠstructural	 ﾠdata	 ﾠpoints	 ﾠtowards	 ﾠsimilar	 ﾠsubstrate	 ﾠ
specificities	 ﾠfor	 ﾠthe	 ﾠtwo	 ﾠkinases	 ﾠand	 ﾠargues	 ﾠfor	 ﾠfunctional	 ﾠredundancy.	 ﾠ
ERK1	 ﾠand	 ﾠERK2	 ﾠemerged	 ﾠearly	 ﾠduring	 ﾠvertebrate	 ﾠevolution	 ﾠwith	 ﾠfish	 ﾠexpressing	 ﾠboth	 ﾠ
isoforms	 ﾠ[357].	 ﾠMoreover,	 ﾠboth	 ﾠenzymes	 ﾠare	 ﾠevolutionary	 ﾠconserved,	 ﾠalthough	 ﾠit	 ﾠhas	 ﾠto	 ﾠ
be	 ﾠnoted	 ﾠthat	 ﾠXenopus	 ﾠlaevis	 ﾠonly	 ﾠexpresses	 ﾠERK2	 ﾠand	 ﾠhas	 ﾠlost	 ﾠthe	 ﾠerk1	 ﾠorthologue	 ﾠ[359].	 ﾠ
Thus,	 ﾠthe	 ﾠquestion	 ﾠarises	 ﾠwhether	 ﾠor	 ﾠnot	 ﾠboth	 ﾠenzymes	 ﾠare	 ﾠfunctionally	 ﾠredundant	 ﾠand	 ﾠ	 ﾠChapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  103 
 
Figure 3-1 Sequence comparison of human ERK1 and ERK2  
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interchangeable	 ﾠand	 ﾠif	 ﾠso,	 ﾠwhy	 ﾠboth	 ﾠproteins	 ﾠhave	 ﾠbeen	 ﾠconserved	 ﾠevolutionarily.	 ﾠLefloch	 ﾠ
et	 ﾠal.	 ﾠproposed	 ﾠthat	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠtwo	 ﾠisoforms	 ﾠwith	 ﾠfunctional	 ﾠredundancy	 ﾠallows	 ﾠthe	 ﾠ
fine-ﾭ‐tuning	 ﾠof	 ﾠERK	 ﾠprotein	 ﾠlevels	 ﾠdepending	 ﾠon	 ﾠthe	 ﾠcellular	 ﾠneeds	 ﾠand	 ﾠthereby	 ﾠrepresents	 ﾠ
an	 ﾠevolutionary	 ﾠadvantage	 ﾠto	 ﾠhigher	 ﾠorganisms	 ﾠ[359].	 ﾠ
3.1.2  ERK isoforms in whole animal studies 
In	 ﾠrecent	 ﾠyears,	 ﾠhowever,	 ﾠmore	 ﾠand	 ﾠmore	 ﾠevidence,	 ﾠsuggesting	 ﾠnon-ﾭ‐redundant	 ﾠfunctions	 ﾠ
for	 ﾠthe	 ﾠtwo	 ﾠERK	 ﾠkinases,	 ﾠhas	 ﾠbeen	 ﾠreported.	 ﾠIn	 ﾠparticular,	 ﾠthe	 ﾠmarked	 ﾠdiscrepancy	 ﾠ
between	 ﾠthe	 ﾠphenotypes	 ﾠof	 ﾠERK1
-ﾭ‐/-ﾭ‐	 ﾠand	 ﾠERK2
-ﾭ‐/-ﾭ‐	 ﾠmice	 ﾠindicates	 ﾠclear	 ﾠfunctional	 ﾠdifferences	 ﾠ
in	 ﾠvivo.	 ﾠERK1
-ﾭ‐/-ﾭ‐	 ﾠmice	 ﾠare	 ﾠviable,	 ﾠfertile	 ﾠand	 ﾠof	 ﾠnormal	 ﾠsize	 ﾠ[360],	 ﾠwhereas	 ﾠERK2
-ﾭ‐/-ﾭ‐	 ﾠmice	 ﾠdie	 ﾠ
early	 ﾠin	 ﾠembryonic	 ﾠdevelopment	 ﾠ[361-ﾭ‐363].	 ﾠMoreover,	 ﾠERK1
-ﾭ‐/-ﾭ‐	 ﾠmice	 ﾠdisplay	 ﾠenhanced	 ﾠ
behavioural	 ﾠresponses	 ﾠin	 ﾠavoidance	 ﾠtasks	 ﾠand	 ﾠare	 ﾠhypersensitive	 ﾠto	 ﾠdrug	 ﾠabuse	 ﾠ[364].	 ﾠIn	 ﾠ
contrast,	 ﾠERK2
+/-ﾭ‐	 ﾠmice,	 ﾠwhich	 ﾠdisplay	 ﾠa	 ﾠ40%	 ﾠreduction	 ﾠin	 ﾠERK2	 ﾠprotein	 ﾠlevels,	 ﾠshow	 ﾠa	 ﾠ
deficit	 ﾠin	 ﾠlong-ﾭ‐term	 ﾠmemory	 ﾠ[365].	 ﾠLikewise,	 ﾠhumans	 ﾠwith	 ﾠonly	 ﾠone	 ﾠERK2	 ﾠallele	 ﾠshow	 ﾠ
learning	 ﾠdisabilities	 ﾠand	 ﾠdevelopmental	 ﾠdelays,	 ﾠthus	 ﾠarguing	 ﾠfor	 ﾠERK-ﾭ‐specific	 ﾠfunction	 ﾠin	 ﾠ
cognition	 ﾠand	 ﾠmemory	 ﾠ[366].	 ﾠIn	 ﾠaddition,	 ﾠERK1-ﾭ‐deficient	 ﾠmice	 ﾠare	 ﾠimpaired	 ﾠin	 ﾠthymocyte	 ﾠ
maturation	 ﾠand	 ﾠadipogenesis	 ﾠ[360,	 ﾠ367].	 ﾠInterestingly,	 ﾠadipocyte	 ﾠdifferentiation	 ﾠin	 ﾠ
isolated	 ﾠERK1
-ﾭ‐/-ﾭ‐	 ﾠpre-ﾭ‐adipocytes	 ﾠwas	 ﾠnot	 ﾠreduced	 ﾠfurther,	 ﾠwhen	 ﾠERK2	 ﾠactivation	 ﾠwas	 ﾠ
inhibited	 ﾠchemically,	 ﾠthus	 ﾠarguing	 ﾠfor	 ﾠan	 ﾠisoform-ﾭ‐specific	 ﾠrole	 ﾠof	 ﾠERK1	 ﾠin	 ﾠthis	 ﾠprocess.	 ﾠThis	 ﾠ
view	 ﾠis	 ﾠfurthermore	 ﾠsupported	 ﾠby	 ﾠthe	 ﾠfact	 ﾠthat,	 ﾠin	 ﾠcontrast	 ﾠto	 ﾠmost	 ﾠtissues,	 ﾠERK1	 ﾠand	 ﾠ
ERK2	 ﾠare	 ﾠexpressed	 ﾠand	 ﾠactivated	 ﾠto	 ﾠsimilar	 ﾠlevels	 ﾠin	 ﾠadipocytes.	 ﾠThus,	 ﾠequal	 ﾠexpression	 ﾠ
levels	 ﾠmay	 ﾠindicate	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠfor	 ﾠERK1	 ﾠin	 ﾠfat	 ﾠtissue.	 ﾠFurthermore,	 ﾠERK1-ﾭ‐deficient	 ﾠ
mice	 ﾠexhibit	 ﾠan	 ﾠincreased	 ﾠmetabolic	 ﾠrate,	 ﾠand	 ﾠare	 ﾠprotected	 ﾠfrom	 ﾠinsulin	 ﾠresistance	 ﾠand	 ﾠ
obesity	 ﾠ[367].	 ﾠ	 ﾠ
Studies	 ﾠin	 ﾠzebrafish	 ﾠprovide	 ﾠfurther	 ﾠevidence	 ﾠof	 ﾠERK	 ﾠisoform-ﾭ‐specific	 ﾠfunctions.	 ﾠFirst,	 ﾠERK1	 ﾠ
and	 ﾠ-ﾭ‐2	 ﾠdisplay	 ﾠdifferential	 ﾠspatio-ﾭ‐temporal	 ﾠexpression	 ﾠpatterns	 ﾠduring	 ﾠzebrafish	 ﾠ
development.	 ﾠSecond,	 ﾠERK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠmorphants	 ﾠshow	 ﾠdistinct	 ﾠphenotypes	 ﾠduring	 ﾠ
embryogenesis	 ﾠ[368].	 ﾠIn	 ﾠagreement	 ﾠwith	 ﾠmice	 ﾠstudies,	 ﾠERK2	 ﾠmorphants	 ﾠare	 ﾠ70%	 ﾠlethal	 ﾠ
and	 ﾠportray	 ﾠsevere	 ﾠdevelopmental	 ﾠdefects.	 ﾠOn	 ﾠthe	 ﾠcontrary,	 ﾠERK1	 ﾠablation	 ﾠduring	 ﾠ
zebrafish	 ﾠdevelopment	 ﾠalso	 ﾠgives	 ﾠrise	 ﾠto	 ﾠa	 ﾠdistinct	 ﾠphenotype	 ﾠwith	 ﾠ10%	 ﾠlethality.	 ﾠ
Remarkably,	 ﾠerk2	 ﾠmRNA	 ﾠis	 ﾠable	 ﾠto	 ﾠcross-ﾭ‐rescue	 ﾠthe	 ﾠERK1	 ﾠmorphant	 ﾠphenotype,	 ﾠwhereas	 ﾠ
erk1	 ﾠmRNA	 ﾠfails	 ﾠto	 ﾠcross-ﾭ‐rescue	 ﾠdevelopmental	 ﾠdefects	 ﾠbrought	 ﾠabout	 ﾠby	 ﾠERK2	 ﾠChapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  105 
knockdown.	 ﾠThus,	 ﾠin	 ﾠzebrafish	 ﾠERK2	 ﾠcan	 ﾠcompensate	 ﾠfor	 ﾠERK1,	 ﾠwhile	 ﾠexhibiting	 ﾠ
isoform-ﾭ‐specific	 ﾠfunctions	 ﾠthat	 ﾠare	 ﾠdistinct	 ﾠfrom	 ﾠERK1	 ﾠ[369].	 ﾠ
3.1.3  ERK isoforms in cell culture studies 
In	 ﾠvitro	 ﾠstudies	 ﾠemploying	 ﾠRNA	 ﾠinterference	 ﾠ(RNAi)	 ﾠhave	 ﾠalso	 ﾠsuggested	 ﾠdistinct	 ﾠbiological	 ﾠ
functions	 ﾠfor	 ﾠERK1	 ﾠand	 ﾠERK2.	 ﾠFor	 ﾠexample,	 ﾠsilencing	 ﾠERK2	 ﾠin	 ﾠC2C12	 ﾠmyoblasts	 ﾠinhibits	 ﾠ
myogenin	 ﾠexpression	 ﾠand	 ﾠblocks	 ﾠmyoblast	 ﾠfusion,	 ﾠwhile	 ﾠERK1	 ﾠablation	 ﾠhas	 ﾠno	 ﾠeffect	 ﾠ[370].	 ﾠ
Owing	 ﾠto	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠERK	 ﾠsignalling	 ﾠplays	 ﾠa	 ﾠcritical	 ﾠrole	 ﾠin	 ﾠproliferation,	 ﾠmultiple	 ﾠstudies	 ﾠ
investigated	 ﾠwhether	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠhave	 ﾠdistinct	 ﾠfunctions	 ﾠin	 ﾠthis	 ﾠcellular	 ﾠprocess.	 ﾠ
Intriguingly,	 ﾠVantaggiato	 ﾠet	 ﾠal.	 ﾠobserved	 ﾠenhanced	 ﾠcell	 ﾠproliferation	 ﾠin	 ﾠmouse	 ﾠfibroblasts	 ﾠ
upon	 ﾠablation	 ﾠof	 ﾠERK1	 ﾠby	 ﾠeither	 ﾠgene	 ﾠtargeting	 ﾠor	 ﾠRNA	 ﾠinterference	 ﾠ(RNAi),	 ﾠwhile	 ﾠ
silencing	 ﾠof	 ﾠERK2	 ﾠreduced	 ﾠthe	 ﾠproliferative	 ﾠresponse	 ﾠto	 ﾠmitogenic	 ﾠstimuli	 ﾠ[371].	 ﾠThe	 ﾠ
authors,	 ﾠtherefore,	 ﾠsuggested	 ﾠan	 ﾠantagonistic	 ﾠrole	 ﾠfor	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠin	 ﾠproliferation.	 ﾠ
However,	 ﾠthis	 ﾠobservation	 ﾠwas	 ﾠchallenged	 ﾠby	 ﾠmultiple	 ﾠstudies	 ﾠshowing	 ﾠno	 ﾠchanges	 ﾠ[357,	 ﾠ
372]	 ﾠor	 ﾠa	 ﾠreduced	 ﾠproliferative	 ﾠresponse	 ﾠupon	 ﾠERK1	 ﾠablation	 ﾠ[373-ﾭ‐375].	 ﾠIn	 ﾠan	 ﾠattempt	 ﾠto	 ﾠ
resolve	 ﾠthese	 ﾠdiscrepant	 ﾠobservations,	 ﾠLefloch	 ﾠet	 ﾠal.	 ﾠturned	 ﾠtheir	 ﾠattention	 ﾠtowards	 ﾠthe	 ﾠ
expression	 ﾠratio	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠand	 ﾠproposed	 ﾠa	 ﾠthreshold-ﾭ‐dependency	 ﾠfor	 ﾠERK	 ﾠ
signalling,	 ﾠi.e.	 ﾠa	 ﾠrequirement	 ﾠfor	 ﾠa	 ﾠcertain	 ﾠpool	 ﾠof	 ﾠactive	 ﾠERK	 ﾠfor	 ﾠthe	 ﾠexecution	 ﾠof	 ﾠ
physiological	 ﾠfunctions	 ﾠ[357].	 ﾠThus,	 ﾠas	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠare	 ﾠmostly	 ﾠexpressed	 ﾠat	 ﾠdifferent	 ﾠ
levels,	 ﾠwith	 ﾠERK2	 ﾠbeing	 ﾠthe	 ﾠpredominant	 ﾠkinase,	 ﾠsilencing	 ﾠERK2	 ﾠmay	 ﾠdecrease	 ﾠtotal	 ﾠERK	 ﾠ
levels	 ﾠbelow	 ﾠa	 ﾠthreshold	 ﾠand	 ﾠresult	 ﾠin	 ﾠfunctional	 ﾠdefects,	 ﾠwhereas	 ﾠERK1	 ﾠknockdown	 ﾠmay	 ﾠ
not	 ﾠmarkedly	 ﾠdecrease	 ﾠthe	 ﾠpool	 ﾠof	 ﾠactive	 ﾠERK,	 ﾠtherefore	 ﾠresulting	 ﾠin	 ﾠno	 ﾠor	 ﾠmild	 ﾠ
phenotypic	 ﾠchanges.	 ﾠThus,	 ﾠapparent	 ﾠbiological	 ﾠdifferences	 ﾠmay	 ﾠbe	 ﾠattributed	 ﾠto	 ﾠ
differences	 ﾠin	 ﾠthe	 ﾠexpression	 ﾠlevels	 ﾠrather	 ﾠthan	 ﾠdistinct	 ﾠbiological	 ﾠfeatures.	 ﾠIndeed,	 ﾠ
redundant	 ﾠfunctions	 ﾠof	 ﾠERK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠin	 ﾠproliferation	 ﾠwere	 ﾠsubsequently	 ﾠconfirmed	 ﾠin	 ﾠ
experiments,	 ﾠwhere	 ﾠconditional	 ﾠinvalidation	 ﾠof	 ﾠERK2	 ﾠin	 ﾠthe	 ﾠdeveloping	 ﾠcortex	 ﾠof	 ﾠmice	 ﾠ
significantly	 ﾠreduced	 ﾠcell	 ﾠproliferation,	 ﾠbut	 ﾠcould	 ﾠbe	 ﾠrescued	 ﾠwhen	 ﾠERK1	 ﾠwas	 ﾠ
overactivated	 ﾠ[366].	 ﾠMoreover,	 ﾠVoisin	 ﾠet	 ﾠal.	 ﾠdemonstrated	 ﾠthat	 ﾠloss	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠ
ERK2	 ﾠreduced	 ﾠproliferation	 ﾠin	 ﾠfibroblasts,	 ﾠwhich	 ﾠreflected	 ﾠtheir	 ﾠexpression	 ﾠlevel	 ﾠ[376].	 ﾠ
Taken	 ﾠtogether,	 ﾠthe	 ﾠdata	 ﾠshows	 ﾠthat	 ﾠboth	 ﾠERKs	 ﾠare	 ﾠpositive	 ﾠregulators	 ﾠof	 ﾠproliferation	 ﾠand	 ﾠ
differences	 ﾠin	 ﾠtheir	 ﾠexpression	 ﾠlevels	 ﾠmay	 ﾠgive	 ﾠthe	 ﾠimpression	 ﾠof	 ﾠdistinct	 ﾠbiological	 ﾠ
functions.	 ﾠThus,	 ﾠstudies	 ﾠinvestigating	 ﾠisoform-ﾭ‐specific	 ﾠfeatures	 ﾠhave	 ﾠto	 ﾠaddress	 ﾠthis	 ﾠissue	 ﾠ
in	 ﾠorder	 ﾠto	 ﾠdraw	 ﾠmeaningful	 ﾠconclusions	 ﾠfrom	 ﾠthe	 ﾠdata.	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3.1.4  ERK isoforms and tumourigenesis 
ERK’s	 ﾠrole	 ﾠin	 ﾠtumourigenesis	 ﾠis	 ﾠwell-ﾭ‐established	 ﾠwith	 ﾠthe	 ﾠkinases	 ﾠimpinging	 ﾠon	 ﾠmany	 ﾠ
hallmarks	 ﾠof	 ﾠcancer.	 ﾠIn	 ﾠ2002,	 ﾠAdeyinka	 ﾠet	 ﾠal.	 ﾠdemonstrated	 ﾠa	 ﾠdirect	 ﾠcorrelation	 ﾠbetween	 ﾠ
pERK1/2	 ﾠlevels	 ﾠand	 ﾠtumour	 ﾠprogression	 ﾠin	 ﾠbreast	 ﾠcancer.	 ﾠThus,	 ﾠa	 ﾠrole	 ﾠfor	 ﾠactive	 ﾠERK	 ﾠin	 ﾠthe	 ﾠ
metastatic	 ﾠprocess	 ﾠwas	 ﾠproposed	 ﾠ[377].	 ﾠMoreover,	 ﾠhigh	 ﾠlevels	 ﾠof	 ﾠactive	 ﾠERK	 ﾠare	 ﾠ
associated	 ﾠwith	 ﾠenhanced	 ﾠcell	 ﾠmotility	 ﾠ[378].	 ﾠ
In	 ﾠexperiments	 ﾠexamining	 ﾠthe	 ﾠrole	 ﾠof	 ﾠERK1	 ﾠin	 ﾠskin	 ﾠhomeostasis	 ﾠand	 ﾠtumourigenesis,	 ﾠ
ERK1-ﾭ‐deficient	 ﾠmice	 ﾠdeveloped	 ﾠfewer	 ﾠpapillomas	 ﾠthan	 ﾠwild	 ﾠtype	 ﾠmice	 ﾠafter	 ﾠtumour	 ﾠ
induction	 ﾠwith	 ﾠDMBA	 ﾠand	 ﾠpromotion	 ﾠwith	 ﾠTPA.	 ﾠAdditionally,	 ﾠtumour	 ﾠonset	 ﾠwas	 ﾠdelayed	 ﾠ
and	 ﾠthe	 ﾠburden	 ﾠdecreased.	 ﾠMoreover,	 ﾠstudies	 ﾠof	 ﾠisolated	 ﾠERK1
-ﾭ‐/-ﾭ‐	 ﾠkeratinocytes	 ﾠshowed	 ﾠan	 ﾠ
impairment	 ﾠof	 ﾠcellular	 ﾠgrowth,	 ﾠa	 ﾠresistance	 ﾠto	 ﾠapoptotic	 ﾠsignals	 ﾠas	 ﾠwell	 ﾠas	 ﾠa	 ﾠdiminished	 ﾠ
expression	 ﾠof	 ﾠfra1	 ﾠ[373].	 ﾠThus,	 ﾠBourcier	 ﾠet	 ﾠal.	 ﾠconcluded	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠof	 ﾠERK1	 ﾠin	 ﾠskin	 ﾠ
tumour	 ﾠdevelopment	 ﾠby	 ﾠcontributing	 ﾠto	 ﾠcellular	 ﾠgrowth	 ﾠand	 ﾠproliferation	 ﾠand	 ﾠpostulated	 ﾠ
a	 ﾠrole	 ﾠof	 ﾠthis	 ﾠisoform	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠinvasion.	 ﾠ
In	 ﾠ2007,	 ﾠBessard	 ﾠet	 ﾠal.	 ﾠinvestigated	 ﾠthe	 ﾠrole	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠcell	 ﾠmotility	 ﾠin	 ﾠhuman	 ﾠ
hepatocarcinoma	 ﾠcells.	 ﾠThe	 ﾠauthors	 ﾠobserved	 ﾠa	 ﾠreduction	 ﾠin	 ﾠcell	 ﾠmotility	 ﾠin	 ﾠwound	 ﾠhealing	 ﾠ
assays	 ﾠafter	 ﾠtreatment	 ﾠwith	 ﾠthe	 ﾠMEK	 ﾠinhibitor,	 ﾠU0126.	 ﾠMoreover,	 ﾠsilencing	 ﾠof	 ﾠERK2	 ﾠbut	 ﾠ
not	 ﾠERK1	 ﾠwith	 ﾠshort	 ﾠhairpin	 ﾠduplexes	 ﾠimpaired	 ﾠwound	 ﾠclosure,	 ﾠreduced	 ﾠuPAR	 ﾠexpression	 ﾠ
and	 ﾠS6K	 ﾠphosphorylation	 ﾠat	 ﾠThr389	 ﾠ[379].	 ﾠAlthough	 ﾠthe	 ﾠdata	 ﾠstrongly	 ﾠsuggest	 ﾠa	 ﾠrole	 ﾠfor	 ﾠ
ERK	 ﾠsignalling	 ﾠin	 ﾠcell	 ﾠmigration,	 ﾠthe	 ﾠstudy	 ﾠdid	 ﾠnot	 ﾠaddress	 ﾠwhether	 ﾠor	 ﾠnot	 ﾠthe	 ﾠobservations	 ﾠ
can	 ﾠtruly	 ﾠbe	 ﾠattributed	 ﾠto	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠfunction	 ﾠor	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠexpression	 ﾠlevels	 ﾠ
of	 ﾠthe	 ﾠtwo	 ﾠkinases	 ﾠ[379].	 ﾠThus,	 ﾠwhether	 ﾠor	 ﾠnot	 ﾠthe	 ﾠmajor	 ﾠERK	 ﾠisoforms	 ﾠhave	 ﾠdistinct	 ﾠ
functions	 ﾠin	 ﾠcell	 ﾠmigration	 ﾠremains	 ﾠan	 ﾠopen	 ﾠissue.	 ﾠ
This	 ﾠpresent	 ﾠstudy	 ﾠset	 ﾠout	 ﾠto	 ﾠaddress	 ﾠthe	 ﾠquestion	 ﾠin	 ﾠdispute	 ﾠby	 ﾠstudying	 ﾠthe	 ﾠrole	 ﾠof	 ﾠERK1	 ﾠ
and	 ﾠERK2	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠmotility	 ﾠin	 ﾠ2D	 ﾠand	 ﾠ3D	 ﾠmicroenvironments	 ﾠand	 ﾠinvestigating	 ﾠ
whether	 ﾠisoform-ﾭ‐specific	 ﾠdifferences	 ﾠobserved	 ﾠin	 ﾠcell	 ﾠmigration	 ﾠexperiments	 ﾠare	 ﾠtrue	 ﾠ
functional	 ﾠdisparities	 ﾠor	 ﾠthe	 ﾠresult	 ﾠof	 ﾠdifferent	 ﾠexpression	 ﾠlevels.	 ﾠ
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3.2  Results 
3.2.1  The invasive phenotype of A2780-Rab25 cells is dependent on ERK 
signalling 
To	 ﾠstudy	 ﾠthe	 ﾠcontribution	 ﾠmade	 ﾠby	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠto	 ﾠinvasive	 ﾠtumour	 ﾠcell	 ﾠmigration,	 ﾠwe	 ﾠ
required	 ﾠa	 ﾠsuitable	 ﾠcancer	 ﾠcell	 ﾠline	 ﾠwith	 ﾠan	 ﾠERK-ﾭ‐dependent	 ﾠinvasive	 ﾠphenotype.	 ﾠTo	 ﾠthis	 ﾠ
end,	 ﾠwe	 ﾠchose	 ﾠthe	 ﾠwell-ﾭ‐characterised	 ﾠinvasive	 ﾠovarian	 ﾠcarcinoma	 ﾠcell	 ﾠline	 ﾠA2780-ﾭ‐Rab25	 ﾠ
which,	 ﾠthrough	 ﾠstable	 ﾠoverexpression	 ﾠof	 ﾠectopic	 ﾠHA-ﾭ‐Rab25,	 ﾠshow	 ﾠenhanced	 ﾠinvasiveness	 ﾠ
into	 ﾠbona	 ﾠfide	 ﾠ3D	 ﾠmatrices	 ﾠsuch	 ﾠas	 ﾠcollagen	 ﾠor	 ﾠMatrigel	 ﾠ[380]	 ﾠand	 ﾠincreased	 ﾠ
aggressiveness	 ﾠin	 ﾠxenograft	 ﾠstudies	 ﾠof	 ﾠovarian	 ﾠand	 ﾠbreast	 ﾠtumours	 ﾠin	 ﾠnude	 ﾠmice	 ﾠ[351].	 ﾠWe	 ﾠ
postulated	 ﾠthat	 ﾠthe	 ﾠinvasive	 ﾠphenotype	 ﾠof	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠrequires	 ﾠERK	 ﾠsignalling	 ﾠand	 ﾠ
performed	 ﾠinverted	 ﾠinvasion	 ﾠassays	 ﾠ(previously	 ﾠdescribed	 ﾠby	 ﾠHennigan	 ﾠet	 ﾠal.	 ﾠ[352]	 ﾠand	 ﾠ
adapted	 ﾠby	 ﾠCaswell	 ﾠet	 ﾠal.	 ﾠ[380]),	 ﾠwhere	 ﾠtumour	 ﾠcells	 ﾠwere	 ﾠplated	 ﾠonto	 ﾠthe	 ﾠunderside	 ﾠof	 ﾠa	 ﾠ
Matrigel	 ﾠplug	 ﾠsupplemented	 ﾠwith	 ﾠ25	 ﾠµg/ml	 ﾠfibronectin.	 ﾠ(N.B.	 ﾠThe	 ﾠaddition	 ﾠof	 ﾠfibronectin	 ﾠ
was	 ﾠshown	 ﾠto	 ﾠbe	 ﾠnecessary	 ﾠfor	 ﾠRab25-ﾭ‐driven	 ﾠinvasion	 ﾠ[380]).	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwere	 ﾠ
allowed	 ﾠto	 ﾠmigrate	 ﾠthrough	 ﾠthe	 ﾠporous	 ﾠmembrane	 ﾠof	 ﾠthe	 ﾠTranswell	 ﾠinsert	 ﾠinto	 ﾠthe	 ﾠ
Matrigel.	 ﾠSubsequently,	 ﾠa	 ﾠchemotactic	 ﾠgradient	 ﾠwas	 ﾠestablished	 ﾠby	 ﾠadding	 ﾠfull	 ﾠmedium	 ﾠ
containing	 ﾠ25	 ﾠng/ml	 ﾠEGF	 ﾠinto	 ﾠthe	 ﾠupper	 ﾠchamber	 ﾠand	 ﾠserum-ﾭ‐free	 ﾠmedium	 ﾠinto	 ﾠthe	 ﾠlower	 ﾠ
chamber	 ﾠ(see	 ﾠFigure	 ﾠ3-ﾭ‐2	 ﾠA	 ﾠfor	 ﾠexperimental	 ﾠset-ﾭ‐up).	 ﾠAfter	 ﾠ36	 ﾠhours,	 ﾠliving	 ﾠcells	 ﾠwere	 ﾠ
stained	 ﾠusing	 ﾠCalcein-ﾭ‐AM	 ﾠand	 ﾠimaged	 ﾠon	 ﾠa	 ﾠconfocal	 ﾠmicroscope.	 ﾠOptical	 ﾠsections	 ﾠwere	 ﾠ
gathered	 ﾠevery	 ﾠ15	 ﾠµm,	 ﾠstarting	 ﾠat	 ﾠthe	 ﾠbottom	 ﾠof	 ﾠthe	 ﾠMatrigel	 ﾠplug	 ﾠand	 ﾠmoving	 ﾠupwards	 ﾠin	 ﾠ
the	 ﾠdirection	 ﾠof	 ﾠcell	 ﾠinvasion.	 ﾠTo	 ﾠtest	 ﾠwhether	 ﾠERK	 ﾠsignalling	 ﾠwas	 ﾠrequired	 ﾠfor	 ﾠthe	 ﾠinvasion	 ﾠ
of	 ﾠA2780-ﾭ‐Rab25	 ﾠcells,	 ﾠthe	 ﾠMEK	 ﾠinhibitor,	 ﾠU0126	 ﾠwas	 ﾠadded	 ﾠto	 ﾠthe	 ﾠlower	 ﾠand	 ﾠupper	 ﾠ
chamber	 ﾠat	 ﾠa	 ﾠconcentration	 ﾠof	 ﾠ10	 ﾠµM.	 ﾠFigure	 ﾠ3-ﾭ‐2	 ﾠB	 ﾠshows	 ﾠrepresentative	 ﾠstrips,	 ﾠwhich	 ﾠ
were	 ﾠassembled	 ﾠfrom	 ﾠindividual	 ﾠimages	 ﾠobtained	 ﾠduring	 ﾠoptical	 ﾠsectioning	 ﾠof	 ﾠthe	 ﾠMatrigel	 ﾠ
plug.	 ﾠCells	 ﾠare	 ﾠstained	 ﾠgreen	 ﾠand	 ﾠtheir	 ﾠmigration	 ﾠfrom	 ﾠleft	 ﾠto	 ﾠright	 ﾠindicated	 ﾠby	 ﾠthe	 ﾠarrow,	 ﾠ
corresponds	 ﾠto	 ﾠtheir	 ﾠupward	 ﾠmigration.	 ﾠQuantification	 ﾠof	 ﾠthree	 ﾠindependent	 ﾠexperiments,	 ﾠ
within	 ﾠwhich	 ﾠeach	 ﾠexperimental	 ﾠcondition	 ﾠwas	 ﾠrepresented	 ﾠby	 ﾠtwo	 ﾠMatrigel	 ﾠplugs	 ﾠand	 ﾠ
three	 ﾠregions	 ﾠ(corresponding	 ﾠto	 ﾠx,y	 ﾠpositions)	 ﾠof	 ﾠeach	 ﾠplug,	 ﾠwas	 ﾠperformed	 ﾠusing	 ﾠthe	 ﾠ
ImageJ.	 ﾠInvasive	 ﾠmigration	 ﾠwas	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠcells	 ﾠthat	 ﾠmigrated	 ﾠbeyond	 ﾠ
45	 ﾠµm	 ﾠrelative	 ﾠto	 ﾠthe	 ﾠcontrol	 ﾠcondition.	 ﾠWhen	 ﾠERK	 ﾠactivation	 ﾠwas	 ﾠinhibited	 ﾠby	 ﾠU0126	 ﾠ
treatment,	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠsignificant	 ﾠdecrease	 ﾠin	 ﾠinvasion	 ﾠby	 ﾠapproximately	 ﾠ50%	 ﾠ
(p<0.0001)	 ﾠ(Figure	 ﾠ3-ﾭ‐2	 ﾠC).	 ﾠFurthermore,	 ﾠERK	 ﾠinhibition	 ﾠwas	 ﾠvalidated	 ﾠby	 ﾠWestern	 ﾠblotting	 ﾠ
to	 ﾠbe	 ﾠcompletely	 ﾠabolished	 ﾠ24	 ﾠhours,	 ﾠand	 ﾠmarginally	 ﾠrecovered	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠU0126	 ﾠ	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Figure 3-2 The invasive phenotype of A2780-Rab27 cells is dependent on ERK signalling 
A. Schematic diagram on how inverse invasion assays are set up and quantified. 
B. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x10
4 A2780-Rab25 cells were plated onto 
the underside of each Transwell. The MEK inhibitor, U0126 (10µM), or DMSO was added to the media. 
After 36 hrs invading cells were visualized by Calcein-AM staining. Serial optical sections were captured 
every 15 µm and are presented as a sequence in which the depth increases from left to right. 
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells treated with DMSO. Values are means ± 
standard error of the mean (SEM) of 18 replicates from three independent experiments. Statistical 
significance of difference was determined by Mann-Whitney U test analysis. 
D. ERK inhibition by U0126 was assessed by Western blotting at 24 hrs and 48 hrs. 
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treatment	 ﾠ(Figure	 ﾠ3-ﾭ‐2	 ﾠD).	 ﾠTaken	 ﾠtogether	 ﾠthe	 ﾠdata	 ﾠindicates	 ﾠthat	 ﾠinvasion	 ﾠof	 ﾠA2780-ﾭ‐Rab25	 ﾠ
cells	 ﾠis	 ﾠdependent	 ﾠon	 ﾠERK	 ﾠsignalling,	 ﾠthus	 ﾠproving	 ﾠas	 ﾠa	 ﾠsuitable	 ﾠcell	 ﾠline	 ﾠto	 ﾠstudy	 ﾠthe	 ﾠ
isoform-ﾭ‐specific	 ﾠcontributions	 ﾠtowards	 ﾠinvasive	 ﾠtumour	 ﾠcell	 ﾠmigration.	 ﾠ
3.2.2  Silencing of ERK2 impairs invasion into Matrigel 
Next,	 ﾠwe	 ﾠwanted	 ﾠto	 ﾠinvestigate	 ﾠthe	 ﾠrespective	 ﾠroles	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠin	 ﾠinvasive	 ﾠ
migration.	 ﾠTherefore,	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwere	 ﾠtransfected	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠ(NT)	 ﾠsiRNA	 ﾠ
oligos	 ﾠor	 ﾠSMARTpools	 ﾠtargeting	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2.	 ﾠKnockdown	 ﾠof	 ﾠERK	 ﾠwas	 ﾠvalidated	 ﾠby	 ﾠ
Western	 ﾠblotting	 ﾠ48	 ﾠand	 ﾠ72	 ﾠhours	 ﾠpost	 ﾠtransfection	 ﾠ(Figure	 ﾠ3-ﾭ‐3	 ﾠA).	 ﾠSurprisingly,	 ﾠsilencing	 ﾠ
of	 ﾠERK1	 ﾠresulted	 ﾠin	 ﾠenhanced	 ﾠinvasion	 ﾠ(p<0.05),	 ﾠwhereas	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠsignificantly	 ﾠ
decreased	 ﾠmigration	 ﾠinto	 ﾠthe	 ﾠMatrigel	 ﾠplug	 ﾠby	 ﾠapproximately	 ﾠ40%	 ﾠ(p<0.0001).	 ﾠWhen	 ﾠboth	 ﾠ
ERK	 ﾠisoforms	 ﾠwere	 ﾠknocked	 ﾠdown	 ﾠsimultaneously,	 ﾠa	 ﾠ30%	 ﾠdecrease	 ﾠin	 ﾠinvasion	 ﾠwas	 ﾠ
observed	 ﾠ(p<0.01)	 ﾠ(Figure	 ﾠ3-ﾭ‐3).	 ﾠ	 ﾠ
RNA	 ﾠinterference	 ﾠis	 ﾠa	 ﾠcommonly	 ﾠused	 ﾠmethod	 ﾠto	 ﾠstudy	 ﾠgene	 ﾠfunction	 ﾠin	 ﾠbiological	 ﾠ
processes,	 ﾠsuch	 ﾠas	 ﾠapoptosis,	 ﾠdifferentiation	 ﾠand	 ﾠcell	 ﾠmigration.	 ﾠHowever,	 ﾠ
short-ﾭ‐interfering	 ﾠRNAs	 ﾠ(siRNAs)	 ﾠhave	 ﾠbeen	 ﾠreported	 ﾠto	 ﾠsilence	 ﾠunintended	 ﾠtranscripts,	 ﾠ
which	 ﾠare	 ﾠonly	 ﾠpartially	 ﾠcomplementary	 ﾠin	 ﾠsequence	 ﾠ[465].	 ﾠMoreover,	 ﾠsiRNAs	 ﾠcan	 ﾠaffect	 ﾠ
mRNA	 ﾠtranslation	 ﾠ[466]	 ﾠand	 ﾠinduce	 ﾠan	 ﾠunspecific	 ﾠinterferon	 ﾠresponse	 ﾠ[467].	 ﾠTherefore,	 ﾠ
caution	 ﾠis	 ﾠwarranted	 ﾠwhen	 ﾠinterpreting	 ﾠfunctional	 ﾠand	 ﾠphenotypical	 ﾠchanges	 ﾠfollowing	 ﾠ
RNAi.	 ﾠThe	 ﾠvalidity	 ﾠof	 ﾠbiological	 ﾠchanges	 ﾠobserved	 ﾠfollowing	 ﾠsiRNA	 ﾠof	 ﾠa	 ﾠgiven	 ﾠtarget	 ﾠgene	 ﾠis	 ﾠ
generally	 ﾠassessed	 ﾠby	 ﾠusing	 ﾠmultiple	 ﾠindependent	 ﾠsiRNA	 ﾠduplexes.	 ﾠThus,	 ﾠwhile	 ﾠall	 ﾠ
duplexes	 ﾠemployed	 ﾠdisplay	 ﾠthe	 ﾠsame	 ﾠon-ﾭ‐target	 ﾠactivity,	 ﾠtheir	 ﾠnon-ﾭ‐specific	 ﾠeffects	 ﾠwill	 ﾠ
differ	 ﾠand	 ﾠfunctional	 ﾠchanges	 ﾠobserved	 ﾠwith	 ﾠat	 ﾠleast	 ﾠtwo	 ﾠsiRNA	 ﾠduplexes	 ﾠare	 ﾠlikely	 ﾠto	 ﾠbe	 ﾠ
attributed	 ﾠto	 ﾠsilencing	 ﾠof	 ﾠthe	 ﾠtarget	 ﾠgene	 ﾠrather	 ﾠthan	 ﾠoverlapping	 ﾠoff-ﾭ‐target	 ﾠeffects.	 ﾠ
In	 ﾠorder	 ﾠto	 ﾠcontrol	 ﾠfor	 ﾠany	 ﾠoff-ﾭ‐target	 ﾠeffects	 ﾠcaused	 ﾠby	 ﾠthe	 ﾠsiRNA	 ﾠoligos	 ﾠof	 ﾠthe	 ﾠ
SMARTpool,	 ﾠinvasion	 ﾠassays	 ﾠwere	 ﾠrepeated	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠtargeting	 ﾠeither	 ﾠ
ERK1	 ﾠor	 ﾠERK2.	 ﾠSilencing	 ﾠof	 ﾠthe	 ﾠrespective	 ﾠisoform	 ﾠwas	 ﾠconfirmed	 ﾠ72	 ﾠand	 ﾠ96	 ﾠhours	 ﾠpost	 ﾠ
transfection	 ﾠby	 ﾠWestern	 ﾠblotting	 ﾠ(Figure	 ﾠ3-ﾭ‐4	 ﾠA).	 ﾠKnockdown	 ﾠof	 ﾠERK1	 ﾠwith	 ﾠoligo	 ﾠ#1	 ﾠor	 ﾠ#2	 ﾠ
showed	 ﾠno	 ﾠsignificant	 ﾠeffect	 ﾠon	 ﾠinvasion	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠNT	 ﾠcontrols.	 ﾠIn	 ﾠcontrast,	 ﾠ
silencing	 ﾠof	 ﾠERK2	 ﾠwith	 ﾠoligos	 ﾠ#1	 ﾠor	 ﾠ#2	 ﾠsignificantly	 ﾠreduced	 ﾠinvasion	 ﾠinto	 ﾠMatrigel	 ﾠby	 ﾠ
approximately	 ﾠ50%	 ﾠ(p<0.0001)	 ﾠ(Figure	 ﾠ3-ﾭ‐4	 ﾠB/C).	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Figure 3-3 Suppression of ERK2 levels reduces invasiveness of A2780-Rab25 cells 
A. A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or SMARTpools targeting ERK1 
or ERK2. The effectiveness of the ERK knockdown was assessed by Western blot 48 hrs and 72 hrs after 
transfection. (S) and (L) refer to a short and long exposure times, respectively. 
B. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x10
4 cells were plated onto the underside of 
each Transwell 24 hrs post transfection. 36 hrs following this, invading cells were visualized by Calcein-AM 
staining. Serial optical sections were captured every 15 µm and are presented as a sequence in which the 
depth increases from left to right. 
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
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Figure 3-4 siRNA of ERK2 opposes invasion into Matrigel 
A. A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2. The effectiveness of the ERK knockdown was assessed by Western blot 72 hrs and 96 hrs after 
transfection. (S) and (L) refer to a short and long exposure times, respectively. 
B. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x10
4 cells were plated onto the underside of 
each Transwell 24 hrs post transfection. 36 hrs following this, invading cells were visualized by Calcein-AM 
staining. Serial optical sections were captured every 15 µm and are presented as a sequence in which the 
depth increases from left to right. 
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.3  Transient knockdown of ERK does not induce apoptosis or alter 
proliferation in A2780-Rab25 cells 
ERK	 ﾠsignalling	 ﾠcooperatively	 ﾠenhances	 ﾠcellular	 ﾠgrowth,	 ﾠproliferation	 ﾠand	 ﾠcell	 ﾠsurvival.	 ﾠ
Thus,	 ﾠdiminishing	 ﾠERK	 ﾠsignalling	 ﾠthrough	 ﾠtransient	 ﾠknockdown	 ﾠmay	 ﾠaffect	 ﾠcell	 ﾠviability	 ﾠand	 ﾠ
thereby	 ﾠalter	 ﾠthe	 ﾠinvasive	 ﾠphenotype	 ﾠof	 ﾠA2780-ﾭ‐Rab25	 ﾠcells.	 ﾠGiven	 ﾠthat	 ﾠERK2	 ﾠis	 ﾠthe	 ﾠ
predominant	 ﾠkinase	 ﾠin	 ﾠthese	 ﾠcells	 ﾠ(Figure	 ﾠ3-ﾭ‐2	 ﾠD),	 ﾠsilencing	 ﾠERK2	 ﾠmay	 ﾠgreatly	 ﾠreduce	 ﾠthe	 ﾠ
amount	 ﾠof	 ﾠactive	 ﾠERK,	 ﾠwhereas	 ﾠknockdown	 ﾠof	 ﾠERK1	 ﾠmight	 ﾠresult	 ﾠin	 ﾠa	 ﾠmarginal	 ﾠreduction	 ﾠ
of	 ﾠpERK	 ﾠlevels.	 ﾠOur	 ﾠdata,	 ﾠhowever,	 ﾠdemonstrates	 ﾠa	 ﾠcompensatory	 ﾠincrease	 ﾠin	 ﾠpERK1	 ﾠlevels	 ﾠ
upon	 ﾠERK2	 ﾠknockdown	 ﾠand	 ﾠvice	 ﾠversa.	 ﾠThus,	 ﾠtransient	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠ
does	 ﾠnot	 ﾠalter	 ﾠthe	 ﾠpool	 ﾠof	 ﾠactive	 ﾠERK	 ﾠdramatically.	 ﾠ
In	 ﾠorder	 ﾠto	 ﾠtest,	 ﾠwhether	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK	 ﾠisoform	 ﾠinduces	 ﾠapoptosis,	 ﾠ
A2780-ﾭ‐Rab25	 ﾠcells	 ﾠwere	 ﾠtransfected	 ﾠwith	 ﾠNT	 ﾠsiRNA	 ﾠand	 ﾠoligos	 ﾠtargeting	 ﾠERK1	 ﾠand	 ﾠERK2.	 ﾠ
As	 ﾠa	 ﾠpositive	 ﾠcontrol	 ﾠthe	 ﾠextrinsic	 ﾠapoptotic	 ﾠpathway	 ﾠwas	 ﾠinduced	 ﾠin	 ﾠnon-ﾭ‐transfected	 ﾠcells	 ﾠ
by	 ﾠtreatment	 ﾠwith	 ﾠFas-ﾭ‐ligand	 ﾠ(50	 ﾠnM)	 ﾠand	 ﾠ5	 ﾠµg/ml	 ﾠcycloheximide	 ﾠfor	 ﾠ24	 ﾠhours.	 ﾠFas-ﾭ‐ligand	 ﾠ
binding	 ﾠto	 ﾠthe	 ﾠdeath	 ﾠreceptor,	 ﾠFasR,	 ﾠactivates	 ﾠthe	 ﾠcaspase	 ﾠcascade,	 ﾠwhile	 ﾠcycloheximide	 ﾠ
inhibits	 ﾠprotein	 ﾠsynthesis	 ﾠby	 ﾠblocking	 ﾠthe	 ﾠtranslational	 ﾠelongation	 ﾠstep	 ﾠ[381].	 ﾠCaspase	 ﾠ
activation	 ﾠwill	 ﾠultimately	 ﾠpromotes	 ﾠthe	 ﾠcleavage	 ﾠof	 ﾠpoly	 ﾠADP	 ﾠribose	 ﾠpolymerase	 ﾠ(PARP),	 ﾠ
which	 ﾠis	 ﾠinvolved	 ﾠin	 ﾠDNA	 ﾠrepair	 ﾠof	 ﾠsingle-ﾭ‐stranded	 ﾠnicks	 ﾠ[382].	 ﾠPARP	 ﾠcleavage	 ﾠgives	 ﾠrise	 ﾠto	 ﾠ
two	 ﾠfragments	 ﾠof	 ﾠ24	 ﾠkDa	 ﾠand	 ﾠ89	 ﾠkDa,	 ﾠwhich	 ﾠcan	 ﾠbe	 ﾠvisualised	 ﾠby	 ﾠWestern	 ﾠblotting.	 ﾠWhen	 ﾠ
examining	 ﾠcells	 ﾠtreated	 ﾠwith	 ﾠFas-ﾭ‐ligand	 ﾠand	 ﾠcycloheximide	 ﾠusing	 ﾠa	 ﾠphase-ﾭ‐contrast	 ﾠlight	 ﾠ
microscope,	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwere	 ﾠround,	 ﾠlargely	 ﾠunattached	 ﾠand	 ﾠfragmented.	 ﾠIn	 ﾠorder	 ﾠ
to	 ﾠharvest	 ﾠany	 ﾠapoptotic	 ﾠcells,	 ﾠwe	 ﾠcollected	 ﾠthe	 ﾠmedia	 ﾠof	 ﾠeach	 ﾠexperimental	 ﾠcondition	 ﾠand	 ﾠ
centrifuged	 ﾠat	 ﾠ10,000	 ﾠrpm	 ﾠfor	 ﾠfive	 ﾠminutes	 ﾠat	 ﾠ4˚C.	 ﾠThe	 ﾠsupernatant	 ﾠwas	 ﾠdiscarded	 ﾠand	 ﾠthe	 ﾠ
pellet	 ﾠkept	 ﾠon	 ﾠice.	 ﾠPBS	 ﾠfrom	 ﾠsubsequent	 ﾠwash	 ﾠsteps	 ﾠand	 ﾠthe	 ﾠtrypsinised	 ﾠcell	 ﾠsuspension	 ﾠ
were	 ﾠalso	 ﾠspun	 ﾠdown	 ﾠin	 ﾠthe	 ﾠsame	 ﾠtube.	 ﾠThe	 ﾠfinal	 ﾠpellet,	 ﾠcontaining	 ﾠboth	 ﾠapoptotic	 ﾠand	 ﾠ
non-ﾭ‐apoptotic	 ﾠcells,	 ﾠwas	 ﾠlysed	 ﾠin	 ﾠHEPES	 ﾠlysis	 ﾠbuffer	 ﾠand	 ﾠPARP-ﾭ‐1	 ﾠcleavage	 ﾠwas	 ﾠdetermined	 ﾠ
by	 ﾠWestern	 ﾠblotting.	 ﾠInterestingly,	 ﾠthe	 ﾠ89	 ﾠkDa	 ﾠPARP-ﾭ‐1	 ﾠfragment	 ﾠwas	 ﾠclearly	 ﾠvisible	 ﾠin	 ﾠ
apoptosis-ﾭ‐induced	 ﾠA2780-ﾭ‐Rab25	 ﾠcells,	 ﾠwhereas	 ﾠcontrol-ﾭ‐transfected	 ﾠand	 ﾠERK	 ﾠknockdown	 ﾠ
cells	 ﾠshowed	 ﾠno	 ﾠPARP-ﾭ‐1	 ﾠcleavage	 ﾠ(Figure	 ﾠ3-ﾭ‐5	 ﾠA).	 ﾠWe,	 ﾠtherefore,	 ﾠconcluded	 ﾠthat	 ﾠapoptosis	 ﾠ
was	 ﾠnot	 ﾠtriggered	 ﾠas	 ﾠa	 ﾠresult	 ﾠof	 ﾠtransient	 ﾠERK	 ﾠknockdown.	 ﾠ
With	 ﾠthe	 ﾠexception	 ﾠof	 ﾠVantaggiato	 ﾠet	 ﾠal.	 ﾠ[371],	 ﾠmultiple	 ﾠreports	 ﾠstudying	 ﾠthe	 ﾠrole	 ﾠof	 ﾠERK1	 ﾠ
and	 ﾠERK2	 ﾠin	 ﾠproliferation	 ﾠhave	 ﾠdemonstrated	 ﾠthat	 ﾠboth	 ﾠisoforms	 ﾠpositively	 ﾠcontribute	 ﾠ	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 ﾠ
Figure 3-5 siRNA of ERK1 or ERK2 does not induce apoptosis or inhibit proliferation 
A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2.  
A. Apoptosis was induced in control transfected cells by Fas-ligand (50nM) and cycloheximide (5µg/ml) 
treatment. PARP-cleavage was determined 24 hours after induction. 
B. The proliferation assay was set up 24 hrs after transfection by seeding 20,000 cells into a 6-well dish. The 
following 4 days, cells were counted using a Casy counter. Relative cell number was plotted against time. 
Values are means ± standard error of the mean (SEM) of 9 replicates from three independent experiments. 
C. The effectiveness of the ERK knockdown was assessed over the course of 6 days by Western blot.  
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towards	 ﾠcellular	 ﾠgrowth	 ﾠ[357,	 ﾠ359,	 ﾠ366,	 ﾠ376]	 ﾠand	 ﾠtherefore	 ﾠreducing	 ﾠthe	 ﾠpool	 ﾠof	 ﾠactive	 ﾠ
ERK	 ﾠby	 ﾠsilencing	 ﾠeither	 ﾠisoform	 ﾠmay	 ﾠresult	 ﾠin	 ﾠproliferative	 ﾠchanges.	 ﾠTo	 ﾠtest	 ﾠthis,	 ﾠwe	 ﾠ
transfected	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwith	 ﾠNT	 ﾠsiRNA,	 ﾠor	 ﾠthose	 ﾠtargeting	 ﾠERK1,	 ﾠor	 ﾠERK2	 ﾠand	 ﾠ
seeded	 ﾠ40,000	 ﾠcells	 ﾠinto	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠdish	 ﾠone	 ﾠday	 ﾠafter	 ﾠtransfection.	 ﾠAs	 ﾠa	 ﾠnegative	 ﾠcontrol,	 ﾠ
one	 ﾠset	 ﾠof	 ﾠcontrol-ﾭ‐transfected	 ﾠcells	 ﾠwere	 ﾠtreated	 ﾠwith	 ﾠthe	 ﾠMEK	 ﾠinhibitor,	 ﾠU0126,	 ﾠwhich	 ﾠ
has	 ﾠpreviously	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠinhibit	 ﾠproliferation	 ﾠin	 ﾠvitro	 ﾠand	 ﾠin	 ﾠvivo	 ﾠ[383-ﾭ‐385].	 ﾠCellular	 ﾠ
growth	 ﾠwas	 ﾠmonitored	 ﾠby	 ﾠcell	 ﾠcounting	 ﾠusing	 ﾠa	 ﾠCasy	 ﾠcell	 ﾠcounter	 ﾠand	 ﾠa	 ﾠhaemocytometer.	 ﾠ
The	 ﾠcell	 ﾠnumber	 ﾠof	 ﾠeach	 ﾠexperimental	 ﾠcondition	 ﾠwas	 ﾠmeasured	 ﾠover	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠfour	 ﾠ
days	 ﾠand	 ﾠis	 ﾠrepresented	 ﾠas	 ﾠa	 ﾠrelative	 ﾠcell	 ﾠnumber	 ﾠin	 ﾠFigure	 ﾠ3-ﾭ‐5	 ﾠB.	 ﾠThree	 ﾠindependent	 ﾠ
experiments	 ﾠwere	 ﾠperformed,	 ﾠin	 ﾠwhich	 ﾠeach	 ﾠexperimental	 ﾠcondition	 ﾠwas	 ﾠset	 ﾠup	 ﾠin	 ﾠ
triplicate.	 ﾠAs	 ﾠexpected,	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠproliferative	 ﾠinhibition	 ﾠtwo	 ﾠdays	 ﾠafter	 ﾠU0126	 ﾠ
treatment.	 ﾠIn	 ﾠcontrast,	 ﾠtransient	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠdid	 ﾠnot	 ﾠaffect	 ﾠcellular	 ﾠ
growth,	 ﾠalthough	 ﾠan	 ﾠefficient	 ﾠknockdown	 ﾠwas	 ﾠachieved	 ﾠduring	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠthe	 ﾠ
experiment	 ﾠ(Figure	 ﾠ3-ﾭ‐5	 ﾠC).	 ﾠ	 ﾠ
In	 ﾠsummary,	 ﾠwe	 ﾠfound	 ﾠthat	 ﾠknocking	 ﾠdown	 ﾠeither	 ﾠERK	 ﾠisoform	 ﾠhad	 ﾠno	 ﾠeffect	 ﾠon	 ﾠ
proliferation	 ﾠor	 ﾠapoptosis	 ﾠindicating	 ﾠthat	 ﾠeffects	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠon	 ﾠcell	 ﾠviability	 ﾠdid	 ﾠnot	 ﾠ
influence	 ﾠour	 ﾠinvasion	 ﾠand	 ﾠmotility	 ﾠresults.	 ﾠ
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3.2.4  Both ERK isoforms contribute to migration on plastic surfaces 
Rab25,	 ﾠwhich	 ﾠwas	 ﾠshown	 ﾠto	 ﾠbe	 ﾠa	 ﾠcomponent	 ﾠof	 ﾠan	 ﾠinvasive	 ﾠgene	 ﾠsignature	 ﾠin	 ﾠbreast	 ﾠ
cancer	 ﾠcells	 ﾠ[386],	 ﾠalters	 ﾠthe	 ﾠway	 ﾠin	 ﾠwhich	 ﾠA2780	 ﾠcells	 ﾠmigrate	 ﾠon	 ﾠextracellular	 ﾠmatrices,	 ﾠ
but	 ﾠnot	 ﾠon	 ﾠ2D	 ﾠplastic	 ﾠsurfaces	 ﾠ[380].	 ﾠGiven	 ﾠthat	 ﾠchanges	 ﾠin	 ﾠinvasiveness	 ﾠdo	 ﾠnot	 ﾠnecessarily	 ﾠ
reflect	 ﾠon	 ﾠplastic,	 ﾠwe	 ﾠset	 ﾠout	 ﾠto	 ﾠinvestigate	 ﾠwhether	 ﾠERK2	 ﾠaltered	 ﾠcell	 ﾠmigration	 ﾠin	 ﾠ2D.	 ﾠ
Thus,	 ﾠwe	 ﾠtransiently	 ﾠtransfected	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠsiRNAs	 ﾠ(NT),	 ﾠor	 ﾠ
single	 ﾠoligos	 ﾠtargeting	 ﾠERK1	 ﾠor	 ﾠERK2.	 ﾠSubsequently,	 ﾠcells	 ﾠwere	 ﾠseeded	 ﾠinto	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠdish,	 ﾠ
so	 ﾠthat	 ﾠthey	 ﾠwere	 ﾠconfluent	 ﾠ48	 ﾠhours	 ﾠpost	 ﾠtransfection.	 ﾠAfter	 ﾠintroducing	 ﾠa	 ﾠwound	 ﾠby	 ﾠ
scratching	 ﾠthe	 ﾠplastic	 ﾠdish	 ﾠwith	 ﾠa	 ﾠ200	 ﾠµl	 ﾠpipette	 ﾠtip,	 ﾠwound	 ﾠclosure	 ﾠwas	 ﾠmonitored	 ﾠat	 ﾠ10	 ﾠ
minute	 ﾠintervals	 ﾠusing	 ﾠa	 ﾠtime-ﾭ‐lapse	 ﾠmicroscope.	 ﾠThe	 ﾠmovement	 ﾠof	 ﾠindividual	 ﾠcells	 ﾠwas	 ﾠ
followed	 ﾠusing	 ﾠthe	 ﾠImageJ	 ﾠcell	 ﾠtracking	 ﾠsoftware.	 ﾠImages	 ﾠwere	 ﾠtaken	 ﾠfrom	 ﾠfive	 ﾠdistinct	 ﾠ
fields	 ﾠalong	 ﾠthe	 ﾠwound	 ﾠin	 ﾠevery	 ﾠwell	 ﾠand	 ﾠa	 ﾠminimum	 ﾠof	 ﾠfive	 ﾠcells	 ﾠwere	 ﾠtracked	 ﾠin	 ﾠeach	 ﾠ
field.	 ﾠThe	 ﾠmigratory	 ﾠspeed,	 ﾠpersistence	 ﾠand	 ﾠFMI	 ﾠwere	 ﾠextracted	 ﾠfrom	 ﾠthe	 ﾠtrackplots	 ﾠfrom	 ﾠ
three	 ﾠindependent	 ﾠexperiments	 ﾠand	 ﾠare	 ﾠrepresented	 ﾠin	 ﾠFigure	 ﾠ3-ﾭ‐6.	 ﾠPersistence	 ﾠis	 ﾠa	 ﾠ
measurement	 ﾠon	 ﾠhow	 ﾠdirect	 ﾠa	 ﾠcell	 ﾠmoves	 ﾠfrom	 ﾠA	 ﾠto	 ﾠB	 ﾠand	 ﾠis	 ﾠcalculated	 ﾠby	 ﾠdividing	 ﾠthe	 ﾠ
vectorial	 ﾠcell	 ﾠpath	 ﾠby	 ﾠthe	 ﾠaccumulated	 ﾠdistance.	 ﾠThe	 ﾠforward	 ﾠmigration	 ﾠindex	 ﾠ(FMI)	 ﾠis	 ﾠ
commonly	 ﾠextracted	 ﾠfrom	 ﾠwound	 ﾠhealing	 ﾠassays,	 ﾠas	 ﾠit	 ﾠis	 ﾠa	 ﾠmeasurement	 ﾠof	 ﾠwound	 ﾠ
sensing.	 ﾠThe	 ﾠFMI	 ﾠrepresents	 ﾠthe	 ﾠratio	 ﾠof	 ﾠthe	 ﾠperpendicular	 ﾠdistance	 ﾠand	 ﾠthe	 ﾠaccumulated	 ﾠ
path	 ﾠ(Figure	 ﾠ3-ﾭ‐6	 ﾠB).	 ﾠThe	 ﾠmigration	 ﾠspeed	 ﾠof	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠwas	 ﾠexpressed	 ﾠ
relative	 ﾠto	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠof	 ﾠcells	 ﾠtransfected	 ﾠwith	 ﾠNT	 ﾠsiRNA	 ﾠto	 ﾠaccount	 ﾠfor	 ﾠ
differences	 ﾠin	 ﾠthe	 ﾠabsolute	 ﾠmigration	 ﾠspeed	 ﾠbetween	 ﾠdifferent	 ﾠexperiments.	 ﾠ
Treatment	 ﾠof	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwith	 ﾠthe	 ﾠMEK	 ﾠinhibitor,	 ﾠU0126,	 ﾠsignificantly	 ﾠimpaired	 ﾠ
wound	 ﾠclosure	 ﾠand	 ﾠseverely	 ﾠreduced	 ﾠthe	 ﾠmigratory	 ﾠspeed	 ﾠto	 ﾠapproximately	 ﾠ50%	 ﾠof	 ﾠ
NT-ﾭ‐transfected	 ﾠcells.	 ﾠInterestingly,	 ﾠsilencing	 ﾠof	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠ
significantly	 ﾠdelayed	 ﾠwound	 ﾠclosure	 ﾠand	 ﾠresulted	 ﾠin	 ﾠa	 ﾠ25%	 ﾠdecrease	 ﾠin	 ﾠmigratory	 ﾠspeed	 ﾠ
(p<0.0001)	 ﾠ(Figure	 ﾠ3-ﾭ‐6	 ﾠA/C).	 ﾠIn	 ﾠcontrast,	 ﾠpersistence	 ﾠand	 ﾠFMI	 ﾠdid	 ﾠnot	 ﾠchange	 ﾠupon	 ﾠ
inhibition	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠwith	 ﾠU0126	 ﾠor	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK	 ﾠisoform	 ﾠ(Figure	 ﾠ
3-ﾭ‐6	 ﾠD/E).	 ﾠThus,	 ﾠwhereas	 ﾠinvasion	 ﾠinto	 ﾠMatrigel	 ﾠis	 ﾠspecifically	 ﾠregulated	 ﾠby	 ﾠERK2	 ﾠin	 ﾠ
A2780-ﾭ‐Rab25	 ﾠcells,	 ﾠmigration	 ﾠon	 ﾠ2D	 ﾠplastic	 ﾠsurfaces	 ﾠappears	 ﾠto	 ﾠbe	 ﾠregulated	 ﾠby	 ﾠboth	 ﾠERK	 ﾠ
isoforms	 ﾠand	 ﾠmay	 ﾠdepend	 ﾠon	 ﾠthe	 ﾠtotal	 ﾠERK	 ﾠactivity	 ﾠpresent	 ﾠin	 ﾠthe	 ﾠcell.	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Figure 3-6 Both ERK isoforms contribute towards migration on plastic in A2780-Rab25 cells 
A. A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2. Subsequently, cells were seeded into a 6-well dish, so that they were confluent 48 hrs post 
transfection. After scratching wound closure was monitored and representative time frames are shown. Scale 
bar, 100 µm.  
B. Schematic outline of the cell tracking analysis. The overall migration velocity is defined as the ratio of 
accumulated path length and time. Persistence is defined as the ratio of the vectorial distance a cell travelled 
and the accumulated path length. The forward migration index (FMI) is a measure for wound sensing and is 
determined by dividing the distance travelled into the wound by the accumulated path length. The 
momentary velocity represents a frame-to-frame migration speed. 
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C-E. The movement of individual cells into the wound was followed using ImageJ cell tracking software. 
The overall migration velocity (C), persistence (D) and forward migration index (FMI) (E) were extracted 
from the trackplots. Values are means ± SEM of >75 trackplots from three independent experiments. 
Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.5  Knockdown of ERK2 impairs migration on cell-derived matrices 
To	 ﾠget	 ﾠa	 ﾠbetter	 ﾠunderstanding	 ﾠof	 ﾠhow	 ﾠERK2	 ﾠsilencing	 ﾠcontrols	 ﾠinvasive	 ﾠcell	 ﾠmigration,	 ﾠwe	 ﾠ
decided	 ﾠto	 ﾠuse	 ﾠcell-ﾭ‐derived	 ﾠmatrix	 ﾠ(CDM),	 ﾠwhich	 ﾠwas	 ﾠpreviously	 ﾠdescribed	 ﾠby	 ﾠCukierman	 ﾠ
et	 ﾠal.,	 ﾠand	 ﾠwhich	 ﾠrepresents	 ﾠa	 ﾠgood	 ﾠphysiological	 ﾠmodel	 ﾠof	 ﾠthe	 ﾠECM	 ﾠ[38].	 ﾠCDMs	 ﾠare	 ﾠ
generated	 ﾠby	 ﾠhuman	 ﾠtelomerase-ﾭ‐immortalised	 ﾠfibroblasts,	 ﾠwhich	 ﾠnaturally	 ﾠproduce	 ﾠ
extracellular	 ﾠmatrix-ﾭ‐like	 ﾠfibres	 ﾠaround	 ﾠthemselves	 ﾠand	 ﾠthereby	 ﾠcreate	 ﾠa	 ﾠrelatively	 ﾠthick	 ﾠ
(10	 ﾠµm),	 ﾠpliable	 ﾠmatrix	 ﾠcomposed	 ﾠmainly	 ﾠof	 ﾠfibrillar	 ﾠcollagen	 ﾠand	 ﾠfibronectin,	 ﾠwhich	 ﾠ
recapitulates	 ﾠkey	 ﾠaspects	 ﾠof	 ﾠthe	 ﾠtype	 ﾠof	 ﾠmatrix	 ﾠfound	 ﾠin	 ﾠconnective	 ﾠtissues	 ﾠ[38,	 ﾠ353].	 ﾠAfter	 ﾠ
growing	 ﾠthese	 ﾠfibroblasts	 ﾠas	 ﾠa	 ﾠconfluent	 ﾠmonolayer	 ﾠfor	 ﾠ10-ﾭ‐14	 ﾠdays,	 ﾠduring	 ﾠwhich	 ﾠECM	 ﾠ
fibers	 ﾠare	 ﾠsynthesized,	 ﾠthe	 ﾠcells	 ﾠwere	 ﾠremoved	 ﾠfrom	 ﾠthe	 ﾠsurrounding	 ﾠECM	 ﾠby	 ﾠtreatment	 ﾠ
with	 ﾠa	 ﾠnon-ﾭ‐ionic	 ﾠdetergent.	 ﾠCancer	 ﾠcells	 ﾠmay	 ﾠthen	 ﾠbe	 ﾠplated	 ﾠonto	 ﾠthe	 ﾠremaining	 ﾠfibrillar	 ﾠ
CDM	 ﾠto	 ﾠstudy	 ﾠtheir	 ﾠmigratory	 ﾠand	 ﾠmorphological	 ﾠcharacteristics	 ﾠin	 ﾠthis	 ﾠquasi-ﾭ‐3D	 ﾠ
environment.	 ﾠAs	 ﾠexpected,	 ﾠthere	 ﾠis	 ﾠa	 ﾠstriking	 ﾠdifference	 ﾠin	 ﾠmorphology	 ﾠand	 ﾠmode	 ﾠof	 ﾠ
migration	 ﾠof	 ﾠA2780-ﾭ‐Rab25	 ﾠbetween	 ﾠplastic	 ﾠsurfaces	 ﾠand	 ﾠCDM	 ﾠ(Figure	 ﾠ3-ﾭ‐7).	 ﾠDuring	 ﾠ
migration	 ﾠon	 ﾠplastic	 ﾠand	 ﾠother	 ﾠrigid	 ﾠsubstrates	 ﾠmany	 ﾠcell	 ﾠtypes	 ﾠmigrate	 ﾠby	 ﾠforming	 ﾠ
lamellipodia	 ﾠand	 ﾠstress	 ﾠfibers	 ﾠ[387,	 ﾠ388].	 ﾠMoreover,	 ﾠadhesion	 ﾠstructures	 ﾠon	 ﾠ2D	 ﾠsurfaces,	 ﾠ
which	 ﾠare	 ﾠdivided	 ﾠinto	 ﾠfocal	 ﾠand	 ﾠfibrillar	 ﾠadhesions,	 ﾠare	 ﾠrich	 ﾠin	 ﾠαvβ3	 ﾠintegrin,	 ﾠpaxillin,	 ﾠ
vinculin	 ﾠand	 ﾠFAK,	 ﾠor	 ﾠα5β1	 ﾠintegrin	 ﾠand	 ﾠtensin,	 ﾠrespectively	 ﾠ[389].	 ﾠIn	 ﾠ3D,	 ﾠhowever,	 ﾠcells	 ﾠ
either	 ﾠacquire	 ﾠan	 ﾠelongated,	 ﾠmesenchymal-ﾭ‐like	 ﾠmorphology,	 ﾠwhich	 ﾠis	 ﾠmarked	 ﾠby	 ﾠ
pseudopod	 ﾠformation	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠfront	 ﾠand	 ﾠrequires	 ﾠmatrix	 ﾠremodeling,	 ﾠor	 ﾠan	 ﾠ
amoeboid,	 ﾠrounded	 ﾠshape,	 ﾠwhich	 ﾠis	 ﾠcharacterized	 ﾠby	 ﾠhigh	 ﾠRho/ROCK	 ﾠactivity	 ﾠand	 ﾠthe	 ﾠ
formation	 ﾠof	 ﾠbleb-ﾭ‐like	 ﾠprotrusions	 ﾠ[34].	 ﾠIn	 ﾠaddition,	 ﾠcells,	 ﾠcultured	 ﾠin	 ﾠ3D,	 ﾠlose	 ﾠthe	 ﾠ
dorsal-ﾭ‐ventral	 ﾠasymmetry	 ﾠand	 ﾠform	 ﾠ3D	 ﾠmatrix	 ﾠadhesions,	 ﾠwhich	 ﾠare	 ﾠcomposed	 ﾠmainly	 ﾠof	 ﾠ
paxillin	 ﾠand	 ﾠα5β1	 ﾠintegrin	 ﾠ[38].	 ﾠ
We	 ﾠtransfected	 ﾠcells	 ﾠwith	 ﾠeither	 ﾠNT	 ﾠsiRNA,	 ﾠor	 ﾠsingle	 ﾠoligos	 ﾠtargeting	 ﾠERK1	 ﾠor	 ﾠERK2.	 ﾠ50,000	 ﾠ
cells	 ﾠwere	 ﾠseeded	 ﾠonto	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠcell	 ﾠculture	 ﾠdish	 ﾠcoated	 ﾠwith	 ﾠCDM	 ﾠ48	 ﾠhours	 ﾠpost	 ﾠ
transfection	 ﾠand	 ﾠallowed	 ﾠto	 ﾠadhere	 ﾠto	 ﾠthe	 ﾠ3D	 ﾠsubstratum	 ﾠfor	 ﾠapproximately	 ﾠfour	 ﾠhours.	 ﾠ
Cell	 ﾠmigration	 ﾠwas	 ﾠmonitored	 ﾠon	 ﾠa	 ﾠtime-ﾭ‐lapse	 ﾠmicroscope	 ﾠover	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠ16	 ﾠhours	 ﾠand	 ﾠ
images	 ﾠwere	 ﾠacquired	 ﾠevery	 ﾠ10	 ﾠminutes.	 ﾠStills	 ﾠof	 ﾠrepresentative	 ﾠmovies	 ﾠare	 ﾠshown	 ﾠin	 ﾠ
Figure	 ﾠ3-ﾭ‐8	 ﾠA.	 ﾠNotably,	 ﾠno	 ﾠmorphological	 ﾠdifferences	 ﾠbetween	 ﾠNT	 ﾠsiRNA-ﾭ‐transfected,	 ﾠ
U0126-ﾭ‐treated	 ﾠand	 ﾠERK	 ﾠknockdown	 ﾠcells	 ﾠwere	 ﾠobserved.	 ﾠHowever,	 ﾠwhen	 ﾠcell	 ﾠmovement	 ﾠ
was	 ﾠanalysed	 ﾠusing	 ﾠthe	 ﾠImageJ	 ﾠcell	 ﾠtracking	 ﾠsoftware,	 ﾠwe	 ﾠdetected	 ﾠa	 ﾠsignificant	 ﾠdecrease	 ﾠ	 ﾠChapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  119 
	 ﾠ
Figure 3-7 Cell-derived matrices (CDM) represent a 3D-like environment 
A. Schematic diagram illustrating the protocol for generating CDM. 
B. Confocal sections of CDM displaying either parallel (left) or intersecting (right) fibronectin fibres. 
Fibronectin was visualised by indirect immunofluorescence using a Cy2-conjugated secondary antibody 
(green). Scale bar, 10 µm 
C. A2780-Rab25 cells were seeded onto plastic and CDM-coated dishes. After 16 hours cells were visualised 
using a bright field microscope. Scale bar, 100 µm. 
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 ﾠ
Figure 3-8 siRNA of ERK2 reduces migration of A2780-Rab25 cells on CDM 
A.A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto cell-derived matrix. Images were captured every 10 minutes over a 16 hrs period using a 
Nikon time-lapse microscope. Still images from a representative movie are displayed. Scale bar, 100 µm. 
B-C. The movement of individual cells was followed using the ImageJ cell tracking software. The overall 
migration velocity (B) and persistence (C) were extracted from the trackplots. Values are means ± SEM of 
>75 trackplots from three independent experiments. Statistical significance of differences was determined by 
Mann-Whitney U test analysis. 
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in	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠon	 ﾠCDM,	 ﾠwhen	 ﾠcells	 ﾠwere	 ﾠtreated	 ﾠwith	 ﾠthe	 ﾠU0126	 ﾠinhibitor	 ﾠor	 ﾠ
ERK2	 ﾠwas	 ﾠsilenced	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠ(p<0.0001).	 ﾠIn	 ﾠcontrast,	 ﾠknockdown	 ﾠof	 ﾠ
ERK1	 ﾠdid	 ﾠnot	 ﾠalter	 ﾠthe	 ﾠmigration	 ﾠspeed	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠcontrol	 ﾠ(Figure	 ﾠ3-ﾭ‐8	 ﾠB).	 ﾠ
Moreover,	 ﾠwe	 ﾠdetermined	 ﾠthe	 ﾠpersistence	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠfound	 ﾠno	 ﾠsignificant	 ﾠ
difference	 ﾠbetween	 ﾠNT	 ﾠsiRNA,	 ﾠU0126	 ﾠtreatment	 ﾠand	 ﾠERK	 ﾠknockdown	 ﾠcells	 ﾠ(Figure	 ﾠ3-ﾭ‐8	 ﾠC).	 ﾠ
During	 ﾠour	 ﾠcell	 ﾠtracking	 ﾠanalysis,	 ﾠwe	 ﾠnoticed	 ﾠthat	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠhad	 ﾠa	 ﾠtendency	 ﾠto	 ﾠ
remain	 ﾠstationary	 ﾠfor	 ﾠextended	 ﾠperiods	 ﾠof	 ﾠtime.	 ﾠThus,	 ﾠthe	 ﾠpreviously	 ﾠobserved	 ﾠdifference	 ﾠ
in	 ﾠthe	 ﾠrelative	 ﾠmigration	 ﾠspeed	 ﾠmay	 ﾠbe	 ﾠattributed	 ﾠto	 ﾠthe	 ﾠstationary	 ﾠphases,	 ﾠwhich	 ﾠwe	 ﾠ
term	 ﾠ‘cellular	 ﾠresting’	 ﾠ(Figure	 ﾠ3-ﾭ‐9	 ﾠB).	 ﾠTo	 ﾠquantify	 ﾠthis	 ﾠwe	 ﾠdefined	 ﾠa	 ﾠcell	 ﾠthat	 ﾠmoved	 ﾠless	 ﾠ
than	 ﾠ2	 ﾠµm	 ﾠwithin	 ﾠ90	 ﾠminutes	 ﾠas	 ﾠone	 ﾠthat	 ﾠwas	 ﾠengaged	 ﾠin	 ﾠ‘cellular	 ﾠresting’.	 ﾠERK2	 ﾠ
knockdown	 ﾠor	 ﾠaddition	 ﾠof	 ﾠU0126	 ﾠmarkedly	 ﾠincreased	 ﾠthe	 ﾠproportion	 ﾠof	 ﾠcells	 ﾠthat	 ﾠwere	 ﾠ
resting,	 ﾠwhereas	 ﾠsiRNA	 ﾠof	 ﾠERK1	 ﾠwas	 ﾠineffective	 ﾠin	 ﾠthis	 ﾠregard	 ﾠ(Figure	 ﾠ3-ﾭ‐9	 ﾠC).	 ﾠMoreover,	 ﾠwe	 ﾠ
compared	 ﾠthe	 ﾠaverage	 ﾠduration	 ﾠof	 ﾠeach	 ﾠrest	 ﾠ(resting	 ﾠtime)	 ﾠand	 ﾠfound	 ﾠno	 ﾠsignificant	 ﾠ
difference	 ﾠamong	 ﾠour	 ﾠvarious	 ﾠexperimental	 ﾠconditions	 ﾠ(Figure	 ﾠ3-ﾭ‐9	 ﾠC).	 ﾠNext,	 ﾠwe	 ﾠ
determined	 ﾠwhether	 ﾠsilencing	 ﾠof	 ﾠERK2	 ﾠinfluenced	 ﾠcell	 ﾠmovement	 ﾠduring	 ﾠthe	 ﾠperiod	 ﾠin	 ﾠ
which	 ﾠcells	 ﾠwere	 ﾠnot	 ﾠresting.	 ﾠTo	 ﾠdo	 ﾠthis,	 ﾠwe	 ﾠcalculated	 ﾠframe-ﾭ‐to-ﾭ‐frame	 ﾠdisplacement	 ﾠof	 ﾠ
cells	 ﾠwhilst	 ﾠthey	 ﾠwere	 ﾠnot	 ﾠresting	 ﾠand	 ﾠtermed	 ﾠthe	 ﾠ‘momentary	 ﾠvelocity’.	 ﾠWe	 ﾠfound	 ﾠthe	 ﾠ
momentary	 ﾠvelocity	 ﾠto	 ﾠbe	 ﾠsignificantly	 ﾠreduced	 ﾠfollowing	 ﾠERK2	 ﾠknockdown	 ﾠor	 ﾠaddition	 ﾠof	 ﾠ
U0126,	 ﾠbut	 ﾠit	 ﾠwas	 ﾠunaffected	 ﾠby	 ﾠsiRNA	 ﾠof	 ﾠERK1	 ﾠ(Figure	 ﾠ3-ﾭ‐9	 ﾠB).	 ﾠTo	 ﾠrepresent	 ﾠthis	 ﾠpictorially,	 ﾠ
we	 ﾠgenerated	 ﾠtrackplots	 ﾠof	 ﾠcells	 ﾠin	 ﾠwhich	 ﾠthe	 ﾠmigration	 ﾠspeed	 ﾠis	 ﾠdenoted	 ﾠby	 ﾠa	 ﾠcolour	 ﾠ
code,	 ﾠthe	 ﾠscale	 ﾠof	 ﾠwhich	 ﾠis	 ﾠindicated	 ﾠon	 ﾠthe	 ﾠleft	 ﾠside	 ﾠof	 ﾠthe	 ﾠpanels,	 ﾠand	 ﾠthe	 ﾠpoints	 ﾠat	 ﾠwhich	 ﾠ
cells	 ﾠmoved	 ﾠless	 ﾠthan	 ﾠ2μm	 ﾠin	 ﾠ90	 ﾠmin	 ﾠ(cellular	 ﾠresting)	 ﾠare	 ﾠindicated	 ﾠby	 ﾠwhite	 ﾠdots.	 ﾠThese	 ﾠ
trackplots	 ﾠindicate	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠincreases	 ﾠcellular	 ﾠresting	 ﾠand	 ﾠdecreases	 ﾠ
momentary	 ﾠvelocity	 ﾠwhilst	 ﾠsiRNA	 ﾠof	 ﾠERK1	 ﾠis	 ﾠineffective	 ﾠin	 ﾠboth	 ﾠthese	 ﾠregards	 ﾠ(Figure	 ﾠ
3-ﾭ‐9	 ﾠD)	 ﾠ
Taken	 ﾠtogether	 ﾠthese	 ﾠdata	 ﾠindicate	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠdecreases	 ﾠcell	 ﾠinvasiveness,	 ﾠ
and	 ﾠthat	 ﾠthis	 ﾠcorresponds	 ﾠto	 ﾠa	 ﾠcombination	 ﾠof	 ﾠreduced	 ﾠmomentary	 ﾠvelocity	 ﾠand	 ﾠan	 ﾠ
increased	 ﾠtendency	 ﾠof	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠto	 ﾠremain	 ﾠimmobile	 ﾠor	 ﾠrest	 ﾠfor	 ﾠextended	 ﾠ
periods	 ﾠon	 ﾠCDM.	 ﾠ
   Chapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  122 
 
Figure 3-9	 ﾠKnockdown of ERK2 decreases the momentary velocity and increases cellular resting	 ﾠ
A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 and 
plated onto cell-derived matrix. Images were captured every 10 min over a 16 hrs period. Cell movement was 
followed using cell-tracking software.  
A. Schematic illustration on how the overall migration velocity can be affected by cellular resting and 
momentary velocity. 
B. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 
10-90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
C. Percentage of resting cells is displayed with absolute numbers for each condition above the column. The 
resting time was extracted from the trackplots and represents means ± SEM of thee independent experiments. 
D. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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3.2.6  ERK2 promotes invasion in the breast cancer cell line MDA-MB-231 
To	 ﾠassess	 ﾠwhether	 ﾠthe	 ﾠresults	 ﾠobtained	 ﾠwith	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwere	 ﾠmore	 ﾠgenerally	 ﾠ
applicable,	 ﾠwe	 ﾠdecided	 ﾠto	 ﾠrepeat	 ﾠthe	 ﾠinvasion	 ﾠand	 ﾠmigration	 ﾠassays	 ﾠin	 ﾠa	 ﾠsecond	 ﾠcell	 ﾠline	 ﾠ
and	 ﾠchose	 ﾠthe	 ﾠwell-ﾭ‐characterised	 ﾠmammary	 ﾠadenocarcinoma	 ﾠcells,	 ﾠMDA-ﾭ‐MB-ﾭ‐231,	 ﾠwhich	 ﾠ
were	 ﾠderived	 ﾠfrom	 ﾠa	 ﾠpleural	 ﾠeffusion.	 ﾠ
Having	 ﾠconfirmed	 ﾠan	 ﾠefficient	 ﾠand	 ﾠprolonged	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠwith	 ﾠtwo	 ﾠ
independent	 ﾠoligos	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ(Figure	 ﾠ3-ﾭ‐10	 ﾠA),	 ﾠwe	 ﾠthen	 ﾠperformed	 ﾠinverted	 ﾠ
invasion	 ﾠassays	 ﾠto	 ﾠtest	 ﾠthe	 ﾠrole	 ﾠof	 ﾠthese	 ﾠhomologous	 ﾠkinases	 ﾠin	 ﾠinvasive	 ﾠcell	 ﾠmigration.	 ﾠAs	 ﾠ
a	 ﾠnegative	 ﾠcontrol,	 ﾠwe	 ﾠinhibited	 ﾠERK	 ﾠactivation	 ﾠby	 ﾠtreating	 ﾠNT	 ﾠsiRNA-ﾭ‐transfected	 ﾠcells	 ﾠwith	 ﾠ
U0126.	 ﾠThis	 ﾠdrug	 ﾠprevents	 ﾠMEK	 ﾠactivation	 ﾠand	 ﾠblocks	 ﾠERK	 ﾠsignalling	 ﾠwithin	 ﾠ30	 ﾠminutes	 ﾠof	 ﾠ
application.	 ﾠIndeed,	 ﾠthe	 ﾠWestern	 ﾠblot	 ﾠin	 ﾠFigure	 ﾠ3-ﾭ‐10	 ﾠB	 ﾠshows	 ﾠa	 ﾠstrong	 ﾠinhibition	 ﾠof	 ﾠERK	 ﾠ
signalling	 ﾠeven	 ﾠafter	 ﾠ48	 ﾠhours	 ﾠof	 ﾠU0126	 ﾠtreatment	 ﾠand	 ﾠtherefore	 ﾠsuggests	 ﾠan	 ﾠefficient	 ﾠ
impediment	 ﾠin	 ﾠERK	 ﾠactivation	 ﾠduring	 ﾠthe	 ﾠassay.	 ﾠWe	 ﾠanalysed	 ﾠthe	 ﾠrelative	 ﾠcontribution	 ﾠof	 ﾠ
ERK1	 ﾠand	 ﾠERK2	 ﾠduring	 ﾠinvasive	 ﾠcell	 ﾠmigration	 ﾠusing	 ﾠinverted	 ﾠinvasion	 ﾠassays.	 ﾠERK1	 ﾠ
knockdown	 ﾠwith	 ﾠeither	 ﾠoligo	 ﾠhad	 ﾠno	 ﾠsignificant	 ﾠeffect	 ﾠon	 ﾠinvasive	 ﾠmigration	 ﾠinto	 ﾠ
fibronectin-ﾭ‐containing	 ﾠMatrigel,	 ﾠwhereas	 ﾠinvasion	 ﾠwas	 ﾠclearly	 ﾠreduced	 ﾠby	 ﾠapproximately	 ﾠ
50%	 ﾠwhen	 ﾠERK2	 ﾠwas	 ﾠsilenced	 ﾠ(Figure	 ﾠ3-ﾭ‐10	 ﾠC/D).	 ﾠMoreover,	 ﾠin	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠU0126	 ﾠ
invasive	 ﾠmigration	 ﾠinto	 ﾠthe	 ﾠMatrigel	 ﾠplug	 ﾠwas	 ﾠsignificantly	 ﾠimpaired	 ﾠ(p<0.0001)	 ﾠwhen	 ﾠ
compared	 ﾠto	 ﾠcontrol.	 ﾠThus,	 ﾠlike	 ﾠA2780-ﾭ‐Rab25,	 ﾠthe	 ﾠinvasive	 ﾠphenotype	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠ
cells	 ﾠrequires	 ﾠactive	 ﾠERK2,	 ﾠbut	 ﾠnot	 ﾠERK1,	 ﾠsignalling.	 ﾠ	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Figure 3-10 ERK2 opposes invasion in MDA-MB-231 cells 
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2. 
The effectiveness of the ERK knockdown was assessed by Western blot 48 hrs after transfection.  
B. ERK inhibition by U0126 (10 µM) was assessed by Western blotting 48 hrs after treatment. 
C. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto plugs of Matrigel supplemented with fibronectin. The MEK inhibitor, U0126 (10µM) was 
included as indicated. 36 hrs following this, invading cells were visualized by Calcein-AM staining. Serial 
optical sections were captured every 15 µm and are presented as a sequence in which the depth increases 
from left to right.  
D. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.7  Transient ERK silencing in MDA-MB-231 cells has no effect on 
apoptosis or proliferation 
As	 ﾠimpaired	 ﾠcell	 ﾠviability	 ﾠmay	 ﾠadversely	 ﾠaffect	 ﾠcellular	 ﾠinvasion	 ﾠand	 ﾠmigration,	 ﾠwe	 ﾠ
investigated,	 ﾠwhether	 ﾠERK	 ﾠknockdown	 ﾠinfluenced	 ﾠapoptosis	 ﾠand	 ﾠcellular	 ﾠgrowth	 ﾠin	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells.	 ﾠTo	 ﾠthis	 ﾠend	 ﾠwe	 ﾠtransiently	 ﾠtransfected	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠwith	 ﾠNT	 ﾠ
siRNA	 ﾠor	 ﾠoligos	 ﾠtargeting	 ﾠERK1	 ﾠand	 ﾠERK2.	 ﾠAs	 ﾠa	 ﾠpositive	 ﾠcontrol,	 ﾠwe	 ﾠinduced	 ﾠthe	 ﾠextrinsic	 ﾠ
apoptotic	 ﾠpathway	 ﾠthrough	 ﾠtreatment	 ﾠwith	 ﾠthe	 ﾠFas-ﾭ‐ligand	 ﾠ(50	 ﾠ	 ﾠnM)	 ﾠand	 ﾠ5	 ﾠµg/ml	 ﾠ
cycloheximide	 ﾠfor	 ﾠ24	 ﾠhours.	 ﾠSimilar	 ﾠto	 ﾠA2780-ﾭ‐Rab25	 ﾠcells,	 ﾠinduction	 ﾠof	 ﾠthe	 ﾠcell	 ﾠdeath	 ﾠ
pathway	 ﾠinduced	 ﾠcell	 ﾠrounding,	 ﾠdetachment	 ﾠand	 ﾠfragmentation,	 ﾠwhich	 ﾠwas	 ﾠvisible	 ﾠwith	 ﾠ
the	 ﾠhelp	 ﾠof	 ﾠa	 ﾠphase-ﾭ‐contrast	 ﾠlight	 ﾠmicroscope.	 ﾠWhen	 ﾠwe	 ﾠassessed	 ﾠPARP-ﾭ‐1	 ﾠcleavage	 ﾠby	 ﾠ
Western	 ﾠblotting,	 ﾠwe	 ﾠdetected	 ﾠan	 ﾠintense	 ﾠband	 ﾠof	 ﾠthe	 ﾠ89	 ﾠkDa	 ﾠfragment	 ﾠin	 ﾠFas-ﾭ‐induced	 ﾠ
cells,	 ﾠwhereas	 ﾠfull-ﾭ‐length	 ﾠPARP-ﾭ‐1	 ﾠwas	 ﾠhardly	 ﾠvisible.	 ﾠIn	 ﾠcontrast,	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ
transfected	 ﾠwith	 ﾠNT	 ﾠsiRNA	 ﾠor	 ﾠoligos	 ﾠtargeting	 ﾠERK1	 ﾠand	 ﾠERK2,	 ﾠpredominantly	 ﾠexhibit	 ﾠthe	 ﾠ
uncleaved	 ﾠPARP-ﾭ‐1	 ﾠprotein	 ﾠwith	 ﾠa	 ﾠvery	 ﾠfaint	 ﾠband	 ﾠfor	 ﾠthe	 ﾠ89	 ﾠkDa	 ﾠfragment	 ﾠ(Figure	 ﾠ3-ﾭ‐11	 ﾠA).	 ﾠ
Although	 ﾠthe	 ﾠ89	 ﾠkDa	 ﾠfragment	 ﾠband	 ﾠis	 ﾠmore	 ﾠintense	 ﾠin	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠwhen	 ﾠ
compared	 ﾠto	 ﾠthe	 ﾠNT	 ﾠsiRNA	 ﾠcontrol,	 ﾠwe	 ﾠconclude	 ﾠthat	 ﾠcell	 ﾠviability	 ﾠis	 ﾠlargely	 ﾠunaffected	 ﾠand	 ﾠ
therefore	 ﾠdoes	 ﾠnot	 ﾠaccount	 ﾠfor	 ﾠthe	 ﾠdifferences	 ﾠseen	 ﾠin	 ﾠthe	 ﾠinverted	 ﾠinvasion	 ﾠassays.	 ﾠ	 ﾠ
Next,	 ﾠwe	 ﾠexamined	 ﾠhow	 ﾠERK	 ﾠknockdown	 ﾠaffected	 ﾠcellular	 ﾠgrowth	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells.	 ﾠ
To	 ﾠthis	 ﾠend,	 ﾠwe	 ﾠtransfected	 ﾠcells	 ﾠwith	 ﾠNT	 ﾠsiRNA,	 ﾠor	 ﾠthose	 ﾠtargeting	 ﾠERK1,	 ﾠor	 ﾠERK2	 ﾠand	 ﾠ
seeded	 ﾠ40,000	 ﾠcells	 ﾠinto	 ﾠa	 ﾠ6-ﾭ‐well	 ﾠdish	 ﾠone	 ﾠday	 ﾠafter	 ﾠtransfection.	 ﾠAs	 ﾠa	 ﾠnegative	 ﾠcontrol,	 ﾠNT	 ﾠ
siRNA-ﾭ‐transfected	 ﾠcells	 ﾠwere	 ﾠtreated	 ﾠwith	 ﾠU0126.	 ﾠAs	 ﾠexpected,	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠ
proliferative	 ﾠinhibition	 ﾠtwo	 ﾠdays	 ﾠafter	 ﾠU0126	 ﾠtreatment	 ﾠ(Figure	 ﾠ3-ﾭ‐11	 ﾠB).	 ﾠIn	 ﾠcontrast,	 ﾠ
transient	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠdid	 ﾠnot	 ﾠaffect	 ﾠcellular	 ﾠgrowth	 ﾠ(Figure	 ﾠ3-ﾭ‐11	 ﾠB),	 ﾠ
even	 ﾠthough	 ﾠan	 ﾠefficient	 ﾠknockdown	 ﾠwas	 ﾠachieved	 ﾠduring	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠthe	 ﾠexperiment	 ﾠas	 ﾠ
was	 ﾠdetermined	 ﾠby	 ﾠWestern	 ﾠblotting	 ﾠ(Figure	 ﾠ3-ﾭ‐11	 ﾠC).	 ﾠIt	 ﾠis	 ﾠworth	 ﾠpointing	 ﾠout,	 ﾠthat	 ﾠERK1	 ﾠ
activation	 ﾠincreased	 ﾠin	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠERK2	 ﾠand	 ﾠresulted	 ﾠin	 ﾠa	 ﾠcompensatory	 ﾠup-ﾭ‐regulation	 ﾠ
of	 ﾠpERK1.	 ﾠThus,	 ﾠthe	 ﾠtotal	 ﾠamount	 ﾠof	 ﾠactive	 ﾠERK	 ﾠhardly	 ﾠchanges,	 ﾠwhen	 ﾠthe	 ﾠpredominant	 ﾠ
kinase	 ﾠERK2	 ﾠis	 ﾠsilenced.	 ﾠ
To	 ﾠconclude,	 ﾠour	 ﾠ3D	 ﾠmigration	 ﾠexperiments	 ﾠare	 ﾠnot	 ﾠimpaired	 ﾠdue	 ﾠto	 ﾠchanges	 ﾠin	 ﾠcellular	 ﾠ
viability,	 ﾠindicating	 ﾠthat	 ﾠtrue	 ﾠmigratory	 ﾠdefects	 ﾠexist	 ﾠwhen	 ﾠERK2	 ﾠis	 ﾠsilenced.	 ﾠChapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  126 
 
Figure 3-11	 ﾠsiRNA of ERK1 or ERK2 does not induce apoptosis or inhibit proliferation	 ﾠ
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2.  
A. Apoptosis was induced in control transfected cells by Fas-ligand (50nM) and cycloheximide (5µg/ml) 
treatment. PARP-cleavage was determined 24 hours after induction by Western blot. 
B. The proliferation assay was set up 24 hrs after transfection by seeding 40,000 cells into a 6-well dish. The 
following 4 days, cells were counted using a Casy counter. Relative cell number was plotted against time. 
Values are means ± standard error of the mean (SEM) of 9 replicates from three independent experiments.
 
C. The effectiveness of the ERK knockdown was assessed over the course of 4 days by Western blot. 
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3.2.8  Migration of MDA-MB-231 cells on plastic surfaces is impaired 
following knockdown of ERK2  
In	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠwe	 ﾠdemonstrated	 ﾠthat	 ﾠsilencing	 ﾠof	 ﾠERK2	 ﾠimpairs	 ﾠinvasion	 ﾠinto	 ﾠ
Matrigel	 ﾠplugs	 ﾠand	 ﾠmigration	 ﾠon	 ﾠcell-ﾭ‐derived	 ﾠmatrix.	 ﾠThis	 ﾠphenomenon,	 ﾠhowever,	 ﾠwas	 ﾠnot	 ﾠ
mirrored	 ﾠin	 ﾠ2D	 ﾠwound	 ﾠhealing	 ﾠassays,	 ﾠwhere	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠcontributed	 ﾠto	 ﾠwound	 ﾠ
closure.	 ﾠHaving	 ﾠobserved	 ﾠthis	 ﾠdiscrepancy	 ﾠbetween	 ﾠ2D	 ﾠand	 ﾠ3D	 ﾠmigration	 ﾠin	 ﾠA2780-ﾭ‐Rab25	 ﾠ
cells,	 ﾠwe	 ﾠset	 ﾠout	 ﾠto	 ﾠinvestigate,	 ﾠhow	 ﾠknockdown	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠaffects	 ﾠmigration	 ﾠon	 ﾠ2D	 ﾠ
surfaces	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells.	 ﾠTo	 ﾠtest	 ﾠthis,	 ﾠwe	 ﾠtransiently	 ﾠknocked	 ﾠdown	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠ
ERK2	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠsiRNA	 ﾠoligos	 ﾠfor	 ﾠeach	 ﾠisoform	 ﾠand	 ﾠplated	 ﾠcells,	 ﾠso	 ﾠthat	 ﾠthey	 ﾠ
were	 ﾠconfluent	 ﾠ48	 ﾠhours	 ﾠpost	 ﾠtransfection.	 ﾠAs	 ﾠa	 ﾠnegative	 ﾠcontrol,	 ﾠwe	 ﾠopposed	 ﾠERK	 ﾠ
signalling	 ﾠby	 ﾠblocking	 ﾠMEK	 ﾠactivation	 ﾠwith	 ﾠU0126	 ﾠ(10	 ﾠµM).	 ﾠAfter	 ﾠintroducing	 ﾠa	 ﾠwound	 ﾠby	 ﾠ
scratching	 ﾠthe	 ﾠplastic	 ﾠdish	 ﾠwith	 ﾠa	 ﾠ200	 ﾠµl	 ﾠpipette	 ﾠtip,	 ﾠwound	 ﾠclosure	 ﾠwas	 ﾠmonitored	 ﾠat	 ﾠ10	 ﾠ
minute	 ﾠintervals	 ﾠusing	 ﾠa	 ﾠtime-ﾭ‐lapse	 ﾠmicroscope.	 ﾠWe	 ﾠfound	 ﾠthat	 ﾠU0126	 ﾠtreatment	 ﾠand	 ﾠ
knockdown	 ﾠof	 ﾠERK2	 ﾠdelayed	 ﾠwound	 ﾠclosure.	 ﾠUsing	 ﾠthe	 ﾠmanual	 ﾠtracking	 ﾠplugin	 ﾠin	 ﾠImageJ,	 ﾠ
we	 ﾠfollowed	 ﾠindividual	 ﾠcells	 ﾠand	 ﾠextracted	 ﾠthe	 ﾠmigration	 ﾠvelocity,	 ﾠpersistence	 ﾠand	 ﾠforward	 ﾠ
migration	 ﾠindex	 ﾠ(FMI)	 ﾠfrom	 ﾠthe	 ﾠtrackplots.	 ﾠAnalysis	 ﾠof	 ﾠU0126-ﾭ‐treated	 ﾠcells	 ﾠshowed	 ﾠa	 ﾠ
significant	 ﾠdecrease	 ﾠin	 ﾠthe	 ﾠmigration	 ﾠspeed	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠNT	 ﾠsiRNA-ﾭ‐transfected	 ﾠcells	 ﾠ
(p<0.0001)	 ﾠ(Figure	 ﾠ3-ﾭ‐12	 ﾠB),	 ﾠwhile	 ﾠpersistence	 ﾠand	 ﾠthe	 ﾠFMI	 ﾠwere	 ﾠunaffected	 ﾠ(Figure	 ﾠ
3-ﾭ‐12	 ﾠC/D).	 ﾠLikewise,	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠsignificantly	 ﾠ
diminished	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠ(p<0.0001),	 ﾠwhile	 ﾠpersistence	 ﾠand	 ﾠFMI	 ﾠwere	 ﾠnot	 ﾠ
altered.	 ﾠIn	 ﾠcontrast,	 ﾠall	 ﾠof	 ﾠthese	 ﾠindices	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠwere	 ﾠunaffected,	 ﾠwhen	 ﾠERK1	 ﾠwas	 ﾠ
silenced.	 ﾠChapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  128 
 
Figure 3-12 ERK2 silencing inhibits migration of MDA-MB-231 cells on plastic 
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2. Subsequently, cells were seeded into a 6-well dish, so that they were confluent 48 hrs post 
transfection. After scratching, wound closure was monitored and representative time frames are shown. Scale 
bar, 100 µm.  
B-D. The movement of individual cells was followed using ImageJ cell tracking software. The overall 
migration velocity (C), persistence (D) and forward migration index (FMI) (E) were extracted from the 
trackplots. Values are means ± SEM of >75 trackplots from three independent experiments. Statistical 
significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.9  Silencing of ERK2 impairs migration on CDM in MDA-MB-231 cells 
We	 ﾠset	 ﾠout	 ﾠto	 ﾠinvestigate	 ﾠthe	 ﾠrespective	 ﾠroles	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcell	 ﾠ
migration,	 ﾠwhen	 ﾠplated	 ﾠonto	 ﾠCDM.	 ﾠTo	 ﾠdo	 ﾠthis,	 ﾠwe	 ﾠtransiently	 ﾠknocked	 ﾠdown	 ﾠeither	 ﾠERK1	 ﾠ
or	 ﾠERK2	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠfor	 ﾠeach	 ﾠisoform	 ﾠand	 ﾠseeded	 ﾠ100,000	 ﾠcells	 ﾠonto	 ﾠ
CDM-ﾭ‐coated	 ﾠ6-ﾭ‐well	 ﾠdishes,	 ﾠwhere	 ﾠcell	 ﾠmotility	 ﾠwas	 ﾠmonitored	 ﾠin	 ﾠfive-ﾭ‐minute	 ﾠintervals	 ﾠ
using	 ﾠa	 ﾠtime-ﾭ‐lapse	 ﾠmicroscope.	 ﾠIn	 ﾠgeneral,	 ﾠit	 ﾠis	 ﾠworth	 ﾠmentioning	 ﾠthat	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ
are	 ﾠsmaller	 ﾠthan	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠand	 ﾠadopt	 ﾠa	 ﾠspindle-ﾭ‐like	 ﾠshape	 ﾠwith	 ﾠsmall	 ﾠ
pseudopods,	 ﾠwhile	 ﾠmigrating	 ﾠon	 ﾠCDM.	 ﾠ	 ﾠ
When	 ﾠERK	 ﾠsignalling	 ﾠwas	 ﾠimpaired	 ﾠby	 ﾠmeans	 ﾠof	 ﾠU0126	 ﾠtreatment	 ﾠor	 ﾠknockdown	 ﾠof	 ﾠERK,	 ﾠ
we	 ﾠobserved	 ﾠno	 ﾠmorphological	 ﾠchanges	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠcontrol-ﾭ‐transfected	 ﾠcells	 ﾠ
(Figure	 ﾠ3-ﾭ‐13	 ﾠA).	 ﾠHowever,	 ﾠthe	 ﾠoverall	 ﾠmigration	 ﾠvelocity	 ﾠwas	 ﾠsignificantly	 ﾠdecreased,	 ﾠwhen	 ﾠ
MEK	 ﾠactivation	 ﾠwas	 ﾠinhibited	 ﾠor	 ﾠERK2	 ﾠwas	 ﾠsilenced	 ﾠwith	 ﾠeither	 ﾠoligo	 ﾠ#1	 ﾠor	 ﾠ#2	 ﾠ(p<0.0001).	 ﾠ
On	 ﾠthe	 ﾠother	 ﾠhand,	 ﾠsilencing	 ﾠof	 ﾠERK1	 ﾠhad	 ﾠno	 ﾠeffect	 ﾠon	 ﾠthe	 ﾠoverall	 ﾠmigratory	 ﾠspeed	 ﾠ(Figure	 ﾠ
3-ﾭ‐13	 ﾠB).	 ﾠMoreover,	 ﾠthe	 ﾠpersistence	 ﾠof	 ﾠmigration	 ﾠwas	 ﾠnot	 ﾠsignificantly	 ﾠaffected	 ﾠby	 ﾠ
knockdown	 ﾠof	 ﾠeither	 ﾠERK	 ﾠor	 ﾠby	 ﾠaddition	 ﾠof	 ﾠU0126	 ﾠ(Figure	 ﾠ3-ﾭ‐13	 ﾠC).	 ﾠ	 ﾠ
During	 ﾠour	 ﾠcell	 ﾠtracking	 ﾠanalysis,	 ﾠit	 ﾠwas	 ﾠapparent	 ﾠthat	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠsilenced	 ﾠfor	 ﾠ
ERK2,	 ﾠlike	 ﾠA2780-ﾭ‐Rab25,	 ﾠhad	 ﾠa	 ﾠtendency	 ﾠto	 ﾠremain	 ﾠstationary	 ﾠfor	 ﾠextended	 ﾠperiods	 ﾠof	 ﾠ
time.	 ﾠThus,	 ﾠwe	 ﾠquantified	 ﾠthe	 ﾠmomentary	 ﾠvelocity	 ﾠand	 ﾠcellular	 ﾠresting,	 ﾠas	 ﾠdefined	 ﾠfor	 ﾠ
A2780-ﾭ‐Rab25	 ﾠcells,	 ﾠand	 ﾠfound	 ﾠa	 ﾠreduced	 ﾠmomentary	 ﾠvelocity	 ﾠand	 ﾠincreased	 ﾠcellular	 ﾠ
resting	 ﾠwhen	 ﾠcells	 ﾠwere	 ﾠtreated	 ﾠwith	 ﾠU0126	 ﾠor	 ﾠsilenced	 ﾠfor	 ﾠERK2.	 ﾠIn	 ﾠcontrast,	 ﾠERK1	 ﾠ
knockdown	 ﾠcells	 ﾠexhibited	 ﾠsimilar	 ﾠmomentary	 ﾠvelocities	 ﾠand	 ﾠresting	 ﾠincidences	 ﾠwhen	 ﾠ
compared	 ﾠto	 ﾠcontrol	 ﾠ(Figure	 ﾠ3-ﾭ‐14	 ﾠA-ﾭ‐C).	 ﾠBecause	 ﾠonly	 ﾠthree	 ﾠresting	 ﾠincidences	 ﾠoccurred	 ﾠin	 ﾠ
control-ﾭ‐transfected	 ﾠcells,	 ﾠwe	 ﾠwere	 ﾠunable	 ﾠto	 ﾠcarry	 ﾠout	 ﾠa	 ﾠmeaningful	 ﾠstatistical	 ﾠcomparison	 ﾠ
of	 ﾠresting	 ﾠtimes	 ﾠbetween	 ﾠour	 ﾠexperimental	 ﾠconditions.	 ﾠThus,	 ﾠthe	 ﾠright	 ﾠpanel	 ﾠof	 ﾠFigure	 ﾠ
3-ﾭ‐14	 ﾠB	 ﾠmay	 ﾠonly	 ﾠbe	 ﾠinterpreted	 ﾠas	 ﾠa	 ﾠrange	 ﾠof	 ﾠresting	 ﾠtimes,	 ﾠfrom	 ﾠwhich	 ﾠno	 ﾠconclusions	 ﾠ
about	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠstationary	 ﾠperiods	 ﾠcan	 ﾠbe	 ﾠdeduced.	 ﾠ	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Figure 3-13 siRNA of ERK2 reduces migration of MDA-MB-231 cells on CDM	 ﾠ
A.MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto cell-derived matrix. Images were captured every 5 minutes over a 16 hrs period using a 
Nikon time-lapse microscope. Still images from a representative movie are displayed. Scale bar, 100 µm. 
B-C. The movement of individual cells was followed using the ImageJ cell tracking software. The overall 
migration velocity (B) and persistence (C) were extracted from the trackplots. Values are means ± SEM of 
>75 trackplots from three independent experiments. Statistical significance of differences was determined by 
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Figure 3-14	 ﾠKnockdown of ERK2 decreases the momentary velocity and increases cellular resting	 ﾠ
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto cell-derived matrix. Images were captured every 10 min over a 16 hrs period. Cell movement 
was followed using cell-tracking software.  
A. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 
10-90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
B. Percentage of resting cells is displayed with absolute numbers for each condition above the column. The 
resting time was extracted from the trackplots and represents means ± SEM of thee independent experiments. 
C. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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3.2.10   Expression of recombinant ERK2 (but not ERK1) restores the 
migratory characteristics of MDA-MB-231 cells after ERK2 
knockdown 
Although	 ﾠour	 ﾠdata	 ﾠobtained	 ﾠin	 ﾠA2780-ﾭ‐Rab25	 ﾠand	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠstrongly	 ﾠsuggests	 ﾠan	 ﾠ
ERK2-ﾭ‐specific	 ﾠfunction	 ﾠin	 ﾠinvasive	 ﾠcell	 ﾠmigration,	 ﾠour	 ﾠexperimental	 ﾠdesign	 ﾠdoes	 ﾠnot	 ﾠ
consider	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠERK2	 ﾠis	 ﾠmuch	 ﾠmore	 ﾠabundant	 ﾠthan	 ﾠERK1	 ﾠin	 ﾠthese	 ﾠcells.	 ﾠTherefore,	 ﾠ
observations	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠaffects	 ﾠinvasion	 ﾠ(whereas	 ﾠsiRNA	 ﾠof	 ﾠERK1	 ﾠdoes	 ﾠnot)	 ﾠ
do	 ﾠnot	 ﾠnecessarily	 ﾠreflect	 ﾠfunctional	 ﾠdifferences	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠkinases,	 ﾠbut	 ﾠmay	 ﾠbe	 ﾠ
attributable	 ﾠto	 ﾠdifferences	 ﾠin	 ﾠtheir	 ﾠexpression	 ﾠlevel	 ﾠas	 ﾠdemonstrated	 ﾠby	 ﾠLefloch	 ﾠand	 ﾠ
colleagues	 ﾠ[357].	 ﾠTo	 ﾠaddress	 ﾠthis,	 ﾠwe	 ﾠcloned	 ﾠexpression	 ﾠplasmids	 ﾠof	 ﾠboth	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠ
and	 ﾠtagged	 ﾠthe	 ﾠkinases	 ﾠN-ﾭ‐terminally	 ﾠwith	 ﾠa	 ﾠStreptavidin-ﾭ‐Flag	 ﾠ(SF)	 ﾠtag	 ﾠ(Figure	 ﾠ3-ﾭ‐15)	 ﾠ[390].	 ﾠ
Using	 ﾠthese	 ﾠconstructs,	 ﾠwe	 ﾠwere	 ﾠable	 ﾠto	 ﾠexpress	 ﾠrecombinant	 ﾠERK1	 ﾠor	 ﾠsiRNA-ﾭ‐resistant	 ﾠ
ERK2	 ﾠto	 ﾠequal	 ﾠlevels	 ﾠafter	 ﾠknocking	 ﾠdown	 ﾠERK2	 ﾠwith	 ﾠoligo	 ﾠ#2.	 ﾠThe	 ﾠectopically-ﾭ‐expressed	 ﾠ
ERK1	 ﾠand	 ﾠERK2	 ﾠisoforms	 ﾠwere	 ﾠphosphorylated	 ﾠat	 ﾠthe	 ﾠThr-ﾭ‐Glu-ﾭ‐Tyr	 ﾠmotif	 ﾠto	 ﾠthe	 ﾠsame	 ﾠextent	 ﾠ
as	 ﾠone	 ﾠanother,	 ﾠindicating	 ﾠthat	 ﾠboth	 ﾠof	 ﾠthese	 ﾠrecombinant	 ﾠERKs	 ﾠwere	 ﾠequally	 ﾠactivated	 ﾠby	 ﾠ
MEK	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ(Figure	 ﾠ3-ﾭ‐16	 ﾠA).	 ﾠMoreover,	 ﾠthe	 ﾠpool	 ﾠof	 ﾠactivated	 ﾠERK	 ﾠwas	 ﾠ
comparable	 ﾠbetween	 ﾠall	 ﾠconditions	 ﾠdespite	 ﾠopposite	 ﾠratios	 ﾠof	 ﾠactivated	 ﾠERK1	 ﾠand	 ﾠERK2,	 ﾠ
thus	 ﾠallowing	 ﾠus	 ﾠto	 ﾠtest	 ﾠwhether	 ﾠthere	 ﾠis	 ﾠa	 ﾠtrue	 ﾠfunctional	 ﾠdifference	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠ
isoforms	 ﾠin	 ﾠcell	 ﾠmigration.	 ﾠ
Next,	 ﾠwe	 ﾠmonitored	 ﾠinvasive	 ﾠcell	 ﾠmigration	 ﾠby	 ﾠmeans	 ﾠof	 ﾠinverted	 ﾠinvasion	 ﾠassays	 ﾠand	 ﾠ
studied	 ﾠcell	 ﾠmovement	 ﾠon	 ﾠCDM	 ﾠusing	 ﾠthe	 ﾠsiRNA-ﾭ‐rescue	 ﾠparadigm.	 ﾠWe	 ﾠfound	 ﾠthat	 ﾠectopic	 ﾠ
expression	 ﾠof	 ﾠERK1	 ﾠdid	 ﾠnot	 ﾠreverse	 ﾠthe	 ﾠinhibitory	 ﾠeffect	 ﾠof	 ﾠERK2	 ﾠknockdown	 ﾠon	 ﾠinvasion,	 ﾠ
whereas	 ﾠsiRNA-ﾭ‐resistant	 ﾠERK2	 ﾠexpression	 ﾠcompletely	 ﾠrescued	 ﾠthe	 ﾠinvasive	 ﾠphenotype	 ﾠof	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ(Figure	 ﾠ3-ﾭ‐16	 ﾠB/C).	 ﾠMoreover,	 ﾠwhen	 ﾠcell	 ﾠmigration	 ﾠon	 ﾠCDM	 ﾠwas	 ﾠ
analysed,	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠsiRNA-ﾭ‐resistant	 ﾠERK2	 ﾠincreased	 ﾠthe	 ﾠmomentary	 ﾠvelocity	 ﾠand	 ﾠ
reduced	 ﾠthe	 ﾠtendency	 ﾠof	 ﾠcells	 ﾠto	 ﾠpause	 ﾠ(cellular	 ﾠresting)	 ﾠrelative	 ﾠto	 ﾠthat	 ﾠof	 ﾠcontrol	 ﾠcells,	 ﾠ
whereas	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK1	 ﾠdid	 ﾠnot	 ﾠrescue	 ﾠthe	 ﾠmigratory	 ﾠdefects	 ﾠof	 ﾠERK2	 ﾠknockdown	 ﾠ
cells	 ﾠ(Figure	 ﾠ3-ﾭ‐17).	 ﾠ	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Figure 3-15 ERK expression vectors	 ﾠ
ERK1 (NM_002746) and ERK2 (NM_002745) genes were amplified from a cDNA library using primers 
with an attB1 and attB2 site and cloned into the N-terminal SF-TAP destination vector [390] via homologous 
recombination, giving rise to N-terminal SF-ERK1 (A) and N-terminal SF-ERK2 
C. Amino acid sequence of the SF-TAP tag is displayed. Residues marking the streptavidin (S) tag are 
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 ﾠ
Figure 3-16 Ectopic expression of ERK2 but not ERK1 restores invasion of ERK2 knockdown cells  
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNA targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV). Cells were 
harvested two days after transfection and ERK expression levels were determined by western blotting.  
B. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNA targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV). Cells were 
plated onto plugs of fibronectin-supplemented Matrigel. 36 hrs following this, invading cells were visualized 
by Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented as a sequence 
in which the depth increases from left to right.  
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
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Figure 3-17 Ectopic expression of ERK2 but not ERK1 restores invasion of ERK2 knockdown cells  
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNA targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV). Cells were 
plated onto cell-derived matrix. Images were captured every 10 min over a 16 hrs period. Cell movement was 
followed using cell-tracking software.  
A. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 
10-90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
B. Percentage of resting cells is displayed with absolute numbers for each condition above the column. The 
resting time was extracted from the trackplots and represents means ± SEM of thee independent experiments. 
C. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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3.3  Discussion 
3.3.1  Summary 
Although	 ﾠsome	 ﾠresearch	 ﾠscientists	 ﾠbelieve	 ﾠthat	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠare	 ﾠfunctionally	 ﾠredundant	 ﾠ
and	 ﾠinterchangeable,	 ﾠour	 ﾠdata	 ﾠsupports	 ﾠthe	 ﾠview	 ﾠthat	 ﾠthese	 ﾠtwo	 ﾠkinases	 ﾠhave	 ﾠdifferent	 ﾠ
roles	 ﾠin	 ﾠcell	 ﾠmigration.	 ﾠIndeed,	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1	 ﾠknockdown	 ﾠsignificantly	 ﾠinhibits	 ﾠ
invasive	 ﾠcell	 ﾠmigration	 ﾠof	 ﾠtwo	 ﾠindependent	 ﾠcancer	 ﾠcell	 ﾠlines.	 ﾠMoreover,	 ﾠa	 ﾠdetailed	 ﾠ
quantitative	 ﾠanalysis	 ﾠof	 ﾠcell	 ﾠmovement	 ﾠon	 ﾠ3D	 ﾠmatrices	 ﾠindicates	 ﾠthat	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠ
knockdown	 ﾠimpairs	 ﾠcellular	 ﾠmotility	 ﾠby	 ﾠdecreasing	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠas	 ﾠwell	 ﾠas	 ﾠ
increasing	 ﾠthe	 ﾠtime	 ﾠthat	 ﾠcells	 ﾠremain	 ﾠstationary.	 ﾠFurthermore,	 ﾠwe	 ﾠshow	 ﾠthat	 ﾠall	 ﾠthese	 ﾠ
migratory	 ﾠdefects	 ﾠcan	 ﾠbe	 ﾠrescued	 ﾠby	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1.	 ﾠTaken	 ﾠtogether,	 ﾠ
our	 ﾠdata	 ﾠprovides	 ﾠevidence	 ﾠthat	 ﾠERK2	 ﾠis	 ﾠparticularly	 ﾠimportant	 ﾠin	 ﾠthe	 ﾠinvasiveness	 ﾠof	 ﾠ
cancer	 ﾠcells	 ﾠand	 ﾠthat	 ﾠtrue	 ﾠfunctional	 ﾠdisparities	 ﾠbetween	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠexist	 ﾠwith	 ﾠregard	 ﾠ
to	 ﾠcell	 ﾠmigration.	 ﾠ
3.3.2  Discrepancy between migration in 2D and 3D in A2780-Rab25 cells 
In	 ﾠ2001,	 ﾠit	 ﾠwas	 ﾠshown	 ﾠthat	 ﾠinhibition	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠwith	 ﾠU0126	 ﾠclearly	 ﾠcompromised	 ﾠ
cell	 ﾠmotility	 ﾠof	 ﾠA375	 ﾠmelanoma	 ﾠcells	 ﾠin	 ﾠinvasion	 ﾠassays	 ﾠ[391].	 ﾠMoreover,	 ﾠBessard	 ﾠand	 ﾠ
colleagues	 ﾠhave	 ﾠcarried	 ﾠout	 ﾠwound	 ﾠhealing	 ﾠassays	 ﾠwith	 ﾠhepatocarcinoma	 ﾠcells	 ﾠand	 ﾠ
showed	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠcompromised	 ﾠmotility	 ﾠin	 ﾠ2D	 ﾠ[379].	 ﾠIn	 ﾠour	 ﾠ
studies,	 ﾠwe	 ﾠhave	 ﾠshown	 ﾠthat	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠrely	 ﾠon	 ﾠboth	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠsignalling	 ﾠ
during	 ﾠscratch	 ﾠwound	 ﾠassays,	 ﾠwhile	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠsilencing	 ﾠof	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1	 ﾠ
decreased	 ﾠwound	 ﾠclosure.	 ﾠIn	 ﾠ3D	 ﾠexperiments,	 ﾠhowever,	 ﾠERK2	 ﾠwas	 ﾠthe	 ﾠmain	 ﾠdriver	 ﾠof	 ﾠcell	 ﾠ
migration	 ﾠin	 ﾠboth	 ﾠcell	 ﾠlines.	 ﾠWhat	 ﾠmay	 ﾠaccount	 ﾠfor	 ﾠthe	 ﾠdifferences	 ﾠin	 ﾠ2D	 ﾠand	 ﾠ3D	 ﾠ
migration?	 ﾠFirstly,	 ﾠwound	 ﾠscratch	 ﾠassays	 ﾠexamine	 ﾠthe	 ﾠability	 ﾠof	 ﾠa	 ﾠcell	 ﾠculture	 ﾠto	 ﾠrecolonize	 ﾠ
the	 ﾠwound,	 ﾠwhich	 ﾠis	 ﾠdependent	 ﾠon	 ﾠboth	 ﾠmigration	 ﾠand	 ﾠcellular	 ﾠgrowth.	 ﾠAlthough	 ﾠthis	 ﾠ
method	 ﾠis	 ﾠwell	 ﾠadapted	 ﾠfor	 ﾠstudying	 ﾠtissue	 ﾠinjury,	 ﾠit	 ﾠhas	 ﾠlimitations	 ﾠwhen	 ﾠassessing	 ﾠ
tumour	 ﾠcell	 ﾠmotility.	 ﾠFirstly,	 ﾠtumour	 ﾠcells	 ﾠare	 ﾠasked	 ﾠto	 ﾠmigrate	 ﾠacross	 ﾠa	 ﾠrigid	 ﾠand	 ﾠplanar	 ﾠ
substrate,	 ﾠwhich	 ﾠhardly	 ﾠresembles	 ﾠan	 ﾠin	 ﾠvivo	 ﾠsituation,	 ﾠwhere	 ﾠcancer	 ﾠcells	 ﾠmigrate	 ﾠinto	 ﾠthe	 ﾠ
extracellular	 ﾠmatrix	 ﾠ[387].	 ﾠSecondly,	 ﾠscratching	 ﾠthe	 ﾠcell	 ﾠmonolayer	 ﾠinduces	 ﾠmorphological	 ﾠ
changes	 ﾠand	 ﾠphysically	 ﾠstresses	 ﾠthe	 ﾠcells	 ﾠat	 ﾠthe	 ﾠedge	 ﾠof	 ﾠthe	 ﾠwound,	 ﾠwhich	 ﾠchanges	 ﾠ
intracellular	 ﾠsignalling	 ﾠevents	 ﾠ[392,	 ﾠ393].	 ﾠThirdly,	 ﾠcells	 ﾠcultured	 ﾠin	 ﾠ2D	 ﾠexhibit	 ﾠcompletely	 ﾠ
different	 ﾠgene	 ﾠexpression	 ﾠsignatures,	 ﾠportray	 ﾠdifferences	 ﾠin	 ﾠproliferation,	 ﾠmorphology,	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and	 ﾠmigration,	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠ3D	 ﾠ[38,	 ﾠ394,	 ﾠ395].	 ﾠMoreover,	 ﾠcell	 ﾠmovement	 ﾠin	 ﾠ2D	 ﾠis	 ﾠ
characterized	 ﾠby	 ﾠstress	 ﾠfibre	 ﾠformation	 ﾠand	 ﾠmembrane	 ﾠruffling	 ﾠat	 ﾠthe	 ﾠcell	 ﾠfront,	 ﾠwhich	 ﾠ
have	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠp38,	 ﾠJNK	 ﾠas	 ﾠwell	 ﾠas	 ﾠERK	 ﾠsignalling	 ﾠ[315,	 ﾠ396,	 ﾠ397].	 ﾠIn	 ﾠ3D,	 ﾠcells	 ﾠmigrate	 ﾠ
by	 ﾠextending	 ﾠa	 ﾠpseudopod	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠfront,	 ﾠwhich	 ﾠattaches	 ﾠto	 ﾠthe	 ﾠextracellular	 ﾠmatrix	 ﾠ
while	 ﾠthe	 ﾠcell’s	 ﾠrear	 ﾠdetaches	 ﾠand	 ﾠretracts.	 ﾠWe	 ﾠbelieve	 ﾠthat	 ﾠsignalling	 ﾠdifferences	 ﾠare	 ﾠthe	 ﾠ
cause	 ﾠof	 ﾠthese	 ﾠdistinct	 ﾠmodes	 ﾠof	 ﾠmotility	 ﾠand	 ﾠtherefore	 ﾠbelieve	 ﾠthat	 ﾠit	 ﾠis	 ﾠplausible	 ﾠthat	 ﾠ
ERK’s	 ﾠrole	 ﾠin	 ﾠ2D	 ﾠmigration	 ﾠmight	 ﾠbe	 ﾠdifferent	 ﾠfrom	 ﾠ3D	 ﾠand	 ﾠthat	 ﾠthese	 ﾠdifferences	 ﾠmight	 ﾠbe	 ﾠ
cell-ﾭ‐type	 ﾠspecific.	 ﾠ
3.3.3  Roles of ERK in tumour cell migration 
Our	 ﾠdata	 ﾠclearly	 ﾠshows	 ﾠthat	 ﾠERK2	 ﾠsignalling	 ﾠorchestrates	 ﾠthe	 ﾠcell	 ﾠmigration	 ﾠmachinery	 ﾠas	 ﾠ
the	 ﾠmomentary	 ﾠvelocity	 ﾠof	 ﾠmigrating	 ﾠcells	 ﾠwas	 ﾠcompromised	 ﾠin	 ﾠERK2	 ﾠknockdown	 ﾠcells.	 ﾠ
Moreover,	 ﾠwe	 ﾠobserved	 ﾠan	 ﾠincrease	 ﾠin	 ﾠcellular	 ﾠresting,	 ﾠwhere	 ﾠA2780-ﾭ‐Rab25	 ﾠcells,	 ﾠin	 ﾠ
particular,	 ﾠdeveloped	 ﾠtwo	 ﾠopposing	 ﾠpseudopods	 ﾠand	 ﾠstruggled	 ﾠto	 ﾠform	 ﾠa	 ﾠsingle	 ﾠdominant	 ﾠ
pseudopod	 ﾠrequired	 ﾠfor	 ﾠmigration.	 ﾠPersistent	 ﾠcellular	 ﾠmovement	 ﾠduring	 ﾠchemotactic	 ﾠ
experiments,	 ﾠsuch	 ﾠas	 ﾠinverted	 ﾠinvasion	 ﾠassays,	 ﾠrequires	 ﾠthe	 ﾠestablishment	 ﾠof	 ﾠa	 ﾠfront	 ﾠto	 ﾠtail	 ﾠ
polarity	 ﾠtowards	 ﾠthe	 ﾠchemotactic	 ﾠgradient,	 ﾠwhich	 ﾠis	 ﾠachieved	 ﾠby	 ﾠthe	 ﾠinterplay	 ﾠof	 ﾠthree	 ﾠ
central	 ﾠsignalling	 ﾠevents.	 ﾠFirstly,	 ﾠdeveloping	 ﾠpseudopods	 ﾠdisplay	 ﾠhigh	 ﾠCdc42	 ﾠand	 ﾠRac1	 ﾠ
activity,	 ﾠwhich	 ﾠare	 ﾠlinked	 ﾠto	 ﾠcellular	 ﾠpolarisation	 ﾠand	 ﾠF-ﾭ‐actin	 ﾠformation	 ﾠrespectively.	 ﾠ
Moreover,	 ﾠincreased	 ﾠphosphoinositide	 ﾠ3-ﾭ‐kinase	 ﾠ(PI3K)	 ﾠactivity	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠfront	 ﾠ
elevates	 ﾠphosphatidylinositol-ﾭ‐3,4,5-ﾭ‐phosphate	 ﾠ(PIP3)	 ﾠlevels,	 ﾠwhich	 ﾠallows	 ﾠthe	 ﾠrecruitment	 ﾠ
of	 ﾠPH-ﾭ‐domain	 ﾠcontaining	 ﾠsignalling	 ﾠproteins	 ﾠand	 ﾠensures	 ﾠfurther	 ﾠpseudopod	 ﾠextension.	 ﾠIn	 ﾠ
order	 ﾠto	 ﾠallow	 ﾠforward	 ﾠmigration	 ﾠthe	 ﾠformation	 ﾠof	 ﾠlateral	 ﾠor	 ﾠopposing	 ﾠpseudopods	 ﾠat	 ﾠthe	 ﾠ
cellular	 ﾠrear	 ﾠmust	 ﾠbe	 ﾠsuppressed	 ﾠ[398].	 ﾠThis	 ﾠis	 ﾠachieved	 ﾠthrough	 ﾠthe	 ﾠestablishment	 ﾠof	 ﾠa	 ﾠ
contractile	 ﾠmyosin	 ﾠcortex,	 ﾠwhere	 ﾠactive	 ﾠRhoA	 ﾠbinds	 ﾠto	 ﾠits	 ﾠdownstream	 ﾠeffector	 ﾠprotein,	 ﾠ
Rho-ﾭ‐associated	 ﾠkinase	 ﾠ(ROCK),	 ﾠwhich	 ﾠgenerates	 ﾠa	 ﾠcontractile	 ﾠforce	 ﾠby	 ﾠphosphorylating	 ﾠ
and	 ﾠinactivating	 ﾠthe	 ﾠmyosin	 ﾠbinding	 ﾠsubunit	 ﾠof	 ﾠmyosin	 ﾠphosphate	 ﾠ(MYPT1),	 ﾠand	 ﾠ
phosphorylating	 ﾠmyosin	 ﾠlight	 ﾠchain	 ﾠ(MLC)	 ﾠdirectly	 ﾠ[399].	 ﾠAs	 ﾠour	 ﾠdata	 ﾠclearly	 ﾠdemonstrates	 ﾠ
a	 ﾠmigratory	 ﾠdefect	 ﾠin	 ﾠERK2	 ﾠknockdown	 ﾠcells,	 ﾠwe	 ﾠbelieve	 ﾠthat	 ﾠERK2	 ﾠmay	 ﾠpartly	 ﾠregulate	 ﾠ
some	 ﾠof	 ﾠthe	 ﾠaforementioned	 ﾠsignalling	 ﾠevents.	 ﾠIndeed,	 ﾠa	 ﾠlink	 ﾠbetween	 ﾠERK	 ﾠsignalling	 ﾠand	 ﾠ
the	 ﾠsmall	 ﾠGTPases	 ﾠcentral	 ﾠto	 ﾠcell	 ﾠmigration	 ﾠhas	 ﾠbeen	 ﾠwell-ﾭ‐established,	 ﾠalbeit	 ﾠthe	 ﾠexact	 ﾠ
mechanism	 ﾠof	 ﾠregulation	 ﾠis	 ﾠstill	 ﾠunknown.	 ﾠIt	 ﾠis	 ﾠthought	 ﾠthat	 ﾠERK	 ﾠsignalling	 ﾠmay	 ﾠcontrol	 ﾠ
Rac1	 ﾠand	 ﾠCdc42	 ﾠactivity	 ﾠby	 ﾠregulating	 ﾠGEF	 ﾠlocalisation	 ﾠand/or	 ﾠactivity.	 ﾠThus,	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extracellular	 ﾠstimuli	 ﾠmay	 ﾠactivate	 ﾠERK	 ﾠsignalling,	 ﾠwhich	 ﾠin	 ﾠturn	 ﾠinduce	 ﾠRac1	 ﾠand	 ﾠCdc42	 ﾠ
activation	 ﾠand	 ﾠthereby	 ﾠpromote	 ﾠpseudopod	 ﾠformation	 ﾠtowards	 ﾠthe	 ﾠchemotactic	 ﾠ
gradient	 ﾠ[190,	 ﾠ398].	 ﾠHowever,	 ﾠRac1	 ﾠand	 ﾠCdc42	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠinduce	 ﾠERK	 ﾠ
activation	 ﾠvia	 ﾠPAK	 ﾠ[400-ﾭ‐402].	 ﾠThus,	 ﾠrather	 ﾠthan	 ﾠERK	 ﾠactivating	 ﾠRac1	 ﾠand	 ﾠCdc42	 ﾠat	 ﾠthe	 ﾠ
leading	 ﾠedge,	 ﾠthese	 ﾠsmall	 ﾠGTPases	 ﾠmight	 ﾠbe	 ﾠresponsible	 ﾠfor	 ﾠactivating	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠthe	 ﾠ
forming	 ﾠpseudopod,	 ﾠwhere	 ﾠthe	 ﾠkinase	 ﾠregulates	 ﾠextracellular	 ﾠmatrix	 ﾠ(ECM)	 ﾠ
adhesions	 ﾠ[216,	 ﾠ276,	 ﾠ403],	 ﾠwhich	 ﾠare	 ﾠcrucial	 ﾠin	 ﾠstabilising	 ﾠthe	 ﾠdeveloping	 ﾠpseudopod.	 ﾠ
Moreover,	 ﾠERK	 ﾠactivity	 ﾠinduces	 ﾠmyosin	 ﾠlight	 ﾠchain	 ﾠphosphorylation	 ﾠby	 ﾠactivating	 ﾠMLCK	 ﾠ
(myosin	 ﾠlight	 ﾠchain	 ﾠkinase)	 ﾠ[277]	 ﾠand	 ﾠthereby	 ﾠcontrols	 ﾠthe	 ﾠgeneration	 ﾠof	 ﾠa	 ﾠcontractile	 ﾠ
force	 ﾠrequired	 ﾠto	 ﾠtranslocate	 ﾠthe	 ﾠcell	 ﾠbody	 ﾠfollowing	 ﾠpseudopodial	 ﾠextension	 ﾠ[404].	 ﾠWhen	 ﾠ
comparing	 ﾠthe	 ﾠpseudopod	 ﾠlength	 ﾠof	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠwith	 ﾠcontrol,	 ﾠhowever,	 ﾠwe	 ﾠdo	 ﾠ
not	 ﾠobserve	 ﾠsignificant	 ﾠchanges	 ﾠ(data	 ﾠnot	 ﾠshown),	 ﾠwhich	 ﾠargues	 ﾠthat	 ﾠinhibition	 ﾠof	 ﾠERK2	 ﾠ
does	 ﾠnot	 ﾠinfluence	 ﾠpseudopod	 ﾠextension	 ﾠor	 ﾠretraction	 ﾠat	 ﾠthe	 ﾠleading	 ﾠedge.	 ﾠOur	 ﾠdata	 ﾠ
rather	 ﾠsuggests	 ﾠa	 ﾠdefect	 ﾠin	 ﾠthe	 ﾠsuppression	 ﾠof	 ﾠlateral	 ﾠor	 ﾠopposing	 ﾠpseudopods	 ﾠat	 ﾠthe	 ﾠ
cellular	 ﾠback,	 ﾠwhen	 ﾠERK2	 ﾠis	 ﾠsilenced.	 ﾠThus,	 ﾠERK2	 ﾠmight	 ﾠbe	 ﾠimportant	 ﾠin	 ﾠregulating	 ﾠRhoA	 ﾠ
signalling	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠrear.	 ﾠIndeed,	 ﾠERK	 ﾠwas	 ﾠshown	 ﾠactivate	 ﾠGEF-ﾭ‐H1,	 ﾠa	 ﾠRhoA	 ﾠGEF,	 ﾠ
through	 ﾠdirect	 ﾠphosphorylation	 ﾠ[405]	 ﾠand	 ﾠmight	 ﾠthus	 ﾠprovide	 ﾠa	 ﾠmeans	 ﾠby	 ﾠwhich	 ﾠERK	 ﾠ
promotes	 ﾠcellular	 ﾠretraction.	 ﾠMoreover,	 ﾠERK	 ﾠis	 ﾠinvolved	 ﾠin	 ﾠfocal	 ﾠadhesion	 ﾠ
disassembly	 ﾠ[276],	 ﾠwhich	 ﾠis	 ﾠrequired	 ﾠfor	 ﾠeffective	 ﾠforward	 ﾠmigration.	 ﾠDefects	 ﾠin	 ﾠadhesion	 ﾠ
turnover	 ﾠor	 ﾠRhoA	 ﾠactivation	 ﾠbrought	 ﾠabout	 ﾠby	 ﾠERK2	 ﾠsilencing	 ﾠmay	 ﾠallow	 ﾠlateral	 ﾠ
pseudopod	 ﾠformation,	 ﾠprevent	 ﾠthe	 ﾠacquisition	 ﾠof	 ﾠa	 ﾠdominant	 ﾠpseudopod	 ﾠand	 ﾠmay	 ﾠ
ultimately	 ﾠdecrease	 ﾠcellular	 ﾠmotility.	 ﾠMoreover,	 ﾠfailure	 ﾠor	 ﾠdelay	 ﾠin	 ﾠGolgi	 ﾠand	 ﾠcentrosome	 ﾠ
orientation	 ﾠmay	 ﾠslow	 ﾠdown	 ﾠcell	 ﾠmigration	 ﾠor	 ﾠinduce	 ﾠcellular	 ﾠresting	 ﾠas	 ﾠseen	 ﾠin	 ﾠour	 ﾠ
experiments.	 ﾠNotably,	 ﾠERK	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠregulate	 ﾠGolgi	 ﾠand	 ﾠcentrosome	 ﾠorientation	 ﾠ
towards	 ﾠthe	 ﾠleading	 ﾠedge	 ﾠof	 ﾠmigrating	 ﾠcells	 ﾠ[406].	 ﾠThus,	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠfunction	 ﾠin	 ﾠthis	 ﾠ
process	 ﾠis	 ﾠalso	 ﾠpossible.	 ﾠ
3.3.4  Isoform-specific functions for ERK1 and ERK2 
In	 ﾠrecent	 ﾠyears,	 ﾠmuch	 ﾠevidence	 ﾠsupporting	 ﾠERK	 ﾠisoform-ﾭ‐specific	 ﾠfunctions	 ﾠhas	 ﾠ
accumulated	 ﾠ(see	 ﾠ3.1.2	 ﾠand	 ﾠ3.1.3).	 ﾠFirst	 ﾠand	 ﾠforemost,	 ﾠstriking	 ﾠdiscrepancies	 ﾠbetween	 ﾠthe	 ﾠ
ERK1
-ﾭ‐/-ﾭ‐	 ﾠand	 ﾠERK2
-ﾭ‐/-ﾭ‐	 ﾠphenotypes	 ﾠin	 ﾠmice	 ﾠargue	 ﾠfor	 ﾠdistinct	 ﾠroles	 ﾠfor	 ﾠthese	 ﾠkinases	 ﾠin	 ﾠ
embryogenesis	 ﾠ[360-ﾭ‐364,	 ﾠ367].	 ﾠMoreover,	 ﾠERK2	 ﾠmay	 ﾠplay	 ﾠspecific	 ﾠroles	 ﾠin	 ﾠlearning	 ﾠand	 ﾠ
memory	 ﾠas	 ﾠwell	 ﾠas	 ﾠdifferentiation	 ﾠ[365,	 ﾠ370].	 ﾠHowever,	 ﾠthis	 ﾠdata	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Lefloch	 ﾠet	 ﾠal.	 ﾠin	 ﾠ2008,	 ﾠwho	 ﾠproposed	 ﾠerk	 ﾠgene	 ﾠdosage	 ﾠas	 ﾠthe	 ﾠreason	 ﾠfor	 ﾠthe	 ﾠdifferences	 ﾠin	 ﾠ
the	 ﾠERK
-ﾭ‐/-ﾭ‐	 ﾠphenotypes	 ﾠ[357].	 ﾠThey	 ﾠshowed	 ﾠthat	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠkinase	 ﾠactivities	 ﾠwere	 ﾠ
indistinguishable	 ﾠin	 ﾠvitro	 ﾠand	 ﾠsuggested	 ﾠthat	 ﾠboth	 ﾠisoforms	 ﾠcontribute	 ﾠtowards	 ﾠsignalling	 ﾠ
outcomes	 ﾠaccording	 ﾠto	 ﾠtheir	 ﾠexpression	 ﾠratio	 ﾠ[357].	 ﾠHowever,	 ﾠexperimental	 ﾠlimitations	 ﾠ
did	 ﾠnot	 ﾠallow	 ﾠLefloch	 ﾠand	 ﾠcolleagues	 ﾠto	 ﾠshow	 ﾠthat	 ﾠan	 ﾠincrease	 ﾠin	 ﾠERK1	 ﾠexpression	 ﾠin	 ﾠthe	 ﾠ
absence	 ﾠof	 ﾠERK2	 ﾠcould	 ﾠindeed	 ﾠrescue	 ﾠthe	 ﾠproliferation	 ﾠdefects	 ﾠobserved	 ﾠ[357].	 ﾠHowever,	 ﾠ
subsequent	 ﾠwork	 ﾠby	 ﾠSamuels	 ﾠand	 ﾠcolleagues	 ﾠshowed	 ﾠthat	 ﾠproliferative	 ﾠdefects	 ﾠin	 ﾠthe	 ﾠ
developing	 ﾠcortex	 ﾠof	 ﾠmice	 ﾠwith	 ﾠconditional	 ﾠERK2	 ﾠknockout	 ﾠcould	 ﾠbe	 ﾠrescued	 ﾠby	 ﾠERK1	 ﾠ
overactivation,	 ﾠthus	 ﾠshowing	 ﾠthat	 ﾠERK’s	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠproliferation	 ﾠis	 ﾠindeed	 ﾠ
dependent	 ﾠon	 ﾠerk	 ﾠgene	 ﾠdosage	 ﾠ[366].	 ﾠHere,	 ﾠwe	 ﾠshow	 ﾠthat	 ﾠERK2	 ﾠis	 ﾠcrucial	 ﾠfor	 ﾠinvasive	 ﾠ
migration,	 ﾠas	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠseverely	 ﾠcompromised	 ﾠinvasion	 ﾠinto	 ﾠMatrigel	 ﾠplugs	 ﾠand	 ﾠ
migration	 ﾠon	 ﾠCDM.	 ﾠThe	 ﾠfact	 ﾠthat	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠcompensatory	 ﾠincrease	 ﾠin	 ﾠpERK1	 ﾠupon	 ﾠ
ERK2	 ﾠknockdown	 ﾠand	 ﾠvice	 ﾠversa	 ﾠin	 ﾠeither	 ﾠA2780-ﾭ‐Rab25	 ﾠor	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠcontradict	 ﾠ
assumptions	 ﾠthat	 ﾠtotal	 ﾠERK	 ﾠsignalling,	 ﾠregardless	 ﾠof	 ﾠthe	 ﾠisoform,	 ﾠregulates	 ﾠcell	 ﾠinvasion.	 ﾠ
Moreover,	 ﾠby	 ﾠdeveloping	 ﾠa	 ﾠsystem,	 ﾠin	 ﾠwhich	 ﾠwe	 ﾠcan	 ﾠknockdown	 ﾠERK2	 ﾠand	 ﾠthen	 ﾠ
ectopically	 ﾠexpress	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠto	 ﾠsimilar	 ﾠlevels,	 ﾠwe	 ﾠhave	 ﾠshown	 ﾠthat	 ﾠERK2	 ﾠis	 ﾠthe	 ﾠ
main	 ﾠdriver	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion	 ﾠin	 ﾠ3D	 ﾠmicroenvironments	 ﾠin	 ﾠa	 ﾠway	 ﾠthat	 ﾠis	 ﾠnot	 ﾠ
influenced	 ﾠby	 ﾠgene	 ﾠdosage.	 ﾠ
The	 ﾠrole	 ﾠof	 ﾠthe	 ﾠERKs	 ﾠin	 ﾠcell	 ﾠmigration	 ﾠhas	 ﾠbeen	 ﾠstudied	 ﾠextensively	 ﾠand	 ﾠit	 ﾠis	 ﾠestablished	 ﾠ
that	 ﾠthese	 ﾠkinases	 ﾠplay	 ﾠa	 ﾠkey	 ﾠrole	 ﾠin	 ﾠtumour	 ﾠprogression	 ﾠby	 ﾠregulating	 ﾠcell	 ﾠinvasiveness	 ﾠ
[277,	 ﾠ314,	 ﾠ407-ﾭ‐409].	 ﾠHowever	 ﾠlittle	 ﾠis	 ﾠknown	 ﾠabout	 ﾠthe	 ﾠrespective	 ﾠcontributions	 ﾠof	 ﾠERK1	 ﾠ
and	 ﾠERK2	 ﾠto	 ﾠcell	 ﾠmigration.	 ﾠOur	 ﾠfinding	 ﾠthat	 ﾠit	 ﾠis	 ﾠERK2,	 ﾠand	 ﾠnot	 ﾠERK1,	 ﾠthat	 ﾠcontributes	 ﾠto	 ﾠ
cell	 ﾠmigration	 ﾠin	 ﾠ3D	 ﾠmicroenvironments	 ﾠis	 ﾠcertainly	 ﾠin	 ﾠagreement	 ﾠwith	 ﾠobservations	 ﾠin	 ﾠ
vivo,	 ﾠwhere	 ﾠERK2
+/-ﾭ‐	 ﾠmice	 ﾠshow	 ﾠa	 ﾠdelay	 ﾠin	 ﾠwound	 ﾠhealing	 ﾠafter	 ﾠpartial-ﾭ‐thickness	 ﾠburn	 ﾠin	 ﾠ
comparison	 ﾠto	 ﾠERK2
+/+	 ﾠmice	 ﾠ[410].	 ﾠSatoh	 ﾠand	 ﾠcolleagues	 ﾠhypothesized	 ﾠthat	 ﾠdifferences	 ﾠ
observed	 ﾠin	 ﾠwound	 ﾠhealing	 ﾠwere	 ﾠdue	 ﾠto	 ﾠdefects	 ﾠin	 ﾠproliferation	 ﾠas	 ﾠwell	 ﾠas	 ﾠmigration.	 ﾠ
Studies	 ﾠin	 ﾠZebrafish	 ﾠfurther	 ﾠsupport	 ﾠthis	 ﾠview	 ﾠas	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1	 ﾠmorphants	 ﾠshowed	 ﾠ
defects	 ﾠin	 ﾠcytoskeletal	 ﾠreorganisation	 ﾠprocesses,	 ﾠwhich	 ﾠled	 ﾠto	 ﾠanterior-ﾭ‐to-ﾭ‐posterior	 ﾠ
migration	 ﾠretardations	 ﾠ[411].	 ﾠMore	 ﾠrecently,	 ﾠby	 ﾠusing	 ﾠa	 ﾠretroviral	 ﾠsystem	 ﾠto	 ﾠexpress	 ﾠERK	 ﾠ1	 ﾠ
and	 ﾠ-ﾭ‐2	 ﾠto	 ﾠsimilar	 ﾠlevels,	 ﾠa	 ﾠstudy	 ﾠhas	 ﾠdemonstrated	 ﾠa	 ﾠspecific	 ﾠrole	 ﾠfor	 ﾠERK2	 ﾠin	 ﾠcell	 ﾠmigration	 ﾠ
in	 ﾠMCF-ﾭ‐10A	 ﾠcells,	 ﾠwhich	 ﾠwas	 ﾠdue	 ﾠto	 ﾠthe	 ﾠparticipation	 ﾠof	 ﾠthis	 ﾠERK	 ﾠisoform	 ﾠin	 ﾠRas-ﾭ‐induced	 ﾠ
epithelial-ﾭ‐to-ﾭ‐mesenchymal	 ﾠtransformation	 ﾠ(EMT)	 ﾠ[412].	 ﾠ	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The	 ﾠERK	 ﾠpathway	 ﾠhas	 ﾠbeen	 ﾠa	 ﾠfavourable	 ﾠtarget	 ﾠin	 ﾠanti-ﾭ‐cancer	 ﾠdrug	 ﾠdevelopment	 ﾠsince	 ﾠa	 ﾠ
study	 ﾠof	 ﾠbreast	 ﾠcancer	 ﾠcarcinomas	 ﾠin	 ﾠ2001	 ﾠshowed	 ﾠa	 ﾠcorrelation	 ﾠbetween	 ﾠhigh	 ﾠpERK	 ﾠlevels	 ﾠ
and	 ﾠlow	 ﾠsurvival	 ﾠfrom	 ﾠthe	 ﾠinitiation	 ﾠof	 ﾠtherapy	 ﾠ[413].	 ﾠOur	 ﾠdata	 ﾠsuggests	 ﾠthat	 ﾠspecific	 ﾠ
targeting	 ﾠof	 ﾠERK2	 ﾠrather	 ﾠthan	 ﾠblocking	 ﾠboth	 ﾠERKs	 ﾠmight	 ﾠprove	 ﾠto	 ﾠbe	 ﾠa	 ﾠmore	 ﾠselective	 ﾠ
anti-ﾭ‐invasive	 ﾠstrategy.	 ﾠThis	 ﾠhypothesis	 ﾠis	 ﾠstrongly	 ﾠsupported	 ﾠby	 ﾠdata	 ﾠfrom	 ﾠMilde-ﾭ‐Langosch	 ﾠ
and	 ﾠcolleagues	 ﾠwho	 ﾠshowed	 ﾠthat	 ﾠhigh	 ﾠpERK1	 ﾠexpression	 ﾠin	 ﾠtumours	 ﾠcorrelated	 ﾠwith	 ﾠlow	 ﾠ
frequencies	 ﾠof	 ﾠrelapses	 ﾠand	 ﾠhigher	 ﾠsurvival.	 ﾠMoreover,	 ﾠpatients	 ﾠwith	 ﾠweak	 ﾠpERK1	 ﾠlevels	 ﾠ
showed	 ﾠan	 ﾠincreased	 ﾠnumber	 ﾠof	 ﾠrecurrences	 ﾠand	 ﾠdeaths	 ﾠof	 ﾠdisease.	 ﾠThe	 ﾠsame	 ﾠtrend	 ﾠwas	 ﾠ
seen	 ﾠwhen	 ﾠhigh	 ﾠlevels	 ﾠof	 ﾠpERK2	 ﾠwere	 ﾠdetected	 ﾠin	 ﾠthe	 ﾠpatients’	 ﾠtumours	 ﾠ[414].	 ﾠConsistent	 ﾠ
with	 ﾠthis,	 ﾠERK1	 ﾠhas	 ﾠbeen	 ﾠhypothesized	 ﾠas	 ﾠa	 ﾠnegative	 ﾠmodulator	 ﾠof	 ﾠERK	 ﾠsignalling	 ﾠin	 ﾠrecent	 ﾠ
years,	 ﾠas	 ﾠectopic	 ﾠexpression	 ﾠof	 ﾠthis	 ﾠkinase	 ﾠattenuates	 ﾠcolony	 ﾠformation	 ﾠof	 ﾠ
Ras-ﾭ‐transformed	 ﾠcells	 ﾠas	 ﾠwell	 ﾠas	 ﾠRas-ﾭ‐dependent	 ﾠtumour	 ﾠgrowth	 ﾠin	 ﾠnude	 ﾠmice	 ﾠ[371].	 ﾠ
Hence,	 ﾠthe	 ﾠdata	 ﾠsuggest	 ﾠthat	 ﾠa	 ﾠtherapy	 ﾠaiming	 ﾠat	 ﾠdecreasing	 ﾠpERK2	 ﾠand	 ﾠincreasing	 ﾠpERK1	 ﾠ
levels	 ﾠmight	 ﾠbe	 ﾠmost	 ﾠbeneficial.	 ﾠOur	 ﾠwork	 ﾠwith	 ﾠthe	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠand	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠ
showed	 ﾠa	 ﾠclear	 ﾠcompensatory	 ﾠincrease	 ﾠof	 ﾠpERK1	 ﾠlevels	 ﾠafter	 ﾠERK2	 ﾠknockdown.	 ﾠThe	 ﾠ
compensatory	 ﾠincrease	 ﾠin	 ﾠpERK1	 ﾠlevels	 ﾠafter	 ﾠERK2	 ﾠsilencing	 ﾠhas	 ﾠbeen	 ﾠobserved	 ﾠin	 ﾠother	 ﾠ
cell	 ﾠlines,	 ﾠsuch	 ﾠas	 ﾠNIH	 ﾠ3T3	 ﾠ[371]	 ﾠas	 ﾠwell	 ﾠas	 ﾠrat	 ﾠand	 ﾠmouse	 ﾠhepatocytes	 ﾠ[372].	 ﾠFurthermore,	 ﾠ
a	 ﾠcompensation	 ﾠin	 ﾠpERK	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠobserved	 ﾠin	 ﾠERK2
+/-ﾭ‐	 ﾠmice	 ﾠcompared	 ﾠto	 ﾠERK2
+/+	 ﾠ
[415].	 ﾠAs	 ﾠMEK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠdo	 ﾠnot	 ﾠdiscriminate	 ﾠbetween	 ﾠthe	 ﾠERKs,	 ﾠwe	 ﾠspeculate	 ﾠthat	 ﾠsilencing	 ﾠ
of	 ﾠERK2	 ﾠmight	 ﾠnot	 ﾠonly	 ﾠcompromise	 ﾠinvasive	 ﾠmigration,	 ﾠbut	 ﾠalso	 ﾠresult	 ﾠin	 ﾠa	 ﾠbeneficial	 ﾠ
increase	 ﾠin	 ﾠpERK1	 ﾠlevels.	 ﾠThus,	 ﾠchanging	 ﾠthe	 ﾠratio	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠshould	 ﾠresult	 ﾠin	 ﾠ
enhanced	 ﾠactivation	 ﾠof	 ﾠthe	 ﾠremaining	 ﾠkinase.	 ﾠ
Our	 ﾠfindings	 ﾠhave	 ﾠshown	 ﾠa	 ﾠclear	 ﾠERK2-ﾭ‐dependent	 ﾠrole	 ﾠin	 ﾠ3D	 ﾠmigration.	 ﾠHow	 ﾠcan	 ﾠthis	 ﾠ
isoform-ﾭ‐specificity	 ﾠbe	 ﾠachieved	 ﾠon	 ﾠa	 ﾠcellular	 ﾠlevel,	 ﾠif	 ﾠboth	 ﾠkinases	 ﾠshow	 ﾠindistinguishable	 ﾠ
kinase	 ﾠactivities	 ﾠin	 ﾠvitro?	 ﾠMarchi	 ﾠet	 ﾠal.	 ﾠhave	 ﾠshown	 ﾠisoform-ﾭ‐specific	 ﾠnuclear	 ﾠshuttling	 ﾠrates	 ﾠ
caused	 ﾠby	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠamino	 ﾠacid	 ﾠsequence,	 ﾠsuggesting	 ﾠthat	 ﾠERK1	 ﾠand	 ﾠ
ERK2	 ﾠmay	 ﾠperform	 ﾠdifferent	 ﾠroles	 ﾠwithin	 ﾠthe	 ﾠnucleus	 ﾠ[416].	 ﾠAs	 ﾠERK	 ﾠisoforms	 ﾠare	 ﾠ
dephosphorylated	 ﾠand	 ﾠtherefore	 ﾠinactivated	 ﾠin	 ﾠthe	 ﾠnucleus	 ﾠ[175],	 ﾠhigh	 ﾠshuttling	 ﾠrates	 ﾠare	 ﾠ
required	 ﾠto	 ﾠmaintain	 ﾠan	 ﾠactive	 ﾠpool	 ﾠof	 ﾠERK.	 ﾠTherefore,	 ﾠlower	 ﾠERK1	 ﾠshuttling	 ﾠrates	 ﾠmake	 ﾠ
ERK2	 ﾠa	 ﾠbetter	 ﾠcandidate	 ﾠfor	 ﾠthe	 ﾠactivation	 ﾠof	 ﾠnuclear	 ﾠtargets	 ﾠ[416].	 ﾠERK1/2	 ﾠhave	 ﾠbeen	 ﾠ
shown	 ﾠto	 ﾠdrive	 ﾠtranscription	 ﾠof	 ﾠnumerous	 ﾠproteins	 ﾠinvolved	 ﾠin	 ﾠmigration,	 ﾠsuch	 ﾠas	 ﾠMMP-ﾭ‐9,	 ﾠ
MMP-ﾭ‐1	 ﾠand	 ﾠuPA	 ﾠ[391,	 ﾠ417,	 ﾠ418].	 ﾠIt	 ﾠis,	 ﾠtherefore,	 ﾠpossible,	 ﾠthat	 ﾠERK2	 ﾠis	 ﾠthe	 ﾠmain	 ﾠdriver	 ﾠof	 ﾠ
transcription	 ﾠof	 ﾠthese	 ﾠpro-ﾭ‐invasive	 ﾠproteins.	 ﾠHowever,	 ﾠit	 ﾠis	 ﾠunlikely	 ﾠthat	 ﾠERK2’s	 ﾠrole	 ﾠin	 ﾠChapter 3 – ERK2 but not ERK1 contributes to invasive cell migration  141 
invasive	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠcan	 ﾠsolely	 ﾠbe	 ﾠtriggered	 ﾠby	 ﾠhigher	 ﾠnuclear	 ﾠactivity,	 ﾠas	 ﾠERK	 ﾠ
signalling	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠlinked	 ﾠcytosolic	 ﾠeffectors	 ﾠinvolved	 ﾠin	 ﾠmigration,	 ﾠsuch	 ﾠas	 ﾠvinexin-ﾭ‐β,	 ﾠ
stathmin	 ﾠand	 ﾠmyosin	 ﾠlight	 ﾠchain	 ﾠkinase	 ﾠ(MLCK)	 ﾠ[316,	 ﾠ403,	 ﾠ419].	 ﾠ	 ﾠ
Isoform	 ﾠspecificity	 ﾠwithin	 ﾠthe	 ﾠcytoplasm	 ﾠmay	 ﾠbe	 ﾠachieved	 ﾠvia	 ﾠdistinct	 ﾠsubcellular	 ﾠ
localisation	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠenzymes.	 ﾠHowever,	 ﾠthere	 ﾠare	 ﾠcurrently	 ﾠno	 ﾠERK	 ﾠisoform-ﾭ‐specific	 ﾠ
antibodies,	 ﾠwhich	 ﾠallow	 ﾠthis	 ﾠhypothesis	 ﾠto	 ﾠbe	 ﾠtested	 ﾠusing	 ﾠimmunofluorescence	 ﾠ
microscopy.	 ﾠMoreover,	 ﾠisoform-ﾭ‐specific	 ﾠscaffolds,	 ﾠas	 ﾠwell	 ﾠas	 ﾠuncharacterized	 ﾠ
isoform-ﾭ‐specific	 ﾠsubstrate	 ﾠbinding	 ﾠdomains,	 ﾠmay	 ﾠexist.	 ﾠIndeed,	 ﾠShin	 ﾠet	 ﾠal.	 ﾠdemonstrated	 ﾠ
an	 ﾠERK2	 ﾠspecificity	 ﾠin	 ﾠFra1	 ﾠphosphorylation,	 ﾠwhich	 ﾠwas	 ﾠdependent	 ﾠon	 ﾠERK2’s	 ﾠFXFP	 ﾠmotif	 ﾠ
[412].	 ﾠIntriguingly,	 ﾠprevious	 ﾠwork	 ﾠby	 ﾠLee	 ﾠand	 ﾠcolleagues	 ﾠshowed	 ﾠthat	 ﾠthe	 ﾠresidues	 ﾠ
constituting	 ﾠthe	 ﾠFXFP-ﾭ‐motif	 ﾠare	 ﾠfully	 ﾠconserved	 ﾠbetween	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠ[131].	 ﾠTo	 ﾠexplain	 ﾠ
this	 ﾠdiscrepancy,	 ﾠwe	 ﾠspeculate	 ﾠthat	 ﾠthe	 ﾠTyr261Ala	 ﾠmutation	 ﾠin	 ﾠthe	 ﾠFXFP-ﾭ‐motif	 ﾠmay	 ﾠ
sterically	 ﾠdistort	 ﾠan	 ﾠunknown	 ﾠisoform-ﾭ‐specific	 ﾠsubstrate	 ﾠbinding	 ﾠdomain	 ﾠin	 ﾠERK2	 ﾠand	 ﾠ
therefore	 ﾠabrogate	 ﾠFra1	 ﾠstabilisation.	 ﾠ	 ﾠ
To	 ﾠconclude,	 ﾠthis	 ﾠstudy	 ﾠis	 ﾠthe	 ﾠfirst	 ﾠto	 ﾠshow	 ﾠa	 ﾠpivotal	 ﾠrole	 ﾠof	 ﾠERK2	 ﾠin	 ﾠinvasive	 ﾠtumour	 ﾠcell	 ﾠ
migration	 ﾠand	 ﾠsuggests	 ﾠthat	 ﾠERK1	 ﾠand	 ﾠ-ﾭ‐2	 ﾠdo	 ﾠhave	 ﾠdistinct	 ﾠfunctions.	 ﾠOur	 ﾠdata	 ﾠchallenges	 ﾠ
the	 ﾠbelief	 ﾠthat	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠare	 ﾠinterchangeable	 ﾠand	 ﾠredundant,	 ﾠand	 ﾠpropose	 ﾠa	 ﾠnew	 ﾠ
level	 ﾠof	 ﾠcomplexity	 ﾠof	 ﾠthe	 ﾠRaf-ﾭ‐MEK-ﾭ‐ERK	 ﾠpathway.	 ﾠ
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4.1  Introduction 
4.1.1  Regulation of gene expression through ERK1/2 
Growth	 ﾠfactors	 ﾠand	 ﾠmitogens	 ﾠinduce	 ﾠsynthesis	 ﾠof	 ﾠnew	 ﾠproteins	 ﾠrequired	 ﾠfor	 ﾠcellular	 ﾠ
responses.	 ﾠChanges	 ﾠin	 ﾠprotein	 ﾠexpression	 ﾠcan	 ﾠbe	 ﾠdetected	 ﾠwithin	 ﾠminutes	 ﾠfollowing	 ﾠ
growth	 ﾠfactor	 ﾠaddition,	 ﾠand	 ﾠgenes	 ﾠencoding	 ﾠthese	 ﾠproteins	 ﾠare	 ﾠknown	 ﾠas	 ﾠimmediate	 ﾠearly	 ﾠ
genes	 ﾠ(IEGs).	 ﾠThis	 ﾠrapid	 ﾠburst	 ﾠin	 ﾠmRNA	 ﾠsynthesis	 ﾠrequires	 ﾠa	 ﾠswitch-ﾭ‐like	 ﾠactivation	 ﾠof	 ﾠ
transcription	 ﾠfactors	 ﾠin	 ﾠthe	 ﾠnucleus,	 ﾠwhich	 ﾠcan	 ﾠbe	 ﾠachieved	 ﾠthrough	 ﾠpost-ﾭ‐translational	 ﾠ
modifications.	 ﾠIndeed,	 ﾠactivation	 ﾠof	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠpromotes	 ﾠtranslocation	 ﾠof	 ﾠ
ERK1/2	 ﾠto	 ﾠthe	 ﾠnucleus,	 ﾠwhere	 ﾠthe	 ﾠkinases	 ﾠphosphorylate	 ﾠtranscription	 ﾠfactors	 ﾠsuch	 ﾠas	 ﾠElk1	 ﾠ
and	 ﾠc-ﾭ‐Fos	 ﾠto	 ﾠdrive	 ﾠexpression	 ﾠof	 ﾠIEGs	 ﾠ[420].	 ﾠPhosphorylation	 ﾠcan	 ﾠaffect	 ﾠtranscription	 ﾠ
factor	 ﾠfunction	 ﾠin	 ﾠvarious	 ﾠways.	 ﾠWhereas	 ﾠphosphorylation	 ﾠof	 ﾠElk1	 ﾠenhances	 ﾠDNA	 ﾠbinding	 ﾠ
and	 ﾠmay	 ﾠinduce	 ﾠthe	 ﾠrecruitment	 ﾠof	 ﾠtranscriptional	 ﾠco-ﾭ‐activators,	 ﾠsuch	 ﾠas	 ﾠp300	 ﾠor	 ﾠ
CREB-ﾭ‐binding	 ﾠprotein	 ﾠ(CBP)	 ﾠ[323],	 ﾠphosphorylation	 ﾠof	 ﾠc-ﾭ‐Fos	 ﾠby	 ﾠERK	 ﾠitself	 ﾠor	 ﾠits	 ﾠ
downstream	 ﾠtarget,	 ﾠRSK,	 ﾠprevents	 ﾠproteasomal	 ﾠdegradation	 ﾠand	 ﾠthus	 ﾠstabilises	 ﾠthe	 ﾠ
transcription	 ﾠfactor	 ﾠ[326].	 ﾠIn	 ﾠcontrast,	 ﾠnuclear	 ﾠERK	 ﾠmay	 ﾠalso	 ﾠinhibit	 ﾠtranscriptional	 ﾠevents	 ﾠ
through	 ﾠdirect	 ﾠor	 ﾠindirect	 ﾠphosphorylation.	 ﾠFor	 ﾠexample,	 ﾠphosphorylation	 ﾠof	 ﾠSer307	 ﾠof	 ﾠ
heat	 ﾠshock	 ﾠfactor-ﾭ‐1	 ﾠ(HSF1)	 ﾠby	 ﾠERK1/2	 ﾠrepresses	 ﾠits	 ﾠtranscriptional	 ﾠactivity	 ﾠduring	 ﾠgrowth	 ﾠ
and	 ﾠdevelopment	 ﾠ[421].	 ﾠFurthermore,	 ﾠERK-ﾭ‐mediated	 ﾠphosphorylation	 ﾠof	 ﾠinducible	 ﾠcAMP	 ﾠ
early	 ﾠrepressor	 ﾠ(ICER)	 ﾠtargets	 ﾠthe	 ﾠtranscription	 ﾠfactor	 ﾠfor	 ﾠubiquitin-ﾭ‐mediated	 ﾠ
degradation	 ﾠ[422].	 ﾠ
In	 ﾠaddition	 ﾠto	 ﾠdirect	 ﾠor	 ﾠindirect	 ﾠphosphorylation	 ﾠof	 ﾠtranscription	 ﾠfactors,	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠ
pathway	 ﾠhas	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠaltering	 ﾠthe	 ﾠchromatin	 ﾠstructure	 ﾠof	 ﾠactively	 ﾠtranscribed	 ﾠ
genes	 ﾠ[423-ﾭ‐425].	 ﾠNucleosomal	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠhistone	 ﾠH3	 ﾠand	 ﾠhigh	 ﾠmobility	 ﾠgroup	 ﾠ
protein	 ﾠ(HMG)-ﾭ‐14,	 ﾠare	 ﾠphosphorylated	 ﾠby	 ﾠERK	 ﾠeffectors	 ﾠ(i.e.	 ﾠMSK1,	 ﾠMSK2,	 ﾠand	 ﾠRSK2)	 ﾠon	 ﾠ
Ser10	 ﾠand	 ﾠSer6,	 ﾠrespectively	 ﾠ[426-ﾭ‐428].	 ﾠPhosphorylated	 ﾠhistone	 ﾠH3	 ﾠand	 ﾠHMG-ﾭ‐14	 ﾠare	 ﾠ
primarily	 ﾠfound	 ﾠat	 ﾠactively	 ﾠtranscribed	 ﾠgenes,	 ﾠe.g.	 ﾠIEGs,	 ﾠand	 ﾠare	 ﾠthought	 ﾠto	 ﾠprovide	 ﾠa	 ﾠ
docking	 ﾠdomain	 ﾠfor	 ﾠthe	 ﾠrecruitment	 ﾠof	 ﾠhistone	 ﾠacetyltransferases,	 ﾠsuch	 ﾠas	 ﾠp300	 ﾠand	 ﾠ
CBP	 ﾠ[427].	 ﾠIndeed,	 ﾠphosphorylation	 ﾠand	 ﾠacetylation	 ﾠcan	 ﾠcoexist	 ﾠon	 ﾠthe	 ﾠsame	 ﾠhistone	 ﾠH3	 ﾠ
tail,	 ﾠas	 ﾠwas	 ﾠrecently	 ﾠshown	 ﾠfor	 ﾠthe	 ﾠc-ﾭ‐fos	 ﾠgene	 ﾠ[429].	 ﾠThus,	 ﾠa	 ﾠfunction	 ﾠof	 ﾠhistone	 ﾠH3	 ﾠand	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HMG-ﾭ‐14	 ﾠphosphorylation	 ﾠmay	 ﾠbe	 ﾠto	 ﾠprime	 ﾠthe	 ﾠhistone	 ﾠtail	 ﾠfor	 ﾠacetylation.	 ﾠHowever,	 ﾠthe	 ﾠ
precise	 ﾠrole	 ﾠof	 ﾠthis	 ﾠERK-ﾭ‐mediated	 ﾠmodification	 ﾠin	 ﾠregulating	 ﾠgene	 ﾠtranscription	 ﾠremains	 ﾠto	 ﾠ
be	 ﾠelucidated.	 ﾠ
The	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠregulate	 ﾠpre-ﾭ‐mRNA	 ﾠprocessing	 ﾠand	 ﾠ
alternative	 ﾠsplicing	 ﾠ[430,	 ﾠ431].	 ﾠThe	 ﾠheterogeneous	 ﾠnuclear	 ﾠribonucleoprotein	 ﾠ(hnRNP)-ﾭ‐K	 ﾠis	 ﾠ
a	 ﾠbona-ﾭ‐fide	 ﾠERK	 ﾠtarget	 ﾠprotein	 ﾠand	 ﾠphosphorylation	 ﾠat	 ﾠSer284	 ﾠand	 ﾠSer353	 ﾠstimulates	 ﾠits	 ﾠ
nuclear	 ﾠexport	 ﾠ[431].	 ﾠIn	 ﾠthe	 ﾠcytoplasm	 ﾠhnRNP-ﾭ‐K’s	 ﾠfunction	 ﾠare	 ﾠdiverse.	 ﾠIt	 ﾠcan	 ﾠinhibit	 ﾠ
mRNA	 ﾠtranslation	 ﾠby	 ﾠbinding	 ﾠto	 ﾠthe	 ﾠdifferentiation-ﾭ‐control	 ﾠelement	 ﾠin	 ﾠthe	 ﾠ3ˊ	 ﾠuntranslated	 ﾠ
region	 ﾠ(UTR)	 ﾠof	 ﾠtarget	 ﾠmRNAs	 ﾠ[431],	 ﾠstabilise	 ﾠmRNA	 ﾠtranscripts	 ﾠand	 ﾠthereby	 ﾠincrease	 ﾠthe	 ﾠ
expression	 ﾠof	 ﾠcertain	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠthymidine	 ﾠphosphorylase	 ﾠ[432],	 ﾠor	 ﾠpromote	 ﾠ
splicing	 ﾠof	 ﾠmRNA	 ﾠprecursors,	 ﾠsuch	 ﾠas	 ﾠEGR1	 ﾠ[433].	 ﾠThus,	 ﾠERK	 ﾠsignalling	 ﾠindirectly	 ﾠimpinges	 ﾠ
on	 ﾠpre-ﾭ‐mRNA	 ﾠprocessing	 ﾠby	 ﾠregulating	 ﾠhnRNP-ﾭ‐K	 ﾠlocalisation	 ﾠand	 ﾠthus	 ﾠaffects	 ﾠgene	 ﾠ
expression	 ﾠboth	 ﾠtranscriptionally	 ﾠand	 ﾠpost-ﾭ‐transcriptionally.	 ﾠ
Additionally,	 ﾠERK	 ﾠsignalling	 ﾠhas	 ﾠrecently	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠregulate	 ﾠgene	 ﾠexpression	 ﾠby	 ﾠ
altering	 ﾠmicroRNA	 ﾠ(miRNA)	 ﾠbiogenesis	 ﾠ[434].	 ﾠMicroRNAs	 ﾠare	 ﾠsmall	 ﾠribonucleic	 ﾠacid	 ﾠ
molecules	 ﾠwith	 ﾠan	 ﾠaverage	 ﾠlength	 ﾠof	 ﾠ21	 ﾠnucleotides.	 ﾠThey	 ﾠbind	 ﾠto	 ﾠspecific	 ﾠsequences	 ﾠof	 ﾠ
their	 ﾠtarget	 ﾠmRNAs	 ﾠand	 ﾠinhibit	 ﾠgene	 ﾠexpression	 ﾠby	 ﾠpromoting	 ﾠmRNA	 ﾠdegradation,	 ﾠ
sequestration,	 ﾠor	 ﾠtranslational	 ﾠsuppression	 ﾠ[435].	 ﾠIn	 ﾠmammals,	 ﾠmiRNA	 ﾠbiogenesis	 ﾠfollows	 ﾠ
a	 ﾠwell-ﾭ‐defined	 ﾠmaturation	 ﾠprocess.	 ﾠFirstly,	 ﾠthe	 ﾠtranscribed	 ﾠprecursor	 ﾠmolecules	 ﾠcalled	 ﾠ
pri-ﾭ‐miRNAs	 ﾠfold	 ﾠinto	 ﾠa	 ﾠdouble	 ﾠstranded	 ﾠhairpin-ﾭ‐like	 ﾠstructure,	 ﾠwhich	 ﾠis	 ﾠprocessed	 ﾠinto	 ﾠ
mature	 ﾠmiRNA	 ﾠmolecules	 ﾠin	 ﾠtwo	 ﾠconsecutive	 ﾠcleavage	 ﾠprocesses	 ﾠinvolving	 ﾠRNase	 ﾠIII	 ﾠtype	 ﾠ
endonucleases.	 ﾠIn	 ﾠthe	 ﾠnucleus	 ﾠthe	 ﾠpri-ﾭ‐miRNA	 ﾠis	 ﾠconverted	 ﾠinto	 ﾠa	 ﾠ70	 ﾠnucleotides	 ﾠlong	 ﾠ
pre-ﾭ‐miRNA	 ﾠby	 ﾠa	 ﾠcomplex	 ﾠcontaining	 ﾠDrosha	 ﾠand	 ﾠDGCR8	 ﾠ(DiGeorge	 ﾠsyndrome	 ﾠcritical	 ﾠ
region	 ﾠgene	 ﾠ8).	 ﾠFollowing	 ﾠexport	 ﾠfrom	 ﾠthe	 ﾠnucleus,	 ﾠa	 ﾠfurther	 ﾠmaturation	 ﾠprocess	 ﾠdriven	 ﾠby	 ﾠ
the	 ﾠmiRNA-ﾭ‐generating	 ﾠcomplex,	 ﾠconsisting	 ﾠof	 ﾠDICER	 ﾠand	 ﾠphospho-ﾭ‐TRBP	 ﾠ(TAR	 ﾠRNA-ﾭ‐binding	 ﾠ
protein),	 ﾠyields	 ﾠa	 ﾠmature	 ﾠmiRNA,	 ﾠwhich	 ﾠis	 ﾠsubsequently	 ﾠassembled	 ﾠinto	 ﾠfunctionally	 ﾠactive	 ﾠ
ribonucleoprotein	 ﾠcomplexes	 ﾠ[435].	 ﾠERK1/2	 ﾠhave	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠinteract	 ﾠwith	 ﾠTRBP	 ﾠin	 ﾠ
vivo	 ﾠand	 ﾠphosphorylate	 ﾠthis	 ﾠcomponent	 ﾠof	 ﾠthe	 ﾠmiRNA-ﾭ‐generating	 ﾠcomplex	 ﾠin	 ﾠvitro.	 ﾠ
Moreover,	 ﾠphosphorylation	 ﾠof	 ﾠTRBP	 ﾠenhances	 ﾠthe	 ﾠstability	 ﾠof	 ﾠthe	 ﾠmiRNA-ﾭ‐generating	 ﾠ
complex,	 ﾠresulting	 ﾠin	 ﾠan	 ﾠincrease	 ﾠin	 ﾠmiRNA	 ﾠbiogenesis	 ﾠand	 ﾠmiRNA-ﾭ‐mediated	 ﾠgene	 ﾠ
silencing	 ﾠ[434].	 ﾠ	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4.1.2  Nuclear translocation of ERK1/2 
The	 ﾠnuclear	 ﾠenvelope	 ﾠseparates	 ﾠthe	 ﾠnucleus	 ﾠfrom	 ﾠthe	 ﾠcytoplasm	 ﾠand	 ﾠensures	 ﾠselective	 ﾠ
transport	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠcellular	 ﾠcompartments.	 ﾠAlthough	 ﾠsmall	 ﾠmolecules	 ﾠcan	 ﾠ
passively	 ﾠenter	 ﾠand	 ﾠexit	 ﾠthe	 ﾠnucleus,	 ﾠtransport	 ﾠof	 ﾠlarger	 ﾠentities,	 ﾠsuch	 ﾠas	 ﾠproteins	 ﾠor	 ﾠRNAs,	 ﾠ
is	 ﾠtightly	 ﾠcontrolled	 ﾠby	 ﾠtransport	 ﾠchannels	 ﾠcalled	 ﾠnuclear	 ﾠpore	 ﾠcomplexes	 ﾠ(NPCs).	 ﾠA	 ﾠfamily	 ﾠ
of	 ﾠproteins	 ﾠcalled	 ﾠnucleoporins	 ﾠ(NUPs)	 ﾠassemble	 ﾠto	 ﾠform	 ﾠthese	 ﾠchannels,	 ﾠwhich	 ﾠare	 ﾠalso	 ﾠ
known	 ﾠas	 ﾠnuclear	 ﾠpores	 ﾠ[436].	 ﾠIn	 ﾠgeneral,	 ﾠproteins,	 ﾠwhich	 ﾠare	 ﾠdesignated	 ﾠfor	 ﾠnuclear	 ﾠ
transport,	 ﾠcarry	 ﾠa	 ﾠnuclear	 ﾠlocalisation	 ﾠsignal	 ﾠ(NLS),	 ﾠwhich	 ﾠis	 ﾠrecognised	 ﾠand	 ﾠbound	 ﾠby	 ﾠ
importins.	 ﾠOnce	 ﾠimportins	 ﾠare	 ﾠloaded	 ﾠwith	 ﾠcargo	 ﾠproteins,	 ﾠthey	 ﾠinteract	 ﾠwith	 ﾠthe	 ﾠNPC	 ﾠand	 ﾠ
travel	 ﾠthrough	 ﾠthe	 ﾠtransport	 ﾠchannels.	 ﾠIn	 ﾠthe	 ﾠnucleus,	 ﾠthe	 ﾠsmall	 ﾠGTPase	 ﾠRAN	 ﾠbinds	 ﾠto	 ﾠthe	 ﾠ
importin-ﾭ‐cargo	 ﾠcomplex	 ﾠand	 ﾠinduces	 ﾠa	 ﾠconformational	 ﾠchange,	 ﾠwhich	 ﾠpromotes	 ﾠ
dissociation	 ﾠof	 ﾠthe	 ﾠcargo	 ﾠfrom	 ﾠimportins	 ﾠand	 ﾠrenders	 ﾠRAN	 ﾠinactive.	 ﾠSubsequently,	 ﾠ
RAN-ﾭ‐GDP	 ﾠand	 ﾠimportin	 ﾠare	 ﾠexported	 ﾠto	 ﾠthe	 ﾠcytoplasm,	 ﾠwhere	 ﾠRAN	 ﾠcan	 ﾠbe	 ﾠactivated	 ﾠby	 ﾠ
GTP	 ﾠloading	 ﾠand	 ﾠimportins	 ﾠcan	 ﾠbind	 ﾠnew	 ﾠcargo	 ﾠproteins	 ﾠ[437].	 ﾠ
Neither	 ﾠERK1/2	 ﾠnor	 ﾠMEK1/2	 ﾠcontain	 ﾠconventional	 ﾠ[438]	 ﾠor	 ﾠnon-ﾭ‐conventional	 ﾠ[439]	 ﾠNLSs,	 ﾠ
which	 ﾠsuggests	 ﾠthat	 ﾠthe	 ﾠkinases	 ﾠmust	 ﾠdepend	 ﾠon	 ﾠalternative	 ﾠmechanisms	 ﾠdriving	 ﾠtheir	 ﾠ
nuclear	 ﾠimport.	 ﾠIt	 ﾠis	 ﾠpossible	 ﾠthat	 ﾠERK1/2	 ﾠinteract	 ﾠwith	 ﾠproteins	 ﾠcontaining	 ﾠNLS,	 ﾠand	 ﾠthus,	 ﾠ
hitch	 ﾠa	 ﾠride	 ﾠinto	 ﾠthe	 ﾠnucleus.	 ﾠHowever,	 ﾠno	 ﾠdirect	 ﾠinteraction	 ﾠpartner	 ﾠcomprising	 ﾠa	 ﾠNLS	 ﾠhas	 ﾠ
so	 ﾠfar	 ﾠbeen	 ﾠidentified,	 ﾠsuggesting	 ﾠthat	 ﾠother	 ﾠmechanisms	 ﾠdrive	 ﾠERK	 ﾠtranslocation	 ﾠinto	 ﾠthe	 ﾠ
nucleus.	 ﾠIn	 ﾠ1999,	 ﾠERK1/2	 ﾠwere	 ﾠshown	 ﾠto	 ﾠpenetrate	 ﾠthe	 ﾠNPC	 ﾠby	 ﾠmeans	 ﾠof	 ﾠpassive	 ﾠdiffusion	 ﾠ
as	 ﾠa	 ﾠmonomer	 ﾠor	 ﾠactive	 ﾠtransport	 ﾠas	 ﾠa	 ﾠdimer	 ﾠ[440].	 ﾠWhether	 ﾠactive	 ﾠimport	 ﾠreally	 ﾠinvolves	 ﾠ
ERK	 ﾠdimerization,	 ﾠhowever,	 ﾠis	 ﾠcontroversial,	 ﾠas	 ﾠmutants	 ﾠimpaired	 ﾠin	 ﾠdimerization	 ﾠwere	 ﾠ
still	 ﾠtranslocated	 ﾠusing	 ﾠan	 ﾠenergy-ﾭ‐dependent	 ﾠmechanism	 ﾠ[441].	 ﾠMoreover,	 ﾠCasar	 ﾠet	 ﾠal.	 ﾠ
demonstrated	 ﾠthat	 ﾠERKs	 ﾠaccumulate	 ﾠin	 ﾠthe	 ﾠnucleus	 ﾠas	 ﾠmonomers,	 ﾠand	 ﾠthat	 ﾠ
phosphorylation	 ﾠof	 ﾠtranscription	 ﾠfactors	 ﾠby	 ﾠERK1/2	 ﾠdoes	 ﾠnot	 ﾠrequire	 ﾠprotein	 ﾠ
dimerization	 ﾠ[442].	 ﾠYet,	 ﾠLidke	 ﾠet	 ﾠal.	 ﾠshowed	 ﾠthat	 ﾠinhibition	 ﾠof	 ﾠERK	 ﾠdimerization	 ﾠresulted	 ﾠin	 ﾠ
delayed	 ﾠnuclear	 ﾠERK	 ﾠaccumulation,	 ﾠsuggesting	 ﾠthat	 ﾠERK	 ﾠdimers	 ﾠand	 ﾠmonomers	 ﾠare	 ﾠ
transported	 ﾠacross	 ﾠnuclear	 ﾠpores	 ﾠwith	 ﾠdifferent	 ﾠkinetics	 ﾠ[443].	 ﾠIntriguingly,	 ﾠMarchi	 ﾠet	 ﾠal.	 ﾠ
demonstrated	 ﾠclear	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠnuclear	 ﾠshuttling	 ﾠfrequencies	 ﾠbetween	 ﾠERK1	 ﾠand	 ﾠ
ERK2,	 ﾠwith	 ﾠERK1	 ﾠbeing	 ﾠimported	 ﾠand	 ﾠexported	 ﾠat	 ﾠa	 ﾠmuch	 ﾠslower	 ﾠrate	 ﾠthan	 ﾠERK2	 ﾠ[416].	 ﾠ
Moreover,	 ﾠdomain	 ﾠswapping	 ﾠinverted	 ﾠthe	 ﾠshuttling	 ﾠfrequencies	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠand	 ﾠ
attributed	 ﾠthe	 ﾠdiscrepancy	 ﾠin	 ﾠnuclear	 ﾠtrafficking	 ﾠto	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠamino	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acid	 ﾠsequence.	 ﾠOwing	 ﾠto	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠERKs	 ﾠare	 ﾠpredominantly	 ﾠinactivated	 ﾠin	 ﾠthe	 ﾠnucleus,	 ﾠ
continuous	 ﾠcytoplasmic-ﾭ‐nuclear	 ﾠshuttling	 ﾠensures	 ﾠa	 ﾠconstant	 ﾠlevel	 ﾠof	 ﾠactive	 ﾠERK.	 ﾠThus,	 ﾠ
lower	 ﾠshuttling	 ﾠrates	 ﾠfor	 ﾠERK1	 ﾠmay	 ﾠmake	 ﾠthe	 ﾠkinase	 ﾠmore	 ﾠsusceptible	 ﾠfor	 ﾠnuclear	 ﾠ
inactivation	 ﾠand	 ﾠERK2	 ﾠthe	 ﾠpredominant	 ﾠkinase	 ﾠdriving	 ﾠgene	 ﾠexpression	 ﾠ[416].	 ﾠ
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 ﾠ(for	 ﾠERK2),	 ﾠhave	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠbe	 ﾠimportant	 ﾠin	 ﾠregulating	 ﾠnuclear	 ﾠ
translocation.	 ﾠThis	 ﾠmotif	 ﾠresides	 ﾠin	 ﾠthe	 ﾠkinase	 ﾠinsert	 ﾠdomain	 ﾠ(KID)	 ﾠof	 ﾠERK	 ﾠand	 ﾠboth	 ﾠserine	 ﾠ
residues	 ﾠundergo	 ﾠphosphorylation	 ﾠfollowing	 ﾠTEY	 ﾠmotif	 ﾠactivation	 ﾠby	 ﾠMEK1/2	 ﾠ[444].	 ﾠ
Synergistic	 ﾠphosphorylation	 ﾠof	 ﾠthe	 ﾠSer-ﾭ‐Pro-ﾭ‐Ser	 ﾠmotif	 ﾠinduces	 ﾠbinding	 ﾠto	 ﾠimportin7,	 ﾠwhich	 ﾠ
is	 ﾠbelieved	 ﾠto	 ﾠescort	 ﾠERK1/2	 ﾠthrough	 ﾠnuclear	 ﾠpores.	 ﾠMoreover,	 ﾠERK1/2	 ﾠmay	 ﾠpromote	 ﾠ
nuclear	 ﾠentry	 ﾠthrough	 ﾠenergy-ﾭ‐independent	 ﾠand	 ﾠenergy-ﾭ‐dependent	 ﾠmechanisms	 ﾠby	 ﾠ
phosphorylating	 ﾠNUPs	 ﾠ(NUP50,	 ﾠNUP153	 ﾠand	 ﾠNUP214)	 ﾠdirectly	 ﾠ[445,	 ﾠ446].	 ﾠ	 ﾠ
Another	 ﾠimportant	 ﾠregulator	 ﾠof	 ﾠnuclear	 ﾠERK	 ﾠshuttling	 ﾠis	 ﾠMxi2,	 ﾠwhich	 ﾠpromotes	 ﾠ
translocation	 ﾠof	 ﾠERK1/2	 ﾠin	 ﾠa	 ﾠstimulus-ﾭ‐independent	 ﾠmanner	 ﾠby	 ﾠacting	 ﾠas	 ﾠan	 ﾠadapter	 ﾠ
molecule.	 ﾠMxi2	 ﾠinteracts	 ﾠwith	 ﾠboth	 ﾠERKs	 ﾠand	 ﾠNUPs	 ﾠdirectly,	 ﾠand	 ﾠthereby	 ﾠpromotes	 ﾠ
nuclear	 ﾠimport	 ﾠ[231].	 ﾠMore	 ﾠwork	 ﾠis	 ﾠrequired	 ﾠto	 ﾠdeduce	 ﾠhow	 ﾠERK1/2	 ﾠare	 ﾠshuttled	 ﾠinto	 ﾠthe	 ﾠ
nucleus	 ﾠand	 ﾠwhether	 ﾠERK-ﾭ‐mediated	 ﾠphosphorylation	 ﾠof	 ﾠNUPs	 ﾠpromotes	 ﾠnuclear	 ﾠentry.	 ﾠ
Moreover,	 ﾠfuture	 ﾠresearch	 ﾠwill	 ﾠhave	 ﾠto	 ﾠaddress	 ﾠthe	 ﾠisoform-ﾭ‐specific	 ﾠshuttling	 ﾠfrequencies	 ﾠ
of	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠquestioning	 ﾠhow	 ﾠthese	 ﾠare	 ﾠprovoked	 ﾠmechanistically.	 ﾠ
4.1.3  The role of extracellular matrix adhesions on nuclear ERK signalling 
The	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠserves	 ﾠto	 ﾠconvert	 ﾠextracellular	 ﾠstimuli	 ﾠinto	 ﾠphysiological	 ﾠ
responses	 ﾠby	 ﾠtransducing	 ﾠinput	 ﾠsignals	 ﾠto	 ﾠsubcellular	 ﾠcompartments	 ﾠand	 ﾠthereby	 ﾠ
regulating	 ﾠfundamental	 ﾠcellular	 ﾠprocesses,	 ﾠsuch	 ﾠas	 ﾠproliferation,	 ﾠdifferentiation	 ﾠand	 ﾠcell	 ﾠ
migration.	 ﾠThis	 ﾠrole	 ﾠin	 ﾠsignal	 ﾠtransduction,	 ﾠhowever,	 ﾠdemands	 ﾠa	 ﾠlink	 ﾠbetween	 ﾠpathway	 ﾠ
activation	 ﾠand	 ﾠthe	 ﾠextracellular	 ﾠenvironment	 ﾠto	 ﾠensure	 ﾠadequate	 ﾠsignalling	 ﾠresponses.	 ﾠ
Interestingly,	 ﾠa	 ﾠbody	 ﾠof	 ﾠwork	 ﾠhas	 ﾠshown	 ﾠthat	 ﾠcell	 ﾠadhesion	 ﾠvia	 ﾠintegrin	 ﾠengagement	 ﾠis	 ﾠ
frequently	 ﾠrequired	 ﾠfor	 ﾠefficient	 ﾠERK	 ﾠactivation,	 ﾠas	 ﾠgrowth	 ﾠfactors	 ﾠfail	 ﾠto	 ﾠinduce	 ﾠERK	 ﾠ
signalling,	 ﾠwhen	 ﾠcells	 ﾠwere	 ﾠkept	 ﾠin	 ﾠsuspension	 ﾠ[447-ﾭ‐450].	 ﾠMoreover,	 ﾠanchorage	 ﾠ
dependency	 ﾠhas	 ﾠalso	 ﾠbeen	 ﾠdemonstrated	 ﾠfor	 ﾠERK’s	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠgene	 ﾠexpression,	 ﾠas	 ﾠ
phosphorylation	 ﾠof	 ﾠthe	 ﾠtranscription	 ﾠfactor	 ﾠELK	 ﾠat	 ﾠSer385	 ﾠis	 ﾠreduced	 ﾠin	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠChapter 4 – ERK2 regulates expression of CSF2, Rab17 and Liprin-β2 in 3D microenvironments  146 
integrin-ﾭ‐mediated	 ﾠadhesions	 ﾠ[451].	 ﾠThis	 ﾠsuggests	 ﾠthat	 ﾠextracellular	 ﾠmatrix	 ﾠadhesions	 ﾠplay	 ﾠ
an	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠactivating	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠcascade	 ﾠas	 ﾠwell	 ﾠas	 ﾠlocalising	 ﾠERK1/2	 ﾠto	 ﾠ
subcellular	 ﾠlocalisations.	 ﾠIntegrins	 ﾠare	 ﾠcell	 ﾠsurface	 ﾠreceptors,	 ﾠwhich	 ﾠcontribute	 ﾠto	 ﾠthe	 ﾠ
tethering	 ﾠof	 ﾠthe	 ﾠactin	 ﾠcytoskeleton	 ﾠto	 ﾠthe	 ﾠmembrane	 ﾠat	 ﾠadhesion	 ﾠsites,	 ﾠand	 ﾠcan	 ﾠalso	 ﾠ
recruit	 ﾠa	 ﾠvariety	 ﾠof	 ﾠstructural	 ﾠand	 ﾠsignalling	 ﾠmolecules.	 ﾠIt	 ﾠis	 ﾠwell-ﾭ‐established	 ﾠthat	 ﾠERK	 ﾠ
signalling	 ﾠis	 ﾠenhanced	 ﾠat	 ﾠfocal	 ﾠadhesions	 ﾠsites	 ﾠ[214],	 ﾠbut	 ﾠit	 ﾠhas	 ﾠyet	 ﾠto	 ﾠbe	 ﾠdetermined	 ﾠhow	 ﾠ
integrin	 ﾠengagement	 ﾠcontrols	 ﾠERK	 ﾠtrafficking.	 ﾠIt	 ﾠis	 ﾠpossible,	 ﾠhowever,	 ﾠthat	 ﾠ
integrin-ﾭ‐mediated	 ﾠorganisation	 ﾠof	 ﾠthe	 ﾠcytoskeleton	 ﾠfacilitates	 ﾠtransport	 ﾠand/or	 ﾠnuclear	 ﾠ
entry	 ﾠof	 ﾠactivated	 ﾠERK	 ﾠmolecules.	 ﾠ
4.1.4  Experimental paradigm 
In	 ﾠthe	 ﾠprevious	 ﾠchapter	 ﾠwe	 ﾠshowed	 ﾠthat	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1	 ﾠdrives	 ﾠtumour	 ﾠcell	 ﾠinvasion	 ﾠ
and	 ﾠmigration	 ﾠon	 ﾠ3D	 ﾠmatrices	 ﾠby	 ﾠincreasing	 ﾠthe	 ﾠmomentary	 ﾠmigration	 ﾠvelocity	 ﾠand	 ﾠ
decreasing	 ﾠcellular	 ﾠresting.	 ﾠAlthough	 ﾠwe	 ﾠwere	 ﾠable	 ﾠto	 ﾠdemonstrate	 ﾠclear	 ﾠfunctional	 ﾠ
disparities	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠkinases	 ﾠwith	 ﾠregards	 ﾠto	 ﾠcell	 ﾠmotility,	 ﾠthe	 ﾠunderlying	 ﾠ
mechanism	 ﾠremained	 ﾠunresolved.	 ﾠGiven	 ﾠthat	 ﾠMarchi	 ﾠet	 ﾠal.	 ﾠdemonstrated	 ﾠdifferential	 ﾠ
nuclear	 ﾠshuttling	 ﾠfrequencies	 ﾠfor	 ﾠERK1	 ﾠand	 ﾠERK2,	 ﾠand	 ﾠproposed	 ﾠERK2	 ﾠto	 ﾠbe	 ﾠthe	 ﾠ
predominant	 ﾠkinase	 ﾠdriving	 ﾠgene	 ﾠexpression	 ﾠ[416],	 ﾠwe	 ﾠdecided	 ﾠto	 ﾠperform	 ﾠa	 ﾠmRNA	 ﾠ
microarray	 ﾠscreen	 ﾠto	 ﾠsearch	 ﾠfor	 ﾠgenes	 ﾠthat	 ﾠare	 ﾠexpressed	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠmanner.	 ﾠAs	 ﾠ
cells	 ﾠcultured	 ﾠin	 ﾠ3D	 ﾠexhibit	 ﾠcompletely	 ﾠdifferent	 ﾠgene	 ﾠexpression	 ﾠsignatures	 ﾠwhen	 ﾠ
compared	 ﾠto	 ﾠ2D	 ﾠ[395]	 ﾠand	 ﾠnuclear	 ﾠtranslocation	 ﾠof	 ﾠERK	 ﾠis	 ﾠaltered	 ﾠby	 ﾠmatrix	 ﾠ
adhesions	 ﾠ[451],	 ﾠwe	 ﾠchose	 ﾠto	 ﾠperform	 ﾠour	 ﾠcomparative	 ﾠgene	 ﾠexpression	 ﾠanalysis	 ﾠin	 ﾠa	 ﾠ3D	 ﾠ
microenvironment.	 ﾠA	 ﾠdiagram	 ﾠillustrating	 ﾠthe	 ﾠexperimental	 ﾠset-ﾭ‐up	 ﾠand	 ﾠour	 ﾠdata	 ﾠfiltering	 ﾠ
strategy	 ﾠis	 ﾠpresented	 ﾠin	 ﾠFigure	 ﾠ4-ﾭ‐1.	 ﾠERK2-ﾭ‐regulated	 ﾠgenes	 ﾠare	 ﾠexpected	 ﾠto	 ﾠshow	 ﾠan	 ﾠ
increase	 ﾠ(or	 ﾠdecrease)	 ﾠin	 ﾠmRNA	 ﾠlevels	 ﾠupon	 ﾠERK2	 ﾠsilencing.	 ﾠRe-ﾭ‐expression	 ﾠof	 ﾠectopic	 ﾠERK2	 ﾠ
(but	 ﾠnot	 ﾠERK1)	 ﾠshould	 ﾠbe	 ﾠable	 ﾠto	 ﾠrevert	 ﾠthe	 ﾠinduction	 ﾠ(or	 ﾠinhibition)	 ﾠof	 ﾠmRNA	 ﾠlevels	 ﾠto	 ﾠ
control.	 ﾠ
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Figure 4-1 Experimental paradigm 
Diagram illustrating the experimental approach for the identification of an ERK2-dependent gene expression 
signature in a 3D microenvironment. In brief, MDA-MB-231 cells are transfected with NT siRNA, single 
oligos targeting ERK1 or ERK2 in combination with expression plasmids for SF-ERK1, siRNA-resistant 
SF-ERK2 or an empty vector control (EV) and plated onto cell-derived matrix. Bar graphs show possible 
mRNA expression levels for genes, which are induced or suppressed in an ERK2-dependent manner.  
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4.2  Results 
4.2.1  Microarray analysis identified an ERK2-specific gene expression 
signature 
4.2.1.1  Quality control of microarray samples 
To	 ﾠdetermine	 ﾠwhether	 ﾠisoform-ﾭ‐specific	 ﾠregulation	 ﾠof	 ﾠgene	 ﾠexpression	 ﾠwas	 ﾠresponsible	 ﾠfor	 ﾠ
ERK2’s	 ﾠinfluence	 ﾠover	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion,	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠwere	 ﾠtransfected	 ﾠ
with	 ﾠnon-ﾭ‐targeting	 ﾠsiRNAs	 ﾠ(NT),	 ﾠor	 ﾠsingle	 ﾠoligos	 ﾠtargeting	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠin	 ﾠcombination	 ﾠ
with	 ﾠexpression	 ﾠplasmids	 ﾠfor	 ﾠSF-ﾭ‐ERK1,	 ﾠsiRNA-ﾭ‐resistant	 ﾠSF-ﾭ‐ERK2	 ﾠor	 ﾠan	 ﾠempty	 ﾠvector	 ﾠcontrol	 ﾠ
(EV)	 ﾠand	 ﾠplated	 ﾠonto	 ﾠcell-ﾭ‐derived	 ﾠmatrix.	 ﾠ16	 ﾠhours	 ﾠfollowing	 ﾠplating,	 ﾠthe	 ﾠcells	 ﾠwere	 ﾠlysed.	 ﾠ
The	 ﾠefficacy	 ﾠof	 ﾠERK	 ﾠknockdown	 ﾠand	 ﾠexpression	 ﾠof	 ﾠSF-ﾭ‐ERKs	 ﾠwere	 ﾠdetermined	 ﾠby	 ﾠWestern	 ﾠ
blotting	 ﾠ(Figure	 ﾠ4-ﾭ‐2	 ﾠA),	 ﾠand	 ﾠthis	 ﾠshowed	 ﾠthat	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠwere	 ﾠefficiently	 ﾠsilenced	 ﾠ
by	 ﾠtheir	 ﾠrespective	 ﾠsiRNAs.	 ﾠFurthermore,	 ﾠSF-ﾭ‐ERK1	 ﾠand	 ﾠsiRNA-ﾭ‐resistant	 ﾠSF-ﾭ‐ERK2	 ﾠwere	 ﾠ
expressed	 ﾠto	 ﾠequal	 ﾠlevels	 ﾠafter	 ﾠknocking	 ﾠdown	 ﾠERK2,	 ﾠthus	 ﾠensuring	 ﾠthat	 ﾠdisparities	 ﾠin	 ﾠthe	 ﾠ
expression	 ﾠlevels	 ﾠof	 ﾠthese	 ﾠkinases	 ﾠwere	 ﾠnot	 ﾠresponsible	 ﾠfor	 ﾠany	 ﾠresults	 ﾠobtained	 ﾠfrom	 ﾠthe	 ﾠ
microarray.	 ﾠ
Total	 ﾠRNA	 ﾠwas	 ﾠharvested	 ﾠfrom	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠusing	 ﾠthe	 ﾠRNeasy	 ﾠKit	 ﾠ(Qiagen)	 ﾠand	 ﾠ
traces	 ﾠof	 ﾠgenomic	 ﾠDNA	 ﾠwere	 ﾠremoved	 ﾠby	 ﾠmechanical	 ﾠshear	 ﾠand	 ﾠDNase1.	 ﾠThe	 ﾠ
concentration	 ﾠand	 ﾠpurity	 ﾠof	 ﾠthe	 ﾠisolated	 ﾠRNA	 ﾠwere	 ﾠdetermined	 ﾠby	 ﾠmeasuring	 ﾠthe	 ﾠ
absorbance	 ﾠat	 ﾠ260	 ﾠnm	 ﾠand	 ﾠ280	 ﾠnm	 ﾠusing	 ﾠa	 ﾠNanoVue	 ﾠspectrophotometer.	 ﾠAll	 ﾠsamples	 ﾠ
exhibited	 ﾠA260nm/A280nm	 ﾠabsorbance	 ﾠratios	 ﾠgreater	 ﾠthan	 ﾠ1.8,	 ﾠindicating	 ﾠthat	 ﾠcontamination	 ﾠ
with	 ﾠprotein	 ﾠwas	 ﾠnegligible.	 ﾠWe	 ﾠthen	 ﾠlabelled	 ﾠthe	 ﾠisolated	 ﾠRNA	 ﾠusing	 ﾠthe	 ﾠIllumina®	 ﾠ
TotalPrep
TM	 ﾠRNA	 ﾠlabelling	 ﾠKit	 ﾠ(Ambion).	 ﾠIn	 ﾠbrief,	 ﾠthe	 ﾠmRNA	 ﾠof	 ﾠeach	 ﾠsample	 ﾠwas	 ﾠconverted	 ﾠ
into	 ﾠcDNA,	 ﾠwhich	 ﾠwas	 ﾠthen	 ﾠused	 ﾠas	 ﾠa	 ﾠtemplate	 ﾠfor	 ﾠin	 ﾠvitro	 ﾠtranscription	 ﾠwith	 ﾠ
biotin-ﾭ‐16-ﾭ‐UTP	 ﾠto	 ﾠproduce	 ﾠlabelled	 ﾠcRNA	 ﾠmolecules.	 ﾠThe	 ﾠyield	 ﾠof	 ﾠthe	 ﾠcRNA	 ﾠamplification	 ﾠ
step	 ﾠwas	 ﾠassessed	 ﾠby	 ﾠmeasuring	 ﾠthe	 ﾠabsorbance	 ﾠat	 ﾠ260	 ﾠnm.	 ﾠAfter	 ﾠadjusting	 ﾠthe	 ﾠcRNA	 ﾠ
concentrations	 ﾠto	 ﾠ0.2	 ﾠµg/µl,	 ﾠthe	 ﾠsamples	 ﾠwere	 ﾠsent	 ﾠto	 ﾠthe	 ﾠWellcome	 ﾠTrust	 ﾠClinical	 ﾠ
Research	 ﾠFacility	 ﾠin	 ﾠEdinburgh,	 ﾠwhere	 ﾠthe	 ﾠintegrity	 ﾠof	 ﾠthe	 ﾠbiotinylated	 ﾠcRNA	 ﾠwas	 ﾠassessed	 ﾠ
using	 ﾠan	 ﾠAgilent	 ﾠBioanalyser.	 ﾠThe	 ﾠelectropherograms	 ﾠfor	 ﾠeach	 ﾠsample	 ﾠdisplayed	 ﾠa	 ﾠ
distribution	 ﾠof	 ﾠRNA	 ﾠmolecules	 ﾠof	 ﾠvarying	 ﾠsizes	 ﾠranging	 ﾠfrom	 ﾠ250	 ﾠto	 ﾠ5500	 ﾠnucleotides	 ﾠwith	 ﾠ
most	 ﾠof	 ﾠthe	 ﾠcRNAs	 ﾠat	 ﾠ1000	 ﾠto	 ﾠ1500	 ﾠnucleotides.	 ﾠThis	 ﾠsuggests	 ﾠthat	 ﾠno	 ﾠmRNA	 ﾠor	 ﾠcRNA	 ﾠ
degradation	 ﾠoccurred	 ﾠduring	 ﾠsample	 ﾠpreparation	 ﾠ(Figure	 ﾠ4-ﾭ‐2	 ﾠB).	 ﾠSubsequently,	 ﾠthe	 ﾠ	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Figure 4-2 Quality control of the microarray samples 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2 in combination with expression plasmids for SF-ERK1, siRNA-resistant SF-ERK2 or an empty vector 
control (EV) and plated onto cell-derived matrix.  
A. The efficacy of RNAi and ectopic ERK expression was assessed by Western blot 16 hours post 
nucleofection for all three microarray samples. 
B. Total RNA was isolated using the RNeasy kit (Qiagen) and subsequently converted into labelled cRNA 
using the TotalPrep RNA Labeling Kit (Ambion). The integrity and concentration of the cRNA samples were 
assessed with the help of an Agilent Bioanalyser. Representative electropherogram scans for all conditions of 
one biological replicate are shown. 
  	 ﾠ
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Genetic	 ﾠCore	 ﾠFacility	 ﾠperformed	 ﾠwhole	 ﾠgenome	 ﾠexpression	 ﾠanalysis	 ﾠon	 ﾠ
HumanHT-ﾭ‐12	 ﾠv4	 ﾠExpression	 ﾠBeadChips,	 ﾠwhich	 ﾠallows	 ﾠcomparative	 ﾠexpression	 ﾠanalysis	 ﾠof	 ﾠ
over	 ﾠ47,000	 ﾠtranscripts.	 ﾠ
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4.2.1.2  Normalisation of microarray data yields good clustering of experimental 
replicas 
As	 ﾠnon-ﾭ‐biological	 ﾠvariations	 ﾠbetween	 ﾠbead	 ﾠchips	 ﾠ(such	 ﾠas	 ﾠtechnical	 ﾠvariations	 ﾠduring	 ﾠbead	 ﾠ
chip	 ﾠgeneration,	 ﾠsample	 ﾠlabelling	 ﾠand	 ﾠhybridisation)	 ﾠmay	 ﾠobscure	 ﾠchanges	 ﾠin	 ﾠgene	 ﾠ
alterations,	 ﾠit	 ﾠis	 ﾠimperative	 ﾠto	 ﾠnormalise	 ﾠraw	 ﾠdata	 ﾠobtained	 ﾠfrom	 ﾠthe	 ﾠBeadArray	 ﾠ
Reader	 ﾠ[452].	 ﾠWe	 ﾠacquired	 ﾠ24	 ﾠgene	 ﾠsignal	 ﾠprofiles	 ﾠafter	 ﾠdirect	 ﾠhybridisation	 ﾠof	 ﾠthe	 ﾠ
HumanHT-ﾭ‐12	 ﾠv4	 ﾠExpression	 ﾠBeadChips,	 ﾠwhich	 ﾠwere	 ﾠnormalised	 ﾠand	 ﾠanalysed	 ﾠwith	 ﾠthe	 ﾠ
help	 ﾠof	 ﾠthe	 ﾠPartek®	 ﾠGenomics	 ﾠSuite	 ﾠSoftware,	 ﾠversion	 ﾠ6.5	 ﾠby	 ﾠDr.	 ﾠGabriela	 ﾠKalna.	 ﾠAll	 ﾠvalues	 ﾠ
were	 ﾠadjusted	 ﾠby	 ﾠquantile	 ﾠnormalisation	 ﾠand	 ﾠlog2	 ﾠtransformation,	 ﾠwhich	 ﾠwas	 ﾠpreviously	 ﾠ
shown	 ﾠto	 ﾠgive	 ﾠthe	 ﾠbest	 ﾠresults	 ﾠfor	 ﾠIllumina	 ﾠgene	 ﾠexpression	 ﾠdata	 ﾠ[453].	 ﾠSubsequent	 ﾠ
principle	 ﾠcomponent	 ﾠanalysis	 ﾠgave	 ﾠrise	 ﾠto	 ﾠscatter	 ﾠplots,	 ﾠwhich	 ﾠshowed	 ﾠa	 ﾠgood	 ﾠoverlap	 ﾠof	 ﾠ
sample	 ﾠreplicates	 ﾠfrom	 ﾠtwo	 ﾠchips	 ﾠ(Figure	 ﾠ4-ﾭ‐3	 ﾠA)	 ﾠbut	 ﾠalso	 ﾠan	 ﾠundesirable	 ﾠexperimental	 ﾠ
replica	 ﾠclustering	 ﾠ(Figure	 ﾠ4-ﾭ‐3	 ﾠB).	 ﾠTo	 ﾠremove	 ﾠthis	 ﾠbatch-ﾭ‐dependent	 ﾠeffect	 ﾠa	 ﾠmixed	 ﾠmodel	 ﾠ
ANOVA	 ﾠ(analysis	 ﾠof	 ﾠvariances)	 ﾠwas	 ﾠperformed,	 ﾠwhich	 ﾠadjusts	 ﾠthe	 ﾠdata	 ﾠin	 ﾠsuch	 ﾠa	 ﾠway	 ﾠthat	 ﾠ
batches	 ﾠare	 ﾠcomparable	 ﾠto	 ﾠone	 ﾠanother	 ﾠ(Figure	 ﾠ4-ﾭ‐3	 ﾠC)	 ﾠ[454].	 ﾠFinally,	 ﾠoutliers	 ﾠof	 ﾠsamples	 ﾠ
were	 ﾠremoved	 ﾠaccording	 ﾠto	 ﾠstandard	 ﾠprotocol	 ﾠand	 ﾠthe	 ﾠremaining	 ﾠ19	 ﾠsamples	 ﾠ
renormalized	 ﾠas	 ﾠdescribed	 ﾠabove,	 ﾠwhich	 ﾠresulted	 ﾠin	 ﾠgood	 ﾠclustering	 ﾠof	 ﾠthe	 ﾠexperimental	 ﾠ
microarray	 ﾠreplicas	 ﾠ(Figure	 ﾠ4-ﾭ‐3	 ﾠD).	 ﾠDifferentially	 ﾠexpressed	 ﾠgenes	 ﾠwere	 ﾠidentified	 ﾠby	 ﾠ
ANOVA	 ﾠ(analysis	 ﾠof	 ﾠvariances)	 ﾠand	 ﾠpost-ﾭ‐hoc	 ﾠlinear	 ﾠcontrasts	 ﾠperformed	 ﾠbetween	 ﾠall	 ﾠpairs	 ﾠ
of	 ﾠexperimental	 ﾠconditions.	 ﾠMultiple	 ﾠtest	 ﾠcorrections	 ﾠ(Bonferroni	 ﾠand	 ﾠstep	 ﾠup	 ﾠBenjamini-ﾭ‐
Hochberg)	 ﾠwere	 ﾠperformed	 ﾠfor	 ﾠall	 ﾠcalculated	 ﾠp-ﾭ‐values.	 ﾠ	 ﾠ
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Figure 4-3 Normalisation results in good clustering of experimental replicas 
Microarray raw data was normalised and analysed in PARTEK ® Genomics Suite Software. Demonstrated 
are: 
A. Clustering patterns of all 24 samples after normalisation and Log2 transformation. 
B. Scatter plots of batch effects from different biological replicas. 
C. Clustering patterns after batch effect removal through mixed model ANOVA. 
D. Data clustering after the removal of outliers, renormalisation and Log2 transformation. 
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4.2.1.3  Microarray analysis identifies genes whose expression is down-regulated 
following ERK2 knockdown 
Following	 ﾠnormalisation,	 ﾠbatch	 ﾠeffect	 ﾠremoval	 ﾠand	 ﾠlog	 ﾠtransformation,	 ﾠMultiway	 ﾠANOVA	 ﾠ
(analysis	 ﾠof	 ﾠvariances)	 ﾠwas	 ﾠused	 ﾠto	 ﾠidentify	 ﾠgenes	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠdown-ﾭ‐regulated	 ﾠ
following	 ﾠERK2	 ﾠsilencing.	 ﾠMultiple	 ﾠfiltering	 ﾠsteps	 ﾠwere	 ﾠperformed	 ﾠto	 ﾠgenerate	 ﾠa	 ﾠlist	 ﾠof	 ﾠ
ERK2-ﾭ‐regulated	 ﾠgenes.	 ﾠThus,	 ﾠgenes	 ﾠhad	 ﾠto	 ﾠshow	 ﾠ(i)	 ﾠa	 ﾠsignificant	 ﾠdecrease	 ﾠin	 ﾠexpression	 ﾠ
when	 ﾠERK2	 ﾠdepleted	 ﾠcells	 ﾠwere	 ﾠcompared	 ﾠto	 ﾠNT	 ﾠsiRNA	 ﾠ(step-ﾭ‐up	 ﾠp-ﾭ‐value	 ﾠ≤	 ﾠ0.05)	 ﾠand	 ﾠ
(ii)	 ﾠinverse	 ﾠchanges	 ﾠwith	 ﾠrespect	 ﾠto	 ﾠfold	 ﾠchanges	 ﾠand	 ﾠp-ﾭ‐value	 ﾠwhen	 ﾠsiRNA-ﾭ‐resistant	 ﾠ
SF-ﾭ‐ERK2	 ﾠwas	 ﾠre-ﾭ‐expressed	 ﾠ(step-ﾭ‐up	 ﾠp-ﾭ‐value	 ﾠ≤	 ﾠ0.05,	 ﾠfold	 ﾠchange	 ﾠ≥	 ﾠ1.3).	 ﾠAfter	 ﾠapplying	 ﾠthese	 ﾠ
filtering	 ﾠcriteria,	 ﾠwe	 ﾠobtained	 ﾠa	 ﾠset	 ﾠof	 ﾠ47	 ﾠgenes,	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠdecreased	 ﾠ
following	 ﾠERK2	 ﾠdepletion	 ﾠ(Figure	 ﾠ4-ﾭ‐4).	 ﾠThese	 ﾠgenes	 ﾠwere	 ﾠthen	 ﾠranked	 ﾠaccording	 ﾠto	 ﾠfold	 ﾠ
changes	 ﾠobtained	 ﾠwhen	 ﾠERK2	 ﾠknockdown	 ﾠwas	 ﾠcompared	 ﾠto	 ﾠERK2	 ﾠre-ﾭ‐expression.	 ﾠ	 ﾠ
To	 ﾠfurther	 ﾠrefine	 ﾠthe	 ﾠlist	 ﾠof	 ﾠgenes	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠregulated	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐dependent	 ﾠ
manner,	 ﾠwe	 ﾠintroduced	 ﾠtwo	 ﾠadditional	 ﾠfilter	 ﾠcriteria.	 ﾠThus,	 ﾠwhen	 ﾠcomparing	 ﾠ
overexpression	 ﾠof	 ﾠSF-ﾭ‐ERK1	 ﾠversus	 ﾠERK2	 ﾠdepletion,	 ﾠno	 ﾠsignificant	 ﾠchanges	 ﾠin	 ﾠgene	 ﾠ
expression	 ﾠwere	 ﾠexpected	 ﾠwith	 ﾠrespect	 ﾠto	 ﾠfold	 ﾠchanges	 ﾠand	 ﾠp-ﾭ‐value	 ﾠ(fold	 ﾠchanges	 ﾠof	 ﾠ≤	 ﾠ1.1,	 ﾠ
step-ﾭ‐up	 ﾠp-ﾭ‐values	 ﾠof	 ﾠ≥	 ﾠ0.35).	 ﾠIndeed,	 ﾠthese	 ﾠcriteria	 ﾠallowed	 ﾠthe	 ﾠidentification	 ﾠof	 ﾠ13	 ﾠgenes,	 ﾠ
whose	 ﾠexpression	 ﾠwas	 ﾠregulated	 ﾠin	 ﾠan	 ﾠisoform-ﾭ‐specific	 ﾠmanner	 ﾠ(Figure	 ﾠ4-ﾭ‐4).	 ﾠERK2	 ﾠitself	 ﾠ
fell	 ﾠinto	 ﾠthis	 ﾠgroup	 ﾠof	 ﾠgenes,	 ﾠvalidating	 ﾠour	 ﾠexperimental	 ﾠset-ﾭ‐up	 ﾠand	 ﾠfiltering	 ﾠstrategy.	 ﾠ
Moreover,	 ﾠour	 ﾠdata	 ﾠsuggest	 ﾠthat	 ﾠthe	 ﾠegr1	 ﾠgene	 ﾠis	 ﾠregulated	 ﾠby	 ﾠboth	 ﾠERK	 ﾠisoforms,	 ﾠas	 ﾠ
ectopic	 ﾠexpression	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠrestored	 ﾠgene	 ﾠexpression	 ﾠto	 ﾠcontrol	 ﾠlevels.	 ﾠThis	 ﾠ
observation	 ﾠis	 ﾠin	 ﾠagreement	 ﾠwith	 ﾠdata	 ﾠpublished	 ﾠby	 ﾠLefloch	 ﾠet	 ﾠal.,	 ﾠwho	 ﾠdemonstrated	 ﾠthat	 ﾠ
re-ﾭ‐expression	 ﾠof	 ﾠeither	 ﾠERK	 ﾠisoform	 ﾠin	 ﾠERK2	 ﾠdepleted	 ﾠcells	 ﾠis	 ﾠsufficient	 ﾠto	 ﾠrestore	 ﾠegr1	 ﾠ
mRNA	 ﾠlevels	 ﾠ[357].	 ﾠ
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Figure 4-4 List of genes down-regulated upon ERK2 silencing 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK1 or ERK2 
in combination with expression plasmids for SF-ERK1, SF-ERK2 or empty vector control (EV) and plated 
onto CDM. Total RNA was extracted, labelled, and comparative whole-genome expression profiling was 
performed using Illumina HT-12 v4 expression chips.  
(see next page also) 
  	 ﾠ
A
Genes downregulated by ERK2 siRNA
B
C
  ERK1 siRNA vs. NT siRNA  ERK2 siRNA vs. NT siRNA  SF-ERK1 vs. ERK2 siRNA  SF-ERK2 vs. ERK2 siRNA 
Gene Symbol  stepup p-value  Fold-Change  stepup p-value  Fold-Change  stepup p-value  Fold-Change  stepup p-value  Fold-Change 
CSF2  0.28708  -1.20  0.01091  -1.53  0.91193  1.033  0.00467  1.90 
ERK2  0.98365  1.00  1.99E-06  -2.62  0.96436  1.01  0.00532  1.59 
SRGN  0.26015  1.09  0.03350  -1.17  0.60708  -1.06  0.00020  1.54 
SRXN1  0.070469  -1.21  0.00792  -1.36  0.84486  -1.04  0.01776  1.43 
ASAM  0.26712  1.09  0.03500  -1.17  0.35304  1.09  0.00106  1.42 
MT1G  0.80039  -1.04  0.02803  -1.27  0.58442  1.09  0.02702  1.38 
AKR1C3  0.24908  1.07  0.02509  -1.14  0.94541  -1.01  0.00030  1.38 
FAM107B  0.05318  -1.24  0.00064  -1.57  0.64543  1.08  0.04006  1.38 
CD83  0.75155  -1.03  0.00042  -1.30  0.45285  1.07  0.00131  1.34 
DNER  0.09728  -1.17  0.00200  -1.39  0.80219  -1.04  0.03532  1.32 
EREG  0.48842  1.07  0.03306  -1.20  0.45378  1.09  0.01646  1.32 
IL24  0.45073  -1.08  1.61E-05  -1.82  0.54048  1.09  0.03798  1.31 
ARL14  0.11769  -1.16  0.00057  -1.48  0.71827  1.06  0.04763  1.30 
 
Genes downregulated by ERK2 siRNA
Gene Symbol  Gene Name 
CSF2  Granulocyte-macrophage colony stimulating factor 2 
MAPK1  Extracellular signal-regulated kinase 2 
SRGN  Serglycin 
SRXN1  Sulfiredoxin 
ASAM  Adipocyte adhesion molecule 
MT1G  Metallothionein-1G 
AKR1C3  Aldo-keto reductase family 1 member C3 
FAM107B  Protein FAM107B 
CD83  CD83 antigen 
DNER  Delta and Notch-like epidermal growth factor-related receptor 
EREG  Epiregulin 
IL24  Interleukin-24 
ARL14  ADP-ribosylation factor-like protein 14 
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A. The heat map displays genes, which are down-regulated in an ERK2-dependent manner. Genes, which 
showed significant changes in expression level when comparing ERK2 knockdown versus NT siRNA 
(step-up p-value < 0.05) and inverse changes when comparing ERK2 knockdown versus re-expression of 
siRNA resistant SF-ERK2 (step-up p-value < 0.05, fold change ≥ 1.3) were identified and ranked according  
to fold changes. The expression of the first 13 genes is regulated in an ERK2-dependent manner (step-up 
 p-values > 0.35, fold change ≤ 1.1 when comparing ERK2 knockdown cells to SF-ERK1 overexpression). 
The colour and intensity of the boxes allocated to each data point represent fold changes in expression level: 
low expression (green), high expression (red). 
B. Table of genes, whose expression is down-regulated in an ERK2-dependent manner. Listed are: gene 
symbols, step-up p-values (significant p-values are in red), and fold changes for experimental comparisons. A 
significant decrease in fold change following ERK2 knockdown is marked by a green background colour, 
while inverse changes upon re-expression of ERK2 are marked by a red background colour. 
C. List of gene names for ERK2-regulated genes from (B).  
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4.2.1.4  Microarray analysis identifies genes whose expression is up-regulated 
following ERK2 knockdown 
Having	 ﾠidentified	 ﾠgenes,	 ﾠwhose	 ﾠexpression	 ﾠis	 ﾠinduced	 ﾠby	 ﾠERK2,	 ﾠwe	 ﾠasked	 ﾠwhether	 ﾠthis	 ﾠ
kinase	 ﾠmay	 ﾠalso	 ﾠact	 ﾠto	 ﾠsuppress	 ﾠgene	 ﾠexpression.	 ﾠThus,	 ﾠwe	 ﾠset	 ﾠout	 ﾠto	 ﾠidentify	 ﾠa	 ﾠset	 ﾠof	 ﾠ
genes,	 ﾠwhose	 ﾠexpression	 ﾠis	 ﾠup-ﾭ‐regulated	 ﾠin	 ﾠcells	 ﾠlacking	 ﾠERK2.	 ﾠWe	 ﾠnormalised	 ﾠand	 ﾠ
processed	 ﾠthe	 ﾠdata	 ﾠas	 ﾠfor	 ﾠFigure	 ﾠ4-ﾭ‐1.	 ﾠSubsequent	 ﾠfiltering	 ﾠsteps	 ﾠgenerated	 ﾠa	 ﾠlist	 ﾠof	 ﾠ
ERK2-ﾭ‐regulated	 ﾠgenes,	 ﾠwhich	 ﾠmet	 ﾠthe	 ﾠfollowing	 ﾠcriteria:	 ﾠgenes	 ﾠshowed	 ﾠ(i)	 ﾠa	 ﾠsignificant	 ﾠ
increase	 ﾠin	 ﾠgene	 ﾠexpression	 ﾠwhen	 ﾠERK2	 ﾠknockdown	 ﾠwas	 ﾠcompared	 ﾠto	 ﾠNT	 ﾠsiRNA	 ﾠ(step-ﾭ‐up	 ﾠ
p-ﾭ‐value	 ﾠ≤	 ﾠ0.05)	 ﾠand	 ﾠ(ii)	 ﾠinverse	 ﾠchanges	 ﾠwith	 ﾠrespect	 ﾠto	 ﾠfold	 ﾠchanges	 ﾠand	 ﾠp-ﾭ‐value,	 ﾠwhen	 ﾠ
siRNA	 ﾠresistant	 ﾠSF-ﾭ‐ERK2	 ﾠwas	 ﾠre-ﾭ‐expressed	 ﾠ(step-ﾭ‐up	 ﾠp-ﾭ‐value	 ﾠ≤	 ﾠ0.05,	 ﾠfold	 ﾠchange	 ﾠ≥	 ﾠ1.3).	 ﾠThis	 ﾠ
produced	 ﾠa	 ﾠset	 ﾠof	 ﾠ36	 ﾠgenes,	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠdecreased	 ﾠfollowing	 ﾠERK2	 ﾠ
depletion	 ﾠ(Figure	 ﾠ4-ﾭ‐5)	 ﾠwhich	 ﾠwere	 ﾠthen	 ﾠranked	 ﾠaccording	 ﾠto	 ﾠfold	 ﾠchanges	 ﾠas	 ﾠbefore.	 ﾠ	 ﾠ
To	 ﾠfurther	 ﾠrefine	 ﾠthis	 ﾠlist	 ﾠwe	 ﾠintroduced	 ﾠan	 ﾠadditional	 ﾠfilter	 ﾠcriterion	 ﾠby	 ﾠpredefining	 ﾠthat	 ﾠ
genes	 ﾠhad	 ﾠto	 ﾠexhibit	 ﾠno	 ﾠsignificant	 ﾠchanges	 ﾠin	 ﾠgene	 ﾠexpression	 ﾠwhen	 ﾠERK1	 ﾠwas	 ﾠ
overexpressed	 ﾠ(fold	 ﾠchanges	 ﾠof	 ﾠ≥	 ﾠ-ﾭ‐1.1,	 ﾠstep-ﾭ‐up	 ﾠp-ﾭ‐values	 ﾠof	 ﾠ≥	 ﾠ0.4).	 ﾠThis	 ﾠallowed	 ﾠthe	 ﾠ
identification	 ﾠof	 ﾠ14	 ﾠgenes	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠsuppressed	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠ
fashion	 ﾠ(Figure	 ﾠ4-ﾭ‐5).	 ﾠInterestingly,	 ﾠERK1	 ﾠdepletion	 ﾠsignificantly	 ﾠinduced	 ﾠgene	 ﾠexpression	 ﾠof	 ﾠ
C10ORF10	 ﾠ(fold	 ﾠchange=1.40,	 ﾠstep-ﾭ‐up	 ﾠp-ﾭ‐value=0.0061),	 ﾠSELENBP1	 ﾠ(fold	 ﾠchange=1.36,	 ﾠ
step-ﾭ‐up	 ﾠp-ﾭ‐value=0.0047),	 ﾠand	 ﾠGPR64	 ﾠ(fold	 ﾠchange=1.44,	 ﾠstep-ﾭ‐up	 ﾠp-ﾭ‐value=0.0002),	 ﾠ
suggesting	 ﾠthat	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠsuppress	 ﾠtheir	 ﾠexpression	 ﾠ(Figure	 ﾠ4-ﾭ‐5).	 ﾠYet,	 ﾠ
overexpression	 ﾠof	 ﾠERK1	 ﾠin	 ﾠcells	 ﾠdepleted	 ﾠfor	 ﾠERK2	 ﾠwas	 ﾠnot	 ﾠsufficient	 ﾠto	 ﾠrestore	 ﾠmRNA	 ﾠ
levels	 ﾠto	 ﾠcontrol,	 ﾠwhich	 ﾠindicates	 ﾠthat	 ﾠthese	 ﾠmRNA	 ﾠtranscripts	 ﾠare	 ﾠregulated	 ﾠ
post-ﾭ‐transcriptionally	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐dependent	 ﾠmanner.	 ﾠ
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Figure 4-5 List of genes up-regulated upon ERK2 silencing 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK1 or ERK2 
in combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and 
plated onto CDM. Total RNA was extracted, labelled, and comparative whole-genome expression profiling 
was performed using Illumina HT-12 v4 expression chips. 
(see next page also) 
  	 ﾠ
β
Genes upregulated by ERK2 siRNA A
B
C Gene Symbol  Gene Name 
TXNIP  Thioredoxin-interacting protein 
RAB17  Ras-related protein 17 
PPFIBP2  Liprin-β2 
DRD1IP  Neuron-specific vesicular protein calcyon 
FLVCR2  Calcium-chelate transporter 
UCP2  Mitochondrial uncoupling protein 2 
C10ORF10  Protein DEPP 
SLC12A9  Solute carrier family 12 member 9 
GOLM1  Golgi membrane protein 1 
SELENBP1  Selenium-binding protein 1 
GPR64  G-protein coupled receptor 64 
SLC44A2  Choline transporter-like protein 2 
PALM  Paralemmin 
MLXIPL  Class D basic helix-loop-helix protein 14 
 
  ERK1 siRNA vs. NT siRNA  ERK2 siRNA vs. NT siRNA  SF-ERK1 vs. ERK2 siRNA  SF-ERK2 vs. ERK2 siRNA 
Gene Symbol  stepup p-value  Fold-Change  stepup p-value  Fold-Change  stepup p-value  Fold-Change  stepup p-value  Fold-Change 
TXNIP  0.27141  1.23  0.01506  1.55  0.89481  1.05  0.00399  -2.04 
RAB17  0.70367  1.05  0.00042  1.52  0.06569  1.25  0.00045  -1.71 
PPFIBP2  0.67640  -1.04  0.00030  1.38  0.40412  -1.09  0.00019  -1.56 
DRD1IP  0.90481  1.02  0.00000  2.09  0.88305  -1.02  0.00010  -1.55 
FLVCR2  0.53329  1.06  0.00017  1.47  0.78177  -1.04  0.00377  -1.40 
UCP2  0.93571  1.02  0.02342  1.30  0.87347  -1.04  0.04242  -1.38 
C10ORF10  0.00609  1.40  0.02280  1.31  0.90116  1.03  0.04975  -1.37 
SLC12A9  0.54041  1.06  0.00032  1.39  0.61508  1.06  0.00399  -1.36 
GOLM1  0.06422  1.21  0.03084  1.25  0.71478  -1.06  0.04763  -1.32 
SELENBP1  0.00467  1.36  0.00155  1.43  0.68077  -1.07  0.04763  -1.32 
GPR64  0.00024  1.44  0.02226  1.29  0.49142  -1.08  0.00704  -1.32 
SLC44A2  0.02955  1.17  0.00006  1.46  0.99673  -1.00  0.00533  -1.32 
PALM  0.04248  1.15  0.00004  1.51  0.96763  -1.01  0.00646  -1.31 
MLXIPL  0.70000  -1.04  0.0122159  1.20  0.56620  -1.06  0.00698  -1.31 
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A. The heat map displays genes, which are up-regulated in an ERK2-dependent manner. Genes, which 
showed significant changes in expression level when comparing ERK2 knockdown versus NT siRNA 
(step-up p-value < 0.05) and inverse changes when comparing ERK2 knockdown versus re-expression of 
siRNA resistant SF-ERK2 (step-up p-value < 0.05, fold change ≥ -1.3) were identified and ranked according 
to fold changes. The expression of the first 14 genes is regulated in an ERK2-dependent manner (step-up 
p-values > 0.4, fold change ≥ -1.1 when comparing ERK2 knockdown cells to SF-ERK1 overexpression). 
The colour and intensity of the boxes allocated to each data point represent fold changes in expression level: 
low expression (green), high expression (red). 
B. Table of genes, whose expression is up-regulated in an ERK2-dependent manner. Listed are: gene 
symbols, step-up p-values (significant p-values are in red), and fold changes for experimental comparisons. A 
significant increase in fold change following ERK1 or ERK2 knockdown is marked by a green background 
colour, while inverse changes upon re-expression of ERK2 are marked by a red background colour. 
C. List of gene names for ERK2-regulated genes from (B).  
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4.2.2  Validation of ERK2-dependent gene expression using qRT-PCR 
4.2.2.1  qRT-PCR primer pairs amplify a single product in a linear manner over a 
range of cDNA concentrations 
Quantitative	 ﾠreal-ﾭ‐time	 ﾠpolymerase	 ﾠchain	 ﾠreaction	 ﾠ(qRT-ﾭ‐PCR)	 ﾠis	 ﾠmethodically	 ﾠbased	 ﾠon	 ﾠthe	 ﾠ
polymerase	 ﾠchain	 ﾠreaction,	 ﾠbut	 ﾠallows	 ﾠsimultaneous	 ﾠquantification	 ﾠof	 ﾠthe	 ﾠamplified	 ﾠ
template.	 ﾠMoreover,	 ﾠwhen	 ﾠqRT-ﾭ‐PCR	 ﾠis	 ﾠcombined	 ﾠwith	 ﾠreverse	 ﾠtranscription,	 ﾠmRNA	 ﾠlevels	 ﾠ
of	 ﾠdifferent	 ﾠtissues	 ﾠor	 ﾠexperimental	 ﾠconditions	 ﾠcan	 ﾠbe	 ﾠcompared.	 ﾠTo	 ﾠthis	 ﾠend	 ﾠthe	 ﾠquantity	 ﾠ
of	 ﾠmRNA	 ﾠfor	 ﾠan	 ﾠexperimental	 ﾠcondition	 ﾠis	 ﾠtypically	 ﾠexpressed	 ﾠrelative	 ﾠto	 ﾠits	 ﾠcontrol	 ﾠ
sample.	 ﾠThis,	 ﾠhowever,	 ﾠrequires	 ﾠequal	 ﾠmRNA	 ﾠloading	 ﾠfor	 ﾠboth	 ﾠsamples,	 ﾠwhich	 ﾠis	 ﾠensured	 ﾠ
by	 ﾠadjusting	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠRNA	 ﾠinput	 ﾠfor	 ﾠeach	 ﾠreverse	 ﾠtranscription	 ﾠand	 ﾠ
normalising	 ﾠobtained	 ﾠvalues	 ﾠfor	 ﾠgenes	 ﾠof	 ﾠinterest	 ﾠagainst	 ﾠa	 ﾠhousekeeping	 ﾠgene,	 ﾠsuch	 ﾠas	 ﾠ
glyceraldehyde	 ﾠ3-ﾭ‐phosphate	 ﾠdehydrogenase	 ﾠ(GAPDH).	 ﾠAmplicon	 ﾠaccumulation	 ﾠduring	 ﾠ
qRT-ﾭ‐PCR	 ﾠis	 ﾠmonitored	 ﾠwith	 ﾠthe	 ﾠhelp	 ﾠof	 ﾠa	 ﾠfluorescent	 ﾠdye	 ﾠ(such	 ﾠas	 ﾠSYBR	 ﾠGreen),	 ﾠwhich	 ﾠ
intercalates	 ﾠwith	 ﾠdsDNA	 ﾠproduct.	 ﾠ	 ﾠ
The	 ﾠqRT-ﾭ‐PCR	 ﾠconsists	 ﾠof	 ﾠfour	 ﾠstages,	 ﾠwhich	 ﾠare	 ﾠcharacterised	 ﾠby	 ﾠdifferent	 ﾠreaction	 ﾠ
kinetics.	 ﾠInitially,	 ﾠproduct	 ﾠamplification	 ﾠdoes	 ﾠnot	 ﾠyield	 ﾠa	 ﾠmeasurable	 ﾠread-ﾭ‐out,	 ﾠbecause	 ﾠthe	 ﾠ
generated	 ﾠfluorescence	 ﾠis	 ﾠbelow	 ﾠthe	 ﾠdetection	 ﾠthreshold.	 ﾠThis	 ﾠstage	 ﾠis	 ﾠcalled	 ﾠthe	 ﾠlag	 ﾠphase	 ﾠ
and	 ﾠis	 ﾠfollowed	 ﾠby	 ﾠthe	 ﾠexponential	 ﾠphase,	 ﾠin	 ﾠwhich	 ﾠthe	 ﾠcopy	 ﾠnumber	 ﾠof	 ﾠthe	 ﾠtemplate	 ﾠ
doubles	 ﾠwith	 ﾠeach	 ﾠamplification	 ﾠcycle	 ﾠand	 ﾠthe	 ﾠfluorescent	 ﾠsignal	 ﾠincreases	 ﾠlinearly.	 ﾠThis	 ﾠ
stage	 ﾠallows	 ﾠthe	 ﾠdetermination	 ﾠof	 ﾠthe	 ﾠthreshold	 ﾠcycle	 ﾠ(Ct),	 ﾠwhich	 ﾠmarks	 ﾠthe	 ﾠcycle	 ﾠin	 ﾠwhich	 ﾠ
the	 ﾠfluorescent	 ﾠsignal	 ﾠcrosses	 ﾠthe	 ﾠthreshold.	 ﾠThe	 ﾠCt	 ﾠvalue	 ﾠis	 ﾠinversely	 ﾠproportional	 ﾠto	 ﾠthe	 ﾠ
log	 ﾠof	 ﾠthe	 ﾠinitial	 ﾠtemplate,	 ﾠwhich	 ﾠmeans	 ﾠthat	 ﾠmore	 ﾠinitial	 ﾠmRNA	 ﾠtranscripts	 ﾠgive	 ﾠrise	 ﾠto	 ﾠ
lower	 ﾠCt	 ﾠvalues.	 ﾠThe	 ﾠexponential	 ﾠphase	 ﾠis	 ﾠfollowed	 ﾠby	 ﾠa	 ﾠretardation	 ﾠphase,	 ﾠwhere	 ﾠreaction	 ﾠ
components	 ﾠbecome	 ﾠlimiting	 ﾠand	 ﾠthus,	 ﾠthe	 ﾠreaction	 ﾠrate	 ﾠdecreases.	 ﾠFinally,	 ﾠamplification	 ﾠ
reaches	 ﾠa	 ﾠplateau,	 ﾠwhen	 ﾠall	 ﾠreaction	 ﾠconstituents	 ﾠare	 ﾠused	 ﾠup	 ﾠand	 ﾠif	 ﾠleft	 ﾠlong	 ﾠenough,	 ﾠthe	 ﾠ
PCR	 ﾠproducts	 ﾠwill	 ﾠbegin	 ﾠto	 ﾠdegrade	 ﾠ[455].	 ﾠ
It	 ﾠis	 ﾠimportant	 ﾠto	 ﾠstress	 ﾠthat	 ﾠSYBR	 ﾠGreen	 ﾠwill	 ﾠintercalate	 ﾠwith	 ﾠany	 ﾠdsDNA	 ﾠmolecules	 ﾠ
present	 ﾠin	 ﾠthe	 ﾠreaction	 ﾠmixture.	 ﾠTherefore,	 ﾠprimer	 ﾠdimers	 ﾠas	 ﾠwell	 ﾠas	 ﾠnon-ﾭ‐specific	 ﾠPCR	 ﾠ
products	 ﾠwill	 ﾠalter	 ﾠyour	 ﾠoverall	 ﾠfluorescent	 ﾠsignal	 ﾠand	 ﾠultimately	 ﾠyour	 ﾠquantitation	 ﾠresults.	 ﾠ
In	 ﾠorder	 ﾠto	 ﾠensure	 ﾠan	 ﾠaccurate	 ﾠamplicon	 ﾠmeasurement,	 ﾠthe	 ﾠchoice	 ﾠof	 ﾠsuitable	 ﾠprimers	 ﾠis	 ﾠa	 ﾠ
crucial	 ﾠstep	 ﾠin	 ﾠsetting	 ﾠup	 ﾠa	 ﾠsuccessful	 ﾠqRT-ﾭ‐PCR.	 ﾠThus,	 ﾠprior	 ﾠto	 ﾠany	 ﾠcomparative	 ﾠqRT-ﾭ‐PCR	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analysis,	 ﾠthe	 ﾠsuitability	 ﾠfor	 ﾠevery	 ﾠprimer	 ﾠused	 ﾠmust	 ﾠbe	 ﾠdetermined.	 ﾠTo	 ﾠassess	 ﾠwhether	 ﾠthe	 ﾠ
primer	 ﾠpairs	 ﾠamplify	 ﾠa	 ﾠsingle	 ﾠproduct,	 ﾠqRT-ﾭ‐PCR	 ﾠreaction	 ﾠmixes	 ﾠwere	 ﾠresolved	 ﾠon	 ﾠagarose	 ﾠ
gels	 ﾠand	 ﾠvisualised	 ﾠwith	 ﾠethidium	 ﾠbromide	 ﾠ(data	 ﾠnot	 ﾠshown).	 ﾠMoreover,	 ﾠdissociation	 ﾠ
(melting)	 ﾠcurves	 ﾠfor	 ﾠeach	 ﾠamplification	 ﾠproduct	 ﾠwere	 ﾠgenerated	 ﾠby	 ﾠthe	 ﾠOpticon	 ﾠMonitor	 ﾠ
Software.	 ﾠThe	 ﾠmelting	 ﾠcurve	 ﾠanalysis	 ﾠof	 ﾠeach	 ﾠamplicon	 ﾠof	 ﾠinterest	 ﾠconfirmed	 ﾠthe	 ﾠpresence	 ﾠ
of	 ﾠa	 ﾠsingle	 ﾠspike,	 ﾠindicative	 ﾠof	 ﾠa	 ﾠsingle	 ﾠamplification	 ﾠproduct	 ﾠ(see	 ﾠfollowing	 ﾠsections	 ﾠfor	 ﾠ
some	 ﾠrepresentative	 ﾠimages).	 ﾠ
Having	 ﾠensured	 ﾠthat	 ﾠthe	 ﾠprimer	 ﾠpairs	 ﾠgive	 ﾠrise	 ﾠto	 ﾠa	 ﾠsingle	 ﾠamplicon	 ﾠduring	 ﾠPCR,	 ﾠwe	 ﾠnext	 ﾠ
assessed	 ﾠwhether	 ﾠprimer	 ﾠpairs	 ﾠwere	 ﾠamplifying	 ﾠin	 ﾠa	 ﾠlinear	 ﾠmanner	 ﾠover	 ﾠa	 ﾠrange	 ﾠof	 ﾠ
different	 ﾠinput	 ﾠconcentrations.	 ﾠWe,	 ﾠtherefore,	 ﾠperformed	 ﾠqRT-ﾭ‐PCR	 ﾠon	 ﾠserial	 ﾠdilutions	 ﾠof	 ﾠ
cDNA	 ﾠtemplates	 ﾠand	 ﾠplotted	 ﾠCt	 ﾠvalues	 ﾠagainst	 ﾠthe	 ﾠlogarithmic	 ﾠvalues	 ﾠof	 ﾠstandard	 ﾠcDNA	 ﾠ
amounts,	 ﾠwhich	 ﾠwere	 ﾠexpressed	 ﾠas	 ﾠdilution	 ﾠfactors	 ﾠ(i.e.	 ﾠ1.75x,	 ﾠ1.5x,	 ﾠ1.25x,	 ﾠ1x,	 ﾠ0.75x,	 ﾠ0.5x).	 ﾠ
The	 ﾠcorrelation	 ﾠcoefficient	 ﾠ(R
2)	 ﾠvalues	 ﾠwere	 ﾠgreater	 ﾠthan	 ﾠ0.98	 ﾠfor	 ﾠall	 ﾠprimers	 ﾠtested,	 ﾠ
suggesting	 ﾠa	 ﾠnear	 ﾠperfect	 ﾠlinear	 ﾠrelationship	 ﾠbetween	 ﾠCt	 ﾠvalue	 ﾠand	 ﾠcDNA	 ﾠ
concentration	 ﾠ(Figure	 ﾠ4-ﾭ‐6).	 ﾠMoreover,	 ﾠthese	 ﾠresults	 ﾠindicate	 ﾠthat	 ﾠthe	 ﾠfluorescence	 ﾠ
measured	 ﾠduring	 ﾠour	 ﾠqRT-ﾭ‐PCR	 ﾠwas	 ﾠproportional	 ﾠto	 ﾠthe	 ﾠtemplate	 ﾠinput.	 ﾠNext,	 ﾠwe	 ﾠassessed	 ﾠ
the	 ﾠamplification	 ﾠefficiencies	 ﾠfor	 ﾠeach	 ﾠamplicon	 ﾠusing	 ﾠthis	 ﾠformula ﾠ𝐸 = 10
  
  − 1,	 ﾠwhere	 ﾠ
‘a’	 ﾠrepresents	 ﾠthe	 ﾠgradient	 ﾠof	 ﾠlinear	 ﾠfit	 ﾠas	 ﾠdefined	 ﾠby	 ﾠArezi	 ﾠet	 ﾠal.	 ﾠ[456].	 ﾠWe	 ﾠobtained	 ﾠ
amplification	 ﾠefficiencies	 ﾠof	 ﾠ0.78,	 ﾠ0.83,	 ﾠ0.73,	 ﾠ0.8,	 ﾠ0.75	 ﾠand	 ﾠ0.73	 ﾠfor	 ﾠGAPDH,	 ﾠCSF2,	 ﾠRab17,	 ﾠ
Liprin-ﾭ‐β2,	 ﾠERK1	 ﾠand	 ﾠERK2,	 ﾠrespectively.	 ﾠ
Changes	 ﾠin	 ﾠmRNA	 ﾠlevels	 ﾠbetween	 ﾠtwo	 ﾠexperimental	 ﾠconditions	 ﾠcan	 ﾠbe	 ﾠexpressed	 ﾠas	 ﾠ
absolute	 ﾠor	 ﾠrelative	 ﾠvalues.	 ﾠAbsolute	 ﾠquantification	 ﾠof	 ﾠinput	 ﾠconcentrations	 ﾠrequires	 ﾠthe	 ﾠ
generation	 ﾠof	 ﾠstandard	 ﾠcurves	 ﾠfrom	 ﾠknown	 ﾠconcentrations	 ﾠof	 ﾠmRNA	 ﾠspecies	 ﾠand	 ﾠis	 ﾠ
commonly	 ﾠused	 ﾠwhen	 ﾠamplification	 ﾠefficiencies	 ﾠfor	 ﾠtarget	 ﾠand	 ﾠreference	 ﾠgene	 ﾠdiffer	 ﾠ
greatly.	 ﾠRelative	 ﾠquantification	 ﾠcan	 ﾠbe	 ﾠobtained	 ﾠby	 ﾠexpressing	 ﾠtarget	 ﾠgene	 ﾠexpression	 ﾠof	 ﾠ
one	 ﾠsample	 ﾠrelative	 ﾠto	 ﾠanother.	 ﾠOne	 ﾠcommonly	 ﾠused	 ﾠmethod	 ﾠfor	 ﾠrelative	 ﾠquantification	 ﾠis	 ﾠ
the	 ﾠΔΔCt	 ﾠmethod	 ﾠ[354],	 ﾠwhich	 ﾠtakes	 ﾠloading	 ﾠvariations	 ﾠinto	 ﾠaccount	 ﾠby	 ﾠnormalising	 ﾠtarget	 ﾠ
gene	 ﾠexpression	 ﾠto	 ﾠa	 ﾠreference	 ﾠgene.	 ﾠHowever,	 ﾠthis	 ﾠquantification	 ﾠmethod	 ﾠassumes	 ﾠnear	 ﾠ
equal	 ﾠamplification	 ﾠefficiencies	 ﾠfor	 ﾠtarget	 ﾠand	 ﾠreference	 ﾠgene.	 ﾠAs	 ﾠwe	 ﾠobtained	 ﾠsimilar	 ﾠ
amplification	 ﾠefficiencies	 ﾠfor	 ﾠour	 ﾠgenes	 ﾠof	 ﾠinterest,	 ﾠwe	 ﾠwere	 ﾠconfident	 ﾠin	 ﾠusing	 ﾠthe	 ﾠΔΔCt	 ﾠ
method	 ﾠto	 ﾠcompare	 ﾠexpression	 ﾠlevels	 ﾠfor	 ﾠCSF2,	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠin	 ﾠdifferent	 ﾠ
experimental	 ﾠconditions.	 ﾠYet,	 ﾠwe	 ﾠalso	 ﾠcalculated	 ﾠrelative	 ﾠexpression	 ﾠratios	 ﾠfor	 ﾠeach	 ﾠof	 ﾠthe	 ﾠ	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Figure 4-6 qRT-PCR primer pairs amplify in a linear manner over a range of cDNA concentrations 
cDNA was synthesised from RNA isolated from MDA-MB-231 cells grown on plastic. Serial dilutions of 
cDNA were used in a qRT-PCR reaction to test the efficiency of amplification of the respective primer sets. 
Standard curves representing a plot of C(t) against the initial log2 quantity of the template and corresponding 
R
2 values are shown for GAPDH (A), CSF2 (B), Rab17 (C), Liprin-β2 (D), ERK1 (E), ERK2 (F). 
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latter	 ﾠgenes	 ﾠusing	 ﾠa	 ﾠmethod	 ﾠwhich	 ﾠdoes	 ﾠnot	 ﾠassume	 ﾠequal	 ﾠamplification	 ﾠefficiencies	 ﾠusing	 ﾠ
the	 ﾠfollowing	 ﾠformula:	 ﾠ𝑟𝑎𝑡𝑖𝑜 =
 
∆        (              )
 
∆           (              )	 ﾠ,	 ﾠwhere	 ﾠ‘E’	 ﾠrepresents	 ﾠthe	 ﾠ
efficiency	 ﾠand	 ﾠ‘ΔCP’	 ﾠthe	 ﾠabsolute	 ﾠdeviation	 ﾠ[457].	 ﾠBoth	 ﾠquantification	 ﾠmethods	 ﾠyielded	 ﾠ
near	 ﾠidentical	 ﾠexpression	 ﾠratios	 ﾠ(data	 ﾠnot	 ﾠshown),	 ﾠthus	 ﾠverifying	 ﾠthe	 ﾠsuitability	 ﾠof	 ﾠthe	 ﾠΔΔCt	 ﾠ
method	 ﾠfor	 ﾠrelative	 ﾠquantification.	 ﾠ
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4.2.2.2  ERK2 (but not ERK1) regulates the expression of CSF2, Rab17 and 
Liprin-β2 in cells attached to CDM 
Our	 ﾠIllumina	 ﾠgene	 ﾠexpression	 ﾠarray	 ﾠallowed	 ﾠthe	 ﾠidentification	 ﾠof	 ﾠ27	 ﾠgenes,	 ﾠwhose	 ﾠ
expression	 ﾠwas	 ﾠeither	 ﾠincreased	 ﾠor	 ﾠdecreased	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐dependent	 ﾠmanner.	 ﾠProminent	 ﾠ
amongst	 ﾠthese	 ﾠwere	 ﾠcolony-ﾭ‐stimulating	 ﾠfactor	 ﾠ2	 ﾠ(CSF2),	 ﾠRas-ﾭ‐related	 ﾠprotein	 ﾠ17	 ﾠ(Rab17)	 ﾠ
and	 ﾠLiprin-ﾭ‐β2,	 ﾠwhose	 ﾠmRNA	 ﾠlevels	 ﾠwere	 ﾠstrongly	 ﾠaltered	 ﾠby	 ﾠknockdown	 ﾠof	 ﾠERK2,	 ﾠand	 ﾠ
normalised	 ﾠby	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠsiRNA-ﾭ‐resistant	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1).	 ﾠCSF2	 ﾠis	 ﾠknown	 ﾠto	 ﾠ
regulate	 ﾠhaematopoiesis,	 ﾠbut	 ﾠrecent	 ﾠevidence	 ﾠsuggests	 ﾠa	 ﾠrole	 ﾠfor	 ﾠthis	 ﾠcytokine	 ﾠin	 ﾠtumour	 ﾠ
cell	 ﾠinvasion	 ﾠand	 ﾠdisease	 ﾠprogression	 ﾠ[458-ﾭ‐461].	 ﾠRab17	 ﾠis	 ﾠa	 ﾠsmall	 ﾠGTPase,	 ﾠwhich	 ﾠhas	 ﾠbeen	 ﾠ
shown	 ﾠto	 ﾠregulate	 ﾠintracellular	 ﾠtransport	 ﾠof	 ﾠproteins	 ﾠand	 ﾠlipids	 ﾠ[462].	 ﾠMoreover,	 ﾠthere	 ﾠare	 ﾠ
indications	 ﾠthat	 ﾠthis	 ﾠGTPase	 ﾠis	 ﾠinvolved	 ﾠin	 ﾠthe	 ﾠmaintenance	 ﾠof	 ﾠepithelial	 ﾠpolarity	 ﾠ[463].	 ﾠ
Liprin-ﾭ‐β2	 ﾠbelongs	 ﾠto	 ﾠthe	 ﾠfamily	 ﾠof	 ﾠLAR-ﾭ‐interacting	 ﾠproteins	 ﾠ(Liprins)	 ﾠand	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠ
predominantly	 ﾠto	 ﾠlocalise	 ﾠto	 ﾠmembrane	 ﾠstructures	 ﾠ[464].	 ﾠTo	 ﾠverify	 ﾠthese	 ﾠERK2-ﾭ‐dependent	 ﾠ
gene	 ﾠexpression	 ﾠsignatures	 ﾠwe	 ﾠtransfected	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠsiRNAs	 ﾠ
(NT),	 ﾠor	 ﾠsiRNAs	 ﾠtargeting	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠin	 ﾠcombination	 ﾠwith	 ﾠexpression	 ﾠplasmids	 ﾠfor	 ﾠ
SF-ﾭ‐ERK1,	 ﾠSF-ﾭ‐ERK2	 ﾠor	 ﾠempty	 ﾠvector	 ﾠcontrol	 ﾠ(EV)	 ﾠand	 ﾠplated	 ﾠcells	 ﾠonto	 ﾠCDM	 ﾠfor	 ﾠ16	 ﾠhours.	 ﾠ
After	 ﾠharvesting	 ﾠthe	 ﾠtotal	 ﾠRNA	 ﾠfor	 ﾠeach	 ﾠexperimental	 ﾠcondition,	 ﾠwe	 ﾠperformed	 ﾠqRT-ﾭ‐PCR	 ﾠ
combined	 ﾠwith	 ﾠreverse	 ﾠtranscription	 ﾠand	 ﾠnormalised	 ﾠour	 ﾠdata	 ﾠto	 ﾠthe	 ﾠhousekeeping	 ﾠgene,	 ﾠ
GAPDH.	 ﾠ
Firstly,	 ﾠwe	 ﾠassessed	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠCSF2	 ﾠin	 ﾠour	 ﾠdifferent	 ﾠexperimental	 ﾠsettings.	 ﾠIt	 ﾠis	 ﾠ
important	 ﾠto	 ﾠstress	 ﾠthat	 ﾠmelting	 ﾠcurve	 ﾠanalysis	 ﾠgave	 ﾠrise	 ﾠto	 ﾠa	 ﾠsingle	 ﾠpeak,	 ﾠwhich	 ﾠis	 ﾠ
indicative	 ﾠof	 ﾠa	 ﾠsingle	 ﾠamplification	 ﾠproduct	 ﾠfor	 ﾠCSF2	 ﾠ(Figure	 ﾠ4-ﾭ‐7	 ﾠA).	 ﾠMoreover,	 ﾠwhen	 ﾠthe	 ﾠ
input	 ﾠcDNA	 ﾠwas	 ﾠreplaced	 ﾠby	 ﾠRNase/DNase-ﾭ‐free	 ﾠwater,	 ﾠno	 ﾠfluorescent	 ﾠsignal	 ﾠwas	 ﾠdetected	 ﾠ
during	 ﾠqRT-ﾭ‐PCR	 ﾠwithin	 ﾠ40	 ﾠreaction	 ﾠcycles	 ﾠ(Figure	 ﾠ4-ﾭ‐7	 ﾠB).	 ﾠThis	 ﾠsuggests	 ﾠthat	 ﾠqRT-ﾭ‐PCR	 ﾠ
components	 ﾠwere	 ﾠnot	 ﾠcontaminated	 ﾠwith	 ﾠDNA	 ﾠor	 ﾠRNA,	 ﾠwhich	 ﾠmight	 ﾠobscure	 ﾠour	 ﾠdata	 ﾠ
analysis.	 ﾠInterestingly,	 ﾠqRT-ﾭ‐PCR	 ﾠof	 ﾠsix	 ﾠindependent	 ﾠexperiments	 ﾠdemonstrated	 ﾠthat	 ﾠ
silencing	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠsignificantly	 ﾠdecreased	 ﾠCSF2	 ﾠmRNA	 ﾠlevels	 ﾠ(Figure	 ﾠ4-ﾭ‐7	 ﾠC).	 ﾠ
This	 ﾠis	 ﾠin	 ﾠdirect	 ﾠcontrast	 ﾠto	 ﾠthe	 ﾠnumerical	 ﾠvalues	 ﾠobtained	 ﾠfrom	 ﾠthe	 ﾠHumanHT-ﾭ‐12	 ﾠ
Expression	 ﾠBeadChip	 ﾠscanning	 ﾠand	 ﾠsuggests	 ﾠthat	 ﾠboth	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠdrive	 ﾠCSF2	 ﾠ
expression.	 ﾠMoreover,	 ﾠconsistent	 ﾠwith	 ﾠthe	 ﾠmicroarray	 ﾠdata	 ﾠthe	 ﾠreduction	 ﾠin	 ﾠCSF2	 ﾠ
transcript	 ﾠlevels	 ﾠobserved	 ﾠupon	 ﾠERK2	 ﾠdepletion	 ﾠcould	 ﾠonly	 ﾠbe	 ﾠrestored	 ﾠto	 ﾠcontrol	 ﾠlevels,	 ﾠ
when	 ﾠsiRNA-ﾭ‐resistant	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠwas	 ﾠre-ﾭ‐expressed	 ﾠ(Figure	 ﾠ4-ﾭ‐7	 ﾠC).	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Figure 4-7 CSF2 expression is reduced upon ERK2 silencing 
A. Primer pairs targeting CSF2 amplify a single product as shown by representative melting curves, which 
were generated using Opticon Monitor software. 
B. qRT-PCR reactions run with the omission of cDNA yield no amplicon as shown on the plot derived from 
Opticon Monitor software. 
C. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and plated 
onto CDM. RNA was extracted, converted into cDNA and qRT-PCR was performed to validate the 
differential regulation of CSF2. Data was normalised to GAPDH and values relative to the control 
transfected are expressed as means ± standard error of the mean (SEM) of 18 replicates from 6 independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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Next,	 ﾠwe	 ﾠused	 ﾠqRT-ﾭ‐PCR	 ﾠto	 ﾠconfirm	 ﾠthat	 ﾠERK2	 ﾠwas	 ﾠable	 ﾠto	 ﾠsuppress	 ﾠRab17	 ﾠand Liprin-ﾭ‐β2	 ﾠ
expression	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells.	 ﾠqRT-ﾭ‐PCR	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠgave	 ﾠrise	 ﾠto	 ﾠ
melting	 ﾠcurves	 ﾠwith	 ﾠone	 ﾠdistinct	 ﾠpeak	 ﾠ(Figure	 ﾠ4-ﾭ‐8	 ﾠand	 ﾠFigure	 ﾠ4-ﾭ‐9	 ﾠA),	 ﾠindicating	 ﾠthat	 ﾠthe	 ﾠ
primer	 ﾠpairs	 ﾠwere	 ﾠspecific.	 ﾠMoreover,	 ﾠwhen	 ﾠreactions	 ﾠwere	 ﾠset	 ﾠup	 ﾠwithout	 ﾠcDNA	 ﾠas	 ﾠa	 ﾠ
template,	 ﾠno	 ﾠamplicon	 ﾠwas	 ﾠdetected	 ﾠby	 ﾠthe	 ﾠOpticon	 ﾠMonitor	 ﾠSoftware	 ﾠwithin	 ﾠ40	 ﾠreaction	 ﾠ
cycles,	 ﾠsuggesting	 ﾠthat	 ﾠreaction	 ﾠcomponents	 ﾠwere	 ﾠnot	 ﾠcontaminated	 ﾠwith	 ﾠDNA	 ﾠor	 ﾠRNA	 ﾠ
molecules,	 ﾠwhich	 ﾠwould	 ﾠobscure	 ﾠour	 ﾠresults	 ﾠ(Figure	 ﾠ4-ﾭ‐8	 ﾠand	 ﾠFigure	 ﾠ4-ﾭ‐9	 ﾠB).	 ﾠImportantly,	 ﾠ
qRT-ﾭ‐PCR	 ﾠof	 ﾠsix	 ﾠindependent	 ﾠexperiments	 ﾠshowed	 ﾠthat	 ﾠtranscript	 ﾠlevels	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠ
Liprin-ﾭ‐β2	 ﾠwere	 ﾠsignificantly	 ﾠincreased	 ﾠfollowing	 ﾠknockdown	 ﾠof	 ﾠERK2,	 ﾠwhile	 ﾠERK1	 ﾠdepletion	 ﾠ
did	 ﾠnot	 ﾠelevate	 ﾠmRNA	 ﾠlevels.	 ﾠFurthermore,	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠsiRNA-ﾭ‐resistant	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠ
ERK1	 ﾠrestored	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠto	 ﾠlevels	 ﾠdisplayed	 ﾠby	 ﾠcontrol	 ﾠ
cells	 ﾠ(Figure	 ﾠ4-ﾭ‐8	 ﾠand	 ﾠFigure	 ﾠ4-ﾭ‐9	 ﾠC).	 ﾠ	 ﾠ
Next,	 ﾠwe	 ﾠdetermined	 ﾠwhether	 ﾠmRNA	 ﾠlevels	 ﾠof	 ﾠrelated	 ﾠmembers	 ﾠof	 ﾠthe	 ﾠRab	 ﾠor	 ﾠLiprin	 ﾠ
family	 ﾠwere	 ﾠregulated	 ﾠby	 ﾠERK2.	 ﾠExpression	 ﾠof	 ﾠRab20,	 ﾠa	 ﾠRab	 ﾠGTPase	 ﾠthat	 ﾠexhibits	 ﾠclose	 ﾠ
homology	 ﾠto	 ﾠRab17,	 ﾠwas	 ﾠminimally,	 ﾠbut	 ﾠsignificantly,	 ﾠaffected	 ﾠby	 ﾠmanipulation	 ﾠof	 ﾠERK2	 ﾠ
expression	 ﾠ(Figure	 ﾠ4-ﾭ‐8	 ﾠD).	 ﾠIn	 ﾠcontrast,	 ﾠtranscript	 ﾠlevels	 ﾠof	 ﾠother	 ﾠLiprin	 ﾠfamily	 ﾠmembers	 ﾠ
expressed	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ(i.e.	 ﾠLiprin-ﾭ‐β1,	 ﾠ-ﾭ‐α2,	 ﾠand	 ﾠ-ﾭ‐α4)	 ﾠwere	 ﾠnot	 ﾠaffected	 ﾠin	 ﾠthe	 ﾠ
same	 ﾠmanner	 ﾠas	 ﾠLiprin-ﾭ‐β2	 ﾠwhen	 ﾠERK2	 ﾠlevels	 ﾠwere	 ﾠmanipulated	 ﾠ(Figure	 ﾠ4-ﾭ‐9	 ﾠD).	 ﾠExpression	 ﾠ
of	 ﾠLiprin-ﾭ‐α2	 ﾠand	 ﾠ-ﾭ‐α4	 ﾠwas	 ﾠdecreased	 ﾠonly	 ﾠwhen	 ﾠsiRNA-ﾭ‐resistant	 ﾠERK2	 ﾠwas	 ﾠre-ﾭ‐expressed	 ﾠ
following	 ﾠERK2	 ﾠdepletion,	 ﾠwhereas	 ﾠLiprin-ﾭ‐β1	 ﾠexpression	 ﾠwas	 ﾠreduced	 ﾠwhen	 ﾠERK2	 ﾠlevels	 ﾠ
were	 ﾠmanipulated	 ﾠby	 ﾠmeans	 ﾠof	 ﾠgene	 ﾠsilencing	 ﾠor	 ﾠectopic	 ﾠexpression.	 ﾠ
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Figure 4-8 Rab17 expression is induced upon ERK2 silencing 
A. Primer pairs targeting Rab17 amplify a single product as shown by representative melting curves, which 
were generated using Opticon Monitor software. 
B. qRT-PCR reactions run with the omission of cDNA yield no amplicon as shown on the plot derived from 
the Opticon Monitor software. 
C-D. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and plated 
onto CDM. RNA was extracted, converted into cDNA and qRT-PCR was performed to validate the 
differential regulation of Rab17 (C) and Rab20 (D). Data was normalised to GAPDH and values relative to 
the control transfected are expressed as means ± standard error of the mean (SEM) of 18 replicates from 6 
independent experiments. Statistical significance of differences was determined by Mann-Whitney U test 
analysis.  
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Figure 4-9 Liprin-β2 expression is induced upon ERK2 silencing 
A. Primer pairs targeting Liprin-β2 amplify a single product as shown by representative melting curves, 
which were generated using Opticon Monitor software. 
B. qRT-PCR reactions run with the omission of cDNA yield no amplicon as shown on the plot derived from 
Opticon Monitor software. 
C-D. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and plated 
onto CDM. RNA was extracted, converted into cDNA and qRT-PCR was performed to validate the 
differential regulation of Liprin-β2 (C) and Liprin-β1/α2/α4 (D). Data was normalised to GAPDH and values 
relative to the control transfected are expressed as means ± standard error of the mean (SEM) of 18 replicates 
from 6 independent experiments. Statistical significance of differences was determined by Mann-Whitney U 
test analysis. 
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4.2.2.3  Single siRNA oligos confirm an induction of Rab17 and Liprin-β2 expression 
following ERK2 depletion 
To	 ﾠdetermine	 ﾠwhether	 ﾠaltered	 ﾠexpression	 ﾠof	 ﾠCSF2,	 ﾠRab17	 ﾠand/or	 ﾠLiprin-ﾭ‐β2	 ﾠwere	 ﾠthe	 ﾠresult	 ﾠ
of	 ﾠoff-ﾭ‐target	 ﾠsiRNA	 ﾠeffects,	 ﾠwe	 ﾠsilenced	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠsiRNA	 ﾠ
duplexes,	 ﾠplated	 ﾠthe	 ﾠcells	 ﾠon	 ﾠCDM	 ﾠand	 ﾠassessed	 ﾠrespective	 ﾠtranscript	 ﾠlevels	 ﾠby	 ﾠRT-ﾭ‐PCR.	 ﾠ
This	 ﾠindicated	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠ
diminished	 ﾠCSF2	 ﾠtranscript	 ﾠlevels	 ﾠ(Figure	 ﾠ4-ﾭ‐10	 ﾠA).	 ﾠFurthermore,	 ﾠlevels	 ﾠof	 ﾠRab17	 ﾠand	 ﾠ
Liprin-ﾭ‐β2	 ﾠmRNA	 ﾠwere	 ﾠsignificantly	 ﾠincreased	 ﾠfollowing	 ﾠknockdown	 ﾠof	 ﾠERK2,	 ﾠwhereas	 ﾠERK1	 ﾠ
silencing	 ﾠwas	 ﾠineffective	 ﾠin	 ﾠthis	 ﾠregard	 ﾠ(Figure	 ﾠ4-ﾭ‐10	 ﾠB/C).	 ﾠWe	 ﾠalso	 ﾠconfirmed	 ﾠthe	 ﾠ
knockdown	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠby	 ﾠmeans	 ﾠof	 ﾠqRT-ﾭ‐PCR	 ﾠ(Figure	 ﾠ4-ﾭ‐10	 ﾠD	 ﾠand	 ﾠE).	 ﾠTaken	 ﾠtogether	 ﾠ
these	 ﾠdata	 ﾠindicate	 ﾠthat	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠsuppresses	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠ
Liprin-ﾭ‐β2,	 ﾠwhile	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠare	 ﾠinvolved	 ﾠin	 ﾠmaintaining	 ﾠthe	 ﾠlevels	 ﾠof	 ﾠCSF2	 ﾠmRNA.	 ﾠ
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Figure 4-10 Validation of ERK2-dependent gene expression using single siRNA oligos for ERK1 and 
ERK2 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or single siRNA oligos targeting 
ERK1 or ERK2 and plated onto CDM. Total RNA was isolated and converted into cDNA.  
A-C. qRT-PCR was performed to assess mRNA expression levels after ERK1 or ERK2 knockdown. Data 
was normalised to GAPDH and values relative to the control transfected are expressed as means ± standard 
error of the mean (SEM) of 9 replicates from 3 independent experiments. Statistical significance of 
differences was determined by Mann-Whitney U test analysis. 
D-E. ERK knockdown was validated for each experiment using qRT-PCR. Data was analysed as in (A). 
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4.2.2.4  ERK2 also acts to suppress Rab17 and Liprin-β2 when cells are grown on 
plastic 
Given	 ﾠthat	 ﾠcells	 ﾠcultured	 ﾠin	 ﾠ3D	 ﾠexhibit	 ﾠcompletely	 ﾠdifferent	 ﾠgene	 ﾠexpression	 ﾠsignatures	 ﾠ
when	 ﾠcompared	 ﾠto	 ﾠ2D	 ﾠ[395],	 ﾠand	 ﾠthat	 ﾠactivation	 ﾠas	 ﾠwell	 ﾠas	 ﾠlocalisation	 ﾠof	 ﾠERK1/2	 ﾠare	 ﾠ
altered	 ﾠdepending	 ﾠon	 ﾠthe	 ﾠsubstratum	 ﾠ[449,	 ﾠ451],	 ﾠwe	 ﾠaimed	 ﾠto	 ﾠinvestigate	 ﾠwhether	 ﾠ
suppression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠby	 ﾠERK2	 ﾠwas	 ﾠspecific	 ﾠto	 ﾠ3D	 ﾠmicroenvironments.	 ﾠTo	 ﾠ
this	 ﾠend,	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠwere	 ﾠtransfected	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠsiRNAs	 ﾠ(NT),	 ﾠor	 ﾠsiRNAs	 ﾠ
targeting	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠand	 ﾠplated	 ﾠonto	 ﾠplastic	 ﾠdishes	 ﾠ(instead	 ﾠof	 ﾠCDM)	 ﾠand	 ﾠdetermined	 ﾠ
the	 ﾠexpression	 ﾠlevels	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2.	 ﾠ	 ﾠ
Clearly,	 ﾠsiRNA	 ﾠof	 ﾠERK2	 ﾠincreased	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠwhen	 ﾠcells	 ﾠwere	 ﾠ
plated	 ﾠonto	 ﾠplastic	 ﾠsurfaces,	 ﾠand	 ﾠknockdown	 ﾠof	 ﾠERK1	 ﾠalso	 ﾠdrove	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠ
expression,	 ﾠbut	 ﾠto	 ﾠa	 ﾠlesser	 ﾠextent	 ﾠ(Figure	 ﾠ4-ﾭ‐11).	 ﾠThese	 ﾠdata	 ﾠindicate	 ﾠthat	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠa	 ﾠ
3D	 ﾠmicroenvironment	 ﾠis	 ﾠnot	 ﾠa	 ﾠprerequisite	 ﾠfor	 ﾠERK2’s	 ﾠability	 ﾠto	 ﾠsuppress	 ﾠRab17	 ﾠand	 ﾠ
Liprin-ﾭ‐β2	 ﾠexpression,	 ﾠbut	 ﾠthat	 ﾠERK1	 ﾠmay	 ﾠalso	 ﾠacquire	 ﾠsome	 ﾠcapacity	 ﾠto	 ﾠcontrol	 ﾠthese	 ﾠ
genes	 ﾠwhen	 ﾠcells	 ﾠare	 ﾠplated	 ﾠonto	 ﾠplastic.	 ﾠ	 ﾠ
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Figure 4-11 Knockdown of ERK2 induces Rab17 and Liprin-β2 expression in 2D 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK1 or ERK2 
and plated onto plastic. Total RNA was isolated and converted into cDNA.  
A-B. qRT-PCR was performed to assess mRNA expression levels after ERK silencing. Data was normalised 
to GAPDH and values relative to the control transfected are expressed as means ± standard error of the mean 
(SEM) of 9 replicates from 3 independent experiments. Statistical significance of differences was determined 
by Mann-Whitney U test analysis. 
C-D. ERK knockdown was validated for each experiment using qRT-PCR. Data was analysed as in (A). 
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4.2.2.5  Regulation of CSF2, Rab17 and Liprin-β2 is dependent on MEK activity 
In	 ﾠan	 ﾠattempt	 ﾠto	 ﾠcharacterise	 ﾠthe	 ﾠhuman	 ﾠprotein-ﾭ‐DNA	 ﾠinteractome,	 ﾠERK2	 ﾠwas	 ﾠidentified	 ﾠ
as	 ﾠan	 ﾠunconventional	 ﾠDNA-ﾭ‐binding	 ﾠprotein,	 ﾠwhich	 ﾠcan	 ﾠbind	 ﾠdirectly	 ﾠto	 ﾠa	 ﾠG/CAAAG/C	 ﾠ
consensus	 ﾠmotif	 ﾠand	 ﾠthereby	 ﾠrepress	 ﾠtranscription	 ﾠas	 ﾠshown	 ﾠby	 ﾠelectrophoretic	 ﾠmobility	 ﾠ
shift	 ﾠassays	 ﾠand	 ﾠcell-ﾭ‐based	 ﾠluciferase	 ﾠanalysis.	 ﾠIntriguingly,	 ﾠthis	 ﾠrole	 ﾠas	 ﾠa	 ﾠtranscriptional	 ﾠ
repressor	 ﾠis	 ﾠindependent	 ﾠof	 ﾠits	 ﾠkinase	 ﾠactivity	 ﾠand	 ﾠcan	 ﾠbe	 ﾠattributed	 ﾠto	 ﾠa	 ﾠcluster	 ﾠof	 ﾠ
positively	 ﾠcharged	 ﾠresidues	 ﾠon	 ﾠthe	 ﾠC-ﾭ‐terminus	 ﾠof	 ﾠthe	 ﾠprotein,	 ﾠwith	 ﾠLys259	 ﾠand	 ﾠArg261	 ﾠ
being	 ﾠthe	 ﾠkey	 ﾠresidues	 ﾠrequired	 ﾠfor	 ﾠDNA	 ﾠbinding	 ﾠ[468].	 ﾠHaving	 ﾠidentified	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠ
gene	 ﾠexpression	 ﾠsignature,	 ﾠwe	 ﾠwanted	 ﾠto	 ﾠinvestigate	 ﾠwhether	 ﾠthis	 ﾠnovel	 ﾠrole	 ﾠas	 ﾠa	 ﾠ
DNA-ﾭ‐binding	 ﾠprotein	 ﾠwas	 ﾠresponsible	 ﾠfor	 ﾠregulating	 ﾠmRNA	 ﾠlevels	 ﾠof	 ﾠCSF2,	 ﾠRab17	 ﾠand	 ﾠ
Liprin-ﾭ‐β2.	 ﾠ
To	 ﾠdetermine	 ﾠwhether	 ﾠphosphorylation	 ﾠof	 ﾠERK	 ﾠby	 ﾠMEK	 ﾠwas	 ﾠnecessary	 ﾠfor	 ﾠits	 ﾠrole	 ﾠin	 ﾠ
regulating	 ﾠRab17,	 ﾠLiprin-ﾭ‐β2	 ﾠand	 ﾠCSF2	 ﾠexpression,	 ﾠwe	 ﾠseeded	 ﾠ300,000	 ﾠcells	 ﾠonto	 ﾠCDM	 ﾠand	 ﾠ
treated	 ﾠthem	 ﾠwith	 ﾠDMSO	 ﾠ(dimethyl	 ﾠsulfoxide)	 ﾠas	 ﾠmock	 ﾠor	 ﾠthe	 ﾠMEK	 ﾠinhibitor,	 ﾠU0126.	 ﾠWe	 ﾠ
harvested	 ﾠcells	 ﾠat	 ﾠdifferent	 ﾠtime	 ﾠpoints	 ﾠfollowing	 ﾠtreatment	 ﾠ(5	 ﾠminutes,	 ﾠ1	 ﾠhour,	 ﾠ2	 ﾠhours	 ﾠ
and	 ﾠ24	 ﾠhours),	 ﾠextracted	 ﾠtotal	 ﾠRNA	 ﾠand	 ﾠperformed	 ﾠqRT-ﾭ‐PCR	 ﾠcombined	 ﾠwith	 ﾠreverse	 ﾠ
transcription.	 ﾠIntriguingly,	 ﾠlevels	 ﾠof	 ﾠCSF2	 ﾠmRNA	 ﾠwere	 ﾠmaximally	 ﾠinhibited	 ﾠone	 ﾠhour	 ﾠafter	 ﾠ
U0126	 ﾠtreatment,	 ﾠindicating	 ﾠthat	 ﾠERK	 ﾠis	 ﾠdirectly	 ﾠinvolved	 ﾠin	 ﾠdriving	 ﾠCSF2	 ﾠexpression,	 ﾠand	 ﾠ
that	 ﾠthis	 ﾠis	 ﾠdepending	 ﾠon	 ﾠits	 ﾠkinase	 ﾠactivity	 ﾠ(Figure	 ﾠ4-ﾭ‐12	 ﾠA).	 ﾠIn	 ﾠcontrast,	 ﾠtranscription	 ﾠof	 ﾠ
Rab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠwere	 ﾠonly	 ﾠinduced	 ﾠ24	 ﾠhours	 ﾠfollowing	 ﾠMEK	 ﾠinhibition,	 ﾠwhich	 ﾠsuggests	 ﾠ
that	 ﾠERK2	 ﾠsuppresses	 ﾠthese	 ﾠtwo	 ﾠgenes	 ﾠless	 ﾠdirectly	 ﾠthan	 ﾠit	 ﾠaffects	 ﾠCSF2	 ﾠexpression	 ﾠ(Figure	 ﾠ
4-ﾭ‐12	 ﾠB/C).	 ﾠ	 ﾠ
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Figure 4-12 Expression of CSF2, Rab17 and Liprin-β2 is dependent on ERK2’s kinase activity 
MDA-MB-231 cells were treated with DMSO or the MEK inhibitor, U0126. Subsequently, cells were lysed, 
total RNA isolated, and converted into cDNA. qRT-PCR was performed to assess mRNA expression levels 
of CSF2 (A), Rab17 (B), and Liprin-β2 (C) following MEK inhibition. Data was normalised to GAPDH and 
values relative to the control transfected are expressed as means ± standard error of the mean (SEM) of 9 
replicates from 3 independent experiments. Statistical significance of differences was determined by Mann-
Whitney U test analysis. 
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4.2.2.6  Rab17 and Liprin-β2 transcription is suppressed by CSF2 
Given	 ﾠthat	 ﾠexpression	 ﾠof	 ﾠCSF2	 ﾠis	 ﾠmaximally	 ﾠreduced	 ﾠafter	 ﾠone	 ﾠhour	 ﾠof	 ﾠU0126	 ﾠtreatment,	 ﾠ
but	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2’s	 ﾠmRNA	 ﾠlevels	 ﾠare	 ﾠonly	 ﾠaltered	 ﾠafter	 ﾠ24	 ﾠhours,	 ﾠwe	 ﾠwanted	 ﾠto	 ﾠ
investigate	 ﾠthe	 ﾠpossibility	 ﾠthat	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠare	 ﾠdownstream	 ﾠeffectors	 ﾠof	 ﾠCSF2,	 ﾠ
which	 ﾠmight	 ﾠexplain	 ﾠthe	 ﾠlate	 ﾠinduction	 ﾠin	 ﾠgene	 ﾠexpression.	 ﾠTo	 ﾠtest	 ﾠthis	 ﾠinterdependency,	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠwere	 ﾠtransfected	 ﾠwith	 ﾠNT	 ﾠsiRNAs,	 ﾠor	 ﾠoligos	 ﾠtargeting	 ﾠCSF2,	 ﾠRab17,	 ﾠor	 ﾠ
Liprin-ﾭ‐β2	 ﾠand	 ﾠplated	 ﾠonto	 ﾠcell-ﾭ‐derived	 ﾠmatrix.	 ﾠWe	 ﾠfound	 ﾠthat	 ﾠsiRNA	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠdid	 ﾠnot	 ﾠ
alter	 ﾠlevels	 ﾠof	 ﾠRab17	 ﾠmRNA,	 ﾠand	 ﾠneither	 ﾠdid	 ﾠRab17	 ﾠknockdown	 ﾠaffect	 ﾠLiprin-ﾭ‐β2	 ﾠ
expression.	 ﾠHowever,	 ﾠsilencing	 ﾠof	 ﾠCSF2	 ﾠsignificantly	 ﾠinduced	 ﾠboth	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠ
expression	 ﾠ(Figure	 ﾠ4-ﾭ‐13	 ﾠA/B),	 ﾠindicating	 ﾠthat	 ﾠtranscription	 ﾠof	 ﾠthese	 ﾠtwo	 ﾠgenes	 ﾠis	 ﾠregulated	 ﾠ
by	 ﾠCSF2.	 ﾠNext,	 ﾠwe	 ﾠwanted	 ﾠto	 ﾠinvestigate	 ﾠwhether	 ﾠexpression	 ﾠof	 ﾠCSF2	 ﾠitself	 ﾠis	 ﾠregulated	 ﾠby	 ﾠ
Rab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠthrough	 ﾠa	 ﾠpositive	 ﾠor	 ﾠnegative	 ﾠfeedback	 ﾠloop.	 ﾠHowever,	 ﾠwe	 ﾠobserved	 ﾠ
no	 ﾠsignificant	 ﾠchanges	 ﾠin	 ﾠCSF2	 ﾠmRNA	 ﾠlevels,	 ﾠwhen	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠwere	 ﾠ
silenced	 ﾠ(Figure	 ﾠ4-ﾭ‐13	 ﾠC).	 ﾠ
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Figure 4-13 Rab17 and Liprin-β2 expression is suppressed by CSF2 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting CSF2, Rab17, or 
Liprin-β2 and plated onto cell-derived matrix. Total RNA was isolated and converted into cDNA. qRT-PCR 
was performed to assess mRNA expression levels of CSF2 (A), Rab17 (B), and Liprin-β2 (C) following 
respective knockdowns. Data was normalised to GAPDH and values relative to the control transfected are 
expressed as means ± standard error of the mean (SEM) of 9 replicates from 3 independent experiments. 
Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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4.3  Discussion 
4.3.1  Summary 
Chapter	 ﾠ3	 ﾠpresented	 ﾠdata	 ﾠdemonstrating	 ﾠthat	 ﾠthe	 ﾠinvasiveness	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ
depends	 ﾠspecifically	 ﾠon	 ﾠERK2	 ﾠand	 ﾠnot	 ﾠERK1.	 ﾠHere,	 ﾠwe	 ﾠperformed	 ﾠa	 ﾠgene	 ﾠexpression	 ﾠarray	 ﾠ
to	 ﾠidentify	 ﾠgenes	 ﾠwhose	 ﾠexpression	 ﾠis	 ﾠregulated	 ﾠby	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1.	 ﾠWe	 ﾠfound	 ﾠ27	 ﾠgenes	 ﾠ
whose	 ﾠexpression	 ﾠwas	 ﾠaltered	 ﾠafter	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠand	 ﾠrestored	 ﾠto	 ﾠnormal	 ﾠlevels	 ﾠ
following	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1).	 ﾠAmong	 ﾠthese,	 ﾠwe	 ﾠconfirmed	 ﾠthe	 ﾠ
ERK2-ﾭ‐dependency	 ﾠfor	 ﾠcsf2,	 ﾠrab17	 ﾠand	 ﾠliprin-ﾭ‐β2	 ﾠon	 ﾠCDM	 ﾠby	 ﾠqRT-ﾭ‐PCR.	 ﾠMoreover,	 ﾠsiRNA	 ﾠof	 ﾠ
ERK2	 ﾠclearly	 ﾠincreased	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠwhen	 ﾠcells	 ﾠare	 ﾠgrown	 ﾠon	 ﾠplastic	 ﾠ
surfaces,	 ﾠindicating	 ﾠthat	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠa	 ﾠ3D	 ﾠmicroenvironment	 ﾠis	 ﾠnot	 ﾠa	 ﾠprerequisite	 ﾠfor	 ﾠ
ERK2’s	 ﾠability	 ﾠto	 ﾠsuppress	 ﾠthese	 ﾠgenes.
	 ﾠ
4.3.2  ERK2 as a regulator of transcriptional initiation 
In	 ﾠthis	 ﾠchapter	 ﾠwe	 ﾠprovide	 ﾠclear	 ﾠevidence	 ﾠfor	 ﾠan	 ﾠisoform-ﾭ‐specific,	 ﾠERK2-ﾭ‐dependent	 ﾠgene	 ﾠ
expression	 ﾠsignature	 ﾠfrom	 ﾠwhich	 ﾠwe	 ﾠvalidated	 ﾠthree	 ﾠgenes,	 ﾠi.e.	 ﾠcsf2,	 ﾠrab17	 ﾠand	 ﾠliprin-ﾭ‐β2.	 ﾠ
Interestingly,	 ﾠwe	 ﾠobserved	 ﾠvery	 ﾠdistinct	 ﾠkinetics	 ﾠof	 ﾠchanges	 ﾠin	 ﾠtranscript	 ﾠlevels	 ﾠfollowing	 ﾠ
U0126	 ﾠtreatment,	 ﾠwhich	 ﾠimplicates	 ﾠthat	 ﾠERK2	 ﾠcan	 ﾠregulate	 ﾠgene	 ﾠexpression	 ﾠboth	 ﾠdirectly	 ﾠ
and	 ﾠindirectly.	 ﾠAlthough	 ﾠwe	 ﾠchose	 ﾠnot	 ﾠto	 ﾠinvestigate	 ﾠhow	 ﾠERK2	 ﾠpromotes	 ﾠor	 ﾠsuppresses	 ﾠ
transcriptional	 ﾠevents	 ﾠin	 ﾠan	 ﾠisoform-ﾭ‐specific	 ﾠmanner,	 ﾠwe	 ﾠwould	 ﾠstill	 ﾠlike	 ﾠto	 ﾠdiscuss	 ﾠvarious	 ﾠ
tiers	 ﾠof	 ﾠgene	 ﾠexpression	 ﾠthat	 ﾠmight	 ﾠbe	 ﾠinfluenced	 ﾠby	 ﾠthis	 ﾠisoform.	 ﾠ	 ﾠ
Active	 ﾠERK	 ﾠsignalling	 ﾠhas	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠchromatin	 ﾠremodelling	 ﾠprocesses	 ﾠgiving	 ﾠrise	 ﾠ
to	 ﾠboth	 ﾠopen	 ﾠ[427]	 ﾠand	 ﾠclosed	 ﾠchromatin	 ﾠstructures	 ﾠ[469].	 ﾠThe	 ﾠdownstream	 ﾠERK	 ﾠtargets	 ﾠ
involved	 ﾠin	 ﾠthese	 ﾠprocesses	 ﾠstill	 ﾠremain	 ﾠto	 ﾠbe	 ﾠelucidated,	 ﾠalthough	 ﾠphosphorylation	 ﾠof	 ﾠ
histone	 ﾠH3	 ﾠand	 ﾠHMG-ﾭ‐14	 ﾠby	 ﾠthe	 ﾠERK	 ﾠeffectors	 ﾠMSK1/2	 ﾠand	 ﾠRSK2	 ﾠare	 ﾠthought	 ﾠto	 ﾠpromote	 ﾠ
loosening	 ﾠof	 ﾠchromatin	 ﾠby	 ﾠrecruiting	 ﾠhistone	 ﾠacetyltransferases	 ﾠ[426-ﾭ‐428].	 ﾠMoreover,	 ﾠ
active	 ﾠERK	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠstimulate	 ﾠtopoisomerase	 ﾠIIα	 ﾠin	 ﾠa	 ﾠmechanism	 ﾠthat	 ﾠis	 ﾠ
independent	 ﾠof	 ﾠits	 ﾠenzymatic	 ﾠactivity	 ﾠ[470].	 ﾠThus,	 ﾠERK2	 ﾠmight	 ﾠpromote	 ﾠor	 ﾠsuppress	 ﾠDNA	 ﾠ
accessibility	 ﾠof	 ﾠa	 ﾠsubset	 ﾠof	 ﾠgenes	 ﾠby	 ﾠregulating	 ﾠthe	 ﾠphosphorylation	 ﾠor	 ﾠactivity	 ﾠof	 ﾠ
chromatin	 ﾠremodelling	 ﾠfactors,	 ﾠsuch	 ﾠas	 ﾠtopoisomerase	 ﾠIIα.	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Once	 ﾠthe	 ﾠchromatin	 ﾠis	 ﾠloosened,	 ﾠtranscription	 ﾠfactors	 ﾠbind	 ﾠto	 ﾠthe	 ﾠexposed	 ﾠDNA	 ﾠsequence	 ﾠ
and	 ﾠthereby	 ﾠenhance	 ﾠor	 ﾠsuppress	 ﾠthe	 ﾠformation	 ﾠof	 ﾠthe	 ﾠtranscription	 ﾠinitiation	 ﾠcomplex.	 ﾠAs	 ﾠ
transcriptional	 ﾠactivators	 ﾠand	 ﾠrepressors	 ﾠgenerally	 ﾠcompete	 ﾠfor	 ﾠthe	 ﾠsame	 ﾠbinding	 ﾠsite	 ﾠon	 ﾠ
the	 ﾠDNA,	 ﾠalterations	 ﾠin	 ﾠDNA	 ﾠbinding	 ﾠaffinities	 ﾠthrough	 ﾠpost-ﾭ‐translational	 ﾠmodifications	 ﾠ
can	 ﾠpromote	 ﾠor	 ﾠinhibit	 ﾠgene	 ﾠtranscription	 ﾠ[471].	 ﾠIndeed,	 ﾠphosphorylation	 ﾠof	 ﾠc-ﾭ‐Jun	 ﾠand	 ﾠ
N-ﾭ‐Myc	 ﾠby	 ﾠERK1/2	 ﾠwas	 ﾠshown	 ﾠto	 ﾠenhance	 ﾠthe	 ﾠtransactivation	 ﾠand	 ﾠtranscriptional	 ﾠ
repression	 ﾠactivity,	 ﾠrespectively	 ﾠ[472,	 ﾠ473].	 ﾠThus,	 ﾠERK2	 ﾠmight	 ﾠregulate	 ﾠgene	 ﾠtranscription	 ﾠ
by	 ﾠaltering	 ﾠthe	 ﾠDNA-ﾭ‐binding	 ﾠaffinity	 ﾠof	 ﾠtranscription	 ﾠfactors	 ﾠthrough	 ﾠdirect	 ﾠor	 ﾠindirect	 ﾠ
phosphorylation.	 ﾠIn	 ﾠaddition,	 ﾠERK2	 ﾠhas	 ﾠrecently	 ﾠbeen	 ﾠidentified	 ﾠas	 ﾠan	 ﾠunconventional	 ﾠ
DNA-ﾭ‐binding	 ﾠprotein	 ﾠ[468],	 ﾠwhich	 ﾠrepresses	 ﾠinterferon	 ﾠgamma	 ﾠsignalling.	 ﾠAlthough	 ﾠnot	 ﾠ
reported	 ﾠso	 ﾠfar,	 ﾠDNA-ﾭ‐binding	 ﾠby	 ﾠERK2	 ﾠmay	 ﾠalso	 ﾠpromote	 ﾠgene	 ﾠtranscription.	 ﾠNotably,	 ﾠboth	 ﾠ
ERK	 ﾠisoforms	 ﾠcontain	 ﾠthe	 ﾠcritical	 ﾠresidues	 ﾠinvolved	 ﾠin	 ﾠDNA	 ﾠbinding	 ﾠ[468],	 ﾠwhich	 ﾠargues	 ﾠ
against	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠfunction	 ﾠin	 ﾠtranscription.	 ﾠHowever,	 ﾠamino	 ﾠacids	 ﾠflanking	 ﾠthe	 ﾠ
critical	 ﾠarginine	 ﾠand	 ﾠlysine	 ﾠare	 ﾠonly	 ﾠpartially	 ﾠconserved	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠkinases	 ﾠ(Figure	 ﾠ
4-ﾭ‐14	 ﾠA)	 ﾠand	 ﾠthis	 ﾠmay	 ﾠgive	 ﾠrise	 ﾠto	 ﾠdiffering	 ﾠDNA	 ﾠbinding	 ﾠgrooves.	 ﾠWhether	 ﾠor	 ﾠnot	 ﾠboth	 ﾠ
kinases	 ﾠrecognise	 ﾠdifferent	 ﾠDNA	 ﾠconsensus	 ﾠmotifs	 ﾠremains	 ﾠto	 ﾠbe	 ﾠelucidated.	 ﾠ	 ﾠ
Interestingly,	 ﾠthe	 ﾠcsf2	 ﾠpromoter	 ﾠregion	 ﾠcontains	 ﾠ2	 ﾠG/CAAAG/C	 ﾠmotifs	 ﾠand	 ﾠthis	 ﾠsuggests	 ﾠ
that	 ﾠERK2	 ﾠmight	 ﾠbind	 ﾠto	 ﾠits	 ﾠ5ˊ	 ﾠUTR.	 ﾠAlthough	 ﾠDNA-ﾭ‐binding	 ﾠis	 ﾠindependent	 ﾠof	 ﾠERK	 ﾠkinase	 ﾠ
activity	 ﾠ[468],	 ﾠit	 ﾠis	 ﾠpossible	 ﾠthat	 ﾠactive	 ﾠERK	 ﾠbound	 ﾠto	 ﾠthe	 ﾠpromoter	 ﾠregion	 ﾠmay	 ﾠ
phosphorylate	 ﾠneighbouring	 ﾠtranscription	 ﾠfactors	 ﾠand	 ﾠthereby	 ﾠalter	 ﾠtheir	 ﾠability	 ﾠto	 ﾠ
transactivate	 ﾠor	 ﾠrepress.	 ﾠMoreover,	 ﾠactive	 ﾠERK	 ﾠmight	 ﾠbe	 ﾠrecruited	 ﾠto	 ﾠspecific	 ﾠgenes	 ﾠ
through	 ﾠits	 ﾠDNA-ﾭ‐binding	 ﾠability.	 ﾠIntriguingly,	 ﾠCSF2	 ﾠmRNA	 ﾠlevels	 ﾠare	 ﾠreduced	 ﾠby	 ﾠknockdown	 ﾠ
of	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2,	 ﾠindicating	 ﾠthat	 ﾠboth	 ﾠkinases	 ﾠare	 ﾠinvolved	 ﾠin	 ﾠdriving	 ﾠCSF2	 ﾠ
expression.	 ﾠYet,	 ﾠCSF2	 ﾠtranscript	 ﾠlevels	 ﾠare	 ﾠonly	 ﾠrestored	 ﾠto	 ﾠcontrol	 ﾠlevels	 ﾠwhen	 ﾠectopic	 ﾠ
ERK2	 ﾠis	 ﾠre-ﾭ‐expressed,	 ﾠindicating	 ﾠthat	 ﾠERK	 ﾠregulates	 ﾠboth	 ﾠthe	 ﾠinitial	 ﾠtranscription	 ﾠas	 ﾠwell	 ﾠas	 ﾠ
mRNA	 ﾠstability.	 ﾠIndeed,	 ﾠthe	 ﾠcsf2	 ﾠpromoter	 ﾠregion	 ﾠcontains	 ﾠan	 ﾠAP-ﾭ‐1-ﾭ‐binding	 ﾠsite,	 ﾠwhich	 ﾠis	 ﾠ
critical	 ﾠfor	 ﾠCSF2	 ﾠtranscription	 ﾠ(personal	 ﾠcommunication	 ﾠwith	 ﾠDr.	 ﾠGareth	 ﾠInman).	 ﾠThe	 ﾠAP-ﾭ‐1	 ﾠ
transcription	 ﾠfactor	 ﾠis	 ﾠregulated	 ﾠboth	 ﾠtranscriptionally	 ﾠand	 ﾠpost-ﾭ‐transcriptionally	 ﾠby	 ﾠboth	 ﾠ
ERK1	 ﾠand	 ﾠERK2.	 ﾠThus,	 ﾠit	 ﾠis	 ﾠnot	 ﾠsurprising	 ﾠthat	 ﾠsilencing	 ﾠof	 ﾠeither	 ﾠgene	 ﾠsignificantly	 ﾠreduces	 ﾠ
CSF2	 ﾠmRNA	 ﾠlevels.	 ﾠYet,	 ﾠthe	 ﾠMEK	 ﾠinhibitor	 ﾠU0126	 ﾠmaximally	 ﾠreduces	 ﾠcsf2	 ﾠmRNA	 ﾠlevels	 ﾠ
within	 ﾠone	 ﾠhour	 ﾠof	 ﾠtreatment,	 ﾠalthough	 ﾠFra	 ﾠand	 ﾠJun	 ﾠlevels	 ﾠonly	 ﾠdecrease	 ﾠafter	 ﾠa	 ﾠprolonged	 ﾠ
inhibition	 ﾠof	 ﾠMEK	 ﾠ[378].	 ﾠThis	 ﾠindicates	 ﾠthat	 ﾠthere	 ﾠare	 ﾠAP-ﾭ‐1	 ﾠindependent	 ﾠmechanisms,	 ﾠ
which	 ﾠare	 ﾠalso	 ﾠimportant	 ﾠin	 ﾠthe	 ﾠinitial	 ﾠstages	 ﾠof	 ﾠcsf2	 ﾠtranscription.	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Figure 4-14 ERK2 as a regulator of gene expression 
A. Comparison of ERK2’s sequence shown to be involved in direct DNA-binding. Crucial basic amino acids 
are coloured in red. Diverging amino acids in the flanking sequences are coloured grey. 
B. Schematic illustration of how ERK2 drives expression of CSF. 
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4.3.3  Post-transcriptional regulation of gene expression 
Messenger	 ﾠRNA	 ﾠlevels	 ﾠare	 ﾠinfluenced	 ﾠby	 ﾠchanges	 ﾠin	 ﾠnuclear	 ﾠtranscription	 ﾠrates,	 ﾠmRNA	 ﾠ
processing	 ﾠand	 ﾠcytoplasmic	 ﾠdecay.	 ﾠInterestingly,	 ﾠmRNA	 ﾠdegradation	 ﾠis	 ﾠthought	 ﾠto	 ﾠbe	 ﾠa	 ﾠ
major	 ﾠregulator	 ﾠof	 ﾠgene	 ﾠexpression	 ﾠand	 ﾠderegulated	 ﾠmRNA	 ﾠstability	 ﾠhas	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠ
diseases,	 ﾠsuch	 ﾠas	 ﾠAlzheimer’s	 ﾠdisease	 ﾠand	 ﾠthalassaemia	 ﾠ[474].	 ﾠEukaryotic	 ﾠmRNAs	 ﾠare	 ﾠ
subject	 ﾠto	 ﾠco-ﾭ‐transcriptional	 ﾠprocessing,	 ﾠwhich	 ﾠprotects	 ﾠthe	 ﾠtranscripts	 ﾠfrom	 ﾠ
phosphatases	 ﾠand	 ﾠribonucleases,	 ﾠand	 ﾠentails	 ﾠ5ˊcapping,	 ﾠ3ˊ	 ﾠpolyadenylation	 ﾠand	 ﾠ
splicing	 ﾠ[475].	 ﾠMoreover,	 ﾠmRNA	 ﾠstability	 ﾠcan	 ﾠbe	 ﾠregulated	 ﾠthrough	 ﾠsequence-ﾭ‐specific	 ﾠ
elements	 ﾠlocated	 ﾠin	 ﾠthe	 ﾠ5ˊ	 ﾠor	 ﾠ3ˊ	 ﾠUTR.	 ﾠFor	 ﾠexample,	 ﾠA+U-ﾭ‐rich	 ﾠelements	 ﾠ(ARE)	 ﾠare	 ﾠpotent	 ﾠ
destabilising	 ﾠfeatures	 ﾠof	 ﾠmRNAs,	 ﾠwhich	 ﾠpromote	 ﾠdegradation	 ﾠby	 ﾠrecruiting	 ﾠRNA-ﾭ‐binding	 ﾠ
proteins,	 ﾠsuch	 ﾠas	 ﾠtristetraprolin	 ﾠ[474].	 ﾠThe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠstimulates	 ﾠthe	 ﾠ
phosphorylation	 ﾠof	 ﾠtristetraprolin	 ﾠand	 ﾠsubsequent	 ﾠbinding	 ﾠto	 ﾠ14-ﾭ‐3-ﾭ‐3	 ﾠproteins,	 ﾠwhich	 ﾠ
sequesters	 ﾠthe	 ﾠRNA-ﾭ‐binding	 ﾠprotein	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠand	 ﾠis	 ﾠlinked	 ﾠto	 ﾠan	 ﾠenhanced	 ﾠ
stability	 ﾠof	 ﾠARE-ﾭ‐containing	 ﾠmRNAs	 ﾠ[476,	 ﾠ477].	 ﾠ
Intriguingly,	 ﾠtristetraprolin	 ﾠwas	 ﾠshown	 ﾠto	 ﾠenhance	 ﾠCSF2	 ﾠmRNA	 ﾠlability	 ﾠby	 ﾠpromoting	 ﾠ
mRNA	 ﾠdeadenylation	 ﾠ[478].	 ﾠGiven	 ﾠthat	 ﾠERK	 ﾠpromotes	 ﾠphosphorylation	 ﾠof	 ﾠtristetraprolin,	 ﾠ
this	 ﾠmay	 ﾠrepresent	 ﾠanother	 ﾠlevel,	 ﾠby	 ﾠwhich	 ﾠERK	 ﾠsignalling	 ﾠcan	 ﾠimpinge	 ﾠon	 ﾠCSF2	 ﾠexpression.	 ﾠ
Indeed,	 ﾠour	 ﾠdata	 ﾠare	 ﾠconsistent	 ﾠwith	 ﾠa	 ﾠmechanism	 ﾠin	 ﾠwhich	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1	 ﾠis	 ﾠ
important	 ﾠin	 ﾠstabilising	 ﾠCSF2	 ﾠmRNA,	 ﾠas	 ﾠoverexpression	 ﾠof	 ﾠectopic	 ﾠERK1	 ﾠwas	 ﾠnot	 ﾠsufficient	 ﾠ
to	 ﾠrestore	 ﾠnormal	 ﾠtranscript	 ﾠlevels	 ﾠafter	 ﾠknockdown	 ﾠof	 ﾠERK2.	 ﾠTaken	 ﾠtogether,	 ﾠour	 ﾠresults	 ﾠ
suggest	 ﾠa	 ﾠmechanism	 ﾠin	 ﾠwhich	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠcontrols	 ﾠcsf2	 ﾠexpression	 ﾠat	 ﾠvarious	 ﾠ
stages	 ﾠ(Figure	 ﾠ4-ﾭ‐14	 ﾠB).	 ﾠFirstly,	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠmay	 ﾠpromote	 ﾠgene	 ﾠtranscription	 ﾠby	 ﾠ
stabilising	 ﾠthe	 ﾠAP-ﾭ‐1	 ﾠtranscription	 ﾠfactor	 ﾠand	 ﾠpotentially	 ﾠinducing	 ﾠan	 ﾠopen-ﾭ‐chromatin	 ﾠ
structure.	 ﾠSecondly,	 ﾠCSF2	 ﾠtranscripts	 ﾠmay	 ﾠbe	 ﾠstabilised	 ﾠvia	 ﾠan	 ﾠisoform-ﾭ‐specific	 ﾠmechanism,	 ﾠ
which	 ﾠmight	 ﾠinvolve	 ﾠphosphorylation	 ﾠof	 ﾠtristetraprolin.	 ﾠThirdly,	 ﾠERK	 ﾠsignalling	 ﾠcould	 ﾠ
stimulate	 ﾠinitiation	 ﾠof	 ﾠthe	 ﾠtranslation	 ﾠmachinery	 ﾠby	 ﾠactivating	 ﾠMNK1	 ﾠ(MAPK	 ﾠinteracting	 ﾠ
kinase	 ﾠ1),	 ﾠwhich	 ﾠin	 ﾠturn	 ﾠphosphorylates	 ﾠand	 ﾠactivates	 ﾠthe	 ﾠtranslational	 ﾠinitiation	 ﾠfactor	 ﾠ
eIF4E	 ﾠ[479].	 ﾠ
Notably,	 ﾠour	 ﾠIllumina	 ﾠgene	 ﾠexpression	 ﾠarray	 ﾠalso	 ﾠidentified	 ﾠgenes,	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠ
induced	 ﾠby	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2,	 ﾠbut	 ﾠcould	 ﾠonly	 ﾠbe	 ﾠrestored	 ﾠto	 ﾠcontrol	 ﾠ
levels,	 ﾠwhen	 ﾠectopic	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠwas	 ﾠre-ﾭ‐expressed	 ﾠand	 ﾠsuggested	 ﾠan	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isoform-ﾭ‐specific	 ﾠrole	 ﾠin	 ﾠmRNA	 ﾠdecay.	 ﾠAmong	 ﾠthose	 ﾠgenes	 ﾠwere	 ﾠthe	 ﾠSelenium-ﾭ‐binding	 ﾠ
protein	 ﾠ(SELENBP1),	 ﾠthe	 ﾠprotein	 ﾠDEPP	 ﾠ(C100RF10)	 ﾠand	 ﾠthe	 ﾠG-ﾭ‐protein	 ﾠcoupled	 ﾠreceptor	 ﾠ64	 ﾠ
(GPR64).	 ﾠThus,	 ﾠa	 ﾠpossible	 ﾠfuture	 ﾠavenue	 ﾠfor	 ﾠinvestigation	 ﾠmay	 ﾠbe	 ﾠto	 ﾠdetermine	 ﾠhow	 ﾠERK2	 ﾠ
signalling	 ﾠcan	 ﾠselectively	 ﾠcontrol	 ﾠstabilisation	 ﾠand	 ﾠdecay	 ﾠof	 ﾠparticular	 ﾠtranscripts.	 ﾠ
4.3.4  ERK signalling differs between 2D and 3D microenvironments 
Transmembrane	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠintegrins	 ﾠor	 ﾠreceptor	 ﾠtyrosine	 ﾠkinases,	 ﾠare	 ﾠable	 ﾠto	 ﾠsense	 ﾠ
changes	 ﾠin	 ﾠthe	 ﾠextracellular	 ﾠenvironment	 ﾠand	 ﾠrelay	 ﾠthis	 ﾠinformation	 ﾠto	 ﾠcytoplasmic	 ﾠ
signalling	 ﾠcircuits	 ﾠlike	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway.	 ﾠIt	 ﾠis	 ﾠtherefore	 ﾠnot	 ﾠsurprising	 ﾠthat	 ﾠthe	 ﾠ
microenvironment	 ﾠin	 ﾠwhich	 ﾠcells	 ﾠare	 ﾠcultured	 ﾠsignificantly	 ﾠinfluences	 ﾠcellular	 ﾠsignalling	 ﾠ
pathways	 ﾠto	 ﾠchange	 ﾠcellular	 ﾠfeatures	 ﾠsuch	 ﾠas	 ﾠcell	 ﾠshape	 ﾠand	 ﾠmigration	 ﾠ[395,	 ﾠ451].	 ﾠRab17	 ﾠ
and	 ﾠliprin-ﾭ‐β2	 ﾠwere	 ﾠsuppressed	 ﾠin	 ﾠan	 ﾠERK	 ﾠisoform-ﾭ‐specific	 ﾠmanner	 ﾠwhen	 ﾠcells	 ﾠwere	 ﾠ
cultured	 ﾠon	 ﾠCDM,	 ﾠbut	 ﾠto	 ﾠa	 ﾠlesser	 ﾠextent	 ﾠwhen	 ﾠcells	 ﾠwere	 ﾠgrown	 ﾠon	 ﾠplastic.	 ﾠThis	 ﾠ
discrepancy	 ﾠin	 ﾠsignalling	 ﾠmay	 ﾠbe	 ﾠthe	 ﾠresult	 ﾠof	 ﾠdifferent	 ﾠsubcellular	 ﾠlocalisations	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠ
isoforms	 ﾠin	 ﾠ2D	 ﾠand	 ﾠ3D.	 ﾠIndeed,	 ﾠAplin	 ﾠet	 ﾠal.	 ﾠhave	 ﾠdemonstrated	 ﾠthat	 ﾠintegrin-ﾭ‐mediated	 ﾠ
adhesions	 ﾠto	 ﾠfibronectin	 ﾠenhance	 ﾠnuclear	 ﾠERK	 ﾠtranslocation	 ﾠvia	 ﾠa	 ﾠmechanism	 ﾠthat	 ﾠis	 ﾠ
dependent	 ﾠin	 ﾠthe	 ﾠorganisation	 ﾠof	 ﾠthe	 ﾠactin	 ﾠcytoskeleton	 ﾠ[451].	 ﾠThus,	 ﾠlocalising	 ﾠERK	 ﾠto	 ﾠ
distinct	 ﾠsubcellular	 ﾠcompartments	 ﾠis	 ﾠlikely	 ﾠto	 ﾠbe	 ﾠaltered	 ﾠby	 ﾠextracellular-ﾭ‐matrix	 ﾠadhesions	 ﾠ
and	 ﾠcontribute	 ﾠto	 ﾠisoform-ﾭ‐specific	 ﾠsignalling.	 ﾠUnfortunately,	 ﾠthere	 ﾠare	 ﾠcurrently	 ﾠno	 ﾠERK	 ﾠ
isoform-ﾭ‐specific	 ﾠantibodies,	 ﾠwhich	 ﾠwould	 ﾠallow	 ﾠcomparison	 ﾠof	 ﾠthe	 ﾠlocalisation	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠ
ERKs	 ﾠbetween	 ﾠ2D	 ﾠand	 ﾠ3D	 ﾠsubstrates.	 ﾠHowever,	 ﾠthe	 ﾠuse	 ﾠof	 ﾠphotoactivatable	 ﾠERK	 ﾠfusion	 ﾠ
proteins,	 ﾠwhich	 ﾠwould	 ﾠallow	 ﾠthe	 ﾠmonitoring	 ﾠof	 ﾠisoform-ﾭ‐specific	 ﾠtrafficking	 ﾠand	 ﾠ
localisation,	 ﾠmight	 ﾠprovide	 ﾠa	 ﾠbetter	 ﾠunderstanding	 ﾠof	 ﾠhow	 ﾠERK	 ﾠlocalisation	 ﾠis	 ﾠregulated	 ﾠin	 ﾠ
2D	 ﾠand	 ﾠ3D	 ﾠmicroenvironments.	 ﾠ
4.3.5  Correlation between mRNA abundance and protein levels 
Unfortunately,	 ﾠwe	 ﾠwere	 ﾠnot	 ﾠable	 ﾠto	 ﾠconfirm	 ﾠthat	 ﾠthe	 ﾠmeasured	 ﾠchanges	 ﾠin	 ﾠRab17	 ﾠand	 ﾠ
Liprin-ﾭ‐β2	 ﾠtranscript	 ﾠlevels	 ﾠwere	 ﾠreflected	 ﾠin	 ﾠtheir	 ﾠprotein	 ﾠlevels,	 ﾠbecause	 ﾠthe	 ﾠcommercially	 ﾠ
available	 ﾠantibodies	 ﾠwere	 ﾠnot	 ﾠcapable	 ﾠof	 ﾠspecifically	 ﾠrecognising	 ﾠthe	 ﾠendogenous	 ﾠprotein	 ﾠ
(data	 ﾠnot	 ﾠshown).	 ﾠMoreover,	 ﾠwe	 ﾠattempted	 ﾠto	 ﾠraise	 ﾠa	 ﾠRab17	 ﾠantibody	 ﾠby	 ﾠinjecting	 ﾠ
purified	 ﾠRab17	 ﾠinto	 ﾠrabbits.	 ﾠHowever,	 ﾠthe	 ﾠresulting	 ﾠantiserum,	 ﾠalthough	 ﾠable	 ﾠto	 ﾠ
distinguish	 ﾠpurified	 ﾠRab17	 ﾠfrom	 ﾠclosely	 ﾠrelated	 ﾠRab20	 ﾠand	 ﾠRab24,	 ﾠwas	 ﾠinsufficiently	 ﾠ
sensitive	 ﾠto	 ﾠspecifically	 ﾠdetect	 ﾠendogenous	 ﾠRab17	 ﾠin	 ﾠcell	 ﾠlysates.	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4.3.6  Other potentially interesting microarray hits 
Due	 ﾠto	 ﾠour	 ﾠprimary	 ﾠinterest	 ﾠin	 ﾠreceptor	 ﾠtrafficking	 ﾠand	 ﾠits	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠtumour	 ﾠcell	 ﾠ
migration,	 ﾠwe	 ﾠchose	 ﾠto	 ﾠfocus	 ﾠour	 ﾠvalidation	 ﾠstudies	 ﾠon	 ﾠtargets	 ﾠwhich	 ﾠhave	 ﾠbeen	 ﾠ
implicated	 ﾠin	 ﾠreceptor	 ﾠtrafficking	 ﾠor	 ﾠintegrin	 ﾠbiology,	 ﾠi.e.	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠ[463,	 ﾠ464].	 ﾠ
However,	 ﾠother	 ﾠcandidate	 ﾠgenes,	 ﾠwhich	 ﾠare	 ﾠup-ﾭ‐	 ﾠor	 ﾠdown-ﾭ‐regulated	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐dependent	 ﾠ
manner,	 ﾠmay	 ﾠalso	 ﾠcontribute	 ﾠto	 ﾠthe	 ﾠinvasive	 ﾠphenotype	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠand	 ﾠmay	 ﾠ
therefore	 ﾠbe	 ﾠdiscussed	 ﾠbriefly	 ﾠin	 ﾠthe	 ﾠfollowing	 ﾠparagraphs.	 ﾠ	 ﾠ
One	 ﾠsuch	 ﾠgene	 ﾠencodes	 ﾠthe	 ﾠproteoglycan	 ﾠserglycin	 ﾠ(SRGN)	 ﾠand	 ﾠthis	 ﾠhas	 ﾠrecently	 ﾠbeen	 ﾠ
implicated	 ﾠas	 ﾠa	 ﾠdriver	 ﾠof	 ﾠmetastasis.	 ﾠSerglycin	 ﾠis	 ﾠone	 ﾠof	 ﾠthe	 ﾠmost	 ﾠup-ﾭ‐regulated	 ﾠgenes	 ﾠ
during	 ﾠthe	 ﾠinvasion-ﾭ‐metastasis	 ﾠcascade	 ﾠand	 ﾠits	 ﾠoverexpression	 ﾠcorrelates	 ﾠwith	 ﾠan	 ﾠ
enhanced	 ﾠmigratory	 ﾠphenotype	 ﾠ[480].	 ﾠGiven	 ﾠthat	 ﾠERK	 ﾠsignalling	 ﾠis	 ﾠgenerally	 ﾠaugmented	 ﾠ
during	 ﾠtumourigenesis	 ﾠand	 ﾠour	 ﾠdata	 ﾠidentified	 ﾠERK2	 ﾠas	 ﾠa	 ﾠdriver	 ﾠof	 ﾠsrgn	 ﾠtranscription,	 ﾠit	 ﾠis	 ﾠ
conceivable,	 ﾠthat	 ﾠboth	 ﾠproteins	 ﾠare	 ﾠfunctionally	 ﾠlinked	 ﾠto	 ﾠpromote	 ﾠmetastasis.	 ﾠ
Sulfiredoxin	 ﾠis	 ﾠanother	 ﾠinteresting	 ﾠmicroarray	 ﾠhit,	 ﾠwhich	 ﾠhas	 ﾠalready	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠthe	 ﾠ
ERK-ﾭ‐MAPK	 ﾠpathway	 ﾠas	 ﾠan	 ﾠAP-ﾭ‐1	 ﾠtarget	 ﾠgene	 ﾠby	 ﾠWei	 ﾠet	 ﾠal.	 ﾠand	 ﾠwas	 ﾠshown	 ﾠto	 ﾠbe	 ﾠrequired	 ﾠ
for	 ﾠcellular	 ﾠtransformation	 ﾠ[481].	 ﾠMoreover,	 ﾠsulfiredoxin	 ﾠhas	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠ
promoting	 ﾠlung	 ﾠcancer	 ﾠprogression	 ﾠby	 ﾠenhancing	 ﾠtumour	 ﾠcell	 ﾠmotility	 ﾠand	 ﾠcellular	 ﾠ
invasion,	 ﾠwhich	 ﾠmakes	 ﾠthis	 ﾠprotein	 ﾠan	 ﾠinteresting	 ﾠtarget	 ﾠfor	 ﾠanti-ﾭ‐cancer	 ﾠtreatment	 ﾠ
strategies	 ﾠ[482].	 ﾠOur	 ﾠmicroarray	 ﾠdata	 ﾠsuggests	 ﾠa	 ﾠtranscriptional	 ﾠregulation	 ﾠcomparable	 ﾠto	 ﾠ
CSF2,	 ﾠwhere	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠERK1	 ﾠor	 ﾠERK2	 ﾠresulted	 ﾠin	 ﾠa	 ﾠsignificant	 ﾠdecrease	 ﾠin	 ﾠ
sulfiredoxin	 ﾠmRNA	 ﾠlevels,	 ﾠwhich	 ﾠcould	 ﾠonly	 ﾠbe	 ﾠrestored	 ﾠto	 ﾠcontrol	 ﾠlevels	 ﾠwhen	 ﾠERK2	 ﾠwas	 ﾠ
re-ﾭ‐expressed.	 ﾠThus,	 ﾠour	 ﾠdata	 ﾠadds	 ﾠto	 ﾠthe	 ﾠcurrent	 ﾠliterature	 ﾠin	 ﾠthat	 ﾠit	 ﾠidentifies	 ﾠsulfiredoxin	 ﾠ
mRNA	 ﾠstability	 ﾠas	 ﾠa	 ﾠregulatory	 ﾠmechanism	 ﾠfor	 ﾠgene	 ﾠexpression,	 ﾠwhich	 ﾠmay	 ﾠbe	 ﾠexploited	 ﾠ
clinically.	 ﾠ
Another	 ﾠcandidate	 ﾠgene	 ﾠwith	 ﾠinteresting	 ﾠclinical	 ﾠimplications	 ﾠis	 ﾠthioredoxin-ﾭ‐interacting	 ﾠ
protein	 ﾠ(TXNIP),	 ﾠwhose	 ﾠexpression	 ﾠaccording	 ﾠto	 ﾠour	 ﾠmicroarray	 ﾠscreen	 ﾠwas	 ﾠincreased	 ﾠby	 ﾠ
ERK2	 ﾠknockdown.	 ﾠIntriguingly,	 ﾠTXNIP	 ﾠis	 ﾠfrequently	 ﾠdown-ﾭ‐regulated	 ﾠin	 ﾠERBB2-ﾭ‐positive	 ﾠ
breast	 ﾠcancer	 ﾠpatients,	 ﾠwhich	 ﾠcorrelates	 ﾠwith	 ﾠpoor	 ﾠsurvival	 ﾠ[483].	 ﾠMoreover,	 ﾠan	 ﾠinverse	 ﾠ
relationship	 ﾠbetween	 ﾠTXNIP	 ﾠexpression	 ﾠand	 ﾠcarcinogenesis	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠfor	 ﾠbladder	 ﾠ
and	 ﾠprostate	 ﾠcancer	 ﾠ[484,	 ﾠ485],	 ﾠindicating	 ﾠa	 ﾠtumour-ﾭ‐suppressive	 ﾠfunction	 ﾠfor	 ﾠthis	 ﾠgene.	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Mechanistically,	 ﾠTXNIP	 ﾠdiminishes	 ﾠERK	 ﾠactivation	 ﾠby	 ﾠattenuating	 ﾠCXCR4	 ﾠexpression	 ﾠin	 ﾠvitro	 ﾠ
and	 ﾠin	 ﾠvivo	 ﾠ[484].	 ﾠOur	 ﾠwork	 ﾠexpands	 ﾠthe	 ﾠcurrent	 ﾠknowledge	 ﾠby	 ﾠsuggesting	 ﾠan	 ﾠ
ERK-ﾭ‐dependent	 ﾠinhibition	 ﾠof	 ﾠtxnip	 ﾠexpression,	 ﾠwhich	 ﾠwarrants	 ﾠcontinuous	 ﾠsignalling	 ﾠ
through	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠand	 ﾠa	 ﾠpro-ﾭ‐invasive	 ﾠphenotype.	 ﾠ	 ﾠ
The	 ﾠtranscriptional	 ﾠregulation	 ﾠof	 ﾠthe	 ﾠselenium-ﾭ‐binding	 ﾠprotein	 ﾠ1	 ﾠ(SELENBP1)	 ﾠby	 ﾠthe	 ﾠ
ERK-ﾭ‐MAPK	 ﾠpathway	 ﾠrepresents	 ﾠanother	 ﾠinteresting	 ﾠobservation	 ﾠfrom	 ﾠour	 ﾠmicroarray	 ﾠ
screen.	 ﾠVarious	 ﾠresearch	 ﾠgroups	 ﾠhave	 ﾠproposed	 ﾠa	 ﾠtumour-ﾭ‐suppressive	 ﾠfunction	 ﾠfor	 ﾠthis	 ﾠ
protein,	 ﾠwhose	 ﾠexpression	 ﾠis	 ﾠfrequently	 ﾠreduced	 ﾠin	 ﾠvarious	 ﾠcancer	 ﾠtypes	 ﾠ[486-ﾭ‐488].	 ﾠ
Moreover,	 ﾠPohl	 ﾠet	 ﾠal.	 ﾠhave	 ﾠshown	 ﾠa	 ﾠclear	 ﾠinhibitory	 ﾠrole	 ﾠfor	 ﾠSELENBP1	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠ
migration	 ﾠand	 ﾠcarcinogenesis	 ﾠ[489].	 ﾠGiven	 ﾠthat	 ﾠthe	 ﾠhighly	 ﾠmotile	 ﾠphenotype	 ﾠof	 ﾠHCT116	 ﾠ
cells	 ﾠis	 ﾠdependent	 ﾠon	 ﾠERK	 ﾠsignalling	 ﾠ[490]	 ﾠand	 ﾠoverexpression	 ﾠof	 ﾠSELENBP1	 ﾠimpairs	 ﾠ
HCT116	 ﾠmotility	 ﾠin	 ﾠvitro,	 ﾠit	 ﾠis	 ﾠpossible	 ﾠthat	 ﾠERK2	 ﾠdrives	 ﾠinvasion	 ﾠby	 ﾠsuppressing	 ﾠa	 ﾠsubset	 ﾠof	 ﾠ
anti-ﾭ‐migratory	 ﾠgenes	 ﾠincluding	 ﾠSELENBP1,	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2.	 ﾠ
Taken	 ﾠtogether	 ﾠour	 ﾠmicroarray	 ﾠscreen	 ﾠidentified	 ﾠseveral	 ﾠinteresting	 ﾠgenes	 ﾠwhose	 ﾠ
expression	 ﾠwas	 ﾠregulated	 ﾠin	 ﾠan	 ﾠERK2-ﾭ‐dependent	 ﾠmanner.	 ﾠGiven	 ﾠthat	 ﾠsome	 ﾠof	 ﾠthese	 ﾠhave	 ﾠ
previously	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠdrive	 ﾠor	 ﾠsuppress	 ﾠtumourigenesis,	 ﾠit	 ﾠwould	 ﾠbe	 ﾠinteresting	 ﾠto	 ﾠ
determine	 ﾠtheir	 ﾠrole	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion	 ﾠin	 ﾠfuture	 ﾠexperiments.	 ﾠ
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5  Rab17 and Liprin-β2 are inhibitors of tumour cell 
migration and invasion 
5.1  Introduction 
In	 ﾠthe	 ﾠprevious	 ﾠchapter	 ﾠwe	 ﾠhave	 ﾠidentified	 ﾠRas-ﾭ‐related	 ﾠprotein	 ﾠ17	 ﾠ(Rab17)	 ﾠand	 ﾠ
LAR-ﾭ‐interacting	 ﾠprotein-ﾭ‐β2	 ﾠ(Liprin-ﾭ‐β2)	 ﾠas	 ﾠgenes,	 ﾠwhose	 ﾠexpression	 ﾠis	 ﾠsuppressed	 ﾠby	 ﾠERK2	 ﾠ
in	 ﾠ3D	 ﾠmicroenvironments.	 ﾠGiven	 ﾠthat	 ﾠboth	 ﾠgenes	 ﾠhave	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠthe	 ﾠregulation	 ﾠ
of	 ﾠvesicular	 ﾠtransport	 ﾠand	 ﾠour	 ﾠprimary	 ﾠresearch	 ﾠinterest	 ﾠlies	 ﾠin	 ﾠreceptor	 ﾠtrafficking	 ﾠand	 ﾠcell	 ﾠ
migration,	 ﾠwe	 ﾠchose	 ﾠto	 ﾠinvestigate	 ﾠa	 ﾠpotential	 ﾠrole	 ﾠfor	 ﾠthese	 ﾠtwo	 ﾠmicroarray	 ﾠhits	 ﾠin	 ﾠ
tumour	 ﾠcell	 ﾠmotility.	 ﾠ
5.1.1  Rab17 - a member of the RAB family of GTPases 
Rab17	 ﾠbelongs	 ﾠto	 ﾠthe	 ﾠRAS-ﾭ‐superfamily	 ﾠof	 ﾠGTPases,	 ﾠwhich	 ﾠcomprises	 ﾠover	 ﾠ170	 ﾠmembers	 ﾠ
including	 ﾠoncogenic	 ﾠH-ﾭ‐Ras,	 ﾠN-ﾭ‐Ras	 ﾠand	 ﾠK-ﾭ‐Ras.	 ﾠMost	 ﾠfamily	 ﾠmembers	 ﾠshare	 ﾠthe	 ﾠcommon	 ﾠ
feature	 ﾠof	 ﾠharbouring	 ﾠan	 ﾠintrinsic	 ﾠhydrolase	 ﾠactivity,	 ﾠwhich	 ﾠconverts	 ﾠGTP	 ﾠ(guanosine	 ﾠ
triphosphate)	 ﾠto	 ﾠGDP	 ﾠ(guanosine	 ﾠdiphosphate).	 ﾠThus,	 ﾠGTPases	 ﾠrepresent	 ﾠmolecular	 ﾠ
switches,	 ﾠwhich	 ﾠcycle	 ﾠbetween	 ﾠan	 ﾠinactive,	 ﾠGDP-ﾭ‐bound	 ﾠand	 ﾠan	 ﾠactive,	 ﾠGTP-ﾭ‐bound	 ﾠ
state	 ﾠ[491].	 ﾠTwo	 ﾠgroups	 ﾠof	 ﾠregulatory	 ﾠproteins,	 ﾠi.e.	 ﾠguanine	 ﾠnucleotide	 ﾠexchange	 ﾠfactors	 ﾠ
(GEFs)	 ﾠand	 ﾠGTPase	 ﾠactivating	 ﾠproteins	 ﾠ(GAPs),	 ﾠact	 ﾠto	 ﾠinfluence	 ﾠthe	 ﾠGTP-ﾭ‐loading	 ﾠof	 ﾠ
GTPases.	 ﾠGEFs	 ﾠpromote	 ﾠGDP	 ﾠdissociation	 ﾠand	 ﾠsubsequent	 ﾠGTP	 ﾠbinding	 ﾠto	 ﾠactivate	 ﾠthe	 ﾠ
GTPases;	 ﾠwhich	 ﾠunmasks	 ﾠprotein	 ﾠinteraction	 ﾠdomains;	 ﾠwhile	 ﾠGAPs	 ﾠenhance	 ﾠthe	 ﾠintrinsic	 ﾠ
hydrolase	 ﾠactivity	 ﾠto	 ﾠaccelerate	 ﾠthe	 ﾠformation	 ﾠof	 ﾠan	 ﾠinactive,	 ﾠGDP-ﾭ‐bound	 ﾠstate.	 ﾠMoreover,	 ﾠ
GDP-ﾭ‐dissociation	 ﾠinhibitors	 ﾠ(GDIs)	 ﾠprevent	 ﾠGTPase	 ﾠactivation	 ﾠby	 ﾠlocking	 ﾠthe	 ﾠenzyme	 ﾠin	 ﾠan	 ﾠ
inactive	 ﾠconformation	 ﾠ[491].	 ﾠ
Rab	 ﾠproteins	 ﾠare	 ﾠperipheral	 ﾠmembrane	 ﾠproteins,	 ﾠwhich	 ﾠare	 ﾠanchored	 ﾠto	 ﾠdestination	 ﾠ
membranes	 ﾠvia	 ﾠa	 ﾠcovalently	 ﾠlinked	 ﾠprenyl	 ﾠgroup	 ﾠat	 ﾠtheir	 ﾠC-ﾭ‐terminus.	 ﾠRab	 ﾠescort	 ﾠproteins	 ﾠ
(REPs)	 ﾠaccompany	 ﾠnewly	 ﾠsynthesised	 ﾠGTPases	 ﾠthrough	 ﾠthe	 ﾠcytoplasm	 ﾠby	 ﾠbinding	 ﾠto	 ﾠand	 ﾠ
shielding	 ﾠthe	 ﾠhydrophobic	 ﾠprenyl	 ﾠgroup.	 ﾠOnce	 ﾠRab	 ﾠproteins	 ﾠreach	 ﾠthe	 ﾠdestination	 ﾠ
membrane,	 ﾠthey	 ﾠinsert	 ﾠinto	 ﾠit	 ﾠusing	 ﾠtheir	 ﾠprenyl	 ﾠgroup.	 ﾠNotably,	 ﾠREPs	 ﾠonly	 ﾠcarry	 ﾠinactive	 ﾠ
GDP-ﾭ‐bound	 ﾠRabs.	 ﾠThus,	 ﾠthe	 ﾠGTPases	 ﾠrequire	 ﾠactivation	 ﾠfollowing	 ﾠmembrane	 ﾠinsertion	 ﾠin	 ﾠ
order	 ﾠfor	 ﾠthem	 ﾠto	 ﾠbind	 ﾠto	 ﾠRab	 ﾠeffector	 ﾠproteins,	 ﾠthrough	 ﾠwhich	 ﾠthe	 ﾠGTPases	 ﾠfunction.	 ﾠ
Following	 ﾠmembrane	 ﾠfusion,	 ﾠRab	 ﾠproteins	 ﾠare	 ﾠrecycled	 ﾠthrough	 ﾠGDIs,	 ﾠwhich	 ﾠlike	 ﾠREPs	 ﾠbind	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to	 ﾠthe	 ﾠprenyl	 ﾠgroup	 ﾠof	 ﾠinactive	 ﾠGTPases	 ﾠand	 ﾠdeliver	 ﾠRabs	 ﾠto	 ﾠtheir	 ﾠdestination	 ﾠ
membrane	 ﾠ[492].	 ﾠ
The	 ﾠRAS-ﾭ‐superfamily	 ﾠof	 ﾠGTPases	 ﾠcan	 ﾠbe	 ﾠsubdivided	 ﾠinto	 ﾠfive	 ﾠsubfamilies;	 ﾠi.e.	 ﾠthe	 ﾠRAS	 ﾠ
family	 ﾠ(due	 ﾠto	 ﾠtheir	 ﾠhomology	 ﾠwith	 ﾠthe	 ﾠrat	 ﾠsarcoma	 ﾠgenes),	 ﾠthe	 ﾠRHO	 ﾠfamily	 ﾠ(Ras	 ﾠ
homologs),	 ﾠthe	 ﾠRAB	 ﾠfamily	 ﾠ(Ras-ﾭ‐related	 ﾠproteins),	 ﾠthe	 ﾠARF	 ﾠfamily	 ﾠ(ADP	 ﾠribosylation	 ﾠ
factors)	 ﾠand	 ﾠthe	 ﾠRAN	 ﾠfamily	 ﾠ(Ras-ﾭ‐related	 ﾠnuclear	 ﾠproteins)	 ﾠ[491].	 ﾠThe	 ﾠRAB	 ﾠfamily	 ﾠ
represents	 ﾠthe	 ﾠlargest	 ﾠof	 ﾠthe	 ﾠfive	 ﾠsubclasses	 ﾠwith	 ﾠover	 ﾠ70	 ﾠmembers	 ﾠand	 ﾠit	 ﾠcontrols	 ﾠ
multiple	 ﾠstages	 ﾠof	 ﾠvesicular	 ﾠtransport,	 ﾠsuch	 ﾠas	 ﾠvesicle	 ﾠformation,	 ﾠmovement	 ﾠand	 ﾠ
fusion	 ﾠ[493].	 ﾠAlthough	 ﾠendocytic	 ﾠvesicles	 ﾠare	 ﾠthought	 ﾠof	 ﾠas	 ﾠhighly	 ﾠplastic	 ﾠstructures,	 ﾠthere	 ﾠ
is	 ﾠevidence	 ﾠthat	 ﾠfunctionally	 ﾠdistinct	 ﾠcompartments	 ﾠexist,	 ﾠand	 ﾠthat	 ﾠthese	 ﾠcan	 ﾠbe	 ﾠ
characterised	 ﾠby	 ﾠspecific	 ﾠRabs.	 ﾠFor	 ﾠexample,	 ﾠRab4	 ﾠand	 ﾠRab5	 ﾠare	 ﾠknown	 ﾠto	 ﾠassociate	 ﾠwith	 ﾠ
early	 ﾠendosomes	 ﾠ[494,	 ﾠ495],	 ﾠwhile	 ﾠRab11	 ﾠserves	 ﾠas	 ﾠa	 ﾠmarker	 ﾠfor	 ﾠrecycling	 ﾠ
endosomes	 ﾠ[496].	 ﾠMoreover,	 ﾠRab7	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠlocalise	 ﾠto	 ﾠlate	 ﾠendosomes	 ﾠ[495].	 ﾠ
Rab17	 ﾠwas	 ﾠidentified	 ﾠas	 ﾠa	 ﾠcell	 ﾠtype-ﾭ‐specific	 ﾠGTPase,	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠthought	 ﾠto	 ﾠbe	 ﾠ
restricted	 ﾠto	 ﾠepithelial	 ﾠcells.	 ﾠNorthern	 ﾠblot	 ﾠanalysis	 ﾠof	 ﾠvarious	 ﾠtissues	 ﾠdemonstrated	 ﾠRab17	 ﾠ
transcripts	 ﾠto	 ﾠbe	 ﾠpresent	 ﾠin	 ﾠkidney,	 ﾠliver	 ﾠand	 ﾠintestine,	 ﾠbut	 ﾠnot	 ﾠin	 ﾠorgans	 ﾠlacking	 ﾠepithelial	 ﾠ
cells	 ﾠ[497].	 ﾠInterestingly,	 ﾠmesenchymal	 ﾠkidney	 ﾠprecursor	 ﾠcells	 ﾠdo	 ﾠnot	 ﾠexpress	 ﾠRab17,	 ﾠyet	 ﾠ
its	 ﾠexpression	 ﾠis	 ﾠinduced	 ﾠduring	 ﾠdifferentiation	 ﾠinto	 ﾠepithelial	 ﾠcells,	 ﾠsuggesting	 ﾠa	 ﾠrole	 ﾠfor	 ﾠ
this	 ﾠGTPase	 ﾠin	 ﾠestablishing	 ﾠand	 ﾠmaintaining	 ﾠepithelial	 ﾠcharacteristics.	 ﾠIn	 ﾠpolarised	 ﾠcells	 ﾠ
with	 ﾠdistinct	 ﾠbasolateral	 ﾠand	 ﾠapical	 ﾠsurfaces,	 ﾠsuch	 ﾠas	 ﾠMadin-ﾭ‐Darby	 ﾠCanine	 ﾠKidney	 ﾠ(MDCK)	 ﾠ
cells,	 ﾠectopically	 ﾠexpressed	 ﾠRab17	 ﾠis	 ﾠlocalised	 ﾠto	 ﾠboth	 ﾠbasolateral	 ﾠand	 ﾠapical	 ﾠstructures,	 ﾠ
which	 ﾠsuggests	 ﾠa	 ﾠrole	 ﾠfor	 ﾠthis	 ﾠprotein	 ﾠin	 ﾠcellular	 ﾠtranscytosis	 ﾠ[497].	 ﾠIndeed,	 ﾠsubsequent	 ﾠ
work	 ﾠshowed	 ﾠthat	 ﾠoverexpression	 ﾠof	 ﾠmutant	 ﾠforms	 ﾠof	 ﾠRab17	 ﾠ(defective	 ﾠin	 ﾠGTP-ﾭ‐binding	 ﾠor	 ﾠ
hydrolysis)	 ﾠresulted	 ﾠin	 ﾠan	 ﾠincrease	 ﾠin	 ﾠtransferrin	 ﾠreceptor	 ﾠtranscytosis	 ﾠin	 ﾠpolarised	 ﾠEph4	 ﾠ
cells	 ﾠ[462].	 ﾠThis	 ﾠfinding	 ﾠwas	 ﾠfurther	 ﾠsupported	 ﾠby	 ﾠHunziker	 ﾠet	 ﾠal.	 ﾠwho	 ﾠshowed	 ﾠthat	 ﾠectopic	 ﾠ
overexpression	 ﾠof	 ﾠwild	 ﾠtype	 ﾠRab17	 ﾠimpaired	 ﾠtranscytosis	 ﾠof	 ﾠdimeric	 ﾠimmunoglobulin	 ﾠA	 ﾠin	 ﾠ
MDCK	 ﾠcells	 ﾠ[498].	 ﾠMoreover,	 ﾠinactive	 ﾠGDP-ﾭ‐loaded	 ﾠRab17	 ﾠmutants	 ﾠwere	 ﾠshown	 ﾠto	 ﾠ
stimulate	 ﾠreceptor	 ﾠrecycling	 ﾠfrom	 ﾠapical	 ﾠendosomes	 ﾠto	 ﾠthe	 ﾠapical	 ﾠsurface	 ﾠ[462].	 ﾠThus,	 ﾠthe	 ﾠ
current	 ﾠevidence	 ﾠsuggests	 ﾠan	 ﾠinhibitory	 ﾠrole	 ﾠof	 ﾠRab17	 ﾠon	 ﾠtranscellular	 ﾠtransport	 ﾠof	 ﾠ
proteins	 ﾠand	 ﾠlipids	 ﾠas	 ﾠwell	 ﾠas	 ﾠreceptor	 ﾠrecycling.	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Phylogenetically,	 ﾠRab17	 ﾠbelongs	 ﾠto	 ﾠthe	 ﾠRab5	 ﾠsubfamily	 ﾠand	 ﾠshares	 ﾠan	 ﾠoverall	 ﾠsequence	 ﾠ
identity	 ﾠof	 ﾠapproximately	 ﾠ40%	 ﾠwith	 ﾠRab5,	 ﾠRab22,	 ﾠRab24	 ﾠand	 ﾠRab20	 ﾠ[497,	 ﾠ499].	 ﾠRab5	 ﾠis	 ﾠ
one	 ﾠof	 ﾠthe	 ﾠbest-ﾭ‐studied	 ﾠRab	 ﾠproteins,	 ﾠwhich	 ﾠmainly	 ﾠassociates	 ﾠwith	 ﾠearly	 ﾠendosomes	 ﾠ
when	 ﾠactivated.	 ﾠRab5’s	 ﾠfunction	 ﾠin	 ﾠvesicle	 ﾠtrafficking	 ﾠis	 ﾠlikely	 ﾠmultifarious,	 ﾠas	 ﾠthe	 ﾠGTPase	 ﾠ
is	 ﾠthought	 ﾠto	 ﾠbe	 ﾠinvolved	 ﾠin	 ﾠprocesses	 ﾠsuch	 ﾠas	 ﾠgenerating	 ﾠendocytic	 ﾠvesicles	 ﾠat	 ﾠthe	 ﾠplasma	 ﾠ
membrane,	 ﾠregulating	 ﾠmembrane	 ﾠfusion	 ﾠevents	 ﾠand	 ﾠcontrolling	 ﾠvesicle	 ﾠtransport	 ﾠby	 ﾠ
recruiting	 ﾠmicrotubule	 ﾠmotor	 ﾠproteins	 ﾠ[500].	 ﾠLike	 ﾠRab5,	 ﾠRab22	 ﾠassociates	 ﾠwith	 ﾠearly	 ﾠ
endosomes.	 ﾠIntriguingly,	 ﾠits	 ﾠectopic	 ﾠexpression	 ﾠresults	 ﾠin	 ﾠan	 ﾠenlargement	 ﾠof	 ﾠendocytic	 ﾠ
vesicles	 ﾠin	 ﾠthe	 ﾠperinuclear	 ﾠcompartment	 ﾠand	 ﾠa	 ﾠdecrease	 ﾠin	 ﾠendocytosis	 ﾠas	 ﾠmeasured	 ﾠby	 ﾠ
fluid	 ﾠphase	 ﾠmarkers	 ﾠ[501].	 ﾠIn	 ﾠcontrast,	 ﾠRab24	 ﾠis	 ﾠan	 ﾠunusual	 ﾠGTPase	 ﾠin	 ﾠthat	 ﾠits	 ﾠGTPase	 ﾠ
activity	 ﾠis	 ﾠimpaired	 ﾠdue	 ﾠto	 ﾠa	 ﾠserine	 ﾠin	 ﾠcodon	 ﾠ61	 ﾠrather	 ﾠthan	 ﾠa	 ﾠglutamine.	 ﾠBecause	 ﾠthe	 ﾠ
enzyme	 ﾠprimarily	 ﾠexists	 ﾠin	 ﾠa	 ﾠswitched-ﾭ‐on	 ﾠstate,	 ﾠRab24	 ﾠdoes	 ﾠnot	 ﾠassociate	 ﾠwith	 ﾠGDIs	 ﾠand	 ﾠ
may	 ﾠemploy	 ﾠnovel	 ﾠmechanisms	 ﾠin	 ﾠregulating	 ﾠvesicular	 ﾠtrafficking	 ﾠ[502].	 ﾠRab20	 ﾠis	 ﾠalso	 ﾠan	 ﾠ
unusual	 ﾠin	 ﾠthat	 ﾠit	 ﾠcontains	 ﾠa	 ﾠ40	 ﾠamino	 ﾠacid	 ﾠinsertion	 ﾠof	 ﾠunknown	 ﾠfunction	 ﾠand	 ﾠan	 ﾠatypical	 ﾠ
codon	 ﾠ61	 ﾠ[503].	 ﾠ
Several	 ﾠputative	 ﾠinteraction	 ﾠpartners	 ﾠfor	 ﾠRab17	 ﾠhave	 ﾠbeen	 ﾠidentified	 ﾠthrough	 ﾠyeast	 ﾠ
two-ﾭ‐hybrid	 ﾠand	 ﾠlarge	 ﾠscale	 ﾠproteomic	 ﾠscreens	 ﾠ(Table	 ﾠ5-ﾭ‐1),	 ﾠyet	 ﾠnone	 ﾠof	 ﾠthese	 ﾠhave	 ﾠbeen	 ﾠ
validated	 ﾠby	 ﾠco-ﾭ‐immunoprecipitation	 ﾠor	 ﾠco-ﾭ‐localisation	 ﾠexperiments.	 ﾠInterestingly,	 ﾠthree	 ﾠ
of	 ﾠthe	 ﾠproposed	 ﾠbinding	 ﾠpartners	 ﾠ(Rab7A,	 ﾠChmp6,	 ﾠand	 ﾠSmurf2)	 ﾠare	 ﾠinvolved	 ﾠin	 ﾠreceptor	 ﾠ
degradation.	 ﾠThus,	 ﾠit	 ﾠis	 ﾠlikely	 ﾠthat	 ﾠRab17	 ﾠmay	 ﾠplay	 ﾠa	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠthe	 ﾠdegradative	 ﾠ
pathway	 ﾠas	 ﾠwell	 ﾠas	 ﾠmodulating	 ﾠreceptor	 ﾠinternalisation	 ﾠand	 ﾠrecycling.	 ﾠTo	 ﾠadd	 ﾠto	 ﾠthis,	 ﾠ
Rab17	 ﾠhas	 ﾠbeen	 ﾠidentified	 ﾠas	 ﾠa	 ﾠregulator	 ﾠof	 ﾠcilium	 ﾠformation,	 ﾠas	 ﾠoverexpression	 ﾠof	 ﾠthe	 ﾠ
Rab17-ﾭ‐specific	 ﾠGAP,	 ﾠTBC1D7,	 ﾠimpaired	 ﾠcilium	 ﾠdevelopment	 ﾠ[504].	 ﾠ
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Gene ID  Gene name  Gene function  Ref. 
TBC1D7  TBC1 domain family 
member 7 
GTPase activating protein  [504] 
RAB7A  Ras-related protein 7A  Late endosomal marker  [505] 
NUDT3  Nudix type motif 3  Implicated in nucleoside 
phosphate metabolic pathways 
[506] 
CHMP6  Chromatin modifying protein 
6 
Involved in surface receptor 
degradation and the formation of 
endocytic multivesicular bodies 
[507] 
SMURF2  SMAD-specific E3 ubiquitin 
ligase 2 
Involved in protein degradation  [508] 
S100A8  S100 calcium binding protein 
A8 
Versatile functions: implicated in 
differentiation and cell cycle 
progression amongst others 
[506] 
RABAC1  Rab acceptor protein 1  GDI displacement factor  [505] 
ACVR1  Activin A receptor type 1  belong to the TGFβ superfamily  [508] 
Table 5-1 Overview of known and putative Rab17 interaction partners as determined by high-
throughput experiments 
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5.1.2  Liprins – a family of LAR-interacting proteins 
Liprin-ﾭ‐β2	 ﾠbelongs	 ﾠto	 ﾠthe	 ﾠfamily	 ﾠof	 ﾠLAR	 ﾠ(leukocyte	 ﾠcommon	 ﾠantigen-ﾭ‐related)-ﾭ‐interacting	 ﾠ
proteins,	 ﾠwhich	 ﾠconstitutes	 ﾠa	 ﾠclass	 ﾠof	 ﾠcytoplasmic	 ﾠadaptor	 ﾠproteins	 ﾠinvolved	 ﾠin	 ﾠneuronal	 ﾠ
and	 ﾠnon-ﾭ‐neuronal	 ﾠprocesses.	 ﾠIn	 ﾠhumans	 ﾠthere	 ﾠare	 ﾠsix	 ﾠliprin	 ﾠgenes,	 ﾠwhich	 ﾠare	 ﾠsubdivided	 ﾠ
into	 ﾠtwo	 ﾠclasses	 ﾠbased	 ﾠon	 ﾠsequence	 ﾠsimilarities	 ﾠand	 ﾠbinding	 ﾠcharacteristics,	 ﾠi.e.	 ﾠα-ﾭ‐type	 ﾠ
(Liprin-ﾭ‐α1	 ﾠto	 ﾠα4)	 ﾠand	 ﾠβ-ﾭ‐type	 ﾠ(Liprin-ﾭ‐β1	 ﾠand	 ﾠ-ﾭ‐β2)	 ﾠ[464].	 ﾠMembers	 ﾠof	 ﾠthe	 ﾠLiprin	 ﾠfamily	 ﾠ
demonstrate	 ﾠa	 ﾠhigh	 ﾠdegree	 ﾠof	 ﾠsequence	 ﾠconservation	 ﾠover	 ﾠa	 ﾠ250	 ﾠamino	 ﾠacid	 ﾠregion	 ﾠin	 ﾠ
their	 ﾠC-ﾭ‐termini.	 ﾠThis	 ﾠregion,	 ﾠdesignated	 ﾠthe	 ﾠLiprin	 ﾠhomology	 ﾠdomain,	 ﾠis	 ﾠunique	 ﾠto	 ﾠthis	 ﾠ
protein	 ﾠfamily	 ﾠand	 ﾠthought	 ﾠto	 ﾠplay	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠtheir	 ﾠfunction	 ﾠby	 ﾠmediating	 ﾠ
protein-ﾭ‐protein	 ﾠinteractions	 ﾠ[464,	 ﾠ509].	 ﾠAlthough	 ﾠthe	 ﾠnomenclature	 ﾠsuggests	 ﾠotherwise,	 ﾠ
only	 ﾠLiprin-ﾭ‐α	 ﾠproteins	 ﾠcan	 ﾠinteract	 ﾠwith	 ﾠLAR	 ﾠproteins	 ﾠ(a	 ﾠfamily	 ﾠof	 ﾠtransmembrane	 ﾠprotein	 ﾠ
tyrosine	 ﾠphosphatases)	 ﾠvia	 ﾠtheir	 ﾠC-ﾭ‐terminal	 ﾠdomain,	 ﾠindicating	 ﾠthat	 ﾠthe	 ﾠbiological	 ﾠ
functions	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠsubclasses	 ﾠmay	 ﾠbe	 ﾠdifferent	 ﾠ[464].	 ﾠRecently,	 ﾠKazrin,	 ﾠknown	 ﾠfor	 ﾠits	 ﾠ
role	 ﾠin	 ﾠdesmosome	 ﾠassembly,	 ﾠwas	 ﾠidentified	 ﾠas	 ﾠa	 ﾠnovel	 ﾠmember	 ﾠof	 ﾠthe	 ﾠLiprin	 ﾠfamily	 ﾠ[510].	 ﾠ
All	 ﾠfamily	 ﾠmembers	 ﾠshare	 ﾠthe	 ﾠsame	 ﾠoverall	 ﾠstructure	 ﾠwith	 ﾠan	 ﾠN-ﾭ‐terminal	 ﾠcoiled-ﾭ‐coil	 ﾠ
domain	 ﾠand	 ﾠa	 ﾠdistinct	 ﾠC-ﾭ‐terminus	 ﾠcomprising	 ﾠthree	 ﾠconsecutive	 ﾠSAM	 ﾠ(steryl	 ﾠalpha	 ﾠmotif)	 ﾠ
domains	 ﾠ(Figure	 ﾠ5-ﾭ‐1	 ﾠA).	 ﾠCo-ﾭ‐immunoprecipitation	 ﾠexperiments	 ﾠhave	 ﾠdemonstrated	 ﾠthat	 ﾠ
Liprins	 ﾠhomodimerise	 ﾠvia	 ﾠtheir	 ﾠN-ﾭ‐terminal	 ﾠcoiled-ﾭ‐coil	 ﾠdomain	 ﾠand	 ﾠheterodimerise	 ﾠvia	 ﾠthe	 ﾠ
C-ﾭ‐terminal	 ﾠregion	 ﾠ[464,	 ﾠ509].	 ﾠNotably,	 ﾠheterodimerisation	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠLiprin	 ﾠsubclasses	 ﾠis	 ﾠ
still	 ﾠcontroversial,	 ﾠas	 ﾠsubsequent	 ﾠwork	 ﾠfailed	 ﾠto	 ﾠisolate	 ﾠLiprin-ﾭ‐α/Liprin-ﾭ‐β	 ﾠcomplexes	 ﾠin	 ﾠ
co-ﾭ‐immunoprecipitation	 ﾠexperiments.	 ﾠHowever,	 ﾠdirect	 ﾠinteraction	 ﾠbetween	 ﾠα-ﾭ‐	 ﾠand	 ﾠ
β-ﾭ‐Liprins	 ﾠwas	 ﾠrecently	 ﾠdemonstrated	 ﾠin	 ﾠco-ﾭ‐crystallisation	 ﾠexperiments	 ﾠby	 ﾠWei	 ﾠet	 ﾠal.,	 ﾠ
arguing	 ﾠfor	 ﾠthe	 ﾠexistence	 ﾠof	 ﾠheterodimers	 ﾠ[511].	 ﾠInterestingly,	 ﾠthe	 ﾠcentral	 ﾠcoiled	 ﾠcoil	 ﾠ
domains	 ﾠof	 ﾠLiprin-ﾭ‐βs	 ﾠform	 ﾠparallel	 ﾠhomodimers	 ﾠand	 ﾠare	 ﾠpredicted	 ﾠto	 ﾠbring	 ﾠall	 ﾠsix	 ﾠSAM	 ﾠ
domains	 ﾠin	 ﾠclose	 ﾠproximity	 ﾠ[512].	 ﾠThus,	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠregions	 ﾠintertwine	 ﾠto	 ﾠform	 ﾠrod-ﾭ‐like	 ﾠ
structures,	 ﾠwhich	 ﾠmay	 ﾠbe	 ﾠorganized	 ﾠinto	 ﾠmore	 ﾠcomplex	 ﾠmolecular	 ﾠnetworks	 ﾠas	 ﾠreported	 ﾠ
for	 ﾠother	 ﾠcoiled-ﾭ‐coil	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠmyosin	 ﾠII	 ﾠheavy	 ﾠchains	 ﾠor	 ﾠintermediate	 ﾠ
filaments	 ﾠ[513,	 ﾠ514].	 ﾠIn	 ﾠaddition,	 ﾠrecent	 ﾠcomputational	 ﾠanalysis	 ﾠidentified	 ﾠLiprin-ﾭ‐β’s	 ﾠ
second	 ﾠSAM	 ﾠdomain	 ﾠas	 ﾠa	 ﾠpotential	 ﾠpolymer	 ﾠforming	 ﾠmodule	 ﾠ[515].	 ﾠThus,	 ﾠ
heterodimerisation	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠLiprin	 ﾠsubclasses	 ﾠis	 ﾠbelieved	 ﾠto	 ﾠgive	 ﾠrise	 ﾠto	 ﾠeither	 ﾠclosed	 ﾠor	 ﾠ
open	 ﾠscaffolds,	 ﾠwhich	 ﾠare	 ﾠthought	 ﾠto	 ﾠregulate	 ﾠthe	 ﾠcytomatrix	 ﾠorganisation	 ﾠof	 ﾠneuronal	 ﾠ
and	 ﾠnon-ﾭ‐neuronal	 ﾠcells	 ﾠ(Figure	 ﾠ5-ﾭ‐1	 ﾠB)	 ﾠ[512].	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Studies	 ﾠon	 ﾠLiprins	 ﾠso	 ﾠfar	 ﾠhave	 ﾠfocused	 ﾠon	 ﾠthe	 ﾠfunction	 ﾠof	 ﾠLiprin-ﾭ‐α1	 ﾠin	 ﾠneuronal	 ﾠand	 ﾠ
non-ﾭ‐neuronal	 ﾠcells.	 ﾠIn	 ﾠneurons,	 ﾠLiprin-ﾭ‐α	 ﾠproteins	 ﾠplay	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠorganizing	 ﾠthe	 ﾠ
pre-ﾭ‐synaptic	 ﾠsite	 ﾠfor	 ﾠrapid	 ﾠneurotransmitter	 ﾠrelease	 ﾠby	 ﾠlocalizing	 ﾠLAR	 ﾠproteins	 ﾠto	 ﾠthe	 ﾠ
active	 ﾠzone	 ﾠ[516].	 ﾠFurthermore,	 ﾠLiprin-ﾭ‐α	 ﾠand	 ﾠLAR	 ﾠproteins	 ﾠare	 ﾠexpressed	 ﾠin	 ﾠpost-ﾭ‐synaptic	 ﾠ
sites,	 ﾠwhere	 ﾠthey	 ﾠregulate	 ﾠdendrite	 ﾠdevelopment	 ﾠ[517].	 ﾠNon-ﾭ‐neuronal	 ﾠfunctions	 ﾠare	 ﾠless	 ﾠ
studied,	 ﾠbut	 ﾠthere	 ﾠis	 ﾠsome	 ﾠevidence	 ﾠfor	 ﾠa	 ﾠrole	 ﾠfor	 ﾠLiprin-ﾭ‐α1	 ﾠin	 ﾠcell	 ﾠmotility	 ﾠ[509,	 ﾠ518,	 ﾠ519].	 ﾠ
Liprin-ﾭ‐α1	 ﾠand	 ﾠLAR	 ﾠcolocalise	 ﾠto	 ﾠfocal	 ﾠadhesions	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠrear	 ﾠand	 ﾠmay	 ﾠfacilitate	 ﾠ
adhesion	 ﾠdisassembly,	 ﾠa	 ﾠprerequisite	 ﾠfor	 ﾠcell	 ﾠmigration	 ﾠ[509].	 ﾠMoreover,	 ﾠoverexpression	 ﾠ
of	 ﾠLiprin-ﾭ‐α1	 ﾠinduces	 ﾠcell	 ﾠspreading	 ﾠon	 ﾠfibronectin,	 ﾠwhile	 ﾠRNAi	 ﾠinhibits	 ﾠcell	 ﾠspreading	 ﾠand	 ﾠ
lamellipodia	 ﾠformation	 ﾠ[519].	 ﾠIntriguingly,	 ﾠLiprin-ﾭ‐α1	 ﾠwas	 ﾠshown	 ﾠto	 ﾠprevent	 ﾠinternalisation	 ﾠ
of	 ﾠinactive	 ﾠβ1	 ﾠintegrin	 ﾠfrom	 ﾠthe	 ﾠcell	 ﾠsurface,	 ﾠthereby	 ﾠincreasing	 ﾠthe	 ﾠamount	 ﾠof	 ﾠintegrin	 ﾠ
available	 ﾠfor	 ﾠECM	 ﾠbinding	 ﾠand	 ﾠactivation	 ﾠ[520].	 ﾠ
Liprin-ﾭ‐β1’s	 ﾠbiological	 ﾠfunctions	 ﾠare	 ﾠless	 ﾠwell	 ﾠcharacterised,	 ﾠalthough	 ﾠrecent	 ﾠevidence	 ﾠ
suggests	 ﾠa	 ﾠrole	 ﾠfor	 ﾠthis	 ﾠprotein	 ﾠin	 ﾠlymphatic	 ﾠvascular	 ﾠdevelopment	 ﾠ[521].	 ﾠMoreover,	 ﾠ
Liprin-ﾭ‐β1	 ﾠhas	 ﾠbeen	 ﾠidentified	 ﾠas	 ﾠa	 ﾠnovel	 ﾠbinding	 ﾠpartner	 ﾠfor	 ﾠthe	 ﾠmetastasis-ﾭ‐associated	 ﾠ
protein	 ﾠS100A4	 ﾠ(Mts1).	 ﾠThe	 ﾠbinding	 ﾠsite	 ﾠfor	 ﾠMts1	 ﾠresides	 ﾠwithin	 ﾠthe	 ﾠC-ﾭ‐terminal	 ﾠportion	 ﾠof	 ﾠ
Liprin-ﾭ‐β1,	 ﾠindicating	 ﾠthe	 ﾠpossibility	 ﾠthat	 ﾠMts1	 ﾠassociation	 ﾠmay	 ﾠinterfere	 ﾠwith	 ﾠ
Liprin-ﾭ‐α/Liprin-ﾭ‐β	 ﾠcomplex	 ﾠformation,	 ﾠthus	 ﾠreleasing	 ﾠLiprin-ﾭ‐α1	 ﾠfrom	 ﾠa	 ﾠheterodimeric	 ﾠ
complex	 ﾠto	 ﾠpromote	 ﾠLAR	 ﾠfunction	 ﾠat	 ﾠfocal	 ﾠadhesions	 ﾠ[522].	 ﾠ
Liprin-ﾭ‐βs	 ﾠhave	 ﾠbeen	 ﾠproposed	 ﾠto	 ﾠregulate	 ﾠLiprin-ﾭ‐αs	 ﾠby	 ﾠmasking	 ﾠthe	 ﾠC-ﾭ‐terminal	 ﾠ
protein-ﾭ‐protein	 ﾠinteraction	 ﾠdomain	 ﾠvia	 ﾠheterodimerisation.	 ﾠThus,	 ﾠLiprin-ﾭ‐βs	 ﾠmay	 ﾠindirectly	 ﾠ
affect	 ﾠthe	 ﾠbiological	 ﾠfunctions	 ﾠof	 ﾠthe	 ﾠα-ﾭ‐types,	 ﾠby	 ﾠsequestering	 ﾠthe	 ﾠadaptor	 ﾠmolecules.	 ﾠTo	 ﾠ
date,	 ﾠLiprin-ﾭ‐α1,	 ﾠ-ﾭ‐2	 ﾠand	 ﾠ-ﾭ‐3	 ﾠhave	 ﾠbeen	 ﾠidentified	 ﾠas	 ﾠLiprin-ﾭ‐β2	 ﾠinteraction	 ﾠpartners	 ﾠin	 ﾠyeast	 ﾠ
two-ﾭ‐hybrid	 ﾠexperiments	 ﾠ[464].	 ﾠFurthermore,	 ﾠlarge	 ﾠscale	 ﾠproteomic	 ﾠscreens	 ﾠhave	 ﾠ
identified	 ﾠPTPRC,	 ﾠTSG101,	 ﾠPRNP,	 ﾠDTNB	 ﾠand	 ﾠ14-ﾭ‐3-ﾭ‐3	 ﾠσ	 ﾠas	 ﾠputative	 ﾠLiprin-ﾭ‐β2	 ﾠbinding	 ﾠ
partners	 ﾠ(Table	 ﾠ5-ﾭ‐2),	 ﾠbut	 ﾠnone	 ﾠof	 ﾠthese	 ﾠhave	 ﾠbeen	 ﾠvalidated	 ﾠin	 ﾠco-ﾭ‐immunoprecipitation	 ﾠor	 ﾠ
pull-ﾭ‐down	 ﾠexperiments.	 ﾠHowever,	 ﾠthere	 ﾠis	 ﾠvery	 ﾠfew	 ﾠpublished	 ﾠstudies	 ﾠthat	 ﾠshine	 ﾠlight	 ﾠon	 ﾠ
the	 ﾠbiological	 ﾠfunctions	 ﾠof	 ﾠLiprin-ﾭ‐β2,	 ﾠand	 ﾠfuture	 ﾠwork	 ﾠwill	 ﾠhave	 ﾠto	 ﾠdetermine	 ﾠthe	 ﾠ
functional	 ﾠsimilarities	 ﾠand	 ﾠdisparities	 ﾠbetween	 ﾠthe	 ﾠβ-ﾭ‐type	 ﾠLiprins	 ﾠand	 ﾠtheir	 ﾠrole	 ﾠin	 ﾠ
regulating	 ﾠLiprin-ﾭ‐αs.	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Figure 5-1 Schematic illustration of Liprin domain organisation and proposed complex formation 
A. The diagram shows the relative sizes and domain composition of Liprin-αs (blue) and Liprin-βs (red) 
B. Speculative scaffold organisations are depicted consisting of Liprin-αs and Liprin-βs. Interactions of the 
three tandem SAM domains can be arranged to form a “closed dimer” or an open scaffold consisting of 
multiple Liprin molecules. 
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Gene ID  Gene name  Gene function  Ref. 
PPFIA1  Liprin-α1 
Proposed scaffolding function for 
the recruitment and anchoring of 
LAR protein tyrosine phosphatases 
[464]  PPFIA2  Liprin-α2 
PPFIA3  Liprin-α3 
PTPRC  Protein tyrosine phosphatase 
receptor type C 
Essential regulator of B- and T-cell 
antigen receptor signalling 
[464] 
TSG101  Tumour susceptibility gene 
101 
Plays a role in late endosomal 
sorting as part of the ESCRT 
complex, frequently mutated in 
breast cancer 
[523] 
PRNP  Prion protein  Remains unclear  [415] 




14-3-3 σ    p53 effector, important in cell cycle 
control, expression frequently lost 
in cancer 
[524] 
Table 5-2 Overview of known and putative Liprin-β2 interaction partners as determined by high-
throughput experiments 
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5.2  Results 
5.2.1  Knockdown of Rab17 and Liprin-β2 promotes tumour cell invasion of 
MDA-MB-231 cells 
To	 ﾠdetermine	 ﾠwhether	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠinfluence	 ﾠcell	 ﾠmotility,	 ﾠwe	 ﾠtransiently	 ﾠknocked	 ﾠ
down	 ﾠtheir	 ﾠexpression	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠusing	 ﾠsiRNA	 ﾠSMARTpools	 ﾠ(consisting	 ﾠof	 ﾠ4	 ﾠ
individual	 ﾠshort	 ﾠinterfering	 ﾠRNA	 ﾠoligonucleotides).	 ﾠUsing	 ﾠqRT-ﾭ‐PCR	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠ60%	 ﾠ
decrease	 ﾠin	 ﾠRab17	 ﾠmRNA	 ﾠlevels	 ﾠ(Figure	 ﾠ5-ﾭ‐2	 ﾠA)	 ﾠand	 ﾠan	 ﾠ80%	 ﾠreduction	 ﾠin	 ﾠLiprin-ﾭ‐β2	 ﾠtranscript	 ﾠ
levels	 ﾠ(Figure	 ﾠ5-ﾭ‐2	 ﾠB),	 ﾠsuggesting	 ﾠan	 ﾠefficient	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠgene.	 ﾠ
Having	 ﾠconfirmed	 ﾠthe	 ﾠefficacy	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠsuppression,	 ﾠwe	 ﾠperformed	 ﾠinverted	 ﾠ
invasion	 ﾠassays	 ﾠto	 ﾠtest	 ﾠwhether	 ﾠthis	 ﾠchange	 ﾠin	 ﾠgene	 ﾠexpression	 ﾠwould	 ﾠaffect	 ﾠtumour	 ﾠcell	 ﾠ
invasion	 ﾠinto	 ﾠfibronectin-ﾭ‐containing	 ﾠMatrigel.	 ﾠInterestingly,	 ﾠknockdown	 ﾠof	 ﾠRab17	 ﾠ
increased	 ﾠthe	 ﾠinvasiveness	 ﾠby	 ﾠapproximately	 ﾠ100%	 ﾠ(p≤0.01).	 ﾠLikewise,	 ﾠsilencing	 ﾠof	 ﾠ
Liprin-ﾭ‐β2	 ﾠsignificantly	 ﾠpromoted	 ﾠinvasion	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠinto	 ﾠMatrigel	 ﾠplugs	 ﾠ
(p≤0.05)	 ﾠ(Figure	 ﾠ5-ﾭ‐2	 ﾠC/D).	 ﾠTaken	 ﾠtogether,	 ﾠthis	 ﾠdata	 ﾠsuggests	 ﾠboth	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠact	 ﾠ
as	 ﾠinhibitors	 ﾠof	 ﾠinvasive	 ﾠcell	 ﾠmigration.	 ﾠ
Next	 ﾠwe	 ﾠwanted	 ﾠto	 ﾠinvestigate	 ﾠwhether	 ﾠthis	 ﾠincrease	 ﾠin	 ﾠinvasiveness	 ﾠwas	 ﾠmirrored	 ﾠby	 ﾠ
changes	 ﾠin	 ﾠmigration	 ﾠon	 ﾠCDM.	 ﾠTo	 ﾠthis	 ﾠend,	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠdepleted	 ﾠfor	 ﾠeither	 ﾠRab17	 ﾠ
or	 ﾠLiprin-ﾭ‐β2	 ﾠwere	 ﾠseeded	 ﾠonto	 ﾠCDM	 ﾠand	 ﾠtheir	 ﾠmotility	 ﾠwas	 ﾠmonitored	 ﾠusing	 ﾠa	 ﾠNikon	 ﾠ
time-ﾭ‐lapse	 ﾠmicroscope	 ﾠover	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠ16	 ﾠhours.	 ﾠInterestingly,	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠmarginal	 ﾠ
but	 ﾠsignificant	 ﾠdecrease	 ﾠin	 ﾠthe	 ﾠoverall	 ﾠmigration	 ﾠvelocity	 ﾠwhen	 ﾠRab17	 ﾠwas	 ﾠdepleted	 ﾠ
(Figure	 ﾠ5-ﾭ‐3	 ﾠB).	 ﾠIn	 ﾠaddition,	 ﾠthe	 ﾠpersistence	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠwas	 ﾠstrongly	 ﾠincreased	 ﾠ
following	 ﾠRab17	 ﾠsilencing	 ﾠ(p≤0.0001)	 ﾠ(Figure	 ﾠ5-ﾭ‐3	 ﾠC).	 ﾠIn	 ﾠcontrast,	 ﾠknockdown	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠ
did	 ﾠnot	 ﾠhave	 ﾠan	 ﾠeffect	 ﾠon	 ﾠthe	 ﾠoverall	 ﾠmigration	 ﾠvelocity,	 ﾠbut	 ﾠsignificantly	 ﾠincreased	 ﾠthe	 ﾠ
migration	 ﾠpersistence	 ﾠ(p≤0.05)	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠNT	 ﾠsiRNA-ﾭ‐transfected	 ﾠcells	 ﾠ(Figure	 ﾠ
5-ﾭ‐3	 ﾠB/C).	 ﾠ
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Figure 5-2 Suppression of Rab17 and Liprin-β2  promotes invasiveness of MDA-MB-231 cells 
A-B. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or SMARTpools targeting 
Rab17 or Liprin-β2. The effectiveness of the knockdown was assessed by qRT-PCR 48 hrs post transfection. 
Statistical significance of differences was determined by Mann-Whitney U test analysis. 
C. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x10
4 cells were plated onto the underside of 
each Transwell 24 hrs post nucleofection. 36 hrs following this, invading cells were visualized by 
Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented as a sequence in 
which the depth increases from left to right. 
D. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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Figure 5-3 Knockdown of Rab17 and Liprin-β2 increases persistence of MDA-MB-231 cells on CDM 
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting Rab17 or 
Liprin-β2 and plated onto cell-derived matrix. Images were captured every 10 minutes over a 16 hrs period 
using a Nikon time-lapse microscope. Still images from a representative movie are displayed. Scale bar, 
100 µm. 
B-C. The movement of individual cells was followed using the ImageJ cell tracking software. The overall 
migration velocity (B) and persistence (C) were extracted from the trackplots. Values are means ± SEM of 
>75 trackplots from three independent experiments. Statistical significance of differences was determined by 
Mann-Whitney U test analysis. 
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5.2.2  Depletion of Rab17 and Liprin-β2 promote invasion of A2780-Rab25 
and BE cells 
To	 ﾠassess	 ﾠwhether	 ﾠRab17’s	 ﾠand	 ﾠLiprin-ﾭ‐β2’s	 ﾠinhibitory	 ﾠrole	 ﾠon	 ﾠinvasive	 ﾠcell	 ﾠmigration	 ﾠwas	 ﾠ
specific	 ﾠto	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠor	 ﾠmore	 ﾠgenerally	 ﾠapplicable,	 ﾠwe	 ﾠdecided	 ﾠto	 ﾠalso	 ﾠperform	 ﾠ
invasion	 ﾠassays	 ﾠin	 ﾠtwo	 ﾠadditional	 ﾠcell	 ﾠlines:	 ﾠ(i)	 ﾠA2780	 ﾠovarian	 ﾠcarcinoma	 ﾠcells	 ﾠstably	 ﾠ
transfected	 ﾠwith	 ﾠRab25	 ﾠand	 ﾠ(ii)	 ﾠBE	 ﾠcolon	 ﾠcarcinoma	 ﾠcells.	 ﾠA2780-ﾭ‐Rab25	 ﾠand	 ﾠBE	 ﾠcells	 ﾠwere	 ﾠ
transfected	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠsiRNA	 ﾠoligos,	 ﾠor	 ﾠthose	 ﾠtargeting	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2.	 ﾠ
qRT-ﾭ‐PCR	 ﾠrevealed	 ﾠa	 ﾠ50%	 ﾠand	 ﾠ60%	 ﾠknockdown	 ﾠof	 ﾠRab17	 ﾠmRNA	 ﾠlevels	 ﾠin	 ﾠA2780-ﾭ‐Rab25	 ﾠand	 ﾠ
BE	 ﾠcells,	 ﾠrespectively	 ﾠ(p≤0.01)	 ﾠ(Figure	 ﾠ5-ﾭ‐4	 ﾠA).	 ﾠLikewise,	 ﾠLiprin-ﾭ‐β2	 ﾠtranscript	 ﾠlevels	 ﾠwere	 ﾠ
significantly	 ﾠdiminished	 ﾠby	 ﾠsiRNA	 ﾠin	 ﾠboth	 ﾠcell	 ﾠlines	 ﾠ(Figure	 ﾠ5-ﾭ‐4	 ﾠB).	 ﾠSilencing	 ﾠof	 ﾠRab17	 ﾠin	 ﾠ
either	 ﾠA2780-ﾭ‐Rab25	 ﾠor	 ﾠBE	 ﾠcells	 ﾠsignificantly	 ﾠincreased	 ﾠthe	 ﾠinvasiveness	 ﾠby	 ﾠ50%	 ﾠ(p≤0.01)	 ﾠor	 ﾠ
200%	 ﾠ(p≤0.0001),	 ﾠrespectively	 ﾠ(Figure	 ﾠ5-ﾭ‐4	 ﾠC/D).	 ﾠSimilarly,	 ﾠsuppression	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠby	 ﾠRNAi	 ﾠ
significantly	 ﾠincreased	 ﾠthe	 ﾠpropensity	 ﾠof	 ﾠA2780-ﾭ‐Rab25	 ﾠ(increase	 ﾠof	 ﾠ50%,	 ﾠp<0.001)	 ﾠand	 ﾠBE	 ﾠ
cells	 ﾠ(increase	 ﾠof	 ﾠ300%,	 ﾠp<0.01)	 ﾠto	 ﾠinvade	 ﾠinto	 ﾠMatrigel	 ﾠ(Figure	 ﾠ5-ﾭ‐4	 ﾠC/D).	 ﾠTaken	 ﾠtogether,	 ﾠ
these	 ﾠdata	 ﾠsuggest	 ﾠthat	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠact	 ﾠas	 ﾠinhibitors	 ﾠof	 ﾠinvasive	 ﾠcell	 ﾠmigration	 ﾠ
into	 ﾠfibronectin-ﾭ‐supplemented	 ﾠMatrigel	 ﾠplugs.	 ﾠ
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Figure 5-4 Depletion of Rab17 and Liprin-β2 promotes invasiveness of A2780-Rab25 and BE cells 
A-B. A2780-Rab25 and BE cells were transfected with non-targeting siRNAs (NT), or SMARTpools 
targeting Rab17 or Liprin-β2. Efficiency of the knockdown was assessed by qRT-PCR 48 hrs post 
transfection. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
C. Matrigel plugs were enriched with 25 µg/ml fibronectin and 3x10
4 cells were plated onto the underside of 
each Transwell 24 hrs post nucleofection. 36 hrs following this, invading cells were visualized by 
Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented as a sequence in 
which the depth increases from left to right. 
D. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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5.2.3  Overexpression of Rab17 and Liprin-β2 impairs invasion into 
Matrigel and migration on cell-derived matrix 
Given	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠpromoted	 ﾠinvasiveness,	 ﾠwe	 ﾠwanted	 ﾠto	 ﾠ
investigate	 ﾠwhether	 ﾠtheir	 ﾠoverexpression	 ﾠwould	 ﾠdecrease	 ﾠthe	 ﾠpropensity	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠ
or	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠto	 ﾠinvade	 ﾠinto	 ﾠMatrigel	 ﾠplugs	 ﾠor	 ﾠto	 ﾠmigrate	 ﾠon	 ﾠCDM.	 ﾠTo	 ﾠdo	 ﾠthis,	 ﾠcells	 ﾠ
were	 ﾠtransfected	 ﾠwith	 ﾠan	 ﾠempty	 ﾠvector	 ﾠcontrol	 ﾠ(pEGFP-ﾭ‐C1),	 ﾠpEGFP-ﾭ‐Rab17	 ﾠand	 ﾠ
pCMV6-ﾭ‐AC-ﾭ‐GFP-ﾭ‐Liprin-ﾭ‐β2.	 ﾠEctopic	 ﾠexpression	 ﾠof	 ﾠall	 ﾠplasmids	 ﾠwas	 ﾠensured	 ﾠby	 ﾠvisual	 ﾠ
inspection	 ﾠof	 ﾠthe	 ﾠcells	 ﾠon	 ﾠa	 ﾠfluorescent	 ﾠmicroscope	 ﾠprior	 ﾠto	 ﾠsetting	 ﾠup	 ﾠinverted	 ﾠinvasion	 ﾠ
assays.	 ﾠExpression	 ﾠof	 ﾠGFP	 ﾠalone	 ﾠreduced	 ﾠthe	 ﾠinvasive	 ﾠpotential	 ﾠof	 ﾠboth	 ﾠcancer	 ﾠcell	 ﾠlines	 ﾠ
and	 ﾠprompted	 ﾠus	 ﾠto	 ﾠcompare	 ﾠthe	 ﾠrelative	 ﾠpercentage	 ﾠof	 ﾠcells	 ﾠthat	 ﾠmigrated	 ﾠbeyond	 ﾠ30	 ﾠµm	 ﾠ
rather	 ﾠthan	 ﾠ45	 ﾠµm.	 ﾠRecombinant	 ﾠexpression	 ﾠof	 ﾠGFP-ﾭ‐Rab17	 ﾠor	 ﾠGFP-ﾭ‐Liprin-ﾭ‐β2	 ﾠsignificantly	 ﾠ
reduced	 ﾠinvasion	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠby	 ﾠ≥	 ﾠ50%	 ﾠ(p≤0.0001)	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠGFP	 ﾠalone	 ﾠ
(Figure	 ﾠ5-ﾭ‐5).	 ﾠConsistent	 ﾠwith	 ﾠthis,	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠ68%	 ﾠdecrease	 ﾠin	 ﾠinvasion	 ﾠ(p≤0.0001),	 ﾠ
when	 ﾠthe	 ﾠGFP-ﾭ‐tagged	 ﾠproteins	 ﾠwere	 ﾠoverexpressed	 ﾠin	 ﾠA2780-ﾭ‐Rab25	 ﾠcells.	 ﾠWe	 ﾠalso	 ﾠ
observed	 ﾠa	 ﾠsignificant	 ﾠdecrease	 ﾠin	 ﾠthe	 ﾠoverall	 ﾠmigration	 ﾠvelocity	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ
plated	 ﾠonto	 ﾠCDM	 ﾠfollowing	 ﾠexpression	 ﾠof	 ﾠeither	 ﾠectopic	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠwhen	 ﾠ
compared	 ﾠto	 ﾠGFP	 ﾠalone	 ﾠ(data	 ﾠnot	 ﾠshown),	 ﾠand	 ﾠthis	 ﾠwas	 ﾠowing	 ﾠto	 ﾠboth	 ﾠa	 ﾠdecrease	 ﾠin	 ﾠthe	 ﾠ
momentary	 ﾠvelocity	 ﾠof	 ﾠmoving	 ﾠcells	 ﾠ(Figure	 ﾠ5-ﾭ‐6	 ﾠB)	 ﾠand	 ﾠan	 ﾠincrease	 ﾠin	 ﾠcellular	 ﾠresting	 ﾠ
(Figure	 ﾠ5-ﾭ‐6	 ﾠC).	 ﾠThus,	 ﾠour	 ﾠdata	 ﾠindicates	 ﾠthat	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠact	 ﾠto	 ﾠrestrict	 ﾠcarcinoma	 ﾠ
cell	 ﾠmigration	 ﾠin	 ﾠ3D	 ﾠmicroenvironments	 ﾠin	 ﾠmuch	 ﾠthe	 ﾠsame	 ﾠway	 ﾠas	 ﾠdoes	 ﾠknockdown	 ﾠof	 ﾠ
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Figure 5-5 Ectopic expression of Rab17 or Liprin-β2 suppresses invasiveness MDA-MB-231 and 
A2780-Rab25 cells 
MDA-MB-231 and A2780-Rab25 cells were transfected with GFP alone, GFP-Rab17 or GFP-Liprin-β2. 
Expression of various constructs was verified by eye on a fluorescent microscope 24 hrs post nucleofection. 
A. Respective cells were plated onto plugs of fibronectin-supplemented Matrigel. 36 hrs following this, 
invading cells were visualized by Calcein-AM staining. Serial optical sections were captured every 15 µm 
and are presented as a sequence in which the depth increases from left to right.  
B. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 30 µm and expressed relative to cells transfected with empty vector control. 
Values are means ± standard error of the mean (SEM) of 18 replicates from three independent experiments. 
Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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Figure 5-6 Ectopic expression of Rab17 or Liprin-β2 decreases the momentary velocity and increases 
cellular resting in MDA-MB-231 cells 
MDA-MB-231 cells were transfected with empty vector control (GFP alone), GFP-Rab17 or Liprin-β2, and 
plated onto cell-derived matrix. Images were captured every 10 minutes over a 16 hrs period. Cell movement 
was followed using cell-tracking software. 
A. Still images from a representative movie are displayed. Scale bar, 100 µm.  
B. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 10-
90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
C. Cellular resting was extracted from manual cell tracking and represents means ± SEM of thee independent 
experiments. Percentage of resting cells is displayed with absolute numbers for each condition above each 
column. 
D. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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5.2.4  ERK2 drives invasive cell migration of MDA-MB-231 cells by 
suppressing expression of Rab17 and Liprin-β2 
Having	 ﾠestablished	 ﾠthat	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠact	 ﾠto	 ﾠrestrict	 ﾠtumour	 ﾠcell	 ﾠinvasion	 ﾠinto	 ﾠ
Matrigel	 ﾠplugs	 ﾠand	 ﾠmigration	 ﾠon	 ﾠCDM,	 ﾠwe	 ﾠwished	 ﾠto	 ﾠdetermine	 ﾠto	 ﾠwhat	 ﾠextent	 ﾠERK2’s	 ﾠ
suppression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠwas	 ﾠresponsible	 ﾠfor	 ﾠthe	 ﾠkinase’s	 ﾠability	 ﾠto	 ﾠdrive	 ﾠ
invasion.	 ﾠTo	 ﾠdo	 ﾠthis,	 ﾠwe	 ﾠsilenced	 ﾠERK2	 ﾠin	 ﾠcombination	 ﾠwith	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠ
Liprin-ﾭ‐β2	 ﾠand	 ﾠcarried	 ﾠout	 ﾠinvasion	 ﾠassays.	 ﾠInterestingly,	 ﾠsiRNA	 ﾠof	 ﾠRab17	 ﾠrestored	 ﾠinvasion	 ﾠ
of	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠto	 ﾠlevels	 ﾠcomparable	 ﾠto	 ﾠcontrol	 ﾠcells	 ﾠ(Figure	 ﾠ5-ﾭ‐7).	 ﾠIn	 ﾠaddition,	 ﾠ
concomitant	 ﾠsilencing	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠwith	 ﾠERK2	 ﾠnot	 ﾠonly	 ﾠrestored	 ﾠthe	 ﾠinvasive	 ﾠphenotype	 ﾠof	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠbut	 ﾠalso	 ﾠenhanced	 ﾠthe	 ﾠinvasive	 ﾠcapacity	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠcontrol	 ﾠ
transfected	 ﾠcells	 ﾠ(p≤0.05)	 ﾠ(Figure	 ﾠ5-ﾭ‐7).	 ﾠConsistent	 ﾠwith	 ﾠthis,	 ﾠwe	 ﾠfound	 ﾠthat	 ﾠconcomitant	 ﾠ
knockdown	 ﾠof	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠwith	 ﾠERK2	 ﾠincreased	 ﾠthe	 ﾠmomentary	 ﾠvelocity	 ﾠand	 ﾠ
reduced	 ﾠthe	 ﾠtendency	 ﾠof	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠto	 ﾠpause	 ﾠ(cellular	 ﾠresting),	 ﾠwhilst	 ﾠ
migrating	 ﾠon	 ﾠCDM	 ﾠ(Figure	 ﾠ5-ﾭ‐8).	 ﾠTo	 ﾠstrengthen	 ﾠthese	 ﾠobservations	 ﾠmade	 ﾠusing	 ﾠSMARTpool	 ﾠ
siRNAs,	 ﾠwe	 ﾠrepeated	 ﾠthe	 ﾠmotility	 ﾠstudies	 ﾠon	 ﾠCDM	 ﾠwith	 ﾠtwo	 ﾠindependent	 ﾠoligos	 ﾠto	 ﾠtarget	 ﾠ
Rab17	 ﾠand	 ﾠLiprin-ﾭ‐β2.	 ﾠFirstly,	 ﾠwe	 ﾠexamined	 ﾠthe	 ﾠknockdown	 ﾠefficiency	 ﾠof	 ﾠthe	 ﾠfour	 ﾠRNA	 ﾠ
duplexes	 ﾠconstituting	 ﾠthe	 ﾠSMARTpool	 ﾠand	 ﾠchose	 ﾠtwo	 ﾠRNA	 ﾠduplexes,	 ﾠwhich	 ﾠdemonstrated	 ﾠ
the	 ﾠmost	 ﾠefficient	 ﾠknockdown	 ﾠ(data	 ﾠnot	 ﾠshown).	 ﾠIndeed,	 ﾠboth	 ﾠof	 ﾠthe	 ﾠduplexes	 ﾠchosen	 ﾠto	 ﾠ
suppress	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠwere	 ﾠable	 ﾠto	 ﾠreverse	 ﾠthe	 ﾠeffect	 ﾠthat	 ﾠERK2	 ﾠknockdown	 ﾠhad	 ﾠ
on	 ﾠmomentary	 ﾠvelocity	 ﾠand	 ﾠcellular	 ﾠresting	 ﾠon	 ﾠCDM	 ﾠ(Figure	 ﾠ5-ﾭ‐8).	 ﾠ	 ﾠ
Taken	 ﾠtogether	 ﾠthese	 ﾠdata	 ﾠindicate	 ﾠthat	 ﾠrab17	 ﾠor	 ﾠliprin-ﾭ‐β2	 ﾠare	 ﾠnovel	 ﾠmotility	 ﾠsuppressor	 ﾠ
genes,	 ﾠand	 ﾠin	 ﾠorder	 ﾠto	 ﾠdrive	 ﾠinvasion	 ﾠand	 ﾠmigration	 ﾠof	 ﾠcarcinoma	 ﾠcells	 ﾠin	 ﾠ3D	 ﾠ
microenvironments,	 ﾠERK2	 ﾠmust	 ﾠreduce	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠat	 ﾠleast	 ﾠone	 ﾠof	 ﾠthese	 ﾠgenes.	 ﾠ	 ﾠ
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Figure 5-7 siRNA of Rab17 or Liprin-β2 restores the invasiveness of ERK2 knockdown cells  
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination those targeting Rab17 or Liprin-β2.  
A. Cells were plated onto plugs of fibronectin-supplemented Matrigel. 36 hrs following this, invading cells 
were visualized by Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented 
as a sequence in which the depth increases from left to right.  
B. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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Figure 5-8 Suppression of Rab17 and Liprin-β2 restores the migratory characteristics of ERK2 
knockdown cells 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination those targeting Rab17 or Liprin-β2 and plated onto cell-derived matrix. Images were captured 
every 10 minutes over a 16 hrs period. Cell movement was followed using cell-tracking software. 
(see next page also) 
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A. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 10-
90 percentile) and represent three independent experiments. “SP” denotes SMARTpool. Statistical 
significance of differences was determined by Mann-Whitney U test analysis. 
B. Cellular resting was extracted from manual cell tracking and represents means ± SEM of thee independent 
experiments. Percentage of resting cells is displayed with absolute numbers for each condition above each 
column.  
C. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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5.2.5  ERK2 drives migration on plastic surfaces but not through Rab17 
and Liprin-β2 
In	 ﾠchapter	 ﾠ3	 ﾠwe	 ﾠestablished	 ﾠthat	 ﾠsilencing	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠ
impaired	 ﾠcell	 ﾠmigration	 ﾠon	 ﾠCDM	 ﾠand	 ﾠplastic	 ﾠsurfaces.	 ﾠThus,	 ﾠmotility	 ﾠof	 ﾠthese	 ﾠcells	 ﾠis	 ﾠ
dependent	 ﾠon	 ﾠERK2	 ﾠsignalling	 ﾠirrespective	 ﾠof	 ﾠthe	 ﾠmicroenvironment.	 ﾠMoreover,	 ﾠin	 ﾠ
chapter	 ﾠ4	 ﾠwe	 ﾠdemonstrated	 ﾠthat	 ﾠERK2	 ﾠsuppressed	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠon	 ﾠ
CDM	 ﾠas	 ﾠwell	 ﾠas	 ﾠon	 ﾠplastic	 ﾠsurfaces.	 ﾠWe,	 ﾠtherefore,	 ﾠwished	 ﾠto	 ﾠinvestigate	 ﾠthe	 ﾠrequirement	 ﾠ
for	 ﾠsuppression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠin	 ﾠERK2-ﾭ‐dependent	 ﾠcell	 ﾠmigration	 ﾠinto	 ﾠscratch	 ﾠ
wounds.	 ﾠTo	 ﾠdo	 ﾠthis,	 ﾠwe	 ﾠsilenced	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠin	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠand	 ﾠ
measured	 ﾠthe	 ﾠspeed,	 ﾠpersistence	 ﾠand	 ﾠFMI	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠinto	 ﾠscratch	 ﾠwounds.	 ﾠAs	 ﾠ
before,	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠsignificantly	 ﾠreduced	 ﾠthe	 ﾠmigratory	 ﾠspeed	 ﾠof	 ﾠ
cells	 ﾠclosing	 ﾠthe	 ﾠscratch	 ﾠwound	 ﾠ(Figure	 ﾠ5-ﾭ‐9	 ﾠA).	 ﾠHowever,	 ﾠby	 ﾠcontrast	 ﾠwith	 ﾠthe	 ﾠsituation	 ﾠin	 ﾠ
3D	 ﾠmicroenvironments,	 ﾠsiRNA	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠin	 ﾠcombination	 ﾠwith	 ﾠERK2	 ﾠwas	 ﾠnot	 ﾠ
sufficient	 ﾠto	 ﾠrestore	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠof	 ﾠERK2	 ﾠknockdown	 ﾠcells	 ﾠ(Figure	 ﾠ5-ﾭ‐9	 ﾠA),	 ﾠ
although	 ﾠthe	 ﾠpersistence	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠknockdown	 ﾠcells	 ﾠwas	 ﾠmarginally	 ﾠ
increased	 ﾠ(Figure	 ﾠ5-ﾭ‐9	 ﾠB/C).	 ﾠTaken	 ﾠtogether,	 ﾠthese	 ﾠdata	 ﾠindicate	 ﾠthat	 ﾠalthough	 ﾠERK2	 ﾠ
controls	 ﾠcell	 ﾠmovement	 ﾠin	 ﾠ3D	 ﾠmicroenvironments	 ﾠby	 ﾠsuppressing	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2,	 ﾠthe	 ﾠ
pathways	 ﾠby	 ﾠwhich	 ﾠERKs	 ﾠcontrol	 ﾠcell	 ﾠmigration	 ﾠon	 ﾠplastic	 ﾠdo	 ﾠnot	 ﾠinvolve	 ﾠthese	 ﾠtwo	 ﾠnovel	 ﾠ
ERK2	 ﾠeffectors.	 ﾠ
	 ﾠ 	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Figure 5-9 RNAi of Rab17 and Liprin-β2 does not restore motility defects of ERK2 knockdown cells on 
plastic 
A-C. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination those targeting Rab17 or Liprin-β2. Subsequently, cells were seeded into a 6-well dish, so that 
they were confluent 48 hrs post nucleofection. After scratching, wound closure was monitored and the 
movement of individual cells was followed using ImageJ cell tracking software. The overall migration 
velocity (A), persistence (B) and forward migration index (FMI) (C) were extracted from the trackplots. 
Values are means ± SEM of >75 trackplots from three independent experiments. Statistical significance of 
differences was determined by Mann-Whitney U test analysis. 
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5.2.6  Rab17 localises to early and recycling endosomes 
Rab17	 ﾠis	 ﾠthought	 ﾠto	 ﾠplay	 ﾠa	 ﾠrole	 ﾠin	 ﾠvesicular	 ﾠtransport.	 ﾠTo	 ﾠcharacterise	 ﾠvesicles	 ﾠto	 ﾠwhich	 ﾠ
Rab17	 ﾠlocalises	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠlines,	 ﾠwe	 ﾠectopically	 ﾠexpressed	 ﾠthe	 ﾠGTPase	 ﾠtagged	 ﾠto	 ﾠeither	 ﾠ
mCherry	 ﾠor	 ﾠGFP	 ﾠin	 ﾠboth	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠand	 ﾠA2780-ﾭ‐Rab25	 ﾠcells.	 ﾠLive	 ﾠcell	 ﾠimaging	 ﾠindicated	 ﾠ
that	 ﾠRab17	 ﾠ(irrespective	 ﾠof	 ﾠthe	 ﾠtag)	 ﾠlocalised	 ﾠto	 ﾠvesicular-ﾭ‐type	 ﾠstructures	 ﾠthat	 ﾠwere	 ﾠ
dynamic	 ﾠand	 ﾠin	 ﾠconstant	 ﾠmovement	 ﾠ(data	 ﾠnot	 ﾠshown).	 ﾠIntriguingly,	 ﾠsmall	 ﾠRab17-ﾭ‐positive	 ﾠ
vesicles	 ﾠlocalised	 ﾠmainly	 ﾠto	 ﾠthe	 ﾠperipheral	 ﾠcytoplasm,	 ﾠwhile	 ﾠlarger	 ﾠvesicles	 ﾠwere	 ﾠfound	 ﾠin	 ﾠ
the	 ﾠperinuclear	 ﾠregion.	 ﾠNext,	 ﾠwe	 ﾠoverexpressed	 ﾠRab17,	 ﾠplated	 ﾠcells	 ﾠon	 ﾠfibronectin-ﾭ‐coated,	 ﾠ
collagen-ﾭ‐coated	 ﾠor	 ﾠuncoated	 ﾠcoverslips	 ﾠand	 ﾠfixed	 ﾠcells	 ﾠwith	 ﾠ4%	 ﾠparaformaldehyde.	 ﾠ
Fixation	 ﾠdid	 ﾠnot	 ﾠalter	 ﾠthe	 ﾠdistribution	 ﾠof	 ﾠthe	 ﾠRab17-ﾭ‐positive	 ﾠvesicles,	 ﾠnor	 ﾠdid	 ﾠthe	 ﾠaddition	 ﾠ
of	 ﾠfibronectin	 ﾠor	 ﾠcollagen	 ﾠaffect	 ﾠthe	 ﾠdistribution	 ﾠof	 ﾠRab17	 ﾠvesicles	 ﾠ(data	 ﾠnot	 ﾠshown).	 ﾠWe	 ﾠ
then	 ﾠstained	 ﾠfor	 ﾠendogenous	 ﾠprotein	 ﾠ(such	 ﾠas	 ﾠEEA1)	 ﾠor	 ﾠoverexpressed	 ﾠfluorescently	 ﾠ
labelled	 ﾠmarker	 ﾠproteins,	 ﾠsuch	 ﾠas	 ﾠRab11,	 ﾠRab7	 ﾠand	 ﾠSialin	 ﾠin	 ﾠcombination	 ﾠwith	 ﾠRab17.	 ﾠ
Confocal	 ﾠimaging	 ﾠidentified	 ﾠRab17	 ﾠon	 ﾠall	 ﾠEEA1	 ﾠpositive	 ﾠearly	 ﾠendosomes.	 ﾠMoreover,	 ﾠ
Rab17	 ﾠpartially	 ﾠco-ﾭ‐localised	 ﾠwith	 ﾠrecycling	 ﾠendosomes	 ﾠas	 ﾠmarked	 ﾠby	 ﾠGFP-ﾭ‐Rab11.	 ﾠIn	 ﾠ
contrast	 ﾠwe	 ﾠobserved	 ﾠno	 ﾠco-ﾭ‐localisation	 ﾠof	 ﾠRab17	 ﾠwith	 ﾠlate	 ﾠendosomes	 ﾠas	 ﾠmarked	 ﾠby	 ﾠ
Rab7,	 ﾠor	 ﾠwith	 ﾠSialin-ﾭ‐positive	 ﾠlysosomes	 ﾠ(Figure	 ﾠ5-ﾭ‐10).	 ﾠThus,	 ﾠRab17	 ﾠlocalises	 ﾠpredominantly	 ﾠ
to	 ﾠearly	 ﾠendosomes,	 ﾠbut	 ﾠalso	 ﾠto	 ﾠsome	 ﾠcentrally	 ﾠlocated	 ﾠrecycling	 ﾠcompartments.	 ﾠ
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Figure 5-10 Rab17 associates with early and recycling endosomes 
MDA-MB-231 cells were transfected as stated below, seeded onto coverslips and fixed with 4% 
paraformaldehyde 24 hrs after transfection. Co-localisation was examined using a confocal microscope. 
Scale bars, 10 µm. 
A. Fixed cells were permeabilised and stained for endogenous early endosome antigen 1 (EEA1) (green).  
B. GFP-Rab11 (green) and mCherry-Rab17 (red) were co-transfected. 
C. GFP-Rab17 (green) and RFP-Rab7 (red) were co-transfected. 
D. GFP-Sialin (green) and mCherry-Rab17 (red) were co-transfected. 
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5.2.7  Rab17 vesicles are positive for β1 integrin 
Enhanced	 ﾠβ1	 ﾠintegrin	 ﾠrecycling	 ﾠis	 ﾠknown	 ﾠto	 ﾠbe	 ﾠassociated	 ﾠwith	 ﾠthe	 ﾠinvasiveness	 ﾠof	 ﾠcancer	 ﾠ
cell	 ﾠlines	 ﾠ[380,	 ﾠ525].	 ﾠTo	 ﾠinitiate	 ﾠstudies	 ﾠto	 ﾠdetermine	 ﾠwhether	 ﾠRab17	 ﾠexpression	 ﾠaffected	 ﾠ
β1	 ﾠintegrin	 ﾠtrafficking,	 ﾠwe	 ﾠexpressed	 ﾠmCherry-ﾭ‐Rab17	 ﾠand	 ﾠstained	 ﾠfor	 ﾠendogenous	 ﾠβ1	 ﾠ
integrin.	 ﾠRab17	 ﾠwas	 ﾠassociated	 ﾠwith	 ﾠa	 ﾠsubset	 ﾠof	 ﾠvesicles,	 ﾠwhose	 ﾠlumen	 ﾠstained	 ﾠpositive	 ﾠfor	 ﾠ
β1	 ﾠintegrin	 ﾠ(Figure	 ﾠ5-ﾭ‐11	 ﾠA),	 ﾠindicating	 ﾠthat	 ﾠthe	 ﾠGTPase	 ﾠmay	 ﾠbe	 ﾠinvolved	 ﾠin	 ﾠsorting	 ﾠand/or	 ﾠ
recycling	 ﾠof	 ﾠthis	 ﾠintegrin	 ﾠreceptor.	 ﾠ	 ﾠ
A	 ﾠprevious	 ﾠstudy	 ﾠby	 ﾠPellinen	 ﾠet	 ﾠal.	 ﾠidentified	 ﾠthe	 ﾠsmall	 ﾠGTPase	 ﾠRab21	 ﾠas	 ﾠa	 ﾠregulator	 ﾠof	 ﾠcell	 ﾠ
adhesion	 ﾠand	 ﾠendosomal	 ﾠtrafficking	 ﾠof	 ﾠβ1	 ﾠintegrin.	 ﾠMoreover,	 ﾠRab21	 ﾠwas	 ﾠshown	 ﾠto	 ﾠ
directly	 ﾠinteract	 ﾠwith	 ﾠβ1	 ﾠintegrin’s	 ﾠcytoplasmic	 ﾠtail	 ﾠin	 ﾠco-ﾭ‐immunoprecipitation	 ﾠ
studies	 ﾠ[526].	 ﾠGiven	 ﾠthat	 ﾠRab21,	 ﾠlike	 ﾠRab17,	 ﾠbelongs	 ﾠto	 ﾠthe	 ﾠRab5	 ﾠfamily	 ﾠof	 ﾠsmall	 ﾠGTPases,	 ﾠ
we	 ﾠpostulated	 ﾠthat	 ﾠRab17	 ﾠmay	 ﾠcompete	 ﾠwith	 ﾠRab21	 ﾠfor	 ﾠβ1	 ﾠintegrin	 ﾠbinding.	 ﾠTo	 ﾠtest	 ﾠthis	 ﾠ
idea,	 ﾠwe	 ﾠnucleofected	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠwith	 ﾠan	 ﾠempty	 ﾠvector	 ﾠcontrol	 ﾠ(GFP	 ﾠalone)	 ﾠor	 ﾠ
GFP-ﾭ‐Rab17,	 ﾠharvested	 ﾠcells	 ﾠ24	 ﾠhours	 ﾠpost	 ﾠtransfection	 ﾠand	 ﾠco-ﾭ‐immunoprecipitated	 ﾠwith	 ﾠ
an	 ﾠantibody	 ﾠrecognising	 ﾠGFP.	 ﾠWe	 ﾠwere	 ﾠnot	 ﾠable	 ﾠto	 ﾠdemonstrate	 ﾠa	 ﾠphysical	 ﾠinteraction	 ﾠ
between	 ﾠRab17	 ﾠand	 ﾠβ1	 ﾠintegrin	 ﾠ(Figure	 ﾠ5-ﾭ‐11),	 ﾠsuggesting	 ﾠthat	 ﾠRab17	 ﾠassociates	 ﾠto	 ﾠβ1	 ﾠ
integrin-ﾭ‐containing	 ﾠvesicles	 ﾠby	 ﾠbinding	 ﾠto	 ﾠother	 ﾠcargo	 ﾠmolecules	 ﾠor	 ﾠadaptor	 ﾠproteins.	 ﾠ
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Figure 5-11 Rab17 associates with β1 integrin-positive vesicles 
A. MDA-MB-231 cells were transfected with mCherry-Rab17, seeded onto coverslips and fixed with 4% 
paraformaldehyde 24 hrs after transfection. Cells were permeabilised with 0.02% Triton-X 100 and stained 
for endogenous β1 integrin. Co-localisation was examined using a confocal microscope. Scale bars, 20 µm. 
B. MDA-MB-231 cells were transfected with empty vector control (GFP alone) or GFP-Rab17, 
immunoprecipitated using a GFP-antibody (mouse) and blotted with anti-GFP (rabbit) and anti-β1 integrin 
(mouse) antibodies.  
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5.3  Discussion 
5.3.1  Summary 
Here,	 ﾠwe	 ﾠshow	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠenhances	 ﾠinvasiveness	 ﾠof	 ﾠthree	 ﾠ
cancer	 ﾠcell	 ﾠlines,	 ﾠwhile	 ﾠtheir	 ﾠoverexpression	 ﾠhas	 ﾠthe	 ﾠopposite	 ﾠeffect.	 ﾠThis	 ﾠsuggests	 ﾠa	 ﾠrole	 ﾠ
for	 ﾠboth	 ﾠproteins	 ﾠin	 ﾠrestricting	 ﾠcarcinoma	 ﾠcell	 ﾠmotility	 ﾠin	 ﾠ3D microenvironments.	 ﾠ
Importantly,	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠrestores	 ﾠinvasiveness	 ﾠof	 ﾠ
ERK2-ﾭ‐depleted	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠindicating	 ﾠthat	 ﾠERK2	 ﾠdrives	 ﾠinvasion	 ﾠby	 ﾠsuppressing	 ﾠ
expression	 ﾠof	 ﾠthese	 ﾠgenes.	 ﾠCharacterisation	 ﾠof	 ﾠRab17-ﾭ‐positive	 ﾠvesicles	 ﾠdemonstrated	 ﾠa	 ﾠ
potential	 ﾠrole	 ﾠfor	 ﾠthis	 ﾠGTPase	 ﾠin	 ﾠregulating	 ﾠearly	 ﾠendocytic	 ﾠevents.	 ﾠMoreover,	 ﾠ
co-ﾭ‐localisation	 ﾠof	 ﾠβ1	 ﾠintegrin	 ﾠwithin	 ﾠRab17	 ﾠvesicles,	 ﾠsuggests	 ﾠa	 ﾠfunction	 ﾠof	 ﾠthis	 ﾠGTPase	 ﾠin	 ﾠ
integrin	 ﾠtrafficking.	 ﾠ	 ﾠ
5.3.2  Rab17 – a novel suppressor of cell motility 
Rab17	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠinfluence	 ﾠreceptor-ﾭ‐mediated	 ﾠtranscytosis	 ﾠand	 ﾠrecycling	 ﾠof	 ﾠ
receptors	 ﾠto	 ﾠthe	 ﾠapical	 ﾠmembrane	 ﾠin	 ﾠnon-ﾭ‐transformed	 ﾠepithelial	 ﾠcells	 ﾠ[462,	 ﾠ498].	 ﾠ
Recently,	 ﾠa	 ﾠstudy	 ﾠby	 ﾠSingh	 ﾠet	 ﾠal.	 ﾠfound	 ﾠthat	 ﾠRab17	 ﾠwas	 ﾠone	 ﾠof	 ﾠmany	 ﾠgenes	 ﾠto	 ﾠbe	 ﾠ
up-ﾭ‐regulated	 ﾠin	 ﾠcancer	 ﾠcell	 ﾠlines	 ﾠexhibiting	 ﾠa	 ﾠmore	 ﾠepithelial	 ﾠmorphology,	 ﾠwhereas	 ﾠthe	 ﾠ
GTPase	 ﾠwas	 ﾠdown-ﾭ‐regulated	 ﾠin	 ﾠcells	 ﾠdisplaying	 ﾠa	 ﾠmore	 ﾠmesenchymal	 ﾠmorphology	 ﾠ[527].	 ﾠ
This	 ﾠindicates	 ﾠthat	 ﾠRab17	 ﾠis	 ﾠassociated	 ﾠwith	 ﾠthe	 ﾠmaintenance	 ﾠof	 ﾠa	 ﾠpolarised	 ﾠepithelial	 ﾠ
morphology	 ﾠand	 ﾠmight	 ﾠprovide	 ﾠan	 ﾠexplanation	 ﾠas	 ﾠto	 ﾠwhy	 ﾠRab17	 ﾠlevels	 ﾠmust	 ﾠbe	 ﾠreduced	 ﾠin	 ﾠ
order	 ﾠfor	 ﾠmetastatic	 ﾠtumour	 ﾠcells	 ﾠto	 ﾠmigrate	 ﾠwith	 ﾠmesenchymal	 ﾠcharacteristics.	 ﾠ	 ﾠ
Given	 ﾠthat	 ﾠRab17	 ﾠwould	 ﾠbe	 ﾠexpected	 ﾠto	 ﾠcontrol	 ﾠmembrane	 ﾠtrafficking,	 ﾠit	 ﾠis	 ﾠinteresting	 ﾠto	 ﾠ
speculate	 ﾠas	 ﾠto	 ﾠhow	 ﾠit	 ﾠmight	 ﾠsuppress	 ﾠcell	 ﾠmigration.	 ﾠRecycling	 ﾠof	 ﾠα5β1	 ﾠintegrin	 ﾠis	 ﾠknown	 ﾠ
to	 ﾠbe	 ﾠkey	 ﾠto	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion	 ﾠ[380,	 ﾠ525,	 ﾠ528]	 ﾠand	 ﾠour	 ﾠdata	 ﾠsuggests	 ﾠ
that	 ﾠoverexpression	 ﾠof	 ﾠRab17	 ﾠleads	 ﾠto	 ﾠthe	 ﾠaccumulation	 ﾠof	 ﾠβ1	 ﾠintegrin	 ﾠwithin	 ﾠlarge	 ﾠ
endosomes	 ﾠto	 ﾠwhich	 ﾠRab17	 ﾠitself	 ﾠis	 ﾠlocalised.	 ﾠTaken	 ﾠtogether	 ﾠwith	 ﾠreports	 ﾠsuggesting	 ﾠthat	 ﾠ
Rab17	 ﾠopposes	 ﾠthe	 ﾠreturn	 ﾠof	 ﾠreceptors	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠ[462,	 ﾠ498],	 ﾠthis	 ﾠmoots	 ﾠ
that	 ﾠRab17	 ﾠmay	 ﾠbe	 ﾠan	 ﾠintegrin	 ﾠrecycling	 ﾠsuppressor,	 ﾠwhose	 ﾠexpression	 ﾠmust	 ﾠbe	 ﾠreduced	 ﾠ
for	 ﾠcells	 ﾠto	 ﾠmigrate	 ﾠefficiently.	 ﾠMoreover,	 ﾠas	 ﾠRab17	 ﾠhas	 ﾠbeen	 ﾠproposed	 ﾠto	 ﾠinteract	 ﾠwith	 ﾠ
signalling	 ﾠmolecules	 ﾠinvolved	 ﾠin	 ﾠreceptor	 ﾠdegradation,	 ﾠsuch	 ﾠas	 ﾠRab7a,	 ﾠCHMP6	 ﾠand	 ﾠSmurf2	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(see	 ﾠTable	 ﾠ5-ﾭ‐1),	 ﾠit	 ﾠis	 ﾠconceivable	 ﾠthat	 ﾠthe	 ﾠGTPase	 ﾠfeeds	 ﾠreceptors	 ﾠinto	 ﾠthe	 ﾠdegradative	 ﾠ
pathway,	 ﾠthereby	 ﾠdecreasing	 ﾠtheir	 ﾠrecycling	 ﾠand	 ﾠultimately	 ﾠinhibiting	 ﾠcell	 ﾠmigration.	 ﾠ
5.3.3  Liprin-β2 – a novel inhibitor of cell motility 
The	 ﾠrole	 ﾠof	 ﾠLiprin	 ﾠfamily	 ﾠmembers,	 ﾠin	 ﾠparticular	 ﾠthe	 ﾠα-ﾭ‐Liprins,	 ﾠhas	 ﾠbeen	 ﾠwell	 ﾠestablished	 ﾠin	 ﾠ
synaptic	 ﾠtransmission.	 ﾠIt	 ﾠis	 ﾠclear	 ﾠfrom	 ﾠreverse	 ﾠgenetic	 ﾠstudies	 ﾠin	 ﾠvertebrates,	 ﾠDrosophila	 ﾠ
and	 ﾠC.	 ﾠelegans	 ﾠthat	 ﾠLiprin	 ﾠmutants	 ﾠhave	 ﾠdefects	 ﾠin	 ﾠsynaptic	 ﾠvesicle	 ﾠtransport,	 ﾠin	 ﾠwhich	 ﾠ
synaptic	 ﾠvesicles	 ﾠaccumulate	 ﾠin	 ﾠaxons	 ﾠ[516].	 ﾠThus,	 ﾠLiprins	 ﾠcontrol	 ﾠvesicular	 ﾠtransport,	 ﾠand	 ﾠ
this	 ﾠis	 ﾠdue	 ﾠto	 ﾠtheir	 ﾠability	 ﾠto	 ﾠact	 ﾠas	 ﾠscaffolds	 ﾠto	 ﾠrecruit	 ﾠand	 ﾠstabilise	 ﾠa	 ﾠnumber	 ﾠof	 ﾠdifferent	 ﾠ
proteins	 ﾠto	 ﾠthe	 ﾠsites	 ﾠof	 ﾠexocytosis	 ﾠ[516].	 ﾠ	 ﾠ
Heterodimerisation	 ﾠof	 ﾠthe	 ﾠtwo	 ﾠLiprin	 ﾠsubclasses	 ﾠis	 ﾠthought	 ﾠto	 ﾠmodify	 ﾠthe	 ﾠbiological	 ﾠ
functions	 ﾠof	 ﾠα-ﾭ‐Liprins,	 ﾠwho	 ﾠhave	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠpromoting	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠ
invasion	 ﾠ[518].	 ﾠIn	 ﾠfact,	 ﾠLiprin-ﾭ‐α1	 ﾠis	 ﾠpart	 ﾠof	 ﾠthe	 ﾠhuman	 ﾠ11q13	 ﾠchromosomal	 ﾠregion	 ﾠthat	 ﾠis	 ﾠ
frequently	 ﾠamplified	 ﾠin	 ﾠmalignant	 ﾠtumours	 ﾠ[529,	 ﾠ530]	 ﾠand	 ﾠwas	 ﾠshown	 ﾠto	 ﾠregulate	 ﾠreceptor	 ﾠ
clustering	 ﾠat	 ﾠneuronal	 ﾠplasma	 ﾠmembranes	 ﾠby	 ﾠinteracting	 ﾠwith	 ﾠGIT1	 ﾠ(G	 ﾠprotein-ﾭ‐coupled	 ﾠ
receptor	 ﾠkinase	 ﾠinteracting	 ﾠArfGAP	 ﾠ1)	 ﾠ[531].	 ﾠMoreover,	 ﾠLiprin-ﾭ‐α1	 ﾠbinds	 ﾠto	 ﾠneuron-ﾭ‐specific	 ﾠ
kinesin	 ﾠmotor	 ﾠproteins,	 ﾠthereby	 ﾠregulating	 ﾠsynaptic	 ﾠvesicle	 ﾠtrafficking	 ﾠ[532].	 ﾠConsistent	 ﾠ
with	 ﾠthis,	 ﾠLiprin-ﾭ‐α1	 ﾠwas	 ﾠshown	 ﾠto	 ﾠalter	 ﾠintegrin	 ﾠtrafficking,	 ﾠwhich	 ﾠmay	 ﾠprovide	 ﾠa	 ﾠmeans	 ﾠby	 ﾠ
which	 ﾠit	 ﾠcontributes	 ﾠto	 ﾠcell	 ﾠmigration	 ﾠ[519].	 ﾠIn	 ﾠcontrast	 ﾠto	 ﾠthis	 ﾠpro-ﾭ‐invasive	 ﾠfunction	 ﾠof	 ﾠ
Liprin-ﾭ‐α1,	 ﾠwe	 ﾠidentify	 ﾠLiprin-ﾭ‐β2	 ﾠis	 ﾠa	 ﾠnovel	 ﾠsuppressor	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion	 ﾠ
downstream	 ﾠof	 ﾠERK2.	 ﾠThus,	 ﾠthe	 ﾠquestion	 ﾠarises	 ﾠas	 ﾠto	 ﾠhow	 ﾠtwo	 ﾠstructurally	 ﾠrelated	 ﾠ
proteins	 ﾠcan	 ﾠhave	 ﾠsuch	 ﾠopposing	 ﾠfunctions.	 ﾠWe	 ﾠmay	 ﾠonly	 ﾠspeculate	 ﾠon	 ﾠthis	 ﾠmatter,	 ﾠas	 ﾠ
apart	 ﾠfrom	 ﾠstructural	 ﾠdata	 ﾠvery	 ﾠlittle	 ﾠis	 ﾠknown	 ﾠabout	 ﾠthe	 ﾠβ-ﾭ‐Liprins.	 ﾠFirstly,	 ﾠβ-ﾭ‐Liprins	 ﾠmay	 ﾠ
act	 ﾠto	 ﾠantagonise	 ﾠthe	 ﾠbiological	 ﾠfunctions	 ﾠof	 ﾠα-ﾭ‐Liprins	 ﾠby	 ﾠmasking	 ﾠprotein-ﾭ‐protein	 ﾠ
interaction	 ﾠdomains	 ﾠduring	 ﾠheterodimerisation.	 ﾠIndeed,	 ﾠstudies	 ﾠindicating	 ﾠthat	 ﾠthe	 ﾠ
C-ﾭ‐terminal	 ﾠSAM	 ﾠdomains	 ﾠalso	 ﾠserve	 ﾠas	 ﾠdocking	 ﾠplatforms	 ﾠfor	 ﾠprotein	 ﾠkinases	 ﾠ(e.g.	 ﾠ
calcium/calmodulin-ﾭ‐dependent	 ﾠserine	 ﾠprotein	 ﾠkinase)	 ﾠand	 ﾠphosphatases	 ﾠ(e.g.	 ﾠLAR,	 ﾠPTPσ	 ﾠ
and	 ﾠPTPδ)	 ﾠsuggest	 ﾠthat	 ﾠthis	 ﾠis	 ﾠa	 ﾠpossibility	 ﾠ[464,	 ﾠ531].	 ﾠAlternatively,	 ﾠheterodimerisation	 ﾠ
might	 ﾠintroduce	 ﾠa	 ﾠconformational	 ﾠchange	 ﾠin	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠcoiled-ﾭ‐coil	 ﾠdomain,	 ﾠthereby	 ﾠ
altering	 ﾠassociation	 ﾠwith	 ﾠproteins	 ﾠsuch	 ﾠas	 ﾠGIT	 ﾠand	 ﾠthe	 ﾠkinesin	 ﾠmotor	 ﾠKIF1A	 ﾠ[531,	 ﾠ532].	 ﾠ
Furthermore,	 ﾠit	 ﾠis	 ﾠalso	 ﾠpossible	 ﾠthat	 ﾠLiprin-ﾭ‐β2	 ﾠmight	 ﾠact	 ﾠto	 ﾠsequester	 ﾠα-ﾭ‐Liprins	 ﾠto	 ﾠimpair	 ﾠits	 ﾠ
function.	 ﾠ	 ﾠChapter 5 – Rab17 and Liprin-β2 are inhibitors of tumour cell migration and invasion  211 
Interestingly,	 ﾠLiprin-ﾭ‐α1	 ﾠis	 ﾠrequired	 ﾠfor	 ﾠthe	 ﾠcorrect	 ﾠsubcellular	 ﾠlocalisation	 ﾠof	 ﾠING4	 ﾠ
(inhibitor	 ﾠof	 ﾠgrowth	 ﾠ4),	 ﾠa	 ﾠsuppressor	 ﾠof	 ﾠcell	 ﾠspreading	 ﾠand	 ﾠcell	 ﾠmigration,	 ﾠwhich	 ﾠimpairs	 ﾠ
actin	 ﾠpolymerisation	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠfront	 ﾠ[533].	 ﾠThus,	 ﾠLiprin-ﾭ‐α1	 ﾠmay	 ﾠrepresent	 ﾠa	 ﾠ
double-ﾭ‐edged	 ﾠsword	 ﾠthat	 ﾠcan	 ﾠeither	 ﾠpromote	 ﾠor	 ﾠinhibit	 ﾠcell	 ﾠmigration	 ﾠdepending	 ﾠon	 ﾠits	 ﾠ
binding	 ﾠpartners.	 ﾠConsistent	 ﾠwith	 ﾠthis	 ﾠidea,	 ﾠa	 ﾠrecent	 ﾠreport	 ﾠidentified	 ﾠLiprin-ﾭ‐α1	 ﾠas	 ﾠan	 ﾠ
inhibitor	 ﾠof	 ﾠcell	 ﾠinvasion	 ﾠin	 ﾠhead	 ﾠand	 ﾠneck	 ﾠsquamous	 ﾠcarcinoma	 ﾠcells	 ﾠ[534].	 ﾠAs	 ﾠLiprin-ﾭ‐β2	 ﾠ
may	 ﾠform	 ﾠa	 ﾠscaffold	 ﾠto	 ﾠorganise	 ﾠα-ﾭ‐Liprins,	 ﾠincreased	 ﾠexpression	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠcould	 ﾠ
promote	 ﾠthe	 ﾠlocalisation	 ﾠof	 ﾠmotility	 ﾠsuppressors	 ﾠat	 ﾠthe	 ﾠcellular	 ﾠfront.	 ﾠThus,	 ﾠdepending	 ﾠon	 ﾠ
the	 ﾠmolecular	 ﾠsignature	 ﾠof	 ﾠthe	 ﾠcell	 ﾠtype	 ﾠLiprin-ﾭ‐β2	 ﾠmay	 ﾠenhance	 ﾠor	 ﾠdecrease	 ﾠcell	 ﾠmotility	 ﾠ
by	 ﾠorganising	 ﾠLiprin-ﾭ‐αs.	 ﾠ
5.3.4  Rab17 and Liprin-β2 - members of the same signalling circuit 
In	 ﾠthis	 ﾠchapter	 ﾠwe	 ﾠshowed	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠwas	 ﾠsufficient	 ﾠto	 ﾠ
restore	 ﾠinvasiveness	 ﾠof	 ﾠERK2-ﾭ‐depleted	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠwhich	 ﾠsuggests	 ﾠthat	 ﾠboth	 ﾠ
proteins	 ﾠare	 ﾠpart	 ﾠof	 ﾠthe	 ﾠsame	 ﾠsignalling	 ﾠcircuit.	 ﾠGiven	 ﾠthat	 ﾠRab17	 ﾠis	 ﾠexpected	 ﾠto	 ﾠregulate	 ﾠ
membrane	 ﾠtrafficking	 ﾠand	 ﾠLiprins	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠcontrol	 ﾠthese	 ﾠprocesses,	 ﾠwe	 ﾠ
would	 ﾠlike	 ﾠto	 ﾠspeculate	 ﾠas	 ﾠto	 ﾠhow	 ﾠthe	 ﾠtwo	 ﾠproteins	 ﾠmay	 ﾠcooperate	 ﾠto	 ﾠinhibit	 ﾠreceptor	 ﾠ
recycling	 ﾠand	 ﾠthereby	 ﾠinhibit	 ﾠcell	 ﾠmigration.	 ﾠ
We	 ﾠpropose	 ﾠa	 ﾠrole	 ﾠfor	 ﾠRab17	 ﾠin	 ﾠvesicle	 ﾠsorting.	 ﾠThus,	 ﾠincreased	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠmay	 ﾠ
either	 ﾠpromote	 ﾠreceptor	 ﾠdegradation,	 ﾠwhich	 ﾠultimately	 ﾠreduces	 ﾠthe	 ﾠamount	 ﾠof	 ﾠrecycled	 ﾠ
receptors,	 ﾠor	 ﾠalter	 ﾠthe	 ﾠrecycling	 ﾠroute	 ﾠfrom	 ﾠa	 ﾠshort	 ﾠto	 ﾠa	 ﾠlong	 ﾠloop.	 ﾠThis	 ﾠmeans	 ﾠthat	 ﾠ
silencing	 ﾠof	 ﾠRab17	 ﾠwould	 ﾠdecrease	 ﾠreceptor	 ﾠdegradation	 ﾠor	 ﾠchange	 ﾠthe	 ﾠrecycling	 ﾠroute,	 ﾠ
and	 ﾠultimately	 ﾠstimulate	 ﾠcell	 ﾠmigration.	 ﾠLiprin-ﾭ‐β2	 ﾠmay	 ﾠeither	 ﾠact	 ﾠupstream	 ﾠor	 ﾠdownstream	 ﾠ
of	 ﾠRab17.	 ﾠOne	 ﾠpossibility	 ﾠis	 ﾠthat	 ﾠthe	 ﾠscaffold	 ﾠcould	 ﾠimpair	 ﾠreceptor	 ﾠclustering	 ﾠat	 ﾠthe	 ﾠ
plasma	 ﾠmembrane,	 ﾠwhich	 ﾠwould	 ﾠresult	 ﾠin	 ﾠa	 ﾠdecrease	 ﾠin	 ﾠendocytosis	 ﾠand	 ﾠdiminish	 ﾠthe	 ﾠ
internal	 ﾠreceptor	 ﾠpool,	 ﾠwhich	 ﾠcan	 ﾠbe	 ﾠrecycled	 ﾠback	 ﾠto	 ﾠthe	 ﾠplasma	 ﾠmembrane.	 ﾠIf	 ﾠthis	 ﾠwas	 ﾠ
true,	 ﾠRNAi	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠwould	 ﾠpromote	 ﾠcell	 ﾠmotility	 ﾠby	 ﾠenhancing	 ﾠendocytosis	 ﾠand	 ﾠthus	 ﾠ
stimulating	 ﾠreceptor	 ﾠcycling.	 ﾠAlternatively,	 ﾠLiprin-ﾭ‐β2	 ﾠmay	 ﾠalso	 ﾠact	 ﾠdownstream	 ﾠof	 ﾠthe	 ﾠ
GTPase.	 ﾠGiven	 ﾠthat	 ﾠLiprins	 ﾠwere	 ﾠshown	 ﾠto	 ﾠrecruit	 ﾠand	 ﾠstabilise	 ﾠsignalling	 ﾠmolecules	 ﾠat	 ﾠthe	 ﾠ
sites	 ﾠof	 ﾠexocytosis,	 ﾠaugmented	 ﾠexpression	 ﾠof	 ﾠLiprin-ﾭ‐β2	 ﾠmay	 ﾠslow	 ﾠthe	 ﾠtrafficking	 ﾠof	 ﾠ
recycling	 ﾠendosomes	 ﾠor	 ﾠimpair	 ﾠfusion	 ﾠevents	 ﾠat	 ﾠthe	 ﾠplasma	 ﾠmembrane	 ﾠ(Figure	 ﾠ5-ﾭ‐12).	 ﾠ
Taken	 ﾠtogether,	 ﾠwe	 ﾠbelieve	 ﾠthat	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠmay	 ﾠchange	 ﾠthe	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dynamics	 ﾠof	 ﾠreceptor	 ﾠrecycling	 ﾠto	 ﾠpromote	 ﾠcell	 ﾠmotility.	 ﾠFuture	 ﾠwork	 ﾠstudying	 ﾠreceptor	 ﾠ
internalisation,	 ﾠrecycling	 ﾠand	 ﾠdegradation	 ﾠwhen	 ﾠeither	 ﾠproteins	 ﾠare	 ﾠdepleted	 ﾠor	 ﾠ
overexpressed	 ﾠshould	 ﾠshed	 ﾠlight	 ﾠon	 ﾠthe	 ﾠsignalling	 ﾠhierarchy	 ﾠand	 ﾠmolecular	 ﾠmechanism	 ﾠ
with	 ﾠwhich	 ﾠboth	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠimpair	 ﾠcell	 ﾠmotility.	 ﾠ
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Figure 5-12 Working paradigm 
Schematic illustration on how Liprin-β2 and Rab17 may cooperate to impair receptor recycling. Liprin-β2 
may act upstream of Rab17 by impairing receptor clustering or internalisation. Alternatively, Liprin-β2 may 
affect receptor recycling by slowing down vesicle trafficking or preventing exocytosis of recycling vesicles. 
Rab17 may act to impair cell motility by either promoting receptor degradation or changing the recycling 
route from a short to a long loop. 
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5.3.5  Rab17 and Liprin-β2 and their potential roles in cancer 
We	 ﾠhave	 ﾠdemonstrated	 ﾠan	 ﾠinhibitory	 ﾠrole	 ﾠfor	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠinvasion	 ﾠ
in	 ﾠthree	 ﾠindependent	 ﾠcarcinoma	 ﾠcell	 ﾠlines,	 ﾠsuggesting	 ﾠthat	 ﾠthis	 ﾠsuppressive	 ﾠfunction	 ﾠmay	 ﾠ
be	 ﾠgenerally	 ﾠapplicable	 ﾠin	 ﾠcancer.	 ﾠIndeed,	 ﾠwhen	 ﾠassessing	 ﾠthe	 ﾠexpression	 ﾠprofile	 ﾠof	 ﾠboth	 ﾠ
proteins	 ﾠin	 ﾠcancer	 ﾠ(using	 ﾠthe	 ﾠoncomine	 ﾠdatabase	 ﾠ[535]),	 ﾠwe	 ﾠfound	 ﾠa	 ﾠfrequent	 ﾠdecrease	 ﾠof	 ﾠ
Rab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠtranscript	 ﾠlevels	 ﾠin	 ﾠtumour	 ﾠtissues	 ﾠ(Figure	 ﾠ5-ﾭ‐13).	 ﾠHowever,	 ﾠchanges	 ﾠin	 ﾠ
mRNA	 ﾠlevels	 ﾠdo	 ﾠnot	 ﾠnecessarily	 ﾠcorrelate	 ﾠwith	 ﾠchanges	 ﾠin	 ﾠrespective	 ﾠprotein	 ﾠlevels	 ﾠ[536].	 ﾠ
Thus,	 ﾠloss	 ﾠof	 ﾠexpression	 ﾠof	 ﾠthese	 ﾠproteins	 ﾠshould	 ﾠideally	 ﾠbe	 ﾠdetermined	 ﾠby	 ﾠ
immunohistochemical	 ﾠprofiling	 ﾠof	 ﾠtissue	 ﾠmicroarrays.	 ﾠYet,	 ﾠthe	 ﾠcurrent	 ﾠlack	 ﾠof	 ﾠantibodies	 ﾠ
recognising	 ﾠthe	 ﾠendogenous	 ﾠprotein	 ﾠprevented	 ﾠus	 ﾠfrom	 ﾠaddressing	 ﾠthis	 ﾠissue.	 ﾠFuture	 ﾠ
studies	 ﾠwill	 ﾠhave	 ﾠto	 ﾠdetermine	 ﾠwhether	 ﾠloss	 ﾠof	 ﾠRab17	 ﾠand/or	 ﾠLiprin-ﾭ‐β2	 ﾠcorrelates	 ﾠwith	 ﾠ
poor	 ﾠprognosis	 ﾠand	 ﾠoverall	 ﾠsurvival	 ﾠand	 ﾠwhether	 ﾠthere	 ﾠare	 ﾠcertain	 ﾠsubtypes	 ﾠof	 ﾠcancer,	 ﾠ
which	 ﾠare	 ﾠmore	 ﾠor	 ﾠless	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠboth	 ﾠproteins.	 ﾠGiven	 ﾠthat	 ﾠRab17	 ﾠis	 ﾠ
highly	 ﾠexpressed	 ﾠin	 ﾠthe	 ﾠkidney	 ﾠand	 ﾠexpression	 ﾠlevels	 ﾠare	 ﾠmarkedly	 ﾠreduced	 ﾠin	 ﾠall	 ﾠkidney	 ﾠ
tumour	 ﾠsamples	 ﾠassessed	 ﾠin	 ﾠthe	 ﾠoncomine	 ﾠdatabase	 ﾠ(Figure	 ﾠ5-ﾭ‐13	 ﾠA),	 ﾠthe	 ﾠGTPase	 ﾠmay	 ﾠplay	 ﾠ
an	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠkidney	 ﾠhomeostasis.	 ﾠ
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Figure 5-13 Expression profiles of Rab17 and Liprin-β2 across various cancer types 
Depicted are mRNA expression profiles of Rab17 (A) and Liprin-β2 (B) across various cancer types, which 
were gathered using the online Oncomine database [535]. Red signifies the gene’s overexpression or copy 
gain, while blue represents the gene’s underexpression or copy loss. Intensity of colour signifies whether the 
gene was in the top 1%, 5%, or 10% of all genes measured. The number in each cell represents the number of 
studies, which met the search criteria as follows fold change ≥1.5, p≤0.05, data type: mRNA and DNA. 
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6  Summary and future directions 
6.1  Final summary 
The	 ﾠERK	 ﾠpathway	 ﾠis	 ﾠhyperactivated	 ﾠin	 ﾠmany	 ﾠhuman	 ﾠcancers	 ﾠas	 ﾠa	 ﾠconsequence	 ﾠof	 ﾠ
increased	 ﾠexpression	 ﾠor	 ﾠactivating	 ﾠmutations	 ﾠof	 ﾠupstream	 ﾠcomponents	 ﾠ[314].	 ﾠAlthough	 ﾠ
the	 ﾠcanonical	 ﾠrole	 ﾠof	 ﾠaberrant	 ﾠERK	 ﾠsignalling	 ﾠis	 ﾠits	 ﾠpositive	 ﾠinfluence	 ﾠon	 ﾠcell	 ﾠsurvival	 ﾠand	 ﾠ
proliferation	 ﾠ[283,	 ﾠ537],	 ﾠmore	 ﾠand	 ﾠmore	 ﾠevidence	 ﾠsuggests	 ﾠa	 ﾠlink	 ﾠbetween	 ﾠthis	 ﾠpathway	 ﾠ
and	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion	 ﾠ[277,	 ﾠ314,	 ﾠ377-ﾭ‐379].	 ﾠGiven	 ﾠthat	 ﾠthe	 ﾠpredominant	 ﾠ
two	 ﾠERK	 ﾠkinases	 ﾠ(ERK1	 ﾠand	 ﾠERK2)	 ﾠare	 ﾠhighly	 ﾠhomologous	 ﾠand	 ﾠhave	 ﾠindistinguishable	 ﾠ
kinase	 ﾠactivities	 ﾠin	 ﾠvitro,	 ﾠboth	 ﾠenzymes	 ﾠwere	 ﾠbelieved	 ﾠto	 ﾠbe	 ﾠredundant	 ﾠand	 ﾠ
interchangeable	 ﾠ[357].	 ﾠ	 ﾠ
To	 ﾠcontrast	 ﾠwith	 ﾠthis	 ﾠview,	 ﾠhere	 ﾠwe	 ﾠshow	 ﾠthat	 ﾠERK2	 ﾠsilencing	 ﾠinhibits	 ﾠinvasive	 ﾠcell	 ﾠ
migration,	 ﾠand	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠERK2	 ﾠ(but	 ﾠnot	 ﾠERK1)	 ﾠrestores	 ﾠthe	 ﾠnormal	 ﾠinvasive	 ﾠ
phenotype;	 ﾠarguing	 ﾠthat	 ﾠtrue	 ﾠfunctional	 ﾠdisparities	 ﾠdo	 ﾠexist	 ﾠbetween	 ﾠthese	 ﾠkinases	 ﾠwhich	 ﾠ
are	 ﾠnot	 ﾠjust	 ﾠa	 ﾠconsequence	 ﾠof	 ﾠdifferent	 ﾠgene	 ﾠdosage.	 ﾠA	 ﾠdetailed	 ﾠquantitative	 ﾠanalysis	 ﾠof	 ﾠ
cell	 ﾠmovement	 ﾠon	 ﾠ3D	 ﾠmatrices	 ﾠrevealed	 ﾠthat	 ﾠERK2	 ﾠdepletion	 ﾠimpairs	 ﾠcellular	 ﾠmotility	 ﾠby	 ﾠ
decreasing	 ﾠthe	 ﾠmigration	 ﾠvelocity	 ﾠas	 ﾠwell	 ﾠas	 ﾠincreasing	 ﾠthe	 ﾠtime	 ﾠthat	 ﾠcells	 ﾠremain	 ﾠ
stationary	 ﾠ(cellular	 ﾠresting).	 ﾠThus,	 ﾠinvasiveness	 ﾠof	 ﾠcancer	 ﾠcells	 ﾠis	 ﾠdirectly	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠ
speed	 ﾠwith	 ﾠwhich	 ﾠthe	 ﾠmigration	 ﾠmachinery	 ﾠpropels	 ﾠthe	 ﾠcell	 ﾠforward	 ﾠand	 ﾠthe	 ﾠability	 ﾠof	 ﾠcells	 ﾠ
to	 ﾠretain	 ﾠa	 ﾠmotile	 ﾠphenotype.	 ﾠ	 ﾠ
To	 ﾠsearch	 ﾠfor	 ﾠERK2-ﾭ‐specific	 ﾠeffectors,	 ﾠwhich	 ﾠinfluence	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion,	 ﾠwe	 ﾠ
performed	 ﾠa	 ﾠmicroarray	 ﾠstudy	 ﾠusing	 ﾠthe	 ﾠrescue	 ﾠparadigm	 ﾠas	 ﾠan	 ﾠexperimental	 ﾠset-ﾭ‐up.	 ﾠ
Interestingly,	 ﾠknockdown	 ﾠof	 ﾠERK2	 ﾠaltered	 ﾠthe	 ﾠexpression	 ﾠof	 ﾠa	 ﾠlarge	 ﾠnumber	 ﾠof	 ﾠgenes,	 ﾠand	 ﾠ
in	 ﾠmost	 ﾠcases	 ﾠexpression	 ﾠof	 ﾠthese	 ﾠwas	 ﾠrestored	 ﾠto	 ﾠnormal	 ﾠlevels	 ﾠby	 ﾠectopic	 ﾠexpression	 ﾠof	 ﾠ
either	 ﾠERK1	 ﾠor	 ﾠ-ﾭ‐2.	 ﾠHowever,	 ﾠwe	 ﾠidentified	 ﾠa	 ﾠsubset	 ﾠof	 ﾠ27	 ﾠgenes	 ﾠwhose	 ﾠexpression	 ﾠwas	 ﾠ
altered	 ﾠby	 ﾠknockdown	 ﾠof	 ﾠERK2,	 ﾠbut	 ﾠrestored	 ﾠto	 ﾠnormal	 ﾠlevels	 ﾠfollowing	 ﾠre-ﾭ‐expression	 ﾠof	 ﾠ
siRNA-ﾭ‐resistant	 ﾠERK2	 ﾠbut	 ﾠnot	 ﾠERK1.	 ﾠProminent	 ﾠamongst	 ﾠthese	 ﾠwere	 ﾠCSF2	 ﾠ(reduced	 ﾠ
expression	 ﾠfollowing	 ﾠERK2	 ﾠdepletion),	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠ(increased	 ﾠexpression	 ﾠ
following	 ﾠERK2	 ﾠdepletion),	 ﾠwhich	 ﾠwe	 ﾠvalidated	 ﾠby	 ﾠqRT-ﾭ‐PCR.	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠplay	 ﾠ
inhibitory	 ﾠroles	 ﾠin	 ﾠthe	 ﾠinvasive	 ﾠbehaviour	 ﾠof	 ﾠthree	 ﾠindependent	 ﾠcancer	 ﾠcell	 ﾠlines.	 ﾠ
Importantly,	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠrestores	 ﾠinvasiveness	 ﾠof	 ﾠ
ERK2-ﾭ‐depleted	 ﾠcells,	 ﾠindicating	 ﾠthat	 ﾠERK2	 ﾠdrives	 ﾠinvasion	 ﾠof	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells	 ﾠby	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suppressing	 ﾠexpression	 ﾠof	 ﾠthese	 ﾠgenes.	 ﾠGiven	 ﾠthat	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠare	 ﾠindirect	 ﾠ
effectors	 ﾠof	 ﾠERK2	 ﾠand	 ﾠsilencing	 ﾠof	 ﾠCSF2	 ﾠinduces	 ﾠtranscription	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2,	 ﾠwe	 ﾠ
propose	 ﾠa	 ﾠmodel	 ﾠin	 ﾠwhich	 ﾠERK2	 ﾠdrives	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠby	 ﾠpromoting	 ﾠCSF2	 ﾠ
transcription	 ﾠand	 ﾠtranslation,	 ﾠwhich	 ﾠin	 ﾠturn	 ﾠsuppresses	 ﾠexpression	 ﾠof	 ﾠthe	 ﾠmotility	 ﾠ
inhibitors	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠ(Figure	 ﾠ6-ﾭ‐1).	 ﾠ
6.2  Future directions 
The	 ﾠidentification	 ﾠof	 ﾠtrue	 ﾠfunctional	 ﾠdifferences	 ﾠbetween	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠposes	 ﾠmany	 ﾠ
open	 ﾠquestions	 ﾠwith	 ﾠregard	 ﾠto	 ﾠtumourigenesis	 ﾠand	 ﾠwe	 ﾠwould	 ﾠlike	 ﾠto	 ﾠdiscuss	 ﾠthe	 ﾠones	 ﾠwe	 ﾠ
believe	 ﾠto	 ﾠbe	 ﾠmost	 ﾠpressing.	 ﾠFirstly,	 ﾠdo	 ﾠtheir	 ﾠfunctional	 ﾠdifferences	 ﾠarise	 ﾠfrom	 ﾠdistinct	 ﾠ
substrate	 ﾠprofiles	 ﾠbetween	 ﾠthe	 ﾠtwo	 ﾠkinases	 ﾠor	 ﾠdo	 ﾠthey	 ﾠbind	 ﾠto	 ﾠthe	 ﾠsame	 ﾠsubstrates	 ﾠwith	 ﾠ
differing	 ﾠbinding	 ﾠaffinities?	 ﾠTo	 ﾠanswer	 ﾠthese	 ﾠquestions	 ﾠit	 ﾠwould	 ﾠbe	 ﾠnecessary	 ﾠto	 ﾠcompare	 ﾠ
the	 ﾠrespective	 ﾠinteractomes	 ﾠof	 ﾠERK1	 ﾠand	 ﾠERK2	 ﾠusing	 ﾠSILAC	 ﾠ(stable	 ﾠisotope	 ﾠlabelling	 ﾠwith	 ﾠ
amino	 ﾠacids	 ﾠin	 ﾠcell	 ﾠculture)	 ﾠmass	 ﾠspectrometry.	 ﾠHowever,	 ﾠa	 ﾠmeaningful	 ﾠcomparison	 ﾠof	 ﾠ
ERK1	 ﾠand	 ﾠERK2	 ﾠsubstrate	 ﾠprofiles	 ﾠrequires	 ﾠthe	 ﾠsame	 ﾠamount	 ﾠof	 ﾠbait	 ﾠprotein,	 ﾠwhich	 ﾠon	 ﾠan	 ﾠ
endogenous	 ﾠlevel	 ﾠis	 ﾠdifficult	 ﾠto	 ﾠachieve	 ﾠdue	 ﾠto	 ﾠdifferent	 ﾠexpression	 ﾠlevels	 ﾠof	 ﾠERK1	 ﾠand	 ﾠ
ERK2.	 ﾠThus,	 ﾠwe	 ﾠpropose	 ﾠusing	 ﾠa	 ﾠcombination	 ﾠof	 ﾠmass	 ﾠspectrometry	 ﾠand	 ﾠthe	 ﾠrescue	 ﾠ
paradigm	 ﾠthat	 ﾠwe	 ﾠhave	 ﾠdeveloped	 ﾠfor	 ﾠthe	 ﾠpresent	 ﾠstudy.	 ﾠAs	 ﾠboth	 ﾠconstructs	 ﾠare	 ﾠtagged,	 ﾠ
recombinant	 ﾠkinases	 ﾠcould	 ﾠbe	 ﾠimmunoprecipitated	 ﾠusing	 ﾠFLAG-ﾭ‐beads,	 ﾠthus	 ﾠavoiding	 ﾠ
problems	 ﾠarising	 ﾠfrom	 ﾠdifferent	 ﾠexpression	 ﾠlevels	 ﾠand	 ﾠcircumventing	 ﾠthe	 ﾠlimitation	 ﾠof	 ﾠ
there	 ﾠcurrently	 ﾠbeing	 ﾠno	 ﾠsuitable	 ﾠantibody	 ﾠfor	 ﾠimmunoprecipitation	 ﾠof	 ﾠendogenous	 ﾠERK2.	 ﾠ
The	 ﾠpresent	 ﾠwork	 ﾠhas	 ﾠidentified	 ﾠan	 ﾠERK2-ﾭ‐specific	 ﾠexpression	 ﾠprofile	 ﾠand	 ﾠsuggests	 ﾠERK2	 ﾠas	 ﾠ
a	 ﾠregulator	 ﾠof	 ﾠtranscriptional	 ﾠand	 ﾠtranslational	 ﾠevents.	 ﾠIntriguingly,	 ﾠERK2	 ﾠhas	 ﾠrecently	 ﾠ
been	 ﾠidentified	 ﾠas	 ﾠan	 ﾠunconventional	 ﾠDNA-ﾭ‐binding	 ﾠprotein,	 ﾠwhich	 ﾠcan	 ﾠdirectly	 ﾠbind	 ﾠto	 ﾠa	 ﾠ
G/CAAAG/C	 ﾠconsensus	 ﾠmotif	 ﾠ[468].	 ﾠOur	 ﾠdata	 ﾠraise	 ﾠthe	 ﾠquestion	 ﾠwhether	 ﾠthis	 ﾠis	 ﾠunique	 ﾠto	 ﾠ
ERK2	 ﾠand	 ﾠif	 ﾠso,	 ﾠwhether	 ﾠthis	 ﾠmight	 ﾠinduce	 ﾠexpression	 ﾠof	 ﾠERK2-ﾭ‐specific	 ﾠgenes,	 ﾠsuch	 ﾠas	 ﾠcsf2.	 ﾠ
ERK1	 ﾠbinding	 ﾠto	 ﾠthe	 ﾠG/CAAG/C	 ﾠmotif	 ﾠcan	 ﾠbe	 ﾠinvestigated	 ﾠby	 ﾠelectromobility	 ﾠshift	 ﾠassays	 ﾠin	 ﾠ
vitro	 ﾠand	 ﾠchromatin	 ﾠimmunoprecipitation	 ﾠin	 ﾠvivo.	 ﾠIf	 ﾠboth	 ﾠERK	 ﾠisoforms	 ﾠwere	 ﾠable	 ﾠto	 ﾠbind	 ﾠ
to	 ﾠDNA,	 ﾠit	 ﾠwould	 ﾠalso	 ﾠbe	 ﾠinteresting	 ﾠto	 ﾠcompare	 ﾠgenome-ﾭ‐wide	 ﾠDNA	 ﾠbinding	 ﾠsites	 ﾠusing	 ﾠ
chromatin	 ﾠimmunoprecipitation	 ﾠsequencing	 ﾠ(ChIP-ﾭ‐Seq).	 ﾠAdditionally,	 ﾠone	 ﾠcould	 ﾠ	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Figure 6-1 Working model demonstrating how ERK2 drives invasive cell migration 
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investigate	 ﾠwhether	 ﾠERK2	 ﾠrecruits	 ﾠtranscription	 ﾠfactors	 ﾠto	 ﾠthe	 ﾠpromoter	 ﾠregions	 ﾠit	 ﾠbinds,	 ﾠ
and	 ﾠthereby	 ﾠcontrols	 ﾠtranscriptional	 ﾠevents.	 ﾠ	 ﾠ
Given	 ﾠthe	 ﾠpublished	 ﾠrole	 ﾠof	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠregion	 ﾠof	 ﾠERK1	 ﾠin	 ﾠcontrolling	 ﾠnuclear	 ﾠshuttling	 ﾠ
frequencies,	 ﾠwhich	 ﾠin	 ﾠturn	 ﾠmay	 ﾠinfluence	 ﾠits	 ﾠcapacity	 ﾠto	 ﾠregulate	 ﾠtranscription,	 ﾠit	 ﾠwould	 ﾠbe	 ﾠ
interesting	 ﾠto	 ﾠdetermine	 ﾠwhether	 ﾠERK2’s	 ﾠfunction	 ﾠin	 ﾠdriving	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠcould	 ﾠ
be	 ﾠlocalised	 ﾠto	 ﾠa	 ﾠspecific	 ﾠdomain	 ﾠof	 ﾠthe	 ﾠkinases,	 ﾠsuch	 ﾠas	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠdomain.	 ﾠThis	 ﾠcould	 ﾠ
be	 ﾠachieved	 ﾠby	 ﾠgenerating	 ﾠERK	 ﾠchimeras	 ﾠand	 ﾠperforming	 ﾠrescue	 ﾠexperiments.	 ﾠIndeed,	 ﾠwe	 ﾠ
have	 ﾠalready	 ﾠmade	 ﾠtwo	 ﾠchimeras,	 ﾠone	 ﾠcontaining	 ﾠthe	 ﾠN-ﾭ‐terminal	 ﾠregion	 ﾠof	 ﾠERK2	 ﾠfused	 ﾠto	 ﾠ
the	 ﾠC-ﾭ‐terminal	 ﾠportion	 ﾠof	 ﾠERK1	 ﾠ(E2>E1)	 ﾠand	 ﾠanother	 ﾠcorresponding	 ﾠchimera	 ﾠof	 ﾠthe	 ﾠ
N-ﾭ‐terminal	 ﾠregion	 ﾠof	 ﾠERK1	 ﾠfused	 ﾠto	 ﾠthe	 ﾠC-ﾭ‐terminal	 ﾠportion	 ﾠof	 ﾠERK2	 ﾠ(E1>E2).	 ﾠWhen	 ﾠboth	 ﾠ
chimeras	 ﾠwere	 ﾠexpressed	 ﾠto	 ﾠsimilar	 ﾠlevels	 ﾠon	 ﾠan	 ﾠERK2	 ﾠknockdown	 ﾠbackground,	 ﾠboth	 ﾠwere	 ﾠ
similarly	 ﾠphosphorylated	 ﾠat	 ﾠthe	 ﾠTEY	 ﾠmotif,	 ﾠsuggesting	 ﾠan	 ﾠintact	 ﾠtertiary	 ﾠstructure	 ﾠ(data	 ﾠnot	 ﾠ
shown).	 ﾠAnalysis	 ﾠof	 ﾠcell	 ﾠmigration	 ﾠon	 ﾠCDM	 ﾠindicated	 ﾠthat	 ﾠalthough	 ﾠexpression	 ﾠof	 ﾠE1>E2	 ﾠ
restored	 ﾠthe	 ﾠmigratory	 ﾠdefects	 ﾠcaused	 ﾠby	 ﾠERK2	 ﾠknockdown,	 ﾠE2>E1	 ﾠwas	 ﾠineffective	 ﾠin	 ﾠthis	 ﾠ
regard	 ﾠ(data	 ﾠnot	 ﾠshown).	 ﾠThese	 ﾠdata	 ﾠindicate	 ﾠthat	 ﾠthe	 ﾠinformation	 ﾠconferring	 ﾠERK2’s	 ﾠ
capacity	 ﾠto	 ﾠdrive	 ﾠmigration	 ﾠis	 ﾠnot	 ﾠlocated	 ﾠwithin	 ﾠthe	 ﾠdivergent	 ﾠN-ﾭ‐terminal	 ﾠportion	 ﾠof	 ﾠthe	 ﾠ
kinase.	 ﾠHowever,	 ﾠthere	 ﾠare	 ﾠother	 ﾠregions	 ﾠof	 ﾠsignificant	 ﾠdivergences	 ﾠbetween	 ﾠERK1	 ﾠand	 ﾠ
ERK2	 ﾠ(for	 ﾠexample	 ﾠa	 ﾠ20	 ﾠamino	 ﾠacid	 ﾠregion	 ﾠclose	 ﾠto	 ﾠthe	 ﾠC-ﾭ‐terminus)	 ﾠand	 ﾠfuture	 ﾠwork	 ﾠwill	 ﾠbe	 ﾠ
necessary	 ﾠto	 ﾠevaluate	 ﾠtheir	 ﾠrole	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠmigration	 ﾠand	 ﾠinvasion.	 ﾠ	 ﾠ
Our	 ﾠgene	 ﾠexpression	 ﾠdata	 ﾠsuggests	 ﾠa	 ﾠrole	 ﾠfor	 ﾠERK2	 ﾠin	 ﾠstabilising	 ﾠand	 ﾠdestabilising	 ﾠmRNA	 ﾠ
transcripts.	 ﾠSo	 ﾠfar,	 ﾠERK	 ﾠhas	 ﾠonly	 ﾠbeen	 ﾠimplicated	 ﾠin	 ﾠregulating	 ﾠthe	 ﾠdestabilising	 ﾠfactor	 ﾠ
tristetraprolin	 ﾠpost-ﾭ‐translationally	 ﾠ[476,	 ﾠ477].	 ﾠYet,	 ﾠERK2	 ﾠis	 ﾠlikely	 ﾠto	 ﾠphosphorylate	 ﾠother	 ﾠ
RNA-ﾭ‐binding	 ﾠproteins	 ﾠand	 ﾠfuture	 ﾠwork	 ﾠwill	 ﾠhave	 ﾠto	 ﾠinvestigate	 ﾠthis.	 ﾠIt	 ﾠis	 ﾠpossible	 ﾠthat	 ﾠour	 ﾠ
microarray	 ﾠdata	 ﾠhold	 ﾠinformation	 ﾠwhich	 ﾠcould	 ﾠbe	 ﾠused	 ﾠto	 ﾠidentify	 ﾠnovel	 ﾠERK2-ﾭ‐regulated	 ﾠ
RNA-ﾭ‐stabilising	 ﾠor	 ﾠdestabilising	 ﾠfactors.	 ﾠBy	 ﾠcomparing	 ﾠthe	 ﾠ5ˊ	 ﾠand	 ﾠ3ˊ	 ﾠUTRs	 ﾠof	 ﾠour	 ﾠ
ERK2-ﾭ‐regulated	 ﾠgenes	 ﾠwe	 ﾠhope	 ﾠto	 ﾠidentify	 ﾠknown	 ﾠregulatory	 ﾠelements	 ﾠinvolved	 ﾠin	 ﾠthe	 ﾠ
recruitment	 ﾠof	 ﾠRNA-ﾭ‐binding	 ﾠproteins.	 ﾠIn	 ﾠfollow-ﾭ‐up	 ﾠstudies,	 ﾠwe	 ﾠwould	 ﾠlike	 ﾠto	 ﾠtest	 ﾠwhether	 ﾠ
these	 ﾠstabilising	 ﾠor	 ﾠdestabilising	 ﾠfactor	 ﾠwere	 ﾠregulated	 ﾠby	 ﾠthe	 ﾠERK-ﾭ‐MAPK	 ﾠpathway	 ﾠand	 ﾠ
whether	 ﾠthis	 ﾠwas	 ﾠlinked	 ﾠto	 ﾠthe	 ﾠgene	 ﾠexpression	 ﾠsignature	 ﾠwe	 ﾠobserved	 ﾠin	 ﾠthis	 ﾠpresent	 ﾠ
study.	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One	 ﾠof	 ﾠthe	 ﾠstrengths	 ﾠof	 ﾠthis	 ﾠstudy	 ﾠis	 ﾠthe	 ﾠidentification	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠas	 ﾠERK	 ﾠ
targets	 ﾠthat	 ﾠare	 ﾠnovel	 ﾠmotility	 ﾠsuppressors.	 ﾠThe	 ﾠfact	 ﾠthat	 ﾠinvasiveness	 ﾠof	 ﾠthree	 ﾠ
independent	 ﾠcell	 ﾠlines	 ﾠis	 ﾠaugmented	 ﾠfollowing	 ﾠknockdown	 ﾠof	 ﾠeither	 ﾠof	 ﾠthese	 ﾠproteins,	 ﾠ
suggests	 ﾠthat	 ﾠtheir	 ﾠfunction	 ﾠin	 ﾠinhibiting	 ﾠcell	 ﾠmigration	 ﾠis	 ﾠgenerally	 ﾠapplicable.	 ﾠHowever,	 ﾠ
whether	 ﾠor	 ﾠnot	 ﾠloss	 ﾠof	 ﾠRab17	 ﾠand/or	 ﾠLiprin-ﾭ‐β2	 ﾠexpression	 ﾠis	 ﾠa	 ﾠgeneral	 ﾠphenomenon	 ﾠduring	 ﾠ
tumourigenesis	 ﾠwill	 ﾠhave	 ﾠto	 ﾠbe	 ﾠexamined	 ﾠby	 ﾠimmunohistochemical	 ﾠstaining	 ﾠof	 ﾠvarious	 ﾠ
cancer	 ﾠtissues.	 ﾠTo	 ﾠdate,	 ﾠwe	 ﾠdo	 ﾠnot	 ﾠknow	 ﾠhow	 ﾠERK2	 ﾠsuppresses	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠin	 ﾠ
MDA-ﾭ‐MB-ﾭ‐231	 ﾠcells,	 ﾠbut	 ﾠthe	 ﾠrate	 ﾠat	 ﾠwhich	 ﾠthey	 ﾠare	 ﾠupregulated	 ﾠfollowing	 ﾠERK	 ﾠinhibition,	 ﾠ
suggests	 ﾠthat	 ﾠthe	 ﾠrab17	 ﾠand	 ﾠliprin	 ﾠβ2	 ﾠgenes	 ﾠare	 ﾠtargeted	 ﾠindirectly.	 ﾠMoreover,	 ﾠsilencing	 ﾠof	 ﾠ
ERK2	 ﾠin	 ﾠA2780-ﾭ‐Rab25	 ﾠcells	 ﾠdoes	 ﾠnot	 ﾠalter	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠ(data	 ﾠnot	 ﾠ
shown),	 ﾠindicating	 ﾠthat	 ﾠERK2	 ﾠdrives	 ﾠtumour	 ﾠcell	 ﾠinvasion	 ﾠdifferently	 ﾠin	 ﾠthese	 ﾠcells	 ﾠand	 ﾠthat	 ﾠ
the	 ﾠlink	 ﾠbetween	 ﾠRab17/Liprin-ﾭ‐β2	 ﾠand	 ﾠERK2	 ﾠis	 ﾠnot	 ﾠgenerally	 ﾠapplicable.	 ﾠThe	 ﾠcurrent	 ﾠ
literature	 ﾠsuggests	 ﾠa	 ﾠrole	 ﾠfor	 ﾠboth	 ﾠproteins	 ﾠin	 ﾠreceptor	 ﾠtrafficking,	 ﾠyet	 ﾠthe	 ﾠmolecular	 ﾠ
mechanism	 ﾠby	 ﾠwhich	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠreduce	 ﾠtumour	 ﾠcell	 ﾠmotility	 ﾠwill	 ﾠhave	 ﾠto	 ﾠbe	 ﾠ
elucidated	 ﾠin	 ﾠthe	 ﾠfuture.	 ﾠFirstly,	 ﾠwhat	 ﾠare	 ﾠthe	 ﾠbiological	 ﾠfunctions	 ﾠof	 ﾠboth	 ﾠproteins?	 ﾠWhat	 ﾠ
drives	 ﾠand	 ﾠsuppresses	 ﾠexpression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2?	 ﾠMoreover,	 ﾠwhat	 ﾠare	 ﾠthe	 ﾠmain	 ﾠ
interacting	 ﾠpartners	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2?	 ﾠDo	 ﾠboth	 ﾠproteins	 ﾠimpair	 ﾠreceptor	 ﾠ
internalisation	 ﾠor	 ﾠrecycling?	 ﾠAlternatively,	 ﾠdo	 ﾠthey	 ﾠpromote	 ﾠreceptor	 ﾠdegradation?	 ﾠWhat	 ﾠ
is	 ﾠthe	 ﾠcargo	 ﾠof	 ﾠRab17-ﾭ‐positive	 ﾠvesicles	 ﾠand	 ﾠwhat	 ﾠis	 ﾠits	 ﾠfunction	 ﾠin	 ﾠtumour	 ﾠcell	 ﾠmigration?	 ﾠ
Future	 ﾠstudies	 ﾠmay	 ﾠwant	 ﾠto	 ﾠdetermine	 ﾠthe	 ﾠinteractome	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠusing	 ﾠmass	 ﾠ
spectrometry.	 ﾠGiven	 ﾠthat	 ﾠthe	 ﾠcommercial	 ﾠantibodies	 ﾠwe	 ﾠhave	 ﾠtested	 ﾠdid	 ﾠnot	 ﾠrecognise	 ﾠ
endogenous	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠwe	 ﾠsuggest	 ﾠoverexpression	 ﾠof	 ﾠthe	 ﾠtagged	 ﾠproteins	 ﾠwhich	 ﾠ
can	 ﾠbe	 ﾠimmunoprecipitated	 ﾠusing	 ﾠa	 ﾠGFP	 ﾠantibody.	 ﾠTo	 ﾠshine	 ﾠlight	 ﾠon	 ﾠhow	 ﾠRab17	 ﾠsignalling	 ﾠ
suppresses	 ﾠtumour	 ﾠcell	 ﾠmotility,	 ﾠit	 ﾠwould	 ﾠbe	 ﾠinteresting	 ﾠto	 ﾠinvestigate	 ﾠif	 ﾠknockdown	 ﾠor	 ﾠ
overexpression	 ﾠof	 ﾠRab17	 ﾠchanges	 ﾠthe	 ﾠsurface	 ﾠproteome	 ﾠusing	 ﾠsurface	 ﾠlabelling	 ﾠ
approaches	 ﾠfollowed	 ﾠby	 ﾠquantitative	 ﾠmass	 ﾠspectrometry.	 ﾠMoreover,	 ﾠone	 ﾠcould	 ﾠdevelop	 ﾠ
new	 ﾠtechniques	 ﾠbased	 ﾠon	 ﾠthe	 ﾠuse	 ﾠof	 ﾠcleavable	 ﾠsurface-ﾭ‐labelling	 ﾠreagents	 ﾠto	 ﾠmeasure	 ﾠ
changes	 ﾠin	 ﾠthe	 ﾠinternalome	 ﾠ(all	 ﾠof	 ﾠthe	 ﾠinternalised	 ﾠsurface	 ﾠproteins)	 ﾠand	 ﾠrecyclome	 ﾠ(all	 ﾠof	 ﾠ
the	 ﾠrecycled	 ﾠproteins),	 ﾠwhich	 ﾠmay	 ﾠgive	 ﾠinsight	 ﾠon	 ﾠtrafficking	 ﾠevents	 ﾠregulated	 ﾠby	 ﾠRab17.	 ﾠ	 ﾠ
In	 ﾠconclusion,	 ﾠthis	 ﾠstudy	 ﾠhas	 ﾠidentified	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠas	 ﾠnovel	 ﾠinhibitors	 ﾠof	 ﾠcell	 ﾠ
motility	 ﾠwhose	 ﾠexpression	 ﾠis	 ﾠregulated	 ﾠby	 ﾠERK2	 ﾠin	 ﾠMDA-ﾭ‐MB-ﾭ‐231	 ﾠcells.	 ﾠMoreover,	 ﾠwe	 ﾠhave	 ﾠ
demonstrated	 ﾠthat	 ﾠsuppression	 ﾠof	 ﾠeither	 ﾠRab17	 ﾠor	 ﾠLiprin-ﾭ‐β2	 ﾠcan	 ﾠcompletely	 ﾠcompensate	 ﾠ
for	 ﾠloss	 ﾠof	 ﾠERK2.	 ﾠThus,	 ﾠwe	 ﾠpropose	 ﾠone	 ﾠway	 ﾠfor	 ﾠERK2	 ﾠto	 ﾠdrive	 ﾠinvasiveness	 ﾠis	 ﾠby	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suppressing	 ﾠRab17	 ﾠand/or	 ﾠLiprin-ﾭ‐β2.	 ﾠThe	 ﾠpotential	 ﾠfor	 ﾠinhibitors	 ﾠof	 ﾠthe	 ﾠMAPK	 ﾠpathway	 ﾠto	 ﾠ
be	 ﾠused	 ﾠas	 ﾠanticancer	 ﾠagents	 ﾠis	 ﾠnow	 ﾠbeing	 ﾠassessed	 ﾠin	 ﾠthe	 ﾠclinic,	 ﾠand	 ﾠour	 ﾠfinding	 ﾠthat	 ﾠ
ERK2-ﾭ‐mediated	 ﾠsuppression	 ﾠof	 ﾠRab17	 ﾠand	 ﾠLiprin-ﾭ‐β2	 ﾠdrives	 ﾠcancer	 ﾠinvasiveness	 ﾠwill	 ﾠbe	 ﾠ
important	 ﾠin	 ﾠthe	 ﾠinterpretation	 ﾠof	 ﾠdata	 ﾠfrom	 ﾠthese	 ﾠstudies.222 
List of references 
1.  Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 
57-70. 
2.  Kinzler, K.W. and B. Vogelstein, Lessons from hereditary colorectal cancer. Cell, 
1996. 87(2): p. 159-70. 
3.  Bergers, G., D. Hanahan, and L.M. Coussens, Angiogenesis and apoptosis are 
cellular parameters of neoplastic progression in transgenic mouse models of 
tumorigenesis. Int J Dev Biol, 1998. 42(7): p. 995-1002. 
4.  Bergers, G., et al., Effects of angiogenesis inhibitors on multistage carcinogenesis 
in mice. Science, 1999. 284(5415): p. 808-12. 
5.  Foulds, L., The Experimental Study of Tumor Progression. Vol. I-III. 1954: 
London: Academic Press. 
6.  Weinberg, R.A., The Nature of Cancer, in The Biology of Cancer. 2007, Garland 
Science, Taylor & Francis group. p. 24. 
7.  Weinberg, R.A., The Nature of Cancer, in The Biology of Cancer. 2007, Garland 
Science, Taylor & Francis group. p. 28-35. 
8.  Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 
2011. 144(5): p. 646-74. 
9.  Colotta, F., et al., Cancer-related inflammation, the seventh hallmark of cancer: 
links to genetic instability. Carcinogenesis, 2009. 30(7): p. 1073-81. 
10.  Tennant, D.A., et al., Metabolic transformation in cancer. Carcinogenesis, 2009. 
30(8): p. 1269-80. 
11.  Wilczynski, J.R. and M. Duechler, How do tumors actively escape from host 
immunosurveillance? Arch Immunol Ther Exp (Warsz), 2010. 58(6): p. 435-48. 
12.  Leber, M.F. and T. Efferth, Molecular principles of cancer invasion and metastasis 
(review). Int J Oncol, 2009. 34(4): p. 881-95. 
13.  Mareel, M., M.J. Oliveira, and I. Madani, Cancer invasion and metastasis: 
interacting ecosystems. Virchows Arch, 2009. 454(6): p. 599-622. 
14.  Christofori, G. and H. Semb, The role of the cell-adhesion molecule E-cadherin as 
a tumour-suppressor gene. Trends Biochem Sci, 1999. 24(2): p. 73-6. 
15.  Hazan, R.B., et al., N-cadherin promotes adhesion between invasive breast cancer 
cells and the stroma. Cell Adhes Commun, 1997. 4(6): p. 399-411. 
16.  Kawamura-Kodama, K., et al., N-cadherin expressed on malignant T cell 
lymphoma cells is functional, and promotes heterotypic adhesion between the 
lymphoma cells and mesenchymal cells expressing N-cadherin. J Invest Dermatol, 
1999. 112(1): p. 62-6. 
17.  Coussens, L.M. and Z. Werb, Matrix metalloproteinases and the development of 
cancer. Chem Biol, 1996. 3(11): p. 895-904. 
18.  Smets, F.N., et al., Loss of cell anchorage triggers apoptosis (anoikis) in primary 
mouse hepatocytes. Mol Genet Metab, 2002. 75(4): p. 344-52. 
19.  Bromberg, M.E., et al., Role of tissue factor in metastasis: functions of the 
cytoplasmic and extracellular domains of the molecule. Thromb Haemost, 1999. 
82(1): p. 88-92. 
20.  Semeraro, N. and M. Colucci, Tissue factor in health and disease. Thromb 
Haemost, 1997. 78(1): p. 759-64. 
21.  Mueller, B.M., et al., Expression of tissue factor by melanoma cells promotes 
efficient hematogenous metastasis. Proc Natl Acad Sci U S A, 1992. 89(24): p. 
11832-6. 
22.  Enns, A., et al., Integrins can directly mediate metastatic tumor cell adhesion 
within the liver sinusoids. J Gastrointest Surg, 2004. 8(8): p. 1049-59; discussion 
1060. 223 
23.  Enns, A., et al., Alphavbeta5-integrins mediate early steps of metastasis formation. 
Eur J Cancer, 2005. 41(7): p. 1065-72. 
24.  Rinker-Schaeffer, C.W., et al., Metastasis suppressor proteins: discovery, 
molecular mechanisms, and clinical application. Clin Cancer Res, 2006. 12(13): p. 
3882-9. 
25.  Steeg, P.S., et al., Evidence for a novel gene associated with low tumor metastatic 
potential. J Natl Cancer Inst, 1988. 80(3): p. 200-4. 
26.  Steeg, P.S., et al., Altered expression of NM23, a gene associated with low tumor 
metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. 
Cancer Res, 1988. 48(22): p. 6550-4. 
27.  Lauffenburger, D.A. and A.F. Horwitz, Cell migration: a physically integrated 
molecular process. Cell, 1996. 84(3): p. 359-69. 
28.  Pankov, R., et al., A Rac switch regulates random versus directionally persistent 
cell migration. J Cell Biol, 2005. 170(5): p. 793-802. 
29.  Friedl, P. and B. Weigelin, Interstitial leukocyte migration and immune function. 
Nat Immunol, 2008. 9(9): p. 960-9. 
30.  Giebel, B., et al., Segregation of lipid raft markers including CD133 in polarized 
human hematopoietic stem and progenitor cells. Blood, 2004. 104(8): p. 2332-8. 
31.  Biname, F., et al., What makes cells move: requirements and obstacles for 
spontaneous cell motility. Mol Biosyst, 2010. 6(4): p. 648-61. 
32.  Friedl, P., et al., CD4+ T lymphocytes migrating in three-dimensional collagen 
lattices lack focal adhesions and utilize beta1 integrin-independent strategies for 
polarization, interaction with collagen fibers and locomotion. Eur J Immunol, 
1998. 28(8): p. 2331-43. 
33.  Brakebusch, C., et al., Beta1 integrin is not essential for hematopoiesis but is 
necessary for the T cell-dependent IgM antibody response. Immunity, 2002. 16(3): 
p. 465-77. 
34.  Sahai, E. and C.J. Marshall, Differing modes of tumour cell invasion have distinct 
requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell 
Biol, 2003. 5(8): p. 711-9. 
35.  Friedl, P. and K. Wolf, Tumour-cell invasion and migration: diversity and escape 
mechanisms. Nat Rev Cancer, 2003. 3(5): p. 362-74. 
36.  Falcioni, R., et al., Expression of beta 1, beta 3, beta 4, and beta 5 integrins by 
human lung carcinoma cells of different histotypes. Exp Cell Res, 1994. 210(1): p. 
113-22. 
37.  Jaspars, L.H., et al., Extracellular matrix and beta 1 integrin expression in nodal 
and extranodal T-cell lymphomas. J Pathol, 1996. 178(1): p. 36-43. 
38.  Cukierman, E., et al., Taking cell-matrix adhesions to the third dimension. Science, 
2001. 294(5547): p. 1708-12. 
39.  Maaser, K., et al., Functional hierarchy of simultaneously expressed adhesion 
receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell 
migration and matrix reorganization within three-dimensional hyaluronan-
containing collagen matrices. Mol Biol Cell, 1999. 10(10): p. 3067-79. 
40.  Friedl, P., Prespecification and plasticity: shifting mechanisms of cell migration. 
Curr Opin Cell Biol, 2004. 16(1): p. 14-23. 
41.  Keely, P.J., et al., Cdc42 and Rac1 induce integrin-mediated cell motility and 
invasiveness through PI(3)K. Nature, 1997. 390(6660): p. 632-6. 
42.  Nobes, C.D. and A. Hall, Rho GTPases control polarity, protrusion, and adhesion 
during cell movement. J Cell Biol, 1999. 144(6): p. 1235-44. 
43.  Friedl, P., S. Borgmann, and E.B. Brocker, Amoeboid leukocyte crawling through 
extracellular matrix: lessons from the Dictyostelium paradigm of cell movement. J 
Leukoc Biol, 2001. 70(4): p. 491-509. 224 
44.  Davidson, L.A. and R.E. Keller, Neural tube closure in Xenopus laevis involves 
medial migration, directed protrusive activity, cell intercalation and convergent 
extension. Development, 1999. 126(20): p. 4547-56. 
45.  Jacques, T.S., et al., Neural precursor cell chain migration and division are 
regulated through different beta1 integrins. Development, 1998. 125(16): p. 3167-
77. 
46.  Simian, M., et al., The interplay of matrix metalloproteinases, morphogens and 
growth factors is necessary for branching of mammary epithelial cells. 
Development, 2001. 128(16): p. 3117-31. 
47.  Hegerfeldt, Y., et al., Collective cell movement in primary melanoma explants: 
plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. 
Cancer Res, 2002. 62(7): p. 2125-30. 
48.  Friedl, P., et al., Migration of coordinated cell clusters in mesenchymal and 
epithelial cancer explants in vitro. Cancer Res, 1995. 55(20): p. 4557-60. 
49.  Nabeshima, K., et al., Cohort migration of carcinoma cells: differentiated 
colorectal carcinoma cells move as coherent cell clusters or sheets. Histol 
Histopathol, 1999. 14(4): p. 1183-97. 
50.  Kraus, A.C., et al., In vitro chemo- and radio-resistance in small cell lung cancer 
correlates with cell adhesion and constitutive activation of AKT and MAP kinase 
pathways. Oncogene, 2002. 21(57): p. 8683-95. 
51.  Friedl, P. and K. Wolf, Plasticity of cell migration: a multiscale tuning model. J 
Cell Biol, 2010. 188(1): p. 11-9. 
52.  Moll, R., et al., Differential loss of E-cadherin expression in infiltrating ductal and 
lobular breast carcinomas. Am J Pathol, 1993. 143(6): p. 1731-42. 
53.  Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat Rev 
Cancer, 2002. 2(6): p. 442-54. 
54.  Byers, S.W., et al., Role of E-cadherin in the response of tumor cell aggregates to 
lymphatic, venous and arterial flow: measurement of cell-cell adhesion strength. J 
Cell Sci, 1995. 108 ( Pt 5): p. 2053-64. 
55.  Boulton, T.G., et al., An insulin-stimulated protein kinase similar to yeast kinases 
involved in cell cycle control. Science, 1990. 249(4964): p. 64-7. 
56.  Courchesne, W.E., R. Kunisawa, and J. Thorner, A putative protein kinase 
overcomes pheromone-induced arrest of cell cycling in S. cerevisiae. Cell, 1989. 
58(6): p. 1107-19. 
57.  Elion, E.A., P.L. Grisafi, and G.R. Fink, FUS3 encodes a cdc2+/CDC28-related 
kinase required for the transition from mitosis into conjugation. Cell, 1990. 60(4): 
p. 649-64. 
58.  Boulton, T.G., et al., ERKs: a family of protein-serine/threonine kinases that are 
activated and tyrosine phosphorylated in response to insulin and NGF. Cell, 1991. 
65(4): p. 663-75. 
59.  Pearson, G., et al., Mitogen-activated protein (MAP) kinase pathways: regulation 
and physiological functions. Endocr Rev, 2001. 22(2): p. 153-83. 
60.  Gonzalez, F.A., et al., Heterogeneous expression of four MAP kinase isoforms in 
human tissues. FEBS Lett, 1992. 304(2-3): p. 170-8. 
61.  Bogoyevitch, M.A. and N.W. Court, Counting on mitogen-activated protein 
kinases--ERKs 3, 4, 5, 6, 7 and 8. Cell Signal, 2004. 16(12): p. 1345-54. 
62.  Dhillon, A.S., et al., MAP kinase signalling pathways in cancer. Oncogene, 2007. 
26(22): p. 3279-90. 
63.  Raman, M., W. Chen, and M.H. Cobb, Differential regulation and properties of 
MAPKs. Oncogene, 2007. 26(22): p. 3100-12. 
64.  Conrad, P.W., D.E. Millhorn, and D. Beitner-Johnson, Hypoxia differentially 
regulates the mitogen- and stress-activated protein kinases. Role of Ca2+/CaM in 225 
the activation of MAPK and p38 gamma. Adv Exp Med Biol, 2000. 475: p. 293-
302. 
65.  Efimova, T., et al., Novel protein kinase C isoforms regulate human keratinocyte 
differentiation by activating a p38 delta mitogen-activated protein kinase cascade 
that targets CCAAT/enhancer-binding protein alpha. J Biol Chem, 2002. 277(35): 
p. 31753-60. 
66.  Henrich, L.M., et al., Extracellular signal-regulated kinase 7, a regulator of 
hormone-dependent estrogen receptor destruction. Mol Cell Biol, 2003. 23(17): p. 
5979-88. 
67.  Ishitani, T., et al., The TAK1-NLK-MAPK-related pathway antagonizes signalling 
between beta-catenin and transcription factor TCF. Nature, 1999. 399(6738): p. 
798-802. 
68.  Smit, L., et al., Wnt activates the Tak1/Nemo-like kinase pathway. J Biol Chem, 
2004. 279(17): p. 17232-40. 
69.  Xia, L., et al., Identification of human male germ cell-associated kinase, a kinase 
transcriptionally activated by androgen in prostate cancer cells. J Biol Chem, 
2002. 277(38): p. 35422-33. 
70.  Abe, S., et al., Molecular cloning of a novel serine/threonine kinase, MRK, possibly 
involved in cardiac development. Oncogene, 1995. 11(11): p. 2187-95. 
71.  Miyata, Y., M. Akashi, and E. Nishida, Molecular cloning and characterization of 
a novel member of the MAP kinase superfamily. Genes Cells, 1999. 4(5): p. 299-
309. 
72.  Meyerson, M., et al., A family of human cdc2-related protein kinases. EMBO J, 
1992. 11(8): p. 2909-17. 
73.  Taglienti, C.A., M. Wysk, and R.J. Davis, Molecular cloning of the epidermal 
growth factor-stimulated protein kinase p56 KKIAMRE. Oncogene, 1996. 13(12): 
p. 2563-74. 
74.  Manning, G., et al., The protein kinase complement of the human genome. Science, 
2002. 298(5600): p. 1912-34. 
75.  Coulombe, P. and S. Meloche, Atypical mitogen-activated protein kinases: 
structure, regulation and functions. Biochim Biophys Acta, 2007. 1773(8): p. 
1376-87. 
76.  Kyriakis, J.M. and J. Avruch, pp54 microtubule-associated protein 2 kinase. A 
novel serine/threonine protein kinase regulated by phosphorylation and stimulated 
by poly-L-lysine. J Biol Chem, 1990. 265(28): p. 17355-63. 
77.  Hibi, M., et al., Identification of an oncoprotein- and UV-responsive protein kinase 
that binds and potentiates the c-Jun activation domain. Genes Dev, 1993. 7(11): p. 
2135-48. 
78.  Kyriakis, J.M., et al., The stress-activated protein kinase subfamily of c-Jun 
kinases. Nature, 1994. 369(6476): p. 156-60. 
79.  Ip, Y.T. and R.J. Davis, Signal transduction by the c-Jun N-terminal kinase (JNK)--
from inflammation to development. Curr Opin Cell Biol, 1998. 10(2): p. 205-19. 
80.  Wu, G.S., The functional interactions between the p53 and MAPK signaling 
pathways. Cancer Biol Ther, 2004. 3(2): p. 156-61. 
81.  Hui, L., et al., Proliferation of human HCC cells and chemically induced mouse 
liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest, 2008. 
118(12): p. 3943-53. 
82.  Sakurai, T., et al., Loss of hepatic NF-kappa B activity enhances chemical 
hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc 
Natl Acad Sci U S A, 2006. 103(28): p. 10544-51. 
83.  Ke, H., et al., The c-Jun NH2-terminal kinase 2 plays a dominant role in human 
epidermal neoplasia. Cancer Res, 2010. 70(8): p. 3080-8. 226 
84.  Das, M., et al., The role of JNK in the development of hepatocellular carcinoma. 
Genes Dev, 2011. 25(6): p. 634-45. 
85.  Feng, Q., et al., Apoptosis induced by genipin in human leukemia K562 cells: 
involvement of c-Jun N-terminal kinase in G(2)/M arrest. Acta Pharmacol Sin, 
2011. 
86.  Lee, J.C., et al., A protein kinase involved in the regulation of inflammatory 
cytokine biosynthesis. Nature, 1994. 372(6508): p. 739-46. 
87.  Brancho, D., et al., Mechanism of p38 MAP kinase activation in vivo. Genes Dev, 
2003. 17(16): p. 1969-78. 
88.  Iyoda, K., et al., Involvement of the p38 mitogen-activated protein kinase cascade 
in hepatocellular carcinoma. Cancer, 2003. 97(12): p. 3017-26. 
89.  Bulavin, D.V., et al., Loss of oncogenic H-ras-induced cell cycle arrest and p38 
mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell 
Biol, 2003. 23(11): p. 3859-71. 
90.  Lee, J.D., R.J. Ulevitch, and J. Han, Primary structure of BMK1: a new mammalian 
map kinase. Biochem Biophys Res Commun, 1995. 213(2): p. 715-24. 
91.  Zhou, G., Z.Q. Bao, and J.E. Dixon, Components of a new human protein kinase 
signal transduction pathway. J Biol Chem, 1995. 270(21): p. 12665-9. 
92.  Kondoh, K., et al., Regulation of nuclear translocation of extracellular signal-
regulated kinase 5 by active nuclear import and export mechanisms. Mol Cell Biol, 
2006. 26(5): p. 1679-90. 
93.  Kasler, H.G., et al., ERK5 is a novel type of mitogen-activated protein kinase 
containing a transcriptional activation domain. Mol Cell Biol, 2000. 20(22): p. 
8382-9. 
94.  Nishimoto, S. and E. Nishida, MAPK signalling: ERK5 versus ERK1/2. EMBO 
Rep, 2006. 7(8): p. 782-6. 
95.  Kato, Y., et al., Bmk1/Erk5 is required for cell proliferation induced by epidermal 
growth factor. Nature, 1998. 395(6703): p. 713-6. 
96.  Arnoux, V., et al., Erk5 controls Slug expression and keratinocyte activation during 
wound healing. Mol Biol Cell, 2008. 19(11): p. 4738-49. 
97.  Regan, C.P., et al., Erk5 null mice display multiple extraembryonic vascular and 
embryonic cardiovascular defects. Proc Natl Acad Sci U S A, 2002. 99(14): p. 
9248-53. 
98.  Nishimoto, S., M. Kusakabe, and E. Nishida, Requirement of the MEK5-ERK5 
pathway for neural differentiation in Xenopus embryonic development. EMBO 
Rep, 2005. 6(11): p. 1064-9. 
99.  Kato, Y., et al., BMK1/ERK5 regulates serum-induced early gene expression 
through transcription factor MEF2C. EMBO J, 1997. 16(23): p. 7054-66. 
100.  English, J.M., et al., Identification of substrates and regulators of the mitogen-
activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem, 1998. 
273(7): p. 3854-60. 
101.  Kamakura, S., T. Moriguchi, and E. Nishida, Activation of the protein kinase 
ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a 
signaling pathway to the nucleus. J Biol Chem, 1999. 274(37): p. 26563-71. 
102.  Mehta, P.B., et al., MEK5 overexpression is associated with metastatic prostate 
cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene, 
2003. 22(9): p. 1381-9. 
103.  Esparis-Ogando, A., et al., Erk5 participates in neuregulin signal transduction and 
is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol, 
2002. 22(1): p. 270-85. 227 
104.  Turgeon, B., B.F. Lang, and S. Meloche, The protein kinase ERK3 is encoded by a 
single functional gene: genomic analysis of the ERK3 gene family. Genomics, 
2002. 80(6): p. 673-80. 
105.  Hunter, T. and G.D. Plowman, The protein kinases of budding yeast: six score and 
more. Trends Biochem Sci, 1997. 22(1): p. 18-22. 
106.  Plowman, G.D., et al., The protein kinases of Caenorhabditis elegans: a model for 
signal transduction in multicellular organisms. Proc Natl Acad Sci U S A, 1999. 
96(24): p. 13603-10. 
107.  Zhang, J., et al., Activity of the MAP kinase ERK2 is controlled by a flexible surface 
loop. Structure, 1995. 3(3): p. 299-307. 
108.  Rowles, J., et al., Purification of casein kinase I and isolation of cDNAs encoding 
multiple casein kinase I-like enzymes. Proc Natl Acad Sci U S A, 1991. 88(21): p. 
9548-52. 
109.  Cheng, M., T.G. Boulton, and M.H. Cobb, ERK3 is a constitutively nuclear protein 
kinase. J Biol Chem, 1996. 271(15): p. 8951-8. 
110.  Julien, C., P. Coulombe, and S. Meloche, Nuclear export of ERK3 by a CRM1-
dependent mechanism regulates its inhibitory action on cell cycle progression. J 
Biol Chem, 2003. 278(43): p. 42615-24. 
111.  Zhu, A.X., et al., Cloning and characterization of p97MAPK, a novel human 
homolog of rat ERK-3. Mol Cell Biol, 1994. 14(12): p. 8202-11. 
112.  Cheng, M., et al., Characterization of a protein kinase that phosphorylates serine 
189 of the mitogen-activated protein kinase homolog ERK3. J Biol Chem, 1996. 
271(20): p. 12057-62. 
113.  Sauma, S. and E. Friedman, Increased expression of protein kinase C beta activates 
ERK3. J Biol Chem, 1996. 271(19): p. 11422-6. 
114.  Coulombe, P., et al., Rapid turnover of extracellular signal-regulated kinase 3 by 
the ubiquitin-proteasome pathway defines a novel paradigm of mitogen-activated 
protein kinase regulation during cellular differentiation. Mol Cell Biol, 2003. 
23(13): p. 4542-58. 
115.  Abe, M.K., et al., Extracellular signal-regulated kinase 7 (ERK7), a novel ERK 
with a C-terminal domain that regulates its activity, its cellular localization, and 
cell growth. Mol Cell Biol, 1999. 19(2): p. 1301-12. 
116.  Abe, M.K., et al., ERK8, a new member of the mitogen-activated protein kinase 
family. J Biol Chem, 2002. 277(19): p. 16733-43. 
117.  Kuo, W.L., et al., ERK7 expression and kinase activity is regulated by the 
ubiquitin-proteosome pathway. J Biol Chem, 2004. 279(22): p. 23073-81. 
118.  Qian, Z., et al., Molecular cloning and characterization of a mitogen-activated 
protein kinase-associated intracellular chloride channel. J Biol Chem, 1999. 
274(3): p. 1621-7. 
119.  Kumar, S., J. Boehm, and J.C. Lee, p38 MAP kinases: key signalling molecules as 
therapeutic targets for inflammatory diseases. Nat Rev Drug Discov, 2003. 2(9): p. 
717-26. 
120.  Kaminska, B., MAPK signalling pathways as molecular targets for anti-
inflammatory therapy--from molecular mechanisms to therapeutic benefits. 
Biochim Biophys Acta, 2005. 1754(1-2): p. 253-62. 
121.  Kim, E.K. and E.J. Choi, Pathological roles of MAPK signaling pathways in 
human diseases. Biochim Biophys Acta, 2010. 1802(4): p. 396-405. 
122.  Rubinfeld, H., T. Hanoch, and R. Seger, Identification of a cytoplasmic-retention 
sequence in ERK2. J Biol Chem, 1999. 274(43): p. 30349-52. 
123.  Tanoue, T., et al., A conserved docking motif in MAP kinases common to 
substrates, activators and regulators. Nat Cell Biol, 2000. 2(2): p. 110-6. 228 
124.  Tanoue, T. and E. Nishida, Docking interactions in the mitogen-activated protein 
kinase cascades. Pharmacol Ther, 2002. 93(2-3): p. 193-202. 
125.  Xie, X., et al., Crystal structure of JNK3: a kinase implicated in neuronal 
apoptosis. Structure, 1998. 6(8): p. 983-91. 
126.  Wilson, K.P., et al., Crystal structure of p38 mitogen-activated protein kinase. J 
Biol Chem, 1996. 271(44): p. 27696-700. 
127.  Sharrocks, A.D., S.H. Yang, and A. Galanis, Docking domains and substrate-
specificity determination for MAP kinases. Trends Biochem Sci, 2000. 25(9): p. 
448-53. 
128.  Smith, J.A., et al., Creation of a stress-activated p90 ribosomal S6 kinase. The 
carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal 
transduction pathway in which they function. J Biol Chem, 2000. 275(41): p. 
31588-93. 
129.  Chang, C.I., et al., Crystal structures of MAP kinase p38 complexed to the docking 
sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell, 2002. 9(6): 
p. 1241-9. 
130.  Zhou, T., et al., Docking interactions induce exposure of activation loop in the 
MAP kinase ERK2. Structure, 2006. 14(6): p. 1011-9. 
131.  Lee, T., et al., Docking motif interactions in MAP kinases revealed by hydrogen 
exchange mass spectrometry. Mol Cell, 2004. 14(1): p. 43-55. 
132.  Jacobs, D., et al., Multiple docking sites on substrate proteins form a modular 
system that mediates recognition by ERK MAP kinase. Genes Dev, 1999. 13(2): p. 
163-75. 
133.  Seidel, J.J. and B.J. Graves, An ERK2 docking site in the Pointed domain 
distinguishes a subset of ETS transcription factors. Genes Dev, 2002. 16(1): p. 
127-37. 
134.  Molina, D.M., S. Grewal, and L. Bardwell, Characterization of an ERK-binding 
domain in microphthalmia-associated transcription factor and differential 
inhibition of ERK2-mediated substrate phosphorylation. J Biol Chem, 2005. 
280(51): p. 42051-60. 
135.  Akella, R., T.M. Moon, and E.J. Goldsmith, Unique MAP Kinase binding sites. 
Biochim Biophys Acta, 2008. 1784(1): p. 48-55. 
136.  Dudley, D.T., et al., A synthetic inhibitor of the mitogen-activated protein kinase 
cascade. Proc Natl Acad Sci U S A, 1995. 92(17): p. 7686-9. 
137.  Wrobleski, S.T. and A.M. Doweyko, Structural comparison of p38 inhibitor-
protein complexes: a review of recent p38 inhibitors having unique binding 
interactions. Curr Top Med Chem, 2005. 5(10): p. 1005-16. 
138.  Ohren, J.F., et al., Structures of human MAP kinase kinase 1 (MEK1) and MEK2 
describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol, 2004. 11(12): 
p. 1192-7. 
139.  Nagar, B., et al., Crystal structures of the kinase domain of c-Abl in complex with 
the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res, 2002. 
62(15): p. 4236-43. 
140.  Ramos, J.W., The regulation of extracellular signal-regulated kinase (ERK) in 
mammalian cells. Int J Biochem Cell Biol, 2008. 40(12): p. 2707-19. 
141.  McCubrey, J.A., et al., Roles of the Raf/MEK/ERK pathway in cell growth, 
malignant transformation and drug resistance. Biochim Biophys Acta, 2007. 
1773(8): p. 1263-84. 
142.  Fang, J.Y. and B.C. Richardson, The MAPK signalling pathways and colorectal 
cancer. Lancet Oncol, 2005. 6(5): p. 322-7. 
143.  Kohno, M. and J. Pouyssegur, Targeting the ERK signaling pathway in cancer 
therapy. Ann Med, 2006. 38(3): p. 200-11. 229 
144.  Vigneri, R., S. Squatrito, and L. Sciacca, Insulin and its analogs: actions via 
insulin and IGF receptors. Acta Diabetol, 2010. 47(4): p. 271-8. 
145.  Petkova, S.B., et al., Cell cycle molecules and diseases of the cardiovascular 
system. Front Biosci, 2000. 5: p. D452-60. 
146.  Wellbrock, C., M. Karasarides, and R. Marais, The RAF proteins take centre stage. 
Nat Rev Mol Cell Biol, 2004. 5(11): p. 875-85. 
147.  Morrison, D.K. and R.E. Cutler, The complexity of Raf-1 regulation. Curr Opin 
Cell Biol, 1997. 9(2): p. 174-9. 
148.  Kolch, W., Coordinating ERK/MAPK signalling through scaffolds and inhibitors. 
Nat Rev Mol Cell Biol, 2005. 6(11): p. 827-37. 
149.  Diaz, B., et al., Phosphorylation of Raf-1 serine 338-serine 339 is an essential 
regulatory event for Ras-dependent activation and biological signaling. Mol Cell 
Biol, 1997. 17(8): p. 4509-16. 
150.  Morrison, D.K., Mechanisms regulating Raf-1 activity in signal transduction 
pathways. Mol Reprod Dev, 1995. 42(4): p. 507-14. 
151.  Fabian, J.R., I.O. Daar, and D.K. Morrison, Critical tyrosine residues regulate the 
enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol, 1993. 13(11): p. 
7170-9. 
152.  Alessi, D.R., et al., Identification of the sites in MAP kinase kinase-1 
phosphorylated by p74raf-1. EMBO J, 1994. 13(7): p. 1610-9. 
153.  Zheng, C.F. and K.L. Guan, Properties of MEKs, the kinases that phosphorylate 
and activate the extracellular signal-regulated kinases. J Biol Chem, 1993. 
268(32): p. 23933-9. 
154.  Shaul, Y.D., et al., Specific phosphorylation and activation of ERK1c by MEK1b: a 
unique route in the ERK cascade. Genes Dev, 2009. 23(15): p. 1779-90. 
155.  Ferrell, J.E., Jr. and R.R. Bhatt, Mechanistic studies of the dual phosphorylation of 
mitogen-activated protein kinase. J Biol Chem, 1997. 272(30): p. 19008-16. 
156.  Yoon, S. and R. Seger, The extracellular signal-regulated kinase: multiple 
substrates regulate diverse cellular functions. Growth Factors, 2006. 24(1): p. 21-
44. 
157.  Gonzalez, F.A., D.L. Raden, and R.J. Davis, Identification of substrate recognition 
determinants for human ERK1 and ERK2 protein kinases. J Biol Chem, 1991. 
266(33): p. 22159-63. 
158.  Aebersold, D.M., et al., Extracellular signal-regulated kinase 1c (ERK1c), a novel 
42-kilodalton ERK, demonstrates unique modes of regulation, localization, and 
function. Mol Cell Biol, 2004. 24(22): p. 10000-15. 
159.  Yung, Y., et al., ERK1b, a 46-kDa ERK isoform that is differentially regulated by 
MEK. J Biol Chem, 2000. 275(21): p. 15799-808. 
160.  Shaul, Y.D. and R. Seger, ERK1c regulates Golgi fragmentation during mitosis. J 
Cell Biol, 2006. 172(6): p. 885-97. 
161.  Marshall, C.J., Specificity of receptor tyrosine kinase signaling: transient versus 
sustained extracellular signal-regulated kinase activation. Cell, 1995. 80(2): p. 
179-85. 
162.  Ebisuya, M., K. Kondoh, and E. Nishida, The duration, magnitude and 
compartmentalization of ERK MAP kinase activity: mechanisms for providing 
signaling specificity. J Cell Sci, 2005. 118(Pt 14): p. 2997-3002. 
163.  Pouyssegur, J., V. Volmat, and P. Lenormand, Fidelity and spatio-temporal control 
in MAP kinase (ERKs) signalling. Biochem Pharmacol, 2002. 64(5-6): p. 755-63. 
164.  Raman, M. and M.H. Cobb, MAP kinase modules: many roads home. Curr Biol, 
2003. 13(22): p. R886-8. 230 
165.  Sontag, E., et al., The interaction of SV40 small tumor antigen with protein 
phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. 
Cell, 1993. 75(5): p. 887-97. 
166.  Alessi, D.R., et al., Inactivation of p42 MAP kinase by protein phosphatase 2A and 
a protein tyrosine phosphatase, but not CL100, in various cell lines. Curr Biol, 
1995. 5(3): p. 283-95. 
167.  Ory, S., et al., Protein phosphatase 2A positively regulates Ras signaling by 
dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol, 
2003. 13(16): p. 1356-64. 
168.  Cho, U.S. and W. Xu, Crystal structure of a protein phosphatase 2A heterotrimeric 
holoenzyme. Nature, 2007. 445(7123): p. 53-7. 
169.  Xu, Y., et al., Structure of the protein phosphatase 2A holoenzyme. Cell, 2006. 
127(6): p. 1239-51. 
170.  McCright, B., et al., The B56 family of protein phosphatase 2A (PP2A) regulatory 
subunits encodes differentiation-induced phosphoproteins that target PP2A to both 
nucleus and cytoplasm. J Biol Chem, 1996. 271(36): p. 22081-9. 
171.  Letourneux, C., G. Rocher, and F. Porteu, B56-containing PP2A dephosphorylate 
ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J, 
2006. 25(4): p. 727-38. 
172.  Saxena, M., et al., Crosstalk between cAMP-dependent kinase and MAP kinase 
through a protein tyrosine phosphatase. Nat Cell Biol, 1999. 1(5): p. 305-11. 
173.  Paul, S., et al., NMDA-mediated activation of the tyrosine phosphatase STEP 
regulates the duration of ERK signaling. Nat Neurosci, 2003. 6(1): p. 34-42. 
174.  Saxena, M. and T. Mustelin, Extracellular signals and scores of phosphatases: all 
roads lead to MAP kinase. Semin Immunol, 2000. 12(4): p. 387-96. 
175.  Patterson, K.I., et al., Dual-specificity phosphatases: critical regulators with 
diverse cellular targets. Biochem J, 2009. 418(3): p. 475-89. 
176.  Marchetti, S., et al., Extracellular signal-regulated kinases phosphorylate mitogen-
activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites 
critical for its proteasomal degradation. Mol Cell Biol, 2005. 25(2): p. 854-64. 
177.  Brondello, J.M., J. Pouyssegur, and F.R. McKenzie, Reduced MAP kinase 
phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. 
Science, 1999. 286(5449): p. 2514-7. 
178.  Kamata, H., et al., Reactive oxygen species promote TNFalpha-induced death and 
sustained JNK activation by inhibiting MAP kinase phosphatases. Cell, 2005. 
120(5): p. 649-61. 
179.  Fukuda, M., Y. Gotoh, and E. Nishida, Interaction of MAP kinase with MAP kinase 
kinase: its possible role in the control of nucleocytoplasmic transport of MAP 
kinase. EMBO J, 1997. 16(8): p. 1901-8. 
180.  Hsiao, K.M., et al., Evidence that inactive p42 mitogen-activated protein kinase 
and inactive Rsk exist as a heterodimer in vivo. Proc Natl Acad Sci U S A, 1994. 
91(12): p. 5480-4. 
181.  Therrien, M., et al., KSR, a novel protein kinase required for RAS signal 
transduction. Cell, 1995. 83(6): p. 879-88. 
182.  Kornfeld, K., D.B. Hom, and H.R. Horvitz, The ksr-1 gene encodes a novel protein 
kinase involved in Ras-mediated signaling in C. elegans. Cell, 1995. 83(6): p. 903-
13. 
183.  Morrison, D.K. and R.J. Davis, Regulation of MAP kinase signaling modules by 
scaffold proteins in mammals. Annu Rev Cell Dev Biol, 2003. 19: p. 91-118. 
184.  Yu, W., et al., Regulation of the MAP kinase pathway by mammalian Ksr through 
direct interaction with MEK and ERK. Curr Biol, 1998. 8(1): p. 56-64. 231 
185.  Therrien, M., et al., KSR modulates signal propagation within the MAPK cascade. 
Genes Dev, 1996. 10(21): p. 2684-95. 
186.  Roy, F., et al., KSR is a scaffold required for activation of the ERK/MAPK module. 
Genes Dev, 2002. 16(4): p. 427-38. 
187.  Schaeffer, H.J., et al., MP1: a MEK binding partner that enhances enzymatic 
activation of the MAP kinase cascade. Science, 1998. 281(5383): p. 1668-71. 
188.  Teis, D., W. Wunderlich, and L.A. Huber, Localization of the MP1-MAPK scaffold 
complex to endosomes is mediated by p14 and required for signal transduction. 
Dev Cell, 2002. 3(6): p. 803-14. 
189.  Wunderlich, W., et al., A novel 14-kilodalton protein interacts with the mitogen-
activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. 
J Cell Biol, 2001. 152(4): p. 765-76. 
190.  Pullikuth, A., et al., The MEK1 scaffolding protein MP1 regulates cell spreading by 
integrating PAK1 and Rho signals. Mol Cell Biol, 2005. 25(12): p. 5119-33. 
191.  Vomastek, T., et al., Modular construction of a signaling scaffold: MORG1 
interacts with components of the ERK cascade and links ERK signaling to specific 
agonists. Proc Natl Acad Sci U S A, 2004. 101(18): p. 6981-6. 
192.  Luttrell, L.M. and R.J. Lefkowitz, The role of beta-arrestins in the termination and 
transduction of G-protein-coupled receptor signals. J Cell Sci, 2002. 115(Pt 3): p. 
455-65. 
193.  Daaka, Y., et al., Essential role for G protein-coupled receptor endocytosis in the 
activation of mitogen-activated protein kinase. J Biol Chem, 1998. 273(2): p. 685-
8. 
194.  DeFea, K.A., et al., The proliferative and antiapoptotic effects of substance P are 
facilitated by formation of a beta -arrestin-dependent scaffolding complex. Proc 
Natl Acad Sci U S A, 2000. 97(20): p. 11086-91. 
195.  DeFea, K.A., et al., beta-arrestin-dependent endocytosis of proteinase-activated 
receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol, 
2000. 148(6): p. 1267-81. 
196.  Tohgo, A., et al., beta-Arrestin scaffolding of the ERK cascade enhances cytosolic 
ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a 
receptor stimulation. J Biol Chem, 2002. 277(11): p. 9429-36. 
197.  Minden, A., et al., Differential activation of ERK and JNK mitogen-activated 
protein kinases by Raf-1 and MEKK. Science, 1994. 266(5191): p. 1719-23. 
198.  Lu, Z., et al., The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and 
mediates ubiquitination and degradation of ERK1/2. Mol Cell, 2002. 9(5): p. 945-
56. 
199.  Xu, S., et al., Cloning of rat MEK kinase 1 cDNA reveals an endogenous 
membrane-associated 195-kDa protein with a large regulatory domain. Proc Natl 
Acad Sci U S A, 1996. 93(11): p. 5291-5. 
200.  Karandikar, M., S. Xu, and M.H. Cobb, MEKK1 binds raf-1 and the ERK2 cascade 
components. J Biol Chem, 2000. 275(51): p. 40120-7. 
201.  Yujiri, T., et al., Role of MEKK1 in cell survival and activation of JNK and ERK 
pathways defined by targeted gene disruption. Science, 1998. 282(5395): p. 1911-
4. 
202.  Therrien, M., A.M. Wong, and G.M. Rubin, CNK, a RAF-binding multidomain 
protein required for RAS signaling. Cell, 1998. 95(3): p. 343-53. 
203.  Lanigan, T.M., et al., Human homologue of Drosophila CNK interacts with Ras 
effector proteins Raf and Rlf. FASEB J, 2003. 17(14): p. 2048-60. 
204.  Rabizadeh, S., et al., The scaffold protein CNK1 interacts with the tumor 
suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem, 
2004. 279(28): p. 29247-54. 232 
205.  Jaffe, A.B., P. Aspenstrom, and A. Hall, Human CNK1 acts as a scaffold protein, 
linking Rho and Ras signal transduction pathways. Mol Cell Biol, 2004. 24(4): p. 
1736-46. 
206.  Ziogas, A., K. Moelling, and G. Radziwill, CNK1 is a scaffold protein that 
regulates Src-mediated Raf-1 activation. J Biol Chem, 2005. 280(25): p. 24205-11. 
207.  Sieburth, D.S., Q. Sun, and M. Han, SUR-8, a conserved Ras-binding protein with 
leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans. 
Cell, 1998. 94(1): p. 119-30. 
208.  Li, W., M. Han, and K.L. Guan, The leucine-rich repeat protein SUR-8 enhances 
MAP kinase activation and forms a complex with Ras and Raf. Genes Dev, 2000. 
14(8): p. 895-900. 
209.  Roy, M., Z. Li, and D.B. Sacks, IQGAP1 is a scaffold for mitogen-activated protein 
kinase signaling. Mol Cell Biol, 2005. 25(18): p. 7940-52. 
210.  Ren, J.G., Z. Li, and D.B. Sacks, IQGAP1 modulates activation of B-Raf. Proc Natl 
Acad Sci U S A, 2007. 104(25): p. 10465-9. 
211.  Roy, M., Z. Li, and D.B. Sacks, IQGAP1 binds ERK2 and modulates its activity. J 
Biol Chem, 2004. 279(17): p. 17329-37. 
212.  Marais, R., et al., Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic 
ras and tyrosine kinases. J Biol Chem, 1997. 272(7): p. 4378-83. 
213.  Bos, J.L., ras oncogenes in human cancer: a review. Cancer Res, 1989. 49(17): p. 
4682-9. 
214.  Hagel, M., et al., The adaptor protein paxillin is essential for normal development 
in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol, 
2002. 22(3): p. 901-15. 
215.  Ishibe, S., et al., Phosphorylation-dependent paxillin-ERK association mediates 
hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell, 2003. 
12(5): p. 1275-85. 
216.  Liu, Z.X., et al., Hepatocyte growth factor induces ERK-dependent paxillin 
phosphorylation and regulates paxillin-focal adhesion kinase association. J Biol 
Chem, 2002. 277(12): p. 10452-8. 
217.  Schmalzigaug, R., et al., GIT1 utilizes a focal adhesion targeting-homology domain 
to bind paxillin. Cell Signal, 2007. 19(8): p. 1733-44. 
218.  Zhang, N., et al., GIT1 is a novel MEK1-ERK1/2 scaffold that localizes to focal 
adhesions. Cell Biol Int, 2010. 34(1): p. 41-7. 
219.  Yin, G., et al., GIT1 functions as a scaffold for MEK1-extracellular signal-
regulated kinase 1 and 2 activation by angiotensin II and epidermal growth factor. 
Mol Cell Biol, 2004. 24(2): p. 875-85. 
220.  Yujiri, T., et al., MEK kinase 1 interacts with focal adhesion kinase and regulates 
insulin receptor substrate-1 expression. J Biol Chem, 2003. 278(6): p. 3846-51. 
221.  Araujo, H., et al., Characterization of PEA-15, a major substrate for protein kinase 
C in astrocytes. J Biol Chem, 1993. 268(8): p. 5911-20. 
222.  Hill, J.M., et al., Recognition of ERK MAP kinase by PEA-15 reveals a common 
docking site within the death domain and death effector domain. EMBO J, 2002. 
21(23): p. 6494-504. 
223.  Vaidyanathan, H., et al., ERK MAP kinase is targeted to RSK2 by the 
phosphoprotein PEA-15. Proc Natl Acad Sci U S A, 2007. 104(50): p. 19837-42. 
224.  Formstecher, E., et al., PEA-15 mediates cytoplasmic sequestration of ERK MAP 
kinase. Dev Cell, 2001. 1(2): p. 239-50. 
225.  Whitehurst, A.W., et al., The death effector domain protein PEA-15 prevents 
nuclear entry of ERK2 by inhibiting required interactions. J Biol Chem, 2004. 
279(13): p. 12840-7. 233 
226.  Yeung, K., et al., Mechanism of suppression of the Raf/MEK/extracellular signal-
regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol, 2000. 
20(9): p. 3079-85. 
227.  Robinson, M.J., et al., A constitutively active and nuclear form of the MAP kinase 
ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol, 1998. 
8(21): p. 1141-50. 
228.  Tsang, M., et al., Identification of Sef, a novel modulator of FGF signalling. Nat 
Cell Biol, 2002. 4(2): p. 165-9. 
229.  Bivona, T.G., et al., Phospholipase Cgamma activates Ras on the Golgi apparatus 
by means of RasGRP1. Nature, 2003. 424(6949): p. 694-8. 
230.  Torii, S., et al., Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell, 
2004. 7(1): p. 33-44. 
231.  Casar, B., et al., Mxi2 promotes stimulus-independent ERK nuclear translocation. 
EMBO J, 2007. 26(3): p. 635-46. 
232.  Sanz, V., I. Arozarena, and P. Crespo, Distinct carboxy-termini confer divergent 
characteristics to the mitogen-activated protein kinase p38alpha and its splice 
isoform Mxi2. FEBS Lett, 2000. 474(2-3): p. 169-74. 
233.  Sanz-Moreno, V., B. Casar, and P. Crespo, p38alpha isoform Mxi2 binds to 
extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase and 
regulates its nuclear activity by sustaining its phosphorylation levels. Mol Cell 
Biol, 2003. 23(9): p. 3079-90. 
234.  Karlsson, M., et al., Both nuclear-cytoplasmic shuttling of the dual specificity 
phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are 
mediated by a conserved nuclear export signal. J Biol Chem, 2004. 279(40): p. 
41882-91. 
235.  Mandl, M., D.N. Slack, and S.M. Keyse, Specific inactivation and nuclear 
anchoring of extracellular signal-regulated kinase 2 by the inducible dual-
specificity protein phosphatase DUSP5. Mol Cell Biol, 2005. 25(5): p. 1830-45. 
236.  Caunt, C.J., et al., Spatiotemporal regulation of ERK2 by dual specificity 
phosphatases. J Biol Chem, 2008. 283(39): p. 26612-23. 
237.  Traverse, S., et al., Sustained activation of the mitogen-activated protein (MAP) 
kinase cascade may be required for differentiation of PC12 cells. Comparison of 
the effects of nerve growth factor and epidermal growth factor. Biochem J, 1992. 
288 ( Pt 2): p. 351-5. 
238.  Eblen, S.T., et al., Mitogen-activated protein kinase feedback phosphorylation 
regulates MEK1 complex formation and activation during cellular adhesion. Mol 
Cell Biol, 2004. 24(6): p. 2308-17. 
239.  Sundberg-Smith, L.J., et al., Adhesion stimulates direct PAK1/ERK2 association 
and leads to ERK-dependent PAK1 Thr212 phosphorylation. J Biol Chem, 2005. 
280(3): p. 2055-64. 
240.  Coles, L.C. and P.E. Shaw, PAK1 primes MEK1 for phosphorylation by Raf-1 
kinase during cross-cascade activation of the ERK pathway. Oncogene, 2002. 
21(14): p. 2236-44. 
241.  Dougherty, M.K., et al., Regulation of Raf-1 by direct feedback phosphorylation. 
Mol Cell, 2005. 17(2): p. 215-24. 
242.  Balan, V., et al., Identification of novel in vivo Raf-1 phosphorylation sites 
mediating positive feedback Raf-1 regulation by extracellular signal-regulated 
kinase. Mol Biol Cell, 2006. 17(3): p. 1141-53. 
243.  Corbalan-Garcia, S., et al., Identification of the mitogen-activated protein kinase 
phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol Cell 
Biol, 1996. 16(10): p. 5674-82. 234 
244.  Owens, D.M. and S.M. Keyse, Differential regulation of MAP kinase signalling by 
dual-specificity protein phosphatases. Oncogene, 2007. 26(22): p. 3203-13. 
245.  Kucharska, A., et al., Regulation of the inducible nuclear dual-specificity 
phosphatase DUSP5 by ERK MAPK. Cell Signal, 2009. 21(12): p. 1794-805. 
246.  Hoshino, R., et al., Constitutive activation of the 41-/43-kDa mitogen-activated 
protein kinase signaling pathway in human tumors. Oncogene, 1999. 18(3): p. 813-
22. 
247.  Stommel, J.M., et al., Coactivation of receptor tyrosine kinases affects the response 
of tumor cells to targeted therapies. Science, 2007. 318(5848): p. 287-90. 
248.  Chrysogelos, S.A., et al., Mechanisms of EGF receptor regulation in breast cancer 
cells. Breast Cancer Res Treat, 1994. 31(2-3): p. 227-36. 
249.  Liu, E., et al., The HER2 (c-erbB-2) oncogene is frequently amplified in in situ 
carcinomas of the breast. Oncogene, 1992. 7(5): p. 1027-32. 
250.  Cirisano, F.D. and B.Y. Karlan, The role of the HER-2/neu oncogene in 
gynecologic cancers. J Soc Gynecol Investig, 1996. 3(3): p. 99-105. 
251.  Di Fiore, P.P., et al., erbB-2 is a potent oncogene when overexpressed in NIH/3T3 
cells. Science, 1987. 237(4811): p. 178-82. 
252.  Grandis, J.R. and J.C. Sok, Signaling through the epidermal growth factor receptor 
during the development of malignancy. Pharmacol Ther, 2004. 102(1): p. 37-46. 
253.  Tong, L.A., et al., Crystal structures at 2.2 A resolution of the catalytic domains of 
normal ras protein and an oncogenic mutant complexed with GDP. J Mol Biol, 
1991. 217(3): p. 503-16. 
254.  Scheffzek, K., et al., The Ras-RasGAP complex: structural basis for GTPase 
activation and its loss in oncogenic Ras mutants. Science, 1997. 277(5324): p. 333-
8. 
255.  Davies, H., et al., Mutations of the BRAF gene in human cancer. Nature, 2002. 
417(6892): p. 949-54. 
256.  Libra, M., et al., Analysis of BRAF mutation in primary and metastatic melanoma. 
Cell Cycle, 2005. 4(10): p. 1382-4. 
257.  Fransen, K., et al., Mutation analysis of the BRAF, ARAF and RAF-1 genes in 
human colorectal adenocarcinomas. Carcinogenesis, 2004. 25(4): p. 527-33. 
258.  Garnett, M.J. and R. Marais, Guilty as charged: B-RAF is a human oncogene. 
Cancer Cell, 2004. 6(4): p. 313-9. 
259.  Wan, P.T., et al., Mechanism of activation of the RAF-ERK signaling pathway by 
oncogenic mutations of B-RAF. Cell, 2004. 116(6): p. 855-67. 
260.  Waskiewicz, A.J., et al., Mitogen-activated protein kinases activate the 
serine/threonine kinases Mnk1 and Mnk2. EMBO J, 1997. 16(8): p. 1909-20. 
261.  Waskiewicz, A.J., et al., Phosphorylation of the cap-binding protein eukaryotic 
translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol, 
1999. 19(3): p. 1871-80. 
262.  Mamane, Y., et al., Epigenetic activation of a subset of mRNAs by eIF4E explains 
its effects on cell proliferation. PLoS One, 2007. 2(2): p. e242. 
263.  Long, X., et al., Rheb binds and regulates the mTOR kinase. Curr Biol, 2005. 15(8): 
p. 702-13. 
264.  Ma, L., et al., Phosphorylation and functional inactivation of TSC2 by Erk 
implications for tuberous sclerosis and cancer pathogenesis. Cell, 2005. 121(2): p. 
179-93. 
265.  Roux, P.P., et al., Tumor-promoting phorbol esters and activated Ras inactivate the 
tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc 
Natl Acad Sci U S A, 2004. 101(37): p. 13489-94. 235 
266.  Stefanovsky, V.Y., et al., An immediate response of ribosomal transcription to 
growth factor stimulation in mammals is mediated by ERK phosphorylation of 
UBF. Mol Cell, 2001. 8(5): p. 1063-73. 
267.  Zhao, J., et al., ERK-dependent phosphorylation of the transcription initiation 
factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol 
Cell, 2003. 11(2): p. 405-13. 
268.  Kim, D.W. and B.H. Cochran, Extracellular signal-regulated kinase binds to TFII-I 
and regulates its activation of the c-fos promoter. Mol Cell Biol, 2000. 20(4): p. 
1140-8. 
269.  Felton-Edkins, Z.A., et al., The mitogen-activated protein (MAP) kinase ERK 
induces tRNA synthesis by phosphorylating TFIIIB. EMBO J, 2003. 22(10): p. 
2422-32. 
270.  Markowitz, R.B., et al., Phosphorylation of the C-terminal domain of RNA 
polymerase II by the extracellular-signal-regulated protein kinase ERK2. Biochem 
Biophys Res Commun, 1995. 207(3): p. 1051-7. 
271.  Suzuki, T., et al., Phosphorylation of three regulatory serines of Tob by Erk1 and 
Erk2 is required for Ras-mediated cell proliferation and transformation. Genes 
Dev, 2002. 16(11): p. 1356-70. 
272.  Alvarez, E., et al., Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for 
substrate protein phosphorylation. Characterization of the phosphorylation of c-
myc and c-jun proteins by an epidermal growth factor receptor threonine 669 
protein kinase. J Biol Chem, 1991. 266(23): p. 15277-85. 
273.  Yang, J.Y., et al., ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-
mediated degradation. Nat Cell Biol, 2008. 10(2): p. 138-48. 
274.  Biswas, S.C. and L.A. Greene, Nerve growth factor (NGF) down-regulates the Bcl-
2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic 
activity by phosphorylation. J Biol Chem, 2002. 277(51): p. 49511-6. 
275.  Allan, L.A., et al., Inhibition of caspase-9 through phosphorylation at Thr 125 by 
ERK MAPK. Nat Cell Biol, 2003. 5(7): p. 647-54. 
276.  Hunger-Glaser, I., et al., Bombesin, lysophosphatidic acid, and epidermal growth 
factor rapidly stimulate focal adhesion kinase phosphorylation at Ser-910: 
requirement for ERK activation. J Biol Chem, 2003. 278(25): p. 22631-43. 
277.  Klemke, R.L., et al., Regulation of cell motility by mitogen-activated protein 
kinase. J Cell Biol, 1997. 137(2): p. 481-92. 
278.  Martinez-Quiles, N., et al., Erk/Src phosphorylation of cortactin acts as a switch 
on-switch off mechanism that controls its ability to activate N-WASP. Mol Cell 
Biol, 2004. 24(12): p. 5269-80. 
279.  Marklund, U., et al., Multiple signal transduction pathways induce phosphorylation 
of serines 16, 25, and 38 of oncoprotein 18 in T lymphocytes. J Biol Chem, 1993. 
268(34): p. 25671-80. 
280.  Mitsushima, M., et al., Extracellular signal-regulated kinase activated by 
epidermal growth factor and cell adhesion interacts with and phosphorylates 
vinexin. J Biol Chem, 2004. 279(33): p. 34570-7. 
281.  Glading, A., et al., Epidermal growth factor activates m-calpain (calpain II), at 
least in part, by extracellular signal-regulated kinase-mediated phosphorylation. 
Mol Cell Biol, 2004. 24(6): p. 2499-512. 
282.  Graves, L.M., et al., Regulation of carbamoyl phosphate synthetase by MAP kinase. 
Nature, 2000. 403(6767): p. 328-32. 
283.  Torii, S., et al., ERK MAP kinase in G cell cycle progression and cancer. Cancer 
Sci, 2006. 97(8): p. 697-702. 236 
284.  Balmanno, K. and S.J. Cook, Sustained MAP kinase activation is required for the 
expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. 
Oncogene, 1999. 18(20): p. 3085-97. 
285.  Yoshida, Y., et al., Mice lacking a transcriptional corepressor Tob are predisposed 
to cancer. Genes Dev, 2003. 17(10): p. 1201-6. 
286.  Garnovskaya, M.N., et al., Mitogen-induced rapid phosphorylation of serine 795 of 
the retinoblastoma gene product in vascular smooth muscle cells involves ERK 
activation. J Biol Chem, 2004. 279(23): p. 24899-905. 
287.  Murphy, L.O., J.P. MacKeigan, and J. Blenis, A network of immediate early gene 
products propagates subtle differences in mitogen-activated protein kinase signal 
amplitude and duration. Mol Cell Biol, 2004. 24(1): p. 144-53. 
288.  Bouchard, C., et al., Direct induction of cyclin D2 by Myc contributes to cell cycle 
progression and sequestration of p27. EMBO J, 1999. 18(19): p. 5321-33. 
289.  Hermeking, H., et al., Identification of CDK4 as a target of c-MYC. Proc Natl Acad 
Sci U S A, 2000. 97(5): p. 2229-34. 
290.  Gartel, A.L. and K. Shchors, Mechanisms of c-myc-mediated transcriptional 
repression of growth arrest genes. Exp Cell Res, 2003. 283(1): p. 17-21. 
291.  Staller, P., et al., Repression of p15INK4b expression by Myc through association 
with Miz-1. Nat Cell Biol, 2001. 3(4): p. 392-9. 
292.  Claassen, G.F. and S.R. Hann, A role for transcriptional repression of p21CIP1 by 
c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. 
Proc Natl Acad Sci U S A, 2000. 97(17): p. 9498-503. 
293.  Adhikary, S. and M. Eilers, Transcriptional regulation and transformation by Myc 
proteins. Nat Rev Mol Cell Biol, 2005. 6(8): p. 635-45. 
294.  Hann, S.R. and R.N. Eisenman, Proteins encoded by the human c-myc oncogene: 
differential expression in neoplastic cells. Mol Cell Biol, 1984. 4(11): p. 2486-97. 
295.  Sears, R., et al., Multiple Ras-dependent phosphorylation pathways regulate Myc 
protein stability. Genes Dev, 2000. 14(19): p. 2501-14. 
296.  Liu, Y., et al., Regulation of p21WAF1/CIP1 expression through mitogen-activated 
protein kinase signaling pathway. Cancer Res, 1996. 56(1): p. 31-5. 
297.  Pumiglia, K.M. and S.J. Decker, Cell cycle arrest mediated by the MEK/mitogen-
activated protein kinase pathway. Proc Natl Acad Sci U S A, 1997. 94(2): p. 448-
52. 
298.  Harrington, E.A., A. Fanidi, and G.I. Evan, Oncogenes and cell death. Curr Opin 
Genet Dev, 1994. 4(1): p. 120-9. 
299.  Kerr, J.F., A.H. Wyllie, and A.R. Currie, Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972. 
26(4): p. 239-57. 
300.  Adams, J.M. and S. Cory, The Bcl-2 apoptotic switch in cancer development and 
therapy. Oncogene, 2007. 26(9): p. 1324-37. 
301.  Puthalakath, H. and A. Strasser, Keeping killers on a tight leash: transcriptional 
and post-translational control of the pro-apoptotic activity of BH3-only proteins. 
Cell Death Differ, 2002. 9(5): p. 505-12. 
302.  Ewings, K.E., et al., ERK1/2-dependent phosphorylation of BimEL promotes its 
rapid dissociation from Mcl-1 and Bcl-xL. EMBO J, 2007. 26(12): p. 2856-67. 
303.  Ley, R., et al., Activation of the ERK1/2 signaling pathway promotes 
phosphorylation and proteasome-dependent degradation of the BH3-only protein, 
Bim. J Biol Chem, 2003. 278(21): p. 18811-6. 
304.  Ley, R., et al., Extracellular signal-regulated kinases 1/2 are serum-stimulated 
"Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its 
phosphorylation and turnover. J Biol Chem, 2004. 279(10): p. 8837-47. 237 
305.  Fang, X., et al., Regulation of BAD phosphorylation at serine 112 by the Ras-
mitogen-activated protein kinase pathway. Oncogene, 1999. 18(48): p. 6635-40. 
306.  Datta, S.R., et al., Akt phosphorylation of BAD couples survival signals to the cell-
intrinsic death machinery. Cell, 1997. 91(2): p. 231-41. 
307.  Lizcano, J.M., N. Morrice, and P. Cohen, Regulation of BAD by cAMP-dependent 
protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J, 
2000. 349(Pt 2): p. 547-57. 
308.  Datta, S.R., et al., 14-3-3 proteins and survival kinases cooperate to inactivate BAD 
by BH3 domain phosphorylation. Mol Cell, 2000. 6(1): p. 41-51. 
309.  Fueller, J., et al., C-RAF activation promotes BAD poly-ubiquitylation and turn-
over by the proteasome. Biochem Biophys Res Commun, 2008. 370(4): p. 552-6. 
310.  Boucher, M.J., et al., MEK/ERK signaling pathway regulates the expression of Bcl-
2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J 
Cell Biochem, 2000. 79(3): p. 355-69. 
311.  Shaywitz, A.J. and M.E. Greenberg, CREB: a stimulus-induced transcription factor 
activated by a diverse array of extracellular signals. Annu Rev Biochem, 1999. 68: 
p. 821-61. 
312.  Arthur, J.S., et al., Mitogen- and stress-activated protein kinase 1 mediates cAMP 
response element-binding protein phosphorylation and activation by neurotrophins. 
J Neurosci, 2004. 24(18): p. 4324-32. 
313.  Domina, A.M., et al., MCL1 is phosphorylated in the PEST region and stabilized 
upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic 
acid or taxol. Oncogene, 2004. 23(31): p. 5301-15. 
314.  Reddy, K.B., S.M. Nabha, and N. Atanaskova, Role of MAP kinase in tumor 
progression and invasion. Cancer Metastasis Rev, 2003. 22(4): p. 395-403. 
315.  Pullikuth, A.K. and A.D. Catling, Scaffold mediated regulation of MAPK signaling 
and cytoskeletal dynamics: a perspective. Cell Signal, 2007. 19(8): p. 1621-32. 
316.  Lovric, J., et al., Activated raf induces the hyperphosphorylation of stathmin and 
the reorganization of the microtubule network. J Biol Chem, 1998. 273(35): p. 
22848-55. 
317.  Chiariello, M., C.B. Bruni, and C. Bucci, The small GTPases Rab5a, Rab5b and 
Rab5c are differentially phosphorylated in vitro. FEBS Lett, 1999. 453(1-2): p. 20-
4. 
318.  Mizutani, K., et al., Essential roles of ERK-mediated phosphorylation of vinexin in 
cell spreading, migration and anchorage-independent growth. Oncogene, 2007. 
26(50): p. 7122-31. 
319.  Carragher, N.O., et al., A novel role for FAK as a protease-targeting adaptor 
protein: regulation by p42 ERK and Src. Curr Biol, 2003. 13(16): p. 1442-50. 
320.  Cortesio, C.L., et al., Calpain-mediated proteolysis of paxillin negatively regulates 
focal adhesion dynamics and cell migration. J Biol Chem, 2011. 286(12): p. 9998-
10006. 
321.  Franco, S.J., et al., Calpain-mediated proteolysis of talin regulates adhesion 
dynamics. Nat Cell Biol, 2004. 6(10): p. 977-83. 
322.  Cortesio, C.L., et al., Calpain 2 and PTP1B function in a novel pathway with Src to 
regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol, 2008. 
180(5): p. 957-71. 
323.  Cruzalegui, F.H., E. Cano, and R. Treisman, ERK activation induces 
phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene, 
1999. 18(56): p. 7948-57. 
324.  Gille, H., A.D. Sharrocks, and P.E. Shaw, Phosphorylation of transcription factor 
p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. 
Nature, 1992. 358(6385): p. 414-7. 238 
325.  Tanimura, S., et al., Prolonged nuclear retention of activated extracellular signal-
regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. 
J Biol Chem, 2002. 277(31): p. 28256-64. 
326.  Murphy, L.O., et al., Molecular interpretation of ERK signal duration by 
immediate early gene products. Nat Cell Biol, 2002. 4(8): p. 556-64. 
327.  Steeg, P.S., Tumor metastasis: mechanistic insights and clinical challenges. Nat 
Med, 2006. 12(8): p. 895-904. 
328.  Hanahan, D. and J. Folkman, Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell, 1996. 86(3): p. 353-64. 
329.  Jiang, B.H. and L.Z. Liu, AKT signaling in regulating angiogenesis. Curr Cancer 
Drug Targets, 2008. 8(1): p. 19-26. 
330.  Mukhopadhyay, D., et al., Hypoxic induction of human vascular endothelial growth 
factor expression through c-Src activation. Nature, 1995. 375(6532): p. 577-81. 
331.  Bancroft, C.C., et al., Effects of pharmacologic antagonists of epidermal growth 
factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation 
and IL-8 and VEGF expression in human head and neck squamous cell carcinoma 
lines. Int J Cancer, 2002. 99(4): p. 538-48. 
332.  Tarkkonen, K., J. Ruohola, and P. Harkonen, Fibroblast growth factor 8 induced 
downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K 
pathways in breast cancer cells. Growth Factors, 2010. 28(4): p. 256-67. 
333.  Ebrahem, Q., et al., Cross-talk between vascular endothelial growth factor and 
matrix metalloproteinases in the induction of neovascularization in vivo. Am J 
Pathol, 2010. 176(1): p. 496-503. 
334.  Hawinkels, L.J., et al., VEGF release by MMP-9 mediated heparan sulphate 
cleavage induces colorectal cancer angiogenesis. Eur J Cancer, 2008. 44(13): p. 
1904-13. 
335.  Versteeg, H.H., M.P. Peppelenbosch, and C.A. Spek, Tissue factor signal 
transduction in angiogenesis. Carcinogenesis, 2003. 24(6): p. 1009-13. 
336.  Zhou, J.N., et al., Activation of tissue-factor gene expression in breast carcinoma 
cells by stimulation of the RAF-ERK signaling pathway. Mol Carcinog, 1998. 
21(4): p. 234-43. 
337.  Kasid, U., Raf-1 protein kinase, signal transduction, and targeted intervention of 
radiation response. Exp Biol Med (Maywood), 2001. 226(7): p. 624-5. 
338.  Weinstein-Oppenheimer, C.R., et al., Role of the Raf signal transduction cascade in 
the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res, 2001. 
7(9): p. 2898-907. 
339.  Kim, S.H., et al., Effect of the activated Raf protein kinase on the human multidrug 
resistance 1 (MDR1) gene promoter. Cancer Lett, 1996. 98(2): p. 199-205. 
340.  Garcia, R., R.A. Franklin, and J.A. McCubrey, EGF induces cell motility and multi-
drug resistance gene expression in breast cancer cells. Cell Cycle, 2006. 5(23): p. 
2820-6. 
341.  Roberts, P.J. and C.J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein 
kinase cascade for the treatment of cancer. Oncogene, 2007. 26(22): p. 3291-310. 
342.  Ng, M. and D. Cunningham, Cetuximab (Erbitux)--an emerging targeted therapy 
for epidermal growth factor receptor-expressing tumours. Int J Clin Pract, 2004. 
58(10): p. 970-6. 
343.  Bonner, J.A., et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of 
the head and neck. N Engl J Med, 2006. 354(6): p. 567-78. 
344.  Cunningham, D., et al., Cetuximab monotherapy and cetuximab plus irinotecan in 
irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004. 351(4): p. 
337-45. 239 
345.  Gibson, T.B., A. Ranganathan, and A. Grothey, Randomized phase III trial results 
of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal 
antibody, in metastatic colorectal cancer. Clin Colorectal Cancer, 2006. 6(1): p. 
29-31. 
346.  Kainuma, O., et al., Inhibition of growth and invasive activity of human pancreatic 
cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas, 1997. 15(4): 
p. 379-83. 
347.  Wilhelm, S.M., et al., BAY 43-9006 exhibits broad spectrum oral antitumor activity 
and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in 
tumor progression and angiogenesis. Cancer Res, 2004. 64(19): p. 7099-109. 
348.  Chapman, P.B., et al., Improved survival with vemurafenib in melanoma with 
BRAF V600E mutation. N Engl J Med, 2011. 364(26): p. 2507-16. 
349.  Davies, S.P., et al., Specificity and mechanism of action of some commonly used 
protein kinase inhibitors. Biochem J, 2000. 351(Pt 1): p. 95-105. 
350.  Rinehart, J., et al., Multicenter phase II study of the oral MEK inhibitor, CI-1040, 
in patients with advanced non-small-cell lung, breast, colon, and pancreatic 
cancer. J Clin Oncol, 2004. 22(22): p. 4456-62. 
351.  Cheng, K.W., et al., The RAB25 small GTPase determines aggressiveness of 
ovarian and breast cancers. Nat Med, 2004. 10(11): p. 1251-6. 
352.  Hennigan, R.F., K.L. Hawker, and B.W. Ozanne, Fos-transformation activates 
genes associated with invasion. Oncogene, 1994. 9(12): p. 3591-600. 
353.  Bass, M.D., et al., Syndecan-4-dependent Rac1 regulation determines directional 
migration in response to the extracellular matrix. J Cell Biol, 2007. 177(3): p. 527-
38. 
354.  Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 
25(4): p. 402-8. 
355.  Papkoff, J., et al., p42 mitogen-activated protein kinase and p90 ribosomal S6 
kinase are selectively phosphorylated and activated during thrombin-induced 
platelet activation and aggregation. Mol Cell Biol, 1994. 14(1): p. 463-72. 
356.  Sarbassov, D.D., L.G. Jones, and C.A. Peterson, Extracellular signal-regulated 
kinase-1 and -2 respond differently to mitogenic and differentiative signaling 
pathways in myoblasts. Mol Endocrinol, 1997. 11(13): p. 2038-47. 
357.  Lefloch, R., J. Pouyssegur, and P. Lenormand, Single and combined silencing of 
ERK1 and ERK2 reveals their positive contribution to growth signaling depending 
on their expression levels. Mol Cell Biol, 2008. 28(1): p. 511-27. 
358.  Lee, S.J., T. Zhou, and E.J. Goldsmith, Crystallization of MAP kinases. Methods, 
2006. 40(3): p. 224-33. 
359.  Lefloch, R., J. Pouyssegur, and P. Lenormand, Total ERK1/2 activity regulates cell 
proliferation. Cell Cycle, 2009. 8(5): p. 705-11. 
360.  Pages, G., et al., Defective thymocyte maturation in p44 MAP kinase (Erk 1) 
knockout mice. Science, 1999. 286(5443): p. 1374-7. 
361.  Hatano, N., et al., Essential role for ERK2 mitogen-activated protein kinase in 
placental development. Genes Cells, 2003. 8(11): p. 847-56. 
362.  Saba-El-Leil, M.K., et al., An essential function of the mitogen-activated protein 
kinase Erk2 in mouse trophoblast development. EMBO Rep, 2003. 4(10): p. 964-8. 
363.  Yao, Y., et al., Extracellular signal-regulated kinase 2 is necessary for mesoderm 
differentiation. Proc Natl Acad Sci U S A, 2003. 100(22): p. 12759-64. 
364.  Mazzucchelli, C., et al., Knockout of ERK1 MAP kinase enhances synaptic 
plasticity in the striatum and facilitates striatal-mediated learning and memory. 
Neuron, 2002. 34(5): p. 807-20. 240 
365.  Satoh, Y., et al., Extracellular signal-regulated kinase 2 (ERK2) knockdown mice 
show deficits in long-term memory; ERK2 has a specific function in learning and 
memory. J Neurosci, 2007. 27(40): p. 10765-76. 
366.  Samuels, I.S., et al., Deletion of ERK2 mitogen-activated protein kinase identifies 
its key roles in cortical neurogenesis and cognitive function. J Neurosci, 2008. 
28(27): p. 6983-95. 
367.  Bost, F., et al., The extracellular signal-regulated kinase isoform ERK1 is 
specifically required for in vitro and in vivo adipogenesis. Diabetes, 2005. 54(2): p. 
402-11. 
368.  Krens, S.F., et al., Characterization and expression patterns of the MAPK family in 
zebrafish. Gene Expr Patterns, 2006. 6(8): p. 1019-26. 
369.  Krens, S.F., et al., Distinct functions for ERK1 and ERK2 in cell migration 
processes during zebrafish gastrulation. Dev Biol, 2008. 319(2): p. 370-83. 
370.  Li, J. and S.E. Johnson, ERK2 is required for efficient terminal differentiation of 
skeletal myoblasts. Biochem Biophys Res Commun, 2006. 345(4): p. 1425-33. 
371.  Vantaggiato, C., et al., ERK1 and ERK2 mitogen-activated protein kinases affect 
Ras-dependent cell signaling differentially. J Biol, 2006. 5(5): p. 14. 
372.  Fremin, C., et al., ERK2 but not ERK1 plays a key role in hepatocyte replication: 
an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null 
hepatocytes. Hepatology, 2007. 45(4): p. 1035-45. 
373.  Bourcier, C., et al., p44 mitogen-activated protein kinase (extracellular signal-
regulated kinase 1)-dependent signaling contributes to epithelial skin 
carcinogenesis. Cancer Res, 2006. 66(5): p. 2700-7. 
374.  Liu, X., et al., The MAP kinase pathway is required for entry into mitosis and cell 
survival. Oncogene, 2004. 23(3): p. 763-76. 
375.  Zeng, P., et al., RNA interference (RNAi) for extracellular signal-regulated kinase 1 
(ERK1) alone is sufficient to suppress cell viability in ovarian cancer cells. Cancer 
Biol Ther, 2005. 4(9): p. 961-7. 
376.  Voisin, L., et al., Genetic demonstration of a redundant role of extracellular signal-
regulated kinase 1 (ERK1) and ERK2 mitogen-activated protein kinases in 
promoting fibroblast proliferation. Mol Cell Biol, 2010. 30(12): p. 2918-32. 
377.  Adeyinka, A., et al., Activated mitogen-activated protein kinase expression during 
human breast tumorigenesis and breast cancer progression. Clin Cancer Res, 
2002. 8(6): p. 1747-53. 
378.  Chen, H., et al., Extracellular signal-regulated kinase signaling pathway regulates 
breast cancer cell migration by maintaining slug expression. Cancer Res, 2009. 
69(24): p. 9228-35. 
379.  Bessard, A., et al., MEK/ERK-dependent uPAR expression is required for motility 
via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol, 
2007. 212(2): p. 526-36. 
380.  Caswell, P.T., et al., Rab25 associates with alpha5beta1 integrin to promote 
invasive migration in 3D microenvironments. Dev Cell, 2007. 13(4): p. 496-510. 
381.  Nagata, S., Apoptosis by death factor. Cell, 1997. 88(3): p. 355-65. 
382.  Soldani, C. and A.I. Scovassi, Poly(ADP-ribose) polymerase-1 cleavage during 
apoptosis: an update. Apoptosis, 2002. 7(4): p. 321-8. 
383.  Gao, J., et al., Significant anti-proliferation of human endometrial cancer cells by 
combined treatment with a selective COX-2 inhibitor NS398 and specific MEK 
inhibitor U0126. Int J Oncol, 2005. 26(3): p. 737-44. 
384.  Lind, C.R., et al., The mitogen-activated/extracellular signal-regulated kinase 
kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and 
reduces the proliferation and migration of C6 glioma cells. Neuroscience, 2006. 
141(4): p. 1925-33. 241 
385.  Marampon, F., et al., MEK/ERK inhibitor U0126 affects in vitro and in vivo growth 
of embryonal rhabdomyosarcoma. Mol Cancer Ther, 2009. 8(3): p. 543-51. 
386.  Wang, W., et al., Identification and testing of a gene expression signature of 
invasive carcinoma cells within primary mammary tumors. Cancer Res, 2004. 
64(23): p. 8585-94. 
387.  Beningo, K.A., M. Dembo, and Y.L. Wang, Responses of fibroblasts to anchorage 
of dorsal extracellular matrix receptors. Proc Natl Acad Sci U S A, 2004. 101(52): 
p. 18024-9. 
388.  Hay, E.D., The mesenchymal cell, its role in the embryo, and the remarkable 
signaling mechanisms that create it. Dev Dyn, 2005. 233(3): p. 706-20. 
389.  Zamir, E., et al., Molecular diversity of cell-matrix adhesions. J Cell Sci, 1999. 112 
( Pt 11): p. 1655-69. 
390.  Gloeckner, C.J., K. Boldt, and M. Ueffing, Strep/FLAG tandem affinity purification 
(SF-TAP) to study protein interactions. Curr Protoc Protein Sci, 2009. Chapter 19: 
p. Unit19 20. 
391.  Ge, X., Y.M. Fu, and G.G. Meadows, U0126, a mitogen-activated protein kinase 
kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett, 
2002. 179(2): p. 133-40. 
392.  Kornyei, Z., et al., Proliferative and migratory responses of astrocytes to in vitro 
injury. J Neurosci Res, 2000. 61(4): p. 421-9. 
393.  Coomber, B.L. and A.I. Gotlieb, In vitro endothelial wound repair. Interaction of 
cell migration and proliferation. Arteriosclerosis, 1990. 10(2): p. 215-22. 
394.  Friedl, P., K.S. Zanker, and E.B. Brocker, Cell migration strategies in 3-D 
extracellular matrix: differences in morphology, cell matrix interactions, and 
integrin function. Microsc Res Tech, 1998. 43(5): p. 369-78. 
395.  Li, S., et al., Genomic analysis of smooth muscle cells in 3-dimensional collagen 
matrix. FASEB J, 2003. 17(1): p. 97-9. 
396.  Coso, O.A., et al., The small GTP-binding proteins Rac1 and Cdc42 regulate the 
activity of the JNK/SAPK signaling pathway. Cell, 1995. 81(7): p. 1137-46. 
397.  Minden, A., et al., Selective activation of the JNK signaling cascade and c-Jun 
transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell, 1995. 81(7): 
p. 1147-57. 
398.  Postma, M., et al., Chemotaxis: signalling modules join hands at front and tail. 
EMBO Rep, 2004. 5(1): p. 35-40. 
399.  Kimura, K., et al., Regulation of myosin phosphatase by Rho and Rho-associated 
kinase (Rho-kinase). Science, 1996. 273(5272): p. 245-8. 
400.  Szczur, K., et al., Rho GTPase CDC42 regulates directionality and random 
movement via distinct MAPK pathways in neutrophils. Blood, 2006. 108(13): p. 
4205-13. 
401.  Eblen, S.T., et al., Rac-PAK signaling stimulates extracellular signal-regulated 
kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol 
Cell Biol, 2002. 22(17): p. 6023-33. 
402.  Zang, M., C. Hayne, and Z. Luo, Interaction between active Pak1 and Raf-1 is 
necessary for phosphorylation and activation of Raf-1. J Biol Chem, 2002. 277(6): 
p. 4395-405. 
403.  Fincham, V.J., et al., Active ERK/MAP kinase is targeted to newly forming cell-
matrix adhesions by integrin engagement and v-Src. EMBO J, 2000. 19(12): p. 
2911-23. 
404.  Brahmbhatt, A.A. and R.L. Klemke, ERK and RhoA differentially regulate 
pseudopodia growth and retraction during chemotaxis. J Biol Chem, 2003. 
278(15): p. 13016-25. 242 
405.  Fujishiro, S.H., et al., ERK1/2 phosphorylate GEF-H1 to enhance its guanine 
nucleotide exchange activity toward RhoA. Biochem Biophys Res Commun, 2008. 
368(1): p. 162-7. 
406.  Bisel, B., et al., ERK regulates Golgi and centrosome orientation towards the 
leading edge through GRASP65. J Cell Biol, 2008. 182(5): p. 837-43. 
407.  Ochieng, J., et al., Increased invasive, chemotactic and locomotive abilities of c-
Ha-ras-transformed human breast epithelial cells. Invasion Metastasis, 1991. 
11(1): p. 38-47. 
408.  Rodier, J.M., et al., pp60c-src is a positive regulator of growth factor-induced cell 
scattering in a rat bladder carcinoma cell line. J Cell Biol, 1995. 131(3): p. 761-73. 
409.  Ueoka, Y., et al., Hepatocyte growth factor modulates motility and invasiveness of 
ovarian carcinomas via Ras-mediated pathway. Br J Cancer, 2000. 82(4): p. 891-9. 
410.  Satoh, Y., et al., ERK2 dependent signaling contributes to wound healing after a 
partial-thickness burn. Biochem Biophys Res Commun, 2009. 381(1): p. 118-22. 
411.  Krens, S.F., et al., ERK1 and ERK2 MAPK are key regulators of distinct gene sets 
in zebrafish embryogenesis. BMC Genomics, 2008. 9: p. 196. 
412.  Shin, S., et al., ERK2 but not ERK1 induces epithelial-to-mesenchymal 
transformation via DEF motif-dependent signaling events. Mol Cell. 38(1): p. 114-
27. 
413.  Gee, J.M., et al., Phosphorylation of ERK1/2 mitogen-activated protein kinase is 
associated with poor response to anti-hormonal therapy and decreased patient 
survival in clinical breast cancer. Int J Cancer, 2001. 95(4): p. 247-54. 
414.  Milde-Langosch, K., et al., Expression and prognostic relevance of activated 
extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer, 2005. 
92(12): p. 2206-15. 
415.  Satoh, J., et al., Protein microarray analysis identifies human cellular prion protein 
interactors. Neuropathol Appl Neurobiol, 2009. 35(1): p. 16-35. 
416.  Marchi, M., et al., The N-terminal domain of ERK1 accounts for the functional 
differences with ERK2. PLoS One, 2008. 3(12): p. e3873. 
417.  Lakka, S.S., et al., Downregulation of MMP-9 in ERK-mutated stable transfectants 
inhibits glioma invasion in vitro. Oncogene, 2002. 21(36): p. 5601-8. 
418.  McCawley, L.J., et al., Sustained activation of the mitogen-activated protein kinase 
pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix 
metalloproteinase-9 induction and cell migration. J Biol Chem, 1999. 274(7): p. 
4347-53. 
419.  Nguyen, D.H., et al., Myosin light chain kinase functions downstream of Ras/ERK 
to promote migration of urokinase-type plasminogen activator-stimulated cells in 
an integrin-selective manner. J Cell Biol, 1999. 146(1): p. 149-64. 
420.  Alblas, J., et al., The role of MAP kinase in TPA-mediated cell cycle arrest of 
human breast cancer cells. Oncogene, 1998. 16(1): p. 131-9. 
421.  Chu, B., et al., Sequential phosphorylation by mitogen-activated protein kinase and 
glycogen synthase kinase 3 represses transcriptional activation by heat shock 
factor-1. J Biol Chem, 1996. 271(48): p. 30847-57. 
422.  Yehia, G., et al., Mitogen-activated protein kinase phosphorylates and targets 
inducible cAMP early repressor to ubiquitin-mediated destruction. J Biol Chem, 
2001. 276(38): p. 35272-9. 
423.  Feng, J. and B. Villeponteau, High-resolution analysis of c-fos chromatin 
accessibility using a novel DNase I-PCR assay. Biochim Biophys Acta, 1992. 
1130(3): p. 253-8. 
424.  Allegra, P., et al., Affinity chromatographic purification of nucleosomes containing 
transcriptionally active DNA sequences. J Mol Biol, 1987. 196(2): p. 379-88. 243 
425.  Chen, T.A. and V.G. Allfrey, Rapid and reversible changes in nucleosome 
structure accompany the activation, repression, and superinduction of murine 
fibroblast protooncogenes c-fos and c-myc. Proc Natl Acad Sci U S A, 1987. 
84(15): p. 5252-6. 
426.  Sassone-Corsi, P., et al., Requirement of Rsk-2 for epidermal growth factor-
activated phosphorylation of histone H3. Science, 1999. 285(5429): p. 886-91. 
427.  Thomson, S., et al., The nucleosomal response associated with immediate-early 
gene induction is mediated via alternative MAP kinase cascades: MSK1 as a 
potential histone H3/HMG-14 kinase. EMBO J, 1999. 18(17): p. 4779-93. 
428.  Soloaga, A., et al., MSK2 and MSK1 mediate the mitogen- and stress-induced 
phosphorylation of histone H3 and HMG-14. EMBO J, 2003. 22(11): p. 2788-97. 
429.  Clayton, A.L., et al., Phosphoacetylation of histone H3 on c-fos- and c-jun-
associated nucleosomes upon gene activation. EMBO J, 2000. 19(14): p. 3714-26. 
430.  Weg-Remers, S., et al., Regulation of alternative pre-mRNA splicing by the ERK 
MAP-kinase pathway. EMBO J, 2001. 20(15): p. 4194-203. 
431.  Habelhah, H., et al., ERK phosphorylation drives cytoplasmic accumulation of 
hnRNP-K and inhibition of mRNA translation. Nat Cell Biol, 2001. 3(3): p. 325-30. 
432.  Chen, L.C., et al., Thymidine phosphorylase mRNA stability and protein levels are 
increased through ERK-mediated cytoplasmic accumulation of hnRNP K in 
nasopharyngeal carcinoma cells. Oncogene, 2009. 28(17): p. 1904-15. 
433.  Mikula, M. and K. Bomsztyk, Direct recruitment of ERK cascade components to 
inducible genes is regulated by heterogeneous nuclear ribonucleoprotein (hnRNP) 
K. J Biol Chem, 2011. 286(11): p. 9763-75. 
434.  Paroo, Z., et al., Phosphorylation of the human microRNA-generating complex 
mediates MAPK/Erk signaling. Cell, 2009. 139(1): p. 112-22. 
435.  Filipowicz, W., S.N. Bhattacharyya, and N. Sonenberg, Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet, 
2008. 9(2): p. 102-14. 
436.  Nigg, E.A., Nucleocytoplasmic transport: signals, mechanisms and regulation. 
Nature, 1997. 386(6627): p. 779-87. 
437.  Stewart, M., Molecular mechanism of the nuclear protein import cycle. Nat Rev 
Mol Cell Biol, 2007. 8(3): p. 195-208. 
438.  Lange, A., et al., Classical nuclear localization signals: definition, function, and 
interaction with importin alpha. J Biol Chem, 2007. 282(8): p. 5101-5. 
439.  Christophe, D., C. Christophe-Hobertus, and B. Pichon, Nuclear targeting of 
proteins: how many different signals? Cell Signal, 2000. 12(5): p. 337-41. 
440.  Adachi, M., M. Fukuda, and E. Nishida, Two co-existing mechanisms for nuclear 
import of MAP kinase: passive diffusion of a monomer and active transport of a 
dimer. EMBO J, 1999. 18(19): p. 5347-58. 
441.  Wolf, I., et al., Involvement of the activation loop of ERK in the detachment from 
cytosolic anchoring. J Biol Chem, 2001. 276(27): p. 24490-7. 
442.  Casar, B., A. Pinto, and P. Crespo, Essential role of ERK dimers in the activation of 
cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell, 2008. 
31(5): p. 708-21. 
443.  Lidke, D.S., et al., ERK nuclear translocation is dimerization-independent but 
controlled by the rate of phosphorylation. J Biol Chem, 2010. 285(5): p. 3092-102. 
444.  Chuderland, D., A. Konson, and R. Seger, Identification and characterization of a 
general nuclear translocation signal in signaling proteins. Mol Cell, 2008. 31(6): 
p. 850-61. 
445.  Matsubayashi, Y., M. Fukuda, and E. Nishida, Evidence for existence of a nuclear 
pore complex-mediated, cytosol-independent pathway of nuclear translocation of 
ERK MAP kinase in permeabilized cells. J Biol Chem, 2001. 276(45): p. 41755-60. 244 
446.  Kosako, H., et al., Phosphoproteomics reveals new ERK MAP kinase targets and 
links ERK to nucleoporin-mediated nuclear transport. Nat Struct Mol Biol, 2009. 
16(10): p. 1026-35. 
447.  Lin, T.H., et al., Cell anchorage permits efficient signal transduction between ras 
and its downstream kinases. J Biol Chem, 1997. 272(14): p. 8849-52. 
448.  Aplin, A.E., S.M. Short, and R.L. Juliano, Anchorage-dependent regulation of the 
mitogen-activated protein kinase cascade by growth factors is supported by a 
variety of integrin alpha chains. J Biol Chem, 1999. 274(44): p. 31223-8. 
449.  Miyamoto, S., et al., Integrins can collaborate with growth factors for 
phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of 
integrin aggregation and occupancy of receptors. J Cell Biol, 1996. 135(6 Pt 1): p. 
1633-42. 
450.  Short, S.M., J.L. Boyer, and R.L. Juliano, Integrins regulate the linkage between 
upstream and downstream events in G protein-coupled receptor signaling to 
mitogen-activated protein kinase. J Biol Chem, 2000. 275(17): p. 12970-7. 
451.  Aplin, A.E., et al., Integrin-mediated adhesion regulates ERK nuclear 
translocation and phosphorylation of Elk-1. J Cell Biol, 2001. 153(2): p. 273-82. 
452.  Bolstad, B.M., et al., A comparison of normalization methods for high density 
oligonucleotide array data based on variance and bias. Bioinformatics, 2003. 
19(2): p. 185-93. 
453.  Schmid, R., et al., Comparison of normalization methods for Illumina BeadChip 
HumanHT-12 v3. BMC Genomics, 2010. 11: p. 349. 
454.  Churchill, G.A., Using ANOVA to analyze microarray data. Biotechniques, 2004. 
37(2): p. 173-5, 177. 
455.  Schefe, J.H., et al., Quantitative real-time RT-PCR data analysis: current concepts 
and the novel "gene expression's CT difference" formula. J Mol Med (Berl), 2006. 
84(11): p. 901-10. 
456.  Arezi, B., et al., Amplification efficiency of thermostable DNA polymerases. Anal 
Biochem, 2003. 321(2): p. 226-35. 
457.  Pfaffl, M.W., A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res, 2001. 29(9): p. e45. 
458.  Bussolino, F., et al., Granulocyte- and granulocyte-macrophage-colony stimulating 
factors induce human endothelial cells to migrate and proliferate. Nature, 1989. 
337(6206): p. 471-3. 
459.  Gutschalk, C.M., et al., Granulocyte colony-stimulating factor and granulocyte-
macrophage colony-stimulating factor promote malignant growth of cells from 
head and neck squamous cell carcinomas in vivo. Cancer Res, 2006. 66(16): p. 
8026-36. 
460.  Lederle, W., et al., IL-6 promotes malignant growth of skin SCCs by regulating a 
network of autocrine and paracrine cytokines. Int J Cancer, 2011. 128(12): p. 2803-
14. 
461.  Gasson, J.C., Molecular physiology of granulocyte-macrophage colony-stimulating 
factor. Blood, 1991. 77(6): p. 1131-45. 
462.  Zacchi, P., et al., Rab17 regulates membrane trafficking through apical recycling 
endosomes in polarized epithelial cells. J Cell Biol, 1998. 140(5): p. 1039-53. 
463.  McMurtrie, E.B., et al., Rab17 and rab18, small GTPases with specificity for 
polarized epithelial cells: genetic mapping in the mouse. Genomics, 1997. 45(3): p. 
623-5. 
464.  Serra-Pages, C., et al., Liprins, a family of LAR transmembrane protein-tyrosine 
phosphatase-interacting proteins. J Biol Chem, 1998. 273(25): p. 15611-20. 
465.  Jackson, A.L., et al., Expression profiling reveals off-target gene regulation by 
RNAi. Nat Biotechnol, 2003. 21(6): p. 635-7. 245 
466.  Scacheri, P.C., et al., Short interfering RNAs can induce unexpected and divergent 
changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad 
Sci U S A, 2004. 101(7): p. 1892-7. 
467.  Williams, B.R.G., et al., Activation of the interferon system by short-interfering 
RNAs. Nature Cell Biology, 2003. 5(9): p. 834-839. 
468.  Hu, S., et al., Profiling the human protein-DNA interactome reveals ERK2 as a 
transcriptional repressor of interferon signaling. Cell, 2009. 139(3): p. 610-22. 
469.  Wang, X., et al., RAF may induce cell proliferation through hypermethylation of 
tumor suppressor gene promoter in gastric epithelial cells. Cancer Sci, 2009. 
100(1): p. 117-25. 
470.  Shapiro, P.S., et al., Extracellular signal-regulated kinase activates topoisomerase 
IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol, 
1999. 19(5): p. 3551-60. 
471.  Karin, M., Too many transcription factors: positive and negative interactions. New 
Biol, 1990. 2(2): p. 126-31. 
472.  Morton, S., et al., A reinvestigation of the multisite phosphorylation of the 
transcription factor c-Jun. EMBO J, 2003. 22(15): p. 3876-86. 
473.  Manabe, A., et al., Transcriptional repression activity of N-MYC protein requires 
phosphorylation by MAP kinase. Biochem Biophys Res Commun, 1996. 219(3): p. 
813-23. 
474.  Guhaniyogi, J. and G. Brewer, Regulation of mRNA stability in mammalian cells. 
Gene, 2001. 265(1-2): p. 11-23. 
475.  Proudfoot, N.J., A. Furger, and M.J. Dye, Integrating mRNA processing with 
transcription. Cell, 2002. 108(4): p. 501-12. 
476.  Brook, M., et al., Posttranslational regulation of tristetraprolin subcellular 
localization and protein stability by p38 mitogen-activated protein kinase and 
extracellular signal-regulated kinase pathways. Mol Cell Biol, 2006. 26(6): p. 
2408-18. 
477.  Essafi-Benkhadir, K., et al., Tristetraprolin inhibits Ras-dependent tumor 
vascularization by inducing vascular endothelial growth factor mRNA degradation. 
Mol Biol Cell, 2007. 18(11): p. 4648-58. 
478.  Carballo, E., W.S. Lai, and P.J. Blackshear, Evidence that tristetraprolin is a 
physiological regulator of granulocyte-macrophage colony-stimulating factor 
messenger RNA deadenylation and stability. Blood, 2000. 95(6): p. 1891-9. 
479.  Raught, B. and A.C. Gingras, eIF4E activity is regulated at multiple levels. Int J 
Biochem Cell Biol, 1999. 31(1): p. 43-57. 
480.  Li, X.J., et al., Serglycin is a theranostic target in nasopharyngeal carcinoma that 
promotes metastasis. Cancer Res, 2011. 71(8): p. 3162-72. 
481.  Wei, Q., et al., Sulfiredoxin is an AP-1 target gene that is required for 
transformation and shows elevated expression in human skin malignancies. Proc 
Natl Acad Sci U S A, 2008. 105(50): p. 19738-43. 
482.  Wei, Q., et al., Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer 
progression through modulation of specific phosphokinase signaling. Proc Natl 
Acad Sci U S A, 2011. 108(17): p. 7004-9. 
483.  Cadenas, C., et al., Role of thioredoxin reductase 1 and thioredoxin interacting 
protein in prognosis of breast cancer. Breast Cancer Res, 2010. 12(3): p. R44. 
484.  Nishizawa, K., et al., Thioredoxin interacting protein suppresses bladder 
carcinogenesis. Carcinogenesis, 2011. 
485.  Dunn, T.A., et al., A novel role of myosin VI in human prostate cancer. Am J 
Pathol, 2006. 169(5): p. 1843-54. 246 
486.  Silvers, A.L., et al., Decreased selenium-binding protein 1 in esophageal 
adenocarcinoma results from posttranscriptional and epigenetic regulation and 
affects chemosensitivity. Clin Cancer Res, 2010. 16(7): p. 2009-21. 
487.  Kim, H., et al., Suppression of human selenium-binding protein 1 is a late event in 
colorectal carcinogenesis and is associated with poor survival. Proteomics, 2006. 
6(11): p. 3466-76. 
488.  Chen, G., et al., Reduced selenium-binding protein 1 expression is associated with 
poor outcome in lung adenocarcinomas. J Pathol, 2004. 202(3): p. 321-9. 
489.  Pohl, N.M., et al., Transcriptional regulation and biological functions of selenium-
binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS 
One, 2009. 4(11): p. e7774. 
490.  Pollock, C.B., et al., Oncogenic K-RAS is required to maintain changes in 
cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res, 
2005. 65(4): p. 1244-50. 
491.  Colicelli, J., Human RAS superfamily proteins and related GTPases. Sci STKE, 
2004. 2004(250): p. RE13. 
492.  Stenmark, H. and V.M. Olkkonen, The Rab GTPase family. Genome Biol, 2001. 
2(5): p. REVIEWS3007. 
493.  Pfeffer, S. and D. Aivazian, Targeting Rab GTPases to distinct membrane 
compartments. Nat Rev Mol Cell Biol, 2004. 5(11): p. 886-96. 
494.  van der Sluijs, P., et al., The small GTP-binding protein rab4 controls an early 
sorting event on the endocytic pathway. Cell, 1992. 70(5): p. 729-40. 
495.  Chavrier, P., et al., Localization of low molecular weight GTP binding proteins to 
exocytic and endocytic compartments. Cell, 1990. 62(2): p. 317-29. 
496.  Ullrich, O., et al., Rab11 regulates recycling through the pericentriolar recycling 
endosome. J Cell Biol, 1996. 135(4): p. 913-24. 
497.  Lutcke, A., et al., Rab17, a novel small GTPase, is specific for epithelial cells and 
is induced during cell polarization. J Cell Biol, 1993. 121(3): p. 553-64. 
498.  Hunziker, W. and P.J. Peters, Rab17 localizes to recycling endosomes and 
regulates receptor-mediated transcytosis in epithelial cells. J Biol Chem, 1998. 
273(25): p. 15734-41. 
499.  Fukuda, M., Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol 
Life Sci, 2008. 65(18): p. 2801-13. 
500.  Woodman, P.G., Biogenesis of the sorting endosome: the role of Rab5. Traffic, 
2000. 1(9): p. 695-701. 
501.  Mesa, R., et al., Rab22a affects the morphology and function of the endocytic 
pathway. J Cell Sci, 2001. 114(Pt 22): p. 4041-9. 
502.  Erdman, R.A., et al., Rab24 is an atypical member of the Rab GTPase family. 
Deficient GTPase activity, GDP dissociation inhibitor interaction, and prenylation 
of Rab24 expressed in cultured cells. J Biol Chem, 2000. 275(6): p. 3848-56. 
503.  Amillet, J.M., et al., Characterization of human Rab20 overexpressed in exocrine 
pancreatic carcinoma. Hum Pathol, 2006. 37(3): p. 256-63. 
504.  Yoshimura, S., et al., Functional dissection of Rab GTPases involved in primary 
cilium formation. J Cell Biol, 2007. 178(3): p. 363-9. 
505.  Bucci, C., et al., Interaction cloning and characterization of the cDNA encoding the 
human prenylated rab acceptor (PRA1). Biochem Biophys Res Commun, 1999. 
258(3): p. 657-62. 
506.  Stelzl, U., et al., A human protein-protein interaction network: a resource for 
annotating the proteome. Cell, 2005. 122(6): p. 957-68. 
507.  Ewing, R.M., et al., Large-scale mapping of human protein-protein interactions by 
mass spectrometry. Mol Syst Biol, 2007. 3: p. 89. 247 
508.  Barrios-Rodiles, M., et al., High-throughput mapping of a dynamic signaling 
network in mammalian cells. Science, 2005. 307(5715): p. 1621-5. 
509.  Serra-Pages, C., et al., The LAR transmembrane protein tyrosine phosphatase and a 
coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J, 1995. 
14(12): p. 2827-38. 
510.  Nachat, R., et al., KazrinE is a desmosome-associated liprin that colocalises with 
acetylated microtubules. J Cell Sci, 2009. 122(Pt 22): p. 4035-41. 
511.  Wei, Z., et al., Liprin-Mediated Large Signaling Complex Organization Revealed 
by the Liprin-alpha/CASK and Liprin-alpha/Liprin-beta Complex Structures. Mol 
Cell, 2011. 43(4): p. 586-98. 
512.  Stafford, R.L., et al., Crystal structure of the central coiled-coil domain from 
human liprin-beta2. Biochemistry, 2011. 50(18): p. 3807-15. 
513.  Parry, D.A., et al., Towards a molecular description of intermediate filament 
structure and assembly. Exp Cell Res, 2007. 313(10): p. 2204-16. 
514.  Miroshnichenko, N.S., I.V. Balanuk, and D.N. Nozdrenko, Packing of myosin 
molecules in muscle thick filaments. Cell Biol Int, 2000. 24(6): p. 327-33. 
515.  Meruelo, A.D. and J.U. Bowie, Identifying polymer-forming SAM domains. 
Proteins, 2009. 74(1): p. 1-5. 
516.  Stryker, E. and K.G. Johnson, LAR, liprin alpha and the regulation of active zone 
morphogenesis. J Cell Sci, 2007. 120(Pt 21): p. 3723-8. 
517.  Spangler, S.A. and C.C. Hoogenraad, Liprin-alpha proteins: scaffold molecules for 
synapse maturation. Biochem Soc Trans, 2007. 35(Pt 5): p. 1278-82. 
518.  de Curtis, I., Function of liprins in cell motility. Exp Cell Res, 2011. 317(1): p. 1-8. 
519.  Asperti, C., et al., Liprin-alpha1 promotes cell spreading on the extracellular 
matrix by affecting the distribution of activated integrins. J Cell Sci, 2009. 122(Pt 
18): p. 3225-32. 
520.  Asperti, C., E. Pettinato, and I. de Curtis, Liprin-alpha1 affects the distribution of 
low-affinity beta1 integrins and stabilizes their permanence at the cell surface. Exp 
Cell Res, 2010. 316(6): p. 915-26. 
521.  Norrmen, C., et al., Liprin (beta)1 is highly expressed in lymphatic vasculature and 
is important for lymphatic vessel integrity. Blood, 2010. 115(4): p. 906-9. 
522.  Kriajevska, M., et al., Liprin beta 1, a member of the family of LAR transmembrane 
tyrosine phosphatase-interacting proteins, is a new target for the metastasis-
associated protein S100A4 (Mts1). J Biol Chem, 2002. 277(7): p. 5229-35. 
523.  Rual, J.F., et al., Towards a proteome-scale map of the human protein-protein 
interaction network. Nature, 2005. 437(7062): p. 1173-8. 
524.  Benzinger, A., et al., Targeted proteomic analysis of 14-3-3 sigma, a p53 effector 
commonly silenced in cancer. Mol Cell Proteomics, 2005. 4(6): p. 785-95. 
525.  Muller, P.A., et al., Mutant p53 drives invasion by promoting integrin recycling. 
Cell, 2009. 139(7): p. 1327-41. 
526.  Pellinen, T., et al., Small GTPase Rab21 regulates cell adhesion and controls 
endosomal traffic of beta1-integrins. J Cell Biol, 2006. 173(5): p. 767-80. 
527.  Singh, A., et al., A gene expression signature associated with "K-Ras addiction" 
reveals regulators of EMT and tumor cell survival. Cancer Cell, 2009. 15(6): p. 
489-500. 
528.  Caswell, P.T., et al., Rab-coupling protein coordinates recycling of alpha5beta1 
integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell 
Biol, 2008. 183(1): p. 143-55. 
529.  Jarvinen, A.K., et al., Identification of target genes in laryngeal squamous cell 
carcinoma by high-resolution copy number and gene expression microarray 
analyses. Oncogene, 2006. 25(52): p. 6997-7008. 248 
530.  Jarvinen, A.K., et al., High-resolution copy number and gene expression 
microarray analyses of head and neck squamous cell carcinoma cell lines of tongue 
and larynx. Genes Chromosomes Cancer, 2008. 47(6): p. 500-9. 
531.  Ko, J., et al., Interaction between liprin-alpha and GIT1 is required for AMPA 
receptor targeting. J Neurosci, 2003. 23(5): p. 1667-77. 
532.  Shin, H., et al., Association of the kinesin motor KIF1A with the multimodular 
protein liprin-alpha. J Biol Chem, 2003. 278(13): p. 11393-401. 
533.  Shen, J.C., et al., Inhibitor of growth 4 suppresses cell spreading and cell migration 
by interacting with a novel binding partner, liprin alpha1. Cancer Res, 2007. 67(6): 
p. 2552-8. 
534.  Tan, K.D., et al., Amplification and overexpression of PPFIA1, a putative 11q13 
invasion suppressor gene, in head and neck squamous cell carcinoma. Genes 
Chromosomes Cancer, 2008. 47(4): p. 353-62. 
535.  Rhodes, D.R., et al., ONCOMINE: a cancer microarray database and integrated 
data-mining platform. Neoplasia, 2004. 6(1): p. 1-6. 
536.  Chen, G., et al., Discordant protein and mRNA expression in lung 
adenocarcinomas. Mol Cell Proteomics, 2002. 1(4): p. 304-13. 
537.  Ewings, K.E., C.M. Wiggins, and S.J. Cook, Bim and the pro-survival Bcl-2 
proteins: opposites attract, ERK repels. Cell Cycle, 2007. 6(18): p. 2236-40. 
 
 